<SEC-DOCUMENT>0001566044-21-000034.txt : 20210812
<SEC-HEADER>0001566044-21-000034.hdr.sgml : 20210812
<ACCEPTANCE-DATETIME>20210812084715
ACCESSION NUMBER:		0001566044-21-000034
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210812
DATE AS OF CHANGE:		20210812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VYNE Therapeutics Inc.
		CENTRAL INDEX KEY:			0001566044
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				453757789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38356
		FILM NUMBER:		211165619

	BUSINESS ADDRESS:	
		STREET 1:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		800-775-7936

	MAIL ADDRESS:	
		STREET 1:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics Inc.
		DATE OF NAME CHANGE:	20180201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170728

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tigercat Pharma, Inc.
		DATE OF NAME CHANGE:	20130104
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vyne-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:40e9affd-2783-4e4a-bd7f-018d2dae4bf0,g:c708fe63-ab77-4120-b7ee-9a72ba48151c,d:25b00c7e5297459bafdb2282aa46fec2--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:vyne="http://www.menlotherapeutics.com/20210630" xmlns:dei="http://xbrl.sec.gov/dei/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vyne-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80L2ZyYWc6YmRmZDdhNzgwZjhjNDM0ZTk3M2EwYzNjMDgwNzNiNmYvdGFibGU6MWM1NzRmMDU2NmJmNDJjMmI3OGFlN2QwMDk4ZmUzZjMvdGFibGVyYW5nZToxYzU3NGYwNTY2YmY0MmMyYjc4YWU3ZDAwOThmZTNmM18yLTEtMS0xLTA_f0b44b40-41da-45fe-8a8d-cc43163bf952">0001566044</ix:nonNumeric><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80L2ZyYWc6YmRmZDdhNzgwZjhjNDM0ZTk3M2EwYzNjMDgwNzNiNmYvdGFibGU6MWM1NzRmMDU2NmJmNDJjMmI3OGFlN2QwMDk4ZmUzZjMvdGFibGVyYW5nZToxYzU3NGYwNTY2YmY0MmMyYjc4YWU3ZDAwOThmZTNmM18zLTEtMS0xLTA_8c6e9518-430c-4929-bd46-98915425c9cc">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80L2ZyYWc6YmRmZDdhNzgwZjhjNDM0ZTk3M2EwYzNjMDgwNzNiNmYvdGFibGU6MWM1NzRmMDU2NmJmNDJjMmI3OGFlN2QwMDk4ZmUzZjMvdGFibGVyYW5nZToxYzU3NGYwNTY2YmY0MmMyYjc4YWU3ZDAwOThmZTNmM180LTEtMS0xLTA_69962c1b-0ae7-462f-8e75-93e8dae484e7">2021</ix:nonNumeric><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80L2ZyYWc6YmRmZDdhNzgwZjhjNDM0ZTk3M2EwYzNjMDgwNzNiNmYvdGFibGU6MWM1NzRmMDU2NmJmNDJjMmI3OGFlN2QwMDk4ZmUzZjMvdGFibGVyYW5nZToxYzU3NGYwNTY2YmY0MmMyYjc4YWU3ZDAwOThmZTNmM181LTEtMS0xLTA_8f10d7bd-823a-4e2c-990f-399f05594455">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80L2ZyYWc6YmRmZDdhNzgwZjhjNDM0ZTk3M2EwYzNjMDgwNzNiNmYvdGFibGU6MWM1NzRmMDU2NmJmNDJjMmI3OGFlN2QwMDk4ZmUzZjMvdGFibGVyYW5nZToxYzU3NGYwNTY2YmY0MmMyYjc4YWU3ZDAwOThmZTNmM182LTEtMS0xLTA_13a2a578-949a-464d-94e2-e0830c915334">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80MC9mcmFnOjg2YzU3MzIwOGQyODQzMjY5MzFiODJiNjA2N2MzYmM5L3RleHRyZWdpb246ODZjNTczMjA4ZDI4NDMyNjkzMWI4MmI2MDY3YzNiYzlfMzU_eda3327b-bfaf-4cc2-a2d6-a57f58ba29f8">.25</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82Ny9mcmFnOmZiMjViZDYxZjA0NDQzMTg5OGNmYmY4MzVlNDY3YTYyL3RleHRyZWdpb246ZmIyNWJkNjFmMDQ0NDMxODk4Y2ZiZjgzNWU0NjdhNjJfMzU_eda3327b-bfaf-4cc2-a2d6-a57f58ba29f8">.25</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vyne-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i87270e9b78864085be8909ec1039d600_I20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i74a36af260014e1f802fe734fdffb5e9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i591be1e0085c41d689fc49b8c603ab69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i84342aca68b243ada9b41fbbc8cf270b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dea735dd11c45e69052123ac0c08ca2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b27fc8830c2496393ef337b50de9d1d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0fbd34450c84e6a85650df0d4e02142_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2debda6fea544c33bd0f7cd7fb0d1eda_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9554f0529f7f46d3b0d37c39bef0330b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9398115216164c628d93c5faa7c9acae_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c6c82cc7d9438c92ca5e369586fa89_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i100dc25a3ccc4b50b433b69ea956736e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idabf5cabf5d146209830192ebd3a2c01_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53788555bd1f4b04be712a3744df4cc3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc49910e5a5430584764df10f7cf924_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i797c66ad7b9c49b5a2ddd97631ae27f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d3a379e953425a9974062231d7dcd0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d13b3790624d87bc0cad0e41052e6d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedde2720a7af4dba914dd3438edc3894_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a3d7596a5a540f69eee45235f538a4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a850254855c4cf1ba7c87d12f8bcf5d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7abf6f21fe40411c8914385be9741d3f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a23cc6461f4ef8bf1b007c53b237f9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ff10b2c08844eabaa679bba7720742e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6791bfcf14401e94eb092718e67ad9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ade32f44d84447498707d4ecef4407a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd67e51186d44f0aa1480b690576bb0d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4f9738453474c059f491621e59dc79b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f2fa509856a406c9e42f24a5f55ac1e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie50700e6e0f1422a89d1383e91db69f6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe5419b81c14a06b772ea4bc01565d0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f29689ea1944eedbbcf9400e04d7ef0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee26fdc1fa14f05a6f311e845ab576b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4227e51ef1044e2b823e33b150d24f26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02af391415841e4b82ed9d48c82edc3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fbd72aac51444cc8e66833339c2e2f3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda95e6e7c234d489db3397bca35bb75_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6eb2e10a04475ab11b11c04ece8082_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb4b5e3e1eb74f53b54afa625f0fd048_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d5a2a3933f4cfbbb3fbb51c20df06d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22fcfd7ed9a543ddb72129476634c780_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78735453789f4a8abdc6053070d56b14_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e7f7d4ebf643ee959c05a474f9c948_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia694da22cf534b119d5bfa52040066d2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b04039f72414cc68135a0028a7ebd45_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc3c6f2f161a493b8e5395bce6f28971_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c74f98bea814d89ae592c883580eba5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44747ec4fa294f50a7469563ddcbafeb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad82d516ac8944c3ab74858aecd5b316_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1755861e14c849d2a5109ccface73c4d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide8e978d00c845e78cd00eaea3509c91_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a34e2be4ddc40a287e56721af2404d1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78a66c4d2a848feb68215cc74cf142d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c0c1b558463459aaba416b532ab05b9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f66d5268c24630ad030416639966ce_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ba6c46ad1554816bcc03cae4a40ea5e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1751f8eb9f24fd8843cb5ad13f6a9e7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5741436efcf7422d8c1efec1a5674e74_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba9266a3f21470b9aea71eb689ca61e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425a84c0240f40dfb5087d836e1a583b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb79d419a25c4a54bd7d489adc952e95_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dff1b7af5184588b64b59aa4e8c1aa3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib29bbbec2a784133904ebf772b749830_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica61d474584c4143988ae02e9fa3856a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e633a691ef420b992fc44538fdc8a7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>vyne:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie36f0645785e4cabba23e0ebc501434b_D20210806-20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833be515ce11411f87485dfaea471f94_D20210806-20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vyne:TopicalBETiOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fcd46d67d92482a938a2ff751b727d8_D20210806-20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vyne:OralBETiOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3a4133507eae4a3293528a38e4dc4312_I20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>vyne:employee</xbrli:measure></xbrli:unit><xbrli:context id="i4a701835f72e475097f033580f5deea7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibace252288db423ca83fb8257a0d36f9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20cbba757ccb4615a4d0cfe3c3f988dd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if12e854e598f4a50aee8bc4d0c1ba30d_I20210211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:MenloPremergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed43e98e5c24ad3a531ae837852997f_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9efde75313c64f94acd2d57c0ac7ad36_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25e62d0cd134ea88998d63b633a4770_D20210811-20210811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-11</xbrli:startDate><xbrli:endDate>2021-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271ffaaf0e574d60ad9235c64c92906e_I20210811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0505b712e847e481143283b66db10b_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37f3b5248df46e8a5d24d2bfdf923c7_D20200401-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb1d0e22f202476fa595bb840d395cd9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68da95855f63445cb75b88e2107393a8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa2d29a04a9d429e8c602ba8cac18f30_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="derivativeinstruments"><xbrli:measure>vyne:derivativeInstruments</xbrli:measure></xbrli:unit><xbrli:context id="ib7eaae92ef0840c2b50b035cf1e0a2e0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vyne:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf646184c9df4d2991aed59bbf06b647_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vyne:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a7f4503f7384e2faaa1111b3d6139c9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vyne:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff048461f0274e04bac7ba4406b49f1c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vyne:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9596c2a29d47439a95abf5bafe122581_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib38e1be8e95d46dc90c6daa98174ed11_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife9a680c8a894189a633707b6fc4831d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a8f4a8fcca4b248c457bd74ec68078_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib008e08d218f4edca1a33f7677210b30_I20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6382cc7a653d404095454dba66f62190_I20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="contingentstockright"><xbrli:measure>vyne:contingentStockRight</xbrli:measure></xbrli:unit><xbrli:context id="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-06</xbrli:startDate><xbrli:endDate>2020-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-07</xbrli:startDate><xbrli:endDate>2020-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7cf85ce0eb405d8a9d3d0c8302a988_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7b882797fb4a558b75c52ad0d3f597_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f810ffe926407c90d135528dbc7806_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc41b531a42468fbf923e22fdb7eabb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db72496b07944a0b0be6eb4aa4ba37a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5bafa21e104483ae7f0f9dc374ea00_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16efb1e654494773b9d6ff2b23dc030b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b69cba5a49141e6bb1ce4370c794990_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vyne:FourCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic43c6e8d9ce64e2d8a1368960b3a7873_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vyne:FourCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85566c685134979a79b4ce6fd888d53_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vyne:ThreeCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d0289842ec41d6a4fcf604ba120cc7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vyne:ThreeCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27b7eaef51134e98829287ba6d768e11_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vyne:AllowanceForSalesReturns1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d3ea68f84b490b9ee1aafc7167b26a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vyne:AllowanceForSalesReturns1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1c6d1a11d554c199e8d8a169359a9a4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd77d34132ca467485ab82d588391ab6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i097981da69d34227853b3f274c4a9834_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b5f9de8edf74567a2af3deb4d32b9e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d8c62eaafd4e3b828916f7e572cd7d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i659a1487487a4e54b0c16d985e15bce3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vyne:IsraeliMutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9adec3b7e764dbea542fb51debbc4a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vyne:IsraeliMutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69de8b4ead5948b29019da8f6937bc7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ace227df814c6da96b3d3c17e550ca_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vyne:ShareholderLenderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lender"><xbrli:measure>vyne:lender</xbrli:measure></xbrli:unit><xbrli:context id="i2384945abf164135b470fbd163ec1a30_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vyne:ShareholderLenderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:RegisteredOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id528c304a55c4353ba23843e402628f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b6c184538354bce82077ac6310639ce_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementTrench1LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a8f341036bc4b7ea7dc739c6499f873_I20191217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementTrench2LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f230d62899b4d71845a983074150045_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementTrench3LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id65641d8ed054571b83e832dbc10772f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e2f164495a40aeb89e017df3b2607c_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vyne:ShareholderLenderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29a95d4d274e49d39b10611f8aa1e359_I20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vyne:ShareholderLenderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f8896bfdb14e839b03b101221cb89b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vyne:ShareholderLenderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08340dd9766c473889a05f2e9e452090_D20190729-20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-29</xbrli:startDate><xbrli:endDate>2019-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615924500e1a48a1b14b32e08fe70444_D20190729-20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementTrench2LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-29</xbrli:startDate><xbrli:endDate>2019-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ee35236062d43f9aceb739ebad9b33d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i742062b5041f42418de6c43a30fbe8a2_I20210719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>vyne:vote</xbrli:measure></xbrli:unit><xbrli:context id="i038228081e6f4f1790fdcab0a61c49d4_D20190201-20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7bc2d54cd0447d85aaad2c755a7b4d_D20190201-20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:CantorSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2f164c78754c5d9affd590f3137bf8_D20210101-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:CantorSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b0dcc45925492cb597c2d5ec8cb906_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:CantorSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a2f99820bb84452aea13ec915c8fa3b_D20210126-20210126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-26</xbrli:startDate><xbrli:endDate>2021-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b0c0ff85cd433787d5bfdd753d8bab_I20210126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7823d514fa4758beb050e55878ced3_D20200609-20200609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-09</xbrli:startDate><xbrli:endDate>2020-06-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8689f9a9a2e144918aa468473d6f4f11_I20200609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if21d5501c5f34c17ae7cdfe02a371143_D20200406-20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-06</xbrli:startDate><xbrli:endDate>2020-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie871aeb88d164ac194fee5617757929b_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i428a7beb16304a1c98e79a87b85028ab_D20190729-20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-29</xbrli:startDate><xbrli:endDate>2019-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27760351ca2c4c7ba4e2acabf5d90f82_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dae593c3d39464ba022d2c59437553f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec332474ea174f79b645e790d02cd783_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:A2018PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i641098fa043e48aa8855d84732b16182_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65cc49f7fccb4771b6f817252050651d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b522232200e4ef29470815637a89d61_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a2ca05fede4ed3bb2d86f4e96744a8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b9c5bc79864c4ebd2e17fb68853be3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i376c62cb8cbc4fefa5c7f2ab24075e54_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4225a6209ef44ddaaa5e82e900a35d56_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3dbfc262f3d4d6e9849df3ec34b7adf_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e1b4af058494e31a6baf54a62b10e9f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaeba42a65bb4908a12b6c42bbe13190_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524e30b547814ce3bcc5776c00614d79_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05c23f9d5dd402b979cd7db4bad4117_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35b1d069ce7e4403bcfb8dc34bb20fdd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fb7478f500346ca86fa53d3e5c1bea3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef2613cb84a47d9b3d12f99f63f3c4b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc383d8b15744bd285e423d24f50602f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd075c5d380f49b1987fa8d6713944de_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19d638103a64be2acf8ac79042f7740_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i753ec734b4784e41991f04acf5c5cc91_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f58347fa5a54704957bea4315cd276b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a28af5f07da4b9898e192b1f7e656df_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i650dc6e79b0646b69e2927249fe8ffd5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id374e55b59954cc8a6044053d732e5bb_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ea0913d468447f90567f896b4278c8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414facc7c16542e9bd4fb7ab3efbe2da_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f1e26cb367a4d819caeb25260e38425_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6624a5563c848348d3967b0dc37ffed_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e62a8b45834716a1bfce75e6f69049_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5dd41a666f44f10b6f7fcf9d08a4914_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0486d94e40b54296be6348fab054286d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84198dfa6a324c93a59ee66d0eee6e13_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1691ef974cfc49b4b36a9537faf2c710_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3146e6cf023a4b3dbb9950d620581293_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81a2e62b1f87439290f96db45c549d64_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea6504990b84f5cbc69647e56ecc4a9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i722a736ad61a4de08b6ba7e77f1bc3bc_D20190313-20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vyne:BridgewaterNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vyne:OriginalSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-13</xbrli:startDate><xbrli:endDate>2019-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381692c3937a48fc9cf55bbc32a4a79f_D20190313-20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vyne:BridgewaterNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vyne:AdditionalSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-13</xbrli:startDate><xbrli:endDate>2019-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1e8908692340b4b78b852928f985fa_I20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vyne:BridgewaterNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vyne:OriginalSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54987e1926fd4ff78e485bd30599b12a_I20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vyne:BridgewaterNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vyne:AdditionalSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c8acb1983b042eca15f9a025c2d4572_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i25b00c7e5297459bafdb2282aa46fec2_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjU1_33064f69-071f-4156-b480-26a8326fab8f">10-Q</ix:nonNumeric></span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjUx_ae95d00a-37ef-4fc9-8dbe-166feb8b9158">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMTE_81a4aec1-1928-48b3-b1ee-8626bb268a09">JUNE&#160;30, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQx_dc28c65b-30cf-43e2-a94a-ff59d05d1e0b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM ___ TO ___.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ2_d759e18b-efcc-444e-bc84-7d6f46bdad79">001-38356</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjU2_640378c1-2491-4492-b59d-f5cd5e9ff75c">VYNE THERAPEUTICS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6ODM0MDg5N2E0NGZjNDgyN2JlOWE3ZGYwYTZlYjAyM2QvdGFibGVyYW5nZTo4MzQwODk3YTQ0ZmM0ODI3YmU5YTdkZjBhNmViMDIzZF8wLTAtMS0xLTA_a21be062-3baa-4bbd-98d6-e86177ed824a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6ODM0MDg5N2E0NGZjNDgyN2JlOWE3ZGYwYTZlYjAyM2QvdGFibGVyYW5nZTo4MzQwODk3YTQ0ZmM0ODI3YmU5YTdkZjBhNmViMDIzZF8wLTItMS0xLTA_8f26a2e4-e83d-4d27-90bd-6bb23966b784">45-3757789</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjUy_b877a289-916a-4458-a347-da208ac76a3a">520 U.S. Highway 22, Suite 204</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ4_6669f126-8d8f-41e4-afc0-8b53a44f295b">Bridgewater</ix:nonNumeric>, <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ5_2c32427c-439d-4e37-a8b9-1c836173dd1f">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ3_07387024-d4e8-42c9-9dc7-c43982880a16">08807</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjUw_4bd615cc-bd4c-4023-84e2-03a12710bf6d">800</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQz_f9d43822-d5ca-4563-b211-cba3cb11f8d3">775-7936</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6ODQ3ZDY5OTE1NGExNGJiNDg5ZGIwNzQ1MjdhZGIwMWQvdGFibGVyYW5nZTo4NDdkNjk5MTU0YTE0YmI0ODlkYjA3NDUyN2FkYjAxZF8xLTAtMS0xLTA_897e52dc-ed26-4af1-b5aa-51daf4546c5e">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6ODQ3ZDY5OTE1NGExNGJiNDg5ZGIwNzQ1MjdhZGIwMWQvdGFibGVyYW5nZTo4NDdkNjk5MTU0YTE0YmI0ODlkYjA3NDUyN2FkYjAxZF8xLTItMS0xLTA_4d01365b-6a00-46e4-9f70-20b0e47c1714">VYNE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6ODQ3ZDY5OTE1NGExNGJiNDg5ZGIwNzQ1MjdhZGIwMWQvdGFibGVyYW5nZTo4NDdkNjk5MTU0YTE0YmI0ODlkYjA3NDUyN2FkYjAxZF8xLTQtMS0xLTA_25854f6c-ba77-4c3d-b808-9da6225af843">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ0_73893873-0492-4137-b2a0-17410379e47a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ1_ffe2adc0-1e83-4e37-90c5-995893f58ccb">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6MGI0ZjAwMWNlNTE5NDM0Nzg1ZDNhMjNhMDg4NjUyNjAvdGFibGVyYW5nZTowYjRmMDAxY2U1MTk0MzQ3ODVkM2EyM2EwODg2NTI2MF8xLTAtMS0xLTA_2740668e-b53a-49fb-9d45-0edcc056b244">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6MGI0ZjAwMWNlNTE5NDM0Nzg1ZDNhMjNhMDg4NjUyNjAvdGFibGVyYW5nZTowYjRmMDAxY2U1MTk0MzQ3ODVkM2EyM2EwODg2NTI2MF8xLTQtMS0xLTA_4cd2c804-198d-4b19-9a85-d7e7d2cb2908">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6MGI0ZjAwMWNlNTE5NDM0Nzg1ZDNhMjNhMDg4NjUyNjAvdGFibGVyYW5nZTowYjRmMDAxY2U1MTk0MzQ3ODVkM2EyM2EwODg2NTI2MF8yLTQtMS0xLTA_da0c5c52-6339-40b9-9ae6-c0672d165f8a">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjU0_63480783-9f56-4930-8d85-a14fa1ec9277">&#9746;</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQy_a45dc573-9884-4d51-aa62-d511c24685d9">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August&#160;6, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i87270e9b78864085be8909ec1039d600_I20210806" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMTU0_d677401a-c828-4156-8f43-b734624a7e9a">51,511,845</ix:nonFraction> shares of the registrant&#8217;s Common Stock, par value $0.0001 per share, outstanding.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_10">Part I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_10">Financial Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_10">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_13">Unaudited Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_13">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_16">Unaudited Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_16">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_19">Unaudited Condensed Consolidated Statements Of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_19">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_22">Unaudited Condensed Consolidated Statements Of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_22">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_25">Unaudited Condensed Consolidated Statements Of Changes In Stockholders' Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_25">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_31">Unaudited Condensed Consolidated Statements Of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_31">11</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_34">Notes to Unaudited Interim Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_34">13</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_76">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_76">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_112">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_112">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_112">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_115">Item 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_115">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_115">44</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_118">Part II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_118">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_118">45</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_121">Item 1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_121">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_121">45</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_124">Item&#160;1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_124">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_124">45</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_127">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_127">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_127">47</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_130">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_130">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_130">47</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_133">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_133">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_133">47</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_136">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_136">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_136">47</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_139">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_139">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_139">48</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_142">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_142">50</a></span></div></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have rights to various copyrights, trademarks, and trade names used in our business in the U.S. and/or other countries, including VYNE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AMZEEQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ZILXI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecule Stabilizing Technology (MST)&#8482; and MST&#8482;. This report also includes trademarks, service marks and trade names of other companies. Trademarks, service marks and trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are statements that could be deemed forward-looking statements reflecting the current beliefs and expectations of management with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These statements are often identified by the use of words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;until,&#8221; &#8220;if&#8221; and similar expressions or variations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following factors, among others, including any described in the section titled &#8220;Risk Factors&#8221; included in this Quarterly Report on Form 10-Q, could cause our future results to differ materially from those expressed in the forward-looking information:</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully complete a sale or out-license of our minocycline franchise on terms acceptable to us in a timely manner or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully execute our business strategy, including our ability to successfully develop our BETi  platform for immuno-inflammatory diseases;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to raise substantial additional financing to fund our operations and continue as a going concern;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the timing of commencement of future non-clinical studies and clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully complete, and receive favorable results in, clinical trials for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disruptions related to COVID-19 or another pandemic, epidemic or outbreak of a contagious disease, on the ability of our suppliers to manufacture and provide materials for our products and product candidates, initiating and retaining patients in our clinical trials, distribution of our products and business sales execution, operating results, liquidity and financial condition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the regulatory approval process for our product candidates, including any delay or failure in obtaining requisite approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the potential market size of treatments for any diseases and market adoption of our products, if approved or cleared for commercial use, by physicians and patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">developments and projections relating to our competitors and our industry, including competing drugs and therapies, particularly if we are unable to receive exclusivity;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our intentions and our ability to establish collaborations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing or likelihood of regulatory filings and approvals or clearances for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to comply with various regulations applicable to our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to create intellectual property and the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the timing, costs or results of litigation, including litigation to protect our intellectual property, including the matter with Padagis Israel Pharmaceuticals Ltd.; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">our ability to successfully challenge intellectual property claimed by others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">estimates of our expenses, capital requirements, our needs for additional financing and our ability to obtain additional capital on acceptable terms or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our defense of litigation that may be initiated against us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our expectations regarding licensing, business transactions and strategic operations; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our future financial performance and liquidity.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in &#8220;Risk Factors&#8221; and elsewhere in our Annual Report on Form 10-K as well as our other filings made with the Securities and Exchange Commission ("SEC"). Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_13"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Unaudited Condensed Consolidated Financial Statements</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_16"></div><div style="margin-top:3pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. dollars in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNC0xLTEtMS0w_19e9c7de-d1a9-4115-8a23-f5af6bf01bbf">103,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNC0zLTEtMS0w_7d3fc502-056c-4f1f-8667-7631975ccbc4">57,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNS0xLTEtMS0w_4ac4cd80-698b-4155-8b2e-d1d26d7a8679">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNS0zLTEtMS0w_b16c7644-402a-4b42-8ef4-c7206deb0ebb">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities (Note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNy0xLTEtMS0w_7536fe34-c1bd-479b-bb62-173307243e2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNy0zLTEtMS0w_e8ad3f82-6af7-419b-b168-1cc3de202b44">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net of allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfOS0xLTEtMS0w_4f837139-c326-4e64-a830-d895cfc2bd62">10,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfOS0zLTEtMS0w_7b49feb6-5051-41b8-a0fd-3f825f507773">15,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTEtMS0xLTEtMA_347d97d1-ed18-4ab5-b8a7-9c0aaf95331d">5,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTEtMy0xLTEtMA_7f249bbb-709a-43b0-a1c5-1c4b4598adc9">4,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory (Note 7)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTItMS0xLTEtMA_6fb0f9e0-aa42-410f-a232-ea77986d563a">8,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTItMy0xLTEtMA_5868baa6-af8c-45cf-a6e0-b9e27d371cb2">7,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTMtMS0xLTEtMA_9c2ae584-3d96-4813-9379-bb5462192699">128,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTMtMy0xLTEtMA_f610d563-c779-4ef6-8f6f-bc6e34f2dcc8">87,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTQtMS0xLTEtMA_86e5715f-06d3-475c-b1cc-665da7051821">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTQtMy0xLTEtMA_9f0bba90-a0e6-478d-b0db-69d09629db42">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets (Note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTUtMS0xLTEtMA_06bccdf3-b2b4-4ca3-96af-e03ab6864c69">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTUtMy0xLTEtMA_31b6ef4a-fa25-4897-af05-0677c5eb8138">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTYtMS0xLTEtMA_7b627e97-c945-45c2-b531-6840b82841bf">3,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTYtMy0xLTEtMA_2ec414d5-a133-4ea4-89d5-7b346a5d5e9d">4,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTctMS0xLTEtMA_86a8289b-19c2-4167-9baa-9d456cc787c9">133,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTctMy0xLTEtMA_980aa88c-3308-4f1b-b74c-51b93d415713">93,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjEtMS0xLTEtMA_66903bd0-c68b-47fe-9a70-739f8bbfdd3c">10,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjEtMy0xLTEtMA_d4b2e240-6857-49c4-98d0-4340a940e868">4,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses (Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjItMS0xLTEtMA_c31e0eb1-fb76-496d-ad8c-aaacb5e5a255">10,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjItMy0xLTEtMA_6f61f2e2-b106-4699-a911-1cd406afc083">11,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjMtMS0xLTEtMTY4Ng_602d2156-b5b1-4279-8b5b-d0755303da22">33,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjMtMy0xLTEtMTY5MQ_56f73af4-355f-4c91-b0fa-4ba461a61e3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjMtMS0xLTEtMA_5a9bb3b9-9533-48b2-a6f2-abe2b3c76be4">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjMtMy0xLTEtMA_970580d3-06f2-4cbd-9d76-adc17dcdd4cb">4,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities (Note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjQtMS0xLTEtMA_a042fe5b-6ef0-4dae-ad45-29e3c422e04e">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjQtMy0xLTEtMA_6bf94f3c-bcd7-4213-a226-2b1b3f0e71a5">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjUtMS0xLTEtMA_406653d1-af3b-4155-a5ac-c12c1fedec5e">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjUtMy0xLTEtMA_90ddbd45-179b-4971-9022-9d93127f1322">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjYtMS0xLTEtMA_103bc037-9c8e-4991-847e-b5ea84cf3117">57,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjYtMy0xLTEtMA_e3f795ef-8cf9-448c-b736-9de8ccf16a44">21,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for employee severance benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjctMS0xLTEtMA_a3f1e373-b6fb-4cea-8750-e6dddb3a3796">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjctMy0xLTEtMA_37e7df20-5768-44d4-8560-497e2917610d">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities (Note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjgtMS0xLTEtMA_3cde9068-e43f-464c-b30c-07f63ff922ab">812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjgtMy0xLTEtMA_2f8ca954-c70a-4834-aeeb-11b59df3fdfe">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjktMS0xLTEtMA_5cc3f1b5-e0f2-4117-b279-a227d5bdcd5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjktMy0xLTEtMA_b4388d30-b1e5-4db0-b9c2-425943ac628c">33,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:OtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzAtMS0xLTEtMA_f29bfe81-8863-424f-9f3c-6af6c2e80a10">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" name="us-gaap:OtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzAtMy0xLTEtMA_cabaafe5-9359-4ba9-8ca7-e528f3a60fea">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzEtMS0xLTEtMA_3a5eacc4-ade3-4a64-aea5-a74712a8503a">59,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzEtMy0xLTEtMA_e0e3c06c-067a-453d-aa41-d40d0e0d6ff6">56,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 11)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzItMS0xLTEtMA_557164a0-38e9-4069-8975-3665c0ff14e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzItMy0xLTEtMA_93a66ea0-e9ce-4404-99cb-83499109e967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' Equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock: $<ix:nonFraction unitRef="usdPerShare" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzIy_2b3cfcab-9cac-4f6e-8fdc-66e60d5288ff"><ix:nonFraction unitRef="usdPerShare" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzIy_7d887bf1-afbc-4f9a-827e-d7c4658025cf">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzM2_b5c50f3a-b6c5-4216-8e8d-8392f4629677"><ix:nonFraction unitRef="shares" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzM2_d7622f47-04f7-4ed4-b914-eb8a32b83a6d">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2021 and December&#160;31, 2020, respectively; <ix:nonFraction unitRef="shares" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzg1_5df6a45c-d40a-4cda-9645-377bfb928e97"><ix:nonFraction unitRef="shares" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzg1_6cca90ab-2baf-46f3-8d74-a26004e97526"><ix:nonFraction unitRef="shares" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzg1_9cf05cbc-35f9-4f51-acb7-012c9d53fc80"><ix:nonFraction unitRef="shares" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzg1_fff4efc9-4b07-4fb6-bb43-dcf783ddf1b2">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMS0xLTEtMA_c6ddc237-0e1e-4346-836e-b5312063ed7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMy0xLTEtMA_f9a21af7-f5ed-4d00-b18b-bc2a11baa7cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock: $<ix:nonFraction unitRef="usdPerShare" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4XzE5_56e9b572-a891-4eac-8102-2a4448e4440c"><ix:nonFraction unitRef="usdPerShare" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4XzE5_9f494ed9-b898-4c86-b0de-8f7b28096340">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4XzMz_9090f16b-753e-4576-b3c7-dc73c3c7dc87"><ix:nonFraction unitRef="shares" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4XzMz_e9a06499-a5ba-4fa1-b5d7-033854630f99">75,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2021 and December&#160;31, 2020, respectively; <ix:nonFraction unitRef="shares" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4Xzgy_16d3b562-940c-451c-ad10-687f1ecc9f18"><ix:nonFraction unitRef="shares" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4Xzgy_fde61675-e2f2-4055-9a30-678351188ac4">51,511,845</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4Xzg5_185b1923-81e8-470d-8efb-0f68952b1627"><ix:nonFraction unitRef="shares" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4Xzg5_d1b759f6-9d5c-43dc-9520-81f6c8578140">43,205,221</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMS0xLTEtMA_84d1d0b2-963b-4543-a7ad-45c5f9c701ec">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMy0xLTEtMA_8f3b896a-a196-41d0-a5b1-43a98c29e902">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzYtMS0xLTEtMA_e1725ee6-39f1-4a68-bfa9-fa3067b226ee">681,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzYtMy0xLTEtMA_4fa1ac1c-c878-4e7a-8054-28a737e03747">603,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzctMS0xLTEtMA_0f0b1a5b-0f57-4962-bde7-23201cfbc360">606,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzctMy0xLTEtMA_78c6363f-c2d5-457b-b3f1-800a0932b748">566,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Shareholders' Equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzktMS0xLTEtMA_b4034d40-27de-44e2-a9aa-78f7f934bfa2">74,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzktMy0xLTEtMA_fdff644d-7aa5-4ea9-9544-1c2b164c461d">37,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities and Shareholders&#8217; Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNDAtMS0xLTEtMA_c92cc7f4-2a49-44bd-a9eb-339d5a0b9f5f">133,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNDAtMy0xLTEtMA_9b7a8e3c-f210-4f67-bb32-5b478308b1ca">93,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. dollars in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84342aca68b243ada9b41fbbc8cf270b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMy0xLTEtMS0w_f4aaf638-bb30-4b21-a72c-2e52d1722702">3,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dea735dd11c45e69052123ac0c08ca2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMy0zLTEtMS0w_f0b2f0c3-4488-4ea7-8967-1397ee698059">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b27fc8830c2496393ef337b50de9d1d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMy01LTEtMS0w_a14e8573-0e93-493f-a636-51fe4ecf309d">7,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fbd34450c84e6a85650df0d4e02142_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMy03LTEtMS0w_2234604f-58ff-4e7d-aa73-e750d7095598">3,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2debda6fea544c33bd0f7cd7fb0d1eda_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNC0xLTEtMS0w_79c9f034-6789-4781-9c09-1e1e2da4ee8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9554f0529f7f46d3b0d37c39bef0330b_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNC0zLTEtMS0w_b9107611-df85-488e-8917-c231f39dc5e9">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9398115216164c628d93c5faa7c9acae_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNC01LTEtMS0w_2d658133-1c0d-4fb3-a01d-b55ca50c4c62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c6c82cc7d9438c92ca5e369586fa89_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNC03LTEtMS0w_c35a6322-e90a-4c5c-9a61-b398c7c4973f">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i100dc25a3ccc4b50b433b69ea956736e_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNS0xLTEtMS0w_d4d6b87e-1933-4fef-b9d2-6a4b2b5f7eb8">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabf5cabf5d146209830192ebd3a2c01_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNS0zLTEtMS0w_417eda27-7fd2-4b50-a390-cfc1ab1f4461">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53788555bd1f4b04be712a3744df4cc3_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNS01LTEtMS0w_11f6e887-2fcd-4a17-9819-9f41669d085e">525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dc49910e5a5430584764df10f7cf924_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNS03LTEtMS0w_1175b79c-69ea-451c-b25f-f6fe7d0e93c6">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNi0xLTEtMS0w_b95ba77e-8ba7-493f-98e3-9cac24654e74">4,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNi0zLTEtMS0w_1419d0eb-f07a-4b35-becc-04fe504c40ae">11,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNi01LTEtMS0w_8d357f03-9a39-4eb2-ac19-68cf963270d6">8,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNi03LTEtMS0w_3a6b5bf3-3dbc-4933-947e-3cd4fb3af4cd">13,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfOC0xLTEtMS0w_203a5290-df2f-43cc-82fb-edf2aeb3a0f6">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfOC0zLTEtMS0w_a5d17872-b8f5-4894-83ff-f843d7ed4890">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfOC01LTEtMS0w_21097004-b0ef-4106-aeb7-a1713d958a14">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfOC03LTEtMS0w_fa5ebead-3a0a-4ec8-9225-4586d5017a1d">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTEtMS0xLTEtMA_b9bfbc6a-96e0-439e-9b91-ff438252f8a1">6,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTEtMy0xLTEtMA_ace2451b-15fd-43d0-af2c-34934e096d38">13,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTEtNS0xLTEtMA_e026f8c1-710f-446c-84c0-23a4845d059d">12,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTEtNy0xLTEtMA_8effc660-2855-4c61-b6fb-1ae0705893e9">29,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTItMS0xLTEtMA_644530f4-cef1-4d92-880e-62062a3916dd">15,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTItMy0xLTEtMA_35a5d08a-975f-4f01-b1ca-352858d41076">26,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTItNS0xLTEtMA_4ca5a4bf-bdd9-46d8-98f5-ac8dc7a105f5">32,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTItNy0xLTEtMA_b08091c7-2fea-44ce-8722-e7c27c472125">51,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and in-process research &amp; development impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTMtMS0xLTEtMA_780d9719-38f0-4b09-a49f-de95f8d1a73f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTMtMy0xLTEtMA_b966b0b7-8fed-4dfa-bd90-cafdd8dbd903">54,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTMtNS0xLTEtMA_4639bf90-808e-42ec-87d9-dd98e2770ae7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTMtNy0xLTEtMA_52a4a1ec-49dd-429d-b3de-2bbf681e7d22">54,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Stock Right Remeasurement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="vyne:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTQtMS0xLTEtMA_d78d469a-789c-4988-946b-b80e93290ea4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="vyne:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTQtMy0xLTEtMA_21774dce-ef63-4c39-940d-171cf9400fdd">84,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="vyne:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTQtNS0xLTEtMA_560a3ce8-923c-4d8b-b172-255c3dd243bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="vyne:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTQtNy0xLTEtMA_d50d0407-fbd1-40e0-a0f7-e3994e00d270">84,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Operating Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTUtMS0xLTEtMA_da3093bc-0d47-415e-882c-adbebca2833c">22,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTUtMy0xLTEtMA_9ba6be25-4a56-4341-96e9-66291abf5a62">178,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTUtNS0xLTEtMA_ee28bb64-aca5-49d9-a570-e80b42a6f56d">45,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTUtNy0xLTEtMA_0e4f8f07-d75a-4747-837e-141d088c7ecd">220,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTYtMS0xLTEtMA_c9b30233-7a2f-4ed9-93c6-caed568067fd">18,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTYtMy0xLTEtMA_5e8487f0-a849-42e9-9fcd-f859feacafec">167,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTYtNS0xLTEtMA_d0e109b5-58a2-4530-80a5-ded27c7a05b3">38,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTYtNy0xLTEtMA_bbc82b24-2a06-4dac-9af7-2fe1f90dc32b">207,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTctMS0xLTEtMA_ebea6ea3-4863-4e75-b418-bd1aec07c56f">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTctMy0xLTEtMA_bffbabce-6bac-477e-b48f-b2caa516288c">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTctNS0xLTEtMA_0dfa509a-44a0-48ec-80e1-f1c73839043f">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTctNy0xLTEtMA_1af95414-df58-4a3e-976c-e661749eded3">2,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTgtMS0xLTEtMA_abdb68b7-d0e9-4a19-9398-ce13aabc0f65">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTgtMy0xLTEtMA_ed7c77e7-8eb2-4e18-bffc-14cbc745d179">548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTgtNS0xLTEtMA_0fce063a-3ece-478b-8b44-3dcc037216b8">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTgtNy0xLTEtMA_402de31a-2d69-4b37-a6ef-6cf28820562e">1,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss Before Income Tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTktMS0xLTEtMA_6d02801f-1267-4316-9a7a-43b742de2caf">19,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTktMy0xLTEtMA_3e70ac33-c746-427b-9cd3-dbffaaf000ad">167,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTktNS0xLTEtMA_75ae4003-4465-4fb0-afe3-73a82fb8fe4c">40,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTktNy0xLTEtMA_e7ce1836-911f-4122-9fb6-0ae04862331f">207,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjAtMS0xLTEtMA_de98432a-0919-4086-9312-c0cd71905851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjAtMy0xLTEtMA_475b4cdf-9a1d-4810-9fe0-83d0cbffd2f8">259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjAtNS0xLTEtMA_3f51494d-facb-4f97-b0e0-4da967c8a544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjAtNy0xLTEtMA_21f83f9e-b440-49c6-8d99-1a4acdd22a83">259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjEtMS0xLTEtMA_3f4a7d40-0349-4d9d-a2d5-b10325e90325">19,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjEtMy0xLTEtMA_8d1c82c6-93b0-48f3-8e6e-418180a0cf8b">167,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjEtNS0xLTEtMA_252aaa66-7407-4685-9c24-7e482ee9e7ff">40,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjEtNy0xLTEtMA_05e52c25-5a24-4aa3-960d-7b84216b71a9">207,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtMS0xLTEtMA_b258f01f-e1e8-46ce-81a2-9fb70490f0d9"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtMS0xLTEtMA_c84a4c9f-a0ea-4889-9924-174a32091860">0.39</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtMy0xLTEtMA_183aa1ed-1044-4438-aaf1-0d79ca2b287b"><ix:nonFraction unitRef="usdPerShare" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtMy0xLTEtMA_5283bf85-bc7e-409c-a97f-935abc74a022">4.83</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtNS0xLTEtMA_5ffe0b07-7ef6-46b8-9ac2-0be84057f98b"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtNS0xLTEtMA_a362689f-54ea-43ae-81e9-1a9c953ba849">0.81</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtNy0xLTEtMA_c4de9380-7a94-4d84-97b5-55ca28682df5"><ix:nonFraction unitRef="usdPerShare" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtNy0xLTEtMA_d3a49046-5d4a-4e2e-99af-cfa5cc4bc9ad">9.17</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtMS0xLTEtMA_7742f984-459d-4a73-998e-5494ecf6968f"><ix:nonFraction unitRef="shares" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtMS0xLTEtMA_e02b26aa-9b12-4474-bc9f-2f0f145bfa9c">51,411</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtMy0xLTEtMA_0de3337f-039c-4a1e-9dd3-4eb8d49c8c48"><ix:nonFraction unitRef="shares" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtMy0xLTEtMA_98ba314d-a68c-4f9c-8fc0-01be55e6623a">34,663</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtNS0xLTEtMA_8233b164-c75b-48e2-8097-f2f55069b1e0"><ix:nonFraction unitRef="shares" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtNS0xLTEtMA_c499a0a5-febf-4bd7-8039-beaf817f702a">50,162</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtNy0xLTEtMA_af0792ba-fe9a-4642-b00b-e45221e7aed0"><ix:nonFraction unitRef="shares" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtNy0xLTEtMA_f3fbd780-ead4-4e94-adb5-4a90cc51121a">22,656</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. dollars in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfMi0xLTEtMS0w_557f9e59-43fb-4af3-8bbd-75a23a3dc18c">19,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfMi0zLTEtMS0w_63e39a81-eb8c-4379-8ebd-0bb77c441e03">167,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfMi01LTEtMS0w_25a4ae09-7d06-4b16-8e77-998362432da6">40,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfMi03LTEtMS0w_027cd975-2952-4fcf-88a2-a26d84c8366e">207,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Comprehensive Loss:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gains) losses from marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNC0xLTEtMS0w_3ee0f274-1650-4c70-949a-a05bbc82fe03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNC0zLTEtMS0w_548900dc-d82b-46fb-8981-37d465e4414d">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNC01LTEtMS0w_43e99696-5153-4618-947d-528a9ca50b88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNC03LTEtMS0w_dce2d32e-2a71-42bb-96ce-4588992a2268">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Losses on marketable securities reclassified into net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNS0xLTEtMS0w_e1a48a9a-cc4c-4956-ae53-c9d802218b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNS0zLTEtMS0w_836d066b-95ed-427b-94c8-35817ffd6ef8">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNS01LTEtMS0w_9fe8d50e-51c0-46cc-a861-3b61a7db34c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNS03LTEtMS0w_e9272768-a42f-40ef-81e6-399238b055ac">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Other Comprehensive Loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNy0xLTEtMS0w_be0afd21-9dea-41f4-a7db-210ccf5451bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNy0zLTEtMS0w_50935457-cebd-4943-aeec-9a872d5e0b4a">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNy01LTEtMS0w_c1fa8f5c-7689-4a2e-838b-73d57be700d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNy03LTEtMS0w_88b1adc5-d39c-4bd2-9401-fca1ef4370f7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Comprehensive Loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfOC0xLTEtMS0w_2da00c7c-dd12-4665-b6c5-a0f1ea14d022">19,924</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfOC0zLTEtMS0w_72b9f7be-2b1e-4f0f-9bda-a2467dea497e">167,400</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfOC01LTEtMS0w_9d6d7fca-1a80-4a33-a646-0a2bfe665b61">40,474</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfOC03LTEtMS0w_fa34df8a-da96-4a0c-b16e-278a73343431">207,678</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. dollars in thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;padding-right:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">capital</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated deficit</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income (loss)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE AT JANUARY 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i797c66ad7b9c49b5a2ddd97631ae27f5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi0xLTEtMS0w_79f5070c-a060-4b74-b0f0-7e05db5e0147">9,120,078</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797c66ad7b9c49b5a2ddd97631ae27f5_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi0zLTEtMS0w_3336c8a2-dba1-463e-a26e-379e41e2616b">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d3a379e953425a9974062231d7dcd0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi01LTEtMS0w_b06efdf0-de07-4b22-84a8-6a63526f60ce">328,156</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03d13b3790624d87bc0cad0e41052e6d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi03LTEtMS0w_84ea1141-f746-4069-bc88-350007315e1b">310,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedde2720a7af4dba914dd3438edc3894_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi05LTEtMS0w_89d0567d-d24d-45cc-99e6-bed6f5b31c5d">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a3d7596a5a540f69eee45235f538a4b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi0xMS0xLTEtMA_a1063d45-a2d4-4e2f-88aa-372282d6e2f9">17,575</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CHANGES DURING THE PERIOD:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a850254855c4cf1ba7c87d12f8bcf5d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNC03LTEtMS0w_3f1e7457-00c5-431d-8a54-79d58aa83ee1">207,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7abf6f21fe40411c8914385be9741d3f_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNC05LTEtMS0w_0288d5f7-f6ac-459c-a1c9-8565594b3a83">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNC0xMS0xLTEtMA_9af7ebbb-b826-4931-b549-b4f382a27644">207,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7a23cc6461f4ef8bf1b007c53b237f9_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNS0xLTEtMS0w_7a356048-c5d8-407b-b7b8-4be425151f55">258,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNS01LTEtMS0w_8c869c8a-885b-4842-aa75-c2a98a978bc4">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNS0xMS0xLTEtMA_ba87f639-467d-4711-bfe3-922d74c9c584">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNi01LTEtMS0w_dd401b6e-de73-4641-a7c0-0894c8a73834">12,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNi0xMS0xLTEtMA_933e277c-fb39-4e6b-a3b8-8d58b621eca5">12,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deemed dividend to warrants holders due to warrant modifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630" decimals="-3" sign="-" name="vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNy01LTEtMS0w_b7b3ce8f-f7c5-406c-8249-b3c031e75f4b">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a850254855c4cf1ba7c87d12f8bcf5d_D20200101-20200630" decimals="-3" name="vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNy03LTEtMS0w_41c92940-4f07-4f05-9738-a28003ceb03e">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNy0xMS0xLTEtMA_c0260189-ad32-4c25-a978-daf389825c3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classification of stock awards to derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630" decimals="-3" name="vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOC01LTEtMS0w_3b7e8514-fba2-40a4-bff3-36473e5b2111">975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOC0xMS0xLTEtMA_588e816e-5adb-41ad-be39-00c4e914dfd7">975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock through a public offering, net of $<ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0wLTEtMS02My90ZXh0cmVnaW9uOjY2NjljYzY5MGExODQ4Njg5YzhiMjAwODIwOTRiMGRlXzEwOTk1MTE2Mjc4NjY_222dbbf0-71d4-4b26-b3cd-dcdc24f1a6c1">3,903</ix:nonFraction> issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ff10b2c08844eabaa679bba7720742e_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0xLTEtMS00NQ_28aa4988-d9b0-4b13-9cd3-ebbba0df2264">7,776,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a23cc6461f4ef8bf1b007c53b237f9_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0zLTEtMS00OA_70bebc60-9006-40fd-8bf1-4243d9211820">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6791bfcf14401e94eb092718e67ad9_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS01LTEtMS01MQ_cfbfeb2f-9784-4fd6-8699-bb48c0659c63">53,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ade32f44d84447498707d4ecef4407a_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0xMS0xLTEtNjA_44666c9f-ce9a-4f64-ac77-b4c82c68d688">53,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock related to merger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7a23cc6461f4ef8bf1b007c53b237f9_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0xLTEtMS0w_f668b0a7-2902-4d8b-9eeb-b106cffcba8b">24,765,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a23cc6461f4ef8bf1b007c53b237f9_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0zLTEtMS0w_21656225-d117-4735-8b66-c4f354af1939">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS01LTEtMS0w_86569afe-94dd-4db9-b1ce-a804553c5e85">196,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0xMS0xLTEtMA_9fb807bf-1709-47ee-b264-7dc813a358ab">196,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE AT JUNE 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd67e51186d44f0aa1480b690576bb0d_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtMS0xLTEtMA_a2c9563e-8c4a-49d9-abc0-efb51a3c03d5">41,920,952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd67e51186d44f0aa1480b690576bb0d_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtMy0xLTEtMA_dcd9b355-0821-4c5d-80c5-c47278f5f1fc">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f9738453474c059f491621e59dc79b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtNS0xLTEtMA_7ee7588e-bade-49b2-a84c-9eedd5b2e708">589,825</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f2fa509856a406c9e42f24a5f55ac1e_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtNy0xLTEtMA_fe3371cb-8346-448d-aa04-97fcfaeb495f">518,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie50700e6e0f1422a89d1383e91db69f6_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtOS0xLTEtMA_80fac675-45ce-4d38-97cf-a55018626d7f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtMTEtMS0xLTA_97b412ee-ac22-4b7c-85f9-582b8eb9f774">71,528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE AT JANUARY 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f29689ea1944eedbbcf9400e04d7ef0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTItMS0xLTEtMA_fde6f359-be00-428d-a3a8-001d0f2e4b1b">43,205,221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f29689ea1944eedbbcf9400e04d7ef0_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTItMy0xLTEtMA_6debd325-dbbb-4608-b396-d155af32bdbc">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee26fdc1fa14f05a6f311e845ab576b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTItNS0xLTEtMA_ac29c3bb-5280-42b1-b27b-8d358841f957">603,685</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4227e51ef1044e2b823e33b150d24f26_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTItNy0xLTEtMA_2c3ce29f-9122-40e0-a193-5c927b7e5556">566,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTItMTEtMS0xLTA_550a4e28-45a8-495c-a762-efb4a7035e73">37,493</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CHANGES DURING THE PERIOD:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if02af391415841e4b82ed9d48c82edc3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTQtNy0xLTEtMA_97bdb0e8-a3a2-4982-9f0f-d0586950d0fc">40,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTQtMTEtMS0xLTA_3dd0b57d-efd9-4711-b758-813883afb8f7">40,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fbd72aac51444cc8e66833339c2e2f3_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTUtMS0xLTEtMA_f29f970f-4687-4d49-a069-cb3412a3a425">254,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda95e6e7c234d489db3397bca35bb75_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTUtNS0xLTEtMA_438cf187-d889-4e19-99b2-4b486d5daf8f">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTUtMTEtMS0xLTA_e801deba-312c-488e-a392-432e20ca7369">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda95e6e7c234d489db3397bca35bb75_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTYtNS0xLTEtMA_a976852a-64e3-4d50-adb7-517f68739f4e">4,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTYtMTEtMS0xLTA_e63cff2d-e14e-4e79-b5cf-4fba2a5cf7d0">4,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock under at-the-market offering, net of $<ix:nonFraction unitRef="usd" contextRef="i2b6eb2e10a04475ab11b11c04ece8082_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTctMC0xLTEtMC90ZXh0cmVnaW9uOjBlODJiNGI0M2RmYTQzZWY4MmMwMjlmZDIyODY5OWZmXzY2_9c77193c-2d51-4bcf-afe3-5ebac64ffe9f">814</ix:nonFraction> issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb4b5e3e1eb74f53b54afa625f0fd048_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTctMS0xLTEtMA_5f4f0977-4855-4296-ac36-57a04eada0b8">2,778,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d5a2a3933f4cfbbb3fbb51c20df06d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTctNS0xLTEtMA_53f089c1-3435-4ab6-9aef-b7c02e840409">26,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6eb2e10a04475ab11b11c04ece8082_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTctMTEtMS0xLTA_f0cfc22d-f6f1-43f7-b189-d8538077007f">26,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock through a registered direct offering, net of $<ix:nonFraction unitRef="usd" contextRef="i22fcfd7ed9a543ddb72129476634c780_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTgtMC0xLTEtMC90ZXh0cmVnaW9uOmEyY2E0MjlmYzI1OTQ0NTI4ODY4NDAwOWMwZjQ3NzkwXzc0_220daa08-569f-4e36-a975-e6c9256966b4">3,177</ix:nonFraction> issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78735453789f4a8abdc6053070d56b14_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTgtMS0xLTEtMA_8ba90271-bca7-4bb2-a013-efd350a3f357">5,274,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fbd72aac51444cc8e66833339c2e2f3_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTgtMy0xLTEtMA_83b01551-5597-4a16-9d38-9ad95b4b072b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e7f7d4ebf643ee959c05a474f9c948_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTgtNS0xLTEtMA_8953d83b-83bf-4334-b337-914bacbf3807">46,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22fcfd7ed9a543ddb72129476634c780_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTgtMTEtMS0xLTA_a77b12f8-26e4-4a0b-ad08-c4d0914bd1d0">46,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE AT JUNE 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia694da22cf534b119d5bfa52040066d2_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTktMS0xLTEtMA_10455f01-872a-4d3c-b3d3-13667dec8c94">51,511,845</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia694da22cf534b119d5bfa52040066d2_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTktMy0xLTEtMA_5f4841a4-fcbb-41dc-846b-ce8925c3df81">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b04039f72414cc68135a0028a7ebd45_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTktNS0xLTEtMA_fe4565f8-9d26-49fb-b9f6-e01b1a986dd0">681,558</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc3c6f2f161a493b8e5395bce6f28971_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTktNy0xLTEtMA_e405f15e-f86f-4691-bba0-1dd8044a19fc">606,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTktMTEtMS0xLTA_991d3664-ee61-41b1-9aba-9cb0db362400">74,893</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_28"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. dollars in thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;padding-right:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">capital</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated deficit</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income (loss)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE AT APRIL 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c74f98bea814d89ae592c883580eba5_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi0xLTEtMS0zMg_d96e89d8-2787-4a33-862e-baf04f04b7ff">15,375,282</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c74f98bea814d89ae592c883580eba5_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi0zLTEtMS0zMg_1f19ef07-7568-45d5-a7dc-480617ab269f">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44747ec4fa294f50a7469563ddcbafeb_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi01LTEtMS0zMg_ee77a6b3-7c70-46e8-adc4-640b9b417033">420,434</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad82d516ac8944c3ab74858aecd5b316_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi03LTEtMS0zMg_223f5a8d-0f9f-4b36-9ae7-c7a6b9c16fce">350,861</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1755861e14c849d2a5109ccface73c4d_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi05LTEtMS0zMg_2723d211-8433-4a8a-b82c-1046facaf43e">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8e978d00c845e78cd00eaea3509c91_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi0xMS0xLTEtMzI_0999333f-8710-4484-a3b6-056615496fbd">69,535</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CHANGES DURING THE PERIOD:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a34e2be4ddc40a287e56721af2404d1_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNC03LTEtMS0zMg_1ed3087e-f261-447f-bc2b-70c0becdcb93">167,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78a66c4d2a848feb68215cc74cf142d_D20200401-20200630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNC05LTEtMS0zMg_a1dad459-8ba8-4eb2-bf8d-a01571989d23">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNC0xMS0xLTEtMzI_daaa1b07-6d3a-4492-9778-829dc7213692">167,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c0c1b558463459aaba416b532ab05b9_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNS0xLTEtMS0zMg_6fb56afc-95e3-4691-a6b4-ee7451135710">132,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f66d5268c24630ad030416639966ce_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNS01LTEtMS0zMg_510c0e86-8afd-4e15-9b05-12c631d16d75">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNS0xMS0xLTEtMzI_6735b8ba-7e0a-4cbd-8441-8079d02af7e3">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f66d5268c24630ad030416639966ce_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNi01LTEtMS0zMg_c42fa6cf-05aa-4d07-8a12-ce8bfc3fe3ad">10,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNi0xMS0xLTEtMzI_86b0e907-319d-47e2-806b-6dbfb8adea11">10,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classification of stock awards to derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f66d5268c24630ad030416639966ce_D20200401-20200630" decimals="-3" sign="-" name="vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNy01LTEtMS0zMg_610196c4-2f0d-4764-a958-09f211b50d35">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" name="vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNy0xMS0xLTEtMzI_ee43be82-4a47-43f4-adff-4e361b9acca1">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock through a public offering, net of $<ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOC0wLTEtMS0xMzgvdGV4dHJlZ2lvbjo1ZDcwZGI2YWM1ZjI0N2U3YjM0N2NjZjkyNGEzZDhkNl8xMDk5NTExNjI3ODY2_222dbbf0-71d4-4b26-b3cd-dcdc24f1a6c1">3,903</ix:nonFraction> issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ba6c46ad1554816bcc03cae4a40ea5e_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOC0xLTEtMS0zMg_b88023d1-d916-4e0d-97c2-3f8d5c2407ca">7,776,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0c1b558463459aaba416b532ab05b9_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOC0zLTEtMS0zMg_885a3d8e-2b2a-4027-8980-93dbff46d5d6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1751f8eb9f24fd8843cb5ad13f6a9e7_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOC01LTEtMS0zMg_5a327701-9be5-419b-a01e-022de9dd429c">53,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5741436efcf7422d8c1efec1a5674e74_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOC0xMS0xLTEtMzI_a020899b-5e00-402b-8469-25cda9d60b84">53,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock related to merger</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c0c1b558463459aaba416b532ab05b9_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOS0xLTEtMS0zMg_f8454389-09fc-49d7-bbe9-25a2ea3a3bd4">18,636,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0c1b558463459aaba416b532ab05b9_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOS0zLTEtMS0zMg_bf4029e3-e825-4f4e-a59a-d3fb07600ad5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f66d5268c24630ad030416639966ce_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOS01LTEtMS0zMg_3d4ffa73-ab7f-4f17-8d62-33e2e0e071ae">104,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOS0xMS0xLTEtMzI_41d8a218-8bca-460d-ba98-89a5c41076a3">104,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE AT JUNE 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd67e51186d44f0aa1480b690576bb0d_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtMS0xLTEtMzI_185c90b1-068a-4b39-be15-02fe7ddd899a">41,920,952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd67e51186d44f0aa1480b690576bb0d_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtMy0xLTEtMzI_e324ef39-5db5-49f6-85ff-712726fa94ad">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f9738453474c059f491621e59dc79b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtNS0xLTEtMzI_521f89f9-f56c-42b0-a169-c72d7e32bc47">589,825</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f2fa509856a406c9e42f24a5f55ac1e_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtNy0xLTEtMzI_a1083b87-dee5-4e11-855c-118fae1b7646">518,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie50700e6e0f1422a89d1383e91db69f6_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtOS0xLTEtMzI_49978a08-aec1-4601-a6dc-6b430f0b6e8c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtMTEtMS0xLTMy_71f3a45a-dc1b-4615-8e1b-af3eebbb83b2">71,528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE AT APRIL 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ba9266a3f21470b9aea71eb689ca61e_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTItMS0xLTEtMzI_21c94fae-ed90-4bd5-bdca-03635c72c252">51,386,596</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba9266a3f21470b9aea71eb689ca61e_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTItMy0xLTEtMzI_e50c65d1-19e3-4838-9009-65c5b22fb347">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425a84c0240f40dfb5087d836e1a583b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTItNS0xLTEtMzI_d9412b2e-3743-44a5-93ab-e0d93809ca30">679,642</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb79d419a25c4a54bd7d489adc952e95_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTItNy0xLTEtMzI_2c88997f-9281-46f9-a943-57bbb733e999">586,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dff1b7af5184588b64b59aa4e8c1aa3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTItMTEtMS0xLTMy_9fcf2550-b659-47dd-b633-9feebc088ec1">92,901</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CHANGES DURING THE PERIOD:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Comprehensive loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib29bbbec2a784133904ebf772b749830_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTQtNy0xLTEtMzI_2c6cc73b-365c-4e38-b549-bb7ae4a66962">19,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTQtMTEtMS0xLTMy_3086e1d3-ee0a-422f-8a6d-4365d474c6ab">19,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica61d474584c4143988ae02e9fa3856a_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTUtMS0xLTEtMzI_01dcda0a-a3b5-4e92-8dca-e748e25c3c2f">125,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e633a691ef420b992fc44538fdc8a7_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTUtNS0xLTEtMzI_feb55282-d219-4cb3-8325-9810ca7a286c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTUtMTEtMS0xLTMy_b8890b37-f4ec-4715-aa45-204b9d230690">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e633a691ef420b992fc44538fdc8a7_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTYtNS0xLTEtMzI_323a97e7-80a9-4010-8979-4e7bf083bb84">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTYtMTEtMS0xLTMy_1bc9b6ce-9910-41a7-9e07-7c0cb68efd6b">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE AT JUNE 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia694da22cf534b119d5bfa52040066d2_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTktMS0xLTEtMzI_9731c83a-2fda-47e7-b7dd-7616e5e2d685">51,511,845</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia694da22cf534b119d5bfa52040066d2_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTktMy0xLTEtMzI_8d7cbbbb-56c7-4768-a9ab-bdb7dc8cb825">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b04039f72414cc68135a0028a7ebd45_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTktNS0xLTEtMzI_08b9c4e4-0c50-4e54-b0fa-58efb206ce64">681,558</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc3c6f2f161a493b8e5395bce6f28971_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTktNy0xLTEtMzI_8e72b4c5-524d-4b2d-9e5a-21da912ad487">606,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTktMTEtMS0xLTMy_8f025613-a24d-426d-8b43-f9cbadcb7c2f">74,893</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VYNE THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(U.S. dollars in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMy0xLTEtMS0w_4a866e72-7c7d-4adb-9040-5f15a5ec890a">40,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMy0zLTEtMS0w_5254cbe5-570d-4192-8f2b-25fb222dea2f">207,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments required to reconcile net loss to net cash used in</span></div><div style="padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNS0xLTEtMS0w_25893ac4-a115-4d8a-910f-1f9d1721c2a2">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNS0zLTEtMS0w_b851d970-a398-4e34-88aa-9a4dcc5eb401">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and in-process research &amp; development impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNi0xLTEtMS0w_d6867db1-d8e4-411e-b6a4-7cba76b6d0eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNi0zLTEtMS0w_e15e6152-7372-4a41-a8e8-2505138623db">54,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent stock right remeasurement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="vyne:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNy0xLTEtMS0w_0798da1a-9c38-4b37-9cc1-8fade65daa04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="vyne:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNy0zLTEtMS0w_1c8a876c-8b98-44ea-be71-89c9ee762219">84,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in marketable securities and bank deposits, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfOS0xLTEtMS0w_90ec903a-69a2-4f57-b90d-0196a971b23d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfOS0zLTEtMS0w_bd8ea882-bd1e-4d90-831c-d62a68b1493e">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in accrued liability for employee severance benefits, net of retirement fund profit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" name="vyne:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTAtMS0xLTEtMA_3446b69f-879d-4681-aa2f-782123270e2e">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" name="vyne:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTAtMy0xLTEtMA_1d056cfc-7279-4346-8381-25dc3215d05b">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTEtMS0xLTEtMA_972c4d64-4374-4a21-b243-c8bd7729df47">4,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTEtMy0xLTEtMA_22793730-0fee-4060-afc7-e9dceed22c63">12,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash finance income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTItMS0xLTEtMA_c45f9d81-2389-4fb0-9230-15f2d9fe6808">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTItMy0xLTEtMA_9d2c1d99-4fc6-4c8c-8d1e-f3f111c6e05f">833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effects of businesses acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decrease (increase)  in trade receivables, prepaid and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTQtMS0xLTEtMA_e51ed8c0-6225-4efa-ac74-87410ee2fbe9">4,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTQtMy0xLTEtMA_c27e1fe0-7980-4a19-887e-dce453a347b9">9,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decrease (increase) in other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTUtMS0xLTEtMA_88575303-aa39-478d-a2d4-49c284e29eb4">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTUtMy0xLTEtMA_4ba9ce6d-7810-40a5-b16e-f2f46496290b">6,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase (decrease) in accounts payable and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTYtMS0xLTEtMA_d6ee2501-a065-42f1-8341-247cffa86afe">3,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTYtMy0xLTEtMA_c416a56a-b50d-4a11-a2c7-af85bde13a7c">10,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTctMS0xLTEtMA_92d44cb1-9fdf-469e-9503-cb4483cd6478">875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTctMy0xLTEtMA_bc82f7b1-98da-412b-820b-454df31d96d8">4,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTgtMS0xLTEtMA_bc187eb9-0bb1-42ea-a924-1eed5609249d">28,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTgtMy0xLTEtMA_592584d7-8331-43c9-80a2-032dcf3dbc2e">88,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjAtMS0xLTEtMA_537b2fbb-718d-4a55-a55b-e73e79ab4fce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjAtMy0xLTEtMA_15336a83-9467-4c45-848e-704c56f600fa">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash acquired through merger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="vyne:ProceedsFromBusinessMerger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjQtMS0xLTEtMA_5e3e6fbf-7a54-4c41-85ed-615e504df777">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="vyne:ProceedsFromBusinessMerger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjQtMy0xLTEtMA_cc33bdc2-dcfd-418c-8fc2-2e738a36f055">38,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale and maturity of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjUtMS0xLTEtMA_bc25472d-f84f-4853-9fcc-ff9843ac217f">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjUtMy0xLTEtMA_a957e76e-b996-4711-8cb5-a96d8b03b65e">48,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjYtMS0xLTEtMA_2fac94d8-81e2-4703-9f05-3a27370cf93a">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjYtMy0xLTEtMA_3f81f25e-3e91-424c-b1b1-3f468c5d8a84">87,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds related to issuance of common shares through offerings, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjgtMS0xLTEtMA_e441dc7e-eefa-4a86-ac7e-6d6053d8e0b7">73,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjgtMy0xLTEtMA_fcb7925a-74a5-4e7d-be22-89dadffb11dc">53,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds related to issuance of stock for stock-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzAtMS0xLTEtMA_42c660cc-e953-4f7f-80ea-80105d319bb9">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzAtMy0xLTEtMA_98097883-a4ec-4172-8b3d-49070d095b09">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzEtMS0xLTEtMA_36623c34-340a-4cb4-a729-bf2293d1fffa">73,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzEtMy0xLTEtMA_ddbac837-e43c-4d20-b357-670a9670d67e">53,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzItMS0xLTEtMA_3fba2631-1e9d-4ced-a2f4-c303d2269d83">45,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzItMy0xLTEtMA_b4eb0239-8b73-4513-8d4c-133eb206484a">52,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of exchange rate on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzMtMS0xLTEtMA_268a4b87-9c75-486b-ad75-6825c3f213da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzMtMy0xLTEtMA_8f648159-2320-4ab3-9db0-63cb64010721">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash at beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzQtMS0xLTEtMA_e57f73f7-fb1c-4339-ac39-9f6ab18ff83a">58,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a3d7596a5a540f69eee45235f538a4b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzQtMy0xLTEtMA_b5c90992-5c72-4cce-b6db-bb12e1558306">44,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash at end of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzUtMS0xLTEtMA_cffda923-04e5-40b9-aaeb-dbf186a819d2">104,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzUtMy0xLTEtMA_4b93c93f-175d-40c9-a8dd-8de1e375ef76">97,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzYtMS0xLTEtMA_e2e84b8e-9202-4998-aabe-2e8a2eba81ae">103,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzYtMy0xLTEtMA_3767c3d7-8558-4d35-8558-46df2539b5fb">96,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzctMS0xLTEtMA_3b3784e2-9536-452c-9d65-9bfcd8eed3a5">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzctMy0xLTEtMA_44ea6c5f-3aca-428e-8eaf-91bf996fd923">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total cash, cash equivalents and restricted cash shown in statement of cash flows</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzgtMS0xLTEtMA_b2508ba0-528e-4aaf-a424-422f87646a9d">104,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzgtMy0xLTEtMA_8b484371-ad05-4f2d-9c14-42f77424f6a1">97,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplementary information on investing and financing activities not involving cash flows:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cashless exercise of warrants and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under employee stock purchase plan</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDEtMS0xLTEtMA_931b533f-94ac-4eb7-afff-35c2ffa89d83">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDEtMy0xLTEtMA_18c98214-11df-4bec-9a44-88dbcf09fc1d">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to operating lease right of use assets</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDItMS0xLTEtMA_c2a5769d-89c9-425d-bc02-a01467956eba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDItMy0xLTEtMA_5be62ff7-a823-4c4e-8b41-e81bee392a18">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalLeaseObligationsIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDMtMS0xLTEtMA_aa2b167f-309b-4f57-8e4b-ff1a7265b4f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalLeaseObligationsIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDMtMy0xLTEtMA_f1058bfb-90f5-46d5-84df-6c29d95132a7">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest received</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" name="vyne:InterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDYtMS0xLTEtMA_1226896f-81ac-4289-b6cc-46f78163f802">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" name="vyne:InterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDYtMy0xLTEtMA_c1bbfff5-fd4d-46cb-8b5d-b40685a289e8">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDctMS0xLTEtMA_eb7bf17b-5520-4565-a258-b0a2f56a88a3">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDctMy0xLTEtMA_1a721954-d7ec-41a3-9db5-28b3934f000c">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDktMS0xLTEtMA_689f4df8-6d10-4d78-818c-aa7529e5244f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDktMy0xLTEtMA_98f427b8-bb05-426c-a8ad-b9ac80c75019">117,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTAtMS0xLTEtMA_8e73422f-ed75-4bb4-9fc4-f07129c5fb5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTAtMy0xLTEtMA_537e7d01-f3f7-4514-8cda-1a303ef68cd8">5,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net acquired (See &#8220;Note 3- Business combination&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTEtMS0xLTEtMA_9d09f0e5-2e27-4865-9284-a66dba8b27c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTEtMy0xLTEtMA_283d3225-883e-492e-8c9e-3465db301305">111,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="vyne:NonCashAcquisitionOfBusinessCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTItMS0xLTEtMA_d4627c6e-e7f9-46cf-a976-c60f81bf1af8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="vyne:NonCashAcquisitionOfBusinessCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTItMy0xLTEtMA_1eeb9a62-ec60-48ea-a52b-47334c2a7349">38,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merger net of cash acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="vyne:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTMtMS0xLTEtMA_cce8a857-2438-40ab-8d0d-a18bb355e1bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="vyne:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTMtMy0xLTEtMA_a567790c-d2a1-43c8-9f9f-4621535db94d">72,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Represents an amount less than one thousand</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VYNE Therapeutics Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_37"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1 - <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMTA4ODU_1057b06b-5911-44e7-b4d6-56ec220ede03" continuedAt="ief265cbf70c946329c22cff42bed80ab" escape="true">NATURE OF OPERATIONS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ief265cbf70c946329c22cff42bed80ab" continuedAt="i0ff8b96183434f03b7c561676539dd2b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VYNE Therapeutics Inc. ("VYNE" or the "Company") is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory diseases of high unmet medical need. The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as&#160;<ix:nonFraction unitRef="segment" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfNDMy_a85b6248-8187-4be9-99a2-fdff608917f1">one</ix:nonFraction>&#160;business segment. The Company currently has two commercial products, AMZEEQ&#174; (minocycline) topical foam, 4%, and ZILXI&#174; (minocycline) topical foam, 1.5%. As discussed below, the Company has initiated a process to explore a possible sale or license of its topical minocycline franchise. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Business Review</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2021, the Company conducted a review of its commercial and research and development portfolio to determine how to optimally deploy capital and drive shareholder value. During the course of this review, the Company carefully considered the revenues received from the commercialization of AMZEEQ and ZILXI and the associated costs to drive those revenues, the protracted negative impact of the COVID-19 pandemic over the past 18 months during the commercial launches of both AMZEEQ and ZILXI, the current payor landscape, as well as the costs to develop each of its pipeline products. During this process, the Company evaluated several strategic options including the acquisition of marketed assets, out-licensing its approved products outside of the United States, and possible partnering or co-development relationships with interested parties. Following its review, the Company has determined to initiate a process to explore a possible sale or license of its topical minocycline franchise, including AMZEEQ, ZILXI, FCD105 (the Company&#8217;s Phase 3 proprietary novel topical combination foam formulation of minocycline and adapalene for the treatment of moderate-to-severe acne vulgaris) and the underlying Molecule Stabilizing Technology platform. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By leveraging its drug development and clinical development capabilities and strong network of discovery and preclinical science partners, the Company will transition its strategic focus to develop therapies for the treatment of immuno-inflammatory diseases of high unmet medical need. The Company expects to continue to invest in FMX114 for the treatment of mild to moderate atopic dermatitis and anticipates the first patient in its Phase 2a proof-of-concept study will be enrolled in the third quarter of 2021. The Company expects results from this study by the end of 2021. In addition, on August 12, 2021, the Company announced a transaction with In4Derm Limited, a company incorporated and registered in Scotland (&#8220;In4Derm&#8221;). In4Derm is a spin-out of the University of Dundee&#8217;s School of Life Sciences which has discovered and is developing proprietary Bromodomain and Extra-Terminal Domain Inhibitors (&#8220;BETi&#8221;) for the treatment of immunology and oncology conditions. On April 30, 2021, the parties entered into an Evaluation and Option Agreement (the &#8220;Option Agreement&#8221;) pursuant to which In4Derm granted the Company an exclusive option to obtain exclusive worldwide rights to research, develop and commercialize products containing In4Derm&#8217;s BETi compounds, which are new chemical entities, in both topical (the &#8220;Topical BETi Option&#8221;) and oral (the &#8220;Oral BETi Option&#8221;) treatments in all fields for any disease, disorder or condition in humans. On August 6, 2021, the Company exercised the Topical BETi Option and the parties entered into a License Agreement granting the Company a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of In4Derm&#8217;s BETi compounds identified to be suitable for topical administration in all fields. The Company paid a $<ix:nonFraction unitRef="usd" contextRef="ie36f0645785e4cabba23e0ebc501434b_D20210806-20210806" decimals="-5" format="ixt:numdotdecimal" name="vyne:PaymentsForLicensingAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMTA5OTUxMTY3MTY1OA_2186a4be-8313-4c36-86e0-68ce3d72053b">1.0</ix:nonFraction>&#160;million cash payment to In4Derm upon the execution of the Option Agreement and $<ix:nonFraction unitRef="usd" contextRef="i833be515ce11411f87485dfaea471f94_D20210806-20210806" decimals="-5" format="ixt:numdotdecimal" name="vyne:PaymentsForLicensingAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMTA5OTUxMTY3MTUzMA_6fec7139-df9d-422c-818e-020488b75fa0">0.5</ix:nonFraction> million in connection with the exercise of the Topical BETi Option. Pursuant to the License Agreement, the Company has agreed to make cash payments to In4Derm upon the achievement of specified clinical development and regulatory approval milestones with respect to each licensed topical product in the U.S. of up to $<ix:nonFraction unitRef="usd" contextRef="i833be515ce11411f87485dfaea471f94_D20210806-20210806" decimals="-4" format="ixt:numdotdecimal" name="vyne:MilestonePaymentsUponAchievingCertainCriteriaMaximum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTExOTYzMw_d773d401-709b-4475-9582-49185b725b22">15.75</ix:nonFraction>&#160;million for all indications. In addition, the Company currently expects to exercise the Oral BETi Option following the selection of a lead candidate for the program. Upon exercise of the exclusive Oral BETi Option, the parties will sign a license agreement (the &#8220;Oral License Agreement&#8221;), and the Company will be required to pay In4Derm a $<ix:nonFraction unitRef="usd" contextRef="i6fcd46d67d92482a938a2ff751b727d8_D20210806-20210806" decimals="-5" format="ixt:numdotdecimal" name="vyne:PaymentsForLicensingAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMTA5OTUxMTY3MTU2OQ_c1ee09e4-4d9f-444f-92f7-6a06ce831bde">4.0</ix:nonFraction>&#160;million cash payment. The Oral License Agreement will include cash payments of up to $<ix:nonFraction unitRef="usd" contextRef="i6fcd46d67d92482a938a2ff751b727d8_D20210806-20210806" decimals="-4" format="ixt:numdotdecimal" name="vyne:MilestonePaymentsUponAchievingCertainCriteriaMaximum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTExOTY0OQ_afd0b587-e66f-4622-b54a-b1fbd96eb1cb">43.75</ix:nonFraction> million payable to In4Derm upon the achievement of specified clinical development and regulatory approval milestones with respect to each licensed oral product in the U.S. for all indications. The license agreements also provide for tiered royalty payments of up to <ix:nonFraction unitRef="number" contextRef="i3a4133507eae4a3293528a38e4dc4312_I20210806" decimals="2" name="vyne:RoyaltyPaymentPercentMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMTA5OTUxMTY3MTYwMQ_f4e7d058-eb8e-42d1-9019-13f86997f196">10</ix:nonFraction>% of net annual sales across licensed BETi products by the Company. In4Derm is entitled to additional milestones upon the achievement of regulatory approvals in certain jurisdictions outside the U.S. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial BETi candidates that the Company plans to develop are VYN201 and VYN202. VYN201 is a pan-bromodomain or pan-BD BET inhibitor.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is a first-in-class &#8220;soft&#8221; pan-BD BET inhibitor that is designed to mitigate systemic drug exposure and will be developed for topical applications. The Company intends to progress VYN201 into rare, neutrophilic, dermatological </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i0ff8b96183434f03b7c561676539dd2b" continuedAt="ie7a3f8fdde7a466596df3bb0e9f31afc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indications where there is significant unmet need due to a lack of indicated treatment options. The Company plans to enter this program into the clinic in 2022 after the prerequisite non-clinical safety assessments have been completed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second candidate, VYN202, is an orally-delivered, first-in-class BET inhibitor that is highly selective for Bromodomain 2 ("BD2"). Recent research has suggested that the majority of pro-inflammatory signaling via BET protein action is via interactions with BD2. By selectively inhibiting BD2, the Company believes VYN202 could have a more targeted anti-inflammatory effect with an improved benefit/risk profile. The Company views VYN202 as having significant potential as a novel, oral treatment for major immuno-inflammatory indications. Following the exercise of the Oral BETi Option, the Company intends to commence a IND-enabling non-clinical safety program for VYN202 and enter the clinic in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company transitions from a commercial organization to one focused on research and development, the Company intends to streamline operations by eliminating the vast majority of planned expenditures supporting its commercial operations. Furthermore, the Company intends to reduce its workforce by terminating approximately <ix:nonFraction unitRef="employee" contextRef="i4a701835f72e475097f033580f5deea7_D20210101-20211231" decimals="INF" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTExODcyOQ_9d24e302-b2cc-4a5d-8462-1cdb444e4417">70</ix:nonFraction> employees, which the Company expects to be completed by December 31, 2021. The Company expects to incur a one-time charge in the range of approximately $<ix:nonFraction unitRef="usd" contextRef="ibace252288db423ca83fb8257a0d36f9_I20210930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMzg0ODI5MDc0NTY2OQ_ce1447a2-9598-4ec6-b232-d2c6f1fdd513">1.5</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i20cbba757ccb4615a4d0cfe3c3f988dd_I20210930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMzg0ODI5MDc0NTY3Ng_5582bfd0-d3bb-498e-b711-05d098e87bd2">2.0</ix:nonFraction>&#160;million, excluding non-cash charges, in connection with this restructuring plan, consisting primarily of employee termination costs, including severance and other benefits. This charge is expected to be incurred during the quarter ending September 30, 2021 with related cash payments expected to be substantially paid out by December 31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Merger</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2019, Menlo, Foamix Pharmaceuticals Ltd. (&#8220;Foamix&#8221;) and Giants Merger Subsidiary Ltd. (&#8220;Merger Sub&#8221;), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the &#8220;Merger Agreement&#8221;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the &#8220;Merger&#8221;) on March 9, 2020 (the &#8220;Effective Date&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#8217;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See &#8220;Note 3 &#8211; Business Combination&#8221; for more information on the Merger.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse stock split and recasting of per-share amounts</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2021, the Company's Board of Directors approved a one-for-four reverse stock split of its outstanding shares of common stock.  The reverse stock split was effected on February 12, 2021, at 5:00 p.m. Eastern time.  At the effective time, every four issued and outstanding shares of the Company's common stock were converted into one share of common stock.  No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each stockholder holding fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company's transfer agent in an amount equal to such stockholder's respective pro rata shares of the total net proceeds from the Company's transfer agent sale of all fractional shares at the then-prevailing prices on the open market.  In connection with the reverse stock split, the number of authorized shares of the Company's common stock was also reduced on a one-for-four basis, from <ix:nonFraction unitRef="shares" contextRef="if12e854e598f4a50aee8bc4d0c1ba30d_I20210211" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjU0OQ_02bac963-578a-4583-8b77-13bb8e27f29f">300</ix:nonFraction> million shares to <ix:nonFraction unitRef="shares" contextRef="i4ed43e98e5c24ad3a531ae837852997f_I20210212" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjU2Mg_0fd6f62b-db5d-4bbd-995e-b5a4aabdf691">75</ix:nonFraction> million shares.  The par value of each share of common stock remained unchanged.  A proportionate adjustment was also made to the maximum number of shares issuable under the Company's 2019 Equity Incentive Plan, 2018 Omnibus Incentive Plan and 2019 Employee Share Purchase Plan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise noted, all common shares and per share amounts contained in the unaudited interim condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topical Minocycline Franchise</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company launched AMZEEQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the U.S. Food and Drug Administration (the "FDA") approved ZILXI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of inflammatory lesions of rosacea in adults.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILXI became available in pharmacies nationwide in October 2020. AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA for any condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMZEEQ and ZILXI utilize the Company&#8217;s proprietary Molecule Stabilizing Technology (MST)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that is also being used in the development of the Company&#8217;s product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, the Company announced positive results from a Phase II clinical trial evaluating </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="ie7a3f8fdde7a466596df3bb0e9f31afc" continuedAt="i267d610ca5b145718302e0edd76d780c"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held an end-of-Phase II meeting with the FDA in the fourth quarter of 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Serlopitant </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company was developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, or&#160;NK1-R, given as a once-daily, oral tablet, for the treatment of pruritus, or itch, associated with various conditions including prurigo nodularis, or PN. On April 6, 2020, the Company announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN, studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. The Company does not currently intend to further pursue the development of serlopitant. As a result, in the second quarter of 2020, the Company recorded a full impairment charge related to the IPR&amp;D and Goodwill assets in its unaudited condensed consolidated statement of operations and comprehensive loss. See "Note 3 - Business Combination" for more information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched AMZEEQ in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company also launched ZILXI in the United States in October 2020 and commenced generating revenues in the fourth quarter of 2020. The Company&#8217;s activities prior to the commercial launches of AMZEEQ and ZILXI had primarily consisted of raising capital, developing product candidates, and performing research and development activities. Since inception, the Company has incurred recurring losses and negative cash flows from operations. For the six months ended June&#160;30, 2021, the Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfNzAyNw_596f0e8f-a266-4cee-aed9-c9efd95fd851">40.5</ix:nonFraction> million and used&#160;$<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfNzAzOQ_490c7af2-bd31-4345-82b2-6aea0106aa0d">28.8</ix:nonFraction> million of cash in operations. As of June&#160;30, 2021, the Company had cash, cash equivalents, restricted cash and investments of $<ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfNzE1MA_e4cf6873-ae0d-42d2-ae44-96c509b6e588">104.0</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfNzE4Mw_b025bd3d-dd06-4bd0-87a7-6a21fd74f28b">606.7</ix:nonFraction> million.  The Company's outstanding debt under its Amended and Restated Credit Agreement at June 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i9efde75313c64f94acd2d57c0ac7ad36_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTEyNTY4Nw_df2782d6-8fa0-4824-ad2f-990b6c1cfaf6">35.0</ix:nonFraction>&#160;million. On August 11, 2021, the Company prepaid the entirety of its outstanding indebtedness, including a prepayment premium and accrued but unpaid interest, for a total amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ic25e62d0cd134ea88998d63b633a4770_D20210811-20210811" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTEyNTcwMg_3b3ac47f-1b32-46e0-9cc9-dab4b3c2034c">36.5</ix:nonFraction>&#160;million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. In addition, the commercial launches of both AMZEEQ and ZILXI have been negatively impacted by unfavorable payor decisions in March 2021 on product pricing. These conditions have impaired the Company's ability to generate revenue consistent with internal forecasts, which has had a negative impact on its financial condition and liquidity. The Company and its lenders discussed revenue expected to be generated for the trailing twelve month period ended June 30, 2021, the revenue targets included in the Amended and Restated Credit Agreement and the Company&#8217;s strategic transition discussed above. Following such discussions, the Company determined to prepay its outstanding indebtedness in addition to a <ix:nonFraction unitRef="number" contextRef="i271ffaaf0e574d60ad9235c64c92906e_I20210811" decimals="2" name="vyne:RepaymentOfDebtPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMzg0ODI5MDc1MjQ5MQ_246aa10b-9de0-4405-bb25-4d6d0852d60b">4</ix:nonFraction>% prepayment fee and accrued but unpaid interest in the total amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ic25e62d0cd134ea88998d63b633a4770_D20210811-20210811" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTEyNTcxNw_4050a060-1488-41bd-839d-b2e994f75269">36.5</ix:nonFraction>&#160;million on August&#160;11, 2021. Following the prepayment, the Amended and Restated Credit Agreement has been terminated and the security interests thereunder will be terminated. As a result of the above, the Company determined that its projected cash flows from operations, combined with its cash balance after the debt prepayment, would not provide sufficient resources to fund its existing operations, for at least the next twelve months from the issuance of these financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the Company completed a strategic review of its business and has determined to initiate a process to explore a sale or license of its minocycline franchise, including AMZEEQ, ZILXI, FCD105 and the underlying MST platform. The Company will refocus its resources on its immuno-inflammatory pipeline and intends to support the FMX114 and the BETi development programs. Research and development activities for these programs, including preclinical and clinical testing of the Company&#8217;s drug candidates, will require significant additional financing. The future viability of the Company is dependent on its ability to successfully pivot to its research and development business strategy and develop commercially viable drug candidates and raise additional capital to finance its operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is contingent on its ability to sell or license its minocycline franchise, develop future commercially viable products and/or to raise sufficient working capital through either debt or equity financing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance the Company will be able to achieve these objectives under acceptable terms or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that its unaudited condensed consolidated financial statements are issued. The accompanying condensed </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i267d610ca5b145718302e0edd76d780c">consolidated financial statements have been prepared assuming that the Company will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company&#8217;s ability to continue as a going concern is expected to be impacted by the outcome of the plans outlined above, including the successful sale or license of its minocycline franchise, positive results from clinical trials for FMX114, and the successful development and positive results from clinical trials for the BETi programs. Based on current plans and assumptions, the Company believes that absent sufficient proceeds received from a sale or license of the minocycline franchise, business development transactions or financing transactions, which are all beyond its control, it will not have sufficient cash and cash equivalents to fund its operations beyond one year from the issuance of these financial statements. Accordingly, the Company will, over the course of the next twelve months, require significant additional financing to continue its operations. Each of these factors are subject to uncertainty, and therefore, raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Failure to successfully complete a sale or license of the minocycline franchise, develop the noted assets, and receive additional financing will require the Company to delay, scale back or otherwise modify its business and its research and development activities and other operations. The accompanying financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</ix:continuation></span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_43"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2 - <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTc_2c5e2690-906e-405a-bd97-14228cabead6" continuedAt="i53328ee03ee143ddbf987e5a85c0ac2c" escape="true">SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i53328ee03ee143ddbf987e5a85c0ac2c" continuedAt="i5178f8e551424512a23d45cbb89fd482"><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTg_4d23bd3f-7722-40cf-ad49-4f5f23de3268" continuedAt="ie41bb14436424d4989813e565906f175" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ie41bb14436424d4989813e565906f175"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. In the opinion of management, the Company has made&#160;all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company&#8217;s condensed consolidated financial position, results of operations, cash flow and statement of stockholders' equity for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.  Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC on March 4, 2021.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results expected for the year ending December&#160;31, 2021.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.94pt"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTQ_881e1b82-675d-4d08-982d-18b944ecb822" continuedAt="id2403eec7bc240b7835277505309aa8d" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id2403eec7bc240b7835277505309aa8d">The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation.</ix:continuation></span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.07pt"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTA_c1c85fb7-533a-41ec-9bdd-7929711cf7cd" continuedAt="i33a057a5f5904ae3b56bb4f67ca6b707" escape="true">Use of Estimates</ix:nonNumeric></span></div><ix:continuation id="i33a057a5f5904ae3b56bb4f67ca6b707" continuedAt="idaf27db0fde74cdf8e5d4636b91997ab"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition and liquidity will depend on future developments that are highly uncertain, subject to change and will continue to evolve with geographical re-openings, surges in cases, the development of new strains and the vaccination effort. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of  June&#160;30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2020, the Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i5178f8e551424512a23d45cbb89fd482" continuedAt="ie9573177566c4cc7a5a0464db21ad077"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="idaf27db0fde74cdf8e5d4636b91997ab">Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods</ix:continuation></span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.94pt"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAyMDA_876ea1fd-3410-45a5-93ba-4d4871f2dedb" continuedAt="i01ccaa08ec02457f85f7cd21c27c3768" escape="true">Business Acquisition</ix:nonNumeric></span></div><ix:continuation id="i01ccaa08ec02457f85f7cd21c27c3768"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited interim condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet.&#160;Transaction costs are expensed as incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, the Company uses fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; The Company estimates fair value using an exit price approach, which requires, among other things, that Company determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following techniques:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach, which is based on the present value of a future stream of net cash flows.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Asset Impairment</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews all of its long-lived assets for impairment indicators throughout the year. Impairment testing is performed for indefinite-lived intangible assets annually (or sooner if warranted) and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.07pt"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTU_9217d043-e473-48db-918b-34142a2a53a9" continuedAt="ib7543247b2a14b078eee47ac9825ff58" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib7543247b2a14b078eee47ac9825ff58" continuedAt="i9c2504a3c1d64df788e9d7c585da50a6">The Company accounts for its revenue transactions under FASB ASC Topic 606,&#160;Revenue from Contracts with Customers. In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue </ix:continuation></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="ie9573177566c4cc7a5a0464db21ad077" continuedAt="i0f6acd8c2fe440ba9b07cf704ece5052"><ix:continuation id="i9c2504a3c1d64df788e9d7c585da50a6"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers include a limited number of national and select regional wholesalers (the &#8220;distributors&#8221;) and certain independent and specialty pharmacies (together, the &#8220;customers&#8221;). These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when customers obtain control of the Company&#8217;s products, which occurs at a point in time, typically upon delivery of product to the customers. The Company evaluates the creditworthiness of its customers to determine whether it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur. The Company does not assess whether a contract has a significant financing component if the expectation is such that the period between the transfer of the promised goods to the customer and the receipt of payment will be less than one year. Standard credit terms do not exceed 75 days. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that would have been recognized is one year or less or the amount is immaterial. Shipping and handling costs related to the Company&#8217;s product sales are included in selling, general and administrative expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues through&#160;June&#160;30, 2021&#160;were primarily generated through sales of AMZEEQ, which was approved by the FDA in October 2019 and was commercially launched in the United States in January 2020, and ZILXI, which was approved by the FDA in May 2020 and was commercially launched in the United States in October 2020. Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, copay program coupons, chargebacks, estimated returns and other incentives. These reserves are classified as either reductions of accounts receivable or as current liabilities. The estimates of reserves established for variable consideration reflect current contractual and statutory requirements, known market events and trends, industry data and forecasted customer mix. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net product revenues only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from these estimates. If actual results vary, estimates may be adjusted in the period such change in estimate becomes known, which could have an impact on earnings in the period of adjustment. See &#8220;Note 4 &#8211; Revenue Recognition&#8221; for more information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for our minocycline products and product candidate, if approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commercial use.  The Company received an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="ie37f3b5248df46e8a5d24d2bfdf923c7_D20200401-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTI0NDk_ed6b43d7-b62c-4ed8-a31b-294bf5c06e03">10.0</ix:nonFraction> million in 2020 ($<ix:nonFraction unitRef="usd" contextRef="ieb1d0e22f202476fa595bb840d395cd9_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTI0NjE_ab6072c8-fcab-4de1-a126-e3336b216c3f">6.0</ix:nonFraction> million received in the three months ended June 30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i68da95855f63445cb75b88e2107393a8_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTI1MTc_b4de7d63-69ab-4653-99bf-d692b9527122">4.0</ix:nonFraction> million received in the three months ended September 30, 2020) and will be eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="iaa2d29a04a9d429e8c602ba8cac18f30_I20210630" decimals="-5" format="ixt:numdotdecimal" name="vyne:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTI2MjE_537a6bad-1917-40b4-b502-b64433dd11da">1.0</ix:nonFraction> million payment upon the receipt of marketing approval in China of the first licensed product.  The Company will also receive royalties on net sales of any licensed products.  The license is determined to be a distinct performance obligation of the arrangement, therefore the Company recognized the revenues from the upfront license fee when the license was transferred to the licensee and the licensee was able to use and benefit from the license.  See "Note 4 - Revenue Recognition" for more information.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.17pt"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxODc_c5f96ce6-8e49-49ae-95e2-89cad39c7396" continuedAt="i2f824d5696574891bae15e352fc51f92" escape="true">Allowance for credit losses</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f824d5696574891bae15e352fc51f92">An allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be&#160;collected.&#160;Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were not material for the three and six months ended June&#160;30, 2021 and June&#160;30, 2020.</ix:continuation></span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTY_4baa9240-ae80-49ec-b2b2-f84a2a4f1b10" continuedAt="ic681a6b2d96a4b2497370a9c1ec75a67" escape="true">Derivative instruments</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic681a6b2d96a4b2497370a9c1ec75a67">The Company recognizes all derivative instruments as either assets or liabilities in the unaudited condensed consolidated balance sheet at their respective fair values. All gains and losses associated with derivatives are reported as other expense (income), net in the accompanying condensed consolidated statements of operations.  As of June&#160;30, 2021 and June&#160;30, 2020, the Company had <ix:nonFraction unitRef="derivativeinstruments" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTQwNjg_c30300ac-2df7-44ef-9d59-df9c30dbbcc3"><ix:nonFraction unitRef="derivativeinstruments" contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTQwNjg_f26da241-f82d-432a-9001-0a1d8db1e301">no</ix:nonFraction></ix:nonFraction> derivative instruments.</ix:continuation></span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">h.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.94pt"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTE_b36db963-b3ac-4885-bbb9-cb9802f877bd" continuedAt="if06a3ee244be4bc0af448ec193ddbfe9" escape="true">Fair value measurement</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i0f6acd8c2fe440ba9b07cf704ece5052" continuedAt="i51b06e2b108b43758ff0eecef3a2d9a0"><ix:continuation id="if06a3ee244be4bc0af448ec193ddbfe9"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:&#160;&#160;&#160;&#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:&#160;&#160;&#160;&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.73pt"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTI_57a23386-95f3-4b89-a151-3ac07f3dc71b" continuedAt="i3d761e0ccf6c4828a44de753e0b84a1c" escape="true">Loss per share</ix:nonNumeric></span></div><ix:continuation id="i3d761e0ccf6c4828a44de753e0b84a1c"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury share method when dilutive.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of the weighted-average number of common stock outstanding during the period in which the reverse merger occurs was based on:</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The number of common stock outstanding from the beginning of that period to the merge date was computed on the basis of the weighted-average number of common stock of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt">The number of common outstanding common stock outstanding from the merge date to the end of that period was the actual number of common stock of the legal acquirer (the accounting acquiree) outstanding during that period.</span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxODg_09bd14a9-8feb-4d19-a10c-5bd0f61efed7" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following average stock options, restricted stock units (&#8220;RSUs&#8221;), warrants and incremental shares to be issued under the employee stock purchase plan (&#8220;ESPP&#8221;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):</span></div><div style="margin-top:5pt;padding-right:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options, RSUs and shares under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7eaae92ef0840c2b50b035cf1e0a2e0_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMi0xLTEtMS0w_a524eaa9-08a6-44a8-b27d-06a2b67e188b">5,378,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf646184c9df4d2991aed59bbf06b647_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMi0zLTEtMS0w_8e9bf37b-1216-491f-ad46-24974b645bf4">3,743,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a7f4503f7384e2faaa1111b3d6139c9_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMi01LTEtMS0w_5a3904c4-65f4-4e45-bd5e-befab1201e5c">5,365,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff048461f0274e04bac7ba4406b49f1c_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMi03LTEtMS0w_4b241cd4-a0dd-4b8b-95e8-3c8f11d85d80">3,020,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9596c2a29d47439a95abf5bafe122581_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMy0xLTEtMS0w_7882a228-4e97-42fa-910b-802b6bbf48e1">495,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib38e1be8e95d46dc90c6daa98174ed11_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMy0zLTEtMS0w_c569fb0c-6ac8-4f23-bc41-534082b01a2a">473,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife9a680c8a894189a633707b6fc4831d_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMy01LTEtMS0w_e98b6829-507d-4344-9411-d80c1ec4644c">495,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70a8f4a8fcca4b248c457bd74ec68078_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMy03LTEtMS0w_09b549ed-881c-42a4-9395-c63e81a84183">318,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, the CSR was excluded from the calculation of the 2020 diluted net loss per share because its effect would have been anti-dilutive for the periods presented. On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Each CSR was converted into <ix:nonFraction unitRef="number" contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406" decimals="INF" name="vyne:ContingentStockRightSharesConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTczOTE_844db8f1-310c-4a5f-b0b5-9fa9d7327a56">1.2082</ix:nonFraction> shares of Menlo common stock, resulting in an effective exchange ratio (the "Exchange Ratio") in the Merger of <ix:nonFraction unitRef="number" contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406" decimals="INF" name="vyne:BusinessCombinationEffectiveExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTc1MDU_d29ccb27-8ee7-41d2-a511-f75a24f5ed16">1.8006</ix:nonFraction> shares of Menlo common stock for each Foamix ordinary share. The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020. See "Note 3 - Business Combination" for more information.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">j.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.17pt"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTM_f77dd37b-468d-454e-b3c1-6d0fc380fb41" continuedAt="ic1c84aac03ec476f8258e0cd22175bdb" escape="true">Newly issued and recently adopted accounting pronouncements</ix:nonNumeric></span></div><ix:continuation id="ic1c84aac03ec476f8258e0cd22175bdb" continuedAt="icab193bfe1674bc0840c5d913b849002"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Guidance Issued:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes," which clarifies and simplifies certain aspects of the accounting for income taxes.  The standard is effective for years beginning after December 15, 2020, and interim periods </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i51b06e2b108b43758ff0eecef3a2d9a0"><ix:continuation id="icab193bfe1674bc0840c5d913b849002"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beginning after December 15, 2020.  This guidance became effective during the first quarter of 2021.  The adoption of the new standard did not have a material impact to the Company's consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update No. 2020-4, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" (ASU 2020-4), which provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying generally accepted accounting principles to contracts, hedging relationships, and other transactions impacted by reference rate reform. The provisions of ASU 2020-4 apply only to those transactions that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-4 are optional and are effective from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-4 on its consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update No. 2016-13,&#160;&#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;&#160;(ASU 2016-13), which requires companies to measure credit losses of financial instruments, including customer accounts receivable, utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. As a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023 or at such time where it is no longer a smaller reporting company.</span></div></ix:continuation></ix:continuation><div id="i25b00c7e5297459bafdb2282aa46fec2_46"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3 &#8211; <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NjM_92861837-3a6c-4bb3-b77e-29af4d54c8aa" continuedAt="i07c13454473844ec9ed9eb1a6efc366b" escape="true">BUSINESS COMBINATION</ix:nonNumeric></span></div><ix:continuation id="i07c13454473844ec9ed9eb1a6efc366b" continuedAt="i08a6b8fc8d48422e960aa738393ee1e9"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2019, Menlo entered into the Merger Agreement with Foamix, and Merger Sub, a direct and wholly-owned Israeli subsidiary of Menlo. On March 9, 2020, the Merger was completed and Foamix is now a wholly-owned subsidiary of the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Effective Date, each ordinary share of Foamix was exchanged for <ix:nonFraction unitRef="number" contextRef="i6382cc7a653d404095454dba66f62190_I20200309" decimals="INF" name="vyne:ExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMzU1_55f37f45-6977-46f7-ad2e-697d12ad8afe">0.5924</ix:nonFraction> shares of common stock of Menlo. In addition, on the Effective Date, Foamix shareholders received <ix:nonFraction unitRef="contingentstockright" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="INF" format="ixt-sec:numwordsen" name="vyne:BusinessAcquisitionContingentStockRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDU2_5414f45c-0c8e-4b06-b242-41386782e168">one</ix:nonFraction> contingent stock right (a &#8220;CSR&#8221;) for each Foamix ordinary share held by them. The CSRs were issued pursuant to the Contingent Stock Rights Agreement (the &#8220;CSR Agreement&#8221;), dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#8217;s phase III clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of prurigo nodularis (the &#8220;Phase III PN Trials&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into <ix:nonFraction unitRef="number" contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406" decimals="INF" name="vyne:ContingentStockRightSharesConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTQ2Mw_0e9530c3-1034-4224-a4dc-bdd36dabe19b">1.2082</ix:nonFraction> additional shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of <ix:nonFraction unitRef="number" contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406" decimals="INF" name="vyne:EffectiveExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTU2NQ_50f5ba14-dcbd-49df-bad9-f707d8ac4582">1.8006</ix:nonFraction> shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of <ix:nonFraction unitRef="shares" contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406" decimals="INF" format="ixt:numdotdecimal" name="vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTY5MA_d307c451-ef4e-4735-ba5e-430c57f4866c">74,544,413</ix:nonFraction> additional shares of Menlo common stock underlying the CSRs, adjusted retrospectively to <ix:nonFraction unitRef="shares" contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212" decimals="INF" format="ixt:numdotdecimal" name="vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTc4Mg_3146b19f-bb79-4305-829f-26d3dc841acb">18,636,103</ix:nonFraction> shares of common stock upon the reverse stock split effective February&#160;12, 2021.  Following the conversion of the CSRs, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders owned approximately <ix:nonFraction unitRef="number" contextRef="i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407" decimals="2" name="vyne:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTk3NQ_971c7d64-4d36-472a-8424-e66ff8ee4480">82</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407" decimals="2" name="vyne:PostMergerParentOwnershipByPreMergerParentStockholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTk4Mg_a8c2ad64-5666-42d5-9092-9551bb2e2392">18</ix:nonFraction>% of post-Merger Menlo, respectively, each calculated on a fully diluted basis. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under U.S. GAAP and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#8217;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under reverse acquisition accounting, the U.S. dollar amount for common stock in the financial statements is based on the value and number of shares issued by Menlo (reflecting the legal structure of Menlo as the legal acquirer) on the Merger date plus subsequent shares issued by the Company. The amounts in additional paid-in capital represent that of Foamix and include the fair value of shares deemed for accounting purposes to have been issued by Foamix on the merger date and the fair value of the Menlo equity awards included in the purchase price calculation. The Foamix additional paid-in capital was also adjusted for the difference between the number of common stock and the historical number of shares of Foamix&#8217;s ordinary shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2020, the Company incurred transaction costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i1a7cf85ce0eb405d8a9d3d0c8302a988_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMzI3Nw_85881940-caf8-43af-ba79-d9af7f2fff03">11.7</ix:nonFraction> million, which are recorded in the condensed consolidated statements of operations and comprehensive income. This amount includes $<ix:nonFraction unitRef="usd" contextRef="i1e7b882797fb4a558b75c52ad0d3f597_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMzQwMg_96d7b0ac-6a17-4ea7-b565-5b2ea7164b88">8.1</ix:nonFraction> million of severance benefits for employees terminated after the Effective Date. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i08a6b8fc8d48422e960aa738393ee1e9" continuedAt="i5d90c112d69a489c9f3a1d87cfba58f4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price</span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="vyne:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NTQ_bc5aad09-9cf7-4b7e-af78-55070663c843" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmE1MWNiZDk0MGJmYjRlMWQ4N2E5NGQwZTQ0NDZmNDViL3RhYmxlcmFuZ2U6YTUxY2JkOTQwYmZiNGUxZDg3YTk0ZDBlNDQ0NmY0NWJfMS0xLTEtMS0w_dd3d88f4-a8b8-4e66-ad1f-a69a7ef8107e">123,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deemed (for accounting purposes only) conversion of Menlo equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="-3" format="ixt:numdotdecimal" name="vyne:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmE1MWNiZDk0MGJmYjRlMWQ4N2E5NGQwZTQ0NDZmNDViL3RhYmxlcmFuZ2U6YTUxY2JkOTQwYmZiNGUxZDg3YTk0ZDBlNDQ0NmY0NWJfMi0xLTEtMS0w_df450f9b-5466-45f8-b1b5-03c0dffc3e85">7,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration*</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="-3" format="ixt:numdotdecimal" name="vyne:BusinessCombinationConsiderationTransferredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmE1MWNiZDk0MGJmYjRlMWQ4N2E5NGQwZTQ0NDZmNDViL3RhYmxlcmFuZ2U6YTUxY2JkOTQwYmZiNGUxZDg3YTk0ZDBlNDQ0NmY0NWJfMy0xLTEtMS0w_51a41563-df01-4577-899b-0c31ae48a829">131,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $<ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMzcyNQ_de7c9e0c-a4b8-435a-9e8f-d9de348bc4fb">19.6</ix:nonFraction> million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders&#8217; relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $<ix:nonFraction unitRef="usd" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDA4NQ_54f04f93-a261-4697-8018-bd4760d0fcf2">111.4</ix:nonFraction> million, as shown in the purchase price allocation table below.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Foamix&#8217;s closing share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDE4NQ_0636a692-765e-4e0c-9e4c-d9f43f1b6602">2.99</ix:nonFraction> as of March 9, 2020, the Merger Consideration under reverse acquisition accounting was approximately $<ix:nonFraction unitRef="usd" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="vyne:BusinessCombinationConsiderationTransferredGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDI4OQ_b3a59b13-739c-42dc-9881-2ec043e11210">131.1</ix:nonFraction> million, consisting of $<ix:nonFraction unitRef="usd" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDMwNw_420b2186-06e0-4d90-be74-ea9583ed594e">123.8</ix:nonFraction> million for the deemed (for accounting purposes only) issuance of <ix:nonFraction unitRef="shares" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="vyne:BusinessCombinationSharesDeemedIssuedForAccountingPurposes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDM2OA_6b0a75b6-39d5-4b6a-a198-bcd9ad6306b9">41.4</ix:nonFraction> million Foamix shares assuming that no upwards adjustment was made to the Exchange Ratio relating to the CSR, and $<ix:nonFraction unitRef="usd" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="vyne:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDQ3Nw_4689fe05-488e-47a2-8aaf-ee96a0b23e92">7.3</ix:nonFraction> million for the fair value of Menlo equity awards deemed (for accounting purposes only) to be converted into Foamix equity awards. The converted stock options represent the fair value of such options attributable to service prior to the Merger date using the Foamix closing share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDc2MQ_9b21def0-9476-45d1-abb0-1de555e815e0">2.99</ix:nonFraction> as of March 9, 2020 as an input to the Black Scholes valuation model to determine the fair value of the options.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NjQ_5bd06b1a-6048-4239-8282-a6f3cc092a08" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 9, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfMS0xLTEtMS0w_53472506-9959-4c3a-88ec-fe81b9d932c8">38,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfMi0xLTEtMS0w_d537e4f9-17a7-4a39-b2d0-848c77c3cc14">22,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfMy0xLTEtMS0w_fc404cbd-3812-4ba1-8e39-7f2005e521bf">1,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfNC0xLTEtMS0w_f494ef6d-47bd-43e3-ad23-5c15c359e3bf">49,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfNS0xLTEtMS0w_8c35bf47-cd51-41fb-9674-b4bc569d9877">4,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfNi0xLTEtMS0w_de526a90-8dba-4ba7-9e29-328f7493b4b1">117,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfNy0xLTEtMS0w_e4678338-5bfa-4147-bb90-fb8fd3f67891">5,827</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfOC0xLTEtMS0w_d8538ffe-091c-46ac-a14d-8d8870bd289a">5,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price*</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfOS0xLTEtMS0w_3020578d-7044-4c65-acbd-95e775045ea6">111,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $<ix:nonFraction unitRef="usd" contextRef="i32f810ffe926407c90d135528dbc7806_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="vyne:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNTIwMw_b4e54b56-6ae6-4277-b9ed-8716b72ab337">19.6</ix:nonFraction> million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#8217;s outstanding shares being owned by Menlo stockholders following the Merger.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually. <ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNTc1Mg_35eaef23-d3ee-4bce-8815-3f9c0ba58dd2">None</ix:nonFraction> of the Goodwill recognized is expected to be deductible for income tax purposes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="vyne:ScheduleOfBusinessCombinationGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NjA_eb388260-2c5d-492a-8e5f-315c60984147" continuedAt="i8b4e3f909e7e494da46c16857052fd49" escape="true">The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i8b4e3f909e7e494da46c16857052fd49"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 9, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjMzZTJlNzQ3NzgyMTQxNmM4ODFjYWM5MWM1YjU0OWQ3L3RhYmxlcmFuZ2U6MzNlMmU3NDc3ODIxNDE2Yzg4MWNhYzkxYzViNTQ5ZDdfMS0xLTEtMS0w_7fd4067e-55da-4f42-a97b-f99bbe3fe0dc">111,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: fair value of net assets acquired, including other identifiable intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="vyne:BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjMzZTJlNzQ3NzgyMTQxNmM4ODFjYWM5MWM1YjU0OWQ3L3RhYmxlcmFuZ2U6MzNlMmU3NDc3ODIxNDE2Yzg4MWNhYzkxYzViNTQ5ZDdfMi0xLTEtMS0w_f9cdfaf2-a21f-44ef-b8cd-b6d22281c7ea">106,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjMzZTJlNzQ3NzgyMTQxNmM4ODFjYWM5MWM1YjU0OWQ3L3RhYmxlcmFuZ2U6MzNlMmU3NDc3ODIxNDE2Yzg4MWNhYzkxYzViNTQ5ZDdfMy0xLTEtMS0w_586581bb-1046-4ac5-a334-0159f867939c">4,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i5d90c112d69a489c9f3a1d87cfba58f4" continuedAt="ia79bfd6393894355b26d05687ed806c5"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to further pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjQ2OQ_a4ee1d62-f696-4611-9708-7409adafb778"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjQ2OQ_c84fb5ff-58cc-4a4f-99d9-fbf078888570">4.5</ix:nonFraction></ix:nonFraction> million related to goodwill in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020.  There were <ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjYzMA_0125203b-198a-42b4-ac8a-03c27cae28e6"><ix:nonFraction unitRef="usd" contextRef="iccc41b531a42468fbf923e22fdb7eabb_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjYzMA_4d6af5fc-cff5-42ed-9271-bf90809619a8"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjYzMA_4e779641-125b-4324-bf39-a02281b11007"><ix:nonFraction unitRef="usd" contextRef="i6db72496b07944a0b0be6eb4aa4ba37a_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjYzMA_614f9c46-8700-41a6-900b-6911bdc5af23">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment charges in the three and six months ended June&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Process Research and Development (&#8220;IPR&amp;D")</span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="vyne:ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NjE_5387762c-cab1-4dd2-998d-099c17022401" continuedAt="ia4f2db2c3cf94f7ba13546c1558948e7" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D recognized relates to Menlo&#8217;s once</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:84.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired indefinite life intangible assets*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwNmI1NDdhMGMxMDQwMDJiNjQ5MjZiZmE5NjAyMWI1L3RhYmxlcmFuZ2U6ZjA2YjU0N2EwYzEwNDAwMmI2NDkyNmJmYTk2MDIxYjVfMi0yLTEtMS0w_303f5bc3-5701-4e7b-942a-d3153748475b">49,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of identified intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwNmI1NDdhMGMxMDQwMDJiNjQ5MjZiZmE5NjAyMWI1L3RhYmxlcmFuZ2U6ZjA2YjU0N2EwYzEwNDAwMmI2NDkyNmJmYTk2MDIxYjVfMy0yLTEtMS0w_bec77355-1c52-4505-8319-ffadc06be77f">49,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia4f2db2c3cf94f7ba13546c1558948e7">* Represents acquired IPR&amp;D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D has been estimated utilizing a multi-period excess earnings method under the income approach, which reflects the present value of the projected cash flows that are expected to be generated, less charges representing the contribution of other assets to those cash flows that use projected cash flows with and without the intangible asset in place.&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to further pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $<ix:nonFraction unitRef="usd" contextRef="icb5bafa21e104483ae7f0f9dc374ea00_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODE1MQ_5f64d3ce-cbfa-4bcf-96d8-73d62b496104"><ix:nonFraction unitRef="usd" contextRef="i16efb1e654494773b9d6ff2b23dc030b_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODE1MQ_96da811a-84c3-48bb-b4bc-c015791967d4">49.8</ix:nonFraction></ix:nonFraction> million related to the IPR&amp;D asset in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020.  There were <ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODMxOQ_0125203b-198a-42b4-ac8a-03c27cae28e6"><ix:nonFraction unitRef="usd" contextRef="iccc41b531a42468fbf923e22fdb7eabb_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODMxOQ_4d6af5fc-cff5-42ed-9271-bf90809619a8"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODMxOQ_4e779641-125b-4324-bf39-a02281b11007"><ix:nonFraction unitRef="usd" contextRef="i6db72496b07944a0b0be6eb4aa4ba37a_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODMxOQ_614f9c46-8700-41a6-900b-6911bdc5af23">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment charges in the three and six months ended June&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CSR</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CSR was issued pursuant to the CSR Agreement, dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#8217;s Phase III PN Trials. The Company recognized a liability of $<ix:nonFraction unitRef="usd" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="vyne:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODcwNg_92a113e7-6281-40be-bf40-d540c0e4c338">19.6</ix:nonFraction> million in the unaudited condensed consolidated balance sheet as of March 9, 2020. The liability was measured at fair value and categorized as level 3 as of the acquisition date in accordance with ASC 805-31-25-5 and subsequently at each reporting date thereafter. The fair value of the CSR was estimated as the incremental value that Foamix would be able to achieve on a probability weighted basis assuming three different potential probabilities of the following scenarios: (a) serlopitant significance was achieved in both Phase III PN Trials (b) serlopitant significance was achieved in only one Phase III PN Trial and (c) serlopitant significance was not achieved or was not determined on or before May 31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into <ix:nonFraction unitRef="number" contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406" decimals="INF" name="vyne:ContingentStockRightSharesConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfOTg1OQ_0e9530c3-1034-4224-a4dc-bdd36dabe19b">1.2082</ix:nonFraction> additional shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of <ix:nonFraction unitRef="number" contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406" decimals="INF" name="vyne:EffectiveExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfOTk2MQ_50f5ba14-dcbd-49df-bad9-f707d8ac4582">1.8006</ix:nonFraction> shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of <ix:nonFraction unitRef="shares" contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406" decimals="INF" format="ixt:numdotdecimal" name="vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTAwODY_d307c451-ef4e-4735-ba5e-430c57f4866c">74,544,413</ix:nonFraction> additional shares of Menlo common stock underlying the CSRs, adjusted retrospectively to <ix:nonFraction unitRef="shares" contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212" decimals="INF" format="ixt:numdotdecimal" name="vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTAxNzg_3146b19f-bb79-4305-829f-26d3dc841acb">18,636,103</ix:nonFraction> shares of common stock upon the reverse stock split effective February&#160;12, 2021.  Following the conversion of the CSRs, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders own approximately <ix:nonFraction unitRef="number" contextRef="i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407" decimals="2" name="vyne:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTAzNjk_971c7d64-4d36-472a-8424-e66ff8ee4480">82</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407" decimals="2" name="vyne:PostMergerParentOwnershipByPreMergerParentStockholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTAzNzY_a8c2ad64-5666-42d5-9092-9551bb2e2392">18</ix:nonFraction>% of post-Merger Menlo, respectively, each calculated on a fully diluted basis.  The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020 and increased the awards available for grant under the Company's equity plan.    </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration associated with the CSR was recognized and measured at fair value as of the acquisition date in accordance with ASC 805-30-25-5. An acquirer's obligation to pay contingent consideration should be classified as a liability or </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="ia79bfd6393894355b26d05687ed806c5"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity in accordance with ASC 480, Distinguishing Liabilities from Equity, ASC 815 Derivatives and Hedging, and other applicable U.S. GAAP.&#160;The contingent consideration associated with the CSR was initially measured at fair value and will subsequently be measured at fair value at each reporting date. The CSR was classified as a liability, as it is settled by issuing a variable number of the Company's common stock.  On April 6, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406" decimals="-3" sign="-" format="ixt:numdotdecimal" name="vyne:ContingentStockConsiderationRemeasurementGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTEzOTU_fd879fc2-5b0d-4c19-8dbd-afbecc34b60d">84.7</ix:nonFraction> million of expense in its unaudited condensed consolidated statements of operations and comprehensive loss to remeasure the CSR liability in its consolidated balance sheet to its fair value of $<ix:nonFraction unitRef="usd" contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTE1ODM_32b77eb0-1801-4b61-b4c1-9b6f537ca591">104.4</ix:nonFraction> million (calculated based on <ix:nonFraction unitRef="shares" contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406" decimals="INF" format="ixt:numdotdecimal" name="vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTE2MDc_d307c451-ef4e-4735-ba5e-430c57f4866c">74,544,413</ix:nonFraction> shares issued, adjusted retrospectively to <ix:nonFraction unitRef="shares" contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212" decimals="INF" format="ixt:numdotdecimal" name="vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTE2NTM_3146b19f-bb79-4305-829f-26d3dc841acb">18,636,103</ix:nonFraction> shares of common stock upon the reverse stock split effective February&#160;12, 2021, and a share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTE3NDM_fb61f625-8b20-4a79-a991-3d150d308be6">1.40</ix:nonFraction> on April 6, 2020) and then settled in connection with the issuance of shares. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual Menlo net loss included in the Company&#8217;s condensed consolidated statements of operations and comprehensive income for the three and six months ended June&#160;30, 2020 (for the period from the March 9, 2020, the Effective Date, through June&#160;30, 2020, which are not indicative of the results to be expected for a full year) and the supplemental unaudited pro forma revenue and net loss of the combined entity had the acquisition been completed on January 1, 2019 are as follows:</span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NjI_0feb1dec-c3b7-4063-a002-d28f2dbfa21e" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June&#160;30, 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:59.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmNlM2U4YzcxODBhYjQyODA5NDZlMTM3OGMyZTQzOTYzL3RhYmxlcmFuZ2U6Y2UzZThjNzE4MGFiNDI4MDk0NmUxMzc4YzJlNDM5NjNfMi0xLTEtMS0w_27df456e-9a2f-482f-a090-5abdd919de1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmNlM2U4YzcxODBhYjQyODA5NDZlMTM3OGMyZTQzOTYzL3RhYmxlcmFuZ2U6Y2UzZThjNzE4MGFiNDI4MDk0NmUxMzc4YzJlNDM5NjNfMi0zLTEtMS0w_4c4f12f8-7e74-451f-ae52-a16e630e89ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss attributable to Menlo</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmNlM2U4YzcxODBhYjQyODA5NDZlMTM3OGMyZTQzOTYzL3RhYmxlcmFuZ2U6Y2UzZThjNzE4MGFiNDI4MDk0NmUxMzc4YzJlNDM5NjNfMy0xLTEtMS0w_732dc8ea-16c9-4b5b-b302-1393c4f0bed5">7,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmNlM2U4YzcxODBhYjQyODA5NDZlMTM3OGMyZTQzOTYzL3RhYmxlcmFuZ2U6Y2UzZThjNzE4MGFiNDI4MDk0NmUxMzc4YzJlNDM5NjNfMy0zLTEtMS0w_7af11836-8a87-42e9-98d4-5246cb335e28">19,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended<br/>June 30, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNC0xLTEtMS0w_f0936ece-7300-4984-9ad6-290fab38a9d6">11,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNC03LTEtMS0w_2e580624-41cb-4e0b-9ef9-334fca468074">13,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNS0xLTEtMS0w_00ca3e65-ed50-4a87-b058-e8c9414b4fd1">167,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNS03LTEtMS0w_b12a1cb1-005e-4b83-b493-92f1afcfdd5f">205,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share - basic and diluted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNi0xLTEtMS0w_fd13f99a-ae04-4bfc-955e-bb3eb96cffd3"><ix:nonFraction unitRef="usdPerShare" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNi0xLTEtMS0w_ffccaf32-2d0f-4271-b5b3-4e330bda91f8">1.21</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNi03LTEtMS0w_3356e9ad-b4c2-4664-9a7c-befb831e9a16"><ix:nonFraction unitRef="usdPerShare" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNi03LTEtMS0w_423dbe1d-888c-4f74-acd7-1a1e6f91245b">1.23</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="vyne:AdjustmentsToSupplementalProformaTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfOS0xLTEtMS0w_cfdb391c-36f2-49df-a63d-879e2ed0435d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="vyne:AdjustmentsToSupplementalProformaTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfOS03LTEtMS0w_fc7f5b66-a386-4354-9e7d-54f2c846d585">14,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of stock based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="vyne:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfMTAtMS0xLTEtMA_3116f6a6-ce2e-483a-a258-6013a48df50a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="vyne:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfMTAtNy0xLTEtMA_3e688c95-7463-4d0f-9d0a-8d95a287bc82">7,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Adjustments</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="vyne:AdjustmentsToSupplementalProformaCombinedResultsOfOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfMTEtMS0xLTEtMA_a3dfe3aa-d3b3-4a5a-a61c-0984c3eaf920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="vyne:AdjustmentsToSupplementalProformaCombinedResultsOfOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfMTEtNy0xLTEtMA_93f64d17-759b-4f67-b2fd-48e85708abef">22,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited pro forma condensed consolidated financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the first day of the earliest period presented, or of future results of the consolidated entities. The unaudited pro forma condensed consolidated financial information does not reflect any operating efficiencies and cost savings that may be realized from the integration of the Merger.</span></div></ix:continuation><div id="i25b00c7e5297459bafdb2282aa46fec2_49"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4 &#8211; <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfODU2NQ_52c782c6-e561-428a-9ad0-a9700b3865d3" continuedAt="i865fab61a19844c6b1a78fdc6253c505" escape="true">REVENUE RECOGNITION</ix:nonNumeric></span></div><ix:continuation id="i865fab61a19844c6b1a78fdc6253c505" continuedAt="ib3f98456cf8648d3a1ed4e216f60545e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues for the three and six months ended&#160;June&#160;30, 2021&#160;were primarily generated from sales of AMZEEQ&#160;which was commercially launched in the United States in January 2020 and ZILXI which became available in pharmacies nationwide on October 1, 2020.  The Company&#8217;s customers include a limited number of national and select regional distributors and certain independent and specialty pharmacies, together (the "customers").  The distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when customers obtain </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="ib3f98456cf8648d3a1ed4e216f60545e" continuedAt="i2a3dceae256b42e7b0e1e985ab49f5ff"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">control of the Company&#8217;s products, which occurs at a point in time, typically upon delivery of product to the customers. For the three months ended June&#160;30, 2021, there were three major customers that each accounted for more than 10% of total product revenues and, as a group, represented <ix:nonFraction unitRef="number" contextRef="i4b69cba5a49141e6bb1ce4370c794990_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzA0NQ_3ac04f0b-fa72-4574-9754-61b1c2566019">56</ix:nonFraction>% of total product revenues.  For the six months ended June&#160;30, 2021, there were four major customers that each accounted for more than 10% of total product revenues and, as a group, represented <ix:nonFraction unitRef="number" contextRef="ic43c6e8d9ce64e2d8a1368960b3a7873_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfOTg4_c400edbc-1fc5-4882-a46b-ead6c6aa1b9f">70</ix:nonFraction>% of total product revenues.  For the three months ended June&#160;30, 2020, there were three major customers that each accounted for more than 10% of total product revenues and as a group, represented <ix:nonFraction unitRef="number" contextRef="if85566c685134979a79b4ce6fd888d53_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzA1OA_fb94e564-50d1-4025-947e-77388af33afd">100</ix:nonFraction>% of total product revenues.  For the six months ended June&#160;30, 2020, there were three major customers that each accounted for more than 10% of total product revenues and as a group, represented <ix:nonFraction unitRef="number" contextRef="i76d0289842ec41d6a4fcf604ba120cc7_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTE2OQ_f0c7ddc2-cd0e-46c0-8151-5877cf9a44f8">99</ix:nonFraction>% of total product revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales Provisions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, chargebacks, estimated returns and other incentives, described below. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company calculates its net product revenue based on the wholesale acquisition cost that the Company charges its customers less provisions for (i) trade discounts and allowances, such as distributor fees and discounts for prompt payment, (ii) estimated rebates to third-party payers, patient co-pay assistance programs, chargebacks and other discount programs and (iii) reserves for expected product returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for distribution fees, trade discounts and chargebacks are reflected as a reduction to trade receivables, net on the condensed consolidated balance sheet. All other provisions, including rebates, other discounts and return provisions are reflected as a liability within accrued expenses on the condensed consolidated balance sheet. Provisions for revenue reserves described below reduced product revenues by&#160;$<ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzQzNw_8749ac8b-b59a-4ce5-acd7-f3ae34865de7">16.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzUwMw_134bac2b-19c3-4a50-b911-4dad2fd59ab8">5.9</ix:nonFraction> million for the three months ended June&#160;30, 2021 and June&#160;30, 2020, respectively.  Provisions for revenue reserves described below reduced product revenues by&#160;$<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMjIxOQ_21d452b5-843b-4152-ac1c-d225c82e6755">31.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMjIyNg_4a728821-178a-458b-8cd1-ec12c846ff4e">14.1</ix:nonFraction> million for the six months ended June&#160;30, 2021 and June&#160;30, 2020, respectively. The revenue reserve accrual at June&#160;30, 2021 and December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i27b7eaef51134e98829287ba6d768e11_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMjMyMw_f14634be-9e10-4950-a402-b5e290c378fa">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i17d3ea68f84b490b9ee1aafc7167b26a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMjMzMA_49467d9f-bb10-496d-aeef-66efb590e173">5.8</ix:nonFraction> million, respectively, reflected in accrued expense in the consolidated balance sheet.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Distribution Fees and Trade Discounts and Allowances</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company pays fees for distribution services and for certain data that distributors provide to the Company and generally provides discounts on sales to its distributors for prompt payment. These fees and discounts are contractual in nature and the Company expects its distributors to earn these fees and discounts, and accordingly deducts the full amount of these fees and discounts from its gross product revenues at the time such revenues are recognized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Rebates, Chargebacks and Other Discounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under managed-care and governmental pricing programs in the U.S. are subject to rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share. Chargebacks relate to contractual agreements to sell products to government agencies and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these government agencies or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers. The Company estimates the rebates and chargebacks it expects to be obligated to provide and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates the rebates and chargebacks that it expects to be obligated to provide based upon (i) the Company's current contracts and negotiations, (ii) estimates regarding the payer mix&#160;based on third-party data and utilization, (iii) inventory held by distributors and (iv) estimates of inventory held at the retail channel. Other discounts include the Company&#8217;s co-pay assistance coupon programs for commercially-insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to pay associated with product that has been recognized as revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return products within a specified period of time before and after its expiration date.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company estimates the amount of product&#160;that will be returned and deducts these estimated amounts from its gross revenue at the time the revenue is recognized. T</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he information utilized to estimate the returns provision includes: (i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> historical industry information regarding rates for comparable pharmaceutical products and product portfolios</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demand</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for products and (iv) remaining shelf lives of products at the date of sale. The Company estimates that approximately <ix:nonFraction unitRef="number" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="2" name="vyne:EstimateOfProductReturnRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNTQ1MQ_445ad0da-3925-47fc-ba78-29b9b476ed67">2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="2" name="vyne:EstimateOfProductReturnRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNTQ1Nw_bedbce1a-1d02-4701-b4da-aa792f3404d5">3</ix:nonFraction>% of product will be returned.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i2a3dceae256b42e7b0e1e985ab49f5ff"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commercial use.  Outside of the license transferred, the Company does not have any additional performance obligations under the arrangement.  In exchange for the license, the Company received an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="ie37f3b5248df46e8a5d24d2bfdf923c7_D20200401-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjI1NA_ed6b43d7-b62c-4ed8-a31b-294bf5c06e03">10.0</ix:nonFraction> million in 2020 ($<ix:nonFraction unitRef="usd" contextRef="ieb1d0e22f202476fa595bb840d395cd9_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjI2Ng_ab6072c8-fcab-4de1-a126-e3336b216c3f">6.0</ix:nonFraction> million received in the three months ended June 30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i68da95855f63445cb75b88e2107393a8_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjMyMg_b4de7d63-69ab-4653-99bf-d692b9527122">4.0</ix:nonFraction> million received in the three months ended September 30, 2020) and will be eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="iaa2d29a04a9d429e8c602ba8cac18f30_I20210630" decimals="-5" format="ixt:numdotdecimal" name="vyne:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjQyNg_537a6bad-1917-40b4-b502-b64433dd11da">1.0</ix:nonFraction> million payment upon the receipt of marketing approval in China of the first licensed product.  The license is considered functional IP as the licensee is able to use and benefit from the license without the continued involvement of the Company.  There was <ix:nonFraction unitRef="usd" contextRef="ib1c6d1a11d554c199e8d8a169359a9a4_D20210401-20210630" decimals="-5" format="ixt-sec:numwordsen" name="vyne:UpfrontRoyaltyReceipt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjY3OA_74380de3-fdf1-4d10-8d8a-7653441fef7a">no</ix:nonFraction> license revenue in the three months ended June&#160;30, 2021.  The Company recorded $<ix:nonFraction unitRef="usd" contextRef="ibd77d34132ca467485ab82d588391ab6_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="vyne:UpfrontRoyaltyReceipt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzY0Ng_ee7e8804-2033-4333-b1db-572281cc7f3a">10.0</ix:nonFraction> million of license revenue in the three and six months ended June&#160;30, 2020.  The Company will also receive royalties on net sales of any licensed products, such royalties will be recognized in the period the sales or usage occurs under the royalties sales-and usage based exception.  The Company has not recorded revenue related to the $<ix:nonFraction unitRef="usd" contextRef="iaa2d29a04a9d429e8c602ba8cac18f30_I20210630" decimals="-5" format="ixt:numdotdecimal" name="vyne:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjk5NA_537a6bad-1917-40b4-b502-b64433dd11da">1.0</ix:nonFraction> million payment due upon receipt of marketing approval for the licensed product as such amount is constrained under the variable consideration guidance under ASC 606, Revenue from Contracts with Customers.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets and Contract Liabilities&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets (unbilled receivables) related to product sales as of&#160;June&#160;30, 2021 and December&#160;31, 2020, as customer invoicing generally occurs before or at the time of revenue recognition.  The Company did not have any contract assets (unbilled receivables) related to its license revenues as of June&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract liabilities as of&#160;June&#160;30, 2021 and December&#160;31, 2020, as the Company did not receive payments in advance of fulfilling its performance obligations to its customers.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Commissions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Component</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.&#160;Standard credit terms do not exceed 75 days.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to royalty payments with respect to sales of a product developed by a customer in collaboration with the Company. Revenues in the amount of $<ix:nonFraction unitRef="usd" contextRef="i100dc25a3ccc4b50b433b69ea956736e_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzODAwMw_bfa6f8ba-4e97-4745-b027-29fccac19412">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i53788555bd1f4b04be712a3744df4cc3_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfODQ1OQ_53703e1c-7e02-47c2-a99a-d12aad788017">0.5</ix:nonFraction> million were recorded during the three and six months ended June&#160;30, 2021, respectively.  Revenues in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1dc49910e5a5430584764df10f7cf924_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzgwMA_5e948d55-f8ca-4448-a7b8-d733493d03f6"><ix:nonFraction unitRef="usd" contextRef="idabf5cabf5d146209830192ebd3a2c01_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzgwMA_8391b13c-4a9a-48e2-a1c4-27da59e7a021">0.2</ix:nonFraction></ix:nonFraction> million were recorded during the three and six months ended June&#160;30, 2020.</span></div></ix:continuation><div id="i25b00c7e5297459bafdb2282aa46fec2_52"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5 - <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RleHRyZWdpb246OTliYzRjM2NmNmNhNDEyYjg4YTM4Yjk5Nzc2ZGY4YWRfOTk2_2f1398b3-b9d7-4ec4-bbbf-7629ff709b8b" continuedAt="ia8a5714547a64389ac0f2051aeeacf66" escape="true">FAIR VALUE MEASUREMENT</ix:nonNumeric></span></div><ix:continuation id="ia8a5714547a64389ac0f2051aeeacf66"><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RleHRyZWdpb246OTliYzRjM2NmNmNhNDEyYjg4YTM4Yjk5Nzc2ZGY4YWRfOTk3_8299311e-c438-4358-96aa-f0e15caef3be" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s assets and liabilities that are measured at fair value as of December&#160;31, 2020, are classified in the table below in one of the three categories described in "Note 2 - Fair value measurement" above:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097981da69d34227853b3f274c4a9834_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RhYmxlOmU2OTk0NGU0MjQxYzRjYTZiYWQwZTI1MWUyOWU5YTdmL3RhYmxlcmFuZ2U6ZTY5OTQ0ZTQyNDFjNGNhNmJhZDBlMjUxZTI5ZTlhN2ZfMi0xLTEtMS0w_13e6039d-da08-4ff2-bea0-fbff14d87275">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5f9de8edf74567a2af3deb4d32b9e7_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RhYmxlOmU2OTk0NGU0MjQxYzRjYTZiYWQwZTI1MWUyOWU5YTdmL3RhYmxlcmFuZ2U6ZTY5OTQ0ZTQyNDFjNGNhNmJhZDBlMjUxZTI5ZTlhN2ZfMi0zLTEtMS0w_ec8d64ae-3365-4580-8fca-a655471524bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d8c62eaafd4e3b828916f7e572cd7d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RhYmxlOmU2OTk0NGU0MjQxYzRjYTZiYWQwZTI1MWUyOWU5YTdmL3RhYmxlcmFuZ2U6ZTY5OTQ0ZTQyNDFjNGNhNmJhZDBlMjUxZTI5ZTlhN2ZfMi01LTEtMS0w_3756b7f6-ff25-4f34-9d6e-e5843e770d1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RhYmxlOmU2OTk0NGU0MjQxYzRjYTZiYWQwZTI1MWUyOWU5YTdmL3RhYmxlcmFuZ2U6ZTY5OTQ0ZTQyNDFjNGNhNmJhZDBlMjUxZTI5ZTlhN2ZfMi03LTEtMS0w_deb9e20d-a54b-4dfa-8b3f-7eac612bdec5">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sold its marketable securities during the six months ended June 30, 2021.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_55"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6 - <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTM5NA_3b0f1502-3891-485e-8172-099fa2e60f19" continuedAt="i0ff18fc782a346109db3a98deb24ad41" escape="true">MARKETABLE SECURITIES</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0ff18fc782a346109db3a98deb24ad41" continuedAt="i2d1f9a54d4c0476c8bcda5f8e7ac08e2">Marketable securities as of December&#160;31, 2020 consist mainly of mutual funds securities. The debt securities are classified as available-for-sale and are recorded at fair value. Changes in fair value, net of taxes (if applicable), are reflected in other comprehensive loss. Realized gains and losses on sales of the securities, as well as premium or discount amortization, are included in the condensed consolidated statement of operations as other expense (income), net.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i2d1f9a54d4c0476c8bcda5f8e7ac08e2" continuedAt="i1b5d9cf6ca894c6f84b95e64c509e449"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair value are measured at fair value. The changes in the fair value of equity investments are recognized through other expense (income), net in the condensed consolidated statements of operations.  </span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTM5MA_920befd6-0b44-4a61-a0ce-7b52209ef56f" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s marketable securities:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israeli mutual funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i659a1487487a4e54b0c16d985e15bce3_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RhYmxlOjY2OWI4MzA3MzAzNTQxNzc5MDg3MmMyYzQyNWY4MGRlL3RhYmxlcmFuZ2U6NjY5YjgzMDczMDM1NDE3NzkwODcyYzJjNDI1ZjgwZGVfMi0xLTEtMS0w_b60e5b7c-f1c4-48c9-8f2d-7dc81a262693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9adec3b7e764dbea542fb51debbc4a1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RhYmxlOjY2OWI4MzA3MzAzNTQxNzc5MDg3MmMyYzQyNWY4MGRlL3RhYmxlcmFuZ2U6NjY5YjgzMDczMDM1NDE3NzkwODcyYzJjNDI1ZjgwZGVfMi0zLTEtMS0w_42cda056-03ef-4a53-b462-e2882ba53dc4">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020 there were <ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfODQz_8c80ef53-eda5-4605-8a9d-04cd2ac1a5c2"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfODQz_b034a3b5-c6a9-4e77-8e20-75c0dc7fc968">no</ix:nonFraction></ix:nonFraction> available-for-sale debt securities.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered factors regarding other than temporary impaired securities and determined that there are <ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTAwMQ_dcd5e102-0a4f-4e12-824b-c23f977fe1fa"><ix:nonFraction unitRef="usd" contextRef="i69de8b4ead5948b29019da8f6937bc7a_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTAwMQ_f20e00f6-0f19-488e-b9cc-ab1c45cfc874">no</ix:nonFraction></ix:nonFraction> securities with impairment that is other than temporary as of June&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021 and June&#160;30, 2020 the Company received aggregate proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTA5OTUxMTYyOTQzMA_4666e816-a472-4f98-acc2-ae7ab08a8291">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTI3Mg_6bb817d9-566a-4e4c-aeb2-d400a627b05f">36.4</ix:nonFraction> million, respectively, upon sale and maturity of marketable securities.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1b5d9cf6ca894c6f84b95e64c509e449">As of June&#160;30, 2021 and December&#160;31, 2020, there were <ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTM1Mw_88bb51e8-8364-464f-90a4-c6eae6d15776"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTM1Mw_fb284c48-b8af-400a-8a67-bdcd9cf85dfa">no</ix:nonFraction></ix:nonFraction> restricted marketable securities.</ix:continuation>  </span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_58"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7 &#8211; <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfOTM3_b0ae47da-c89f-4ef8-882c-6836f02bf40f" continuedAt="ic4df20cdc96a41e0b87236bdf409d58e" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="ic4df20cdc96a41e0b87236bdf409d58e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. The Company commenced capitalizing inventory for AMZEEQ and ZILXI upon FDA approval in October 2019 and May 2020, respectively. The Company periodically reviews its inventory levels and, if necessary, writes down inventory that is expected to expire prior to being sold, inventory in excess of expected sales requirements and inventory that fails to meet commercial sale specifications, with a corresponding charge to cost of goods sold. There were <ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfODE0_691e56db-5f72-4072-9373-ea8355759ad3"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfODE0_9290801d-4457-4cca-a85f-66d703ed335e"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfODE0_adc69feb-1e32-40dc-a5b7-da134f86e9f9"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfODE0_c9fba298-a68a-428a-899d-6ede014c7d71">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> inventory write-downs during the three and six months ended June&#160;30, 2021 and June&#160;30, 2020.</span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfOTM0_7e4377bb-f936-4132-87e9-fd0494a3e77f" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s inventory:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfMi0xLTEtMS0w_6109a239-535a-4b88-8770-7491ab2860e3">3,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfMi0zLTEtMS0w_2057c16d-21f0-427e-ba38-9d35095a96d7">4,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfMy0xLTEtMS0w_a466555f-0e3e-43ce-abb9-4f3acacc486f">680</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfMy0zLTEtMS0w_04c146c2-c7bf-4c35-87c5-1a89cd2a76ba">662</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfNC0xLTEtMS0w_0a33b663-f865-489a-bc56-2ce4b45fa6d6">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfNC0zLTEtMS0w_33dc553d-c8c4-45d6-88cc-515141d3b0ab">2,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfNS0xLTEtMS0w_7c63b58b-8504-45f0-9174-295a9043d0b0">8,279</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfNS0zLTEtMS0w_d6a7e714-9cbd-453a-b7ba-2c62564d1a34">7,404</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i25b00c7e5297459bafdb2282aa46fec2_61"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8 - <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI4Mw_f2e2ca2f-298d-4cbb-851e-cd3405148168" continuedAt="ib18807e766dd4b7095cf45731158ee00" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="ib18807e766dd4b7095cf45731158ee00" continuedAt="i33afdb7aa0304b18955fc00b51c6dcc1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2019, Foamix entered into a Credit Agreement (the "Credit Agreement") to secure up to $<ix:nonFraction unitRef="usd" contextRef="if4ace227df814c6da96b3d3c17e550ca_I20190729" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTI3_82e48305-bd50-450a-bd89-b13fe6ccfb62">50</ix:nonFraction>&#160;million from two lenders, one of which is a significant stockholder of the Company and is considered a related party, and a Securities Purchase Agreement with <ix:nonFraction unitRef="lender" contextRef="i2384945abf164135b470fbd163ec1a30_I20190729" decimals="INF" format="ixt-sec:numwordsen" name="vyne:NumberOfLenders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMjgx_57e35412-f6b6-4687-8787-deb4ee438e34">one</ix:nonFraction> of the lenders for gross proceeds of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i2384945abf164135b470fbd163ec1a30_I20190729" decimals="-6" format="ixt:numdotdecimal" name="vyne:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMzM1_07fbcc0d-626c-4c9a-8db8-cd857bd0b450">14</ix:nonFraction> million, before deducting offering expenses (see &#8220;Note 9- Share Capital&#8221; for more information). On March 9, 2020, the Company entered into an Amended and Restated Credit Agreement and Guaranty (as further amended on August 5, 2020, the &#8220;Amended and Restated Credit Agreement&#8221;), whereby the Company has guaranteed the indebtedness obligations of the borrower and granted a first priority security interest in substantially all of our assets for the benefit of the lenders. As of June&#160;30, 2021 and December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="id528c304a55c4353ba23843e402628f1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzgx_2cdecd04-0d2b-44fe-bd60-05340fae1a1d"><ix:nonFraction unitRef="usd" contextRef="i9efde75313c64f94acd2d57c0ac7ad36_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzgx_b45110fe-1932-4a76-a8e9-ef51dd3bc6a0">35.0</ix:nonFraction></ix:nonFraction>&#160;million was drawn under the Amended and Restated Credit Agreement.  The Company did not incur the remaining $<ix:nonFraction unitRef="usd" contextRef="id528c304a55c4353ba23843e402628f1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfODg0_22d2d38c-ac81-46cf-9aad-ab8db271c92e"><ix:nonFraction unitRef="usd" contextRef="i9efde75313c64f94acd2d57c0ac7ad36_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfODg0_88068a6a-0c81-4553-b99f-d9254b47101d">15.0</ix:nonFraction></ix:nonFraction>&#160;million under the Amended and Restated Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term loans available under the Amended and Restated Credit Agreement were comprised as follows: (a) $<ix:nonFraction unitRef="usd" contextRef="i0b6c184538354bce82077ac6310639ce_I20190729" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTAzOQ_7240e90c-d1f8-4466-99f4-152e3d9d32d1">15</ix:nonFraction> million that was funded on July 29, 2019 (the &#8220;Tranche 1 Loan&#8221;), (b) $<ix:nonFraction unitRef="usd" contextRef="i0a8f341036bc4b7ea7dc739c6499f873_I20191217" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTEwMw_66fb7196-e5b7-41af-9f23-161fb805f071">20</ix:nonFraction> million that was funded on December 17, 2019 (the &#8220;Tranche 2 Loan&#8221;) and (c) up to $<ix:nonFraction unitRef="usd" contextRef="i9f230d62899b4d71845a983074150045_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTE4MA_fcddd69d-9a78-49a1-b290-6f35065923e4">15</ix:nonFraction> million that was available prior to September 30, 2020 (the &#8220;Tranche 3 Loan&#8221;). The Tranche 2 Loan was borrowed following the FDA&#8217;s approval of the NDA for AMZEEQ and listing of AMZEEQ in the FDA&#8217;s &#8220;Orange Book,&#8221; in addition to maintaining arrangements with a third party for the commercial supply and manufacture of AMZEEQ. The Company did not incur the Tranche 3 Loan. Interest on the loans was equal to the sum of (A) <ix:nonFraction unitRef="number" contextRef="i9efde75313c64f94acd2d57c0ac7ad36_I20210630" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTY1MjAzMg_8e26d10c-ae02-4009-a7b6-4c5c97e894ed">8.25</ix:nonFraction>% (subject to increase in accordance with the terms of the Amended and Restated Credit Agreement) plus (B) the greater of (x) the one-month LIBOR as </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i33afdb7aa0304b18955fc00b51c6dcc1" continuedAt="i941ee28635c442dc9cac9a447ec51903"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the second business day immediately preceding the first day of the calendar month or the date of borrowing (if such loan is not outstanding as of the first day of the calendar month), as applicable, and (y) <ix:nonFraction unitRef="number" contextRef="id65641d8ed054571b83e832dbc10772f_D20210101-20210630" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTY1MjAzNg_3863203d-735f-4e3a-9f55-3439d4d0b94b">2.75</ix:nonFraction>%. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loans were scheduled to mature on July&#160;29, 2024. However, the Company and its lenders discussed the revenue expected to be generated for the trailing twelve month period ended June&#160;30, 2021, the revenue targets included in the Amended and Restated Credit Agreement and the Company&#8217;s strategic transition discussed above. Following such discussions, the Company determined to prepay its outstanding indebtedness in addition to a <ix:nonFraction unitRef="number" contextRef="i271ffaaf0e574d60ad9235c64c92906e_I20210811" decimals="2" name="vyne:RepaymentOfDebtPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMzg0ODI5MDcyMTE2Mg_246aa10b-9de0-4405-bb25-4d6d0852d60b">4</ix:nonFraction>% prepayment fee and accrued but unpaid interest in the total amount of approximately $<ix:nonFraction unitRef="usd" contextRef="ic25e62d0cd134ea88998d63b633a4770_D20210811-20210811" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMjc0ODc3OTA5NDAzOA_cb9a855d-9401-44a2-a1df-3c0e6e72e6eb">36.5</ix:nonFraction>&#160;million on August&#160;11, 2021. Following the prepayment, the Amended and Restated Credit Agreement has been terminated and the security interests thereunder will be terminated. The Company reclassified the outstanding indebtedness as a current liability based on the conditions existing as of June&#160;30, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on July 29, 2019, the lenders under the Credit Agreement were issued warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic3e2f164495a40aeb89e017df3b2607c_I20190729" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNDc4NQ_8fe490ac-f34e-42e8-894b-e7f75ed9dd49">1,100,000</ix:nonFraction> of Foamix ordinary shares, at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3e2f164495a40aeb89e017df3b2607c_I20190729" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNDgzOQ_6b88ebb8-b6a4-4fc7-b36f-cffd05ef5bda">2.09</ix:nonFraction> per share (the &#8220;Warrants&#8221;), which represented the five-day volume weighted average price of the Foamix ordinary shares as of the trading day immediately prior to the issuance of the Warrants. In connection with the completion of the Merger, the exchange ratio was applied to the Warrants such that they became exercisable for <ix:nonFraction unitRef="shares" contextRef="i29a95d4d274e49d39b10611f8aa1e359_I20200309" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNTE2OA_f65141e5-42cb-4a0e-bff4-0e775268a058">651,640</ix:nonFraction> shares of the Company&#8217;s common stock, and the exercise price was adjusted to $<ix:nonFraction unitRef="usdPerShare" contextRef="i29a95d4d274e49d39b10611f8aa1e359_I20200309" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNTI0OA_1c3f2842-61e8-44ec-8dd7-3e0a999c0d30">3.53</ix:nonFraction>. Following the Phase 3 PN Trial results, the Warrants were further adjusted for the CSR and reverse stock split and they are currently exercisable for <ix:nonFraction unitRef="shares" contextRef="i48f8896bfdb14e839b03b101221cb89b_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI4MA_b01fa099-515b-4b3d-84a4-bf6a1611b2ac">495,165</ix:nonFraction> shares of our common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i48f8896bfdb14e839b03b101221cb89b_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI4MQ_319aaed4-aa8a-4464-b4b7-b98df1cd0212">4.64</ix:nonFraction> per share. Payment of the exercise price will be made, at the option of the holder, either in cash or as a reduction of common stock issuable upon exercise of the Warrant, with an aggregate fair value equal to the aggregate exercise price ("cashless exercise"), or any combination of the foregoing.&#160;The Warrants are exercisable pursuant to the terms, and subject to the conditions, thereof and expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants' expiration date, if in the money. The Warrants issued were classified as equity in accordance with ASC 815-40. Proceeds received under the Tranche 1 Loan were allocated to the Warrants and the Tranche 1 Loan on a relative fair value basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i08340dd9766c473889a05f2e9e452090_D20190729-20190729" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNjI0NA_bd96596a-d0de-4d53-b4b9-f5ad174c889b">1.1</ix:nonFraction> million in connection with transactions contemplated by the Credit Agreement and the Securities Purchase Agreement, which were allocated to the Warrants, shares and debt consistently with the allocation of proceeds. The Company incurred additional expenses in the amount of $<ix:nonFraction unitRef="usd" contextRef="i615924500e1a48a1b14b32e08fe70444_D20190729-20190729" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNjUxMw_c26eb408-5f6e-458d-a158-9436a389cbcd">0.3</ix:nonFraction> million from the borrowing of Tranche 2 Loan, allocated only to the debt.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liabilities. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts allocated to the debt, net of issuance cost, are subsequently recognized at amortized cost using the effective interest method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt as of June&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i3ee35236062d43f9aceb739ebad9b33d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNjg1Ng_a0f6b11e-5ca6-44fa-a908-2b07d6c9aa53">36.9</ix:nonFraction> million and is categorized as Level 3. The valuation was performed by applying the income approach, under which the contractual present value method was used. The estimation of risk adjusted discount curve was based on public information reported in the financial statements of publicly traded venture lending companies.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i941ee28635c442dc9cac9a447ec51903">During the three months ended June&#160;30, 2021 and June&#160;30, 2020, the Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTYzNjY3Mw_16fd3a4e-f051-4d38-a5b6-398713b5ce09"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTYzNjY3Mw_e67507b9-c66a-4472-ae1b-244c76e45576">1.0</ix:nonFraction></ix:nonFraction> million and discount cost of $<ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTYzNjY3Nw_16533189-4fd1-44eb-bda3-d2e4d069b0dc"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTYzNjY3Nw_66042f9a-222b-42e8-bc25-3afa306e03fc">0.1</ix:nonFraction></ix:nonFraction> million. During the six months ended June&#160;30, 2021 and June&#160;30, 2020, the Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI1MQ_2e5891e6-4ec5-41fd-b536-678f0bd516f2"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI1MQ_c4ef6a1d-4759-4663-b0b4-0d16687d7eb8">1.9</ix:nonFraction></ix:nonFraction> million and discount cost of $<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI3NQ_5b118f55-0b44-4c13-bbd5-ce2676807c17"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI3NQ_dc04c59c-3acc-4d0c-806e-3e37bea9417f">0.2</ix:nonFraction></ix:nonFraction> million.</ix:continuation>  </span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_64"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9 &#8211; <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTEwMTQ_b0402e86-0e24-4b4d-a34a-79202fe383cc" continuedAt="i6269054c780b4cb49ab1d2b21b3110bb" escape="true">SHARE CAPITAL</ix:nonNumeric></span></div><ix:continuation id="i6269054c780b4cb49ab1d2b21b3110bb" continuedAt="i0b173a03e91043a18a360f48ce8a41ad"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company's Certificate of Incorporation, as amended, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTQy_772d950c-1e2a-4d17-b225-c22e70bac62b">20,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTgy_f799d240-bcc6-449c-ab17-68fe8fcad25e">0.0001</ix:nonFraction> per share.  There were <ix:nonFraction unitRef="shares" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjA4_7beda4fe-72ba-490b-aeca-b7109ede6385"><ix:nonFraction unitRef="shares" contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjA4_83b6b3a8-faed-405b-9d1f-94040d09874b"><ix:nonFraction unitRef="shares" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjA4_98ae118d-7121-4069-b343-f96efcaf8a9c"><ix:nonFraction unitRef="shares" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjA4_bdad4b32-27e6-4d84-917c-3564623fab88">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of preferred stock may be issued from time to time in one or more series.  The voting powers (if any), preferences and relative, participating, optional or other special rights, and the qualifications, limitations and restrictions of any series of preferred stock will be set forth in a Certificate of Designation filed pursuant to the Delaware General Corporation Law, as determined by the Company's Board of Directors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock authorized under the Company's Amended and Restated Certificate of Incorporation was proportionately reduced in connection with the Company's one-for-four reverse stock split in February 2021. On July 19, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i0b173a03e91043a18a360f48ce8a41ad" continuedAt="ib2a6858f847c404f913cdadd2a2e96af"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, the Company held its annual meeting of stockholders (the "Annual Meeting"). Following the approval by the holders of a majority of the outstanding shares of common stock at the Annual Meeting, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTY0MTMzMw_26b052fe-fe3a-4784-9aa2-1b5b0ac990ef">75,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i742062b5041f42418de6c43a30fbe8a2_I20210719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTY0MTM0Nw_ec424366-276f-49d9-a234-e53827f0b0a5">150,000,000</ix:nonFraction> shares, effective as of July 19, 2021. Accordingly, the Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i742062b5041f42418de6c43a30fbe8a2_I20210719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTY0MTM2MQ_ec424366-276f-49d9-a234-e53827f0b0a5">150,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i742062b5041f42418de6c43a30fbe8a2_I20210719" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTAxNA_2f7112a7-5774-406a-aaf5-b3dd79beb248"><ix:nonFraction unitRef="usdPerShare" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTAxNA_4fb880d9-d9ef-45e5-aecf-65bb38ded0e0">0.0001</ix:nonFraction></ix:nonFraction> per share. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="ia694da22cf534b119d5bfa52040066d2_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="vyne:CommonStockVotingRightsNumberPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA3MQ_b0bf8797-68bd-4593-980a-f09970bd535a">one</ix:nonFraction> vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of preferred stock outstanding. The Company has never declared any dividends on common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuance of stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2019, the Company entered into a Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp; Co., or Cantor Fitzgerald, to sell shares of the Company's common stock, from time to time, with aggregate gross sales proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="i038228081e6f4f1790fdcab0a61c49d4_D20190201-20190201" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTY1Mg_23f55e19-e9b2-44bf-9128-ef2d8d3ba133">50.0</ix:nonFraction> million through an at-the-market equity offering program under which Cantor Fitzgerald will act as our sales agent.  The issuance and sale of shares of common stock by us pursuant to the Sales Agreement are deemed an "at-the-market" offering under the Securities Act.  Cantor Fitzgerald is entitled to compensation for its services equal to up to <ix:nonFraction unitRef="number" contextRef="i3f7bc2d54cd0447d85aaad2c755a7b4d_D20190201-20190201" decimals="INF" name="vyne:CommissionFromGrossProceedsFromIssuanceOfCommonStock" scale="1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTk5NA_9ea3b184-7643-4c2b-8bc1-aeff39d8014f">3.0</ix:nonFraction>% of the gross proceeds of any shares of common stock sold under the Sales Agreement.  From January 1, 2021 through January 25, 2021, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="i9a2f164c78754c5d9affd590f3137bf8_D20210101-20210125" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjE1Nw_c695fbd8-deec-4a78-a58e-9c77a6a6a8a6">2,778,012</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i49b0dcc45925492cb597c2d5ec8cb906_I20210125" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjIyNA_6b63ad23-bb2e-41fa-9e68-7c0b64fba252">9.76</ix:nonFraction> pursuant to the Sales Agreement for $<ix:nonFraction unitRef="usd" contextRef="i9a2f164c78754c5d9affd590f3137bf8_D20210101-20210125" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjI2Mw_39c54c60-41bc-4f94-9ab9-65418a5e4bf6">26.3</ix:nonFraction> million in net proceeds. Effective as of January 25, 2021, the Company terminated the Sales Agreement and will not make any additional sales thereunder.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 26, 2021, the Company entered into a Securities Purchase Agreement with certain institutional and accredited investors for the sale of an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6a2f99820bb84452aea13ec915c8fa3b_D20210126-20210126" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjU3Mw_aeafbd11-c45b-4603-8eea-d0f4c318005b">5,274,261</ix:nonFraction> shares of common stock of the Company, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i50b0c0ff85cd433787d5bfdd753d8bab_I20210126" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjYzOA_2e9b3d94-bae5-41ce-8621-b1a99cc5d9eb">9.48</ix:nonFraction> per share in a registered direct offering. The offering was completed on January 28, 2021 and the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="i6a2f99820bb84452aea13ec915c8fa3b_D20210126-20210126" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjc3MA_4a505e08-b659-4273-8175-4d3c73e1fbdb">46.8</ix:nonFraction> million in net proceeds, after deducting placement agent fees and other offering expenses. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="iac7823d514fa4758beb050e55878ced3_D20200609-20200609" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjkzMQ_41b11520-0fe3-4b19-8c14-df8a144da566">7,776,875</ix:nonFraction> shares of common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8689f9a9a2e144918aa468473d6f4f11_I20200609" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjk4NQ_dc5d2002-af39-429f-a0e2-91cabe6513ec">7.40</ix:nonFraction> per share.  The net proceeds of the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="iac7823d514fa4758beb050e55878ced3_D20200609-20200609" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzA1Mg_f26b4563-6dd0-45d0-8013-31dd290bb894">53.6</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and other offering expenses.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the completion of the merger, on March 9, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzIyMQ_b330c401-9cd9-4578-bdc2-109847db3426">36,550,335</ix:nonFraction> shares to Foamix shareholders.  On April 6, 2020, pursuant to the terms of the CSR Agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="if21d5501c5f34c17ae7cdfe02a371143_D20200406-20200406" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzMzNw_4f7701be-1e0e-49c5-b798-a76a47ed431c">74,544,413</ix:nonFraction> shares to Foamix shareholders, adjusted retrospectively to <ix:nonFraction unitRef="shares" contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212" decimals="INF" format="ixt:numdotdecimal" name="vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzM5OQ_a1932318-2e26-439a-93c9-e0ad11dcd2f7">18,636,103</ix:nonFraction> shares of common stock upon the reverse stock split effective February 12, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entering into the Credit Agreement on July 29, 2019, Foamix issued to the lenders Warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="ie871aeb88d164ac194fee5617757929b_I20190729" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzYzNg_cecc631e-a168-4cb4-8a22-fb2fef428239">1,100,000</ix:nonFraction> of its ordinary shares, later exchanged to Warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i428a7beb16304a1c98e79a87b85028ab_D20190729-20190729" decimals="0" format="ixt:numdotdecimal" name="vyne:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzcwOQ_e8f6a41c-b6a8-4f11-a303-373705759e3c">1,980,660</ix:nonFraction> shares of Menlo&#8217;s common stock, adjusted retrospectively to <ix:nonFraction unitRef="shares" contextRef="i27760351ca2c4c7ba4e2acabf5d90f82_D20210212-20210212" decimals="0" format="ixt:numdotdecimal" name="vyne:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzc3Mg_3f26064a-5367-43c1-b9b5-51dde2db83c0">495,165</ix:nonFraction> shares of common stock upon the reverse stock split effective February 12, 2021. Upon the closing of the Merger, each Warrant received <ix:nonFraction unitRef="contingentstockright" contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309" decimals="INF" format="ixt-sec:numwordsen" name="vyne:BusinessAcquisitionContingentStockRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzkxMA_5273aa91-f8c3-4f4f-90f3-012e1625aa45">one</ix:nonFraction> CSR as described in Note 3- Business Combinations.  The Warrants were exercisable immediately following the closing of the Credit Agreement, subject to the terms of the warrant, and are due to expire on July 29, 2026.  Any Warrants left outstanding will be cashless exercised on the Warrants&#8217; expiration date, if in the money. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange of Warrants from Foamix warrants to Menlo warrants and the additional CSR was accounted for as a modification, by analogy, from the modification&#8217;s guidance under ASC 260-10-S99-2. The Company assessed the significance of the modification of the Warrants by comparing the fair value of the Warrants immediately before and after the amendments. In its assessment, it also considered additional qualitative factors. The Company concluded that the change of terms was not significant. Therefore, the incremental fair value, in the amount of $<ix:nonFraction unitRef="usd" contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309" decimals="-3" format="ixt:numdotdecimal" name="vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNDc5MQ_fc72b054-3fcd-4532-92d6-91fca36dd8f8">41,000</ix:nonFraction>, of the modified Warrants over the original ones (as of modification date) was recognized in retained earnings as a deemed dividend to the Warrants holders in the six months ended June&#160;30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-based compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity incentive plans:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the Merger, the Company adopted Foamix&#8217;s 2019 Equity incentive plan (the &#8220;2019 Plan&#8221;). As of June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i5dae593c3d39464ba022d2c59437553f_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNTEzOQ_fd79e7e6-6c76-4b77-af44-006232244cbd">1,240,195</ix:nonFraction> shares remain issuable under the 2019 Plan.  In addition, the Company adopted the 2018 Omnibus Incentive Plan (the "2018 Plan") in January 2018.  In January 2020, the number of shares reserved under the 2018 Plan automatically </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="ib2a6858f847c404f913cdadd2a2e96af" continuedAt="i5dbb946649d0411983fae767e8706a7d"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased by <ix:nonFraction unitRef="shares" contextRef="iec332474ea174f79b645e790d02cd783_I20210630" decimals="INF" format="ixt:numdotdecimal" name="vyne:CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNTM4Mg_8e6e0601-4d3d-4814-a5ad-5763fc337888">750,000</ix:nonFraction> shares of common stock pursuant to the terms thereof.  As of June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="iec332474ea174f79b645e790d02cd783_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNTQ1MA_77f4fbb2-6385-4a38-ada7-bd3751b28736">519,928</ix:nonFraction> shares remain issuable under the 2018 Plan.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Share Purchase Plan:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the Merger, the Company adopted Foamix&#8217;s Employee Share Purchase Plan ("ESPP") pursuant to which qualified employees (as defined in the ESPP) may elect to purchase designated shares of the Company&#8217;s common stock at a price equal to&#160;<ix:nonFraction unitRef="number" contextRef="i641098fa043e48aa8855d84732b16182_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNTc3Nw_8567405b-97f8-43b2-bcd0-a3f941cc1d37">85</ix:nonFraction>%&#160;of the lesser of the fair market value of the common stock at the beginning or end of each semi-annual share purchase period (&#8220;Purchase Period&#8221;). Employees are permitted to purchase the number of shares purchasable with up to <ix:nonFraction unitRef="number" contextRef="i65cc49f7fccb4771b6f817252050651d_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjAwNg_edf43709-0082-457b-8e09-4fe6ffb0b2d9">15</ix:nonFraction>% of the earnings paid (as such term is defined in the ESPP) to each of the participating employees during the Purchase Period, subject to certain limitations under Section 423 of the U.S. Internal Revenue&#160;Code.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i65cc49f7fccb4771b6f817252050651d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjIyOQ_ab5e8883-f951-40e2-b7c8-f5a69799e336">2,261,108</ix:nonFraction> shares remain available for grant under the ESPP.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i3b522232200e4ef29470815637a89d61_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTYzOTUxNQ_fb22cd75-aab4-4460-aef1-5da86d5258ac">42,989</ix:nonFraction> shares were issued to employees pursuant to the ESPP. During the six months ended June&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="i22a2ca05fede4ed3bb2d86f4e96744a8_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjQyOQ_4aaca6eb-fad0-4386-9272-7376c5b593d5">61,031</ix:nonFraction> Foamix ordinary shares were purchased by Foamix employees pursuant to the ESPP prior to the Merger. Such shares were later exchanged for <ix:nonFraction unitRef="shares" contextRef="i22b9c5bc79864c4ebd2e17fb68853be3_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjU2OQ_21de6847-af23-454d-b54a-95a47d256fcf">36,155</ix:nonFraction> shares of the Company's common stock and <ix:nonFraction unitRef="contingentstockright" contextRef="i376c62cb8cbc4fefa5c7f2ab24075e54_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="vyne:BusinessAcquisitionContingentStockRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjYxMw_55d627a2-a4f0-4199-bbed-b151c0bd4103">one</ix:nonFraction> CSR in the Merger, adjusted retrospectively to <ix:nonFraction unitRef="shares" contextRef="i4225a6209ef44ddaaa5e82e900a35d56_D20210212-20210212" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjY2Mw_65b98b2a-41f5-4516-ad42-7f3504017a49">9,038</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="contingentstockright" contextRef="ib3dbfc262f3d4d6e9849df3ec34b7adf_I20210212" decimals="INF" format="ixt-sec:numwordsen" name="vyne:BusinessAcquisitionContingentStockRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjY5Mw_bd049163-57c0-4999-b218-9c692e51248e">one</ix:nonFraction> CSR upon the reverse stock split effective February 12, 2021.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options and RSUs granted to employees and directors:</span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="vyne:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTEwMTU_24a01f00-df08-4cf4-82d3-e1821d08972c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended June&#160;30, 2021 and 2020, the Company granted options and RSU as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award<br/>amount*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price<br/>range*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy0xLTEtMS0w_2d344645-4d2a-49d3-a9ab-330b25b15b72">957,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy0zLTEtMS0wL3RleHRyZWdpb246ODFmNWYzZDM5ZjhiNDFmODlhYWIxZjNlNTI4OWU0Y2ZfNA_12b2dc41-a6be-42df-a713-ab2899d3fcc1">5.02</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy0zLTEtMS0wL3RleHRyZWdpb246ODFmNWYzZDM5ZjhiNDFmODlhYWIxZjNlNTI4OWU0Y2ZfNw_b0dd06c8-ea2e-4084-856b-f0f8a5c2ae15">11.08</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7e1b4af058494e31a6baf54a62b10e9f_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy01LTEtMS0wL3RleHRyZWdpb246NDQwODhkNTZiYWRkNDE0NTg1YzI3ZTk1ZDRmNzU4ZjNfNA_651b44ab-2b73-4e88-8588-767608443f27">1</ix:nonNumeric> year -<ix:nonNumeric contextRef="icaeba42a65bb4908a12b6c42bbe13190_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy01LTEtMS0wL3RleHRyZWdpb246NDQwODhkNTZiYWRkNDE0NTg1YzI3ZTk1ZDRmNzU4ZjNfOA_2e3149ab-07e1-495f-9ae9-c2de436cf413">4</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy03LTEtMS0w_a0801322-2822-427b-9d5c-21a2d23d20b0">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i524e30b547814ce3bcc5776c00614d79_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfNC0xLTEtMS0w_f51d0454-acb9-43dd-a9da-e6775e166706">366,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia05c23f9d5dd402b979cd7db4bad4117_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfNC01LTEtMS0wL3RleHRyZWdpb246MjJlMmM0YWQ2ZDBhNDFiYjgwMjM4Yjc1OWE4MGE1NzNfNA_feb0c6bb-7eef-4d6d-9cbb-c5fe3a4e57b6">1</ix:nonNumeric> year -<ix:nonNumeric contextRef="i35b1d069ce7e4403bcfb8dc34bb20fdd_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfNC01LTEtMS0wL3RleHRyZWdpb246MjJlMmM0YWQ2ZDBhNDFiYjgwMjM4Yjc1OWE4MGE1NzNfOA_ab71173d-9e2a-404c-bb14-b06ff43cc83c">4</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award<br/>amount*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price<br/>range*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy0xLTEtMS0w_7e762fc7-b3c6-4de7-b93d-1b7552238560">1,195,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy0zLTEtMS0wL3RleHRyZWdpb246MDI5ZTk0NzYyOTAzNDRjNGI1YWY3Mjc4MDNkYzcwMzRfNA_8d1e1823-9813-4712-ad54-ca46fe2c957a">7.80</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy0zLTEtMS0wL3RleHRyZWdpb246MDI5ZTk0NzYyOTAzNDRjNGI1YWY3Mjc4MDNkYzcwMzRfNw_17d32f85-f4dc-4527-acef-6815d99312ed">12.52</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8fb7478f500346ca86fa53d3e5c1bea3_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy01LTEtMS0wL3RleHRyZWdpb246ODVkNTBjOGI4OWVkNGUyNDg4YjMxMjMyZDVhNjUyNThfNA_9a5cdef6-b91a-416a-9214-64a0acdaa4d3">1</ix:nonNumeric> year -<ix:nonNumeric contextRef="i2ef2613cb84a47d9b3d12f99f63f3c4b_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy01LTEtMS0wL3RleHRyZWdpb246ODVkNTBjOGI4OWVkNGUyNDg4YjMxMjMyZDVhNjUyNThfOA_d074ca12-3536-4be3-8e77-87214ab9bb3b">4</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy03LTEtMS0w_2f595636-dd24-49ba-8ed5-757067235618">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc383d8b15744bd285e423d24f50602f_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfNC0xLTEtMS0w_6c25aab6-b459-4edb-b914-534e2afc3b11">647,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd075c5d380f49b1987fa8d6713944de_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfNC01LTEtMS0wL3RleHRyZWdpb246ZWRhZjk1ZmE1NmM5NGRlNGJmMzMwZTQ1Nzk0Mjk5ODlfNA_62597a65-2b4b-4386-9b7f-e9390fb390cb">1</ix:nonNumeric> year -<ix:nonNumeric contextRef="id19d638103a64be2acf8ac79042f7740_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfNC01LTEtMS0wL3RleHRyZWdpb246ZWRhZjk1ZmE1NmM5NGRlNGJmMzMwZTQ1Nzk0Mjk5ODlfOA_287676df-3b59-457c-91f2-bb75f8d9300e">4</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* All amounts and exercise prices for pre-Merger grants are presented following the exchange to Menlo options and RSUs at the Exchange Ratio described in Note 3-Business Combination.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options and RSUs granted to employees and directors during the six months ended June&#160;30, 2021 and the six months ended June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="vyne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNzIxNg_7df0035f-beff-448f-a11a-55ed98c86f7d">7.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="vyne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNzIyMw_887c8535-a700-47b5-80a3-5ec23ce04d06">11.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs granted is based on the share price on the grant date.</span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTEwMTY_230c0939-99d7-49e9-8955-0e5fc6a6dc9d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMi0xLTEtMS0w_37a51ab2-58cd-43e8-b9bf-58f9a887cfcf">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMi0zLTEtMS0w_de753d46-494e-4134-8045-2b0585bc3c4d">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMy0xLTEtMS0wL3RleHRyZWdpb246Njk1ZTNmYzQxZmFiNDUyMjhmNzQwNmY2NDhmODRhOGRfNA_cb6c5dc1-57dc-4c4c-973c-c97b1db5447d">68.38</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMy0xLTEtMS0wL3RleHRyZWdpb246Njk1ZTNmYzQxZmFiNDUyMjhmNzQwNmY2NDhmODRhOGRfNw_5dc2f41b-65ac-4c28-9fca-63eec6701a6a">69.12</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMy0zLTEtMS0wL3RleHRyZWdpb246ZTcyZDcwMjc3ZmVhNDVhMzkyNGUxYWVmYTMzM2ZjNTVfNA_975ebdb1-418d-449f-9044-d7aa4144db4a">60.44</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMy0zLTEtMS0wL3RleHRyZWdpb246ZTcyZDcwMjc3ZmVhNDVhMzkyNGUxYWVmYTMzM2ZjNTVfNw_a16c5cb6-ad26-42ab-aed4-aeccde38b4d6">69.83</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNC0xLTEtMS0wL3RleHRyZWdpb246YmQxMmEyNjc4NDFkNGY0MzgxYTA2MTg3ZmM3NzQyZWVfNA_6407e72e-7816-49e0-af98-c19dfe3e35f8">0.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNC0xLTEtMS0wL3RleHRyZWdpb246YmQxMmEyNjc4NDFkNGY0MzgxYTA2MTg3ZmM3NzQyZWVfNw_1c43c316-a7f3-43c3-b115-fd7ab96d17df">1.07</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNC0zLTEtMS0wL3RleHRyZWdpb246OWZiOWIwYWI0Y2UxNGM1ODkzZWI1YjYyYTFjZmJhMDJfNA_ede475b0-408b-4653-b06d-9ce1d45b64ae">0.44</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNC0zLTEtMS0wL3RleHRyZWdpb246OWZiOWIwYWI0Y2UxNGM1ODkzZWI1YjYyYTFjZmJhMDJfNw_45b3dfce-537e-43c2-8b30-32442e41a934">1.26</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNS0xLTEtMS0w_124ab78a-0cf3-4e42-9721-ea640b600176">6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNS0zLTEtMS0w_5fa1b5d5-7689-40f4-8070-f0959a8969c1">6</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger, all outstanding options and RSUs granted by Foamix were exchanged for stock options and RSUs of Menlo&#8217;s common stock according to the Exchange Ratio. In addition, for each option and RSU the holder received a CSR as </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i5dbb946649d0411983fae767e8706a7d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">described in Note 3- Business Combination. This transaction was considered by the company to be a modification under ASC 718, Compensation - Stock Compensation. The modification did not affect the remaining requisite service period. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded immaterial incremental compensation expense for the three months ended March 31, 2020.  As described in Note 3 - Business Combination, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into <ix:nonFraction unitRef="number" contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406" decimals="INF" name="vyne:ContingentStockRightSharesConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfODMwMQ_b81553da-afc3-4bc0-b78a-184707d40834">1.2082</ix:nonFraction> shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of <ix:nonFraction unitRef="number" contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406" decimals="4" name="vyne:EffectiveExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfODM5Mg_c7be5fdc-d8a4-45ff-a8ff-9d55c04c95e0">1.8006</ix:nonFraction> shares of Menlo common stock for each Foamix ordinary share.  The conversion was considered by the company to be a modification under ASC 718. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded incremental compensation of $<ix:nonFraction unitRef="usd" contextRef="i753ec734b4784e41991f04acf5c5cc91_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTYzOTE0Mg_a7e5ccdf-924a-40fc-8b02-66ef7f027f9e">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f58347fa5a54704957bea4315cd276b_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfODY5OA_ffe3fdbb-398c-4789-8fc6-f616e4639897">1.4</ix:nonFraction> million for the three and six months ended June&#160;30, 2021, respectively and $<ix:nonFraction unitRef="usd" contextRef="i8a28af5f07da4b9898e192b1f7e656df_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTYzOTExNw_5a0d212f-0331-4b56-9806-f240b3da7e1a"><ix:nonFraction unitRef="usd" contextRef="i650dc6e79b0646b69e2927249fe8ffd5_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTYzOTExNw_de81dff0-3ae6-49bc-8bd0-3dffb63f54ce">9.3</ix:nonFraction></ix:nonFraction> million for the three and six months ended June&#160;30, 2020.  As of June&#160;30, 2021 there is $<ix:nonFraction unitRef="usd" contextRef="i8f58347fa5a54704957bea4315cd276b_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="vyne:ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfODc0OA_3227d95c-80a1-4538-91c8-58a8066fa38c">1.9</ix:nonFraction> million of unrecognized incremental compensation expense related to the modification which will primarily be amortized using a graded vesting method over the next <ix:nonNumeric contextRef="i8f58347fa5a54704957bea4315cd276b_D20210101-20210630" format="ixt-sec:duryear" name="vyne:ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfODkwNg_c93d10af-c577-40ec-bd95-1d069a491b54">2</ix:nonNumeric> years.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards granted to holders who are no longer employed or providing services to the Company are accounted for in accordance with ASC 815-40, Derivatives and Hedging. Under this guidance, the awards are classified as a derivative liability because the award no longer exchanges a fixed amount of cash for a fixed number of shares. Accordingly, as of March 9, 2020 the Company reclassified $<ix:nonFraction unitRef="usd" contextRef="id374e55b59954cc8a6044053d732e5bb_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfOTI5Ng_cc69a039-010f-450d-a114-bce04d5960e4">1.6</ix:nonFraction> million from additional paid-in capital to derivative liability on the unaudited condensed consolidated balance sheet. Prior to the reclassification of these awards as a liability instrument, the Company recorded an incremental compensation expense of $<ix:nonFraction unitRef="usd" contextRef="id374e55b59954cc8a6044053d732e5bb_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfOTU0Mw_26792529-7c91-4952-ada2-7922c67e6518">0.6</ix:nonFraction> million due to the above mentioned modification in accordance with ASC 718. Subsequent to the reclassification of these awards as a liability instrument, the Company recorded incremental compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i62ea0913d468447f90567f896b4278c8_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfOTc0OQ_6a2ca766-4286-46c3-8b60-01ba9cef1f88">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i414facc7c16542e9bd4fb7ab3efbe2da_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTYzOTIyMw_7420b9dc-0b8d-4ede-b5e0-0595381b8556">1.0</ix:nonFraction> million million for the three and six months ended June 30, 2020.  There was <ix:nonFraction unitRef="usd" contextRef="i2f1e26cb367a4d819caeb25260e38425_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfOTgwNg_6495eed3-5d52-4161-9f8c-702d9bc0ce93"><ix:nonFraction unitRef="usd" contextRef="if6624a5563c848348d3967b0dc37ffed_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfOTgwNg_f1dbe07e-7ee4-4135-b255-55e97b36acde">no</ix:nonFraction></ix:nonFraction> incremental compensation expense for the three and six months ended June&#160;30, 2021.  As described in Note 3 - Business Combination, on April 6, 2020, the Company announced that study MTI-105 and study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis.  Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into <ix:nonFraction unitRef="number" contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406" decimals="INF" name="vyne:ContingentStockRightSharesConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTAzMjQ_b81553da-afc3-4bc0-b78a-184707d40834">1.2082</ix:nonFraction> shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of <ix:nonFraction unitRef="number" contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406" decimals="4" name="vyne:EffectiveExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA0MTU_3468e6b0-8dda-41a4-b94a-67a6bc7d129b">1.8006</ix:nonFraction> shares of Menlo common stock for each Foamix ordinary share.  On April 6, 2020, the awards are exchangeable for a fixed amount of cash for a fixed number of shares and were remeasured to fair value and reclassified from derivative liability to additional paid-in capital.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, Menlo recognized all expenses relating to awards outstanding as of the Effective Date. These awards were subject to acceleration upon the change of control per the previous Menlo stock option plan.</span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTEwMTc_792ebd01-6180-44cf-a4a1-22c6b1a2e94d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the effect of share-based compensation on the statements of operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e62a8b45834716a1bfce75e6f69049_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMi0xLTEtMS0w_fb80f893-fb64-44c4-a752-6420d9d9116c">442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5dd41a666f44f10b6f7fcf9d08a4914_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMi0zLTEtMS0w_acbe5c01-ef36-45f1-b346-62d4ac57f8dc">3,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0486d94e40b54296be6348fab054286d_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMi01LTEtMS0w_757b2602-19e2-4372-8259-69c3503541b2">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84198dfa6a324c93a59ee66d0eee6e13_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMi03LTEtMS0w_6da52471-abc1-4b37-94c1-a5eb10699206">3,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1691ef974cfc49b4b36a9537faf2c710_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMy0xLTEtMS0w_6cd6737a-f57d-4a5d-be8b-0495591a3720">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3146e6cf023a4b3dbb9950d620581293_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMy0zLTEtMS0w_626672df-84fa-4ef0-a697-fe44d3c05f0b">7,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a2e62b1f87439290f96db45c549d64_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMy01LTEtMS0w_c8312677-9f32-4c8f-a4cc-3433bdffb2eb">3,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea6504990b84f5cbc69647e56ecc4a9_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMy03LTEtMS0w_7743382b-90d7-4003-a32e-1434b5eb4994">8,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfNC0xLTEtMS0w_9bc6971d-5135-4589-b4b9-1a4c29d12544">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfNC0zLTEtMS0w_ef817be6-d81c-4309-a55c-f1784f5254bf">10,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfNC01LTEtMS0w_89aee8bd-9e04-49ad-a127-8f4a10f365c9">4,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfNC03LTEtMS0w_cdaab3f1-c22a-4861-991a-ab514fe866a6">12,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i25b00c7e5297459bafdb2282aa46fec2_70"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10 &#8211; <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMTcxMQ_ae762630-4be1-4935-8c6d-185819d97609" continuedAt="i1583492bd76c4cbeb02973ec8e24cc96" escape="true">OPERATING LEASE</ix:nonNumeric></span></div><ix:continuation id="i1583492bd76c4cbeb02973ec8e24cc96" continuedAt="i61c2a0912b8f402f94686d74c71bed94"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating lease agreements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for corporate offices and vehicles. The properties primarily relate to the Company&#8217;s principal executive office in Bridgewater, New Jersey and office space in Israel.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2019, the Company signed an amendment to the original lease agreement for its principal executive office in Bridgewater, New Jersey (the &#8220;Lease Amendment&#8221;). The Lease Amendment includes an extension of the lease period of the <ix:nonFraction unitRef="sqft" contextRef="i722a736ad61a4de08b6ba7e77f1bc3bc_D20190313-20190313" decimals="-4" format="ixt:numdotdecimal" name="vyne:FacilitySpaceUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfNDk3_38ebd0f3-9740-4319-b272-bc9666d8828d">10,000</ix:nonFraction> square feet previously leased under the original agreement (the &#8220;Original Space&#8221;) and an addition of <ix:nonFraction unitRef="sqft" contextRef="i381692c3937a48fc9cf55bbc32a4a79f_D20190313-20190313" decimals="0" format="ixt:numdotdecimal" name="vyne:FacilitySpaceUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfNjAx_8b50bef1-6cf8-449a-bd10-ea9bc9ad21de">4,639</ix:nonFraction> square feet (the &#8220;Additional Space&#8221;). The Company entered the Additional Space following a period of preparation by the lessor completed during September 2019 (the &#8220;Commencement Date&#8221;). The Lease Amendment is due to expire on August 31, 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Lease Amendment, the Company recognized an additional right of use asset and liability in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1d1e8908692340b4b78b852928f985fa_I20190313" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfOTY3_c15953ec-420a-4fad-adda-b478505747e1">0.7</ix:nonFraction> million. The Additional Space was considered a new lease agreement and was recognized as a right of use asset and liability, in the amount of $<ix:nonFraction unitRef="usd" contextRef="i54987e1926fd4ff78e485bd30599b12a_I20190313" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMTEwNA_f3a17e95-76ed-4f34-961e-7b7261fad4be">0.3</ix:nonFraction> million, on the Commencement Date.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><ix:continuation id="i61c2a0912b8f402f94686d74c71bed94"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease agreement for the office space in Israel is a <ix:nonNumeric contextRef="i0c8acb1983b042eca15f9a025c2d4572_I20210630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMjc0ODc3OTA3MTE2Mg_92f07aba-0996-4a3c-9b6d-0d146f2f4377">one year</ix:nonNumeric> lease that expires in December 2021.  Given the short-term nature of the lease term, the Company did not recognize a right-of-use asset and liability.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company entered into operating lease agreements in connection with the leasing of vehicles. The lease periods are generally for <ix:nonNumeric contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMTcxMg_73235b14-943d-4991-92bf-b6a3e1a4833f">three years</ix:nonNumeric>. </span></div><ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMTcxMw_4be0ec94-f1b8-47f4-a0d9-e4f18ffb93eb" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfMS0xLTEtMS0w_ab83f527-14ef-4913-9331-87a7d0fd9be6">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfMi0xLTEtMS0w_f58dceb0-bd1d-47d9-8df3-a64c5336466a">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfMy0xLTEtMS0w_40ebdcca-8349-41c8-96b7-ed5c30960aeb">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfNS0xLTEtMS0w_866635a8-e119-490c-8384-1524efd5a015">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfNi0xLTEtMS0w_274ee47c-3544-4a19-92ba-8e17efebf2d4">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfNy0xLTEtMS0w_e31a0fce-d66a-4835-a591-e0d3e3a03e16">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company had a lien in the amount of $<ix:nonFraction unitRef="usd" contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="vyne:RestrictedInvestmentsToSecureLeaseAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMTYwOQ_a635e8ea-2d4e-4206-b771-c98ca6dc473a">0.6</ix:nonFraction> million on the Company&#8217;s cash in respect of bank guarantees granted in order to secure the lease agreements.</span></div></ix:continuation><div id="i25b00c7e5297459bafdb2282aa46fec2_73"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11 &#8211; <ix:nonNumeric contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83My9mcmFnOmVhMjhjZGRlYjMyYzRmYjE4M2M3OGQwY2RlZDNlNWEzL3RleHRyZWdpb246ZWEyOGNkZGViMzJjNGZiMTgzYzc4ZDBjZGVkM2U1YTNfMzIx_71b42217-8842-4e11-8772-c462f18b11ed" continuedAt="i63d529daaba147118b293beb76661c6a" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i63d529daaba147118b293beb76661c6a" continuedAt="i9a4e64f7379f487597a23eaae8e38132"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may periodically become subject to legal proceedings and claims arising in connection with its business. As of June&#160;30, 2021, no claims or actions are pending against the Company that, in the opinion of management, are likely to have a material adverse effect on the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on June 30, 2021, the Company received a paragraph IV certification notice (the &#8220;Notice&#8221;) from Padagis Israel Pharmaceuticals Ltd. (f/k/a Perrigo Israel Pharmaceuticals Ltd. (&#8220;Padagis&#8221;)) advising that Padagis has submitted to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) an Abbreviated New Drug Application (&#8220;ANDA&#8221;) seeking approval to manufacture and sell a generic version of the Company&#8217;s product AMZEEQ&#174; (minocycline) topical foam, 4% in the United States prior to the expiration of the Company&#8217;s U.S. patents Nos. 8,865,139, 8,945,516, 8,992,896, 9,675,700, 10,086,080, 10,137,200, 10,213,512, 10,265,404, 10,398,641, 10,517,882, 10,821,187, and 10,849,847 (the &#8220;Listed Patents&#8221;), which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the &#8220;Orange Book.&#8221; The Notice alleges that the Listed Patents are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Padagis&#8217;s ANDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, the Company initiated a patent infringement suit against Padagis in the United States District Court for the District of Delaware arising from Padagis&#8217;s ANDA filing with the FDA. The patent infringement suit asserts each of the Listed Patents. As a result, under applicable law, the FDA cannot grant final approval to Padagis&#8217;s ANDA before December 30, 2023, or a court decision in Padagis&#8217;s favor. VYNE is seeking, among other relief, an order that the effective date of any FDA approval of Padagis&#8217;s ANDA be no earlier than the expiration of the Listed Patents, the latest of which expires on September 8, 2037, and such further and other relief as the court may deem appropriate.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9a4e64f7379f487597a23eaae8e38132">The Company intends to vigorously defend its intellectual property rights, including the Listed Patents.</ix:continuation> </span></div><div><span><br/></span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_1137"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form&#160;10-Q and our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020. In this Quarterly Report on Form 10-Q, unless otherwise indicated, all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; or similar terms refer to VYNE Therapeutics Inc. The disclosure set forth in this section reflects the Company's 1-for-4 reverse stock split, which was effected on February 12, 2021. Accordingly, all share amounts and per share amounts have been adjusted. </span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_79"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2021, we conducted a review of our commercial and research and development portfolio to determine how to optimally deploy capital and drive shareholder value. During the course of this review, we carefully considered the revenues received from the commercialization of AMZEEQ and ZILXI and the associated costs to drive those revenues, the protracted negative impact of the COVID-19 pandemic over the past 18 months during the commercial launches of both AMZEEQ and ZILXI, the current payor landscape, as well as the costs to develop each of our pipeline products. During this process, we evaluated several strategic options, including the acquisition of marketed assets, out-licensing our approved products outside of the United States, and possible partnering or co-development relationships with interested parties. Following our review, we have determined to initiate a process to explore a possible sale or license of our topical minocycline franchise, including AMZEEQ, ZILXI, FCD105 (the Company&#8217;s Phase 3 proprietary novel topical combination foam formulation of minocycline and adapalene for the treatment of moderate-to-severe acne vulgaris) and the underlying Molecule Stabilizing Technology platform.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By leveraging our drug development and clinical development capabilities and strong network of discovery and preclinical science partners, we will transition our strategic focus to develop therapies for the treatment of immuno-inflammatory diseases of high unmet medical need. We expect to continue to invest in FMX114 for the treatment of mild to moderate atopic dermatitis and anticipate the first patient in our Phase 2a proof-of-concept study will be enrolled in the third quarter of 2021. We expect results from this study by the end of 2021. In addition, on August 12, 2021, we announced a transaction with In4Derm Limited, a company incorporated and registered in Scotland (&#8220;In4Derm&#8221;). In4Derm is a spin-out of the University of Dundee&#8217;s School of Life Sciences which has discovered and is developing proprietary Bromodomain and Extra-Terminal Domain Inhibitors (&#8220;BETi&#8221;) for the treatment of immunology and oncology conditions. On April 30, 2021, the parties entered into an Evaluation and Option Agreement (the &#8220;Option Agreement&#8221;) pursuant to which In4Derm granted us an exclusive option to obtain exclusive worldwide rights to research, develop and commercialize products containing In4Derm&#8217;s BETi compounds, which are new chemical entities, in both topical (the &#8220;Topical BETi Option&#8221;) and oral (the &#8220;Oral BETi Option&#8221;) treatments in all fields for any disease, disorder or condition in humans. On August 6, 2021, we exercised the Topical BETi Option and the parties entered into a License Agreement granting VYNE a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of In4Derm&#8217;s BETi compounds identified to be suitable for topical administration in all fields. We paid a $1.0 million cash payment to In4Derm upon the execution of the Option Agreement and $0.5 million in connection with the exercise of the Topical BETi Option. Pursuant to the License Agreement, we have agreed to make cash payments to In4Derm upon the achievement of specified clinical development and regulatory approval milestones with respect to each licensed topical product in the U.S. of up to $15.75 million for all indications. In addition, we currently expect to exercise the Oral BETi Option following the selection of a lead candidate for the program. Upon exercise of the exclusive Oral BETi Option, the parties will sign a license agreement (the &#8220;Oral License Agreement&#8221;), and we will pay In4Derm a $4.0 million cash payment. The Oral License Agreement will include cash payments of up to $43.75 million payable to In4Derm upon the achievement of specified clinical development and regulatory approval milestones with respect to each licensed oral product in the U.S. for all indications. The license agreements also provide for tiered royalty payments of up to 10% of net annual sales across licensed BETi products by VYNE. In4Derm is entitled to additional milestones upon the achievement of regulatory approvals in certain jurisdictions outside the U.S. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The initial BETi candidates that we plan to develop are VYN201 and VYN202. VYN201 is a pan-bromodomain or pan-BD BET inhibitor.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It is a first-in-class &#8220;soft&#8221; pan-BD BET inhibitor that is designed to mitigate systemic drug exposure and will be developed for topical applications. We intend to progress VYN201 into rare, neutrophilic, dermatological indications where there is significant unmet need due to a lack of indicated treatment options. We plan to enter this program into the clinic in 2022 after the prerequisite non-clinical safety assessments have been completed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The second candidate, VYN202, is an orally-delivered, first-in-class BET inhibitor that is highly selective for Bromodomain 2 ("BD2"). Recent research has suggested that the majority of pro-inflammatory signaling via BET protein action is via interactions with BD2. By selectively inhibiting BD2, we believe VYN202 could have a more targeted anti-inflammatory effect with an improved benefit/risk profile. We view VYN202 as having significant potential as a novel, oral treatment for major </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">immuno-inflammatory indications. Following the exercise of the Oral BETi Option, we intend to commence a IND-enabling non-clinical safety program for VYN202 and enter the clinic in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As we transition from a commercial organization to one focused on research and development, we intend to streamline operations by eliminating the vast majority of planned expenditures supporting our commercial operations. Furthermore, we intend to reduce our workforce by terminating approximately 70 employees, which we expect to be completed by December 31, 2021. We expect to incur a one-time charge in the range of approximately $<ix:nonFraction unitRef="usd" contextRef="ibace252288db423ca83fb8257a0d36f9_I20210930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83OS9mcmFnOjIwNWE2MThjMzE5NzQyOTFhZjNmY2NhZjViOGQ0OTRlL3RleHRyZWdpb246MjA1YTYxOGMzMTk3NDI5MWFmM2ZjY2FmNWI4ZDQ5NGVfMzg0ODI5MDcwOTc3Ng_ce1447a2-9598-4ec6-b232-d2c6f1fdd513">1.5</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i20cbba757ccb4615a4d0cfe3c3f988dd_I20210930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83OS9mcmFnOjIwNWE2MThjMzE5NzQyOTFhZjNmY2NhZjViOGQ0OTRlL3RleHRyZWdpb246MjA1YTYxOGMzMTk3NDI5MWFmM2ZjY2FmNWI4ZDQ5NGVfMzg0ODI5MDcwOTc4Mw_5582bfd0-d3bb-498e-b711-05d098e87bd2">2.0</ix:nonFraction>&#160;million, excluding non-cash charges, in connection with this restructuring plan, consisting primarily of employee termination costs, including severance and other benefits. This charge is expected to be incurred during the quarter ending September 30, 2021 with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">related cash payments expected to be substantially paid out by December 31, 2021.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_82"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Developments</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of selected key developments affecting our business that have occurred since December 31, 2020:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">From January 1, 2021 through January 25, 2021, the Company issued and sold  2,778,012 shares of common stock at a weighted average price per share of $9.76 for $26.3 million in net proceeds pursuant to a Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp; Co. ("Cantor Fitzgerald") through an at-the-market equity offering program under which Cantor Fitzgerald acted as our sales agent. Effective as of January 25, 2021, the Company terminated the Sales Agreement and will not make any additional sales thereunder.  </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 21, 2021, the Company announced the execution of a contract with CVS Caremark ("Caremark"), one of the largest pharmacy benefit managers in the U.S., with respect to AMZEEQ and ZILXI. In late March 2021, Caremark informed the Company that it decided to not include these products, and other new branded comparator drugs, on its national formulary for 2021. Certain custom plans under the Caremark umbrella have decided to add the Company's drugs to their respective formularies. This could have an unfavorable pricing impact in the future.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 28, 2021, the Company completed a registered direct offering of 5,274,261 shares of common stock at a price of $9.48 per share. The net proceeds of the offering were approximately $46.7 million, after deducting placement agent fees and other offering expenses. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On February 1, 2021, we announced that the FDA approved a label update for AMZEEQ, including new information indicating the low propensity of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Propionibacterium acnes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (more commonly known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">P. acnes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) to develop resistance to minocycline.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On February 10, 2021, our Board of Directors approved a one-for-four reverse stock split of our outstanding shares of common stock. The reverse stock split was effected on February 12, 2021 at 5:00 p.m. Eastern time. At the effective time, every four issued and outstanding shares of our common stock were converted into one share of common stock. No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each stockholder holding fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company&#8217;s transfer agent in an amount equal to such stockholder&#8217;s respective pro rata share of the total net proceeds from the Company&#8217;s transfer agent sale of all fractional shares at the then-prevailing prices on the open market. In connection with the reverse stock split, the number of authorized shares of our common stock was also reduced on a one-for-four basis, from 300 million to 75 million. The par value of each share of common stock remained unchanged. A proportionate adjustment was also made to the maximum number of shares issuable under the Company&#8217;s 2019 Equity Incentive Plan, 2018 Omnibus Incentive Plan and 2019 Employee Share Purchase Plan. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 1, 2021, we announced development plans for FMX114 for the potential treatment of mild-to-moderate atopic dermatitis. FMX114 is a fixed combination of tofacitinib, which is a pan-Janus kinase (JAK) inhibitor, and fingolimod, a sphingosine 1-phosphate receptor modulator. FMX114 attempts to address both the source and cause of inflammation in atopic dermatitis and support skin barrier recovery.  </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tyler Zeronda was appointed as our interim Chief Financial Officer and Treasurer, effective as of June 18, 2021, following the resignation of Andrew Saik. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On July 19, 2021, the Company amended its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 75,000,000 to 150,000,000 shares. The increase in the number of authorized shares was approved by the holders of a majority of the outstanding shares of common stock at the Company's annual meeting of stockholders held on July 19, 2021. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">On August 9, 2021, we initiated a patent infringement suit against Padagis Israel Pharmaceuticals Ltd. (f/k/a Perrigo Israel Pharmaceuticals Ltd. (&#8220;Padagis&#8221;)) in the United States District Court for the District of Delaware arising from Padagis&#8217;s ANDA filing with the FDA. The patent infringement suit asserts each of the patents related to AMZEEQ listed in the Orange Book (the &#8220;Listed Patents&#8221;). As a result, under applicable law, the FDA cannot grant final approval to Padagis&#8217;s ANDA before December 30, 2023, or a court decision in Padagis&#8217;s favor. VYNE is seeking, among other relief, an order that the effective date of any FDA approval of Padagis&#8217;s ANDA be no earlier than the expiration of the Listed Patents, the latest of which expires on September 8, 2037, and such further and other relief as the court may deem appropriate.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On August 11, 2021, the Company prepaid its outstanding indebtedness in addition to a 4% prepayment fee and accrued but unpaid interest. Following the prepayment, the Amended and Restated Credit Agreement has been terminated and the security interests thereunder will be terminated. See "Part I&#8212;Item 1. Unaudited Condensed Consolidated Financial Statements&#8212;Note 8. Debt."</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">On August 12, 2021, we announced a licensing arrangement with In4Derm, giving us access to their library of novel BETi compounds. See "&#8212;Company Overview."</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">On August 12, 2021, we announced that we have initiated a process to explore a sale or license of our topical minocycline franchise. In addition, we will refocus our resources on our immuno-inflammatory development programs, including the compounds that we licensed from In4Derm. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;&#8212;Company Overview.&#8221;</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_85"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception. Until the first quarter of 2020, when we commenced commercial operations, our business activities were primarily limited to developing product candidates, raising capital and performing research and development activities. As of&#160;June&#160;30, 2021, we had an accumulated deficit of $606.7 million. We recorded net losses of $19.9 million and $167.4 million for the three months ended June&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our capital resources and business efforts have largely been focused on activities relating to the commercialization of AMZEEQ and ZILXI and advancing our product candidates and pipeline. As discussed above, we completed a strategic review of our business and have determined to explore a possible sale or license of our minocycline franchise, including AMZEEQ, ZILXI, FCD105 and the underlying MST platform. We will refocus our resources on our immuno-inflammatory pipeline and expect to support the continued development of FMX114 and the BETi research and development programs. Research and development activities for these programs, including preclinical and clinical testing of the Company&#8217;s drug candidates, will require significant additional financing. The future viability of the Company is dependent on our ability to successfully execute our business strategy and develop our drug candidates and raise additional capital to finance operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our failure to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_88"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Operating Results</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue during the periods presented has been comprised of AMZEEQ and ZILXI product sales and collaboration revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received FDA approval for AMZEEQ on October 18, 2019 and launched AMZEEQ in the United States in January 2020. We commercially launched ZILXI on October 1, 2020. We have generated product revenue of $7.9 million for the six months ended June&#160;30, 2021. We will not commercially launch our other product candidates in the United States or generate any revenues from sales of any of our product candidates unless and until we obtain marketing approval. Our ability to generate revenues from sales will depend on the successful commercialization of our drug products AMZEEQ and ZILXI and any other product candidates that receive marketing approval.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have generated revenues under development and license agreements including royalty payments in relation to Finacea, the prescription foam product that we developed in collaboration with Bayer, which later assigned it to Leo Pharma A/S ("LEO"). In the three months ended March 31, 2020, we did not receive or become entitled to any royalty payments due to the suspension of the manufacturing of Finacea by LEO, following inadequate supply of quality-compliant batches of the API used in such product. In April 2020, LEO informed us that it had reestablished the supply of Finacea foam and resumed commercial sale in the United States. In the six months ended June&#160;30, 2021 we received royalties of $0.5 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become entitled to additional contingent payments in the future, subject to achievement of the applicable clinical results by our other licensees. However, in light of the current phase of development and associated milestone schedules under these agreements, we do not expect to receive significant payments in the near term, if at all. We are also entitled to additional royalties from net sales or net profits generated by other products to be developed under these agreements, if they are successfully commercialized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on April 23, 2020, we entered into a licensing agreement with Cutia for AMZEEQ as well as certain of our other topical minocycline product candidates,&#160;once approved, on an exclusive basis in&#160;Greater China. Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the&#160;U.S., FCD105 in the&#160;Greater China&#160;territory. We will supply the finished licensed products to Cutia for clinical and commercial use. We received an upfront cash payment of&#160;$10.0 million&#160;in 2020 ($6.0 million received in the three months ended June 30, 2020 and $4.0 million received in the three months ended September 30, 2020) and will be eligible to receive an additional&#160;$1 million&#160;payment upon the receipt of marketing approval in&#160;China&#160;of the first licensed product. We will also receive royalties on net sales of any licensed products pursuant to the agreement.  There was no license revenue for the six months ended June&#160;30, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold for the six months ended June&#160;30, 2021 and 2020 were approximately $1.4 million and $0.5 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross margin percentage of&#160;82%&#160;and 85% was favorably impacted during the six months ended June&#160;30, 2021&#160;and June 30, 2020, respectively, by product sales with certain materials produced prior to FDA approval and therefore expensed in prior periods. If inventory sold during the six months ended June&#160;30, 2021 and June&#160;30, 2020&#160;was valued at cost, our gross margin for the period then ended would have been&#160;80% and 80%, respectively.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold expenses consist primarily of:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">third party expenses incurred in manufacturing product for sale;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">transportation costs incurred in shipping manufacturing materials between third parties; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">other costs associated with delivery and manufacturing of product.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses to date relate primarily to the development of AMZEEQ, ZILXI, serlopitant, FCD105 and FMX114. Our total research and development expenses for the six months ended June&#160;30, 2021 and 2020 were approximately $12.7 million and $29.1 million, respectively. We charge all research and development expenses to operations as they are incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits and related expenses, including share-based compensation expenses;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses incurred under agreements with third parties, including subcontractors, suppliers and consultants that conduct regulatory activities, clinical trials and preclinical studies;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses incurred to acquire, develop and manufacture clinical trial materials;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and other operating costs;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs associated with the creation, development and protection of intellectual property;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">other costs associated with preclinical and clinical activities and regulatory operations; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">materials and manufacturing costs related to commercial production prior to FDA approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses for the six months ended June&#160;30, 2021 and 2020 were approximately $32.5 million and $51.9 million, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist principally of:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits and related expenses, including share-based compensation expenses;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with selling, marketing and shipping and handling costs;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legal and professional fees for auditors and other consulting expenses; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility, information technology and depreciation expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily consists of interest expense on our long-term debt.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense, net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Expense, net primarily consists of gains from interest earned from our bank deposits, financial income on our marketable securities and a revaluation of our derivative liability. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes and Net Operating Loss Carryforwards</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net operating losses (&#8220;NOLs&#8221;) since our inception. We expect to continue to incur NOLs until such a time when AMZEEQ, ZILXI&#160;or any other product, if approved in the future, generates adequate revenues for us to reach profitability. As of December 31, 2020, we had federal and state net operating loss carryforwards of $243.2 million and $66.3&#160;million, respectively, of which $44.3 million and $66.3 million of these carryforwards will begin to expire in 2031 for federal and state purposes, respectively. As of December 31, 2020, we had federal and state research and development tax credit carryforwards of $6.2 million and $1.2 million, respectively. The federal credits begin to expire in 2031 and the California research credits have no expiration dates. As of December 31, 2020, the company had $198.9 million in federal and state NOLs with no limited period of use.  There are no significant updates through June&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of our company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. State NOLs and tax credit carryforwards may be subject to similar limitations under state laws. We have not determined if we have experienced Section&#160;382 ownership changes in the past and if a portion of our net operating loss and tax credit carryforwards are subject to an annual limitation under Sections&#160;382 or 383. We may have experienced ownership changes in the past, including in connection to our initial public offering (&#8220;IPO&#8221;), and as a result of the Merger and/or subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, even if we earn net taxable income, our ability to use the NOL and tax credit carryforwards may be materially limited, which could harm our future operating results by effectively increasing our future tax obligations.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_91"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three-Month Periods Ended June&#160;30, 2021 and 2020</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues totaled $4.3 million and $11.7 million for the three months ended June&#160;30, 2021 and 2020, respectively. For the three months ended June&#160;30, 2021, our revenue consisted of $4.0 million of product sales and $0.3 million of royalty revenue. For the three months ended June&#160;30, 2020, revenues consisted of $1.5 million of product sales, $0.2 million of royalty revenue and $10.0 million of license revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in product sales is due to the ZILXI product launch in October 2020 and an increase in demand for AMZEEQ.  The decrease in license revenue for the three months ended June 30, 2021 as compared to license revenue for the three months ended June 30, 2020 is due to the upfront cash payment received in 2020 under the licensing agreement with Cutia for the sale and marketing of our topical minocycline products in China.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on our operations. Access to healthcare providers has been limited through the second quarter of 2021, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI.  The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition and liquidity will depend on future developments that are highly uncertain, subject to change and will continue to evolve with geographical re-openings, surges in cases, the development of new strains and the vaccination effort</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $0.8 million and $0.2 million for the three months ended June&#160;30, 2021 and 2020, respectively. The increase in cost of goods sold is primarily due to an increase in sales volume.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross margin percentage was 80% for the three months ended June&#160;30, 2021.  Our gross margin percentage of&#160;85%&#160;for the three months ended June&#160;30, 2020 was favorably impacted by product sales with certain materials produced prior to FDA approval and therefore expensed in prior periods. If inventory sold during the three months ended June&#160;30, 2020&#160;was valued at cost, our gross margin for the period then ended would have been 80%.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses for the three months ended June&#160;30, 2021 were $6.4 million, representing a decrease of $6.7 million, or 51.1%, compared to $13.1 million for the three months ended June&#160;30, 2020.  Employee-related expenses decreased $4.6 million primarily due to severance costs incurred in 2020 due to the Merger, including  stock based compensation.  Clinical trial and manufacturing expenses decreased with the completion of FCD105 and serlopitant clinical trials and the product launches of AMZEEQ and ZILXI during 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses for the three months ended June&#160;30, 2021 were $15.8 million, representing a decrease of $10.6 million, or 40.2%, compared to $26.5 million for the three months ended June&#160;30, 2020. Employee-related expenses decreased by $8.5 million primarily due to severance costs incurred in 2020 due to the Merger.   Professional services spend decreased as these expenses were incurred in 2020 as a result of the Merger.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended June&#160;30, 2021 and June&#160;30, 2020 was $1.1 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense (Income), net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net for the three months ended June&#160;30, 2021 was $0.1 million of expense as compared with $0.5 million of income for the three months ended June&#160;30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2021 there was no income tax expense.  Income tax benefit for the three months ended June&#160;30, 2020 was $0.3 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six-Month Periods Ended June&#160;30, 2021 and 2020</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues totaled $8.4 million and $13.4 million for the six months ended June&#160;30, 2021 and 2020, respectively. For the six months ended June&#160;30, 2021, our revenue consisted of $7.9 million of product sales and $0.5 million of royalty revenue. For the six months ended June&#160;30, 2020, revenues consisted of $3.2 million of product sales, $0.2 million of royalty revenue and $10.0 million of license revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in product sales is due to the ZILXI product launch in October 2020 and an increase in demand for AMZEEQ. The decrease in license revenue for the six months ended June 30, 2021 as compared to license revenue for the six months ended </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2020 is due to the upfront cash payment received in 2020 under the licensing agreement with Cutia for the sale and marketing of our topical minocycline products in China.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $1.4 million and $0.5 million for the six months ended June&#160;30, 2021 and 2020, respectively. The increase in cost of goods sold is primarily due to an increase in sales volume.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross margin percentage of&#160;82%&#160;and 85% for the six months ended June&#160;30, 2021&#160;and June 30, 2020, respectively, was favorably impacted by product sales with certain materials produced prior to FDA approval and therefore expensed in prior periods. If inventory sold during the six months ended June&#160;30, 2021 and June 30, 2020&#160;was valued at cost, our gross margin for the period then ended would have been&#160;80% and 80%, respectively.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses for the six months ended June&#160;30, 2021 were $12.7 million, representing a decrease of $16.3 million, or 56.2%, compared to $29.1 million for the six months ended June&#160;30, 2020.  Employee-related expenses decreased $9.6 million primarily due to severance costs incurred in 2020 due to the Merger including stock based compensation.  Clinical trial and manufacturing expenses decreased with the completion of FCD105 and serlopitant clinical trials and the product launches of AMZEEQ and ZILXI during 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses for the six months ended June&#160;30, 2021 were $32.5 million, representing a decrease of $19.4 million, or 37.4%, compared to $51.9 million for the six months ended June&#160;30, 2020. Employee-related expenses decreased by $13.6 million primarily due to severance costs incurred in 2020 due to the Merger, including stock based compensation.   Professional services spend decreased as these expenses were incurred in 2020 as a result of the Merger.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the six months ended June&#160;30, 2021 and June&#160;30, 2020 was $2.1 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense (Income), net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net for the six months ended June&#160;30, 2021 was $0.1 million of expense as compared with $1.3 million of income for the six months ended June&#160;30, 2020.  Other income decreased primarily due to a decrease in gains on derivative liabilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021 there was no income tax expense.  Income tax benefit for the six months ended June&#160;30, 2020 was $0.3 million.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_94"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched AMZEEQ in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company also launched ZILXI in the United States in October 2020 and commenced generating revenues in the fourth quarter of 2020. The Company&#8217;s activities prior to the commercial launches of AMZEEQ and ZILXI had primarily consisted of raising capital, developing product candidates, and performing research and development activities. Since inception, the Company has incurred recurring losses and negative cash flows from operations. As of June&#160;30, 2021, we had cash, cash equivalents, restricted cash and investments of $104.0 million. The outstanding debt under our Amended and Restated Credit Agreement at June 30, 2021 was $35.0 million. On August 11, 2021, we prepaid the entirety of our outstanding indebtedness, including a prepayment premium and accrued but unpaid interest, for a total amount of approximately $36.5 million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. In addition, the commercial launches of both AMZEEQ and ZILXI have been negatively impacted by unfavorable payor decisions in March 2021 on product pricing. These conditions have impaired our ability to generate revenue consistent with internal forecasts, which has had a negative impact on our financial condition and liquidity. The Company and its lenders discussed revenue expected to be generated for the trailing twelve month period ended June 30, 2021, the revenue targets included in the Amended and Restated Credit Agreement and the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company&#8217;s strategic transition discussed above. Following such discussions, the Company determined to prepay its outstanding indebtedness in addition to a 4% prepayment fee and accrued but unpaid interest in the total amount of approximately $36.5 million on August&#160;11, 2021. Following the prepayment, the Amended and Restated Credit Agreement has been terminated and the security interests thereunder will be terminated. See "Part I&#8212;Item 1. Unaudited Condensed Consolidated Financial Statements&#8212;Note 1. Nature of Operations&#8212;Liquidity and Capital Resources and  &#8212;Note 8. Debt."</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the Company completed a strategic review of its business and has determined to initiate a process to explore a sale or license of its minocycline franchise, including AMZEEQ, ZILXI, FCD105 and the underlying MST platform. The Company will refocus its resources on its immuno-inflammatory pipeline and intends to support the FMX114 and the BETi development programs. Research and development activities for these programs, including preclinical and clinical testing of the Company&#8217;s drug candidates, will require significant additional financing. The future viability of the Company is dependent on its ability to successfully pivot to its research and development business strategy and develop commercially viable drug candidates and raise additional capital to finance its operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is contingent on its ability to sell or license its minocycline franchise, develop future commercially viable products and/or to raise sufficient working capital through either debt or equity financing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance the Company will be able to achieve these objectives under acceptable terms or at all.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that its unaudited condensed consolidated financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company&#8217;s ability to continue as a going concern is expected to be impacted by the outcome of the plans outlined above, including the successful sale or license of its minocycline franchise, positive results from clinical trials for FMX114, and the successful development and positive results from clinical trials for the BETi programs. The Company will not have sufficient cash and cash equivalents to fund its operations beyond one year from the issuance of its June 30, 2021 financial statements. Based on its plans to conduct a Phase 2b clinical trial for FMX114 (assuming positive results in the Phase 2a study) and progress both the topical and oral BETi programs into the clinic in 2022, the Company currently believes it has sufficient cash and cash equivalents to fund its operations through the end of the second quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This assumes that operating expenses will be significantly reduced in connection with the disposition of the minocycline franchise and projected clinical trial costs. This excludes potential proceeds received from a sale or license of the minocycline franchise, business development transactions or financing transactions which are all beyond the Company&#8217;s control. As such, the Company will, over the course of the next twelve months, require significant additional financing to continue its operations. Each of these factors are subject to uncertainty, and therefore, raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Failure to successfully complete a sale or license of the minocycline franchise, develop the noted assets, and receive additional financing will require the Company to delay, scale back or otherwise modify its business and its research and development activities and other operations.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary Statement of Cash Flows</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our statement of cash flows for the six months ended June&#160;30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands of U.S. dollars)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) / provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,808)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,070)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. Adjustments to net income for non-cash items mainly include depreciation and amortization, share-based compensation, goodwill and in-process research and development impairment, and contingent stock right remeasurement.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $28.8 million in the six months ended June&#160;30, 2021, compared to $88.1 million in the six months ended June&#160;30, 2020. The decrease was attributable primarily to increases in revenues with the launch of AMZEEQ and ZILXI in January 2020 and October 2020, respectively, as well as decreased costs associated with the Merger.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Used in (Provided by) Investing Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $1.0 million in the six months ended June&#160;30, 2021, compared to $87.1 million in the six months ended June&#160;30, 2020. The change was primarily attributable to the cash acquired through the Merger and a decrease in investments in bank deposits and marketable securities in the six months ended June 30, 2020.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $73.4 million provided by financing activities in the six months ended June&#160;30, 2021, compared to $53.7 million in the six months ended June&#160;30, 2020. The increase was attributable to proceeds from the offering of common stock in January 2021, along with the exercise of options and issuance of shares under our equity incentive plan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Funding Sources</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sources of liquidity in the six months ended June&#160;30, 2021 consisted primarily of proceeds from the issuance of common stock under the at-the-market offering and the registered direct offering in January 2021 and sales of AMZEEQ and ZILXI. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sources of liquidity in the six months ended June&#160;30, 2020 consisted primarily of cash and investments acquired in the Merger.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no ongoing material financial commitments (such as lines of credit) that may affect our liquidity over the next five years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our present and future funding requirements will depend on many factors, including, among other things:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of proceeds, if any, received from the possible sale or license of the minocycline franchise, other business transactions or financing activities;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to reduce selling, marketing and patent-related activities undertaken in connection with the commercialization of AMZEEQ, ZILXI, as well as costs involved to support an effective sales and marketing organization as we go through the divestiture process;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and completion of preclinical testing and clinical trials for pipeline product candidates, including FMX114, VYN201 and VYN202;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approval for our other pipeline product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of these product candidates;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of potential new products we identify and decide to develop; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending against claims or infringements raised by third parties, and license royalties or other amounts we may be required to pay to obtain rights to third party intellectual property rights.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating plan may change as a result of many factors currently unknown to us, and any such change may affect our funding requirements. We may therefore need to seek additional capital sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations or additional license arrangements. Such financings may result in dilution to stockholders, imposition of debt covenants and repayment obligations or other restrictions that may affect our business.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_97"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are described in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 4, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in the Notes to our financial statements, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results. These policies relate to the more significant areas involving management&#8217;s judgments and estimates and they require our most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition and liquidity will depend on future developments that are highly uncertain, subject to change and will continue to evolve with geographical re-openings, surges in cases, the development of new strains and the vaccination effort. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June&#160;30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition. In 2020, the Company recorded impairments of goodwill and certain indefinite-lived intangibles; however, these impairments were unrelated to the impact of COVID-19 (See &#8220;Note 3 &#8211; Business Combination&#8221; for more information). The Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenue based on a five-step model in accordance with Accounting Standards Codification ("ASC") 606,&#160;Revenue from Contracts with Customers&#160;("ASC 606"). For the Collaboration Agreement under ASC 606, we identify the performance obligations, determine the transaction price, allocate the contract transaction price to the performance obligations, and recognize the revenue when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identify the performance obligations included within the agreement and evaluate which performance obligations are distinct. Upfront payments for licenses are evaluated to determine if the license is capable of being distinct from the obligations to participate on certain&#160;development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials. For performance obligations that are satisfied over time, we utilize the input method and revenue is recognized by consistently applying a method of measuring progress toward complete satisfaction of that performance obligation. We periodically review our estimated periods of performance based on the progress under each arrangement and account for the impact of any changes in estimated periods of performance on a prospective basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments are a form of variable consideration as the payments are contingent upon achievement of a substantive event. Milestone payments are estimated and included in the transaction price when we determine that it is probable that there will not be a significant reversal of cumulative revenue recognized in future periods.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Acquisition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements include the operations of an acquired business after the completion of the acquisition. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet. Transaction costs are expensed as incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, we use fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach, which is based on the present value of a future stream of net cash flows.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairment</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_100"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_103"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law and in accordance with our bylaws, we are required to indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. We are also party to indemnification agreements with our directors. We believe the fair value of the indemnification rights and agreements is minimal. Accordingly, we have not recorded any liabilities for these indemnification rights and agreements as of June&#160;30, 2021 and December 31, 2020.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_106"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to &#8220;opt out&#8221; of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period under the JOBS Act is irrevocable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued and Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Recent Accounting Pronouncements&#8221; in Note&#160;2, &#8220;Significant Accounting Policies&#8221; in the Notes to Unaudited Interim Condensed Consolidated Financial Statements for a discussion of recently adopted accounting pronouncements and accounting pronouncements not yet adopted, and their expected impact on our financial position and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and Item 10 of Regulation S-K. As such, we are not required to provide the information set forth in this item.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_115"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our chief executive and financial officers, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of June&#160;30, 2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2021 our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal controls over financial reporting during the three months ended June&#160;30, 2021 identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. OTHER INFORMATION</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_121"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may periodically become subject to legal proceedings and claims arising in connection with its business. As of June&#160;30, 2021, no claims or actions are pending against the Company that, in the opinion in management, are likely to have a material adverse effect on the Company. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on June 30, 2021, the Company received a paragraph IV certification notice (the &#8220;Notice&#8221;) from Padagis Israel Pharmaceuticals Ltd. (f/k/a Perrigo Israel Pharmaceuticals Ltd. (&#8220;Padagis&#8221;)) advising that Padagis has submitted to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) an Abbreviated New Drug Application (&#8220;ANDA&#8221;) seeking approval to manufacture and sell a generic version of the Company&#8217;s product AMZEEQ&#174; (minocycline) topical foam, 4% in the United States prior to the expiration of the Company&#8217;s U.S. patents Nos. 8,865,139, 8,945,516, 8,992,896, 9,675,700, 10,086,080, 10,137,200, 10,213,512, 10,265,404, 10,398,641, 10,517,882, 10,821,187, and 10,849,847 (the &#8220;Listed Patents&#8221;), which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the &#8220;Orange Book.&#8221; The Notice alleges that the Listed Patents are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Padagis&#8217;s ANDA.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, the Company initiated a patent infringement suit against Padagis in the United States District Court for the District of Delaware arising from Padagis&#8217;s ANDA filing with the FDA. The patent infringement suit asserts each of the Listed Patents. As a result, under applicable law, the FDA cannot grant final approval to Padagis&#8217;s ANDA before December 30, 2023, or a court decision in Padagis&#8217;s favor. VYNE is seeking, among other relief, an order that the effective date of any FDA approval of Padagis&#8217;s ANDA be no earlier than the expiration of the Listed Patents, the latest of which expires on September 8, 2037, and such further and other relief as the court may deem appropriate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company intends to vigorously defend its intellectual property rights, including the Listed Patents</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_124"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1A. Risk Factors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our risk factors is contained in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 4, 2021. As of June 30, 2021 there have been no material changes in our risk factors from those disclosed in Item 1A of our Annual Report on Form 10-K, except as set forth below. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our recently announced decision to sell or license our commercial business may not result in a successful transaction or create any shareholder value. Uncertainty regarding a potential transaction may adversely impact our business, financial condition, results of operations and stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we announced that we completed a strategic review of our business to determine how to optimally deploy capital and drive shareholder value. After completing an exhaustive review, we determined to initiate a process to sell or license our commercial business, including AMZEEQ and ZILXI. We may not identify or effect any transaction to divest our commercial assets in a timely manner, or at all, and any transaction we do undertake may not be on terms that are favorable to us or that yield any value for shareholders. Further, the anticipated benefits of eliminating these assets from our portfolio, including anticipated expense reductions, may not be realized at expected levels, or at all. Identifying and completing any potential transaction depends on a number of factors, many of which are beyond our control, including, among other things, market conditions, the interest of third parties in a potential transaction with us on terms that are acceptable and the availability of financing for potential buyers on reasonable terms, if required. If we fail to consummate a transaction to sell or otherwise divest our commercial business or if such transaction is significantly delayed beyond our expected timeline, our results of operations may be adversely affected or we may not be able to adequately fund our clinical development programs on the anticipated timelines, or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of divesting these assets will be time consuming and disruptive to our business operations and could have a negative impact on our stock price for the following reasons:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We could incur substantial expenses associated with identifying, evaluating and effecting a divestiture, including those related to severance pay, vendor cancellation fees, legal, accounting and financial advisory fees and other fees or costs that may be payable regardless of whether we successfully divest these assets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may experience a negative impact on our ability to attract, retain and motivate key personnel;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Uncertainty regarding any developments related to our plans to divest our commercial assets and any other perceived uncertainties related to the future of our company; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The attention of management and the Board of Directors may be diverted from our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent on the successful development of our drug candidate FMX114 and the advancement of our BETi platform.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the determination to pursue a sale or license of its commercial business, we are now focused on the development of treatments for immuno-inflammatory diseases of high unmet medical need. This includes the continued development of FMX114 for the treatment of mild-to-moderate atopic dermatitis as well as the development of BETi-based formulations pursuant to the licensing arrangements with In4Derm. Both of these pipeline development programs are in early stages. Clinical drug development is very expensive, time-consuming and difficult to design and implement, and its outcome is inherently uncertain. Before obtaining regulatory approval for the commercial sale of a product candidate, we must demonstrate through clinical trials that a product candidate is both safe and effective for use in the target indication. Most product candidates that commence clinical trials are never approved by regulatory authorities for commercialization. The clinical trials for these product candidates may take significantly longer than expected to complete. Any setbacks in pre-clinical or clinical testing for these programs would have a material adverse effect on our financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding to fund our operations, and we may not be able to continue as a going concern if we are unable to do so. We could also be forced to delay, reduce or terminate our research and development activities which would have a material adverse effect on our financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing and commercializing biopharmaceutical products, including launching new products into the marketplace and conducting preclinical studies and clinical trials, is an expensive and highly uncertain process that takes years to complete. As of June 30, 2021, we had approximately $104.0 million in cash, cash equivalents and restricted cash as well as negative cash flows from operating activities. Following the prepayment of our indebtedness, we do not have sufficient cash and cash equivalents to fund our anticipated level of operations as they become due during the twelve months following the date of filing of this Quarterly Report on Form 10-Q. The aforementioned factors raise substantial doubt about our ability to continue as a going concern. See &#8220;Part I. Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8221; for further discussion regarding our liquidity. We may not be able to raise any proceeds from the sale or license of our minocycline franchise or from other financing transactions. Accordingly, additional funds may not be obtained for our ongoing operations and we may not succeed in our future operations. Unless we are able to raise additional capital to finance our operations, our long-term business plan may not be accomplished, and we may be forced to cease, reduce, or delay operations. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of its existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have received a notice letter of an ANDA submitted to the FDA seeking approval to manufacture and sell a generic version of AMZEEQ, which may lead to substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and such litigation may divert the attention of our management and scientific personnel and adversely affect our development and commercialization efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have various patents listed in the FDA&#8217;s Orange Book in respect of our AMZEEQ and ZILXI products. Competitors may infringe our patents. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and may be unsuccessful in whole or part. For example, on June 30, 2021, we received a paragraph IV certification notice (the &#8220;Notice&#8221;) from Padagis Israel Pharmaceuticals Ltd. (formerly Perrigo Israel Pharmaceuticals Ltd., &#8220;Padagis&#8221;) advising that Padagis has submitted to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) an Abbreviated New Drug Application (&#8220;ANDA&#8221;) seeking approval to manufacture and sell a generic version of AMZEEQ&#174; (minocycline) topical foam, 4% in the United States prior to the expiration of the Listed Patents, which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the &#8220;Orange Book.&#8221; The Notice alleges that the Challenged Patents are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Padagis&#8217;s ANDA. On August 9, 2021, we initiated a patent infringement suit against </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Padagis in the United States District Court for the District of Delaware arising from Padagis&#8217;s ANDA filing with the FDA. The patent infringement suit asserts each of the Listed Patents. As a result, under applicable law, the FDA cannot grant final approval to Padagis&#8217;s ANDA before December 30, 2023, or a court decision in Padagis&#8217;s favor. We are seeking, among other relief, an order that the effective date of any FDA approval of Padagis&#8217;s ANDA be no earlier than the expiration of the Listed Patents, the latest of which expires on September 8, 2037, and such further and other relief as the court may deem appropriate. See &#8220;Item 1. Legal Proceedings.&#8221; Litigation proceedings with respect to this matter, or any future matters, may also fail, and even if successful, they may result in substantial costs and distraction of our management and other employees. Furthermore, in any infringement proceeding, a court may decide that a patent of ours, or one or more claims of such patent, is not valid or is unenforceable, or may refuse to stop the other party from using the supposedly infringing technology on the grounds that our patents, or one or more claims of such patents, do not cover such technology. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could also put one or more of our pending patent applications at risk of not issuing. Our product candidates may be subject to the same risks.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_127"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_130"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_133"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i25b00c7e5297459bafdb2282aa46fec2_136"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;Other Information.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 12, 2021, the Company and its Board of Directors announced that it has initiated a process to explore a possible sale or license of its minocycline franchise. In addition, the Company is assessing capital expenditures and plans to significantly reduce operating expenses by immediately eliminating the vast majority of spend currently supporting commercial operations. As the Company transitions from a commercial organization to one focused on research and development, the Company intends to streamline operations by eliminating the vast majority of planned expenditures supporting its commercial operations. Furthermore, the Company intends to reduce its workforce by terminating approximately <ix:nonFraction unitRef="employee" contextRef="i4a701835f72e475097f033580f5deea7_D20210101-20211231" decimals="INF" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xMzYvZnJhZzo3MTg3NjRkNDdmODA0YjkyOTY3MDcyODRiMTZkZjNlOS90ZXh0cmVnaW9uOjcxODc2NGQ0N2Y4MDRiOTI5NjcwNzI4NGIxNmRmM2U5XzM4NDgyOTA3MDg1MDA_9d24e302-b2cc-4a5d-8462-1cdb444e4417">70</ix:nonFraction> employees, which the Company expects to be completed by December 31, 2021. The Company expects to incur a one-time charge in the range of approximately $<ix:nonFraction unitRef="usd" contextRef="ibace252288db423ca83fb8257a0d36f9_I20210930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xMzYvZnJhZzo3MTg3NjRkNDdmODA0YjkyOTY3MDcyODRiMTZkZjNlOS90ZXh0cmVnaW9uOjcxODc2NGQ0N2Y4MDRiOTI5NjcwNzI4NGIxNmRmM2U5XzM4NDgyOTA3MDg2NTY_ce1447a2-9598-4ec6-b232-d2c6f1fdd513">1.5</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i20cbba757ccb4615a4d0cfe3c3f988dd_I20210930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xMzYvZnJhZzo3MTg3NjRkNDdmODA0YjkyOTY3MDcyODRiMTZkZjNlOS90ZXh0cmVnaW9uOjcxODc2NGQ0N2Y4MDRiOTI5NjcwNzI4NGIxNmRmM2U5XzM4NDgyOTA3MDg2NjM_5582bfd0-d3bb-498e-b711-05d098e87bd2">2.0</ix:nonFraction>&#160;million, excluding non-cash charges, in connection with this restructuring plan, consisting primarily of employee termination costs, including severance and other benefits. This charge is expected to be incurred during the quarter ending September 30, 2021 with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related cash payments expected to be substantially paid out by December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepayment of Indebtedness</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2021, in connection with the Company's strategic transition, the Company prepaid the entirety of its outstanding indebtedness under the Amended and Restated Credit Agreement. The Company paid to its lenders approximately $36.5 million, consisting of $35 million aggregate principal amount of indebtedness, $1.4 million representing a 4% prepayment premium on the total principal amount prepaid and approximately $0.1 million of accrued but unpaid interest. Following the prepayment, the Amended and Restated Credit Agreement has been terminated and all security interests thereunder will be terminated. </span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160; Exhibits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed, or furnished as applicable, as part of this Quarterly Report on Form 10-Q:</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.726%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filed</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Herewith</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1566044/000156604421000010/exhibit31vynecertificateof.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/4/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1566044/000110465921093527/tm2122512d1_ex3-1.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation, dated as of July 19, 2021. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/19/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1566044/000110465920102850/tm2029742d2_ex3-2.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/08/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101zeronda-executiveempl.htm">Offer Letter, dated as of June 7, 2021, by and between Tyler Zeronda and VYNE Pharmaceuticals Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-20210630xexx311.htm">Certification of Chief Executive Officer required by Rule&#160;13a-14(a)&#160;or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-20210630xexx312.htm">Certification of Chief Financial Officer required by Rule&#160;13a-14(a)&#160;or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-20210630xexx321.htm">Certification of Chief Executive Officer required by Rule&#160;13a-14(b)&#160;or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vyne-20210630xexx322.htm">Certification of Chief Financial Officer required by Rule&#160;13a-14(b) or Rule 15d-14(b)&#160;and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.726%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page of VYNE Therapeutics Inc.'s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2021, formatted in Inline XBRL (included within Exhibit 101 attachments).</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;The certifications attached as Exhibit&#160;32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form&#160;10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of VYNE Therapeutics&#160;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form&#160;10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i25b00c7e5297459bafdb2282aa46fec2_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25b00c7e5297459bafdb2282aa46fec2_7">Table of contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: August&#160;12, 2021 </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.209%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VYNE Therapeutics Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Domzalski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Domzalski</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Tyler Zeronda</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyler Zeronda</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief&#160;Financial&#160;Officer and Treasurer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101zeronda-executiveempl.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i11dbff721a4d4df7bf27058b04d997da_1"></div><div style="min-height:74.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">June 7, 2021</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tyler Zeronda</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Tyler,</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This letter (the &#8220;Offer Letter&#8221;) contains the terms and conditions of your employment with VYNE Pharmaceuticals Inc. (the &#8220;Company&#8221;), a subsidiary of VYNE Therapeutics Inc. (&#8220;VYNE&#8221;), effective as of June 18, 2021 (the &#8220;Effective Date&#8221;). The Company, together with its ultimate parent and their respective affiliates and subsidiaries, are hereinafter referred to as the &#8220;Group Companies.&#8221; Your employment pursuant to this Offer Letter will commence as of the Effective Date and the terms and conditions of this Offer Letter shall be effective as of the Effective Date.  Unless stated otherwise herein, this Offer Letter will supersede any prior offer letters between you and the Company or any of its affiliates, including the letter dated May 11, 2021, April 8, 2019 and any amendments thereto (together, the &#8220;Previous Offer Letter&#8221;). You may be interchangeably referred to as &#8220;you&#8221; or &#8220;the Executive&#8221; within this Offer Letter. Additionally, where the context permits, references to &#8220;the Company&#8221; shall include the Company, its subsidiaries and affiliates and any successor thereto. </font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Brief Description of Role, Reporting Structure and Major Responsibilities&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We are pleased to offer you the position of VYNE&#8217;s Interim Chief Financial Officer (&#8220;Interim CFO&#8221;) and Treasurer until a permanent replacement is identified. You will also continue to serve as Vice President of Finance. You will report to VYNE&#8217;s Chief Executive Officer, David Domzalski or his designee.</font></div><div style="margin-bottom:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As the Interim CFO, you will work closely with the CEO and leadership team to craft the long-term financing and corporate development strategy and play an important role in guiding the Group Companies in its next growth phase.  The Interim CFO will be a partner to the CEO in communicating the Group Companies&#8217; strategy to VYNE&#8217;s board of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), investors and other stakeholders.  The Interim CFO will execute the financial strategy by assessing and leading the execution of all capital raising for the Group Companies and will provide financial and business expertise in assessing and crafting the financial structures of licensing and strategic partnerships&#47;collaborations. </font></div><div style="margin-bottom:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Interim CFO will be the most senior executive responsible for overseeing and directing the financial, investor relations, supply chain and IT functions of VYNE. The Interim CFO will be relied upon as a financial thought leader in the Group Companies&#8217; business and as such, be a trusted sounding board to the CEO and leadership team. You will play a critical role in the Group Companies&#8217; strategic positioning and will lead the finance, investor relations, supply chain and IT organizations to ensure they can meet the future needs and direction of the Group Companies. </font></div><div style="margin-bottom:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Interim CFO will approach the role as a strategic one as well as hands-on to ensure the organizations they oversee constantly seek improvement, with a balance of superior technical, operational and leadership skills. As the Interim CFO you must be a strong communicator, collaborator and able to fit in with an entrepreneurial environment that is dynamic and results oriented. </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Specific responsibilities as the Interim CFO shall be as mutually agreed between you and the CEO, and shall include strategic and tactical business growth and business development, financing and fundraising matters, financial, tax and risk management for VYNE, participation on board of directors meetings, general management of financial matters for VYNE and investor and public relations. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As the Vice President of Finance, your responsibilities are to continue to lead the F,P&#38;A&#47;strategic planning, supply chain, trade and distribution and treasury functions and work closely with the chief financial officer, CEO  and internal stakeholders to support VYNE&#8217;s investor relations and business development capabilities. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Specific responsibilities will include, inter alia&#58; strategic planning and business development for VYNE, managing treasury-related matters, overseeing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">supply chain, trade and distribution matters for VYNE, and working closely with VYNE&#8217;s key internal stakeholders and our external agency to lead our dialogue with the US financial community.</font></div><div><font><br></font></div><div style="padding-right:6.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compensation</font></div><div style="padding-right:6.2pt;text-align:justify"><font><br></font></div><div style="padding-right:6.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You will be paid a base salary at an annual rate of $300,000, payable in accordance with the Company&#8217;s payroll policies, less applicable deductions and employment taxes.  Currently, the Company&#8217;s regular pay period is bi-monthly (the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of each month). </font></div><div style="padding-right:6.2pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You will be eligible to receive a cash bonus of up to 35% of your base salary based on achievement of milestones and targets set by VYNE&#8217;s Chief Executive Officer (CEO), under the framework of the applicable bonus plan of VYNE for the relevant year. </font></div><div style="margin-top:3.45pt;padding-right:5.9pt;text-align:justify"><font><br></font></div><div style="padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The payment and grant of the cash bonus, if awarded, shall be made no later than March 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the calendar year following the year to which the performance relates, upon evaluation of your performance and the achievement of milestones and targets set for the performance year, and in accordance with the then-current general bonus plan.  You must be employed by the Company on the bonus payment date to be eligible to receive the bonus.</font></div><div style="padding-right:5.8pt;text-align:justify"><font><br></font></div><div style="padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You will receive annual equity awards to acquire common stock in VYNE with a per share exercise price for the options equal to the fair market value of one share of VYNE common stock on the grant date. The annual equity grants are expected to be granted in March and will vest over a period of four years following the last day of the calendar quarter in which the grant was made as follows&#58; 25% on the first anniversary of the vesting commencement date and 6.25% on the last day of each subsequent calendar quarter, subject to your continued employment with VYNE or one of its subsidiaries through the applicable vesting date.  Please note that such vesting period does not amount to an undertaking of the Company or VYNE to employ you for any given period.  The equity grants shall be subject to the execution of a share award agreement with VYNE and the terms and conditions of VYNE's 2019 Equity Incentive Plan, or VYNE's 2018 Omnibus Equity Incentive Plan, in each case, as may be amended or amended and restated from time to time. </font></div><div style="padding-right:5.8pt;text-align:justify"><font><br></font></div><div style="padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consistent with its policies as established from time to time, the Company will also cover all expenses directly related to your job performance, in accordance with the Company&#8217;s policies as in effect from time to time. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You will be entitled to four (4) weeks of paid vacation.  These vacation days accrue ratably over the calendar year and may not be carried forward from year to year or paid out at the termination of employment, except as described below or if your state laws mandate this payout. You will be </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">entitled to participate in the Company&#8217;s healthcare plan, then in effect, or, at the Company&#8217;s election, the Company may direct you to purchase an individual plan providing equivalent coverage and will reimburse you for all premium payments under such individual plan, upon proof of payment. All matters of eligibility under the Company&#8217;s plans will be determined solely by the carriers providing such insurance.  You will continue to be eligible to participate in the Company&#8217;s 401(k) plan.  </font></div><div style="padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company will also recognize certain holidays. These dates are communicated each year by the Company and may change based upon business needs. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination of Employment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Your employment with the Company is at-will and may be terminated by either you or the Company at any time, with or without reason.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event of a termination for Cause (as defined on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) by the Company, your employment will end immediately without notice and the Company and its subsidiaries and affiliates will have no further liability towards you except for payment of (1) any earned but unpaid base salary, (2) any incurred but unreimbursed business expenses and (3) any accrued but unused vacation days that exist as of the date of your termination of employment to the extent mandated by state law (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accrued Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event of your death or the termination of your employment as a result of your disability (as determined by the Company in good faith), the Company will have no further liability to you except for payment of the Accrued Benefits through the date of your death or the first day of your disability.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You shall have the right to resign at any time by giving the Company thirty (30) days&#8217; notice of the termination date, subject to the Company&#8217;s right, at its election, to reduce the duration of the notice period upon notice to you, in which case the last day of the reduced notice period shall constitute your employment termination date. The Company shall not have any further liability to you except for payment of all Accrued Benefits due through the date of termination unless such resignation is for Good Reason which shall be governed by the provisions below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may terminate your employment without Cause upon thirty (30) days&#8217; notice, during which notice period you will receive your full compensation and benefits. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If your employment is terminated without Cause or you resign for Good Reason, subject to your execution and non-revocation of a release of claims in a form acceptable to the Company in its sole discretion within 55 days following your termination of employment, you will be entitled to receive, in addition to the Accrued Benefits, (i) a severance payment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-CIC Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) equal to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">better</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (A) three (3) months salary plus one (1) month for every full year of your employment by a Group Company (up to a maximum of twelve (12) months) or (B) (i) a severance payment  in accordance with the terms set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to this Offer Letter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Severance Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) based on your then-current position as set forth therein and (ii) if you qualify for and timely elect continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), continued payment by the Company of monthly contributions in respect of your coverage under the Company&#8217;s healthcare plan for the number of months following the date of termination that corresponds to your severance payment, in an amount equal to the contribution the Company would have made if you had continued to be an active employee (assuming the applicable rates in effect as of the date of your termination of employment)&#59; provided that, the Company&#8217;s </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">obligations under this clause (ii) shall terminate on the earlier of (x) the date on which you enroll in a group health plan offered by another employer and (y) the date on which you are no longer eligible for continuation coverage under COBRA&#59; provided further that, notwithstanding the foregoing, in the event such Company contributions, may, in the Company&#8217;s reasonable view, result in tax or other penalties on the Company, this provision shall terminate and the parties shall, in good faith, negotiate for a substitute provision that provides substantially a similar benefit to you but does not result in such tax or other penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the above, if you experience a Qualifying Termination within the twelve (12) month period after a Change in Control (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Qualifying Change in Control Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), subject to your execution and non-revocation of a release of claims in a form acceptable to the Company in its sole discretion within 55 days following your termination of employment, you will be entitled to receive, in addition to the Accrued Benefits, (i) a severance payment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CIC Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with the Non-CIC Severance Payment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Severance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that is equal to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">better</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of&#58; (A) twelve (12) months of your then current base salary or (B) a severance payment in accordance with the Severance Policy as applicable for a termination of employment that occurs following a change in control, plus a cash payment equal to your target annual bonus for the year of termination multiplied by a fraction, the numerator of which is the number of days you were employed with the Company during the calendar year in which the date of termination occurs, and the denominator of which is 365 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pro-rated Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii) if you qualify for and timely elect continuation coverage under COBRA, continued payment by the Company of monthly contributions in respect of your coverage under the Company&#8217;s healthcare plan for the number of months following the date of termination that corresponds to your severance payment, in an amount equal to the contribution the Company would have made if you had continued to be an active employee (assuming the applicable rates in effect as of the date of your termination of employment)&#59; provided that, the Company&#8217;s obligations under this clause (ii) shall terminate on the earlier of (x) the date on which you enroll in a group health plan offered by another employer and (y) the date on which you are no longer eligible for continuation coverage under COBRA&#59; provided further that, notwithstanding the foregoing, in the event such Company contributions, may, in the Company&#8217;s reasonable view, result in tax or other penalties on the Company, this provision shall terminate and the parties shall, in good faith, negotiate for a substitute provision that provides substantially a similar benefit to you but does not result in such tax or other penalties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Furthermore, notwithstanding the terms of the Company equity incentive plan under which your equity awards are granted or any applicable award agreements, in the event of a Qualifying Change in Control Termination, all of your outstanding, unvested Company employee stock options and unvested restricted stock units, if any, shall become fully vested and any restrictions thereon shall lapse.  </font></div><div style="padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the purpose of this Offer Letter, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58; (i) a material reduction in your base salary&#59; (ii) a material reduction in your target annual bonus opportunity&#59; (iii) a relocation of your principal place of employment by more than twenty-five  (25) miles provided that such relocation increases your daily commute&#59; or (iv) an adverse change in your position, including title, reporting relationship(s), authority, duties or responsibilities&#59; all of the above without your consent.  You must provide notice of the existence of the Good Reason condition within thirty (30) days of the date you learn of the condition, and the Company shall have a period of thirty (30) days during which it may remedy the condition, and in case of full remedy such condition shall not be deemed to constitute Good Reason hereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Offer Letter, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Company&#8217;s 2019 Equity Plan.  For the avoidance of doubt, the term Change in Control shall not include a sale of assets, merger or other transaction effected primarily for the purpose of changing the domicile of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Timing of Payment</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The applicable Severance Payment (in the event of a Qualifying Change in Control Termination) will be paid in a lump sum within sixty (60) days following the date of your termination of employment subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and as set forth below.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The payments and benefits under this Offer Letter are intended to qualify for exemptions from the application of Section 409A of the Internal Revenue Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and this Offer Letter will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Offer Letter (and any definitions hereunder) will be construed in a manner that complies with Section 409A to the extent necessary to avoid adverse taxation under Section 409A.   Notwithstanding anything to the contrary herein, to the extent required to comply with Section 409A, a termination of employment shall not be deemed to have occurred for purposes of any provision of this Offer Letter providing for the payment of amounts or benefits upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A.  Your right to receive any installment payments will be treated as a right to receive a series of separate payments and, accordingly, each installment payment shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Offer Letter, if you are deemed by the Company at the time of your separation from service to be a &#8220;specified employee&#8221; for purposes of Section 409A, and if any of the payments upon separation from service set forth herein and&#47;or under any other agreement with the Company are deemed to be &#8220;deferred compensation,&#8221; then, to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Section 409A and the related adverse taxation under Section 409A, such payments shall not be provided to you prior to the earliest of (i) the expiration of the six-month period measured from the date of separation from service, (ii) the date of your death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation.   With respect to payments to be made upon execution of an effective release, if the release revocation period spans two calendar years, payments will be made in the second of the two calendar years to the extent necessary to avoid adverse taxation under Section 409A.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Miscellaneous</font></div><div style="padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You represent that (i) there is no legal restriction and&#47;or contractual restriction prohibiting you from entering into an employment relationship with the Company, (ii) that by doing so you are not violating any third party&#8217;s rights, including any undertaking entered into with any former employer, and (iii) that you know that the Company is employing you based upon this statement.</font></div><div style="padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A dispute under this Offer Letter shall be heard and governed by the procedural and substantive laws of the State of New Jersey or of your primary workplace. BY SIGNING THIS OFFER LETTER YOU AND THE COMPANY AGREE TO WAIVE ANY RIGHT TO A JURY TRIAL FOR ANY DISPUTES ARISING OUT OF THIS OFFER LETTER.</font></div><div style="padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Offer Letter constitutes and expresses the entire agreement of the parties hereto with reference to any of the matters or things herein provided for or herein before discussed or mentioned with reference to your employment, and it cancels and replaces any and all prior understandings and agreements between you and the Company, except the Non-Solicitation, Non-Competition, Confidentiality and Intellectual Property Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All other promises, representations, collateral agreements and understandings not expressly incorporated in this Offer Letter are hereby superseded by this Offer Letter.</font></div><div style="padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may withhold from any amounts payable under this Offer Letter all federal, state, city or other taxes as it is required to withhold pursuant to any applicable law, regulation or ruling. Notwithstanding any other provision of this Offer Letter, the Company shall not be obligated to guarantee any particular tax result for you with respect to any payment provided to you hereunder, and you shall be responsible for any taxes imposed on you with respect to any such payment.</font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Without derogating from the above, you will be required to abide by the Company&#8217;s policies, rules and procedures, as may be in effect from time to time, at the Company&#8217;s sole discretion, and that may be modified or changed as circumstances warrant.  </font></div><div style="padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prior to your commencement of work, you will be required to sign a Non-Solicitation, Non-Competition, Confidentiality and Intellectual Property Agreement, which is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You will be bound by the terms of the document.</font></div><div style="padding-right:5.9pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We are pleased to present this Offer Letter to you. Please sign below to indicate your acceptance of this employment offer on the basis of the foregoing terms.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely,</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; David Domzalski</font></div><div style="padding-left:216pt;padding-right:137.5pt"><font><br></font></div><div style="padding-right:137.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">David Domzalski</font></div><div style="padding-right:137.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="padding-left:180pt;padding-right:137.5pt;text-indent:36pt"><font><br></font></div><div style="padding-left:180pt;padding-right:137.5pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I hereby confirm that I have carefully read and understood this offer of employment and I have accepted it and entered into it of my own free will.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Tyler Zeronda</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tyler Zeronda</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SEVERANCE POLICY</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.889%"><tr><td style="width:1.0%"></td><td style="width:12.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:5pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:93%">Provision</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:5pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:93%">CEO</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:5pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:93%">SVP+</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:5pt;padding-left:2.65pt;padding-right:2.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:93%">VP</font></div></td></tr><tr style="height:82pt"><td colspan="3" rowspan="4" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:25.2pt;margin-top:6.45pt;padding-left:2.62pt;padding-right:2.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:92%">Non-CIC Severance</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non CIC-Severance Trigger</font></td><td colspan="9" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6.2pt;padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">A termination of employment (i) by the Company and its subsidiaries without &#8220;Cause&#8221; or (ii) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">by the employee </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">for &#8220;Good Reason&#8221;  (each, a &#8220;Qualifying Termination).*</font></div></td></tr><tr style="height:42pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Severance</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.0x base salary**</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">0.75x base salary**</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">0.5x base salary**</font></td></tr><tr style="height:30pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Benefits</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12 months benefits continuation</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9 months benefits continuation</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6 months benefits continuation</font></td></tr><tr style="height:44pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Equity Treatment</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Full vesting acceleration of time-based awards</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As provided in the applicable equity plan and award agreement</font></td></tr><tr style="height:36pt"><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5.05pt;margin-top:6.5pt;padding-left:2.62pt;padding-right:2.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:92%">CIC Severance</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Protection Period</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12 months following a Change in Control***</font></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CIC Severance Trigger</font></td><td colspan="9" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5.25pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:96%">Double trigger (i.e., a Qualifying Termination during the Protection Period)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div></td></tr><tr style="height:47pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Severance</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.5x (salary + target bonus), plus pro-rata target bonus**</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.0x (salary + target bonus), plus pro-rata target bonus**</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">0.5x (salary + target bonus), plus pro-rata target bonus**</font></td></tr><tr style="height:30pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Benefits</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18 months benefits continuation</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12 months benefits continuation</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6 months benefits continuation</font></td></tr><tr style="height:29pt"><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Equity Treatment</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Double trigger full vesting acceleration of time-based awards</font></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excise Tax</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:4.75pt;margin-top:6pt;padding-left:3.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">Best net provision</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div></td></tr></table></div><div><font><br></font></div><div style="padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*&#8220;Cause&#8221; shall have the meaning set forth in the VYNE&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) and &#8220;Good Reason&#8221; shall have the meaning set forth in the Offer Letter</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">**Amounts shall be paid in a cash lump sum within 60 days following the date of termination&#59; provided that, if (i) the employee was party to an employment agreement or other plan, agreement or arrangement with the Company or any of its subsidiaries or affiliates prior to the effective date of this severance policy that provided for severance payments and benefits upon a termination of employment (each such employment agreement or other plan, agreement or arrangement, a &#8220;Prior Agreement&#8221;) and (ii) the payments and benefits provided pursuant to this severance policy are determined to be &#8220;deferred compensation&#8221; for purposes of Section 409A of the Internal Revenue Code or any successor provision thereto (the &#8220;Code&#8221;), then, to the extent necessary to avoid accelerated taxation and&#47;or tax penalties under Section 409A of the Code, the payments and benefits </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided pursuant to this severance policy shall be paid at the same time(s) and in the same form(s) provided in the Prior Agreement, at all times, in accordance with Section 409A of the Code. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">***&#8221;Change in Control&#8221; shall have the meaning set forth in the 2019 Plan.  For the avoidance of doubt, the consummation of the merger contemplated by that certain Agreement and Plan of Merger by and among VYNE, Foamix Pharmaceuticals Ltd. and Giants Merger Subsidiary Ltd., dated as of November 10, 2019 (as amended), shall not constitute a Change in Control for purposes of this severance policy.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Solicitation, Non-Competition, Confidentiality and Intellectual Property Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Non-Solicitation, Non-Competition, Confidentiality and Intellectual Property Agreement (&#8220;Agreement&#8221;), is made and entered into by and between, VYNE Pharmaceuticals Inc. (the &#8220;Company&#8221;) and Tyler Zeronda (&#8220;you&#8221; and &#8220;your&#8221;).  The Company, together with its ultimate parent and their respective affiliates and subsidiaries, are hereinafter referred to as the &#8220;Group Companies.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties hereby agree to the following in exchange for your employment with the Company&#58;</font></div><div style="padding-right:28.3pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You recognize that your knowledge of the Confidential Information (as defined below) and trade secrets of the Group Companies and your role in the Group Companies&#8217; business may allow you to compete or to assist a third party to compete unfairly with the Group Companies. </font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">During the term of this Agreement, and for a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12 months </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">following the termination of your employment with any member of the Group Companies (the &#8220;Restricted Period&#8221;), you agree that you shall not, without the prior consent of the Company and its ultimate parent, directly or indirectly, as an employee, executive, agent, principal, partner, stockholder, officer, director, consultant, independent contractor, advisor, investor or any other representative, work with or without compensation in any business that develops or commercializes foam or topical tetracycline antibiotics or is otherwise directly competitive with, the business of the Group Companies (i.e., any compound that is the same or substantially similar to a compound being developed or sold by any member of the Group Companies) (each, a &#8220;Competitive Business&#8221;) within the same geographic territory in which you operated during your last year of employment with any member of the Group Companies.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt;text-decoration:underline">Necessary and Reasonable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You acknowledge that this non-compete provision is necessary and reasonable to protect Group Companies&#8217;  business interests.  You further acknowledge that the Group Companies would suffer irreparable harm and other damage in the event of a breach of this provision.  You agree that the term, scope and geographic area of the covenants contained herein are reasonable.  However, if any court of competent jurisdiction determines that this covenant is unenforceable as to the term, scope or geographic area then this covenant nevertheless shall be enforceable by such court as to such shorter term, such lesser scope or within such lesser geographic area as the court determines to be reasonable and enforceable.  </font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You will not, in any manner whatsoever, directly or indirectly, without the prior written consent of the Company and its ultimate parent, at any time during the Restricted Period&#58;</font></div><div style="margin-top:3.45pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-left:27.35pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  induce or endeavor to induce (A) any employee of any member of the Group Companies to leave employment with any member of the Group Companies, or (B) any consultant or contractor of any member of the Group Companies to terminate its relationship as such with any member of the Group Companies during any period of time that the business services provided, directly or indirectly, by such consultant or contractor are exclusively or primarily being provided to any member of the Group Companies, provided that this clause shall not </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="margin-top:3.45pt;padding-left:27.35pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">preclude customary non-targeted recruiting efforts or general solicitations that are not specifically directed to, but which may have the effect of causing an employee, consultant or contractor to leave the employment or arrangement with any member of the Group Companies&#59; or</font></div><div style="margin-top:3.45pt;padding-left:27.35pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-left:27.35pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  employ or attempt to employ or assist any individual or other entity to employ&#160;&#160;&#160;&#160; any employee of any member of the Group Companies or to retain any consultant or contractor during any period of time that the business services provided, directly or indirectly, by such consultant or contractor are exclusively or primarily being provided to any member of the Group Companies, provided, that this clause shall not preclude an employer of yours from offering employment or consulting or contracting services to anyone without your direct or indirect assistance</font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You acknowledge that by reason of your employment with any member of the Group Companies, you have had access to Confidential Information and trade secrets of the Group Companies, and that such Confidential Information and trade secrets are essential components of the business of the Group Companies, and are proprietary and would be of great value and benefit to competitors of the Group Companies. &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; is to be broadly defined and includes anything respecting the Company and its affiliates or their respective businesses, customers, supplier or operations, and which is not made readily available to the general public. You agree that both during and after your employment with any member of the Group Companies, you will not disclose to any individual or other entity, except in the proper course of your employment with any member of the Group Companies, or use for your own purposes or for purposes other than those of any member of the Group Companies, any Confidential Information or trade secrets of any member of the Group Companies acquired by you. You agree that at all times after your employment with any member of the Group Companies, you will hold in trust, keep confidential, and not publish, disclose or otherwise disseminate to any third party or make any use of the Confidential Information of any member of the Group Companies except for the benefit of the Group Companies and in the course of employment with any member of the Group Companies. You further agree not to cause the transmission, removal or transport of Confidential Information from the Group Companies&#8217; place of business (principal, remote or otherwise), whether by hard or electronic copy, without prior written approval of the Company and its ultimate parent, except for the benefit of the Group Companies and in the course of your employment relationship with any member of the Group Companies.  You acknowledge that you are aware that the unauthorized disclosure of Confidential Information of any member of the Group Companies may be highly prejudicial to the Group Companies&#8217; interests, an invasion of privacy and an improper disclosure of proprietary information. You agree, promptly and without request, to deliver to and inform the Company and its ultimate parent of all documents and data pertaining to your services to the any member of the Group Companies and the Confidential Information of the Group Companies, whether prepared by you or otherwise coming into your possession or control.  You will not retain any written or other tangible material containing any information concerning or disclosing any of the Confidential Information of any member of the Group Companies, including but not limited to any electronically stored data.</font></div><div style="margin-top:3.45pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">If information enters the public domain, except as a result of a breach of this Section (c) by you or a breach of another confidentiality agreement to which any member of the Group Companies is a party, the information will not be deemed Confidential Information, or a trade secret protected by this Section (c). If you are compelled by law to disclose Confidential </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inf</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ormation or trade secrets of any member of the Group Companies, pursuant to subpoena, an order from a court of </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">competent jurisdiction, or other applicable legal authority, you may disclose such Confidential Information or trade secrets to the extent so required, but you will, if possible, (i) provide reasonable advance notice of the subpoena, court order, or legal authority to the Company and its ultimate parent, and (ii) afford the Group Companies the reasonable opportunity to take legal action to contest, challenge, narrow or otherwise limit or condition the disclosure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt;text-decoration:underline">Sanctions for Unauthorized Taking of Confidential Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> You recognize that the unauthorized taking of the Group Companies&#8217;  Confidential Information could result in civil liability and that willful misappropriation may result in an award against you for damages and attorney&#8217;s fees and costs in collecting such damages.  The unauthorized taking of trade secrets is a crime and may be punishable by imprisonment, or a fine, or both, and&#47;or may result in civil liability, including, where applicable, punitive or similar damages, under applicable federal and state trade secret laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Notice of Immunity Under the Economic Espionage&#160;Act&#160;of 1996, as amended by the&#160;Defend&#160;Trade&#160;Secrets Act&#160;of 2016 (&#34;DTSA&#34;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of this Agreement&#58;</font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">You will not be held criminally or civilly liable under any federal or state&#160;trade&#160;secret&#160;law for any disclosure of a&#160;trade&#160;secret&#160;that&#58; (1) is made&#58; in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney&#59; and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;If you file a lawsuit for retaliation by any member of the Group Companies for reporting a suspected violation of law, you may disclose the Group Companies&#8217; trade&#160;secrets&#160;to your attorney and use the&#160;trade&#160;secret</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">information in the court proceeding if you&#58; (1) file any document containing the&#160;trade&#160;secret&#160;under seal&#59; and (2) do not disclose the&#160;trade&#160;secret, except pursuant to court order.</font></div><div style="margin-top:3.45pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;margin-top:3.45pt;padding-left:27.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) You have attached hereto as Exhibit 1, a list describing all inventions, original works of authorship, developments, improvements, copyrights and patents that were made or developed by you prior to the date you sign this Agreement, that belong to you.  If such list is not attached or is left blank, you represent that no such inventions exist.</font></div><div style="margin-bottom:12pt;margin-top:3.45pt;padding-left:27.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) You agree that all ideas, techniques, inventions, systems, business and marketing plans, projections and analyses, discoveries, technical information, programs, prototypes, copyrightable works of authorship, including without limitation software code, and similar developments, improvements or creations developed, conceived, created, discovered, made, or written by you in the course of or as the result, directly or indirectly, of the performance of your employment with any member of the Group Companies (hereinafter called &#34;Developments&#34;), and all related intellectual property rights, including but not limited to, writings and other works of authorship, United States and foreign patents, mask works, copyright and trademark registrations and other forms of intellectual property protection, shall be and remain the property of the Group Companies.  You further agree to assign (or cause to be assigned) and do hereby assign fully to the Group Companies all such Developments and </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="margin-bottom:12pt;margin-top:3.45pt;padding-left:27.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any copyrights, patents, mask work rights or other intellectual property rights relating thereto.  In the event copyrightable works do not fall within the theory of works made for hire, you agree to assign, and do hereby assign, all rights, title and interest therein, without further consideration, to the Group Companies.  You, insofar as you have the right to do so, agree that you will execute or cause to be executed such United States and foreign patents, mask works, copyright and trademark registrations and other documents and agreements and take such other action as may be desirable in the opinion of the Group Companies to enable intellectual property, copyright and other forms of protection for Developments to be obtained, maintained, renewed, preserved and protected throughout the world by or on behalf of the Group Companies.  </font></div><div style="margin-bottom:12pt;margin-top:3.45pt;padding-left:27.35pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) If any member of the Group Companies is unable, after exercising reasonable efforts, to secure your signature on any application for patent, copyright, analogous registration, or other documents regarding any legal protection regarding Developments or other works and inventions, whether because of your physical or mental incapacity or for any other reason, you hereby irrevocably designate and appoint the Group Companies and their duly authorized officers and agents as your agent and attorney-in-fact to act for and on your behalf and to execute and file any such application or applications or other documents and to do all other lawfully permitted acts to further the prosecution and issuance of such patent, copyright or trademark registrations or any other legal protection thereon with the same legal force and effect as if executed by you.</font></div><div style="margin-bottom:12pt;margin-top:3.45pt;padding-left:27.35pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) Incorporation into Company Products.  You agree that if in the course of your employment with any member of the Group Companies, you incorporate into any invention, service, or product any invention, improvement, Development, concept, discovery or other proprietary information owned by you or in which you have an interest, (i) you will inform the Company and its ultimate parent, in writing, before incorporating such invention, improvement, development, concept, discovery or other proprietary information into any invention, Service, or Development&#59; and (ii) the Group Companies are hereby granted and will have a nonexclusive, royalty-free, perpetual, irrevocable, worldwide license to make, have made, modify, use and sell such item as part of or in connection with such invention, services, or Development.  You will not incorporate any invention, improvement, development, concept, discovery or other proprietary information owned by any third party into any invention without the Company's and its ultimate parent&#8217;s prior written permission.</font></div><div style="margin-bottom:12pt;margin-top:3.45pt;padding-left:27.35pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v) Subsequent Use Restrictions.  During the course of employment and during the Restricted Period, you agree to promptly notify the Company and its ultimate parent of any inventions you develop that are based on, relate to or are a derivative of Developments or Confidential Information.  You agree that any invention or work involving you after the separation of your employment shall be deemed to result from access to the Company&#8217;s Developments or Confidential Information (including without limitation patentable inventions and copyrightable works) if such invention or work&#58; (i) arose from your work with any member of the Group Companies&#59; or (ii) is related to the business of the Group Companies and is made, created, used, sold, exploited or reduced to practice, or an application for patent, trademark, copyright or other proprietary protection is filed by you and&#47;or with your significant aid by a third party, within the Restricted Period.</font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Disclosure of New Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In light of your obligations under this Agreement,  you agree to disclose the name of any future employer to the Company and its ultimate parent in writing (even if you intend to be self-employed), along with your future business contact information, </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">including name and full address of the new employer.  Where necessary to protect the Group Companies&#8217; interests, any member of the Group Companies may notify any future or prospective employer of the existence of this Agreement and&#47;or the terms and conditions of your employment with any member of the Group Companies.   This obligation shall continue until the end of the time periods under the Non-Competition and Non-Solicitation provisions above. </font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You shall provide reasonable cooperation in connection with any legal action or proceeding (or any appeal from any action or proceeding) which relates to events during your employment hereunder. The Company shall reimburse you for your reasonable travel expenses incurred in connection with the foregoing, in accordance with the Company&#8217;s policies and subject to the delivery of reasonable support for such expenses.  </font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline"> Restrictions Reasonable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You confirm that all restrictions and covenants in this Agreement are reasonable and valid, and waive all objections to and defenses to the strict enforcement thereof.</font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Survival of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   This Agreement shall survive the termination of the Offer Letter between you and the Company and the termination of your employment with any member of the Group Companies, whether such termination is voluntary or involuntary, and regardless of the reason(s) for such termination.  </font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of breach or threatened breach by you of any provision of this Agreement, any member of the Group Companies shall be entitled to (i) injunctive relief by temporary restraining order, preliminary injunction, and&#47;or permanent injunction, (ii) recovery of the attorneys&#8217; fees and costs incurred by any member of the Group Companies in obtaining such relief, and (iii) any other legal and equitable relief to which it may be entitled, including any and all monetary damages which any member of the Group Companies may incur as a result of said breach or threatened breach.  Injunctive relief shall not be the exclusive relief and may be in addition to any other relief to which any member of the Group Companies would otherwise be entitled.  The existence of any cause of action by you against the Company shall not constitute a defense to enforcement of the restrictions on you created by this Agreement.  If you fail to comply with this Agreement during the Restricted Period, the time period for that the Restricted Period will be extended by one day for each day that you are found to have violated this Agreement, up to a maximum extension of twelve (12) months.  In the event that a court finds the restrictions on you in this Agreement are unenforceable as written, then the parties shall consent to the reformation of the Agreement to make it enforceable to protect the interests of the Group Companies to the maximum extent legally allowed.  </font></div><div style="margin-top:3.45pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Parties Benefited&#59; Assignments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall inure to the benefit of the Group Companies&#8217; owners, successors, assigns and affiliates, and may be assigned to and enforced by any of the foregoing.  Neither this Agreement nor any rights or obligations hereunder may be assigned by you.</font></div><div style="margin-top:3.45pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required or permitted by this Agreement shall be in writing sent by personal delivery, or by registered or certified mail, return receipt requested, addressed to the Company at its then principal office, or to you at your last known address, or to such other address or addressees as any party may from time to time specify in writing.  Notices shall be deemed given when received.</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="margin-top:3.45pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Governing Law, Jurisdiction and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and any issues arising from it or regarding its provisions shall be governed by and construed in accordance with the substantive and procedural laws of the state of your primary workplace without reference to such jurisdiction&#8217;s choice of law rules.</font></div><div style="margin-top:3.45pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement are severable so that in the event any provision(s) in this Agreement is held to be illegal or unenforceable by any court or agency of competent jurisdiction, or by operation of any applicable law, the remaining terms of this Agreement shall remain valid and in full force and effect.  Further, such court or agency shall modify the offending provision to conform to the most expansive permissible reading under the law to protect the interests of the Group Companies.</font></div><div style="margin-top:3.45pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No waiver of any breach or default hereunder shall be considered valid unless in writing and signed by the party giving such waiver, and no waiver shall be deemed a waiver of any subsequent breach or default of the same or similar nature.  No failure on the part of any party to exercise, and no delay in exercising, any right, remedy, power or privilege hereunder shall operate as a waiver thereof&#59; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.</font></div><div><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Comprehension&#59; Consultation with Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You acknowledge having read and understood this Agreement and further acknowledge being hereby advised, by this paragraph, to consult independent legal counsel. Accordingly, you acknowledge that you are voluntarily entering into this Agreement of your own volition and not under duress.</font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">YOU AND THE GROUP COMPANIES KNOWINGLY AND WILLINGLY WAIVE ANY RIGHT TO A TRIAL BY JURY IN ANY DISPUTE ARISING OUT OF OR RELATING TO THIS AGREEMENT.</font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.4pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:167px"></div></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THE PARTIES ACKNOWLEDGE THAT THEY HAVE READ AND UNDERSTAND THIS AGREEMENT, THAT THEY HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL IF THEY SO CHOSE, AND THAT THEY ENTER INTO THIS AGREEMENT FREELY AND VOLUNTARILY.</font></div><div style="margin-top:3.45pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________ </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tyler Zeronda</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________ </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VYNE Pharmaceuticals Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">David Domzalski, Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________ </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-29.8pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font><br></font></div><div style="padding-right:-15.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vyne Therapeutics Inc.</font></div><div style="padding-right:-29.8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>vyne-20210630xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2fb124f1f55744759719609c3e8bac73_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Domzalski, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of VYNE Therapeutics Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Domzalski</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Domzalski<br>Principal Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>vyne-20210630xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i98d5f2c11b0b44c296c55ecce6189f4c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tyler Zeronda, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of VYNE Therapeutics Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Tyler Zeronda</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyler Zeronda<br>Principal Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>vyne-20210630xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie2cde9f695294edc83dfeb16cba7cafc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of VYNE Therapeutics Inc. (the &#8220;Company&#8221;), for the quarterly period ended June&#160;30, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, David Domzalski, President and Chief Executive Officer and principal executive officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:334.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:148.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Domzalski</font></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Domzalski<br>Principal Executive Officer</font></td></tr></table></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>vyne-20210630xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i21f6300ab1044bb892cadb32a5299712_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of VYNE Therapeutics Inc. (the &#8220;Company&#8221;), for the quarterly period ended June&#160;30, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Tyler Zeronda, Chief Financial Officer, Treasurer and principal financial officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:334.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:148.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Tyler Zeronda</font></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tyler Zeronda<br>Principal Financial Officer</font></td></tr></table></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>vyne-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:40e9affd-2783-4e4a-bd7f-018d2dae4bf0,g:c708fe63-ab77-4120-b7ee-9a72ba48151c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vyne="http://www.menlotherapeutics.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.menlotherapeutics.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vyne-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vyne-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vyne-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vyne-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.menlotherapeutics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONS" roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS">
        <link:definition>2101101 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSDetails" roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails">
        <link:definition>2402401 - Disclosure - NATURE OF OPERATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails" roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails">
        <link:definition>2407403 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of AntiDilutive Equity Awards Not Included in the Calculation of EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATION" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION">
        <link:definition>2108103 - Disclosure - BUSINESS COMBINATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONTables" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables">
        <link:definition>2309302 - Disclosure - BUSINESS COMBINATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONNarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails">
        <link:definition>2410404 - Disclosure - BUSINESS COMBINATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails">
        <link:definition>2411405 - Disclosure - BUSINESS COMBINATION - Consideration Transferred in Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONPurchasePriceAllocationDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails">
        <link:definition>2412406 - Disclosure - BUSINESS COMBINATION - Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONGoodwillDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails">
        <link:definition>2413407 - Disclosure - BUSINESS COMBINATION - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONIPRDandCSRDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails">
        <link:definition>2414408 - Disclosure - BUSINESS COMBINATION - IPRD and CSR (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONProFormaDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails">
        <link:definition>2415409 - Disclosure - BUSINESS COMBINATION - Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITION">
        <link:definition>2116104 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONDetails" roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails">
        <link:definition>2417410 - Disclosure - REVENUE RECOGNITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENT" roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT">
        <link:definition>2118105 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTTables" roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables">
        <link:definition>2319303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2420411 - Disclosure - FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIES" roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIES">
        <link:definition>2121106 - Disclosure - MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESTables" roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables">
        <link:definition>2322304 - Disclosure - MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESMarketableSecuritiesDetails" roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails">
        <link:definition>2423412 - Disclosure - MARKETABLE SECURITIES - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESNarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails">
        <link:definition>2424413 - Disclosure - MARKETABLE SECURITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORY" roleURI="http://www.menlotherapeutics.com/role/INVENTORY">
        <link:definition>2125107 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYTables" roleURI="http://www.menlotherapeutics.com/role/INVENTORYTables">
        <link:definition>2326305 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYNarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/INVENTORYNarrativeDetails">
        <link:definition>2427414 - Disclosure - INVENTORY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYScheduleofInventoryComponentsDetails" roleURI="http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails">
        <link:definition>2428415 - Disclosure - INVENTORY - Schedule of Inventory Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.menlotherapeutics.com/role/DEBT">
        <link:definition>2129108 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/DEBTNarrativeDetails">
        <link:definition>2430416 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITAL" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITAL">
        <link:definition>2131109 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALTables" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALTables">
        <link:definition>2332306 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails">
        <link:definition>2433417 - Disclosure - SHARE CAPITAL - Common Stock, Preferred Stock, and Warrants Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALSharebasedCompensationNarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails">
        <link:definition>2434418 - Disclosure - SHARE CAPITAL - Share-based Compensation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALOptionsandRSUGrantsDetails" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails">
        <link:definition>2435419 - Disclosure - SHARE CAPITAL - Options and RSU Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALFairvalueassumptionsDetails" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails">
        <link:definition>2436420 - Disclosure - SHARE CAPITAL - Fair value assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALScheduleofSharebasedCompensationDetails" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails">
        <link:definition>2437421 - Disclosure - SHARE CAPITAL - Schedule of Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATINGLEASE" roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASE">
        <link:definition>2138110 - Disclosure - OPERATING LEASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATINGLEASETables" roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASETables">
        <link:definition>2339307 - Disclosure - OPERATING LEASE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATINGLEASENarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails">
        <link:definition>2440422 - Disclosure - OPERATING LEASE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>2441423 - Disclosure - OPERATING LEASE - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>2441423 - Disclosure - OPERATING LEASE - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2142111 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vyne_ExchangeRatio" abstract="false" name="ExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vyne_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_ContingentStockConsiderationRemeasurementGainLoss" abstract="false" name="ContingentStockConsiderationRemeasurementGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_RepaymentOfDebtPrepaymentFeePercentage" abstract="false" name="RepaymentOfDebtPrepaymentFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" abstract="false" name="IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_BusinessCombinationEffectiveExchangeRatio" abstract="false" name="BusinessCombinationEffectiveExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum" abstract="false" name="MilestonePaymentsUponAchievingCertainCriteriaMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" abstract="false" name="BusinessCombinationSharesDeemedIssuedForAccountingPurposes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vyne_InterestReceived" abstract="false" name="InterestReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_AdditionalSpaceMember" abstract="true" name="AdditionalSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" abstract="false" name="BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_BusinessAcquisitionContingentStockRightIssued" abstract="false" name="BusinessAcquisitionContingentStockRightIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vyne_NumberOfLenders" abstract="false" name="NumberOfLenders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock" abstract="false" name="CommissionFromGrossProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vyne_BridgewaterNewJerseyMember" abstract="true" name="BridgewaterNewJerseyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_OriginalSpaceMember" abstract="true" name="OriginalSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" abstract="true" name="ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" abstract="false" name="BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" abstract="false" name="ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vyne_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_UpfrontRoyaltyReceipt" abstract="false" name="UpfrontRoyaltyReceipt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_GrossProceedsFromIssuanceOfCommonStock" abstract="false" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_RestrictedInvestmentsToSecureLeaseAgreements" abstract="false" name="RestrictedInvestmentsToSecureLeaseAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_CantorSalesAgreementMember" abstract="true" name="CantorSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_ClassOfWarrantAbstract" abstract="true" name="ClassOfWarrantAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vyne_NonCashAcquisitionOfBusinessCashAcquired" abstract="false" name="NonCashAcquisitionOfBusinessCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember" abstract="true" name="AmendedAndRestatedCreditAgreementTrench1LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_FourCustomersMember" abstract="true" name="FourCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_CommonStockVotingRightsNumberPerShare" abstract="false" name="CommonStockVotingRightsNumberPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vyne_IsraeliMutualFundsMember" abstract="true" name="IsraeliMutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_OralBETiOptionAgreementMember" abstract="true" name="OralBETiOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" abstract="false" name="ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember" abstract="true" name="AmendedAndRestatedCreditAgreementTrench3LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_EstimateOfProductReturnRateMaximum" abstract="false" name="EstimateOfProductReturnRateMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vyne_RegisteredOfferingMember" abstract="true" name="RegisteredOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember" abstract="true" name="AmendedAndRestatedCreditAgreementTrench2LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" abstract="false" name="AdjustmentsToSupplementalProformaCombinedResultsOfOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" abstract="false" name="AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" abstract="false" name="PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vyne_ProceedsFromBusinessMerger" abstract="false" name="ProceedsFromBusinessMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_PostMergerParentOwnershipByPreMergerParentStockholders" abstract="false" name="PostMergerParentOwnershipByPreMergerParentStockholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vyne_FacilitySpaceUnderLease" abstract="false" name="FacilitySpaceUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" abstract="false" name="CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vyne_AdjustmentsToSupplementalProformaTransactionCosts" abstract="false" name="AdjustmentsToSupplementalProformaTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vyne_ShareholderLenderMember" abstract="true" name="ShareholderLenderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification" abstract="false" name="DeemedDividendToWarrantsHoldersDueToWarrantModification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" abstract="false" name="BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances" abstract="false" name="RevenueRecognitionDistributionTradeDiscountsAndAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_EffectiveExchangeRatio" abstract="false" name="EffectiveExchangeRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vyne_BusinessCombinationConsiderationTransferredGross" abstract="false" name="BusinessCombinationConsiderationTransferredGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_PaymentsForLicensingAgreements" abstract="false" name="PaymentsForLicensingAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_A2018PlanMember" abstract="true" name="A2018PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" abstract="false" name="ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" abstract="false" name="ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_AmendedAndRestatedCreditAgreementMember" abstract="true" name="AmendedAndRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" abstract="false" name="AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" abstract="false" name="SharesIssuedUponConversionOfCommonStockRightsPerAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vyne_ContingentStockRightSharesConversion" abstract="false" name="ContingentStockRightSharesConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock" abstract="false" name="ScheduleOfBusinessCombinationGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vyne_AllowanceForSalesReturns1Member" abstract="true" name="AllowanceForSalesReturns1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_FoamixMember" abstract="true" name="FoamixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_A2019PlanMember" abstract="true" name="A2019PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_MenloPremergerMember" abstract="true" name="MenloPremergerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_ThreeCustomersMember" abstract="true" name="ThreeCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" abstract="false" name="NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vyne_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_TopicalBETiOptionAgreementMember" abstract="true" name="TopicalBETiOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vyne_EstimateOfProductReturnRateMinimum" abstract="false" name="EstimateOfProductReturnRateMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vyne_RoyaltyPaymentPercentMaximum" abstract="false" name="RoyaltyPaymentPercentMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>vyne-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:40e9affd-2783-4e4a-bd7f-018d2dae4bf0,g:c708fe63-ab77-4120-b7ee-9a72ba48151c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6c3c79b7-f4b0-4e73-be88-2830a3fdd323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e5940c8e-ade9-49cd-b8d4-b49a7abbca0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c3c79b7-f4b0-4e73-be88-2830a3fdd323" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e5940c8e-ade9-49cd-b8d4-b49a7abbca0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e2ff83ef-2da0-4a62-9c2b-215949f92b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c3c79b7-f4b0-4e73-be88-2830a3fdd323" xlink:to="loc_us-gaap_AssetsCurrent_e2ff83ef-2da0-4a62-9c2b-215949f92b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7613f752-51b5-45ca-a6a1-0d2e8e566f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c3c79b7-f4b0-4e73-be88-2830a3fdd323" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7613f752-51b5-45ca-a6a1-0d2e8e566f49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_31459a9a-acb4-44e6-95e5-52064384490d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c3c79b7-f4b0-4e73-be88-2830a3fdd323" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_31459a9a-acb4-44e6-95e5-52064384490d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5540c029-7d3b-44fc-9574-7859a12a0c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4b896061-d56d-4183-b893-8d187bc953d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5540c029-7d3b-44fc-9574-7859a12a0c22" xlink:to="loc_us-gaap_Liabilities_4b896061-d56d-4183-b893-8d187bc953d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cbc7ecd6-dad1-4647-96f2-b0947dfb2a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5540c029-7d3b-44fc-9574-7859a12a0c22" xlink:to="loc_us-gaap_StockholdersEquity_cbc7ecd6-dad1-4647-96f2-b0947dfb2a26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_276558bc-3c6d-43b7-b3ce-d5664f615658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5540c029-7d3b-44fc-9574-7859a12a0c22" xlink:to="loc_us-gaap_CommitmentsAndContingencies_276558bc-3c6d-43b7-b3ce-d5664f615658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_12b56484-72e3-400f-bc0a-22a8535c2aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fbd41cd5-2691-454e-a947-ee727af8dd54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12b56484-72e3-400f-bc0a-22a8535c2aec" xlink:to="loc_us-gaap_CommonStockValue_fbd41cd5-2691-454e-a947-ee727af8dd54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_735e9dee-d924-4e2f-9328-a7b77c8b05b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12b56484-72e3-400f-bc0a-22a8535c2aec" xlink:to="loc_us-gaap_AdditionalPaidInCapital_735e9dee-d924-4e2f-9328-a7b77c8b05b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_afdf4dc7-fc52-4d3e-9c47-b4282e30525f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12b56484-72e3-400f-bc0a-22a8535c2aec" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_afdf4dc7-fc52-4d3e-9c47-b4282e30525f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7aebf1d6-ac2c-4a29-af38-ad857a29bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12b56484-72e3-400f-bc0a-22a8535c2aec" xlink:to="loc_us-gaap_PreferredStockValue_7aebf1d6-ac2c-4a29-af38-ad857a29bfd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c91e29cf-d989-40fd-aa04-f9552c0e903b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d37112b3-ac36-4cfc-ad1f-dc72e931389e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c91e29cf-d989-40fd-aa04-f9552c0e903b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d37112b3-ac36-4cfc-ad1f-dc72e931389e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_83e40ac6-0c5f-4126-934f-66ac87a256f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c91e29cf-d989-40fd-aa04-f9552c0e903b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_83e40ac6-0c5f-4126-934f-66ac87a256f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_aa4bfb6b-2b19-4030-a59b-e3f03d7cb1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c91e29cf-d989-40fd-aa04-f9552c0e903b" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_aa4bfb6b-2b19-4030-a59b-e3f03d7cb1b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a3bb6621-deac-46d7-a6d3-c4aab95e2bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c91e29cf-d989-40fd-aa04-f9552c0e903b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a3bb6621-deac-46d7-a6d3-c4aab95e2bbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_22efef60-3ea5-43c4-9ef3-6a48f54da0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c91e29cf-d989-40fd-aa04-f9552c0e903b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_22efef60-3ea5-43c4-9ef3-6a48f54da0e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9cdf3cb3-10f8-494c-aa1d-4c63dd092893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c91e29cf-d989-40fd-aa04-f9552c0e903b" xlink:to="loc_us-gaap_LongTermDebtCurrent_9cdf3cb3-10f8-494c-aa1d-4c63dd092893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4c18fbc4-27e6-46f0-9a22-a7c67e9e480c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ec451de-40b1-4af1-9090-bac38288ecde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c18fbc4-27e6-46f0-9a22-a7c67e9e480c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ec451de-40b1-4af1-9090-bac38288ecde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_66a3525b-a8c0-45d0-b59e-11a10402c93f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c18fbc4-27e6-46f0-9a22-a7c67e9e480c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_66a3525b-a8c0-45d0-b59e-11a10402c93f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ae0c18ee-8f4d-4151-8ed1-350cd64e0e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c18fbc4-27e6-46f0-9a22-a7c67e9e480c" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ae0c18ee-8f4d-4151-8ed1-350cd64e0e7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_31c16851-22d8-45f9-8187-ec68a721d14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c18fbc4-27e6-46f0-9a22-a7c67e9e480c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_31c16851-22d8-45f9-8187-ec68a721d14a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_811dfda6-2927-474c-802c-8ff64aeae945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c18fbc4-27e6-46f0-9a22-a7c67e9e480c" xlink:to="loc_us-gaap_InventoryNet_811dfda6-2927-474c-802c-8ff64aeae945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a3fcf372-8751-4b8c-94f8-58016026af4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c18fbc4-27e6-46f0-9a22-a7c67e9e480c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a3fcf372-8751-4b8c-94f8-58016026af4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d90d1ad7-198e-4a23-94b0-67dffdf904f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_60183687-50f2-43e4-9a1a-19311b0b781e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d90d1ad7-198e-4a23-94b0-67dffdf904f9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_60183687-50f2-43e4-9a1a-19311b0b781e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_d3b1085e-880d-4c4c-ab9f-9de2ea6aea0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d90d1ad7-198e-4a23-94b0-67dffdf904f9" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_d3b1085e-880d-4c4c-ab9f-9de2ea6aea0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b95bd75a-a902-4973-b488-2995b8046a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d90d1ad7-198e-4a23-94b0-67dffdf904f9" xlink:to="loc_us-gaap_LiabilitiesCurrent_b95bd75a-a902-4973-b488-2995b8046a3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_3cdd4284-ae87-4e69-b7e5-0ebd306db696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d90d1ad7-198e-4a23-94b0-67dffdf904f9" xlink:to="loc_us-gaap_OtherLiabilities_3cdd4284-ae87-4e69-b7e5-0ebd306db696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_832d8e49-caa3-4452-bd15-7af74ddfc39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d90d1ad7-198e-4a23-94b0-67dffdf904f9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_832d8e49-caa3-4452-bd15-7af74ddfc39f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_331a32a3-e4dc-4488-a8b1-558731f2e6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_49aa2d67-d752-43f9-97ee-1649afd34105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_331a32a3-e4dc-4488-a8b1-558731f2e6e5" xlink:to="loc_us-gaap_InterestExpense_49aa2d67-d752-43f9-97ee-1649afd34105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2652b336-21f4-4ee9-ac6c-c56a1d53f514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_331a32a3-e4dc-4488-a8b1-558731f2e6e5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2652b336-21f4-4ee9-ac6c-c56a1d53f514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_44e1dc54-bdcd-46ed-bd37-fa6478b03018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_331a32a3-e4dc-4488-a8b1-558731f2e6e5" xlink:to="loc_us-gaap_OperatingIncomeLoss_44e1dc54-bdcd-46ed-bd37-fa6478b03018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_68671572-3d75-4d86-98bc-80a1115785b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_35942112-692a-4463-bb91-515336c29b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_68671572-3d75-4d86-98bc-80a1115785b5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_35942112-692a-4463-bb91-515336c29b36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05f8e534-2874-4792-877b-800192ed587b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_68671572-3d75-4d86-98bc-80a1115785b5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_05f8e534-2874-4792-877b-800192ed587b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_14b807df-139a-4d7c-af24-3183911dd799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_68671572-3d75-4d86-98bc-80a1115785b5" xlink:to="loc_us-gaap_CostsAndExpenses_14b807df-139a-4d7c-af24-3183911dd799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f176fdd4-f51c-4b16-a6c3-0ddca5889b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d76fda59-69a1-483a-bea3-a2802bc25dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f176fdd4-f51c-4b16-a6c3-0ddca5889b49" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d76fda59-69a1-483a-bea3-a2802bc25dfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11c7d33d-8aaa-4218-b625-077020e955c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f176fdd4-f51c-4b16-a6c3-0ddca5889b49" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11c7d33d-8aaa-4218-b625-077020e955c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f4b900ff-71d1-4051-a91b-f763bff42203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5235cad7-a007-4c36-8627-fa16d2464eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f4b900ff-71d1-4051-a91b-f763bff42203" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5235cad7-a007-4c36-8627-fa16d2464eb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a1566fe9-8c29-4be3-a576-a2ad20e240a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f4b900ff-71d1-4051-a91b-f763bff42203" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a1566fe9-8c29-4be3-a576-a2ad20e240a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_82f2b3db-d3b4-4baf-809f-1c07c5f52815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f4b900ff-71d1-4051-a91b-f763bff42203" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_82f2b3db-d3b4-4baf-809f-1c07c5f52815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_42f95cf7-a2b4-4e31-ab26-d52f3e014598" xlink:href="vyne-20210630.xsd#vyne_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f4b900ff-71d1-4051-a91b-f763bff42203" xlink:to="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_42f95cf7-a2b4-4e31-ab26-d52f3e014598" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bc6a2e77-8654-4fd8-b75d-9b1683a2d564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8a1feef-4999-4b3d-b76e-8b3e95fe34f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bc6a2e77-8654-4fd8-b75d-9b1683a2d564" xlink:to="loc_us-gaap_NetIncomeLoss_f8a1feef-4999-4b3d-b76e-8b3e95fe34f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b4c282a-dadb-413e-917f-ba6213b5f2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bc6a2e77-8654-4fd8-b75d-9b1683a2d564" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b4c282a-dadb-413e-917f-ba6213b5f2e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a3a5f08d-1c77-4b55-bccf-68d8befee955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5ed80c7f-6e35-4502-8746-ee27235064a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a3a5f08d-1c77-4b55-bccf-68d8befee955" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5ed80c7f-6e35-4502-8746-ee27235064a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_115d9157-7e52-4861-945c-33e6bc8073d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a3a5f08d-1c77-4b55-bccf-68d8befee955" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_115d9157-7e52-4861-945c-33e6bc8073d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_0a0897de-5c59-4c14-b65c-6e1de2a6ca1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_NonCashAcquisitionOfBusinessCashAcquired_efe664be-9d61-47d2-8761-32b875ae5318" xlink:href="vyne-20210630.xsd#vyne_NonCashAcquisitionOfBusinessCashAcquired"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_0a0897de-5c59-4c14-b65c-6e1de2a6ca1d" xlink:to="loc_vyne_NonCashAcquisitionOfBusinessCashAcquired_efe664be-9d61-47d2-8761-32b875ae5318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_63370426-d9d4-4517-8864-48f902368c9d" xlink:href="vyne-20210630.xsd#vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_0a0897de-5c59-4c14-b65c-6e1de2a6ca1d" xlink:to="loc_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_63370426-d9d4-4517-8864-48f902368c9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f760c134-0d08-4748-aa2f-dcffa5696d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fdf7ef2c-acc6-4461-b90d-956e9e6a0eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f760c134-0d08-4748-aa2f-dcffa5696d47" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fdf7ef2c-acc6-4461-b90d-956e9e6a0eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ad7aac39-c73b-41f7-b35e-8a42206035bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f760c134-0d08-4748-aa2f-dcffa5696d47" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ad7aac39-c73b-41f7-b35e-8a42206035bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_8a5f1673-6c01-43fa-af02-bdd1e1d07150" xlink:href="vyne-20210630.xsd#vyne_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_8a5f1673-6c01-43fa-af02-bdd1e1d07150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ff80587a-e9e0-4397-b7bf-2f940025b13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ff80587a-e9e0-4397-b7bf-2f940025b13d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3c33adee-e6d8-4844-a853-2ce7a43a8b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3c33adee-e6d8-4844-a853-2ce7a43a8b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_14873e75-4788-4b79-b4af-4c48f496af19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_14873e75-4788-4b79-b4af-4c48f496af19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4ff400e4-6ce6-4d6e-b6d8-136fd838b2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4ff400e4-6ce6-4d6e-b6d8-136fd838b2e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0f0f487f-9047-489c-a2e5-8657554ec531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0f0f487f-9047-489c-a2e5-8657554ec531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1315c721-6e2c-4ea5-93fe-4c682189f227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_us-gaap_ShareBasedCompensation_1315c721-6e2c-4ea5-93fe-4c682189f227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e41a6154-0e22-40ee-941c-50012a1e37ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_us-gaap_NetIncomeLoss_e41a6154-0e22-40ee-941c-50012a1e37ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_64941362-068c-4a32-97cb-20347970b210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_64941362-068c-4a32-97cb-20347970b210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_834bf88c-db67-49bc-b2c7-742457721468" xlink:href="vyne-20210630.xsd#vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_834bf88c-db67-49bc-b2c7-742457721468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_92febe97-8e5f-4e89-b3af-e5d700c27c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_92febe97-8e5f-4e89-b3af-e5d700c27c5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_43696762-863c-415e-9f1a-80a2a0ce4c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d973b8cc-8e1e-42b5-9ffc-6fed24f54e6a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_43696762-863c-415e-9f1a-80a2a0ce4c14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b04275bc-9cdc-4c67-a455-21308e9feaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ProceedsFromBusinessMerger_510834c4-c059-46e5-9dec-f6a248f4d1cc" xlink:href="vyne-20210630.xsd#vyne_ProceedsFromBusinessMerger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b04275bc-9cdc-4c67-a455-21308e9feaa0" xlink:to="loc_vyne_ProceedsFromBusinessMerger_510834c4-c059-46e5-9dec-f6a248f4d1cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2afbe92b-f729-4451-9e93-4d51e66dee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b04275bc-9cdc-4c67-a455-21308e9feaa0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2afbe92b-f729-4451-9e93-4d51e66dee6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3c1aa49d-22dc-4903-b9a8-02b8d5ea73ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b04275bc-9cdc-4c67-a455-21308e9feaa0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3c1aa49d-22dc-4903-b9a8-02b8d5ea73ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_03512e23-7ab1-4fd4-922a-1fbca36e6f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3deeb837-9a54-4efc-b12f-f4a53ddc6906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_03512e23-7ab1-4fd4-922a-1fbca36e6f8a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3deeb837-9a54-4efc-b12f-f4a53ddc6906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6834e3e-2fea-47ff-bbf5-9f6bac588e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_03512e23-7ab1-4fd4-922a-1fbca36e6f8a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6834e3e-2fea-47ff-bbf5-9f6bac588e94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1318b899-6109-4aa3-8376-6f2131a25508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_03512e23-7ab1-4fd4-922a-1fbca36e6f8a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1318b899-6109-4aa3-8376-6f2131a25508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef67740b-be6f-43d6-be3c-6739204e20b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_d76b84b0-f3ac-4f61-ae1d-55ce5b775a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef67740b-be6f-43d6-be3c-6739204e20b1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_d76b84b0-f3ac-4f61-ae1d-55ce5b775a2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aeb972e1-1cbe-4d7e-a828-d8da8ecd4b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef67740b-be6f-43d6-be3c-6739204e20b1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aeb972e1-1cbe-4d7e-a828-d8da8ecd4b27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredGross_28b1cb74-a10e-4c56-9ba1-b1aa2f08064d" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_78bfb21a-761a-4321-828d-372ff3864945" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vyne_BusinessCombinationConsiderationTransferredGross_28b1cb74-a10e-4c56-9ba1-b1aa2f08064d" xlink:to="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_78bfb21a-761a-4321-828d-372ff3864945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_12ffe560-a96c-4a4a-9868-6b68db6b0990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vyne_BusinessCombinationConsiderationTransferredGross_28b1cb74-a10e-4c56-9ba1-b1aa2f08064d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_12ffe560-a96c-4a4a-9868-6b68db6b0990" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONPurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6bc935fd-23b8-4bc1-ba7f-cddd610e6e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_b55e244d-6a09-4d4c-bff7-4b3190619812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6bc935fd-23b8-4bc1-ba7f-cddd610e6e97" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_b55e244d-6a09-4d4c-bff7-4b3190619812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_02aa2bae-3731-4db9-a08b-d6438167951d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6bc935fd-23b8-4bc1-ba7f-cddd610e6e97" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_02aa2bae-3731-4db9-a08b-d6438167951d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ee51952c-906a-4bb5-ab3d-c377842646c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_b5889ca3-229e-4774-8b43-db5a3736a70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ee51952c-906a-4bb5-ab3d-c377842646c3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_b5889ca3-229e-4774-8b43-db5a3736a70f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0d0fd66a-fb54-4ede-9553-336740aef022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b58c0069-a072-4e07-ac1c-ad6dde81ed70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0d0fd66a-fb54-4ede-9553-336740aef022" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b58c0069-a072-4e07-ac1c-ad6dde81ed70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_a341c82c-d9ac-4a6d-b7ab-a842862bfc83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0d0fd66a-fb54-4ede-9553-336740aef022" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_a341c82c-d9ac-4a6d-b7ab-a842862bfc83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_ebf2f4b2-cbd9-4407-8996-bdabf2d2eb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0d0fd66a-fb54-4ede-9553-336740aef022" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_ebf2f4b2-cbd9-4407-8996-bdabf2d2eb72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_56a63d3f-1d90-469f-8602-b5d37381cf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0d0fd66a-fb54-4ede-9553-336740aef022" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_56a63d3f-1d90-469f-8602-b5d37381cf9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_597e37eb-8e28-44fc-8a70-87a76eedfd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_0d0fd66a-fb54-4ede-9553-336740aef022" xlink:to="loc_us-gaap_Goodwill_597e37eb-8e28-44fc-8a70-87a76eedfd1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_84a5524d-5f4b-407e-bd72-77b9d84520b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_94b65406-3a6e-4df7-892e-96ac6c756937" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_84a5524d-5f4b-407e-bd72-77b9d84520b6" xlink:to="loc_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_94b65406-3a6e-4df7-892e-96ac6c756937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0648fb6c-e39f-4bb1-8592-f212e2196b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_84a5524d-5f4b-407e-bd72-77b9d84520b6" xlink:to="loc_us-gaap_Goodwill_0648fb6c-e39f-4bb1-8592-f212e2196b32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONIPRDandCSRDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4a03863d-d493-4bee-883b-df371a28449f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b398be50-3734-40dd-9f5e-e87806d13d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_4a03863d-d493-4bee-883b-df371a28449f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b398be50-3734-40dd-9f5e-e87806d13d0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONProFormaDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_4bdef7b6-faeb-448b-8c38-d0f29198f63e" xlink:href="vyne-20210630.xsd#vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_841101cc-075a-4396-a516-b0352b190725" xlink:href="vyne-20210630.xsd#vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_4bdef7b6-faeb-448b-8c38-d0f29198f63e" xlink:to="loc_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_841101cc-075a-4396-a516-b0352b190725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdjustmentsToSupplementalProformaTransactionCosts_cee9f476-4d6e-441b-9937-7ed225dd1c8a" xlink:href="vyne-20210630.xsd#vyne_AdjustmentsToSupplementalProformaTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_4bdef7b6-faeb-448b-8c38-d0f29198f63e" xlink:to="loc_vyne_AdjustmentsToSupplementalProformaTransactionCosts_cee9f476-4d6e-441b-9937-7ed225dd1c8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#INVENTORYScheduleofInventoryComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_f04b61f3-4287-40ab-9ec8-77dc83b7da55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_b3cadfe0-688a-407c-b80e-0d3f204abe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_f04b61f3-4287-40ab-9ec8-77dc83b7da55" xlink:to="loc_us-gaap_InventoryFinishedGoods_b3cadfe0-688a-407c-b80e-0d3f204abe81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_30f0ebbc-7b69-47ae-aeef-e0e82e0e50d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_f04b61f3-4287-40ab-9ec8-77dc83b7da55" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_30f0ebbc-7b69-47ae-aeef-e0e82e0e50d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_6c093c26-790b-458f-8a9c-aacab3d6c9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_f04b61f3-4287-40ab-9ec8-77dc83b7da55" xlink:to="loc_us-gaap_InventoryWorkInProcess_6c093c26-790b-458f-8a9c-aacab3d6c9d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_808555c3-44e6-4b28-9697-4d725f92faf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_455a78de-dd7f-42f1-bcdc-932a52d2e217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_808555c3-44e6-4b28-9697-4d725f92faf7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_455a78de-dd7f-42f1-bcdc-932a52d2e217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_880f90b5-0b21-4ad4-9049-931b7f7afdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_808555c3-44e6-4b28-9697-4d725f92faf7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_880f90b5-0b21-4ad4-9049-931b7f7afdb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bdc5f35e-afef-4ba8-87a0-01401f8a4cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_808555c3-44e6-4b28-9697-4d725f92faf7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bdc5f35e-afef-4ba8-87a0-01401f8a4cff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="vyne-20210630.xsd#OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_001281a8-0fc4-44ba-b180-4284498d15a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9a021d08-80ee-493c-a442-a660dbaa022c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_001281a8-0fc4-44ba-b180-4284498d15a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9a021d08-80ee-493c-a442-a660dbaa022c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5d0b4b12-1851-4065-9a1d-7a328fdf1d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_001281a8-0fc4-44ba-b180-4284498d15a2" xlink:to="loc_us-gaap_OperatingLeaseLiability_5d0b4b12-1851-4065-9a1d-7a328fdf1d97" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>vyne-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:40e9affd-2783-4e4a-bd7f-018d2dae4bf0,g:c708fe63-ab77-4120-b7ee-9a72ba48151c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i8a06dda5f6d949fdafc8166d9c6e682f_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_86d08bf7-2dac-433e-b049-a4004f2cd7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_86d08bf7-2dac-433e-b049-a4004f2cd7c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_78dd1908-a552-457a-b03a-8b108d629206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_78dd1908-a552-457a-b03a-8b108d629206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_74306271-6d66-4345-8cb0-8772d3904382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_74306271-6d66-4345-8cb0-8772d3904382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6a604ff1-ca9f-4d78-ba9b-85d9e4ce4254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6a604ff1-ca9f-4d78-ba9b-85d9e4ce4254" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_b5a6972a-ed78-479f-abfb-8ded4968a102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_b5a6972a-ed78-479f-abfb-8ded4968a102" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_809e8e9c-fd81-466f-bc88-7809b85bb41f" xlink:href="vyne-20210630.xsd#vyne_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:to="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_809e8e9c-fd81-466f-bc88-7809b85bb41f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0208847d-8737-4540-bbdf-7f08c3fbff70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:to="loc_us-gaap_CostsAndExpenses_0208847d-8737-4540-bbdf-7f08c3fbff70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_84fe7126-6d58-4120-9206-1d6b6470a91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_OperatingIncomeLoss_84fe7126-6d58-4120-9206-1d6b6470a91d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a2446c45-ec37-4c33-a9e5-570afcd8d4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_InterestExpense_a2446c45-ec37-4c33-a9e5-570afcd8d4d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_56dc6105-35a9-49f1-a645-711d6b95b1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_56dc6105-35a9-49f1-a645-711d6b95b1cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d296d64a-b084-4191-9f04-196872f85370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d296d64a-b084-4191-9f04-196872f85370" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_aa9cfddf-b493-4350-9ca5-a1d6d3f21040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_aa9cfddf-b493-4350-9ca5-a1d6d3f21040" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1277bd09-7522-4fc9-97c7-c4147493779c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_NetIncomeLoss_1277bd09-7522-4fc9-97c7-c4147493779c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_94966dd9-c939-4130-b8fa-1f2a41a2231b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_EarningsPerShareBasic_94966dd9-c939-4130-b8fa-1f2a41a2231b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c8f7a0bb-8804-49f0-bf3f-2ab3dc29a1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c8f7a0bb-8804-49f0-bf3f-2ab3dc29a1f6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8b3464a8-9b25-45aa-b4a0-2d6ee5dbfa8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8b3464a8-9b25-45aa-b4a0-2d6ee5dbfa8e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_87006751-5594-4764-becd-f09135826e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_87006751-5594-4764-becd-f09135826e1f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_29a31621-d3f3-4b3f-9c4f-a05d443ea2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_StatementTable_29a31621-d3f3-4b3f-9c4f-a05d443ea2fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e8240c1-65bb-4c7a-8b3a-da86b8661887" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_29a31621-d3f3-4b3f-9c4f-a05d443ea2fc" xlink:to="loc_srt_ProductOrServiceAxis_8e8240c1-65bb-4c7a-8b3a-da86b8661887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8e8240c1-65bb-4c7a-8b3a-da86b8661887_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8e8240c1-65bb-4c7a-8b3a-da86b8661887" xlink:to="loc_srt_ProductsAndServicesDomain_8e8240c1-65bb-4c7a-8b3a-da86b8661887_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_473550a7-230c-4cdd-b700-23099b61c4b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8e8240c1-65bb-4c7a-8b3a-da86b8661887" xlink:to="loc_srt_ProductsAndServicesDomain_473550a7-230c-4cdd-b700-23099b61c4b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5e14b8d8-572a-4763-99f7-a9bae66e25ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_473550a7-230c-4cdd-b700-23099b61c4b7" xlink:to="loc_us-gaap_ProductMember_5e14b8d8-572a-4763-99f7-a9bae66e25ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b08897fc-f4bb-4cab-8574-52f1494f0fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_473550a7-230c-4cdd-b700-23099b61c4b7" xlink:to="loc_us-gaap_LicenseMember_b08897fc-f4bb-4cab-8574-52f1494f0fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_6c2df47c-3db1-4fa6-bcd7-59356217fc98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_473550a7-230c-4cdd-b700-23099b61c4b7" xlink:to="loc_us-gaap_RoyaltyMember_6c2df47c-3db1-4fa6-bcd7-59356217fc98" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="if8b5bebd9c6f4c9d8f65c7c12daadb02_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ae840ad1-9219-4ab7-a390-6c601b461383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ae840ad1-9219-4ab7-a390-6c601b461383" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ad139995-fd72-47cd-a1bd-93c5a074df8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockholdersEquity_ad139995-fd72-47cd-a1bd-93c5a074df8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_30e7891f-4352-484e-b170-dbd1cd4298bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_30e7891f-4352-484e-b170-dbd1cd4298bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_27a00f63-7e54-4616-af2f-0f9cfa613e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_27a00f63-7e54-4616-af2f-0f9cfa613e64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_afb47b97-6cd7-460c-a2bd-6bd75ae14f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_afb47b97-6cd7-460c-a2bd-6bd75ae14f14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d2b1740-5892-489e-be02-9ead903b4d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d2b1740-5892-489e-be02-9ead903b4d63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_9157f91a-d687-4ef7-beaf-6d1bb2840f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_9157f91a-d687-4ef7-beaf-6d1bb2840f5b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_e9f90fff-8bea-486e-9e3d-52ebd6fadc0c" xlink:href="vyne-20210630.xsd#vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_e9f90fff-8bea-486e-9e3d-52ebd6fadc0c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_010b1177-8bcb-4276-a792-f0fdcdd00c6c" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_010b1177-8bcb-4276-a792-f0fdcdd00c6c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cf91e8d5-e537-4442-8c98-cb45e1e6b6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cf91e8d5-e537-4442-8c98-cb45e1e6b6b4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7c5c773d-fa5a-49ad-89dc-c25f5328988a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7c5c773d-fa5a-49ad-89dc-c25f5328988a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_0aa9a457-c8b9-4138-82d6-767a1a937e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_0aa9a457-c8b9-4138-82d6-767a1a937e91" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_347f20a5-0983-4908-8a2d-a0627173ea83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_347f20a5-0983-4908-8a2d-a0627173ea83" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_865ea829-1e63-441f-a741-bb0550669cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_83507679-8964-4111-af6b-f3191b82f8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_71f962d3-4da9-4913-bff2-b999df5e91d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ae840ad1-9219-4ab7-a390-6c601b461383" xlink:to="loc_us-gaap_StatementTable_71f962d3-4da9-4913-bff2-b999df5e91d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9c867ee9-f7b2-4f55-be9b-beb4843c5859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_71f962d3-4da9-4913-bff2-b999df5e91d1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9c867ee9-f7b2-4f55-be9b-beb4843c5859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c867ee9-f7b2-4f55-be9b-beb4843c5859_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c867ee9-f7b2-4f55-be9b-beb4843c5859" xlink:to="loc_us-gaap_EquityComponentDomain_9c867ee9-f7b2-4f55-be9b-beb4843c5859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c867ee9-f7b2-4f55-be9b-beb4843c5859" xlink:to="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_978ad166-58ff-45d6-91b6-9eeb83e9613f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:to="loc_us-gaap_CommonStockMember_978ad166-58ff-45d6-91b6-9eeb83e9613f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_67e60265-92d4-48ac-bb43-c358f1ee393e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_67e60265-92d4-48ac-bb43-c358f1ee393e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b9d5e207-6624-497d-a233-ef6b227d8acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:to="loc_us-gaap_RetainedEarningsMember_b9d5e207-6624-497d-a233-ef6b227d8acb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c10fbf2d-67e8-45b5-a78c-9df22da3fd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c10fbf2d-67e8-45b5-a78c-9df22da3fd4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_94cdbc90-c1ed-4e89-b8e1-0ea3d85398b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_71f962d3-4da9-4913-bff2-b999df5e91d1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_94cdbc90-c1ed-4e89-b8e1-0ea3d85398b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94cdbc90-c1ed-4e89-b8e1-0ea3d85398b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_94cdbc90-c1ed-4e89-b8e1-0ea3d85398b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94cdbc90-c1ed-4e89-b8e1-0ea3d85398b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fb51372-6957-43d0-adeb-8c02f1bdc899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_94cdbc90-c1ed-4e89-b8e1-0ea3d85398b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fb51372-6957-43d0-adeb-8c02f1bdc899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AtTheMarketOfferingMember_ce4ad014-d877-4f50-9232-b2c1462606be" xlink:href="vyne-20210630.xsd#vyne_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fb51372-6957-43d0-adeb-8c02f1bdc899" xlink:to="loc_vyne_AtTheMarketOfferingMember_ce4ad014-d877-4f50-9232-b2c1462606be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PublicOfferingMember_d03aad58-2a49-4f42-8214-90a2b23e8abd" xlink:href="vyne-20210630.xsd#vyne_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fb51372-6957-43d0-adeb-8c02f1bdc899" xlink:to="loc_vyne_PublicOfferingMember_d03aad58-2a49-4f42-8214-90a2b23e8abd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="i394ec753e4614475a37948a1563c32cb_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c40eb14a-7a1e-49df-9c41-abc2e7f90341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a9b25d07-532c-41fb-8d12-ae75f1f243d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c40eb14a-7a1e-49df-9c41-abc2e7f90341" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a9b25d07-532c-41fb-8d12-ae75f1f243d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ddd488f0-9701-4052-81a5-9c367cf07fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c40eb14a-7a1e-49df-9c41-abc2e7f90341" xlink:to="loc_us-gaap_StatementTable_ddd488f0-9701-4052-81a5-9c367cf07fd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6af0f4a4-0c28-4ef5-8281-00bf61c5cc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ddd488f0-9701-4052-81a5-9c367cf07fd3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6af0f4a4-0c28-4ef5-8281-00bf61c5cc1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6af0f4a4-0c28-4ef5-8281-00bf61c5cc1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6af0f4a4-0c28-4ef5-8281-00bf61c5cc1f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6af0f4a4-0c28-4ef5-8281-00bf61c5cc1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3230cfbf-952a-4af6-8bb3-4578c0c914ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6af0f4a4-0c28-4ef5-8281-00bf61c5cc1f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3230cfbf-952a-4af6-8bb3-4578c0c914ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AtTheMarketOfferingMember_dc1145a0-54bc-4aba-af2a-bcc8e9aead0e" xlink:href="vyne-20210630.xsd#vyne_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3230cfbf-952a-4af6-8bb3-4578c0c914ec" xlink:to="loc_vyne_AtTheMarketOfferingMember_dc1145a0-54bc-4aba-af2a-bcc8e9aead0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PublicOfferingMember_690d9820-1c17-46f1-b01c-a2788dbabc1e" xlink:href="vyne-20210630.xsd#vyne_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3230cfbf-952a-4af6-8bb3-4578c0c914ec" xlink:to="loc_vyne_PublicOfferingMember_690d9820-1c17-46f1-b01c-a2788dbabc1e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#NATUREOFOPERATIONSDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails" xlink:type="extended" id="i268a3a1c181a44a1a57975f6617700b5_NATUREOFOPERATIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5a808d7d-ff12-4015-9cd4-24ec878eab35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_NumberOfReportableSegments_5a808d7d-ff12-4015-9cd4-24ec878eab35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PaymentsForLicensingAgreements_4989f89a-3bad-492d-a3e8-9722bb59a26f" xlink:href="vyne-20210630.xsd#vyne_PaymentsForLicensingAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_vyne_PaymentsForLicensingAgreements_4989f89a-3bad-492d-a3e8-9722bb59a26f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum_e7e4bff0-a1ee-4622-ae00-0d74ce44ac86" xlink:href="vyne-20210630.xsd#vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum_e7e4bff0-a1ee-4622-ae00-0d74ce44ac86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RoyaltyPaymentPercentMaximum_9c4d5e9c-1414-4936-b69f-648b36def423" xlink:href="vyne-20210630.xsd#vyne_RoyaltyPaymentPercentMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_vyne_RoyaltyPaymentPercentMaximum_9c4d5e9c-1414-4936-b69f-648b36def423" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_41d1fa54-8c95-48a0-83df-72844925e81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_41d1fa54-8c95-48a0-83df-72844925e81e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_911e3dfe-3942-423f-a211-7d96092c45a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_911e3dfe-3942-423f-a211-7d96092c45a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6fb75aff-1a69-4107-b71c-aa88d19bfb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6fb75aff-1a69-4107-b71c-aa88d19bfb28" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9fb0a738-d7db-46da-95b5-feb6a034a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9fb0a738-d7db-46da-95b5-feb6a034a3dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f87c195a-1a75-4d31-94b8-2f4cfbf3e0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_NetIncomeLoss_f87c195a-1a75-4d31-94b8-2f4cfbf3e0f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0b8e4d-53e8-4747-9142-2f97dd0bf424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0b8e4d-53e8-4747-9142-2f97dd0bf424" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3d535d8c-42c3-42e0-84cd-d8e3c642d4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3d535d8c-42c3-42e0-84cd-d8e3c642d4a2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ea10c85-369c-4357-8300-c61ccc481feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ea10c85-369c-4357-8300-c61ccc481feb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a771f21-b4f8-47c9-95d9-13d37fc997ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a771f21-b4f8-47c9-95d9-13d37fc997ac" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_31548b95-8d0b-489e-b4bc-5ac7c2d019f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_LongTermDebt_31548b95-8d0b-489e-b4bc-5ac7c2d019f8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cf8f2406-8cab-4a8b-8ce4-11017025c7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cf8f2406-8cab-4a8b-8ce4-11017025c7c5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RepaymentOfDebtPrepaymentFeePercentage_c77430e5-5076-47b5-a474-06d965dd7e59" xlink:href="vyne-20210630.xsd#vyne_RepaymentOfDebtPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_vyne_RepaymentOfDebtPrepaymentFeePercentage_c77430e5-5076-47b5-a474-06d965dd7e59" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_59135a85-19f2-4c47-bcdc-933355fb0d6e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_dei_LegalEntityAxis_59135a85-19f2-4c47-bcdc-933355fb0d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_59135a85-19f2-4c47-bcdc-933355fb0d6e_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_59135a85-19f2-4c47-bcdc-933355fb0d6e" xlink:to="loc_dei_EntityDomain_59135a85-19f2-4c47-bcdc-933355fb0d6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_47633c75-b769-4059-9a65-e1383541b5ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_59135a85-19f2-4c47-bcdc-933355fb0d6e" xlink:to="loc_dei_EntityDomain_47633c75-b769-4059-9a65-e1383541b5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_MenloPremergerMember_9e7b3d2a-1fdb-4e67-9062-67215b8cd8f2" xlink:href="vyne-20210630.xsd#vyne_MenloPremergerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_47633c75-b769-4059-9a65-e1383541b5ce" xlink:to="loc_vyne_MenloPremergerMember_9e7b3d2a-1fdb-4e67-9062-67215b8cd8f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_13eb3052-e39d-461f-b6c3-858d83e357df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_us-gaap_TypeOfArrangementAxis_13eb3052-e39d-461f-b6c3-858d83e357df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13eb3052-e39d-461f-b6c3-858d83e357df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_13eb3052-e39d-461f-b6c3-858d83e357df" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13eb3052-e39d-461f-b6c3-858d83e357df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d655a2e-8894-4eb1-abb8-25682bf5ff25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_13eb3052-e39d-461f-b6c3-858d83e357df" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d655a2e-8894-4eb1-abb8-25682bf5ff25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_66fced2d-ee42-4052-881b-93a833bb6797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d655a2e-8894-4eb1-abb8-25682bf5ff25" xlink:to="loc_us-gaap_LicensingAgreementsMember_66fced2d-ee42-4052-881b-93a833bb6797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_TopicalBETiOptionAgreementMember_6cb5e719-1a31-4cac-8612-c96b1e2eceea" xlink:href="vyne-20210630.xsd#vyne_TopicalBETiOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LicensingAgreementsMember_66fced2d-ee42-4052-881b-93a833bb6797" xlink:to="loc_vyne_TopicalBETiOptionAgreementMember_6cb5e719-1a31-4cac-8612-c96b1e2eceea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_OralBETiOptionAgreementMember_f6408447-a611-4bfb-bd95-a79af1c5fa11" xlink:href="vyne-20210630.xsd#vyne_OralBETiOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LicensingAgreementsMember_66fced2d-ee42-4052-881b-93a833bb6797" xlink:to="loc_vyne_OralBETiOptionAgreementMember_f6408447-a611-4bfb-bd95-a79af1c5fa11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_89c4b93d-355d-4ecf-93ee-3238945497bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_89c4b93d-355d-4ecf-93ee-3238945497bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_89c4b93d-355d-4ecf-93ee-3238945497bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_89c4b93d-355d-4ecf-93ee-3238945497bd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_89c4b93d-355d-4ecf-93ee-3238945497bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_566f16f3-047e-4a25-901b-f5b9e055a847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_89c4b93d-355d-4ecf-93ee-3238945497bd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_566f16f3-047e-4a25-901b-f5b9e055a847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a4734997-b686-4002-8273-61fc4ff50726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_566f16f3-047e-4a25-901b-f5b9e055a847" xlink:to="loc_us-gaap_SubsequentEventMember_a4734997-b686-4002-8273-61fc4ff50726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_ee13cb50-f08a-4f63-a7ab-09e80703a437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_ee13cb50-f08a-4f63-a7ab-09e80703a437" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ee13cb50-f08a-4f63-a7ab-09e80703a437_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ee13cb50-f08a-4f63-a7ab-09e80703a437" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ee13cb50-f08a-4f63-a7ab-09e80703a437_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a4bdcb02-984a-4dfc-8bf6-cfa9d0e96fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ee13cb50-f08a-4f63-a7ab-09e80703a437" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a4bdcb02-984a-4dfc-8bf6-cfa9d0e96fab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_dba180ce-7019-4aae-9410-eb0eb04186a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a4bdcb02-984a-4dfc-8bf6-cfa9d0e96fab" xlink:to="loc_us-gaap_EmployeeSeveranceMember_dba180ce-7019-4aae-9410-eb0eb04186a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_deffbdf0-7e1b-4998-ba92-06769fd6da5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_srt_RangeAxis_deffbdf0-7e1b-4998-ba92-06769fd6da5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_deffbdf0-7e1b-4998-ba92-06769fd6da5d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_deffbdf0-7e1b-4998-ba92-06769fd6da5d" xlink:to="loc_srt_RangeMember_deffbdf0-7e1b-4998-ba92-06769fd6da5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f1c3ba32-2889-43af-8681-0893b8084f79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_deffbdf0-7e1b-4998-ba92-06769fd6da5d" xlink:to="loc_srt_RangeMember_f1c3ba32-2889-43af-8681-0893b8084f79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_36cd00ec-5cf2-424e-8463-e800d6467100" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f1c3ba32-2889-43af-8681-0893b8084f79" xlink:to="loc_srt_MinimumMember_36cd00ec-5cf2-424e-8463-e800d6467100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_390bba86-7b7d-4ac7-85b1-1d81dc9a15e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f1c3ba32-2889-43af-8681-0893b8084f79" xlink:to="loc_srt_MaximumMember_390bba86-7b7d-4ac7-85b1-1d81dc9a15e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_acba8061-241e-4bfe-88d0-163a51034eb4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_srt_StatementScenarioAxis_acba8061-241e-4bfe-88d0-163a51034eb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_acba8061-241e-4bfe-88d0-163a51034eb4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_acba8061-241e-4bfe-88d0-163a51034eb4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_acba8061-241e-4bfe-88d0-163a51034eb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b4085a48-63ef-41fd-b3d7-26f83ee4c285" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_acba8061-241e-4bfe-88d0-163a51034eb4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b4085a48-63ef-41fd-b3d7-26f83ee4c285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5c822415-a846-4b13-aead-a0761b7e1583" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b4085a48-63ef-41fd-b3d7-26f83ee4c285" xlink:to="loc_srt_ScenarioForecastMember_5c822415-a846-4b13-aead-a0761b7e1583" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9eba8074-4733-4564-bcf9-ad6996f32a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_us-gaap_DebtInstrumentAxis_9eba8074-4733-4564-bcf9-ad6996f32a75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9eba8074-4733-4564-bcf9-ad6996f32a75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9eba8074-4733-4564-bcf9-ad6996f32a75" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9eba8074-4733-4564-bcf9-ad6996f32a75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8cdd7ce3-ee6d-46a8-8947-fe1b0f2a308f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9eba8074-4733-4564-bcf9-ad6996f32a75" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8cdd7ce3-ee6d-46a8-8947-fe1b0f2a308f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementMember_4d5feb52-244d-421f-9853-deaaaf5959b1" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cdd7ce3-ee6d-46a8-8947-fe1b0f2a308f" xlink:to="loc_vyne_AmendedAndRestatedCreditAgreementMember_4d5feb52-244d-421f-9853-deaaaf5959b1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="ic4d9147c6acb492885b68cb67cb7f124_SIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_44c94ad5-0284-4770-85f3-138cb67523ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_44c94ad5-0284-4770-85f3-138cb67523ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_809104fd-6c57-41b1-ab62-a589d7445edb" xlink:href="vyne-20210630.xsd#vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_809104fd-6c57-41b1-ab62-a589d7445edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_c13597ed-13b5-41e4-a8fb-ccf1d222734e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_c13597ed-13b5-41e4-a8fb-ccf1d222734e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockRightSharesConversion_f090d9f7-9f78-4204-b4c7-f1853e4ad173" xlink:href="vyne-20210630.xsd#vyne_ContingentStockRightSharesConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_vyne_ContingentStockRightSharesConversion_f090d9f7-9f78-4204-b4c7-f1853e4ad173" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationEffectiveExchangeRatio_e0caf9e8-bb87-4e0b-8bd9-0ed47a7a8464" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationEffectiveExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_vyne_BusinessCombinationEffectiveExchangeRatio_e0caf9e8-bb87-4e0b-8bd9-0ed47a7a8464" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66f61202-47ac-42f0-b7d3-862f8f36aa71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66f61202-47ac-42f0-b7d3-862f8f36aa71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5f2be2b6-94ea-42c6-b8b0-4e63418faff4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66f61202-47ac-42f0-b7d3-862f8f36aa71" xlink:to="loc_dei_LegalEntityAxis_5f2be2b6-94ea-42c6-b8b0-4e63418faff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5f2be2b6-94ea-42c6-b8b0-4e63418faff4_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5f2be2b6-94ea-42c6-b8b0-4e63418faff4" xlink:to="loc_dei_EntityDomain_5f2be2b6-94ea-42c6-b8b0-4e63418faff4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_092cc6cc-3ae1-4f1d-9148-7fe47d4a203f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5f2be2b6-94ea-42c6-b8b0-4e63418faff4" xlink:to="loc_dei_EntityDomain_092cc6cc-3ae1-4f1d-9148-7fe47d4a203f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_527287f1-2ffd-4151-a327-afc2babb7d56" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_092cc6cc-3ae1-4f1d-9148-7fe47d4a203f" xlink:to="loc_vyne_FoamixMember_527287f1-2ffd-4151-a327-afc2babb7d56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails" xlink:type="extended" id="id1fe663e1ac0440caf224894a8912d98_SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ad2b7bf2-99dc-4099-ac43-50c24c20c155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_baffde00-9691-4d76-b003-ff8b52fca40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ad2b7bf2-99dc-4099-ac43-50c24c20c155" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_baffde00-9691-4d76-b003-ff8b52fca40b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b35f7020-a5b7-42d5-870f-5ba7410397b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ad2b7bf2-99dc-4099-ac43-50c24c20c155" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b35f7020-a5b7-42d5-870f-5ba7410397b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_63e8efc9-500c-4261-bc9f-fc34195349d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b35f7020-a5b7-42d5-870f-5ba7410397b9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_63e8efc9-500c-4261-bc9f-fc34195349d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_63e8efc9-500c-4261-bc9f-fc34195349d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_63e8efc9-500c-4261-bc9f-fc34195349d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_63e8efc9-500c-4261-bc9f-fc34195349d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fc8081e-7942-4fb0-86a2-5279fc1cb756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_63e8efc9-500c-4261-bc9f-fc34195349d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fc8081e-7942-4fb0-86a2-5279fc1cb756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_9fd27802-7090-4d41-9147-ce1c2020f69a" xlink:href="vyne-20210630.xsd#vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fc8081e-7942-4fb0-86a2-5279fc1cb756" xlink:to="loc_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_9fd27802-7090-4d41-9147-ce1c2020f69a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_12d6da25-6847-4bc6-872f-402176ffd1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fc8081e-7942-4fb0-86a2-5279fc1cb756" xlink:to="loc_us-gaap_WarrantMember_12d6da25-6847-4bc6-872f-402176ffd1fd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="extended" id="i3df2f085d5ec4992afdcb6ff84d46201_BUSINESSCOMBINATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ExchangeRatio_f730f5bb-13e7-4af5-aeea-3e6bbcf32814" xlink:href="vyne-20210630.xsd#vyne_ExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_ExchangeRatio_f730f5bb-13e7-4af5-aeea-3e6bbcf32814" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessAcquisitionContingentStockRightIssued_e87697bd-1fc8-4047-ae03-463d4b454ceb" xlink:href="vyne-20210630.xsd#vyne_BusinessAcquisitionContingentStockRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_BusinessAcquisitionContingentStockRightIssued_e87697bd-1fc8-4047-ae03-463d4b454ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockRightSharesConversion_6372b2a9-380a-4927-8648-6845fbf23d56" xlink:href="vyne-20210630.xsd#vyne_ContingentStockRightSharesConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_ContingentStockRightSharesConversion_6372b2a9-380a-4927-8648-6845fbf23d56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EffectiveExchangeRatio_0391e2ef-2765-4e05-94fd-0389b420ad48" xlink:href="vyne-20210630.xsd#vyne_EffectiveExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_EffectiveExchangeRatio_0391e2ef-2765-4e05-94fd-0389b420ad48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_4f3a8b0f-f2b6-485e-a3c3-d03dfaa1303f" xlink:href="vyne-20210630.xsd#vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_4f3a8b0f-f2b6-485e-a3c3-d03dfaa1303f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_2ff3d5e3-02fd-4b7b-8431-61a974327e13" xlink:href="vyne-20210630.xsd#vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_2ff3d5e3-02fd-4b7b-8431-61a974327e13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PostMergerParentOwnershipByPreMergerParentStockholders_58cae0af-02b5-49ca-899f-a9df31c29f7c" xlink:href="vyne-20210630.xsd#vyne_PostMergerParentOwnershipByPreMergerParentStockholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_PostMergerParentOwnershipByPreMergerParentStockholders_58cae0af-02b5-49ca-899f-a9df31c29f7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_52198e71-da2c-48bf-8839-4849c8dfb43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_52198e71-da2c-48bf-8839-4849c8dfb43e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_951dc55a-6b4c-4333-b0d0-2cb33383e302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_SharePrice_951dc55a-6b4c-4333-b0d0-2cb33383e302" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredGross_5abe130d-3552-408c-91f8-6f7290835b04" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_BusinessCombinationConsiderationTransferredGross_5abe130d-3552-408c-91f8-6f7290835b04" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c01dd609-4563-42b7-8cc4-d9a52bb5c835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c01dd609-4563-42b7-8cc4-d9a52bb5c835" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_e31cc748-e78a-4e66-bf6c-018eff5f46c9" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_e31cc748-e78a-4e66-bf6c-018eff5f46c9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_b95b3761-890b-4d61-8972-9f405982b351" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_b95b3761-890b-4d61-8972-9f405982b351" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_35eac50d-bae2-42a5-9920-97a2c59fbe06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_35eac50d-bae2-42a5-9920-97a2c59fbe06" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_3016a790-7357-4847-bcc8-ec6ca91508d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_3016a790-7357-4847-bcc8-ec6ca91508d4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_2556ff28-61c7-4bc6-9dd2-c2302f629330" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_2556ff28-61c7-4bc6-9dd2-c2302f629330" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_201bd778-918b-4098-9197-352501813570" xlink:href="vyne-20210630.xsd#vyne_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_201bd778-918b-4098-9197-352501813570" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_976d6e75-d54a-4706-a756-67c577362cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_976d6e75-d54a-4706-a756-67c577362cc4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_de00a4b7-10a5-42c8-b607-8fa69a3cd26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_de00a4b7-10a5-42c8-b607-8fa69a3cd26c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_de00a4b7-10a5-42c8-b607-8fa69a3cd26c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_de00a4b7-10a5-42c8-b607-8fa69a3cd26c" xlink:to="loc_us-gaap_EquityComponentDomain_de00a4b7-10a5-42c8-b607-8fa69a3cd26c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_90eda51a-abb7-4cea-a5c3-95200d9b0792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_de00a4b7-10a5-42c8-b607-8fa69a3cd26c" xlink:to="loc_us-gaap_EquityComponentDomain_90eda51a-abb7-4cea-a5c3-95200d9b0792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bc0d43f3-25aa-40ce-ae0d-32469e282be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_90eda51a-abb7-4cea-a5c3-95200d9b0792" xlink:to="loc_us-gaap_CommonStockMember_bc0d43f3-25aa-40ce-ae0d-32469e282be3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eb71275d-519c-4587-aa2b-dfc24ac0a011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eb71275d-519c-4587-aa2b-dfc24ac0a011" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb71275d-519c-4587-aa2b-dfc24ac0a011_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb71275d-519c-4587-aa2b-dfc24ac0a011" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb71275d-519c-4587-aa2b-dfc24ac0a011_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3daeafd2-32f1-4479-920a-ab75de07deda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb71275d-519c-4587-aa2b-dfc24ac0a011" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3daeafd2-32f1-4479-920a-ab75de07deda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_47eebb5c-eddc-490e-b3f7-1c955c8207ff" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3daeafd2-32f1-4479-920a-ab75de07deda" xlink:to="loc_vyne_FoamixMember_47eebb5c-eddc-490e-b3f7-1c955c8207ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f8568f3f-2c37-4b1f-80c6-d9ce4a23efc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f8568f3f-2c37-4b1f-80c6-d9ce4a23efc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f8568f3f-2c37-4b1f-80c6-d9ce4a23efc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f8568f3f-2c37-4b1f-80c6-d9ce4a23efc5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f8568f3f-2c37-4b1f-80c6-d9ce4a23efc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9a92ab80-b3ff-4499-8a4a-257b866919fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f8568f3f-2c37-4b1f-80c6-d9ce4a23efc5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9a92ab80-b3ff-4499-8a4a-257b866919fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_45a859be-2305-43a7-bcbc-6d25099b5446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9a92ab80-b3ff-4499-8a4a-257b866919fb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_45a859be-2305-43a7-bcbc-6d25099b5446" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_829eb22c-986f-4a4b-a9dd-e4de24ed292f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_829eb22c-986f-4a4b-a9dd-e4de24ed292f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_829eb22c-986f-4a4b-a9dd-e4de24ed292f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_829eb22c-986f-4a4b-a9dd-e4de24ed292f" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_829eb22c-986f-4a4b-a9dd-e4de24ed292f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f740fa83-736d-4ed1-8da3-5ea96bd49e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_829eb22c-986f-4a4b-a9dd-e4de24ed292f" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f740fa83-736d-4ed1-8da3-5ea96bd49e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_3273377c-8531-46b8-be10-3fa33ad3e8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f740fa83-736d-4ed1-8da3-5ea96bd49e7b" xlink:to="loc_us-gaap_EmployeeSeveranceMember_3273377c-8531-46b8-be10-3fa33ad3e8e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4f5530a-137e-4edb-b7b8-264993f3ad02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4f5530a-137e-4edb-b7b8-264993f3ad02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4f5530a-137e-4edb-b7b8-264993f3ad02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4f5530a-137e-4edb-b7b8-264993f3ad02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b4f5530a-137e-4edb-b7b8-264993f3ad02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_649b92ed-f924-414f-8b82-306074830dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4f5530a-137e-4edb-b7b8-264993f3ad02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_649b92ed-f924-414f-8b82-306074830dcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9eeba8ef-2518-4b9b-a6ae-7590a3cffbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_649b92ed-f924-414f-8b82-306074830dcb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9eeba8ef-2518-4b9b-a6ae-7590a3cffbc3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="extended" id="i8692702ebe7a4193b75b9610655e9c0f_BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f95b6df0-a65f-432a-a506-164ef45ada3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f95b6df0-a65f-432a-a506-164ef45ada3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_f58e06bc-b095-44ff-a57e-cbb12ab58482" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_f58e06bc-b095-44ff-a57e-cbb12ab58482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredGross_7c338529-8576-4049-b44a-28b1414cf04d" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_vyne_BusinessCombinationConsiderationTransferredGross_7c338529-8576-4049-b44a-28b1414cf04d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b45b9ead-5505-4db4-bf79-520e74ba06c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b45b9ead-5505-4db4-bf79-520e74ba06c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3af1724e-8980-4d55-8aa3-0e639ad4643b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3af1724e-8980-4d55-8aa3-0e639ad4643b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6f56b2f0-22a7-47e9-b820-07bff54704e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6f56b2f0-22a7-47e9-b820-07bff54704e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0a0daf4a-b6ca-4b88-816f-f01037761b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6f56b2f0-22a7-47e9-b820-07bff54704e9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0a0daf4a-b6ca-4b88-816f-f01037761b10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0a0daf4a-b6ca-4b88-816f-f01037761b10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0a0daf4a-b6ca-4b88-816f-f01037761b10" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0a0daf4a-b6ca-4b88-816f-f01037761b10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2fa78b79-c5fe-4a12-8691-0012e12b835d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0a0daf4a-b6ca-4b88-816f-f01037761b10" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2fa78b79-c5fe-4a12-8691-0012e12b835d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_cae62d62-b718-4f06-920c-7652d4a2c275" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2fa78b79-c5fe-4a12-8691-0012e12b835d" xlink:to="loc_vyne_FoamixMember_cae62d62-b718-4f06-920c-7652d4a2c275" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="extended" id="ife1ee8de6bec4886a3eabd9a8efb66e8_BUSINESSCOMBINATIONPurchasePriceAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f5397cff-ad91-4b57-a585-a415c139d970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5397cff-ad91-4b57-a585-a415c139d970" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f52b6749-bc5f-49ff-8c3c-d44bfe44d044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f52b6749-bc5f-49ff-8c3c-d44bfe44d044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_587ffac2-fc2c-4e19-a072-e41d5b7a0f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_587ffac2-fc2c-4e19-a072-e41d5b7a0f21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3b982f72-8528-462a-9aa2-6af143333428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3b982f72-8528-462a-9aa2-6af143333428" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_39c89c1b-fa89-40ca-a175-1b6a13314e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_39c89c1b-fa89-40ca-a175-1b6a13314e10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4184f874-d49f-4c3b-81dc-56817c66fe11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_Goodwill_4184f874-d49f-4c3b-81dc-56817c66fe11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2a147cf9-ae98-4ba7-a453-05473e2dde6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2a147cf9-ae98-4ba7-a453-05473e2dde6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_e2d133f3-cebb-4971-8bae-77dadbb78277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_e2d133f3-cebb-4971-8bae-77dadbb78277" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_5e979d5c-e1a8-411d-83aa-51232ffa8739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_5e979d5c-e1a8-411d-83aa-51232ffa8739" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a3323ab1-8949-468c-9039-deccf5854e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a3323ab1-8949-468c-9039-deccf5854e87" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_ed58fb80-9e55-4eeb-b6a0-5f039ef8531d" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_ed58fb80-9e55-4eeb-b6a0-5f039ef8531d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_131916ce-64fe-4c90-b1d1-6ab33a34959b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5397cff-ad91-4b57-a585-a415c139d970" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_131916ce-64fe-4c90-b1d1-6ab33a34959b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dcc18d6b-755d-44c6-a887-5246f476744a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_131916ce-64fe-4c90-b1d1-6ab33a34959b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dcc18d6b-755d-44c6-a887-5246f476744a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcc18d6b-755d-44c6-a887-5246f476744a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dcc18d6b-755d-44c6-a887-5246f476744a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcc18d6b-755d-44c6-a887-5246f476744a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99359d17-b9c0-4e4e-871b-6970ca5f8ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dcc18d6b-755d-44c6-a887-5246f476744a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99359d17-b9c0-4e4e-871b-6970ca5f8ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_1cf793dc-a4cb-4de7-a7af-f6f0475c9b0d" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99359d17-b9c0-4e4e-871b-6970ca5f8ff1" xlink:to="loc_vyne_FoamixMember_1cf793dc-a4cb-4de7-a7af-f6f0475c9b0d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="extended" id="iaa0ee417c8c443e6a622dba36c8fc598_BUSINESSCOMBINATIONGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9063b034-531b-4ed3-a06f-2bce0272c26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9063b034-531b-4ed3-a06f-2bce0272c26e" xlink:to="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_f27bf65a-4ee5-4416-9db5-820222697bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_f27bf65a-4ee5-4416-9db5-820222697bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_eaf244cd-58d8-4146-9a1c-8e83d9025673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_eaf244cd-58d8-4146-9a1c-8e83d9025673" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_6add5180-6e79-4b53-a050-6c6cc7552aaa" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:to="loc_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_6add5180-6e79-4b53-a050-6c6cc7552aaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ee87888d-0159-45ec-a590-cea1fa481502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:to="loc_us-gaap_Goodwill_ee87888d-0159-45ec-a590-cea1fa481502" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_decf3782-9f08-42b3-bfc3-28dd5b982531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9063b034-531b-4ed3-a06f-2bce0272c26e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_decf3782-9f08-42b3-bfc3-28dd5b982531" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f60854f6-4a6a-4a74-a3be-72783a2e41ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_decf3782-9f08-42b3-bfc3-28dd5b982531" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f60854f6-4a6a-4a74-a3be-72783a2e41ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f60854f6-4a6a-4a74-a3be-72783a2e41ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f60854f6-4a6a-4a74-a3be-72783a2e41ec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f60854f6-4a6a-4a74-a3be-72783a2e41ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9962fe65-56f6-4918-af00-bb6eeb12ce56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f60854f6-4a6a-4a74-a3be-72783a2e41ec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9962fe65-56f6-4918-af00-bb6eeb12ce56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_dc28e77c-db68-44f7-bd00-7ef56bc9ba3f" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9962fe65-56f6-4918-af00-bb6eeb12ce56" xlink:to="loc_vyne_FoamixMember_dc28e77c-db68-44f7-bd00-7ef56bc9ba3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONIPRDandCSRDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="extended" id="if87bd6ab8125452f96291a8cad44b54e_BUSINESSCOMBINATIONIPRDandCSRDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f206e0b1-6957-44d0-85fc-a91e88142935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_3010cb40-ea96-42b8-aef6-1744a2a069c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f206e0b1-6957-44d0-85fc-a91e88142935" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_3010cb40-ea96-42b8-aef6-1744a2a069c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_738685ad-e88d-423e-a7fc-9b4749caf1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_3010cb40-ea96-42b8-aef6-1744a2a069c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_738685ad-e88d-423e-a7fc-9b4749caf1bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5300f52d-fe61-4c82-ac55-906a3501fd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_3010cb40-ea96-42b8-aef6-1744a2a069c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5300f52d-fe61-4c82-ac55-906a3501fd15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_727efb75-4f3a-42af-8f86-8dc98153c27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f206e0b1-6957-44d0-85fc-a91e88142935" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_727efb75-4f3a-42af-8f86-8dc98153c27f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_43e771f6-de62-4d35-a259-e389c782c347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_727efb75-4f3a-42af-8f86-8dc98153c27f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_43e771f6-de62-4d35-a259-e389c782c347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43e771f6-de62-4d35-a259-e389c782c347_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43e771f6-de62-4d35-a259-e389c782c347" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43e771f6-de62-4d35-a259-e389c782c347_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bcc375ed-6c5b-46dc-a8c3-34ab53ab1ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43e771f6-de62-4d35-a259-e389c782c347" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bcc375ed-6c5b-46dc-a8c3-34ab53ab1ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_df200ca0-19b1-40b3-9953-6c28a619d277" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bcc375ed-6c5b-46dc-a8c3-34ab53ab1ee6" xlink:to="loc_vyne_FoamixMember_df200ca0-19b1-40b3-9953-6c28a619d277" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#REVENUERECOGNITIONDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails" xlink:type="extended" id="i7c28fcad85aa473894f62a28660421ae_REVENUERECOGNITIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_625bbea3-d164-4d14-a292-36c209a8e49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_625bbea3-d164-4d14-a292-36c209a8e49f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances_762ea092-120a-4294-80d1-af7aca866cf1" xlink:href="vyne-20210630.xsd#vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances_762ea092-120a-4294-80d1-af7aca866cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0644e819-8550-4680-91b9-8bbb245c0277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0644e819-8550-4680-91b9-8bbb245c0277" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EstimateOfProductReturnRateMinimum_8d4de2f6-c71a-40eb-9558-c2cefbfa7af6" xlink:href="vyne-20210630.xsd#vyne_EstimateOfProductReturnRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_vyne_EstimateOfProductReturnRateMinimum_8d4de2f6-c71a-40eb-9558-c2cefbfa7af6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EstimateOfProductReturnRateMaximum_a28416da-1053-4314-844d-b943aa80c894" xlink:href="vyne-20210630.xsd#vyne_EstimateOfProductReturnRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_vyne_EstimateOfProductReturnRateMaximum_a28416da-1053-4314-844d-b943aa80c894" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_a5db294c-2164-43c2-841d-3f3063384acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_a5db294c-2164-43c2-841d-3f3063384acb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_UpfrontRoyaltyReceipt_006c48fc-88c0-41ac-b775-c1644d27a6d2" xlink:href="vyne-20210630.xsd#vyne_UpfrontRoyaltyReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_vyne_UpfrontRoyaltyReceipt_006c48fc-88c0-41ac-b775-c1644d27a6d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_f0badb02-e446-4995-ba64-af97939eaa4c" xlink:href="vyne-20210630.xsd#vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_f0badb02-e446-4995-ba64-af97939eaa4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec7d6884-21fc-4fe8-882e-3883ede5512b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec7d6884-21fc-4fe8-882e-3883ede5512b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a1d6d85b-cd79-4a0d-bf8f-5e2700fe7443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a1d6d85b-cd79-4a0d-bf8f-5e2700fe7443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a1d6d85b-cd79-4a0d-bf8f-5e2700fe7443_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a1d6d85b-cd79-4a0d-bf8f-5e2700fe7443" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a1d6d85b-cd79-4a0d-bf8f-5e2700fe7443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cb03610d-a138-4702-b8ee-b243d02d9d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a1d6d85b-cd79-4a0d-bf8f-5e2700fe7443" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cb03610d-a138-4702-b8ee-b243d02d9d3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4f9b3412-bcbf-4b46-9445-7578102b4e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cb03610d-a138-4702-b8ee-b243d02d9d3d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4f9b3412-bcbf-4b46-9445-7578102b4e9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0316a2e-bf8c-4012-a824-2ffa8b3a7af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0316a2e-bf8c-4012-a824-2ffa8b3a7af5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c0316a2e-bf8c-4012-a824-2ffa8b3a7af5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0316a2e-bf8c-4012-a824-2ffa8b3a7af5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c0316a2e-bf8c-4012-a824-2ffa8b3a7af5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4172fe1e-b0a0-4331-bda7-a077482adfba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0316a2e-bf8c-4012-a824-2ffa8b3a7af5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4172fe1e-b0a0-4331-bda7-a077482adfba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_af2c8076-c007-4404-87e0-71974ecd9a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4172fe1e-b0a0-4331-bda7-a077482adfba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_af2c8076-c007-4404-87e0-71974ecd9a17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_44abc55f-1b93-43dc-bb38-3705903f4b3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_srt_MajorCustomersAxis_44abc55f-1b93-43dc-bb38-3705903f4b3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_44abc55f-1b93-43dc-bb38-3705903f4b3d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_44abc55f-1b93-43dc-bb38-3705903f4b3d" xlink:to="loc_srt_NameOfMajorCustomerDomain_44abc55f-1b93-43dc-bb38-3705903f4b3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_36415c84-27e8-4d24-8cf2-af76c8bf4870" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_44abc55f-1b93-43dc-bb38-3705903f4b3d" xlink:to="loc_srt_NameOfMajorCustomerDomain_36415c84-27e8-4d24-8cf2-af76c8bf4870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FourCustomersMember_d57b6da8-0f49-47f1-a30e-3109a1965902" xlink:href="vyne-20210630.xsd#vyne_FourCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_36415c84-27e8-4d24-8cf2-af76c8bf4870" xlink:to="loc_vyne_FourCustomersMember_d57b6da8-0f49-47f1-a30e-3109a1965902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ThreeCustomersMember_5242958a-94d0-4b2f-b4b4-3358232155a2" xlink:href="vyne-20210630.xsd#vyne_ThreeCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_36415c84-27e8-4d24-8cf2-af76c8bf4870" xlink:to="loc_vyne_ThreeCustomersMember_5242958a-94d0-4b2f-b4b4-3358232155a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7d568aca-fdeb-4427-a9c4-bcef6b411fbe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_dei_LegalEntityAxis_7d568aca-fdeb-4427-a9c4-bcef6b411fbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7d568aca-fdeb-4427-a9c4-bcef6b411fbe_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7d568aca-fdeb-4427-a9c4-bcef6b411fbe" xlink:to="loc_dei_EntityDomain_7d568aca-fdeb-4427-a9c4-bcef6b411fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_168f4883-8215-44a7-88e7-3885a0d30b25" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7d568aca-fdeb-4427-a9c4-bcef6b411fbe" xlink:to="loc_dei_EntityDomain_168f4883-8215-44a7-88e7-3885a0d30b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_cb1d0925-d909-4b03-af35-0a38a0bed53e" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_168f4883-8215-44a7-88e7-3885a0d30b25" xlink:to="loc_vyne_FoamixMember_cb1d0925-d909-4b03-af35-0a38a0bed53e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_719e3e9a-009b-48c5-9504-79f05282773a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_srt_ProductOrServiceAxis_719e3e9a-009b-48c5-9504-79f05282773a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_719e3e9a-009b-48c5-9504-79f05282773a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_719e3e9a-009b-48c5-9504-79f05282773a" xlink:to="loc_srt_ProductsAndServicesDomain_719e3e9a-009b-48c5-9504-79f05282773a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bd125217-db22-4270-8552-4718707871ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_719e3e9a-009b-48c5-9504-79f05282773a" xlink:to="loc_srt_ProductsAndServicesDomain_bd125217-db22-4270-8552-4718707871ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_debce777-ba16-4d29-ae79-8738336694fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bd125217-db22-4270-8552-4718707871ab" xlink:to="loc_us-gaap_RoyaltyMember_debce777-ba16-4d29-ae79-8738336694fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AllowanceForSalesReturns1Member_868d7da8-d7ee-4e01-8f6a-428f9275bbe9" xlink:href="vyne-20210630.xsd#vyne_AllowanceForSalesReturns1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bd125217-db22-4270-8552-4718707871ab" xlink:to="loc_vyne_AllowanceForSalesReturns1Member_868d7da8-d7ee-4e01-8f6a-428f9275bbe9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="ibf825e8a8c024a8aa88ad4d0be7a90df_FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55896c7f-5713-445d-aeed-5e59f64084f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_ceab75d8-db1b-4ff3-98f8-8f8e9f94ad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55896c7f-5713-445d-aeed-5e59f64084f5" xlink:to="loc_us-gaap_MarketableSecurities_ceab75d8-db1b-4ff3-98f8-8f8e9f94ad6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b712dab0-4971-463a-8cd9-5c2569c46542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55896c7f-5713-445d-aeed-5e59f64084f5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b712dab0-4971-463a-8cd9-5c2569c46542" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1b885a-bbbf-452f-81aa-d8eba40885db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b712dab0-4971-463a-8cd9-5c2569c46542" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1b885a-bbbf-452f-81aa-d8eba40885db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b1b885a-bbbf-452f-81aa-d8eba40885db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1b885a-bbbf-452f-81aa-d8eba40885db" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b1b885a-bbbf-452f-81aa-d8eba40885db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f9809a6-d0e1-48ce-b552-6321eb684601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1b885a-bbbf-452f-81aa-d8eba40885db" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f9809a6-d0e1-48ce-b552-6321eb684601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ae6865ed-771e-4ec1-8cfe-cdd13a1dfd19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f9809a6-d0e1-48ce-b552-6321eb684601" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ae6865ed-771e-4ec1-8cfe-cdd13a1dfd19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dd49dfd6-1e0e-434c-943f-d5be4c2d90ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f9809a6-d0e1-48ce-b552-6321eb684601" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dd49dfd6-1e0e-434c-943f-d5be4c2d90ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_69edeb1d-88af-4163-bb3a-72a0ebb5118b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f9809a6-d0e1-48ce-b552-6321eb684601" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_69edeb1d-88af-4163-bb3a-72a0ebb5118b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#MARKETABLESECURITIESMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails" xlink:type="extended" id="i29d2cea0747c48e9a05230ea0c377bb8_MARKETABLESECURITIESMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3630e222-f1ba-4484-a136-ac97c82017ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c61ae58e-10a8-45c5-8e9a-6712c20e16a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3630e222-f1ba-4484-a136-ac97c82017ab" xlink:to="loc_us-gaap_ShortTermInvestments_c61ae58e-10a8-45c5-8e9a-6712c20e16a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_668b0b61-e169-484c-8530-f840da22f2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3630e222-f1ba-4484-a136-ac97c82017ab" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_668b0b61-e169-484c-8530-f840da22f2f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e1c4e3a5-93ed-4af0-a1f8-9a8fb56c3aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_668b0b61-e169-484c-8530-f840da22f2f8" xlink:to="loc_us-gaap_InvestmentTypeAxis_e1c4e3a5-93ed-4af0-a1f8-9a8fb56c3aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e1c4e3a5-93ed-4af0-a1f8-9a8fb56c3aa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_e1c4e3a5-93ed-4af0-a1f8-9a8fb56c3aa9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e1c4e3a5-93ed-4af0-a1f8-9a8fb56c3aa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7be3650f-3e77-4556-9170-a9b255b0e455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_e1c4e3a5-93ed-4af0-a1f8-9a8fb56c3aa9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7be3650f-3e77-4556-9170-a9b255b0e455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_IsraeliMutualFundsMember_80e154ab-f846-4784-9fb2-50d4c83b05cd" xlink:href="vyne-20210630.xsd#vyne_IsraeliMutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7be3650f-3e77-4556-9170-a9b255b0e455" xlink:to="loc_vyne_IsraeliMutualFundsMember_80e154ab-f846-4784-9fb2-50d4c83b05cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#DEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/DEBTNarrativeDetails" xlink:type="extended" id="iec914f8e15634ea3b8fd4e1447e2fe33_DEBTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8d1bab1f-81eb-4c91-b2a9-7b765946ea47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8d1bab1f-81eb-4c91-b2a9-7b765946ea47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_NumberOfLenders_179a706e-1b63-47a8-ae70-1939c5d39c30" xlink:href="vyne-20210630.xsd#vyne_NumberOfLenders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_vyne_NumberOfLenders_179a706e-1b63-47a8-ae70-1939c5d39c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_GrossProceedsFromIssuanceOfCommonStock_b52a5c7a-1b0d-4d4e-8019-1a687d4010f3" xlink:href="vyne-20210630.xsd#vyne_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_vyne_GrossProceedsFromIssuanceOfCommonStock_b52a5c7a-1b0d-4d4e-8019-1a687d4010f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_41e7e456-aeff-490f-b7a3-c5a4a7a9ab0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_41e7e456-aeff-490f-b7a3-c5a4a7a9ab0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_edee9d16-31b4-482a-9bf4-bbf70ce02f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_edee9d16-31b4-482a-9bf4-bbf70ce02f3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9f65e190-02a4-4beb-a250-af4ba85aeddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9f65e190-02a4-4beb-a250-af4ba85aeddd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0554600a-61eb-4087-944a-201b4d3fe0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0554600a-61eb-4087-944a-201b4d3fe0e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_374ec64b-e887-4a7d-8aac-632167dbea2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_374ec64b-e887-4a7d-8aac-632167dbea2b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RepaymentOfDebtPrepaymentFeePercentage_7b052d52-8118-434c-b8ee-59d4f012dacf" xlink:href="vyne-20210630.xsd#vyne_RepaymentOfDebtPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_vyne_RepaymentOfDebtPrepaymentFeePercentage_7b052d52-8118-434c-b8ee-59d4f012dacf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_6f760d4d-f342-4bce-9556-bbc13f57a9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_6f760d4d-f342-4bce-9556-bbc13f57a9ec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ClassOfWarrantAbstract_ca2a57ac-12a0-47df-99e3-32ae14f76801" xlink:href="vyne-20210630.xsd#vyne_ClassOfWarrantAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_vyne_ClassOfWarrantAbstract_ca2a57ac-12a0-47df-99e3-32ae14f76801" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c276863d-926c-405e-be2b-97b66ee07b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vyne_ClassOfWarrantAbstract_ca2a57ac-12a0-47df-99e3-32ae14f76801" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c276863d-926c-405e-be2b-97b66ee07b7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9af128cb-d5ae-49b6-a99c-b252fefb19f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vyne_ClassOfWarrantAbstract_ca2a57ac-12a0-47df-99e3-32ae14f76801" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9af128cb-d5ae-49b6-a99c-b252fefb19f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_18bf03b1-547c-4faf-9860-589943c7d7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_18bf03b1-547c-4faf-9860-589943c7d7f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_7682bc9e-8c69-48af-bfeb-d6916aba57aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:to="loc_us-gaap_DebtInstrumentFairValue_7682bc9e-8c69-48af-bfeb-d6916aba57aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f94c8295-21df-456e-b67a-eff0b520bf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:to="loc_us-gaap_InterestExpenseDebt_f94c8295-21df-456e-b67a-eff0b520bf6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_b4a57a9f-595a-47f4-8d91-f28147d03dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_b4a57a9f-595a-47f4-8d91-f28147d03dd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_85b3642d-c198-4e4b-b30a-2dfc89c2945d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_85b3642d-c198-4e4b-b30a-2dfc89c2945d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85b3642d-c198-4e4b-b30a-2dfc89c2945d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_85b3642d-c198-4e4b-b30a-2dfc89c2945d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85b3642d-c198-4e4b-b30a-2dfc89c2945d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0b3d7511-72b1-488e-b737-2888cbb125a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_85b3642d-c198-4e4b-b30a-2dfc89c2945d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0b3d7511-72b1-488e-b737-2888cbb125a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RegisteredOfferingMember_598b2714-23d0-498c-84e7-701132c83e8b" xlink:href="vyne-20210630.xsd#vyne_RegisteredOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0b3d7511-72b1-488e-b737-2888cbb125a9" xlink:to="loc_vyne_RegisteredOfferingMember_598b2714-23d0-498c-84e7-701132c83e8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_786b7f99-03e9-4877-be57-abc62e2d41d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_786b7f99-03e9-4877-be57-abc62e2d41d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_786b7f99-03e9-4877-be57-abc62e2d41d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_786b7f99-03e9-4877-be57-abc62e2d41d7" xlink:to="loc_us-gaap_RelatedPartyDomain_786b7f99-03e9-4877-be57-abc62e2d41d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bf920b3c-0a54-4bbb-9830-2aeebb1fcdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_786b7f99-03e9-4877-be57-abc62e2d41d7" xlink:to="loc_us-gaap_RelatedPartyDomain_bf920b3c-0a54-4bbb-9830-2aeebb1fcdb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareholderLenderMember_469fc674-6aca-4e1b-8349-c4fcf849a58e" xlink:href="vyne-20210630.xsd#vyne_ShareholderLenderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_bf920b3c-0a54-4bbb-9830-2aeebb1fcdb0" xlink:to="loc_vyne_ShareholderLenderMember_469fc674-6aca-4e1b-8349-c4fcf849a58e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f1f77a95-be04-490d-9036-a608f9a92fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_DebtInstrumentAxis_f1f77a95-be04-490d-9036-a608f9a92fbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f1f77a95-be04-490d-9036-a608f9a92fbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1f77a95-be04-490d-9036-a608f9a92fbe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f1f77a95-be04-490d-9036-a608f9a92fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f8765fe5-387e-42dc-89e3-1d4116ed9b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1f77a95-be04-490d-9036-a608f9a92fbe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f8765fe5-387e-42dc-89e3-1d4116ed9b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_dfef687e-d0dd-46d7-ac1f-a3808a11f0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f8765fe5-387e-42dc-89e3-1d4116ed9b04" xlink:to="loc_us-gaap_SecuredDebtMember_dfef687e-d0dd-46d7-ac1f-a3808a11f0f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementMember_c4476d80-7b7b-4be3-b40f-309feec58d25" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f8765fe5-387e-42dc-89e3-1d4116ed9b04" xlink:to="loc_vyne_AmendedAndRestatedCreditAgreementMember_c4476d80-7b7b-4be3-b40f-309feec58d25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember_108334c4-b598-4b80-ac70-0b7639d8d4b9" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vyne_AmendedAndRestatedCreditAgreementMember_c4476d80-7b7b-4be3-b40f-309feec58d25" xlink:to="loc_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember_108334c4-b598-4b80-ac70-0b7639d8d4b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember_d2d3b76e-f3d4-4d06-9612-57b33e5829ad" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vyne_AmendedAndRestatedCreditAgreementMember_c4476d80-7b7b-4be3-b40f-309feec58d25" xlink:to="loc_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember_d2d3b76e-f3d4-4d06-9612-57b33e5829ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember_7de74fdb-6259-4727-bda1-20a82daeaf43" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vyne_AmendedAndRestatedCreditAgreementMember_c4476d80-7b7b-4be3-b40f-309feec58d25" xlink:to="loc_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember_7de74fdb-6259-4727-bda1-20a82daeaf43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_31c1a11a-d487-4bab-ae5b-39074788b1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_VariableRateAxis_31c1a11a-d487-4bab-ae5b-39074788b1ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_31c1a11a-d487-4bab-ae5b-39074788b1ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_31c1a11a-d487-4bab-ae5b-39074788b1ed" xlink:to="loc_us-gaap_VariableRateDomain_31c1a11a-d487-4bab-ae5b-39074788b1ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d969b70a-b405-46cb-9ea9-e9075d9aed73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_31c1a11a-d487-4bab-ae5b-39074788b1ed" xlink:to="loc_us-gaap_VariableRateDomain_d969b70a-b405-46cb-9ea9-e9075d9aed73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_092bc9bf-2f83-4ec8-b44a-49670db14df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_d969b70a-b405-46cb-9ea9-e9075d9aed73" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_092bc9bf-2f83-4ec8-b44a-49670db14df5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_110be6db-06a3-4ae3-878a-7c817d6cd812" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_srt_StatementScenarioAxis_110be6db-06a3-4ae3-878a-7c817d6cd812" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_110be6db-06a3-4ae3-878a-7c817d6cd812_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_110be6db-06a3-4ae3-878a-7c817d6cd812" xlink:to="loc_srt_ScenarioUnspecifiedDomain_110be6db-06a3-4ae3-878a-7c817d6cd812_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_78506293-9be7-4d53-b3ba-d046956b9b28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_110be6db-06a3-4ae3-878a-7c817d6cd812" xlink:to="loc_srt_ScenarioUnspecifiedDomain_78506293-9be7-4d53-b3ba-d046956b9b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c139e64a-bf6c-4e38-b9de-e42b82142891" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_78506293-9be7-4d53-b3ba-d046956b9b28" xlink:to="loc_srt_ScenarioForecastMember_c139e64a-bf6c-4e38-b9de-e42b82142891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c0c41a5f-0ee7-4dec-b76b-866189e5597f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_dei_LegalEntityAxis_c0c41a5f-0ee7-4dec-b76b-866189e5597f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c0c41a5f-0ee7-4dec-b76b-866189e5597f_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c0c41a5f-0ee7-4dec-b76b-866189e5597f" xlink:to="loc_dei_EntityDomain_c0c41a5f-0ee7-4dec-b76b-866189e5597f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd2b10cd-7056-4da3-9bed-a9ffee04eaad" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c0c41a5f-0ee7-4dec-b76b-866189e5597f" xlink:to="loc_dei_EntityDomain_bd2b10cd-7056-4da3-9bed-a9ffee04eaad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_c87f8770-9919-4546-b84e-6873d7d533dc" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bd2b10cd-7056-4da3-9bed-a9ffee04eaad" xlink:to="loc_vyne_FoamixMember_c87f8770-9919-4546-b84e-6873d7d533dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fde14b3e-967c-424d-9bc9-ec36a4c9a315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fde14b3e-967c-424d-9bc9-ec36a4c9a315" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fde14b3e-967c-424d-9bc9-ec36a4c9a315_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fde14b3e-967c-424d-9bc9-ec36a4c9a315" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fde14b3e-967c-424d-9bc9-ec36a4c9a315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46340261-a482-460a-a336-5e36a78a7993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fde14b3e-967c-424d-9bc9-ec36a4c9a315" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46340261-a482-460a-a336-5e36a78a7993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6e4cce86-c6fd-4a24-a5c7-26daf69e8437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46340261-a482-460a-a336-5e36a78a7993" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6e4cce86-c6fd-4a24-a5c7-26daf69e8437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7767a3b1-f6fc-4aae-83a5-e35b2668ce38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_srt_RangeAxis_7767a3b1-f6fc-4aae-83a5-e35b2668ce38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7767a3b1-f6fc-4aae-83a5-e35b2668ce38_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7767a3b1-f6fc-4aae-83a5-e35b2668ce38" xlink:to="loc_srt_RangeMember_7767a3b1-f6fc-4aae-83a5-e35b2668ce38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_933422b7-2cfb-4694-b21e-499325fbecb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7767a3b1-f6fc-4aae-83a5-e35b2668ce38" xlink:to="loc_srt_RangeMember_933422b7-2cfb-4694-b21e-499325fbecb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1eb691bc-4e88-4feb-92ac-4a37d07c9dc5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_933422b7-2cfb-4694-b21e-499325fbecb3" xlink:to="loc_srt_MinimumMember_1eb691bc-4e88-4feb-92ac-4a37d07c9dc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_688457c6-fbeb-4594-9c90-a0d06395f0fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_933422b7-2cfb-4694-b21e-499325fbecb3" xlink:to="loc_srt_MaximumMember_688457c6-fbeb-4594-9c90-a0d06395f0fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_99067bbc-9504-427d-831c-812e3c563b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_99067bbc-9504-427d-831c-812e3c563b30" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_99067bbc-9504-427d-831c-812e3c563b30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_99067bbc-9504-427d-831c-812e3c563b30" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_99067bbc-9504-427d-831c-812e3c563b30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ad15f0e0-cab5-48bb-b756-74607c84a165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_99067bbc-9504-427d-831c-812e3c563b30" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ad15f0e0-cab5-48bb-b756-74607c84a165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dd0edc2b-319d-470f-adac-00a5943fe300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ad15f0e0-cab5-48bb-b756-74607c84a165" xlink:to="loc_us-gaap_SubsequentEventMember_dd0edc2b-319d-470f-adac-00a5943fe300" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails" xlink:type="extended" id="i7f87b85bbd8f4a5e874377e2090b879f_SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_98926162-3300-47b5-a480-9fa81656a526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_98926162-3300-47b5-a480-9fa81656a526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_617dee6b-3922-496f-9b42-efebc7d118a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_617dee6b-3922-496f-9b42-efebc7d118a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6e3cf4ec-9504-462c-bd11-828c4be57dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6e3cf4ec-9504-462c-bd11-828c4be57dc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_77016069-0de5-49b2-9824-f25b759fdae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_77016069-0de5-49b2-9824-f25b759fdae4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_17cdb2b6-fe80-48f9-b7da-bbe22d3d376a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_17cdb2b6-fe80-48f9-b7da-bbe22d3d376a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_23e2f5cb-dc67-4a0e-8fc9-fe64ece88e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_23e2f5cb-dc67-4a0e-8fc9-fe64ece88e49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d80c2171-d257-458f-aa7e-af170587c229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d80c2171-d257-458f-aa7e-af170587c229" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CommonStockVotingRightsNumberPerShare_9146d37d-04e6-43e9-8740-ea1441c63a6c" xlink:href="vyne-20210630.xsd#vyne_CommonStockVotingRightsNumberPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_CommonStockVotingRightsNumberPerShare_9146d37d-04e6-43e9-8740-ea1441c63a6c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_7dda4384-d0d5-4dde-afdc-7d5dc4033506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_7dda4384-d0d5-4dde-afdc-7d5dc4033506" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock_1becd4bc-940b-473b-ac84-7fbce3fe6883" xlink:href="vyne-20210630.xsd#vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock_1becd4bc-940b-473b-ac84-7fbce3fe6883" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b8bad167-e23c-4096-8a91-36b629580a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b8bad167-e23c-4096-8a91-36b629580a9e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1ac591a2-1393-4014-9bc2-dc2bc2aca5db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1ac591a2-1393-4014-9bc2-dc2bc2aca5db" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ee0350d2-06a8-44d6-a989-8b77efcfff90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ee0350d2-06a8-44d6-a989-8b77efcfff90" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0756137d-08c8-4f77-b2e1-d2e69caaa1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0756137d-08c8-4f77-b2e1-d2e69caaa1ae" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_22a30ae7-0672-411e-8adc-1f8dc5fefe99" xlink:href="vyne-20210630.xsd#vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_22a30ae7-0672-411e-8adc-1f8dc5fefe99" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c167e622-f91e-4f8a-8bae-251861c3ac34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c167e622-f91e-4f8a-8bae-251861c3ac34" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_StockIssuedDuringPeriodSharesWarrantsExercised_806c175f-f1fc-4e34-8296-da20b78ca220" xlink:href="vyne-20210630.xsd#vyne_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_StockIssuedDuringPeriodSharesWarrantsExercised_806c175f-f1fc-4e34-8296-da20b78ca220" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessAcquisitionContingentStockRightIssued_7870f4d0-d08c-453b-a21c-795c8287d6ce" xlink:href="vyne-20210630.xsd#vyne_BusinessAcquisitionContingentStockRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_BusinessAcquisitionContingentStockRightIssued_7870f4d0-d08c-453b-a21c-795c8287d6ce" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_8fd2a8c0-7809-4471-9761-d8a09195c910" xlink:href="vyne-20210630.xsd#vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_8fd2a8c0-7809-4471-9761-d8a09195c910" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7bd02571-51f6-4733-9897-2237584b7402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7bd02571-51f6-4733-9897-2237584b7402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7bd02571-51f6-4733-9897-2237584b7402_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7bd02571-51f6-4733-9897-2237584b7402" xlink:to="loc_us-gaap_EquityComponentDomain_7bd02571-51f6-4733-9897-2237584b7402_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e6b1541f-1d22-42c8-9845-64bc41359f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7bd02571-51f6-4733-9897-2237584b7402" xlink:to="loc_us-gaap_EquityComponentDomain_e6b1541f-1d22-42c8-9845-64bc41359f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_33b1706c-36f3-44a3-b5f3-508014112cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e6b1541f-1d22-42c8-9845-64bc41359f17" xlink:to="loc_us-gaap_CommonStockMember_33b1706c-36f3-44a3-b5f3-508014112cb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4f0f2455-2c1e-4be7-aa4d-4d74cfeb3b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e6b1541f-1d22-42c8-9845-64bc41359f17" xlink:to="loc_us-gaap_WarrantMember_4f0f2455-2c1e-4be7-aa4d-4d74cfeb3b3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3e7b41b3-2841-41f0-a6c8-2dcb1e98ad6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3e7b41b3-2841-41f0-a6c8-2dcb1e98ad6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e7b41b3-2841-41f0-a6c8-2dcb1e98ad6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e7b41b3-2841-41f0-a6c8-2dcb1e98ad6e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e7b41b3-2841-41f0-a6c8-2dcb1e98ad6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60777077-e76b-4341-bdcf-03addf916b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e7b41b3-2841-41f0-a6c8-2dcb1e98ad6e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60777077-e76b-4341-bdcf-03addf916b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CantorSalesAgreementMember_3dab1303-0e3b-47a6-9398-274f5501e3f8" xlink:href="vyne-20210630.xsd#vyne_CantorSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60777077-e76b-4341-bdcf-03addf916b25" xlink:to="loc_vyne_CantorSalesAgreementMember_3dab1303-0e3b-47a6-9398-274f5501e3f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RegisteredDirectOfferingMember_f8ebd414-4ed1-458f-a354-9c35cb7a5d93" xlink:href="vyne-20210630.xsd#vyne_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60777077-e76b-4341-bdcf-03addf916b25" xlink:to="loc_vyne_RegisteredDirectOfferingMember_f8ebd414-4ed1-458f-a354-9c35cb7a5d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PublicStockOfferingMember_a88d1ef7-feaa-43c1-8f31-337afdb35d79" xlink:href="vyne-20210630.xsd#vyne_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60777077-e76b-4341-bdcf-03addf916b25" xlink:to="loc_vyne_PublicStockOfferingMember_a88d1ef7-feaa-43c1-8f31-337afdb35d79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_be8e9d29-28c2-4cec-9e48-62ba7a80392b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_dei_LegalEntityAxis_be8e9d29-28c2-4cec-9e48-62ba7a80392b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_be8e9d29-28c2-4cec-9e48-62ba7a80392b_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_be8e9d29-28c2-4cec-9e48-62ba7a80392b" xlink:to="loc_dei_EntityDomain_be8e9d29-28c2-4cec-9e48-62ba7a80392b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e7523e98-5723-4568-b06e-b5a22af69347" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_be8e9d29-28c2-4cec-9e48-62ba7a80392b" xlink:to="loc_dei_EntityDomain_e7523e98-5723-4568-b06e-b5a22af69347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_71c1b9da-d732-48fd-9c8e-da1e465a4b8e" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e7523e98-5723-4568-b06e-b5a22af69347" xlink:to="loc_vyne_FoamixMember_71c1b9da-d732-48fd-9c8e-da1e465a4b8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b380a773-3fea-428e-8875-40b6c93a7ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b380a773-3fea-428e-8875-40b6c93a7ff2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b380a773-3fea-428e-8875-40b6c93a7ff2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b380a773-3fea-428e-8875-40b6c93a7ff2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b380a773-3fea-428e-8875-40b6c93a7ff2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3edd4518-8760-4d02-8331-e40b5609428e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b380a773-3fea-428e-8875-40b6c93a7ff2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3edd4518-8760-4d02-8331-e40b5609428e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_07ce94c6-2574-4c7e-b029-c10976e0bfab" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3edd4518-8760-4d02-8331-e40b5609428e" xlink:to="loc_vyne_FoamixMember_07ce94c6-2574-4c7e-b029-c10976e0bfab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d04ccd74-3930-4552-aedb-ee30cfaaced6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_srt_RangeAxis_d04ccd74-3930-4552-aedb-ee30cfaaced6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d04ccd74-3930-4552-aedb-ee30cfaaced6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d04ccd74-3930-4552-aedb-ee30cfaaced6" xlink:to="loc_srt_RangeMember_d04ccd74-3930-4552-aedb-ee30cfaaced6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90eab45e-c21a-46c5-b172-c026659e0bfc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d04ccd74-3930-4552-aedb-ee30cfaaced6" xlink:to="loc_srt_RangeMember_90eab45e-c21a-46c5-b172-c026659e0bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_409e7acd-8099-4653-b629-781509191923" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90eab45e-c21a-46c5-b172-c026659e0bfc" xlink:to="loc_srt_MaximumMember_409e7acd-8099-4653-b629-781509191923" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7da42509-b935-43be-bc24-a1c5f0d1b0f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90eab45e-c21a-46c5-b172-c026659e0bfc" xlink:to="loc_srt_MinimumMember_7da42509-b935-43be-bc24-a1c5f0d1b0f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a9fe681a-4642-4e97-b6e4-759612476bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a9fe681a-4642-4e97-b6e4-759612476bf5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a9fe681a-4642-4e97-b6e4-759612476bf5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a9fe681a-4642-4e97-b6e4-759612476bf5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a9fe681a-4642-4e97-b6e4-759612476bf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e4523ba1-9088-4f9c-8379-107ef4eaf850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a9fe681a-4642-4e97-b6e4-759612476bf5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e4523ba1-9088-4f9c-8379-107ef4eaf850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1f40787d-a99a-4134-924d-216ebd8bbbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e4523ba1-9088-4f9c-8379-107ef4eaf850" xlink:to="loc_us-gaap_SubsequentEventMember_1f40787d-a99a-4134-924d-216ebd8bbbd0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALSharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails" xlink:type="extended" id="i11a7e656b68a47a693e9e4b575839b96_SHARECAPITALSharebasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e30250d6-bd2d-486f-93e4-3ab520638c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e30250d6-bd2d-486f-93e4-3ab520638c0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_a556cc21-dfa6-48b7-936d-1d7cbba8c56c" xlink:href="vyne-20210630.xsd#vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_a556cc21-dfa6-48b7-936d-1d7cbba8c56c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_58dab4df-49a3-4073-88f0-a5d7876de132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_58dab4df-49a3-4073-88f0-a5d7876de132" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7ea48fb8-70bf-485d-9d29-37627b3e7edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7ea48fb8-70bf-485d-9d29-37627b3e7edf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4e964893-e9ed-4040-b729-af95ffd28a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4e964893-e9ed-4040-b729-af95ffd28a91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_ef0f234a-09ed-47a3-b1c4-943663f3ef96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_ef0f234a-09ed-47a3-b1c4-943663f3ef96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessAcquisitionContingentStockRightIssued_dfb71382-b127-4212-9cc9-29f2332e0bd7" xlink:href="vyne-20210630.xsd#vyne_BusinessAcquisitionContingentStockRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_BusinessAcquisitionContingentStockRightIssued_dfb71382-b127-4212-9cc9-29f2332e0bd7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_dc5b6025-8af3-4999-87ee-0bcf044f6dd9" xlink:href="vyne-20210630.xsd#vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_dc5b6025-8af3-4999-87ee-0bcf044f6dd9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockRightSharesConversion_79e44955-8dcc-4453-86bd-43ddf87d45ae" xlink:href="vyne-20210630.xsd#vyne_ContingentStockRightSharesConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_ContingentStockRightSharesConversion_79e44955-8dcc-4453-86bd-43ddf87d45ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EffectiveExchangeRatio_fe68584e-9ca6-482a-8135-977c0350b27e" xlink:href="vyne-20210630.xsd#vyne_EffectiveExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_EffectiveExchangeRatio_fe68584e-9ca6-482a-8135-977c0350b27e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_eeee87bb-21b8-4abf-9ca7-6744e454c5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_eeee87bb-21b8-4abf-9ca7-6744e454c5a8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_3256cb78-fa4c-4294-9c9f-80afa736de64" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_3256cb78-fa4c-4294-9c9f-80afa736de64" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_9a9abfb1-897f-4ce8-9def-ba0e0668a2bb" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_9a9abfb1-897f-4ce8-9def-ba0e0668a2bb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_f90d1255-7b28-4ac2-a1a7-aeead014a540" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_f90d1255-7b28-4ac2-a1a7-aeead014a540" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_719219b9-8772-44d8-9ad9-ff0ea8f841cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_719219b9-8772-44d8-9ad9-ff0ea8f841cb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a1e96588-ec1c-4488-9746-c424465d3e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_us-gaap_PlanNameAxis_a1e96588-ec1c-4488-9746-c424465d3e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a1e96588-ec1c-4488-9746-c424465d3e8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a1e96588-ec1c-4488-9746-c424465d3e8d" xlink:to="loc_us-gaap_PlanNameDomain_a1e96588-ec1c-4488-9746-c424465d3e8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6af32290-fd6c-45f2-80d9-cb83629c9395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a1e96588-ec1c-4488-9746-c424465d3e8d" xlink:to="loc_us-gaap_PlanNameDomain_6af32290-fd6c-45f2-80d9-cb83629c9395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_A2019PlanMember_d3b4629a-c81c-4758-a8c0-508bb8d39d94" xlink:href="vyne-20210630.xsd#vyne_A2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6af32290-fd6c-45f2-80d9-cb83629c9395" xlink:to="loc_vyne_A2019PlanMember_d3b4629a-c81c-4758-a8c0-508bb8d39d94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_A2018PlanMember_75119764-7918-49ec-a983-8ae03cee4886" xlink:href="vyne-20210630.xsd#vyne_A2018PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6af32290-fd6c-45f2-80d9-cb83629c9395" xlink:to="loc_vyne_A2018PlanMember_75119764-7918-49ec-a983-8ae03cee4886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EmployeeStockPurchasePlanMember_f415d478-e8f0-4cb5-8006-61a294fa176f" xlink:href="vyne-20210630.xsd#vyne_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6af32290-fd6c-45f2-80d9-cb83629c9395" xlink:to="loc_vyne_EmployeeStockPurchasePlanMember_f415d478-e8f0-4cb5-8006-61a294fa176f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_864438f1-7306-402b-9c01-f516df0d3267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_864438f1-7306-402b-9c01-f516df0d3267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_864438f1-7306-402b-9c01-f516df0d3267_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_864438f1-7306-402b-9c01-f516df0d3267" xlink:to="loc_us-gaap_EquityComponentDomain_864438f1-7306-402b-9c01-f516df0d3267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33801eca-61ed-461a-b5a2-056d976bbb93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_864438f1-7306-402b-9c01-f516df0d3267" xlink:to="loc_us-gaap_EquityComponentDomain_33801eca-61ed-461a-b5a2-056d976bbb93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_aeff66d4-8741-4a44-824e-9c7054253496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33801eca-61ed-461a-b5a2-056d976bbb93" xlink:to="loc_us-gaap_CommonStockMember_aeff66d4-8741-4a44-824e-9c7054253496" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7050bbb7-9f5d-45d9-b1a1-985f684d53c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_dei_LegalEntityAxis_7050bbb7-9f5d-45d9-b1a1-985f684d53c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7050bbb7-9f5d-45d9-b1a1-985f684d53c6_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7050bbb7-9f5d-45d9-b1a1-985f684d53c6" xlink:to="loc_dei_EntityDomain_7050bbb7-9f5d-45d9-b1a1-985f684d53c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fe78770e-7333-4005-9521-2399f08116f3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7050bbb7-9f5d-45d9-b1a1-985f684d53c6" xlink:to="loc_dei_EntityDomain_fe78770e-7333-4005-9521-2399f08116f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_37dc3ae9-fe6a-4679-8496-af0a3c80adbb" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_fe78770e-7333-4005-9521-2399f08116f3" xlink:to="loc_vyne_FoamixMember_37dc3ae9-fe6a-4679-8496-af0a3c80adbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_520d1d78-5082-4003-9741-6f638e6cd896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_520d1d78-5082-4003-9741-6f638e6cd896" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_520d1d78-5082-4003-9741-6f638e6cd896_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_520d1d78-5082-4003-9741-6f638e6cd896" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_520d1d78-5082-4003-9741-6f638e6cd896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e10db87-9316-4778-a8b4-e419f0beb17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_520d1d78-5082-4003-9741-6f638e6cd896" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e10db87-9316-4778-a8b4-e419f0beb17e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_580e8a3c-583d-4a0f-b011-c5947feb7624" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e10db87-9316-4778-a8b4-e419f0beb17e" xlink:to="loc_vyne_FoamixMember_580e8a3c-583d-4a0f-b011-c5947feb7624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_69289dc3-de9d-4c89-a150-67e69d1fe44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_us-gaap_GranteeStatusAxis_69289dc3-de9d-4c89-a150-67e69d1fe44d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_69289dc3-de9d-4c89-a150-67e69d1fe44d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_69289dc3-de9d-4c89-a150-67e69d1fe44d" xlink:to="loc_us-gaap_GranteeStatusDomain_69289dc3-de9d-4c89-a150-67e69d1fe44d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_e34fb97a-8c9a-45a4-9a6f-eee7fa14294b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_69289dc3-de9d-4c89-a150-67e69d1fe44d" xlink:to="loc_us-gaap_GranteeStatusDomain_e34fb97a-8c9a-45a4-9a6f-eee7fa14294b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_83493f76-03f0-4d1b-961a-95bcb4808a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_e34fb97a-8c9a-45a4-9a6f-eee7fa14294b" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_83493f76-03f0-4d1b-961a-95bcb4808a98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_31df66d7-d49e-4667-ad15-8a9a300d0d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_e34fb97a-8c9a-45a4-9a6f-eee7fa14294b" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_31df66d7-d49e-4667-ad15-8a9a300d0d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_54bcd8c5-629f-4932-baeb-f45915914a83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_srt_CounterpartyNameAxis_54bcd8c5-629f-4932-baeb-f45915914a83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_54bcd8c5-629f-4932-baeb-f45915914a83_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_54bcd8c5-629f-4932-baeb-f45915914a83" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_54bcd8c5-629f-4932-baeb-f45915914a83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5d6ef40-254c-467a-befb-0b09849cb5fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_54bcd8c5-629f-4932-baeb-f45915914a83" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5d6ef40-254c-467a-befb-0b09849cb5fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_e234de89-44c7-434e-af80-03bd383ce7d5" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5d6ef40-254c-467a-befb-0b09849cb5fe" xlink:to="loc_vyne_FoamixMember_e234de89-44c7-434e-af80-03bd383ce7d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALOptionsandRSUGrantsDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails" xlink:type="extended" id="i08020daf7c054f8abd91840a93a99132_SHARECAPITALOptionsandRSUGrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0c8e719f-5dc6-4001-9661-7ea409662444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0c8e719f-5dc6-4001-9661-7ea409662444" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba74842c-6f09-48b8-8722-31eaca69e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba74842c-6f09-48b8-8722-31eaca69e4e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_d670d0db-6a21-45ed-830f-df889e11b88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_d670d0db-6a21-45ed-830f-df889e11b88f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_a3f61464-ac37-4a05-b0ca-ab4d45dbdea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_a3f61464-ac37-4a05-b0ca-ab4d45dbdea6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74b6b26a-9289-48eb-b0b4-440cc0331f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74b6b26a-9289-48eb-b0b4-440cc0331f9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3becf7ff-a0b3-4ec2-9688-c5d5bf2b52c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3becf7ff-a0b3-4ec2-9688-c5d5bf2b52c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206a078-5ebf-431b-a9cd-658a538cc48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206a078-5ebf-431b-a9cd-658a538cc48f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99005a19-fd31-47ed-b514-d731296397fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206a078-5ebf-431b-a9cd-658a538cc48f" xlink:to="loc_us-gaap_AwardTypeAxis_99005a19-fd31-47ed-b514-d731296397fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99005a19-fd31-47ed-b514-d731296397fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_99005a19-fd31-47ed-b514-d731296397fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99005a19-fd31-47ed-b514-d731296397fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5496ed3-6905-45b4-b464-0cc158f92311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_99005a19-fd31-47ed-b514-d731296397fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5496ed3-6905-45b4-b464-0cc158f92311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_03c0d88b-a45f-4aca-b24a-1168ad72b5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5496ed3-6905-45b4-b464-0cc158f92311" xlink:to="loc_us-gaap_EmployeeStockOptionMember_03c0d88b-a45f-4aca-b24a-1168ad72b5fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4007dd3e-0377-4a6c-b14e-cf8d731b823d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5496ed3-6905-45b4-b464-0cc158f92311" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4007dd3e-0377-4a6c-b14e-cf8d731b823d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_48bd5a08-0256-4a31-84cd-f78596a0ae2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206a078-5ebf-431b-a9cd-658a538cc48f" xlink:to="loc_srt_RangeAxis_48bd5a08-0256-4a31-84cd-f78596a0ae2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48bd5a08-0256-4a31-84cd-f78596a0ae2a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_48bd5a08-0256-4a31-84cd-f78596a0ae2a" xlink:to="loc_srt_RangeMember_48bd5a08-0256-4a31-84cd-f78596a0ae2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb2050d3-c6f1-4429-9c9f-821df5bb0b7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_48bd5a08-0256-4a31-84cd-f78596a0ae2a" xlink:to="loc_srt_RangeMember_cb2050d3-c6f1-4429-9c9f-821df5bb0b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca875fe3-d2d3-4203-b416-31065cadc251" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb2050d3-c6f1-4429-9c9f-821df5bb0b7f" xlink:to="loc_srt_MinimumMember_ca875fe3-d2d3-4203-b416-31065cadc251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6d234977-fe59-43fa-8179-94bae2fb1508" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb2050d3-c6f1-4429-9c9f-821df5bb0b7f" xlink:to="loc_srt_MaximumMember_6d234977-fe59-43fa-8179-94bae2fb1508" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALFairvalueassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails" xlink:type="extended" id="i30be36da19d54bfcbf89894ee2899290_SHARECAPITALFairvalueassumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ebd8c108-7a47-4c16-93fa-43c061ebdd22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ebd8c108-7a47-4c16-93fa-43c061ebdd22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_95ade927-78e3-4236-88eb-ee33d232a284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_95ade927-78e3-4236-88eb-ee33d232a284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_98d398df-9a73-406a-80f8-3d269d446a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_98d398df-9a73-406a-80f8-3d269d446a1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ad970c72-a6cf-4d51-a01d-16e2882a84ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ad970c72-a6cf-4d51-a01d-16e2882a84ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_d4799da0-1bf2-4f7d-9694-3fefdf520ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_d4799da0-1bf2-4f7d-9694-3fefdf520ba8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_518a1b29-a714-4d6d-840b-bf0a78c365c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_518a1b29-a714-4d6d-840b-bf0a78c365c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_00296b2d-79b1-48bf-b3cd-50dabca718a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_00296b2d-79b1-48bf-b3cd-50dabca718a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a7e29fa-8fa0-44b2-97e2-f383f9590e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ebd8c108-7a47-4c16-93fa-43c061ebdd22" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a7e29fa-8fa0-44b2-97e2-f383f9590e18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dd733497-a8dc-4811-bf8a-417425c4b42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a7e29fa-8fa0-44b2-97e2-f383f9590e18" xlink:to="loc_us-gaap_AwardTypeAxis_dd733497-a8dc-4811-bf8a-417425c4b42d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd733497-a8dc-4811-bf8a-417425c4b42d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dd733497-a8dc-4811-bf8a-417425c4b42d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd733497-a8dc-4811-bf8a-417425c4b42d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d96b9218-67c4-41ed-8c94-ba4b6f52fe59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dd733497-a8dc-4811-bf8a-417425c4b42d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d96b9218-67c4-41ed-8c94-ba4b6f52fe59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_55040afa-2434-44ac-ad3b-2ef2a7fc0677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d96b9218-67c4-41ed-8c94-ba4b6f52fe59" xlink:to="loc_us-gaap_EmployeeStockOptionMember_55040afa-2434-44ac-ad3b-2ef2a7fc0677" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALScheduleofSharebasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails" xlink:type="extended" id="id806aaa2f8994c5f9472cb03b4e18994_SHARECAPITALScheduleofSharebasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_432ce279-0158-41c6-9a73-e8d4966135b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0cf74076-2868-4b4f-acbe-0d1299bd2f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_432ce279-0158-41c6-9a73-e8d4966135b1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0cf74076-2868-4b4f-acbe-0d1299bd2f0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_99a058d2-6ce7-4c6e-ba08-0d20142b04cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_432ce279-0158-41c6-9a73-e8d4966135b1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_99a058d2-6ce7-4c6e-ba08-0d20142b04cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6ed09453-236f-477d-bf7c-84b25d8ccb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_99a058d2-6ce7-4c6e-ba08-0d20142b04cc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6ed09453-236f-477d-bf7c-84b25d8ccb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6ed09453-236f-477d-bf7c-84b25d8ccb08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6ed09453-236f-477d-bf7c-84b25d8ccb08" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6ed09453-236f-477d-bf7c-84b25d8ccb08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3e4a1f10-6a8c-4790-b4b0-35fe3035c3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6ed09453-236f-477d-bf7c-84b25d8ccb08" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3e4a1f10-6a8c-4790-b4b0-35fe3035c3a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba9224fc-3b13-4dac-836a-86df65e74166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3e4a1f10-6a8c-4790-b4b0-35fe3035c3a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba9224fc-3b13-4dac-836a-86df65e74166" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_755817d2-6bf7-4dae-9a7d-3141cbffa571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3e4a1f10-6a8c-4790-b4b0-35fe3035c3a9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_755817d2-6bf7-4dae-9a7d-3141cbffa571" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#OPERATINGLEASENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails" xlink:type="extended" id="id5d4460a95d24e43994e5625436e8351_OPERATINGLEASENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FacilitySpaceUnderLease_e8330a62-3cee-4cff-b3b3-8ab2ea85b0df" xlink:href="vyne-20210630.xsd#vyne_FacilitySpaceUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:to="loc_vyne_FacilitySpaceUnderLease_e8330a62-3cee-4cff-b3b3-8ab2ea85b0df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7246691d-44c0-417a-91ff-e07c9470590d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7246691d-44c0-417a-91ff-e07c9470590d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_bc24b642-7c1d-4bca-81d8-a841be5d5b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_bc24b642-7c1d-4bca-81d8-a841be5d5b10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RestrictedInvestmentsToSecureLeaseAgreements_ba2bdeb8-a7b6-40c4-8a59-fa55c552ccfe" xlink:href="vyne-20210630.xsd#vyne_RestrictedInvestmentsToSecureLeaseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:to="loc_vyne_RestrictedInvestmentsToSecureLeaseAgreements_ba2bdeb8-a7b6-40c4-8a59-fa55c552ccfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a25cfd4b-bd20-421e-94de-1fc74461d0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a25cfd4b-bd20-421e-94de-1fc74461d0f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58e5e0fc-140e-4996-9f53-102e3104a102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a25cfd4b-bd20-421e-94de-1fc74461d0f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58e5e0fc-140e-4996-9f53-102e3104a102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_58e5e0fc-140e-4996-9f53-102e3104a102_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58e5e0fc-140e-4996-9f53-102e3104a102" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_58e5e0fc-140e-4996-9f53-102e3104a102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96a1317d-7c8d-4dcd-968d-18b511c3963d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58e5e0fc-140e-4996-9f53-102e3104a102" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96a1317d-7c8d-4dcd-968d-18b511c3963d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_OriginalSpaceMember_e41a9091-a3ca-42c3-9056-16a0070982ba" xlink:href="vyne-20210630.xsd#vyne_OriginalSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96a1317d-7c8d-4dcd-968d-18b511c3963d" xlink:to="loc_vyne_OriginalSpaceMember_e41a9091-a3ca-42c3-9056-16a0070982ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdditionalSpaceMember_3d104f88-f6b2-466e-bf6c-b1c66daaf093" xlink:href="vyne-20210630.xsd#vyne_AdditionalSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96a1317d-7c8d-4dcd-968d-18b511c3963d" xlink:to="loc_vyne_AdditionalSpaceMember_3d104f88-f6b2-466e-bf6c-b1c66daaf093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d38180e1-0f54-4bff-a067-4c50ff86fe19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a25cfd4b-bd20-421e-94de-1fc74461d0f6" xlink:to="loc_srt_StatementGeographicalAxis_d38180e1-0f54-4bff-a067-4c50ff86fe19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d38180e1-0f54-4bff-a067-4c50ff86fe19_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d38180e1-0f54-4bff-a067-4c50ff86fe19" xlink:to="loc_srt_SegmentGeographicalDomain_d38180e1-0f54-4bff-a067-4c50ff86fe19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d76c19f2-6cbb-4bfa-a46f-6018a12ec0d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d38180e1-0f54-4bff-a067-4c50ff86fe19" xlink:to="loc_srt_SegmentGeographicalDomain_d76c19f2-6cbb-4bfa-a46f-6018a12ec0d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BridgewaterNewJerseyMember_2bf14343-c84c-4485-af9a-35691f4f8863" xlink:href="vyne-20210630.xsd#vyne_BridgewaterNewJerseyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d76c19f2-6cbb-4bfa-a46f-6018a12ec0d7" xlink:to="loc_vyne_BridgewaterNewJerseyMember_2bf14343-c84c-4485-af9a-35691f4f8863" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IL_74354db2-4759-47be-8fa7-61691d62a442" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d76c19f2-6cbb-4bfa-a46f-6018a12ec0d7" xlink:to="loc_country_IL_74354db2-4759-47be-8fa7-61691d62a442" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>vyne-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:40e9affd-2783-4e4a-bd7f-018d2dae4bf0,g:c708fe63-ab77-4120-b7ee-9a72ba48151c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_470fdf61-a5b3-4f56-87d4-ee74ffe1e523_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_09105afe-06ec-48bc-a76b-839ffb5425e2_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_c007cb1c-f35e-4223-b8cc-8deecf0fc44d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_b78ee539-25bc-4ede-81e3-ce19a707e5ba_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b91554a9-8c99-4140-8b20-66b73a5f2b98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_30fdad31-0961-4330-8199-56b9681cdd8e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6e5697ec-665c-486f-8908-6191c4fab2c0_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6598dd1d-039f-41b8-8c1f-d6048cb1c0e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f53ac538-e178-46bb-a992-67964b0dc19f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_51460cb2-dbc0-4109-8396-6eada70b826f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets (Note 10)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7e00de82-ad16-4a35-b601-9e6baa9ab05c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_PostMergerParentOwnershipByPreMergerParentStockholders_79989137-23de-48ca-8a4d-a4fd5ed0471b_terseLabel_en-US" xlink:label="lab_vyne_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of parent by parent stockholders</link:label>
    <link:label id="lab_vyne_PostMergerParentOwnershipByPreMergerParentStockholders_label_en-US" xlink:label="lab_vyne_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post Merger Parent Ownership By Pre Merger Parent Stockholders</link:label>
    <link:label id="lab_vyne_PostMergerParentOwnershipByPreMergerParentStockholders_documentation_en-US" xlink:label="lab_vyne_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of post-merger Menlo ownership held by pre-merger Menlo stockholders, as a percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:href="vyne-20210630.xsd#vyne_PostMergerParentOwnershipByPreMergerParentStockholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:to="lab_vyne_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_82358594-d53c-4f7c-bc0f-d1d50283484f_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share - basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6d403a7c-858e-426c-b035-0aeafbf98203_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_21721fbd-f6f2-42f5-ae19-22a000209906_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_26c0dfba-a9f0-4195-bb0e-d0d65b191793_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c721e93c-ec10-4d70-9b4c-5f29d5b3f8b1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_89627b13-bcb3-4bed-b3d0-fd568d231299_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_06b60b2b-50ec-48c8-b838-3c72fe8197c6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_6b5f3157-e43c-4863-9bde-e60c3c418010_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No longer employed or providing services</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_fd6166bf-b981-4bd9-b302-517ed143e6ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair market value used as purchase price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_fe389d6a-5de8-4180-99b7-98d0c1d59245_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ad46b659-e4a9-4ff1-b2e8-e718a71cb7b6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_c942a215-fb42-4ac7-a686-b7123b6a6afe_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e38ad58f-ef94-41a4-84ca-c905f7695f93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_5dd0086f-550f-4725-bf9f-af537d9b655d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_25a86201-45d5-4693-a866-81508c246ab0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_67a3f438-8166-4b41-86b3-1d7388283623_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock_83bdb0c1-7e20-4d0a-988e-ca13f8388456_terseLabel_en-US" xlink:label="lab_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission from gross proceeds from issuance of common stock</link:label>
    <link:label id="lab_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission from Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label id="lab_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock_documentation_en-US" xlink:label="lab_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission from Gross Proceeds From Issuance Of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock" xlink:href="vyne-20210630.xsd#vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock" xlink:to="lab_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum_67511fb9-dd2e-4c45-a625-8117f81efe13_terseLabel_en-US" xlink:label="lab_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments upon achieving certain criteria, maximum</link:label>
    <link:label id="lab_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum_label_en-US" xlink:label="lab_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Upon Achieving Certain Criteria, Maximum</link:label>
    <link:label id="lab_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum_documentation_en-US" xlink:label="lab_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Upon Achieving Certain Criteria, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum" xlink:href="vyne-20210630.xsd#vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum" xlink:to="lab_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fba289e0-3633-4b78-b54d-0e045d4acbc0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_d98465e8-127e-4982-ae6d-b50574aab66d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range, minimum (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4f693a60-178d-4bad-84b8-e651d5e830ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_ab320503-b593-4ac3-bc87-a09c75120e70_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_FoamixMember_c04b953e-d3d5-4e46-8563-f70b150ada42_terseLabel_en-US" xlink:label="lab_vyne_FoamixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foamix</link:label>
    <link:label id="lab_vyne_FoamixMember_label_en-US" xlink:label="lab_vyne_FoamixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foamix [Member]</link:label>
    <link:label id="lab_vyne_FoamixMember_documentation_en-US" xlink:label="lab_vyne_FoamixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the merger of Foamix.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_FoamixMember" xlink:to="lab_vyne_FoamixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_dcf70ffe-9f69-421b-b5c4-4670ea8241cd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_078d978e-66fc-4a99-85c5-5040223c185a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_95220439-d9be-445b-b6d4-4f8dd0b5a926_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of identified intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_77fe538c-4808-4139-a65c-0a9d1fc6ea28_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net acquired (See &#8220;Note 3- Business combination&#8221;)</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_EmployeeStockPurchasePlanMember_3df8f099-9292-492f-b86b-ee3e4339f32c_terseLabel_en-US" xlink:label="lab_vyne_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_vyne_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_vyne_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_vyne_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_vyne_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EmployeeStockPurchasePlanMember" xlink:href="vyne-20210630.xsd#vyne_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_EmployeeStockPurchasePlanMember" xlink:to="lab_vyne_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_e57ef0a3-86b2-4b8f-b0c6-afc9f7f6d30e_negatedLabel_en-US" xlink:label="lab_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: fair value of net assets acquired, including other identifiable intangibles</link:label>
    <link:label id="lab_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_label_en-US" xlink:label="lab_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Assets Acquired Including Other Identifiable Intangible Assets</link:label>
    <link:label id="lab_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_documentation_en-US" xlink:label="lab_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of net assets acquired including other identifiable intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:to="lab_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4e8d675e-9509-43be-8847-2c9d05a41f99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5ccb91e-c980-441d-bf9a-3dcc91bcdee8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_InterestReceived_1f4579ee-dbf0-4384-9ddd-9e086f0e307b_terseLabel_en-US" xlink:label="lab_vyne_InterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_vyne_InterestReceived_label_en-US" xlink:label="lab_vyne_InterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_vyne_InterestReceived_documentation_en-US" xlink:label="lab_vyne_InterestReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_InterestReceived" xlink:href="vyne-20210630.xsd#vyne_InterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_InterestReceived" xlink:to="lab_vyne_InterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_96f08e09-7a45-4a91-9f70-44b109ecbdf7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b4e1d22f-0ea8-41af-9114-657108b01f3e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_StockIssuedDuringPeriodSharesWarrantsExercised_514fe571-3e04-4c3d-b44c-bd5eab71ee48_terseLabel_en-US" xlink:label="lab_vyne_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for warrants exercised</link:label>
    <link:label id="lab_vyne_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_vyne_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_vyne_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_vyne_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for warrants exercised during the current period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="vyne-20210630.xsd#vyne_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_vyne_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_d5b4b235-95c5-413d-bf81-c512449961f8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to Menlo</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_68698df6-474b-426c-92ba-53c5f47b84d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split, conversion ratio (share/share)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_ec56cd0e-5284-47c3-b93d-54f1ef189e0c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_56303d86-a5b7-4680-b87b-fcde20f139e9_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (gains) losses from marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_46ccc4ac-9d4f-4387-89fe-08940254520a_terseLabel_en-US" xlink:label="lab_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Increase in Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_documentation_en-US" xlink:label="lab_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Increase in Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:href="vyne-20210630.xsd#vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:to="lab_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ContingentStockRightSharesConversion_872a06e1-89e0-4a22-8941-6b93778ebc6a_terseLabel_en-US" xlink:label="lab_vyne_ContingentStockRightSharesConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares issued per CSR (in shares)</link:label>
    <link:label id="lab_vyne_ContingentStockRightSharesConversion_label_en-US" xlink:label="lab_vyne_ContingentStockRightSharesConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Stock Right Shares Conversion</link:label>
    <link:label id="lab_vyne_ContingentStockRightSharesConversion_documentation_en-US" xlink:label="lab_vyne_ContingentStockRightSharesConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued per each contingent stock right.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockRightSharesConversion" xlink:href="vyne-20210630.xsd#vyne_ContingentStockRightSharesConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ContingentStockRightSharesConversion" xlink:to="lab_vyne_ContingentStockRightSharesConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d73d6e07-017d-48ae-810b-01ea0565e42d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_A2018PlanMember_6efc5d43-62c8-49e7-8024-20cab48cca51_terseLabel_en-US" xlink:label="lab_vyne_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_vyne_A2018PlanMember_label_en-US" xlink:label="lab_vyne_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan [Member]</link:label>
    <link:label id="lab_vyne_A2018PlanMember_documentation_en-US" xlink:label="lab_vyne_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_A2018PlanMember" xlink:href="vyne-20210630.xsd#vyne_A2018PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_A2018PlanMember" xlink:to="lab_vyne_A2018PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b92cbe94-2d6e-47d6-9de3-4f3f733ce5b6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_42893e12-2bdc-4053-9ccb-164ee66648e5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and in-process research &amp; development impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33fd6566-80ab-48f0-9594-cf55800ffc1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU, award amount (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_4c9ab096-c631-478b-983c-8dd0670c083d_terseLabel_en-US" xlink:label="lab_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares deemed (for accounting purposes only) issued (in shares)</link:label>
    <link:label id="lab_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_label_en-US" xlink:label="lab_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Shares Deemed Issued For Accounting Purposes</link:label>
    <link:label id="lab_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_documentation_en-US" xlink:label="lab_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares deemed, for accounting purposes only, to be issued in the merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:to="lab_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_FacilitySpaceUnderLease_36894a82-a391-465c-85de-3d2099eac94d_terseLabel_en-US" xlink:label="lab_vyne_FacilitySpaceUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility space leased</link:label>
    <link:label id="lab_vyne_FacilitySpaceUnderLease_label_en-US" xlink:label="lab_vyne_FacilitySpaceUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Space Under Lease</link:label>
    <link:label id="lab_vyne_FacilitySpaceUnderLease_documentation_en-US" xlink:label="lab_vyne_FacilitySpaceUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Size of the facility under lease, in square feet.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FacilitySpaceUnderLease" xlink:href="vyne-20210630.xsd#vyne_FacilitySpaceUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_FacilitySpaceUnderLease" xlink:to="lab_vyne_FacilitySpaceUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_7115e0ea-1b4a-432f-8f35-2a9d64bb2828_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0d671038-1e43-4414-865e-a64514cc2b99_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock: $0.0001 par value; 20,000,000 shares authorized at June&#160;30, 2021 and December&#160;31, 2020, respectively; no shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalIncomeStatementElementsAbstract_e13a2094-0144-4d7e-b58c-5aa535a82cc2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:</link:label>
    <link:label id="lab_us-gaap_SupplementalIncomeStatementElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Income Statement Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:to="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0eb35664-65b6-41fa-8c82-200ad4e160e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_CommonStockVotingRightsNumberPerShare_0435488c-f52c-45c9-8c7a-7e8fe439570c_terseLabel_en-US" xlink:label="lab_vyne_CommonStockVotingRightsNumberPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes entitled to each ordinary share</link:label>
    <link:label id="lab_vyne_CommonStockVotingRightsNumberPerShare_label_en-US" xlink:label="lab_vyne_CommonStockVotingRightsNumberPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Voting Rights Number Per Share</link:label>
    <link:label id="lab_vyne_CommonStockVotingRightsNumberPerShare_documentation_en-US" xlink:label="lab_vyne_CommonStockVotingRightsNumberPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes entitled to each ordinary share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CommonStockVotingRightsNumberPerShare" xlink:href="vyne-20210630.xsd#vyne_CommonStockVotingRightsNumberPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_CommonStockVotingRightsNumberPerShare" xlink:to="lab_vyne_CommonStockVotingRightsNumberPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_bb752499-f16a-4466-8c8f-25ef036ba6ef_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7334738e-6b08-4287-9978-38ec9e0881ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2989726a-06e9-4771-b16f-ad00a118b8e2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in trade receivables, prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_545612af-4265-462f-9f59-311fa11db8d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_9789c7ec-8f51-4afd-8a8e-55cce36a207d_negatedLabel_en-US" xlink:label="lab_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acceleration of stock based compensation</link:label>
    <link:label id="lab_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_label_en-US" xlink:label="lab_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation</link:label>
    <link:label id="lab_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_documentation_en-US" xlink:label="lab_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of acceleration of stock based compensation as adjustment to pro-forma results of the combined operation after business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:href="vyne-20210630.xsd#vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:to="lab_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3739bf5d-8f91-43fa-ab1a-fa28ca2e1c95_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_BusinessAcquisitionContingentStockRightIssued_cf2678e4-5cb5-49b3-97db-077427a2f6f6_terseLabel_en-US" xlink:label="lab_vyne_BusinessAcquisitionContingentStockRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contingent stock rights issued (in CSR)</link:label>
    <link:label id="lab_vyne_BusinessAcquisitionContingentStockRightIssued_label_en-US" xlink:label="lab_vyne_BusinessAcquisitionContingentStockRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Stock Right Issued</link:label>
    <link:label id="lab_vyne_BusinessAcquisitionContingentStockRightIssued_documentation_en-US" xlink:label="lab_vyne_BusinessAcquisitionContingentStockRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of contingent stock right issued in connection with the business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessAcquisitionContingentStockRightIssued" xlink:href="vyne-20210630.xsd#vyne_BusinessAcquisitionContingentStockRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_BusinessAcquisitionContingentStockRightIssued" xlink:to="lab_vyne_BusinessAcquisitionContingentStockRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cee60e8c-3e6a-4ace-b89c-22d888104e7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8a6443eb-f754-4ae8-82e9-ab47dd395150_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_BusinessCombinationEffectiveExchangeRatio_f016cbf8-6b8e-4f7d-ac8b-ff52ec784fed_terseLabel_en-US" xlink:label="lab_vyne_BusinessCombinationEffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective exchange ratio of Foamix ordinary shares into Menlo common stock (share/share)</link:label>
    <link:label id="lab_vyne_BusinessCombinationEffectiveExchangeRatio_label_en-US" xlink:label="lab_vyne_BusinessCombinationEffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Effective Exchange Ratio</link:label>
    <link:label id="lab_vyne_BusinessCombinationEffectiveExchangeRatio_documentation_en-US" xlink:label="lab_vyne_BusinessCombinationEffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The effective exchange ratio of ordinary shares for shares of common stock from the merger as adjusted for the conversion of contingent stock rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationEffectiveExchangeRatio" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationEffectiveExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_BusinessCombinationEffectiveExchangeRatio" xlink:to="lab_vyne_BusinessCombinationEffectiveExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_166e289a-bf87-46e2-ab10-d762520dfe71_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9dc375b5-a3f9-4ab2-9ea0-a58aa6a2cd98_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_5cbcb049-32e2-4d2d-9da9-d8eea50845fa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_d5dae3af-b453-4139-8525-29c7adeceef2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of annual earnings that may be used to purchase shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationGoodwillAbstract_bf40192b-cacb-4fb3-a2fa-07e42f17267a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Goodwill [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock_592a3b00-f857-4b71-a7d7-e5cb4d44928a_terseLabel_en-US" xlink:label="lab_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Merger Consideration to be Transferred</link:label>
    <link:label id="lab_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock_label_en-US" xlink:label="lab_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisition Consideration [Table Text Block]</link:label>
    <link:label id="lab_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock_documentation_en-US" xlink:label="lab_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of consideration to be transferred to effect the Merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:href="vyne-20210630.xsd#vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:to="lab_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fefe0cf5-db30-489d-8c78-be255fd4a7d4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b9990e51-25b7-4d62-b196-3eee8175cc92_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_d0138890-d067-4114-a1a0-7a2309776651_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c2ca26a9-d6f1-4669-8715-e81b6a7a419a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_BusinessCombinationConsiderationTransferredGross_78b2db78-e7fe-43c8-8aa8-8b2219c5fdb0_terseLabel_en-US" xlink:label="lab_vyne_BusinessCombinationConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_vyne_BusinessCombinationConsiderationTransferredGross_cd632dcd-9a5e-4974-a9c2-b940109b8a16_totalLabel_en-US" xlink:label="lab_vyne_BusinessCombinationConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_vyne_BusinessCombinationConsiderationTransferredGross_label_en-US" xlink:label="lab_vyne_BusinessCombinationConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Consideration Transferred Gross</link:label>
    <link:label id="lab_vyne_BusinessCombinationConsiderationTransferredGross_documentation_en-US" xlink:label="lab_vyne_BusinessCombinationConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer prior to the reduction in respect of the contingent stock rights issued to acquired shareholders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredGross" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_BusinessCombinationConsiderationTransferredGross" xlink:to="lab_vyne_BusinessCombinationConsiderationTransferredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_55449718-1386-4385-96bd-3c6cc1f4a362_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances_c6541417-347d-44fc-ab75-0e46f12e3cdb_terseLabel_en-US" xlink:label="lab_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales provisions</link:label>
    <link:label id="lab_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances_label_en-US" xlink:label="lab_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Distribution, Trade Discounts and Allowances</link:label>
    <link:label id="lab_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances_documentation_en-US" xlink:label="lab_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate of fee the entity pays for distribution services and certain date that distributors provide to the entity and sales discounts given by the entity, including, but not limited to, early payments of accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:href="vyne-20210630.xsd#vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:to="lab_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_f089763b-414f-4773-bf2f-07d244ca14d6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_c2205329-d218-45c2-bd09-40a6dcc4272b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_311ff943-6006-4758-9ac2-c1242ea50ae1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_4d670c65-7d7e-4ce5-81f8-f78d4cec1d49_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_42d156fa-e16d-43bf-8e26-75b84dd06927_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_94b7b371-b7f9-4a77-9aac-3039690c7277_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_dc398ca0-7fe2-49d5-b939-09ae8aa6e2ea_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash finance income, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_bcd7aa02-e79f-4ad1-8b37-75459548084f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_d9da7afe-f8d4-4c6c-92a4-e9b913c98dbf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration net of the effect of CSRs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_e9f55a73-6760-412e-8d35-98dddeed7499_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_79f9c432-e1fb-4767-b06b-2a698fc868c0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_0aea561b-f0f2-4b72-8845-a48ebbca797e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_dbe0d40c-1132-4b64-a3b0-a19c77c4fa8d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9f700874-bd19-457e-a360-d5d44480fde2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b3f73b18-8e64-4ee0-b422-313023b0553c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_37cb487d-2a84-4a77-ac3f-090703f0fe19_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1dc23772-1c9c-42d0-adcb-8a4ef6f24ed5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_aa0fcd8f-4899-40e4-97fd-cf007c591e6e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_5d638b4d-ed83-448b-a4c6-1a5dfc57b5d3_negatedTerseLabel_en-US" xlink:label="lab_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend to warrants holders due to warrant modifications</link:label>
    <link:label id="lab_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_f33de8ab-e993-4496-b85d-92e3e255f451_terseLabel_en-US" xlink:label="lab_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend to warrants holders due to warrant modifications</link:label>
    <link:label id="lab_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_label_en-US" xlink:label="lab_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend To Warrants Holders Due To Warrant Modification</link:label>
    <link:label id="lab_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_documentation_en-US" xlink:label="lab_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from modification of warrants that is deemed dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:href="vyne-20210630.xsd#vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:to="lab_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d2f490ae-eeba-4866-84bd-7b92aef4afa0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_a40e324e-b24f-4555-abbf-04b04e9a1726_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_84521f74-8a5a-43c7-887c-f3c5ee6021a6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_266f1334-befc-4ca8-a626-1c5a79fe36bf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_5d7fcf11-32e8-46db-bf86-3be0da4499b3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_FourCustomersMember_c5a0e6b7-6f47-4da2-9c0d-6157eb23f38c_terseLabel_en-US" xlink:label="lab_vyne_FourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Customers</link:label>
    <link:label id="lab_vyne_FourCustomersMember_label_en-US" xlink:label="lab_vyne_FourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Customers [Member]</link:label>
    <link:label id="lab_vyne_FourCustomersMember_documentation_en-US" xlink:label="lab_vyne_FourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FourCustomersMember" xlink:href="vyne-20210630.xsd#vyne_FourCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_FourCustomersMember" xlink:to="lab_vyne_FourCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_70808f3e-c6ad-4b14-9844-11d740c84f9a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6313317f-56fb-4679-a0d8-8661ec7fbce2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b426d711-1536-4345-8f84-347f0cc4720e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AdjustmentsToSupplementalProformaTransactionCosts_3f535b38-0062-4148-8a94-d6cc512e1330_negatedLabel_en-US" xlink:label="lab_vyne_AdjustmentsToSupplementalProformaTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_vyne_AdjustmentsToSupplementalProformaTransactionCosts_label_en-US" xlink:label="lab_vyne_AdjustmentsToSupplementalProformaTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Supplemental Proforma Transaction Costs</link:label>
    <link:label id="lab_vyne_AdjustmentsToSupplementalProformaTransactionCosts_documentation_en-US" xlink:label="lab_vyne_AdjustmentsToSupplementalProformaTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount pertaining to transaction costs as adjustment to pro-forma results of the combined operation after business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdjustmentsToSupplementalProformaTransactionCosts" xlink:href="vyne-20210630.xsd#vyne_AdjustmentsToSupplementalProformaTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AdjustmentsToSupplementalProformaTransactionCosts" xlink:to="lab_vyne_AdjustmentsToSupplementalProformaTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5edc7791-d9ab-4ded-90a8-4f566dda51b3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_7cb4ed3c-a67e-419c-bd98-ea2125e17f06_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in marketable securities (Note 6)</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8e5c2830-9b84-4ef4-9820-40af709c0a63_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89425b7a-3ef9-4f9c-a2f9-b0dd46d7c002_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_8082b2ee-a03e-4fcd-9717-0334f5d2808d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d657c2a9-4a30-4751-949e-fda11ed61753_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8a722783-9e72-4ba3-9696-96b5addd4c1b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ebb8cf96-fa00-4e92-95c4-0005ff9bf564_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1a9ab7a5-6a32-47cb-a1d2-5d108721d029_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock related to merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_EffectiveExchangeRatio_4d8e5492-b034-4e46-9ccb-c5a4c3a94461_terseLabel_en-US" xlink:label="lab_vyne_EffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective exchange ratio (CSR per share)</link:label>
    <link:label id="lab_vyne_EffectiveExchangeRatio_label_en-US" xlink:label="lab_vyne_EffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Exchange Ratio</link:label>
    <link:label id="lab_vyne_EffectiveExchangeRatio_documentation_en-US" xlink:label="lab_vyne_EffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EffectiveExchangeRatio" xlink:href="vyne-20210630.xsd#vyne_EffectiveExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_EffectiveExchangeRatio" xlink:to="lab_vyne_EffectiveExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7b2a47be-cc4f-48bd-8489-6da944740b0e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_15da1294-22f5-45e8-920f-3ae30468f3b9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_e4cb9c41-ed33-4bdb-993f-bc126c591e4e_terseLabel_en-US" xlink:label="lab_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed (for accounting purposes only) conversion of Menlo equity awards</link:label>
    <link:label id="lab_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_label_en-US" xlink:label="lab_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Consideration Transferred Conversion Of Acquirer Equity Awards</link:label>
    <link:label id="lab_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_documentation_en-US" xlink:label="lab_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of consideration transferred consisting of the conversion of equity awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:to="lab_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7541dbaf-acbb-421c-b0a2-c5db01e85247_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_UpfrontRoyaltyReceipt_fc5128f3-5cb2-4954-8ba8-10ae92a36745_terseLabel_en-US" xlink:label="lab_vyne_UpfrontRoyaltyReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront royalty receipt</link:label>
    <link:label id="lab_vyne_UpfrontRoyaltyReceipt_label_en-US" xlink:label="lab_vyne_UpfrontRoyaltyReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Royalty Receipt</link:label>
    <link:label id="lab_vyne_UpfrontRoyaltyReceipt_documentation_en-US" xlink:label="lab_vyne_UpfrontRoyaltyReceipt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of upfront royalty receipt upon delivery of licensed products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_UpfrontRoyaltyReceipt" xlink:href="vyne-20210630.xsd#vyne_UpfrontRoyaltyReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_UpfrontRoyaltyReceipt" xlink:to="lab_vyne_UpfrontRoyaltyReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_36fc2237-6fc4-423c-8685-470b4c512578_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ad8cef3a-39e8-4455-9462-87be1e863c96_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_4ce334b9-c6df-45de-a878-263a780de21b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d6669557-882a-4de8-9c29-3b0088281a3a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_f2833ecf-f334-4e99-bb66-c8ebb8d8d0f5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AdditionalSpaceMember_6c0d162d-f7db-48a4-acef-bc59d750c9cd_terseLabel_en-US" xlink:label="lab_vyne_AdditionalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Space</link:label>
    <link:label id="lab_vyne_AdditionalSpaceMember_label_en-US" xlink:label="lab_vyne_AdditionalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Space [Member]</link:label>
    <link:label id="lab_vyne_AdditionalSpaceMember_documentation_en-US" xlink:label="lab_vyne_AdditionalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the additional leased facility space.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdditionalSpaceMember" xlink:href="vyne-20210630.xsd#vyne_AdditionalSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AdditionalSpaceMember" xlink:to="lab_vyne_AdditionalSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_fad4f05e-0fe4-4fe0-a7b0-4b9b7576ab79_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c3692e60-1ece-4862-bdd1-5942dc162912_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock: $0.0001 par value; 75,000,000 shares authorized at June&#160;30, 2021 and December&#160;31, 2020, respectively; 51,511,845 and 43,205,221 shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2b6e680b-c7ae-42f5-bae5-3c4220dd06b0_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract_cc157670-fa22-4a78-8518-09cd1697309c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c00d9bb1-5562-4d63-a64a-ffc341c9ed74_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3a82e9fb-9f45-41d9-8e0e-06da9449464b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_74044244-7c82-45bf-b862-33c30c06709a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_32bce29d-2947-467c-aa1e-707c2830d2a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING LEASE</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNetAbstract_9997ef06-02ec-44f2-a224-65fd4baab671_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt offering expenses</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract" xlink:to="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_bc0436d7-f699-4c90-ae64-53af8e4957f7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d3c05ecc-2f1d-45f3-b45b-74abde7c5cea_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9655b715-371d-4218-a092-ea715da45be5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS COMBINATION</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1ebe34a2-36c3-4c9d-9c55-aacf445fa2fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_8cf22f27-b771-4bf0-aa24-d0fa45c19f8a_terseLabel_en-US" xlink:label="lab_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger net of cash acquired</link:label>
    <link:label id="lab_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_label_en-US" xlink:label="lab_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Acquisition Of Business, Net Assets After Cash Acquired</link:label>
    <link:label id="lab_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_documentation_en-US" xlink:label="lab_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of net assets acquired in non-cash acquisition, net of cash acquired included in the acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:href="vyne-20210630.xsd#vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:to="lab_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_eaf485b3-cf0c-4e9f-b738-7e8777067819_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d0c38912-0c1a-4162-8e6c-a04f7a06192a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_de14e93a-477a-4422-93ec-3d8f2f89ebf0_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock_9bc8ff1d-d083-404f-9671-b6d019bdb8c6_terseLabel_en-US" xlink:label="lab_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Based Compensation by Share Based Payment Award Grants in Period</link:label>
    <link:label id="lab_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock_label_en-US" xlink:label="lab_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation By Share Based Payment Award Grants In Period [Table Text Block]</link:label>
    <link:label id="lab_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock_documentation_en-US" xlink:label="lab_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the share-based compensation awards granted during the period, exercise price range, vesting period and expiration of awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:href="vyne-20210630.xsd#vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:to="lab_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_5f8b5a14-2618-44d2-804d-d6733af5601f_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Operating Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_61cf4b58-5a20-4482-9502-e8cc2a7c737d_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f8c75b9e-ec01-4aba-924b-9a6277723e27_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_254c627a-1ab9-420e-b119-8575544eb0bd_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0bbb8ffa-21c2-439b-b877-7a42942f3be2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6a09d7da-1f06-4104-a6a6-52b86277ae7d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received in a transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_75ac7419-3a12-411c-9d6e-720028c78e66_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_bdf1b0b3-f880-40fe-8061-b32d4c64eecc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued pursuant to the merger (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_def14260-3c36-4b0b-9a08-d98e7ea26690_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c1c978e4-cf48-42b8-8016-2a539f7473d7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses (Note 4)</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1cc8a855-abe1-42ae-bb45-a0cf88a5207c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2e786dd-84ae-4749-85ab-8e37397d3c76_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_065e7808-0ae6-49ca-ad93-f97f4e2d3555_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_4470ec2e-99e4-448d-94dc-b73bd29602cc_terseLabel_en-US" xlink:label="lab_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of CSR converted into additional shares of the combined company</link:label>
    <link:label id="lab_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_label_en-US" xlink:label="lab_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquiree Common Stock Rights Converted to Common Stock</link:label>
    <link:label id="lab_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_documentation_en-US" xlink:label="lab_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquiree Common Stock Rights Converted to Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:to="lab_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ebb169cb-0e0f-45c2-9edb-a767b37977ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ContingentStockConsiderationRemeasurementGainLoss_fa309aab-57f9-4ab8-b587-7bdd1d584259_negatedTerseLabel_en-US" xlink:label="lab_vyne_ContingentStockConsiderationRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Stock Right Remeasurement</link:label>
    <link:label id="lab_vyne_ContingentStockConsiderationRemeasurementGainLoss_label_en-US" xlink:label="lab_vyne_ContingentStockConsiderationRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Stock Consideration, Remeasurement Gain (Loss)</link:label>
    <link:label id="lab_vyne_ContingentStockConsiderationRemeasurementGainLoss_documentation_en-US" xlink:label="lab_vyne_ContingentStockConsiderationRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Stock Consideration, Remeasurement Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss" xlink:href="vyne-20210630.xsd#vyne_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss" xlink:to="lab_vyne_ContingentStockConsiderationRemeasurementGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_564489de-6fee-4669-86f6-562a4d87c6d5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0b042fe4-d707-486c-bad8-40703b63b6a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock_c06bb8aa-325f-4a6e-a688-2f570cf85e34_terseLabel_en-US" xlink:label="lab_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of In Process Research and Development Assets Acquired Through Business Combination</link:label>
    <link:label id="lab_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock_label_en-US" xlink:label="lab_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of In Process Research And Development Assets Acquired Through Business Combination [Table Text Block]</link:label>
    <link:label id="lab_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock_documentation_en-US" xlink:label="lab_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of in-process research and development indefinite lived intangible assets acquired in the merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:href="vyne-20210630.xsd#vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:to="lab_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7f725924-dc0b-401b-9569-def409c60954_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_9ccaadc2-7c55-4fe7-a4d5-95d94fbece7d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_669a4b65-df1f-4d7d-9f6d-9c4285df83fc_terseLabel_en-US" xlink:label="lab_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options and RSUs granted</link:label>
    <link:label id="lab_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_label_en-US" xlink:label="lab_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options And Equity Instruments Other Than Options Grants in Period Total Grant Date Fair Value</link:label>
    <link:label id="lab_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_documentation_en-US" xlink:label="lab_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total fair value of options and equity instruments other than options granted during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:href="vyne-20210630.xsd#vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:to="lab_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e7c25414-a219-4f6b-a503-f8a6e79796fa_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_PublicOfferingMember_48eeebd2-927a-4fd0-bbd2-435f1132676f_terseLabel_en-US" xlink:label="lab_vyne_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_vyne_PublicOfferingMember_label_en-US" xlink:label="lab_vyne_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_vyne_PublicOfferingMember_documentation_en-US" xlink:label="lab_vyne_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PublicOfferingMember" xlink:href="vyne-20210630.xsd#vyne_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_PublicOfferingMember" xlink:to="lab_vyne_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48ff22ce-5e58-41ce-a17a-4fb8c0866cf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_64e5164c-0328-4efc-bd35-cd75202ca471_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities (Note 10)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_GrossProceedsFromIssuanceOfCommonStock_9e2d853a-04b4-46b8-9477-feb243f5b475_terseLabel_en-US" xlink:label="lab_vyne_GrossProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
    <link:label id="lab_vyne_GrossProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_vyne_GrossProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label id="lab_vyne_GrossProceedsFromIssuanceOfCommonStock_documentation_en-US" xlink:label="lab_vyne_GrossProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross proceeds from issuance of common stock before deducting offering expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_GrossProceedsFromIssuanceOfCommonStock" xlink:href="vyne-20210630.xsd#vyne_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_GrossProceedsFromIssuanceOfCommonStock" xlink:to="lab_vyne_GrossProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b4fca1fe-7a1f-4ac0-8ab5-36492cd2a85d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHANGES DURING THE PERIOD:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_fa98ef85-4e46-4a45-a886-0b252be282c3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Recognition and Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_63f249f5-7b56-476e-879c-ed8f32883e84_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_81d7ae6f-e6a1-4188-bd61-1a188be7cb5a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f07fd401-bd15-4f04-b7ff-8a2a107453e5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b569df21-07d3-41ff-a91c-45023853ce49_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_967792c8-4a71-4113-8fc3-b991fc84ec1d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_106de446-4b4c-4c32-9c82-5418d7eb56a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period, conversion of units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementMember_fe8d4418-2ef1-4c58-9b0b-54e586ce80bf_terseLabel_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Credit Agreement</link:label>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementMember_label_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Amended and Restated Credit Agreement entered into on March 9, 2020.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementMember" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AmendedAndRestatedCreditAgreementMember" xlink:to="lab_vyne_AmendedAndRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04c666b3-c546-47fc-ab8c-d17a5589219e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2f7b7bd0-dcdc-44eb-87fa-76cbbf394526_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares that may be purchased by exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_85d6f888-2dc5-4ebc-9193-bc0ca2570405_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_BridgewaterNewJerseyMember_0d8922dc-dd2a-4cc2-9e82-6e96afef1317_terseLabel_en-US" xlink:label="lab_vyne_BridgewaterNewJerseyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridgewater, New Jersey</link:label>
    <link:label id="lab_vyne_BridgewaterNewJerseyMember_label_en-US" xlink:label="lab_vyne_BridgewaterNewJerseyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridgewater New Jersey [Member]</link:label>
    <link:label id="lab_vyne_BridgewaterNewJerseyMember_documentation_en-US" xlink:label="lab_vyne_BridgewaterNewJerseyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the location in Bridgewater, New Jersey.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BridgewaterNewJerseyMember" xlink:href="vyne-20210630.xsd#vyne_BridgewaterNewJerseyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_BridgewaterNewJerseyMember" xlink:to="lab_vyne_BridgewaterNewJerseyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_402c16a0-95e6-4f8d-ad92-310daae2d6ce_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf5b3473-97db-42b9-98ed-26e1020e9109_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_c002c2ab-7518-40e6-87cb-7e84def1229c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_bc31bdb2-08cf-469b-8e7f-e9e3e79d9ae5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ca350aca-4194-4c32-b4ca-35fa913409e5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2e946b00-d2aa-49fe-aaec-a323a00bb6d1_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_1fb91122-ea8e-4e75-8afb-fce59a25a3b2_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ThreeCustomersMember_948c79fc-4c19-4e1a-8888-b088536ce8e1_terseLabel_en-US" xlink:label="lab_vyne_ThreeCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Customers</link:label>
    <link:label id="lab_vyne_ThreeCustomersMember_label_en-US" xlink:label="lab_vyne_ThreeCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Customers [Member]</link:label>
    <link:label id="lab_vyne_ThreeCustomersMember_documentation_en-US" xlink:label="lab_vyne_ThreeCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ThreeCustomersMember" xlink:href="vyne-20210630.xsd#vyne_ThreeCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ThreeCustomersMember" xlink:to="lab_vyne_ThreeCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6b146f0c-2028-4a72-bd5f-b5f937d2ef5e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_691c6648-8da3-48bd-8e92-36fca1c0ddb7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d370d35e-5348-4179-a6d6-0bc683a5ab1b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ea3b0200-52ef-4ab5-99a2-d0ff20b66d94_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fb28320b-67a6-4d41-a775-41c215fbac46_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d0790c45-9e55-4c61-8dd2-6327c7804501_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_PublicStockOfferingMember_195de997-439e-4ed1-a721-f4d33b17f153_terseLabel_en-US" xlink:label="lab_vyne_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:label id="lab_vyne_PublicStockOfferingMember_label_en-US" xlink:label="lab_vyne_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_vyne_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_vyne_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PublicStockOfferingMember" xlink:href="vyne-20210630.xsd#vyne_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_PublicStockOfferingMember" xlink:to="lab_vyne_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_a0e3abbc-244b-43f5-b3a4-402daba60be2_terseLabel_en-US" xlink:label="lab_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of parent by subsidiary stockholders</link:label>
    <link:label id="lab_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_label_en-US" xlink:label="lab_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders</link:label>
    <link:label id="lab_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_documentation_en-US" xlink:label="lab_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of post-merger Menlo ownership held by pre-merger Foamix shareholders, as a percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:href="vyne-20210630.xsd#vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:to="lab_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e5ba423f-e540-4172-810d-b6f6ab2859b1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ca5dacd8-f5d7-48c4-a2ff-91a8b46bfcc4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_dce8b1a2-d285-4d05-9949-f8b7237cd235_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a21c5fed-186e-4464-89a0-b6e05e87eda2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired indefinite life intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e32078c5-dca1-4774-97ec-3704f6ccd7ac_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IL_8d9fadbe-fcad-465b-856e-2997cd1ac376_terseLabel_en-US" xlink:label="lab_country_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ISRAEL</link:label>
    <link:label id="lab_country_IL_label_en-US" xlink:label="lab_country_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ISRAEL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IL" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL" xlink:to="lab_country_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9e3dd1c9-25a2-44fd-b563-4c7aedb28604_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6d126303-3784-4b1c-8b6e-75179f4961c8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary information on investing and financing activities not involving cash flows:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1607e8a9-dc68-4be5-afe0-503092efced4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e5d24646-7b72-4337-a665-5704bbe95283_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities (Note 10)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3694ee30-61d2-42f9-8eb3-567955cbf984_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_bf462add-5e18-4250-941a-e85222d2fba5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_0204a202-b7de-4e69-9021-cc68c9ff0631_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c572ea63-0e45-4815-b3ac-2c9bc451da7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock_324d82ed-2c0b-4e21-98f0-5ad3911c003d_terseLabel_en-US" xlink:label="lab_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Calculation for Goodwill of Merger</link:label>
    <link:label id="lab_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock_label_en-US" xlink:label="lab_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Combination Goodwill [Table Text Block]</link:label>
    <link:label id="lab_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the calculation of goodwill from the business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:href="vyne-20210630.xsd#vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:to="lab_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0d07889b-ed46-4ea4-b82e-b1f8e09eb34e_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_90e3487a-2d3c-4f2f-bfc2-c389e7e59137_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_b4c0745a-33a9-452b-8878-a68aad189d8a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing share price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_36fe69f7-3d6e-4b02-92ca-d849ac6a4211_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_08275aa6-85fe-4078-beba-c7f4a7e5a98b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a8c883b8-ab9b-4fce-b4e5-fdf599d1c524_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c931a53b-1dfd-46bb-b202-4f4e527a04aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3fc2adb9-cf38-4c15-9151-091959fb2b87_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_da24c352-fa2e-4695-a483-855129e26cb3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_9ca16814-5bf2-479a-8b04-25323ae2d120_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of the Purchase Price to the Fair Values of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_OriginalSpaceMember_728f8ec4-9656-4f55-a822-65b5eb69c1a3_terseLabel_en-US" xlink:label="lab_vyne_OriginalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original Space</link:label>
    <link:label id="lab_vyne_OriginalSpaceMember_label_en-US" xlink:label="lab_vyne_OriginalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original Space [Member]</link:label>
    <link:label id="lab_vyne_OriginalSpaceMember_documentation_en-US" xlink:label="lab_vyne_OriginalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the original leased facility space.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_OriginalSpaceMember" xlink:href="vyne-20210630.xsd#vyne_OriginalSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_OriginalSpaceMember" xlink:to="lab_vyne_OriginalSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_3f888e00-9f2f-430c-8749-828ba919e8ec_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_bb0228bd-7d15-4f8f-9d9a-170c60d45bfb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent impairment loss, debt securities, available for sale</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9862449c-1497-4258-8a88-65860aec1702_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7f0a1a3d-d748-417c-aba3-3d770755b972_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_aaa60a04-a513-4bb3-871f-660c68fa0b9a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_RepaymentOfDebtPrepaymentFeePercentage_f3b96b3c-28a8-43c7-b8f1-2ec36d201ec6_terseLabel_en-US" xlink:label="lab_vyne_RepaymentOfDebtPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee, percentage</link:label>
    <link:label id="lab_vyne_RepaymentOfDebtPrepaymentFeePercentage_label_en-US" xlink:label="lab_vyne_RepaymentOfDebtPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Debt, Prepayment Fee, Percentage</link:label>
    <link:label id="lab_vyne_RepaymentOfDebtPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_vyne_RepaymentOfDebtPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Debt, Prepayment Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RepaymentOfDebtPrepaymentFeePercentage" xlink:href="vyne-20210630.xsd#vyne_RepaymentOfDebtPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_RepaymentOfDebtPrepaymentFeePercentage" xlink:to="lab_vyne_RepaymentOfDebtPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_93d1fd14-06ab-4deb-a386-1749e594ce7a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_02509b61-526d-404e-8556-26291e385b07_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of derivative instruments held</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_86dc8cf2-5bb4-47b5-ab62-293617f9872b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_75be70c8-8102-42c4-a57f-567335b92c67_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_50464677-12b7-414e-bdeb-28b95bd9bc1b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds related to issuance of stock for stock-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_3339892c-08ec-4376-925c-1ca9ed3ec007_terseLabel_en-US" xlink:label="lab_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in accrued liability for employee severance benefits, net of retirement fund profit</link:label>
    <link:label id="lab_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_label_en-US" xlink:label="lab_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits</link:label>
    <link:label id="lab_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_documentation_en-US" xlink:label="lab_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of noncash increase (decrease) in employee severance benefit liability net of profit from retirement fund.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:href="vyne-20210630.xsd#vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:to="lab_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b440ba9a-5b53-401a-b67e-65b5a51da3dd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f3ff82ca-a576-45db-8de2-bf7b3c0247d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6457d9ad-31a0-44a3-88e9-c6a2ffd872de_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net of allowances</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ec8ceacd-f639-4ca6-87c3-c23af1e09e0b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_f782051b-5672-4b4c-bab4-aaa40d99f7b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_87bfc345-51b2-4434-b389-92d2fe059270_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_EstimateOfProductReturnRateMaximum_e81d3f3a-69f2-4f8f-9ebd-8aefa9a3fa67_terseLabel_en-US" xlink:label="lab_vyne_EstimateOfProductReturnRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum estimate product return (as a percent)</link:label>
    <link:label id="lab_vyne_EstimateOfProductReturnRateMaximum_label_en-US" xlink:label="lab_vyne_EstimateOfProductReturnRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Product Return Rate, Maximum</link:label>
    <link:label id="lab_vyne_EstimateOfProductReturnRateMaximum_documentation_en-US" xlink:label="lab_vyne_EstimateOfProductReturnRateMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum estimate of product sales return rate at reporting date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EstimateOfProductReturnRateMaximum" xlink:href="vyne-20210630.xsd#vyne_EstimateOfProductReturnRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_EstimateOfProductReturnRateMaximum" xlink:to="lab_vyne_EstimateOfProductReturnRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aa71f14c-29c3-471f-b48d-796e90f776bb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ab6bc2c7-6c68-4b15-a1b0-e1a4f50d94ac_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9caa344d-b9c0-44f3-992c-0d64d23f7850_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1009de9b-efd1-4862-86bc-c40f908d21b8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_76c036b4-8474-41a6-91b9-4317894d0992_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_906bc2a0-9161-4a6a-b5e7-d8b6ac700a3b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory (Note 7)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b68e4474-1e9e-45ed-b2da-8829ee43cebf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_64ae0d7d-0cb3-415b-aa0d-884da59f5f4b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_864e9f56-2c71-4dd7-8486-ff6692607c78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_d4c094c4-8f85-413c-a3d3-7090d9eb1c0b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_66d95e43-e6f1-4045-9193-6f6caa5bfa93_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt (Note 8)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a4cc7927-2773-49b7-9ed8-939a41caa7dd_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6c56104-5956-4de0-bca0-303ff4768717_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9db911d-6885-4975-9bf3-0d17368d9577_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_78f71449-fcd5-472f-9042-a8aace1a901c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ec4fab3a-5fb9-4588-9535-8e02967c7ef1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_a9a24794-84e4-4399-b54f-80ed13d7f579_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_4b871693-b9a1-4dba-98ba-253320802670_terseLabel_en-US" xlink:label="lab_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issued and delivered upon CSR conversion (in shares)</link:label>
    <link:label id="lab_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_label_en-US" xlink:label="lab_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Upon Conversion of Common Stock Rights, Per Agreement</link:label>
    <link:label id="lab_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_documentation_en-US" xlink:label="lab_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number shares issued upon conversion of common stock rights arising form the certain events as provided for in the commons stock rights agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:href="vyne-20210630.xsd#vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:to="lab_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d46c8adb-901f-40c9-b165-b883631e52aa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (USD/share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d41acdea-bfde-4d6a-bb6e-10dbc0505a08_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6d172283-d6aa-4bea-876b-c606e2aa519b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9d12091f-0c3c-4468-94c3-70a7df28a8f8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_9693a7fc-a403-446e-bdda-e2d2e52569d7_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_IsraeliMutualFundsMember_86a64b4a-4caf-4086-b983-9454d71c9c54_terseLabel_en-US" xlink:label="lab_vyne_IsraeliMutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israeli mutual funds</link:label>
    <link:label id="lab_vyne_IsraeliMutualFundsMember_label_en-US" xlink:label="lab_vyne_IsraeliMutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israeli Mutual Funds [Member]</link:label>
    <link:label id="lab_vyne_IsraeliMutualFundsMember_documentation_en-US" xlink:label="lab_vyne_IsraeliMutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israeli Mutual Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_IsraeliMutualFundsMember" xlink:href="vyne-20210630.xsd#vyne_IsraeliMutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_IsraeliMutualFundsMember" xlink:to="lab_vyne_IsraeliMutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_fc903ed4-b6e9-4cfe-976a-16cae522500e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental compensation costs incurred</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_6b1b1840-6f53-4cd3-8661-395cf91f87c3_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount cost</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_41e8b7e1-78e5-46fa-b6c5-45d9a1d84191_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2c6190bd-e81b-4f46-9d6b-36d39bf6bb1f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_54962a15-ce88-4a86-b404-e2e9537beff1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock related to merger (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_4f22786c-be1e-4484-9523-ef274544d1f1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In process research and development impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_5fa4b06a-ac9f-44f4-9458-9aeeecfeb5a8_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0ab9d32c-771f-403a-a7e0-dc032e3b8b05_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a7bec74-c02a-4ca3-ad1e-986bc391df84_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_ee372e10-27b0-412c-8ce1-8a7fb0b36933_negatedTotalLabel_en-US" xlink:label="lab_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Adjustments</link:label>
    <link:label id="lab_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_label_en-US" xlink:label="lab_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Supplemental Proforma Combined Results of Operations</link:label>
    <link:label id="lab_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_documentation_en-US" xlink:label="lab_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of adjustments to supplemental proforma combined results of operations of the combined operation after business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:href="vyne-20210630.xsd#vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:to="lab_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9c348179-376a-41d4-bc51-54ac5aaf8874_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_86bf3bbe-2c8b-41d9-952f-51a1dad6521d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for employee severance benefits</link:label>
    <link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_label_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Unemployment Benefits, Severance Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:to="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_939d9ed1-06c8-41e4-8768-19fb006ba7f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_39c1171c-62fd-4537-82db-52a5512fe9a8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_935bbd1e-2f71-434c-ae1c-846622c4687c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Before Income Tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9f8bf402-4512-4c20-adea-2fde6c286cda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dca04e1c-4300-41cc-9b14-8f4eb4d81595_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_148824d6-bf18-4392-94a5-9c3e23adb9e7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_abafe633-05a5-4c13-a32e-d87e68bfe20c_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_ccb122c0-3631-48a3-82b7-e0eb8cfb7e7b_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ceaa57a3-1fbd-46a9-81ec-3dfe9729b1b4_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d1b6dea-398d-402f-b50e-a459ff0fc7cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option, award amount (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_MenloPremergerMember_8babb9f1-1d66-48c5-aed7-b164c8e2c47a_terseLabel_en-US" xlink:label="lab_vyne_MenloPremergerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Menlo - Premerger</link:label>
    <link:label id="lab_vyne_MenloPremergerMember_label_en-US" xlink:label="lab_vyne_MenloPremergerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Menlo - Premerger [Member]</link:label>
    <link:label id="lab_vyne_MenloPremergerMember_documentation_en-US" xlink:label="lab_vyne_MenloPremergerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Menlo - Premerger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_MenloPremergerMember" xlink:href="vyne-20210630.xsd#vyne_MenloPremergerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_MenloPremergerMember" xlink:to="lab_vyne_MenloPremergerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f32c7897-fdc4-40fa-9ba3-d0c552621d05_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_57d3d837-932d-4e24-98c8-6603cd8b3dcd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4016a68b-77f2-4bd2-8e06-3e15e51b7a61_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_254e04d7-2192-4b62-9438-fb6d20bc59fa_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_332f4c47-3091-4002-a8d6-4a709769b598_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_5fde263a-1893-49f0-8dc8-fa016a722422_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_4e7cd79d-ad1a-44ab-bd69-a494c26a29f9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_f4cfbafb-da4e-4570-a5b3-a557dbfa4487_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8e5d3200-57cf-4bbc-a5e6-2ef15f24227d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds related to issuance of common shares through offerings, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b699536e-6e3a-4d1d-8247-8f384cf55022_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_aaca42d7-f2ad-4aef-af2e-4040e4287021_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a2e51c81-f344-4dbf-9b21-5e9c5a833679_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_69ade528-c32b-4151-94b7-bdef671e6be3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8490e16a-69d8-47f4-879e-b2dbc2ef8468_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_ad1dbc7d-e1d2-4578-8de2-5c057b9bd2ca_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee termination costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d8dbc4c6-00b5-4aea-ace9-cc7f94462195_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9d8941fd-abbe-45eb-803e-708881839c2c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4388ace1-a4f3-490a-862a-2f4164b76cb5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_NumberOfLenders_901a8f74-f053-436d-96d4-1f76d1052870_terseLabel_en-US" xlink:label="lab_vyne_NumberOfLenders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lenders involved</link:label>
    <link:label id="lab_vyne_NumberOfLenders_label_en-US" xlink:label="lab_vyne_NumberOfLenders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lenders</link:label>
    <link:label id="lab_vyne_NumberOfLenders_documentation_en-US" xlink:label="lab_vyne_NumberOfLenders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of lenders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_NumberOfLenders" xlink:href="vyne-20210630.xsd#vyne_NumberOfLenders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_NumberOfLenders" xlink:to="lab_vyne_NumberOfLenders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestments_a38361fd-129d-4266-9dad-d4effddf5632_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments" xlink:to="lab_us-gaap_RestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_2a1d05f4-7be7-406b-b1ff-326fd4ed0cfa_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_RegisteredDirectOfferingMember_8641a65a-79ac-4c4f-bde1-0d8ad877fc6a_terseLabel_en-US" xlink:label="lab_vyne_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_vyne_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_vyne_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_vyne_RegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_vyne_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RegisteredDirectOfferingMember" xlink:href="vyne-20210630.xsd#vyne_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_RegisteredDirectOfferingMember" xlink:to="lab_vyne_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0eb7dc90-7a58-4d52-9f0e-b267195996ef_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, fair value of liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b7115513-a037-414b-a02c-e5719a3625ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3caeefd4-2fac-4bad-9dbc-f7045bf8db77_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e587d17-09ef-4400-86f2-798409354c85_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4586e7c-6c23-4b21-9423-c87d88859555_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c90b6f42-cac5-4ee4-9786-4d3939fce8ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses on marketable securities reclassified into net loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b206de3-0db9-4687-835d-4568f027d4af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_58e7fe26-05f0-450e-bc54-d6c10d761322_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_75a9a096-ac3f-4be0-ae1a-fd7ccb99277c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_697ea932-5b0d-47fc-b2fe-0049c7f6dd0d_terseLabel_en-US" xlink:label="lab_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional royalty upon receipt of marketing approval in China</link:label>
    <link:label id="lab_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_label_en-US" xlink:label="lab_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalty Receipt Upon Occurrence Of Certain Events</link:label>
    <link:label id="lab_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_documentation_en-US" xlink:label="lab_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of additional royalty receipt upon occurrence of certain event related to licensed products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:href="vyne-20210630.xsd#vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:to="lab_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_fcbcac4e-682a-489d-a4eb-ab4722c59e1a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5b5eecf8-f383-4c9c-be4c-b026cee1cf03_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8424a7dc-333b-4626-8a3f-902d44957dda_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_2abe6593-edb8-4181-8bb2-da21d76c7c36_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (USD/share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_56b83bf2-6925-45a7-8349-8a35938bc27a_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7c7a4ba-91ef-41ce-8539-72929366c30f_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_dd5984b8-e300-4af8-90b3-0a73ad673f06_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1c934bb5-a57b-41c7-addc-98aa0e87ddad_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_d1921e6d-7b1c-4c61-853e-171671ec8431_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_e4d03215-07c8-4dd1-93a1-d291214410e0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_847ed62d-0e18-436c-8e32-484b740b678b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill deductible for income tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_c42af98c-eecf-41d9-a976-594dcb614b13_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in marketable securities and bank deposits, net</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_CantorSalesAgreementMember_b9804a51-e406-43d2-b25e-c928d20735e0_terseLabel_en-US" xlink:label="lab_vyne_CantorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cantor Sales Agreement</link:label>
    <link:label id="lab_vyne_CantorSalesAgreementMember_label_en-US" xlink:label="lab_vyne_CantorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cantor Sales Agreement [Member]</link:label>
    <link:label id="lab_vyne_CantorSalesAgreementMember_documentation_en-US" xlink:label="lab_vyne_CantorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cantor Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CantorSalesAgreementMember" xlink:href="vyne-20210630.xsd#vyne_CantorSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_CantorSalesAgreementMember" xlink:to="lab_vyne_CantorSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_0b03a009-7ef3-48bb-bde3-ab6108671bef_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees expected to be terminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f405e39-cadc-4b8f-be57-55bf58fb5a53_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_606e82c5-0c5a-42d5-b7c7-b0c0d57b5402_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_RestrictedInvestmentsToSecureLeaseAgreements_deb773cd-32ff-4725-96d2-e5c024ae4222_terseLabel_en-US" xlink:label="lab_vyne_RestrictedInvestmentsToSecureLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lien on marketable securities to secure lease agreements</link:label>
    <link:label id="lab_vyne_RestrictedInvestmentsToSecureLeaseAgreements_label_en-US" xlink:label="lab_vyne_RestrictedInvestmentsToSecureLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments To Secure Lease Agreements</link:label>
    <link:label id="lab_vyne_RestrictedInvestmentsToSecureLeaseAgreements_documentation_en-US" xlink:label="lab_vyne_RestrictedInvestmentsToSecureLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of lien on marketable securities in respect of bank guarantees granted in order to secure lease agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RestrictedInvestmentsToSecureLeaseAgreements" xlink:href="vyne-20210630.xsd#vyne_RestrictedInvestmentsToSecureLeaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_RestrictedInvestmentsToSecureLeaseAgreements" xlink:to="lab_vyne_RestrictedInvestmentsToSecureLeaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b704a421-defe-4499-818a-174be146f0c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_461556ce-b50a-4d67-b9bb-184fb832a379_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ShareholderLenderMember_a2d06418-dded-47c8-aa51-d8c9691c5c35_terseLabel_en-US" xlink:label="lab_vyne_ShareholderLenderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Lender</link:label>
    <link:label id="lab_vyne_ShareholderLenderMember_label_en-US" xlink:label="lab_vyne_ShareholderLenderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Lender [Member]</link:label>
    <link:label id="lab_vyne_ShareholderLenderMember_documentation_en-US" xlink:label="lab_vyne_ShareholderLenderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to shareholders that are also lenders of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareholderLenderMember" xlink:href="vyne-20210630.xsd#vyne_ShareholderLenderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ShareholderLenderMember" xlink:to="lab_vyne_ShareholderLenderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_4b1b4936-4021-4d8b-b417-9e89de4666c9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_15043ac5-ef82-4761-946f-9962eb808676_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_0e249349-694e-4e85-9707-dc1308bdc7e0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1e007722-5335-4523-8d91-ef7a311a5d58_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ProceedsFromBusinessMerger_092f18e0-7302-42d8-83c9-1aebe2d198ab_terseLabel_en-US" xlink:label="lab_vyne_ProceedsFromBusinessMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired through merger</link:label>
    <link:label id="lab_vyne_ProceedsFromBusinessMerger_label_en-US" xlink:label="lab_vyne_ProceedsFromBusinessMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Business Merger</link:label>
    <link:label id="lab_vyne_ProceedsFromBusinessMerger_documentation_en-US" xlink:label="lab_vyne_ProceedsFromBusinessMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash inflow from business merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ProceedsFromBusinessMerger" xlink:href="vyne-20210630.xsd#vyne_ProceedsFromBusinessMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ProceedsFromBusinessMerger" xlink:to="lab_vyne_ProceedsFromBusinessMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f3c9cde5-5cc8-4f70-b83b-8f3e80934524_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_OralBETiOptionAgreementMember_eddaca84-7f7d-44d5-9e4b-7be8d2f780ca_terseLabel_en-US" xlink:label="lab_vyne_OralBETiOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral BETi Option Agreement</link:label>
    <link:label id="lab_vyne_OralBETiOptionAgreementMember_label_en-US" xlink:label="lab_vyne_OralBETiOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral BETi Option Agreement [Member]</link:label>
    <link:label id="lab_vyne_OralBETiOptionAgreementMember_documentation_en-US" xlink:label="lab_vyne_OralBETiOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral BETi Option Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_OralBETiOptionAgreementMember" xlink:href="vyne-20210630.xsd#vyne_OralBETiOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_OralBETiOptionAgreementMember" xlink:to="lab_vyne_OralBETiOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_27e6662a-325a-4242-848f-01938123d54e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ddea0f43-dc24-4d00-a4f9-75180d43ae49_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_eac70aea-c3d9-4e08-94a2-7e98720c4971_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_EstimateOfProductReturnRateMinimum_e7ba8c16-7882-487a-8f10-2ddd3ea4bdb4_terseLabel_en-US" xlink:label="lab_vyne_EstimateOfProductReturnRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum estimate product return (as a percent)</link:label>
    <link:label id="lab_vyne_EstimateOfProductReturnRateMinimum_label_en-US" xlink:label="lab_vyne_EstimateOfProductReturnRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Product Return Rate, Minimum</link:label>
    <link:label id="lab_vyne_EstimateOfProductReturnRateMinimum_documentation_en-US" xlink:label="lab_vyne_EstimateOfProductReturnRateMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum estimate of product sales return rate at reporting date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EstimateOfProductReturnRateMinimum" xlink:href="vyne-20210630.xsd#vyne_EstimateOfProductReturnRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_EstimateOfProductReturnRateMinimum" xlink:to="lab_vyne_EstimateOfProductReturnRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSupplies_ee56c7ee-7b1d-4a2a-a85f-dcfab9c7ba79_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSupplies_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_325a59c1-ac07-4ccb-a987-dd1298d5c4d2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_699027a1-5ddd-457f-86d7-eee7ac8a3191_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5395b402-f57d-4153-825c-ca07a84491dd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1d23bb0e-7c26-49c8-8843-e7f564f85d1b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_48fe39fd-1577-4b0b-ac69-94245f02cc58_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_6f41b7ec-fef6-4015-998e-f49eb9b9dd24_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range, maximum (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0848aa89-e37c-40d9-a323-b8c75d795b3c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_0ee1090a-105d-409e-90b4-c185c0387f42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and consultants</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_f60647f0-37ae-45d3-9e49-745c7e2fee1f_terseLabel_en-US" xlink:label="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental compensation costs incurred</link:label>
    <link:label id="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_label_en-US" xlink:label="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Unrecognized Cost</link:label>
    <link:label id="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_documentation_en-US" xlink:label="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Unrecognized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:to="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6e93aee3-ff1e-4710-85b3-fee955510079_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_af6f5861-bfbd-437b-9928-8915209ec53f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument information</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_327b820f-9a6b-4554-904d-cfb0518f684d_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b195709f-8b77-41ff-8303-e34d2cc32b24_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on outstanding debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_1953e8a3-1a80-47d6-b943-3aa5bf5e9222_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_d23816bf-3c58-4d89-922c-6d67419996f7_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b6478823-58e1-438e-a00d-9a9295f9ec39_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_332a085b-01df-445c-b3aa-1a0ff5a75013_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_2b04cc19-dc6a-48f0-b02c-674b6ada5da9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_8d25d872-7001-4f1a-95be-d6f242f69090_terseLabel_en-US" xlink:label="lab_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options, RSUs and shares under the ESPP</link:label>
    <link:label id="lab_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_label_en-US" xlink:label="lab_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options Restricted Stock Units R S U And Shares Under Espp [Member]</link:label>
    <link:label id="lab_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_documentation_en-US" xlink:label="lab_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options RSUs and Shares Under ESPP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:href="vyne-20210630.xsd#vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:to="lab_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_e07cce22-a9c2-4907-b27c-747d7f74b7c6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a96aa701-6fbc-4fd4-9905-fb15bcf6962e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_0d68d085-6086-49d2-a63b-05938fc1fa34_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b27446b0-b984-4666-ab5d-13b85cc88a4e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 8)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_235396c7-b456-456b-9ddb-22357e8ee328_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember_5852bab4-7760-44c2-8ea9-af5f3194c56e_terseLabel_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Credit Agreement, Trench 1 Loan</link:label>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember_label_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Credit Agreement Trench1 Loan [Member]</link:label>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember_documentation_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents trench 1 loan of the Amended and Restated Credit Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:to="lab_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_28b9c328-4324-451f-9c49-e2a6e22478dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5aa995e4-f97a-4dca-ab76-660b8aab0bce_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_edffd245-aa04-4e03-b26c-43cd6e7390ad_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_39edc3ca-0b15-437a-8d23-4dfa41d0dd05_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e58a88fc-a555-4a8c-b169-b4e67e485f3e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_bd7cf200-53cb-40f5-a64a-f839d75b0da3_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_fc03f5f1-7856-4e87-8ea8-d99b8014dd87_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue reserve accrual</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40b84bdb-4511-46f7-b896-b565a9df73f5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b48d9cf9-43ef-4569-9788-2817212c9733_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a361103-ce6e-49e8-a49f-4a408fda98ac_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in statement of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1266129b-5f5b-42e0-9cb1-b1ac10557d9c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma cash, cash equivalents, restricted cash and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_85c943b4-39ba-4ceb-8583-7245f790a4b8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1fccd854-f5f2-4e31-9994-cd8abbcd4bdc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (USD/share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_188d48d9-98fb-4df8-87fd-98a842889748_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_87d7fa9e-6a10-4975-88b3-333695523636_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_50b63948-5a79-4e60-8138-1f8759430edd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4c2ade70-0fc3-4dac-a8eb-54e3812fa7b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_a34674bb-bf0a-455b-9e53-e0b756df905a_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2b4d1f87-7c88-45f1-9d30-c11d23d5fdf7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_1e78224f-6d09-4ac6-80cc-00ab7bb0bec2_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-month LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f1051bef-3c37-4938-84ca-60ba858823a0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ExchangeRatio_25244df8-49be-4013-a35f-396e38f11154_terseLabel_en-US" xlink:label="lab_vyne_ExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange ratio per ordinary share for common stock (share per share)</link:label>
    <link:label id="lab_vyne_ExchangeRatio_label_en-US" xlink:label="lab_vyne_ExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Ratio</link:label>
    <link:label id="lab_vyne_ExchangeRatio_documentation_en-US" xlink:label="lab_vyne_ExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio applied to the exchange of ordinary shares of acquiree for common stock of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ExchangeRatio" xlink:href="vyne-20210630.xsd#vyne_ExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ExchangeRatio" xlink:to="lab_vyne_ExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5e18c23e-5625-48fe-8c92-99897412e0fa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AllowanceForSalesReturns1Member_39f7d5e3-d1eb-464f-afeb-e87f5e77bf33_terseLabel_en-US" xlink:label="lab_vyne_AllowanceForSalesReturns1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Sales Returns</link:label>
    <link:label id="lab_vyne_AllowanceForSalesReturns1Member_label_en-US" xlink:label="lab_vyne_AllowanceForSalesReturns1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Sales Returns1 [Member]</link:label>
    <link:label id="lab_vyne_AllowanceForSalesReturns1Member_documentation_en-US" xlink:label="lab_vyne_AllowanceForSalesReturns1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Sales Returns1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AllowanceForSalesReturns1Member" xlink:href="vyne-20210630.xsd#vyne_AllowanceForSalesReturns1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AllowanceForSalesReturns1Member" xlink:to="lab_vyne_AllowanceForSalesReturns1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a4bb581a-dccf-4bc2-b321-2ffe0e8f5369_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ClassOfWarrantAbstract_5f284e5b-1c35-4cc9-a37a-1fc99bdd9cbc_terseLabel_en-US" xlink:label="lab_vyne_ClassOfWarrantAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued</link:label>
    <link:label id="lab_vyne_ClassOfWarrantAbstract_label_en-US" xlink:label="lab_vyne_ClassOfWarrantAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant [Abstract]</link:label>
    <link:label id="lab_vyne_ClassOfWarrantAbstract_documentation_en-US" xlink:label="lab_vyne_ClassOfWarrantAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ClassOfWarrantAbstract" xlink:href="vyne-20210630.xsd#vyne_ClassOfWarrantAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ClassOfWarrantAbstract" xlink:to="lab_vyne_ClassOfWarrantAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_a272cfb5-4996-423e-8f3a-422be9b3af81_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_e53cf6e7-7204-4b76-87b1-e4b17f302ce7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_51ea0ea9-8fc9-41db-89f5-a54fde2972a8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_923611ee-e2e2-4208-ab3a-943e315c7a17_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ab6b8db9-ccc3-4725-8353-292b89a9ad94_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_705118bf-1d0c-46ad-830b-224f9f2c9e6a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE CAPITAL</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_17f727ca-53dc-4da4-bf87-fd08376a338d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_84bbe797-1009-4239-aa79-f3e1ba929eaf_terseLabel_en-US" xlink:label="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental compensation costs, recognition period</link:label>
    <link:label id="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_label_en-US" xlink:label="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Unrecognized Costs, Recognition Period</link:label>
    <link:label id="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_documentation_en-US" xlink:label="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Unrecognized Costs, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:to="lab_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_408fa7e1-c1ed-467c-a5c0-fac250d74800_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_24f46f21-cac2-4488-8348-9424c3373f0b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_43604f35-5b1d-4d07-b7b1-92e45eb6b9e9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_47cdca4f-ad61-424c-8c8f-65d3ae839144_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5f66e85-a14d-4340-8d17-446d4a3d4d99_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_0bd2b2fd-ea14-40bd-81fa-957609e01abd_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_82171af9-dc90-4164-9116-e88ab7b8aec3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_314d6d94-5984-48d9-95c0-c7ab763f6d58_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of effects of businesses acquired:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_e44bf151-4fb1-4703-a874-71f3bd1fec60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental compensation cost</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_0e5bd3e8-442b-4a16-801d-f423c8334669_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_a5f42a43-6309-45d9-995d-f4bf40c1049f_negatedLabel_en-US" xlink:label="lab_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of stock awards to derivative liability</link:label>
    <link:label id="lab_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_722bd477-b223-4c18-93fb-e5b43b5e680f_terseLabel_en-US" xlink:label="lab_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital reclassified to derivate liabilities</link:label>
    <link:label id="lab_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_label_en-US" xlink:label="lab_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment, Modification of Terms, Incremental Compensation, Modification of Terms, Incremental Compensation Cost, Reclassified Adjustment</link:label>
    <link:label id="lab_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_documentation_en-US" xlink:label="lab_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The excess of the fair value of the modified award over the fair value of the award immediately before the modification pertaining grantees not employed or providing services after the modification and reclassified from additional paid-in capital to derivative liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:to="lab_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_23c99566-df6e-4665-b8a9-7f0f18bb73e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AtTheMarketOfferingMember_3474c953-589b-4149-8cd4-9f24efc3222d_terseLabel_en-US" xlink:label="lab_vyne_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Offering</link:label>
    <link:label id="lab_vyne_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_vyne_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Offering [Member]</link:label>
    <link:label id="lab_vyne_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_vyne_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AtTheMarketOfferingMember" xlink:href="vyne-20210630.xsd#vyne_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AtTheMarketOfferingMember" xlink:to="lab_vyne_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_878d31e4-cd4a-4cd1-8c1f-635e258e1700_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember_82269c3a-1535-4344-9ee3-bfe9d0f180e7_terseLabel_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Credit Agreement, Trench 3 Loan</link:label>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember_label_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Credit Agreement Trench3 Loan [Member]</link:label>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember_documentation_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents trench 3 loan of the Amended and Restated Credit Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:to="lab_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ccec5e1c-93c5-4ba0-b142-983953e80482_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_19c4b388-25cd-4fe4-84b9-3adf3e08bf61_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred expenses related to Credit Agreement and Securities Purchase Agreement</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_0061b8fb-a2b0-47f1-a282-5f8dc4b633f9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing and stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_42da23cd-4c5a-4061-be08-a50b0a4d3912_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocations of purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_NonCashAcquisitionOfBusinessCashAcquired_eb404063-6992-4663-8d2f-08fc5db08e59_terseLabel_en-US" xlink:label="lab_vyne_NonCashAcquisitionOfBusinessCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less cash acquired</link:label>
    <link:label id="lab_vyne_NonCashAcquisitionOfBusinessCashAcquired_label_en-US" xlink:label="lab_vyne_NonCashAcquisitionOfBusinessCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Acquisition Of Business, Cash Acquired</link:label>
    <link:label id="lab_vyne_NonCashAcquisitionOfBusinessCashAcquired_documentation_en-US" xlink:label="lab_vyne_NonCashAcquisitionOfBusinessCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash as part of a non-cash business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_NonCashAcquisitionOfBusinessCashAcquired" xlink:href="vyne-20210630.xsd#vyne_NonCashAcquisitionOfBusinessCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_NonCashAcquisitionOfBusinessCashAcquired" xlink:to="lab_vyne_NonCashAcquisitionOfBusinessCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_a1ccca22-b705-43d6-850f-d51747799317_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligation Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_RoyaltyPaymentPercentMaximum_0d4b66e9-b897-4e6d-86e2-a96e10ce9290_terseLabel_en-US" xlink:label="lab_vyne_RoyaltyPaymentPercentMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percent, maximum</link:label>
    <link:label id="lab_vyne_RoyaltyPaymentPercentMaximum_label_en-US" xlink:label="lab_vyne_RoyaltyPaymentPercentMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment, Percent, Maximum</link:label>
    <link:label id="lab_vyne_RoyaltyPaymentPercentMaximum_documentation_en-US" xlink:label="lab_vyne_RoyaltyPaymentPercentMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment, Percent, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RoyaltyPaymentPercentMaximum" xlink:href="vyne-20210630.xsd#vyne_RoyaltyPaymentPercentMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_RoyaltyPaymentPercentMaximum" xlink:to="lab_vyne_RoyaltyPaymentPercentMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_312295e3-fc71-4d4a-8d50-74ef66348a6c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_e42c4eae-c897-4dc8-9c41-bdb6b658ae11_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f04e20aa-4ded-4f36-a5c9-7e7ede10fe63_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_14b62c27-c754-47d4-a665-4f288ba27279_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_PaymentsForLicensingAgreements_e79a11fc-fb08-43b4-a586-9c4918a29367_terseLabel_en-US" xlink:label="lab_vyne_PaymentsForLicensingAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for licensing agreements</link:label>
    <link:label id="lab_vyne_PaymentsForLicensingAgreements_label_en-US" xlink:label="lab_vyne_PaymentsForLicensingAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Licensing Agreements</link:label>
    <link:label id="lab_vyne_PaymentsForLicensingAgreements_documentation_en-US" xlink:label="lab_vyne_PaymentsForLicensingAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Licensing Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PaymentsForLicensingAgreements" xlink:href="vyne-20210630.xsd#vyne_PaymentsForLicensingAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_PaymentsForLicensingAgreements" xlink:to="lab_vyne_PaymentsForLicensingAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_A2019PlanMember_186cd55d-d63e-4bf9-a293-11cb68a49782_terseLabel_en-US" xlink:label="lab_vyne_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:label id="lab_vyne_A2019PlanMember_label_en-US" xlink:label="lab_vyne_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan [Member]</link:label>
    <link:label id="lab_vyne_A2019PlanMember_documentation_en-US" xlink:label="lab_vyne_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_A2019PlanMember" xlink:href="vyne-20210630.xsd#vyne_A2019PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_A2019PlanMember" xlink:to="lab_vyne_A2019PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_7858b460-e6eb-4018-82cb-b06e11584ced_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in marketable securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f5159f24-a7fd-4c9e-8513-0b8a24f34043_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_553c754c-bff3-403a-a212-3120479ab8d2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4d316793-0250-4c91-b315-9016ae702d42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_cadb06e6-a4c8-4452-b060-e6f9aea30907_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f2b9a180-5714-4d17-9f41-7fedceca7e36_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_TopicalBETiOptionAgreementMember_8c74aab8-7f42-452e-8b5a-fde5f670b66e_terseLabel_en-US" xlink:label="lab_vyne_TopicalBETiOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Topical BETi Option Agreement</link:label>
    <link:label id="lab_vyne_TopicalBETiOptionAgreementMember_label_en-US" xlink:label="lab_vyne_TopicalBETiOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Topical BETi Option Agreement [Member]</link:label>
    <link:label id="lab_vyne_TopicalBETiOptionAgreementMember_documentation_en-US" xlink:label="lab_vyne_TopicalBETiOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Topical BETi Option Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_TopicalBETiOptionAgreementMember" xlink:href="vyne-20210630.xsd#vyne_TopicalBETiOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_TopicalBETiOptionAgreementMember" xlink:to="lab_vyne_TopicalBETiOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8be55ed1-42fa-4863-9343-2a3f020193d8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newly issued and recently adopted accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ff1660c9-59b7-42c9-b145-04fdca8c5627_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_6c644ff0-13c4-46e6-80e2-eea669ca309b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment assumptions for computing fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e8db07de-bceb-4fab-909c-52451f35adc0_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d25134fb-5557-4426-a210-77667390b4f4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_d0b8260a-c85c-4cc6-a702-69c44977e8c7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_6e0f228e-40be-4419-80ba-7178a2097331_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_RegisteredOfferingMember_e37697ac-59e2-49bb-9de7-f11fccdead9e_terseLabel_en-US" xlink:label="lab_vyne_RegisteredOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered offering per securities purchase agreement</link:label>
    <link:label id="lab_vyne_RegisteredOfferingMember_label_en-US" xlink:label="lab_vyne_RegisteredOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Offering [Member]</link:label>
    <link:label id="lab_vyne_RegisteredOfferingMember_documentation_en-US" xlink:label="lab_vyne_RegisteredOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of entity stock pursuant to a Securities Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RegisteredOfferingMember" xlink:href="vyne-20210630.xsd#vyne_RegisteredOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_RegisteredOfferingMember" xlink:to="lab_vyne_RegisteredOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_8608de4a-9209-4829-91c4-4ac7590517da_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_4008dfa7-f306-4869-9923-243e98f5555e_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_e6cc3ee4-255d-426e-9594-9f7a64aee57e_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a964f030-cb0a-4f18-8903-9b0478a1af7f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_983d9498-ad71-4471-9a39-5e626905801c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_859fd086-083c-423d-a90d-52c964740203_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember_f5e2ebdd-326b-47a5-8db9-dbd98922eb50_terseLabel_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Credit Agreement, Trench 2 Loan</link:label>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember_label_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Credit Agreement Trench2 Loan [Member]</link:label>
    <link:label id="lab_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember_documentation_en-US" xlink:label="lab_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents trench 2 loan of the Amended and Restated Credit Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:to="lab_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_cee647b6-574b-4877-b243-e81e74e58b6a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>vyne-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:40e9affd-2783-4e4a-bd7f-018d2dae4bf0,g:c708fe63-ab77-4120-b7ee-9a72ba48151c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/Cover" xlink:type="simple" xlink:href="vyne-20210630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_28005765-74a6-4aeb-a1ba-823fd8953b4e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_DocumentType_28005765-74a6-4aeb-a1ba-823fd8953b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f2eb85fb-fb49-48ee-85ed-aac761e8fb04" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_DocumentPeriodEndDate_f2eb85fb-fb49-48ee-85ed-aac761e8fb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4180609d-adb6-4a7b-a00b-b60e5ed9ee94" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_DocumentQuarterlyReport_4180609d-adb6-4a7b-a00b-b60e5ed9ee94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d850ba99-ce8f-43d8-9188-6338a6d068b6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_DocumentTransitionReport_d850ba99-ce8f-43d8-9188-6338a6d068b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ea9321cd-14c6-4589-b2cc-39fcafa4fff8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityFileNumber_ea9321cd-14c6-4589-b2cc-39fcafa4fff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_60002f62-19f6-4d14-9ddc-2ee40fb6ea83" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityRegistrantName_60002f62-19f6-4d14-9ddc-2ee40fb6ea83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a5d9dc7e-49e1-4514-9f10-d494b474a5b2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a5d9dc7e-49e1-4514-9f10-d494b474a5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8f177c5d-9f08-4a28-bed9-10a4068d794e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityTaxIdentificationNumber_8f177c5d-9f08-4a28-bed9-10a4068d794e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6274dfeb-3340-4bfd-9d99-745f7fd61b1b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityAddressAddressLine1_6274dfeb-3340-4bfd-9d99-745f7fd61b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1b9462ec-7f4b-4c0e-a826-2ce2816572ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityAddressCityOrTown_1b9462ec-7f4b-4c0e-a826-2ce2816572ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c7ae021b-7c2d-4bc4-adde-3144542ab1b0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityAddressStateOrProvince_c7ae021b-7c2d-4bc4-adde-3144542ab1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_11466221-c346-45b7-a6a9-1acc8e365185" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityAddressPostalZipCode_11466221-c346-45b7-a6a9-1acc8e365185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7b3c4c95-c251-4a3d-a5df-0b1a22b6054d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_CityAreaCode_7b3c4c95-c251-4a3d-a5df-0b1a22b6054d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d2cc8653-e5ee-4780-b21b-52a1ff992f72" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_LocalPhoneNumber_d2cc8653-e5ee-4780-b21b-52a1ff992f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_790638b1-c623-4a7b-8d2f-1d8755c2dded" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_Security12bTitle_790638b1-c623-4a7b-8d2f-1d8755c2dded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3fccd2f9-2722-4c24-8b63-dac03a8c214c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_TradingSymbol_3fccd2f9-2722-4c24-8b63-dac03a8c214c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ab517acb-3a7f-4e17-afc3-9fd209d2d017" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_SecurityExchangeName_ab517acb-3a7f-4e17-afc3-9fd209d2d017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_cc8f2f09-61ea-49f4-b9d0-c3054a8e0d22" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityCurrentReportingStatus_cc8f2f09-61ea-49f4-b9d0-c3054a8e0d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_adedb69b-b901-4bed-b798-b65dc57a0901" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityInteractiveDataCurrent_adedb69b-b901-4bed-b798-b65dc57a0901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f309ad37-69fd-4040-be1a-5955c3478aa1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityFilerCategory_f309ad37-69fd-4040-be1a-5955c3478aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dd52129d-f0ce-40b3-b6a9-dba4d7426cf3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntitySmallBusiness_dd52129d-f0ce-40b3-b6a9-dba4d7426cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_96e04349-1ecf-4b37-851c-d0d402ec48af" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityEmergingGrowthCompany_96e04349-1ecf-4b37-851c-d0d402ec48af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_89844639-b58e-4283-afba-943342300339" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityShellCompany_89844639-b58e-4283-afba-943342300339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_37dd956c-9918-4b02-8c9e-5c9b591955bd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityCentralIndexKey_37dd956c-9918-4b02-8c9e-5c9b591955bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d828c0e1-ecb6-45dc-831c-f85a199e1c70" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_CurrentFiscalYearEndDate_d828c0e1-ecb6-45dc-831c-f85a199e1c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ee3d8dde-ca1c-4731-aa35-1546d647b84f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_DocumentFiscalYearFocus_ee3d8dde-ca1c-4731-aa35-1546d647b84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_48baa62e-e28e-4017-84ce-235a0157ac90" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_DocumentFiscalPeriodFocus_48baa62e-e28e-4017-84ce-235a0157ac90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d4945865-6250-439b-a02d-123649b7d479" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_AmendmentFlag_d4945865-6250-439b-a02d-123649b7d479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_b1e6c938-1cc6-44fa-bf46-8a962854d3b9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityExTransitionPeriod_b1e6c938-1cc6-44fa-bf46-8a962854d3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3f3a9425-2307-43d3-9ee9-fe644c6bc0cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab126516-177b-42ff-8b2d-27837d65e469" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3f3a9425-2307-43d3-9ee9-fe644c6bc0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bdbe32b3-cd29-41ea-a1c2-0c645d2f989b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3994eb16-d57a-4de3-b140-20570af68e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bdbe32b3-cd29-41ea-a1c2-0c645d2f989b" xlink:to="loc_us-gaap_AssetsAbstract_3994eb16-d57a-4de3-b140-20570af68e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d42242cc-64e1-4732-8a1c-371954e75215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3994eb16-d57a-4de3-b140-20570af68e8e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d42242cc-64e1-4732-8a1c-371954e75215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6de65c1-1622-4412-8354-54c8106fd12e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d42242cc-64e1-4732-8a1c-371954e75215" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6de65c1-1622-4412-8354-54c8106fd12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_77329d62-c55e-4f56-82d2-3480d25543be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d42242cc-64e1-4732-8a1c-371954e75215" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_77329d62-c55e-4f56-82d2-3480d25543be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e1238bca-ed7d-4376-a6e3-ff845a8b8255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d42242cc-64e1-4732-8a1c-371954e75215" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e1238bca-ed7d-4376-a6e3-ff845a8b8255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_846702c6-5fb6-4334-bd4d-5e33ca02ee63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d42242cc-64e1-4732-8a1c-371954e75215" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_846702c6-5fb6-4334-bd4d-5e33ca02ee63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09a6e26e-7c9f-41d6-8584-8ada471dae55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d42242cc-64e1-4732-8a1c-371954e75215" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09a6e26e-7c9f-41d6-8584-8ada471dae55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a5a3b7d9-8791-4933-9567-bba9aa441bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d42242cc-64e1-4732-8a1c-371954e75215" xlink:to="loc_us-gaap_InventoryNet_a5a3b7d9-8791-4933-9567-bba9aa441bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4de810ea-7e23-48b1-9426-cee825960f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d42242cc-64e1-4732-8a1c-371954e75215" xlink:to="loc_us-gaap_AssetsCurrent_4de810ea-7e23-48b1-9426-cee825960f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9175e45b-1e93-45b8-808e-e77a7fd18e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3994eb16-d57a-4de3-b140-20570af68e8e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9175e45b-1e93-45b8-808e-e77a7fd18e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4aa8170e-b8fa-4fc5-aa78-8b27c44e27d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3994eb16-d57a-4de3-b140-20570af68e8e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4aa8170e-b8fa-4fc5-aa78-8b27c44e27d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_8468cd40-5262-4daf-8deb-92629651e280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3994eb16-d57a-4de3-b140-20570af68e8e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_8468cd40-5262-4daf-8deb-92629651e280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5c88f091-ddba-40b5-97c8-cccf679fe115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3994eb16-d57a-4de3-b140-20570af68e8e" xlink:to="loc_us-gaap_Assets_5c88f091-ddba-40b5-97c8-cccf679fe115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bdbe32b3-cd29-41ea-a1c2-0c645d2f989b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d22f3875-837e-4b78-89c3-061d751b32cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d22f3875-837e-4b78-89c3-061d751b32cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_4056a38b-eee0-472a-9d5f-21b4f215600a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d22f3875-837e-4b78-89c3-061d751b32cd" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_4056a38b-eee0-472a-9d5f-21b4f215600a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8e2b8f42-dbcd-4629-8836-ee06faf9fd75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d22f3875-837e-4b78-89c3-061d751b32cd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8e2b8f42-dbcd-4629-8836-ee06faf9fd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ffda19bb-f282-4443-bde5-69b67a0f2f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d22f3875-837e-4b78-89c3-061d751b32cd" xlink:to="loc_us-gaap_LongTermDebtCurrent_ffda19bb-f282-4443-bde5-69b67a0f2f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_74a0f3fa-fef9-456a-8025-af541518a6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d22f3875-837e-4b78-89c3-061d751b32cd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_74a0f3fa-fef9-456a-8025-af541518a6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b8e22159-93b6-4c17-8835-adf8a79bccfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d22f3875-837e-4b78-89c3-061d751b32cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b8e22159-93b6-4c17-8835-adf8a79bccfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8b8a312c-35a5-4599-aa82-41b4d859f775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d22f3875-837e-4b78-89c3-061d751b32cd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8b8a312c-35a5-4599-aa82-41b4d859f775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3191cbe5-e791-457e-987c-6af6115a1ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d22f3875-837e-4b78-89c3-061d751b32cd" xlink:to="loc_us-gaap_LiabilitiesCurrent_3191cbe5-e791-457e-987c-6af6115a1ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_82a684f8-3d95-4276-ad36-1ea3b50d2b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_82a684f8-3d95-4276-ad36-1ea3b50d2b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d9537965-1b4a-4f97-b0ce-e90912976e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d9537965-1b4a-4f97-b0ce-e90912976e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ad48e1a5-2ac0-4131-950f-30d1691ff4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ad48e1a5-2ac0-4131-950f-30d1691ff4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_101608fa-2edc-4946-921a-77e6eb03caa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:to="loc_us-gaap_OtherLiabilities_101608fa-2edc-4946-921a-77e6eb03caa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_160f98e4-3dd4-4051-b13d-65994dd1b2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:to="loc_us-gaap_Liabilities_160f98e4-3dd4-4051-b13d-65994dd1b2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_412a9e33-1cab-4419-b288-b6fb59fee2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:to="loc_us-gaap_CommitmentsAndContingencies_412a9e33-1cab-4419-b288-b6fb59fee2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_24a83dfc-a499-4621-969a-461ab5ec558f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:to="loc_us-gaap_StockholdersEquityAbstract_24a83dfc-a499-4621-969a-461ab5ec558f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a3d686ad-b022-4a28-b15f-610ab8833e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_24a83dfc-a499-4621-969a-461ab5ec558f" xlink:to="loc_us-gaap_PreferredStockValue_a3d686ad-b022-4a28-b15f-610ab8833e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_768e5e04-1422-46d0-a143-5967bcfca50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_24a83dfc-a499-4621-969a-461ab5ec558f" xlink:to="loc_us-gaap_CommonStockValue_768e5e04-1422-46d0-a143-5967bcfca50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ae965e3a-77aa-48fa-8812-f1132991df43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_24a83dfc-a499-4621-969a-461ab5ec558f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ae965e3a-77aa-48fa-8812-f1132991df43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14e845dc-1ecd-41d8-be29-8a4e0ad5a65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_24a83dfc-a499-4621-969a-461ab5ec558f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14e845dc-1ecd-41d8-be29-8a4e0ad5a65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_38c5e637-6a38-4558-8406-33958c0ccf78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_24a83dfc-a499-4621-969a-461ab5ec558f" xlink:to="loc_us-gaap_StockholdersEquity_38c5e637-6a38-4558-8406-33958c0ccf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1cc33608-89fa-4454-bca4-c721340c0251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1bdcce42-e1e7-4dfa-b477-f1998c256047" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1cc33608-89fa-4454-bca4-c721340c0251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_157f586a-2720-4e9e-921a-214939eb337b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ec17d59d-0733-44c8-a120-6aadff6a4365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_157f586a-2720-4e9e-921a-214939eb337b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ec17d59d-0733-44c8-a120-6aadff6a4365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d8745b1a-9117-47d1-b0f3-b59b266f6d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_157f586a-2720-4e9e-921a-214939eb337b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d8745b1a-9117-47d1-b0f3-b59b266f6d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_a14e3dcb-8c91-48a1-91fb-601b3f3a9050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_157f586a-2720-4e9e-921a-214939eb337b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_a14e3dcb-8c91-48a1-91fb-601b3f3a9050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7e9d5244-3a37-454a-8687-362fc7f397c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_157f586a-2720-4e9e-921a-214939eb337b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7e9d5244-3a37-454a-8687-362fc7f397c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9a17b488-a29f-4f56-82f4-f0c529d90a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_157f586a-2720-4e9e-921a-214939eb337b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9a17b488-a29f-4f56-82f4-f0c529d90a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c0417604-251b-4b74-b38c-b36a2e0a6155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_157f586a-2720-4e9e-921a-214939eb337b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c0417604-251b-4b74-b38c-b36a2e0a6155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4b0ac2c8-7fca-4977-a3b8-23b444397d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_157f586a-2720-4e9e-921a-214939eb337b" xlink:to="loc_us-gaap_CommonStockSharesIssued_4b0ac2c8-7fca-4977-a3b8-23b444397d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8fd3d50d-27dd-475b-8e10-e199c0e1491b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_157f586a-2720-4e9e-921a-214939eb337b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8fd3d50d-27dd-475b-8e10-e199c0e1491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_19efc1f7-11f0-449d-92c9-69f10ba8af01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_29a31621-d3f3-4b3f-9c4f-a05d443ea2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_19efc1f7-11f0-449d-92c9-69f10ba8af01" xlink:to="loc_us-gaap_StatementTable_29a31621-d3f3-4b3f-9c4f-a05d443ea2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e8240c1-65bb-4c7a-8b3a-da86b8661887" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29a31621-d3f3-4b3f-9c4f-a05d443ea2fc" xlink:to="loc_srt_ProductOrServiceAxis_8e8240c1-65bb-4c7a-8b3a-da86b8661887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_473550a7-230c-4cdd-b700-23099b61c4b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8e8240c1-65bb-4c7a-8b3a-da86b8661887" xlink:to="loc_srt_ProductsAndServicesDomain_473550a7-230c-4cdd-b700-23099b61c4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5e14b8d8-572a-4763-99f7-a9bae66e25ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_473550a7-230c-4cdd-b700-23099b61c4b7" xlink:to="loc_us-gaap_ProductMember_5e14b8d8-572a-4763-99f7-a9bae66e25ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b08897fc-f4bb-4cab-8574-52f1494f0fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_473550a7-230c-4cdd-b700-23099b61c4b7" xlink:to="loc_us-gaap_LicenseMember_b08897fc-f4bb-4cab-8574-52f1494f0fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_6c2df47c-3db1-4fa6-bcd7-59356217fc98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_473550a7-230c-4cdd-b700-23099b61c4b7" xlink:to="loc_us-gaap_RoyaltyMember_6c2df47c-3db1-4fa6-bcd7-59356217fc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29a31621-d3f3-4b3f-9c4f-a05d443ea2fc" xlink:to="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_86d08bf7-2dac-433e-b049-a4004f2cd7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_86d08bf7-2dac-433e-b049-a4004f2cd7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_78dd1908-a552-457a-b03a-8b108d629206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_78dd1908-a552-457a-b03a-8b108d629206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_74306271-6d66-4345-8cb0-8772d3904382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_74306271-6d66-4345-8cb0-8772d3904382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6a604ff1-ca9f-4d78-ba9b-85d9e4ce4254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6a604ff1-ca9f-4d78-ba9b-85d9e4ce4254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_b5a6972a-ed78-479f-abfb-8ded4968a102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_b5a6972a-ed78-479f-abfb-8ded4968a102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_809e8e9c-fd81-466f-bc88-7809b85bb41f" xlink:href="vyne-20210630.xsd#vyne_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:to="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_809e8e9c-fd81-466f-bc88-7809b85bb41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0208847d-8737-4540-bbdf-7f08c3fbff70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0b396de6-294a-400c-be40-59b657f7daaa" xlink:to="loc_us-gaap_CostsAndExpenses_0208847d-8737-4540-bbdf-7f08c3fbff70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_84fe7126-6d58-4120-9206-1d6b6470a91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_OperatingIncomeLoss_84fe7126-6d58-4120-9206-1d6b6470a91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a2446c45-ec37-4c33-a9e5-570afcd8d4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_InterestExpense_a2446c45-ec37-4c33-a9e5-570afcd8d4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_56dc6105-35a9-49f1-a645-711d6b95b1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_56dc6105-35a9-49f1-a645-711d6b95b1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d296d64a-b084-4191-9f04-196872f85370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d296d64a-b084-4191-9f04-196872f85370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_aa9cfddf-b493-4350-9ca5-a1d6d3f21040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_aa9cfddf-b493-4350-9ca5-a1d6d3f21040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1277bd09-7522-4fc9-97c7-c4147493779c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_NetIncomeLoss_1277bd09-7522-4fc9-97c7-c4147493779c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_94966dd9-c939-4130-b8fa-1f2a41a2231b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_EarningsPerShareBasic_94966dd9-c939-4130-b8fa-1f2a41a2231b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c8f7a0bb-8804-49f0-bf3f-2ab3dc29a1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c8f7a0bb-8804-49f0-bf3f-2ab3dc29a1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8b3464a8-9b25-45aa-b4a0-2d6ee5dbfa8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8b3464a8-9b25-45aa-b4a0-2d6ee5dbfa8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_87006751-5594-4764-becd-f09135826e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_937b94b8-1523-4473-8ca1-cf66d3c9dc9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_87006751-5594-4764-becd-f09135826e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b4e58bd-f939-46d7-89b1-7ce2f3c57011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_99c5fd42-45b0-402a-b35b-b74dd139f6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b4e58bd-f939-46d7-89b1-7ce2f3c57011" xlink:to="loc_us-gaap_NetIncomeLoss_99c5fd42-45b0-402a-b35b-b74dd139f6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6554480a-949e-46a0-b0a8-7f16a2b3ddbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b4e58bd-f939-46d7-89b1-7ce2f3c57011" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6554480a-949e-46a0-b0a8-7f16a2b3ddbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_cb47f26f-8597-4a31-a994-4de1187c6a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6554480a-949e-46a0-b0a8-7f16a2b3ddbb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_cb47f26f-8597-4a31-a994-4de1187c6a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_55485488-bf9a-4652-90e6-6ca1392f7dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6554480a-949e-46a0-b0a8-7f16a2b3ddbb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_55485488-bf9a-4652-90e6-6ca1392f7dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ff5fb030-2e25-41f3-8e06-6dd9d6d232a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6554480a-949e-46a0-b0a8-7f16a2b3ddbb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ff5fb030-2e25-41f3-8e06-6dd9d6d232a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a1a23540-5af1-4bf3-9713-4b6412f20cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b4e58bd-f939-46d7-89b1-7ce2f3c57011" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a1a23540-5af1-4bf3-9713-4b6412f20cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0d3bfa52-78e1-40ad-89e8-9272d5bdd9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_71f962d3-4da9-4913-bff2-b999df5e91d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0d3bfa52-78e1-40ad-89e8-9272d5bdd9d9" xlink:to="loc_us-gaap_StatementTable_71f962d3-4da9-4913-bff2-b999df5e91d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9c867ee9-f7b2-4f55-be9b-beb4843c5859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71f962d3-4da9-4913-bff2-b999df5e91d1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9c867ee9-f7b2-4f55-be9b-beb4843c5859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c867ee9-f7b2-4f55-be9b-beb4843c5859" xlink:to="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_978ad166-58ff-45d6-91b6-9eeb83e9613f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:to="loc_us-gaap_CommonStockMember_978ad166-58ff-45d6-91b6-9eeb83e9613f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_67e60265-92d4-48ac-bb43-c358f1ee393e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_67e60265-92d4-48ac-bb43-c358f1ee393e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b9d5e207-6624-497d-a233-ef6b227d8acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:to="loc_us-gaap_RetainedEarningsMember_b9d5e207-6624-497d-a233-ef6b227d8acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c10fbf2d-67e8-45b5-a78c-9df22da3fd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0333820b-cf87-4826-a5c8-920d7af70305" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c10fbf2d-67e8-45b5-a78c-9df22da3fd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_94cdbc90-c1ed-4e89-b8e1-0ea3d85398b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71f962d3-4da9-4913-bff2-b999df5e91d1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_94cdbc90-c1ed-4e89-b8e1-0ea3d85398b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fb51372-6957-43d0-adeb-8c02f1bdc899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_94cdbc90-c1ed-4e89-b8e1-0ea3d85398b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fb51372-6957-43d0-adeb-8c02f1bdc899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AtTheMarketOfferingMember_ce4ad014-d877-4f50-9232-b2c1462606be" xlink:href="vyne-20210630.xsd#vyne_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fb51372-6957-43d0-adeb-8c02f1bdc899" xlink:to="loc_vyne_AtTheMarketOfferingMember_ce4ad014-d877-4f50-9232-b2c1462606be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PublicOfferingMember_d03aad58-2a49-4f42-8214-90a2b23e8abd" xlink:href="vyne-20210630.xsd#vyne_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fb51372-6957-43d0-adeb-8c02f1bdc899" xlink:to="loc_vyne_PublicOfferingMember_d03aad58-2a49-4f42-8214-90a2b23e8abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ae840ad1-9219-4ab7-a390-6c601b461383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71f962d3-4da9-4913-bff2-b999df5e91d1" xlink:to="loc_us-gaap_StatementLineItems_ae840ad1-9219-4ab7-a390-6c601b461383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ae840ad1-9219-4ab7-a390-6c601b461383" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ad139995-fd72-47cd-a1bd-93c5a074df8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockholdersEquity_ad139995-fd72-47cd-a1bd-93c5a074df8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_30e7891f-4352-484e-b170-dbd1cd4298bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_30e7891f-4352-484e-b170-dbd1cd4298bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_27a00f63-7e54-4616-af2f-0f9cfa613e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_27a00f63-7e54-4616-af2f-0f9cfa613e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_afb47b97-6cd7-460c-a2bd-6bd75ae14f14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_afb47b97-6cd7-460c-a2bd-6bd75ae14f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d2b1740-5892-489e-be02-9ead903b4d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d2b1740-5892-489e-be02-9ead903b4d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_9157f91a-d687-4ef7-beaf-6d1bb2840f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_9157f91a-d687-4ef7-beaf-6d1bb2840f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_e9f90fff-8bea-486e-9e3d-52ebd6fadc0c" xlink:href="vyne-20210630.xsd#vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_e9f90fff-8bea-486e-9e3d-52ebd6fadc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_010b1177-8bcb-4276-a792-f0fdcdd00c6c" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_010b1177-8bcb-4276-a792-f0fdcdd00c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cf91e8d5-e537-4442-8c98-cb45e1e6b6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cf91e8d5-e537-4442-8c98-cb45e1e6b6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7c5c773d-fa5a-49ad-89dc-c25f5328988a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7c5c773d-fa5a-49ad-89dc-c25f5328988a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_0aa9a457-c8b9-4138-82d6-767a1a937e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_0aa9a457-c8b9-4138-82d6-767a1a937e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_347f20a5-0983-4908-8a2d-a0627173ea83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_347f20a5-0983-4908-8a2d-a0627173ea83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_865ea829-1e63-441f-a741-bb0550669cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_StockholdersEquity_865ea829-1e63-441f-a741-bb0550669cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_83507679-8964-4111-af6b-f3191b82f8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f410f4f2-c02c-42cd-89c9-309d8a13b5b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_83507679-8964-4111-af6b-f3191b82f8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_74099d37-1a7f-4793-a1dc-f09fd72685c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ddd488f0-9701-4052-81a5-9c367cf07fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_74099d37-1a7f-4793-a1dc-f09fd72685c7" xlink:to="loc_us-gaap_StatementTable_ddd488f0-9701-4052-81a5-9c367cf07fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6af0f4a4-0c28-4ef5-8281-00bf61c5cc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ddd488f0-9701-4052-81a5-9c367cf07fd3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6af0f4a4-0c28-4ef5-8281-00bf61c5cc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3230cfbf-952a-4af6-8bb3-4578c0c914ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6af0f4a4-0c28-4ef5-8281-00bf61c5cc1f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3230cfbf-952a-4af6-8bb3-4578c0c914ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AtTheMarketOfferingMember_dc1145a0-54bc-4aba-af2a-bcc8e9aead0e" xlink:href="vyne-20210630.xsd#vyne_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3230cfbf-952a-4af6-8bb3-4578c0c914ec" xlink:to="loc_vyne_AtTheMarketOfferingMember_dc1145a0-54bc-4aba-af2a-bcc8e9aead0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PublicOfferingMember_690d9820-1c17-46f1-b01c-a2788dbabc1e" xlink:href="vyne-20210630.xsd#vyne_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3230cfbf-952a-4af6-8bb3-4578c0c914ec" xlink:to="loc_vyne_PublicOfferingMember_690d9820-1c17-46f1-b01c-a2788dbabc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c40eb14a-7a1e-49df-9c41-abc2e7f90341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ddd488f0-9701-4052-81a5-9c367cf07fd3" xlink:to="loc_us-gaap_StatementLineItems_c40eb14a-7a1e-49df-9c41-abc2e7f90341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a9b25d07-532c-41fb-8d12-ae75f1f243d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c40eb14a-7a1e-49df-9c41-abc2e7f90341" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a9b25d07-532c-41fb-8d12-ae75f1f243d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vyne-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d4e5ec41-22c3-416e-9760-18c455fd2c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d4e5ec41-22c3-416e-9760-18c455fd2c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20536aa7-1960-4379-9c9a-6e48858aad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d4e5ec41-22c3-416e-9760-18c455fd2c10" xlink:to="loc_us-gaap_NetIncomeLoss_20536aa7-1960-4379-9c9a-6e48858aad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edf0812f-b401-466b-9ecd-b5d07fc00b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d4e5ec41-22c3-416e-9760-18c455fd2c10" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edf0812f-b401-466b-9ecd-b5d07fc00b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b110ccfe-cb4a-4739-8f45-0584eeceb26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edf0812f-b401-466b-9ecd-b5d07fc00b68" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b110ccfe-cb4a-4739-8f45-0584eeceb26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_caaf8cc0-f329-4d83-ac3e-9912831fcf10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edf0812f-b401-466b-9ecd-b5d07fc00b68" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_caaf8cc0-f329-4d83-ac3e-9912831fcf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_00e6f284-7b2a-4c0b-afb4-fc5b5d7cd0be" xlink:href="vyne-20210630.xsd#vyne_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edf0812f-b401-466b-9ecd-b5d07fc00b68" xlink:to="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_00e6f284-7b2a-4c0b-afb4-fc5b5d7cd0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_7c2211cb-9477-47d2-bf31-cefe235bcfda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edf0812f-b401-466b-9ecd-b5d07fc00b68" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_7c2211cb-9477-47d2-bf31-cefe235bcfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_6b2e44e1-f72d-45a4-b4c0-1b7c366897a7" xlink:href="vyne-20210630.xsd#vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edf0812f-b401-466b-9ecd-b5d07fc00b68" xlink:to="loc_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_6b2e44e1-f72d-45a4-b4c0-1b7c366897a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1ed3f546-87fa-4465-a80a-4ee4631af9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edf0812f-b401-466b-9ecd-b5d07fc00b68" xlink:to="loc_us-gaap_ShareBasedCompensation_1ed3f546-87fa-4465-a80a-4ee4631af9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f687875b-6e20-4f0a-a0c9-81f79105a157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_edf0812f-b401-466b-9ecd-b5d07fc00b68" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f687875b-6e20-4f0a-a0c9-81f79105a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2f5303b5-1c64-4e23-b6bb-a3f499d4ae5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d4e5ec41-22c3-416e-9760-18c455fd2c10" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2f5303b5-1c64-4e23-b6bb-a3f499d4ae5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_de9cfb5e-86bc-4223-8e0b-c85b02583aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2f5303b5-1c64-4e23-b6bb-a3f499d4ae5e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_de9cfb5e-86bc-4223-8e0b-c85b02583aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f7dde37c-9f82-4112-bd1c-aff6dfb4b7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2f5303b5-1c64-4e23-b6bb-a3f499d4ae5e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f7dde37c-9f82-4112-bd1c-aff6dfb4b7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_45718fad-79e3-4c26-a6c2-f2a6b847e0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2f5303b5-1c64-4e23-b6bb-a3f499d4ae5e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_45718fad-79e3-4c26-a6c2-f2a6b847e0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1ebdbac6-1336-4834-bdda-5647413de449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2f5303b5-1c64-4e23-b6bb-a3f499d4ae5e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1ebdbac6-1336-4834-bdda-5647413de449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e78d590-5811-4076-9d16-af4f1efc1749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_d4e5ec41-22c3-416e-9760-18c455fd2c10" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5e78d590-5811-4076-9d16-af4f1efc1749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c15d9584-1745-437b-ae45-78f26c5c495b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c15d9584-1745-437b-ae45-78f26c5c495b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_43766bfb-7922-45ed-a587-52fc555be029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c15d9584-1745-437b-ae45-78f26c5c495b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_43766bfb-7922-45ed-a587-52fc555be029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ProceedsFromBusinessMerger_25a8196c-b835-49a9-ba1e-513bbdacbe30" xlink:href="vyne-20210630.xsd#vyne_ProceedsFromBusinessMerger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c15d9584-1745-437b-ae45-78f26c5c495b" xlink:to="loc_vyne_ProceedsFromBusinessMerger_25a8196c-b835-49a9-ba1e-513bbdacbe30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1ce0b9ff-e91c-4b93-88a7-b36de75738f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c15d9584-1745-437b-ae45-78f26c5c495b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_1ce0b9ff-e91c-4b93-88a7-b36de75738f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d83b95aa-50a8-434c-a66b-bcd955be725d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c15d9584-1745-437b-ae45-78f26c5c495b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d83b95aa-50a8-434c-a66b-bcd955be725d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_782c909a-7816-49e6-a525-9e8356237d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_782c909a-7816-49e6-a525-9e8356237d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b9f5afd2-39f8-4aab-81be-19179ed57d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_782c909a-7816-49e6-a525-9e8356237d3e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b9f5afd2-39f8-4aab-81be-19179ed57d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6104657c-08cb-4938-9571-42f63c87892f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_782c909a-7816-49e6-a525-9e8356237d3e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6104657c-08cb-4938-9571-42f63c87892f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109cb2c4-728e-403c-bd7a-1599aefa7c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_782c909a-7816-49e6-a525-9e8356237d3e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109cb2c4-728e-403c-bd7a-1599aefa7c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0397e853-ce89-4b5b-876c-91dc4205e807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0397e853-ce89-4b5b-876c-91dc4205e807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cf205f0-a5c3-42bd-92eb-bbb978a3333b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cf205f0-a5c3-42bd-92eb-bbb978a3333b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b1dddc27-d277-4221-8f1b-f263903e5b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b1dddc27-d277-4221-8f1b-f263903e5b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e42d29e2-f41a-4862-8ec7-c3fcb8e9ce4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e42d29e2-f41a-4862-8ec7-c3fcb8e9ce4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5745ac87-74b5-4558-bd79-f88e0eba2994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5745ac87-74b5-4558-bd79-f88e0eba2994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_cee97b62-8622-4480-a358-f58d62c9b23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_cee97b62-8622-4480-a358-f58d62c9b23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43ba7b74-a414-46b9-9182-627bd9e2fec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43ba7b74-a414-46b9-9182-627bd9e2fec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_712792d2-1150-463b-94ad-0614a63f881c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_712792d2-1150-463b-94ad-0614a63f881c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_0e89b644-c6e0-4b00-badf-29f773d169a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_712792d2-1150-463b-94ad-0614a63f881c" xlink:to="loc_us-gaap_StockIssued1_0e89b644-c6e0-4b00-badf-29f773d169a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4c190d81-c71e-4657-9897-1bc3ea979032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_712792d2-1150-463b-94ad-0614a63f881c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4c190d81-c71e-4657-9897-1bc3ea979032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_fd0fa680-6564-4ab1-b9e7-ee7f63e38ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_712792d2-1150-463b-94ad-0614a63f881c" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_fd0fa680-6564-4ab1-b9e7-ee7f63e38ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b82458a0-e387-4440-8cb8-7c76d7900d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2bf37b2c-c0b1-4583-a598-17dc0ee68903" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b82458a0-e387-4440-8cb8-7c76d7900d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_InterestReceived_d12c4db3-5216-4036-af81-93f6fb3e74be" xlink:href="vyne-20210630.xsd#vyne_InterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b82458a0-e387-4440-8cb8-7c76d7900d1f" xlink:to="loc_vyne_InterestReceived_d12c4db3-5216-4036-af81-93f6fb3e74be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_93758957-c499-48e8-9b7b-ef038e60e87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b82458a0-e387-4440-8cb8-7c76d7900d1f" xlink:to="loc_us-gaap_InterestPaidNet_93758957-c499-48e8-9b7b-ef038e60e87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_d36eac3b-ef27-49e7-bff6-e53d3e3df1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b82458a0-e387-4440-8cb8-7c76d7900d1f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_d36eac3b-ef27-49e7-bff6-e53d3e3df1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_f331f8ce-eeb4-46e0-958f-a97dde02781b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b82458a0-e387-4440-8cb8-7c76d7900d1f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_f331f8ce-eeb4-46e0-958f-a97dde02781b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_f4558083-043e-41f7-9fc1-aab6cd790059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b82458a0-e387-4440-8cb8-7c76d7900d1f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_f4558083-043e-41f7-9fc1-aab6cd790059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_NonCashAcquisitionOfBusinessCashAcquired_6f6d9008-48cf-4652-8c68-4814798d7fa5" xlink:href="vyne-20210630.xsd#vyne_NonCashAcquisitionOfBusinessCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b82458a0-e387-4440-8cb8-7c76d7900d1f" xlink:to="loc_vyne_NonCashAcquisitionOfBusinessCashAcquired_6f6d9008-48cf-4652-8c68-4814798d7fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_b56aa4d3-f351-4112-ab6a-bd40fb69d59b" xlink:href="vyne-20210630.xsd#vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b82458a0-e387-4440-8cb8-7c76d7900d1f" xlink:to="loc_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_b56aa4d3-f351-4112-ab6a-bd40fb69d59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS" xlink:type="simple" xlink:href="vyne-20210630.xsd#NATUREOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_940b8ed0-2343-4a2d-b2c6-c26cb22b1faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_e991baf1-2386-42f0-9c82-b944715c04c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_940b8ed0-2343-4a2d-b2c6-c26cb22b1faa" xlink:to="loc_us-gaap_NatureOfOperations_e991baf1-2386-42f0-9c82-b944715c04c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#NATUREOFOPERATIONSDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6e6f0602-f34a-4dc8-9af8-4085f8bb2194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6e6f0602-f34a-4dc8-9af8-4085f8bb2194" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_59135a85-19f2-4c47-bcdc-933355fb0d6e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_dei_LegalEntityAxis_59135a85-19f2-4c47-bcdc-933355fb0d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_47633c75-b769-4059-9a65-e1383541b5ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_59135a85-19f2-4c47-bcdc-933355fb0d6e" xlink:to="loc_dei_EntityDomain_47633c75-b769-4059-9a65-e1383541b5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_MenloPremergerMember_9e7b3d2a-1fdb-4e67-9062-67215b8cd8f2" xlink:href="vyne-20210630.xsd#vyne_MenloPremergerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_47633c75-b769-4059-9a65-e1383541b5ce" xlink:to="loc_vyne_MenloPremergerMember_9e7b3d2a-1fdb-4e67-9062-67215b8cd8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_13eb3052-e39d-461f-b6c3-858d83e357df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_us-gaap_TypeOfArrangementAxis_13eb3052-e39d-461f-b6c3-858d83e357df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d655a2e-8894-4eb1-abb8-25682bf5ff25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_13eb3052-e39d-461f-b6c3-858d83e357df" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d655a2e-8894-4eb1-abb8-25682bf5ff25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_66fced2d-ee42-4052-881b-93a833bb6797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d655a2e-8894-4eb1-abb8-25682bf5ff25" xlink:to="loc_us-gaap_LicensingAgreementsMember_66fced2d-ee42-4052-881b-93a833bb6797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_TopicalBETiOptionAgreementMember_6cb5e719-1a31-4cac-8612-c96b1e2eceea" xlink:href="vyne-20210630.xsd#vyne_TopicalBETiOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LicensingAgreementsMember_66fced2d-ee42-4052-881b-93a833bb6797" xlink:to="loc_vyne_TopicalBETiOptionAgreementMember_6cb5e719-1a31-4cac-8612-c96b1e2eceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_OralBETiOptionAgreementMember_f6408447-a611-4bfb-bd95-a79af1c5fa11" xlink:href="vyne-20210630.xsd#vyne_OralBETiOptionAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LicensingAgreementsMember_66fced2d-ee42-4052-881b-93a833bb6797" xlink:to="loc_vyne_OralBETiOptionAgreementMember_f6408447-a611-4bfb-bd95-a79af1c5fa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_89c4b93d-355d-4ecf-93ee-3238945497bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_89c4b93d-355d-4ecf-93ee-3238945497bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_566f16f3-047e-4a25-901b-f5b9e055a847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_89c4b93d-355d-4ecf-93ee-3238945497bd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_566f16f3-047e-4a25-901b-f5b9e055a847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a4734997-b686-4002-8273-61fc4ff50726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_566f16f3-047e-4a25-901b-f5b9e055a847" xlink:to="loc_us-gaap_SubsequentEventMember_a4734997-b686-4002-8273-61fc4ff50726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_ee13cb50-f08a-4f63-a7ab-09e80703a437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_ee13cb50-f08a-4f63-a7ab-09e80703a437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a4bdcb02-984a-4dfc-8bf6-cfa9d0e96fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ee13cb50-f08a-4f63-a7ab-09e80703a437" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a4bdcb02-984a-4dfc-8bf6-cfa9d0e96fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_dba180ce-7019-4aae-9410-eb0eb04186a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a4bdcb02-984a-4dfc-8bf6-cfa9d0e96fab" xlink:to="loc_us-gaap_EmployeeSeveranceMember_dba180ce-7019-4aae-9410-eb0eb04186a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_deffbdf0-7e1b-4998-ba92-06769fd6da5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_srt_RangeAxis_deffbdf0-7e1b-4998-ba92-06769fd6da5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f1c3ba32-2889-43af-8681-0893b8084f79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_deffbdf0-7e1b-4998-ba92-06769fd6da5d" xlink:to="loc_srt_RangeMember_f1c3ba32-2889-43af-8681-0893b8084f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_36cd00ec-5cf2-424e-8463-e800d6467100" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f1c3ba32-2889-43af-8681-0893b8084f79" xlink:to="loc_srt_MinimumMember_36cd00ec-5cf2-424e-8463-e800d6467100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_390bba86-7b7d-4ac7-85b1-1d81dc9a15e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f1c3ba32-2889-43af-8681-0893b8084f79" xlink:to="loc_srt_MaximumMember_390bba86-7b7d-4ac7-85b1-1d81dc9a15e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_acba8061-241e-4bfe-88d0-163a51034eb4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_srt_StatementScenarioAxis_acba8061-241e-4bfe-88d0-163a51034eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b4085a48-63ef-41fd-b3d7-26f83ee4c285" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_acba8061-241e-4bfe-88d0-163a51034eb4" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b4085a48-63ef-41fd-b3d7-26f83ee4c285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5c822415-a846-4b13-aead-a0761b7e1583" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b4085a48-63ef-41fd-b3d7-26f83ee4c285" xlink:to="loc_srt_ScenarioForecastMember_5c822415-a846-4b13-aead-a0761b7e1583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9eba8074-4733-4564-bcf9-ad6996f32a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_us-gaap_DebtInstrumentAxis_9eba8074-4733-4564-bcf9-ad6996f32a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8cdd7ce3-ee6d-46a8-8947-fe1b0f2a308f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9eba8074-4733-4564-bcf9-ad6996f32a75" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8cdd7ce3-ee6d-46a8-8947-fe1b0f2a308f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementMember_4d5feb52-244d-421f-9853-deaaaf5959b1" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8cdd7ce3-ee6d-46a8-8947-fe1b0f2a308f" xlink:to="loc_vyne_AmendedAndRestatedCreditAgreementMember_4d5feb52-244d-421f-9853-deaaaf5959b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_e53c35fd-d687-4cb4-b48e-8f63be1b4971" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5a808d7d-ff12-4015-9cd4-24ec878eab35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_NumberOfReportableSegments_5a808d7d-ff12-4015-9cd4-24ec878eab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PaymentsForLicensingAgreements_4989f89a-3bad-492d-a3e8-9722bb59a26f" xlink:href="vyne-20210630.xsd#vyne_PaymentsForLicensingAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_vyne_PaymentsForLicensingAgreements_4989f89a-3bad-492d-a3e8-9722bb59a26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum_e7e4bff0-a1ee-4622-ae00-0d74ce44ac86" xlink:href="vyne-20210630.xsd#vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum_e7e4bff0-a1ee-4622-ae00-0d74ce44ac86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RoyaltyPaymentPercentMaximum_9c4d5e9c-1414-4936-b69f-648b36def423" xlink:href="vyne-20210630.xsd#vyne_RoyaltyPaymentPercentMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_vyne_RoyaltyPaymentPercentMaximum_9c4d5e9c-1414-4936-b69f-648b36def423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_41d1fa54-8c95-48a0-83df-72844925e81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_41d1fa54-8c95-48a0-83df-72844925e81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_911e3dfe-3942-423f-a211-7d96092c45a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_911e3dfe-3942-423f-a211-7d96092c45a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6fb75aff-1a69-4107-b71c-aa88d19bfb28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6fb75aff-1a69-4107-b71c-aa88d19bfb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9fb0a738-d7db-46da-95b5-feb6a034a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9fb0a738-d7db-46da-95b5-feb6a034a3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f87c195a-1a75-4d31-94b8-2f4cfbf3e0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_NetIncomeLoss_f87c195a-1a75-4d31-94b8-2f4cfbf3e0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0b8e4d-53e8-4747-9142-2f97dd0bf424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0b8e4d-53e8-4747-9142-2f97dd0bf424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3d535d8c-42c3-42e0-84cd-d8e3c642d4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3d535d8c-42c3-42e0-84cd-d8e3c642d4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ea10c85-369c-4357-8300-c61ccc481feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ea10c85-369c-4357-8300-c61ccc481feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a771f21-b4f8-47c9-95d9-13d37fc997ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a771f21-b4f8-47c9-95d9-13d37fc997ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_31548b95-8d0b-489e-b4bc-5ac7c2d019f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_LongTermDebt_31548b95-8d0b-489e-b4bc-5ac7c2d019f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cf8f2406-8cab-4a8b-8ce4-11017025c7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cf8f2406-8cab-4a8b-8ce4-11017025c7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RepaymentOfDebtPrepaymentFeePercentage_c77430e5-5076-47b5-a474-06d965dd7e59" xlink:href="vyne-20210630.xsd#vyne_RepaymentOfDebtPrepaymentFeePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_cae63c00-3eb3-4147-bcb0-6b5df09998c5" xlink:to="loc_vyne_RepaymentOfDebtPrepaymentFeePercentage_c77430e5-5076-47b5-a474-06d965dd7e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="vyne-20210630.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_89f29363-b0ab-41e7-8c48-a75dc0ae6a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4071d880-75ca-4d49-99e1-b69a44b2f172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89f29363-b0ab-41e7-8c48-a75dc0ae6a82" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4071d880-75ca-4d49-99e1-b69a44b2f172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="vyne-20210630.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02083c80-053b-4e1e-b6fb-918a6a24132c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_02083c80-053b-4e1e-b6fb-918a6a24132c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_759511be-a4dc-4050-aafc-b932c398714a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_759511be-a4dc-4050-aafc-b932c398714a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_44f419ba-3668-420d-b591-43fe189fb42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:to="loc_us-gaap_UseOfEstimates_44f419ba-3668-420d-b591-43fe189fb42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_667b4209-629f-48ec-9bc5-6d13c67d76b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_667b4209-629f-48ec-9bc5-6d13c67d76b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_88664ada-1119-430d-81b1-b3f0615abb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_88664ada-1119-430d-81b1-b3f0615abb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_fe11953c-f9fc-4234-af3f-0295b6d87d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_fe11953c-f9fc-4234-af3f-0295b6d87d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_24ee110b-b7c0-4179-84da-586f748b35b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_24ee110b-b7c0-4179-84da-586f748b35b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_c05235e5-848f-46d3-beed-bc8e57d4af4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_c05235e5-848f-46d3-beed-bc8e57d4af4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_af2b0404-6d53-4f00-a83b-901d7804cce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_af2b0404-6d53-4f00-a83b-901d7804cce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73038852-5dc9-4e72-8e64-396de00731cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c43a5af9-56e8-4a97-a5a2-fa809ce9d328" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73038852-5dc9-4e72-8e64-396de00731cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="vyne-20210630.xsd#SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d326ae84-e8ea-42e9-82ef-e889e9e256f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_182e4daa-e692-480b-a441-c2c6b35b2820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d326ae84-e8ea-42e9-82ef-e889e9e256f5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_182e4daa-e692-480b-a441-c2c6b35b2820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_84f89260-58cc-4648-9c2b-572252a1e9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66f61202-47ac-42f0-b7d3-862f8f36aa71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_84f89260-58cc-4648-9c2b-572252a1e9fb" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66f61202-47ac-42f0-b7d3-862f8f36aa71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5f2be2b6-94ea-42c6-b8b0-4e63418faff4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66f61202-47ac-42f0-b7d3-862f8f36aa71" xlink:to="loc_dei_LegalEntityAxis_5f2be2b6-94ea-42c6-b8b0-4e63418faff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_092cc6cc-3ae1-4f1d-9148-7fe47d4a203f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5f2be2b6-94ea-42c6-b8b0-4e63418faff4" xlink:to="loc_dei_EntityDomain_092cc6cc-3ae1-4f1d-9148-7fe47d4a203f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_527287f1-2ffd-4151-a327-afc2babb7d56" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_092cc6cc-3ae1-4f1d-9148-7fe47d4a203f" xlink:to="loc_vyne_FoamixMember_527287f1-2ffd-4151-a327-afc2babb7d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_66f61202-47ac-42f0-b7d3-862f8f36aa71" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_44c94ad5-0284-4770-85f3-138cb67523ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_44c94ad5-0284-4770-85f3-138cb67523ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_809104fd-6c57-41b1-ab62-a589d7445edb" xlink:href="vyne-20210630.xsd#vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_809104fd-6c57-41b1-ab62-a589d7445edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_c13597ed-13b5-41e4-a8fb-ccf1d222734e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_c13597ed-13b5-41e4-a8fb-ccf1d222734e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockRightSharesConversion_f090d9f7-9f78-4204-b4c7-f1853e4ad173" xlink:href="vyne-20210630.xsd#vyne_ContingentStockRightSharesConversion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_vyne_ContingentStockRightSharesConversion_f090d9f7-9f78-4204-b4c7-f1853e4ad173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationEffectiveExchangeRatio_e0caf9e8-bb87-4e0b-8bd9-0ed47a7a8464" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationEffectiveExchangeRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d8520e53-0156-4dc9-9837-8ec18a7193aa" xlink:to="loc_vyne_BusinessCombinationEffectiveExchangeRatio_e0caf9e8-bb87-4e0b-8bd9-0ed47a7a8464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ad2ea93d-01cb-466f-8ba6-7a141f65894a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b35f7020-a5b7-42d5-870f-5ba7410397b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad2ea93d-01cb-466f-8ba6-7a141f65894a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b35f7020-a5b7-42d5-870f-5ba7410397b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_63e8efc9-500c-4261-bc9f-fc34195349d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b35f7020-a5b7-42d5-870f-5ba7410397b9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_63e8efc9-500c-4261-bc9f-fc34195349d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fc8081e-7942-4fb0-86a2-5279fc1cb756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_63e8efc9-500c-4261-bc9f-fc34195349d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fc8081e-7942-4fb0-86a2-5279fc1cb756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_9fd27802-7090-4d41-9147-ce1c2020f69a" xlink:href="vyne-20210630.xsd#vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fc8081e-7942-4fb0-86a2-5279fc1cb756" xlink:to="loc_vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_9fd27802-7090-4d41-9147-ce1c2020f69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_12d6da25-6847-4bc6-872f-402176ffd1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fc8081e-7942-4fb0-86a2-5279fc1cb756" xlink:to="loc_us-gaap_WarrantMember_12d6da25-6847-4bc6-872f-402176ffd1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ad2b7bf2-99dc-4099-ac43-50c24c20c155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b35f7020-a5b7-42d5-870f-5ba7410397b9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ad2b7bf2-99dc-4099-ac43-50c24c20c155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_baffde00-9691-4d76-b003-ff8b52fca40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ad2b7bf2-99dc-4099-ac43-50c24c20c155" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_baffde00-9691-4d76-b003-ff8b52fca40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATION"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_fc979ed2-20c1-4b98-a99f-21c94dff0d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_310bc0c3-a684-493b-9f5a-e3c03516761e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_fc979ed2-20c1-4b98-a99f-21c94dff0d37" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_310bc0c3-a684-493b-9f5a-e3c03516761e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_54535985-09d0-425a-8378-4fe80bd1e5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock_a72681fe-b602-4735-ab8e-91ac41ebf391" xlink:href="vyne-20210630.xsd#vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_54535985-09d0-425a-8378-4fe80bd1e5de" xlink:to="loc_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock_a72681fe-b602-4735-ab8e-91ac41ebf391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_8605d63d-a60e-4786-9635-aae8048749be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_54535985-09d0-425a-8378-4fe80bd1e5de" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_8605d63d-a60e-4786-9635-aae8048749be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock_fd0e97fc-df46-49cd-9dde-a3c5e5623dfc" xlink:href="vyne-20210630.xsd#vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_54535985-09d0-425a-8378-4fe80bd1e5de" xlink:to="loc_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock_fd0e97fc-df46-49cd-9dde-a3c5e5623dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock_9cc8f5b7-70a9-4cf7-ab64-56a49911403c" xlink:href="vyne-20210630.xsd#vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_54535985-09d0-425a-8378-4fe80bd1e5de" xlink:to="loc_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock_9cc8f5b7-70a9-4cf7-ab64-56a49911403c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_cc138d70-807b-47a5-a97b-74320e25dd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_54535985-09d0-425a-8378-4fe80bd1e5de" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_cc138d70-807b-47a5-a97b-74320e25dd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_c39ab47a-3963-4131-8bf9-1b5294e9340d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c39ab47a-3963-4131-8bf9-1b5294e9340d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_de00a4b7-10a5-42c8-b607-8fa69a3cd26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_de00a4b7-10a5-42c8-b607-8fa69a3cd26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_90eda51a-abb7-4cea-a5c3-95200d9b0792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_de00a4b7-10a5-42c8-b607-8fa69a3cd26c" xlink:to="loc_us-gaap_EquityComponentDomain_90eda51a-abb7-4cea-a5c3-95200d9b0792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bc0d43f3-25aa-40ce-ae0d-32469e282be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_90eda51a-abb7-4cea-a5c3-95200d9b0792" xlink:to="loc_us-gaap_CommonStockMember_bc0d43f3-25aa-40ce-ae0d-32469e282be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eb71275d-519c-4587-aa2b-dfc24ac0a011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eb71275d-519c-4587-aa2b-dfc24ac0a011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3daeafd2-32f1-4479-920a-ab75de07deda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb71275d-519c-4587-aa2b-dfc24ac0a011" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3daeafd2-32f1-4479-920a-ab75de07deda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_47eebb5c-eddc-490e-b3f7-1c955c8207ff" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3daeafd2-32f1-4479-920a-ab75de07deda" xlink:to="loc_vyne_FoamixMember_47eebb5c-eddc-490e-b3f7-1c955c8207ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f8568f3f-2c37-4b1f-80c6-d9ce4a23efc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f8568f3f-2c37-4b1f-80c6-d9ce4a23efc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9a92ab80-b3ff-4499-8a4a-257b866919fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f8568f3f-2c37-4b1f-80c6-d9ce4a23efc5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9a92ab80-b3ff-4499-8a4a-257b866919fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_45a859be-2305-43a7-bcbc-6d25099b5446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9a92ab80-b3ff-4499-8a4a-257b866919fb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_45a859be-2305-43a7-bcbc-6d25099b5446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_829eb22c-986f-4a4b-a9dd-e4de24ed292f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_829eb22c-986f-4a4b-a9dd-e4de24ed292f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f740fa83-736d-4ed1-8da3-5ea96bd49e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_829eb22c-986f-4a4b-a9dd-e4de24ed292f" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f740fa83-736d-4ed1-8da3-5ea96bd49e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_3273377c-8531-46b8-be10-3fa33ad3e8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f740fa83-736d-4ed1-8da3-5ea96bd49e7b" xlink:to="loc_us-gaap_EmployeeSeveranceMember_3273377c-8531-46b8-be10-3fa33ad3e8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4f5530a-137e-4edb-b7b8-264993f3ad02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4f5530a-137e-4edb-b7b8-264993f3ad02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_649b92ed-f924-414f-8b82-306074830dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b4f5530a-137e-4edb-b7b8-264993f3ad02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_649b92ed-f924-414f-8b82-306074830dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9eeba8ef-2518-4b9b-a6ae-7590a3cffbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_649b92ed-f924-414f-8b82-306074830dcb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9eeba8ef-2518-4b9b-a6ae-7590a3cffbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_85e3fb67-4fa1-45f8-a08b-b42f0c2c07c4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ExchangeRatio_f730f5bb-13e7-4af5-aeea-3e6bbcf32814" xlink:href="vyne-20210630.xsd#vyne_ExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_ExchangeRatio_f730f5bb-13e7-4af5-aeea-3e6bbcf32814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessAcquisitionContingentStockRightIssued_e87697bd-1fc8-4047-ae03-463d4b454ceb" xlink:href="vyne-20210630.xsd#vyne_BusinessAcquisitionContingentStockRightIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_BusinessAcquisitionContingentStockRightIssued_e87697bd-1fc8-4047-ae03-463d4b454ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockRightSharesConversion_6372b2a9-380a-4927-8648-6845fbf23d56" xlink:href="vyne-20210630.xsd#vyne_ContingentStockRightSharesConversion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_ContingentStockRightSharesConversion_6372b2a9-380a-4927-8648-6845fbf23d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EffectiveExchangeRatio_0391e2ef-2765-4e05-94fd-0389b420ad48" xlink:href="vyne-20210630.xsd#vyne_EffectiveExchangeRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_EffectiveExchangeRatio_0391e2ef-2765-4e05-94fd-0389b420ad48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_4f3a8b0f-f2b6-485e-a3c3-d03dfaa1303f" xlink:href="vyne-20210630.xsd#vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_4f3a8b0f-f2b6-485e-a3c3-d03dfaa1303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_2ff3d5e3-02fd-4b7b-8431-61a974327e13" xlink:href="vyne-20210630.xsd#vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_2ff3d5e3-02fd-4b7b-8431-61a974327e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PostMergerParentOwnershipByPreMergerParentStockholders_58cae0af-02b5-49ca-899f-a9df31c29f7c" xlink:href="vyne-20210630.xsd#vyne_PostMergerParentOwnershipByPreMergerParentStockholders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_PostMergerParentOwnershipByPreMergerParentStockholders_58cae0af-02b5-49ca-899f-a9df31c29f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_52198e71-da2c-48bf-8839-4849c8dfb43e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_52198e71-da2c-48bf-8839-4849c8dfb43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_951dc55a-6b4c-4333-b0d0-2cb33383e302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_SharePrice_951dc55a-6b4c-4333-b0d0-2cb33383e302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredGross_5abe130d-3552-408c-91f8-6f7290835b04" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_BusinessCombinationConsiderationTransferredGross_5abe130d-3552-408c-91f8-6f7290835b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c01dd609-4563-42b7-8cc4-d9a52bb5c835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c01dd609-4563-42b7-8cc4-d9a52bb5c835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_e31cc748-e78a-4e66-bf6c-018eff5f46c9" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_e31cc748-e78a-4e66-bf6c-018eff5f46c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_b95b3761-890b-4d61-8972-9f405982b351" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_b95b3761-890b-4d61-8972-9f405982b351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_35eac50d-bae2-42a5-9920-97a2c59fbe06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_35eac50d-bae2-42a5-9920-97a2c59fbe06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_3016a790-7357-4847-bcc8-ec6ca91508d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_3016a790-7357-4847-bcc8-ec6ca91508d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_2556ff28-61c7-4bc6-9dd2-c2302f629330" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_2556ff28-61c7-4bc6-9dd2-c2302f629330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_201bd778-918b-4098-9197-352501813570" xlink:href="vyne-20210630.xsd#vyne_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_vyne_ContingentStockConsiderationRemeasurementGainLoss_201bd778-918b-4098-9197-352501813570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_976d6e75-d54a-4706-a756-67c577362cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91a2ade1-a98d-45d4-ac50-8885f8570c40" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_976d6e75-d54a-4706-a756-67c577362cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5ec923c9-5f6d-428d-89f6-1055142bf822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6f56b2f0-22a7-47e9-b820-07bff54704e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5ec923c9-5f6d-428d-89f6-1055142bf822" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6f56b2f0-22a7-47e9-b820-07bff54704e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0a0daf4a-b6ca-4b88-816f-f01037761b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6f56b2f0-22a7-47e9-b820-07bff54704e9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0a0daf4a-b6ca-4b88-816f-f01037761b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2fa78b79-c5fe-4a12-8691-0012e12b835d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0a0daf4a-b6ca-4b88-816f-f01037761b10" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2fa78b79-c5fe-4a12-8691-0012e12b835d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_cae62d62-b718-4f06-920c-7652d4a2c275" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2fa78b79-c5fe-4a12-8691-0012e12b835d" xlink:to="loc_vyne_FoamixMember_cae62d62-b718-4f06-920c-7652d4a2c275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6f56b2f0-22a7-47e9-b820-07bff54704e9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f95b6df0-a65f-432a-a506-164ef45ada3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f95b6df0-a65f-432a-a506-164ef45ada3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_f58e06bc-b095-44ff-a57e-cbb12ab58482" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_f58e06bc-b095-44ff-a57e-cbb12ab58482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationConsiderationTransferredGross_7c338529-8576-4049-b44a-28b1414cf04d" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationConsiderationTransferredGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_vyne_BusinessCombinationConsiderationTransferredGross_7c338529-8576-4049-b44a-28b1414cf04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b45b9ead-5505-4db4-bf79-520e74ba06c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b45b9ead-5505-4db4-bf79-520e74ba06c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3af1724e-8980-4d55-8aa3-0e639ad4643b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7dae2218-4607-431c-a937-b6a92dc057bf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3af1724e-8980-4d55-8aa3-0e639ad4643b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1a6ef21b-6374-4c4b-a3c1-e9847f24ec92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_131916ce-64fe-4c90-b1d1-6ab33a34959b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1a6ef21b-6374-4c4b-a3c1-e9847f24ec92" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_131916ce-64fe-4c90-b1d1-6ab33a34959b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_dcc18d6b-755d-44c6-a887-5246f476744a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_131916ce-64fe-4c90-b1d1-6ab33a34959b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_dcc18d6b-755d-44c6-a887-5246f476744a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99359d17-b9c0-4e4e-871b-6970ca5f8ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_dcc18d6b-755d-44c6-a887-5246f476744a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99359d17-b9c0-4e4e-871b-6970ca5f8ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_1cf793dc-a4cb-4de7-a7af-f6f0475c9b0d" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99359d17-b9c0-4e4e-871b-6970ca5f8ff1" xlink:to="loc_vyne_FoamixMember_1cf793dc-a4cb-4de7-a7af-f6f0475c9b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f5397cff-ad91-4b57-a585-a415c139d970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_131916ce-64fe-4c90-b1d1-6ab33a34959b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f5397cff-ad91-4b57-a585-a415c139d970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f5397cff-ad91-4b57-a585-a415c139d970" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f52b6749-bc5f-49ff-8c3c-d44bfe44d044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_f52b6749-bc5f-49ff-8c3c-d44bfe44d044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_587ffac2-fc2c-4e19-a072-e41d5b7a0f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_587ffac2-fc2c-4e19-a072-e41d5b7a0f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3b982f72-8528-462a-9aa2-6af143333428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3b982f72-8528-462a-9aa2-6af143333428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_39c89c1b-fa89-40ca-a175-1b6a13314e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_39c89c1b-fa89-40ca-a175-1b6a13314e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4184f874-d49f-4c3b-81dc-56817c66fe11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_Goodwill_4184f874-d49f-4c3b-81dc-56817c66fe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2a147cf9-ae98-4ba7-a453-05473e2dde6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2a147cf9-ae98-4ba7-a453-05473e2dde6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_e2d133f3-cebb-4971-8bae-77dadbb78277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_e2d133f3-cebb-4971-8bae-77dadbb78277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_5e979d5c-e1a8-411d-83aa-51232ffa8739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_5e979d5c-e1a8-411d-83aa-51232ffa8739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a3323ab1-8949-468c-9039-deccf5854e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a3323ab1-8949-468c-9039-deccf5854e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_ed58fb80-9e55-4eeb-b6a0-5f039ef8531d" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_2dd0a30c-274a-42b3-bb22-9f4bc69aa4eb" xlink:to="loc_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_ed58fb80-9e55-4eeb-b6a0-5f039ef8531d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_625348da-91ff-4312-a1c0-bfb012df6b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_decf3782-9f08-42b3-bfc3-28dd5b982531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_625348da-91ff-4312-a1c0-bfb012df6b43" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_decf3782-9f08-42b3-bfc3-28dd5b982531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f60854f6-4a6a-4a74-a3be-72783a2e41ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_decf3782-9f08-42b3-bfc3-28dd5b982531" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f60854f6-4a6a-4a74-a3be-72783a2e41ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9962fe65-56f6-4918-af00-bb6eeb12ce56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f60854f6-4a6a-4a74-a3be-72783a2e41ec" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9962fe65-56f6-4918-af00-bb6eeb12ce56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_dc28e77c-db68-44f7-bd00-7ef56bc9ba3f" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9962fe65-56f6-4918-af00-bb6eeb12ce56" xlink:to="loc_vyne_FoamixMember_dc28e77c-db68-44f7-bd00-7ef56bc9ba3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9063b034-531b-4ed3-a06f-2bce0272c26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_decf3782-9f08-42b3-bfc3-28dd5b982531" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9063b034-531b-4ed3-a06f-2bce0272c26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9063b034-531b-4ed3-a06f-2bce0272c26e" xlink:to="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_f27bf65a-4ee5-4416-9db5-820222697bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_f27bf65a-4ee5-4416-9db5-820222697bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_eaf244cd-58d8-4146-9a1c-8e83d9025673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_eaf244cd-58d8-4146-9a1c-8e83d9025673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_6add5180-6e79-4b53-a050-6c6cc7552aaa" xlink:href="vyne-20210630.xsd#vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:to="loc_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_6add5180-6e79-4b53-a050-6c6cc7552aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ee87888d-0159-45ec-a590-cea1fa481502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_36927a28-796c-4707-8d6a-fe0443dd9f74" xlink:to="loc_us-gaap_Goodwill_ee87888d-0159-45ec-a590-cea1fa481502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONIPRDandCSRDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_26f58d31-0c69-44be-8bad-d4c0d188deb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_727efb75-4f3a-42af-8f86-8dc98153c27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_26f58d31-0c69-44be-8bad-d4c0d188deb7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_727efb75-4f3a-42af-8f86-8dc98153c27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_43e771f6-de62-4d35-a259-e389c782c347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_727efb75-4f3a-42af-8f86-8dc98153c27f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_43e771f6-de62-4d35-a259-e389c782c347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bcc375ed-6c5b-46dc-a8c3-34ab53ab1ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43e771f6-de62-4d35-a259-e389c782c347" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bcc375ed-6c5b-46dc-a8c3-34ab53ab1ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_df200ca0-19b1-40b3-9953-6c28a619d277" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bcc375ed-6c5b-46dc-a8c3-34ab53ab1ee6" xlink:to="loc_vyne_FoamixMember_df200ca0-19b1-40b3-9953-6c28a619d277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f206e0b1-6957-44d0-85fc-a91e88142935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_727efb75-4f3a-42af-8f86-8dc98153c27f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f206e0b1-6957-44d0-85fc-a91e88142935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_3010cb40-ea96-42b8-aef6-1744a2a069c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f206e0b1-6957-44d0-85fc-a91e88142935" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_3010cb40-ea96-42b8-aef6-1744a2a069c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_738685ad-e88d-423e-a7fc-9b4749caf1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_3010cb40-ea96-42b8-aef6-1744a2a069c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_738685ad-e88d-423e-a7fc-9b4749caf1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5300f52d-fe61-4c82-ac55-906a3501fd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_3010cb40-ea96-42b8-aef6-1744a2a069c7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5300f52d-fe61-4c82-ac55-906a3501fd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#BUSINESSCOMBINATIONProFormaDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7b32ab53-67f0-40d9-9839-94a381eb4991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_388f98a4-f2e0-4187-87d1-6128c27303eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7b32ab53-67f0-40d9-9839-94a381eb4991" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_388f98a4-f2e0-4187-87d1-6128c27303eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_9b4aa4ba-2c3d-42ff-89b9-62ac47421286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7b32ab53-67f0-40d9-9839-94a381eb4991" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_9b4aa4ba-2c3d-42ff-89b9-62ac47421286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_3aac58a2-bfc9-4ab9-97a7-d4bccdf4ee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7b32ab53-67f0-40d9-9839-94a381eb4991" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_3aac58a2-bfc9-4ab9-97a7-d4bccdf4ee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_ddb792c8-d5fb-4f64-a975-15b2910679a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_3aac58a2-bfc9-4ab9-97a7-d4bccdf4ee2d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_ddb792c8-d5fb-4f64-a975-15b2910679a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_87580ba4-6d61-498a-a38d-5eda3243bd31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_3aac58a2-bfc9-4ab9-97a7-d4bccdf4ee2d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_87580ba4-6d61-498a-a38d-5eda3243bd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_a93c67e6-c270-4495-9c82-491243dfedee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_3aac58a2-bfc9-4ab9-97a7-d4bccdf4ee2d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_a93c67e6-c270-4495-9c82-491243dfedee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_a68e1d7e-c598-4d6d-80fe-43d43187d499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_3aac58a2-bfc9-4ab9-97a7-d4bccdf4ee2d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_a68e1d7e-c598-4d6d-80fe-43d43187d499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_550b04d2-29aa-4a05-b2e9-5fc018d1188f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7b32ab53-67f0-40d9-9839-94a381eb4991" xlink:to="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_550b04d2-29aa-4a05-b2e9-5fc018d1188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdjustmentsToSupplementalProformaTransactionCosts_060cd1a7-d494-4597-a0e1-c54c30775d9c" xlink:href="vyne-20210630.xsd#vyne_AdjustmentsToSupplementalProformaTransactionCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_550b04d2-29aa-4a05-b2e9-5fc018d1188f" xlink:to="loc_vyne_AdjustmentsToSupplementalProformaTransactionCosts_060cd1a7-d494-4597-a0e1-c54c30775d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_51df278a-d95f-4b38-afe9-05fd39b3d859" xlink:href="vyne-20210630.xsd#vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_550b04d2-29aa-4a05-b2e9-5fc018d1188f" xlink:to="loc_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_51df278a-d95f-4b38-afe9-05fd39b3d859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_c7228e26-8f33-4539-8f9c-825ec45f0e0c" xlink:href="vyne-20210630.xsd#vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_550b04d2-29aa-4a05-b2e9-5fc018d1188f" xlink:to="loc_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_c7228e26-8f33-4539-8f9c-825ec45f0e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="vyne-20210630.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f1e3f22e-a229-45dd-a7eb-f855f95f38b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_35507e04-a65b-4452-9ae2-f19c498244a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f1e3f22e-a229-45dd-a7eb-f855f95f38b9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_35507e04-a65b-4452-9ae2-f19c498244a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#REVENUERECOGNITIONDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fd4f54c9-812f-4c99-9739-f48e725db3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fd4f54c9-812f-4c99-9739-f48e725db3f4" xlink:to="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a1d6d85b-cd79-4a0d-bf8f-5e2700fe7443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a1d6d85b-cd79-4a0d-bf8f-5e2700fe7443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cb03610d-a138-4702-b8ee-b243d02d9d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a1d6d85b-cd79-4a0d-bf8f-5e2700fe7443" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cb03610d-a138-4702-b8ee-b243d02d9d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4f9b3412-bcbf-4b46-9445-7578102b4e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cb03610d-a138-4702-b8ee-b243d02d9d3d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4f9b3412-bcbf-4b46-9445-7578102b4e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0316a2e-bf8c-4012-a824-2ffa8b3a7af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0316a2e-bf8c-4012-a824-2ffa8b3a7af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4172fe1e-b0a0-4331-bda7-a077482adfba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0316a2e-bf8c-4012-a824-2ffa8b3a7af5" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4172fe1e-b0a0-4331-bda7-a077482adfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_af2c8076-c007-4404-87e0-71974ecd9a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4172fe1e-b0a0-4331-bda7-a077482adfba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_af2c8076-c007-4404-87e0-71974ecd9a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_44abc55f-1b93-43dc-bb38-3705903f4b3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_srt_MajorCustomersAxis_44abc55f-1b93-43dc-bb38-3705903f4b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_36415c84-27e8-4d24-8cf2-af76c8bf4870" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_44abc55f-1b93-43dc-bb38-3705903f4b3d" xlink:to="loc_srt_NameOfMajorCustomerDomain_36415c84-27e8-4d24-8cf2-af76c8bf4870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FourCustomersMember_d57b6da8-0f49-47f1-a30e-3109a1965902" xlink:href="vyne-20210630.xsd#vyne_FourCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_36415c84-27e8-4d24-8cf2-af76c8bf4870" xlink:to="loc_vyne_FourCustomersMember_d57b6da8-0f49-47f1-a30e-3109a1965902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ThreeCustomersMember_5242958a-94d0-4b2f-b4b4-3358232155a2" xlink:href="vyne-20210630.xsd#vyne_ThreeCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_36415c84-27e8-4d24-8cf2-af76c8bf4870" xlink:to="loc_vyne_ThreeCustomersMember_5242958a-94d0-4b2f-b4b4-3358232155a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7d568aca-fdeb-4427-a9c4-bcef6b411fbe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_dei_LegalEntityAxis_7d568aca-fdeb-4427-a9c4-bcef6b411fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_168f4883-8215-44a7-88e7-3885a0d30b25" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7d568aca-fdeb-4427-a9c4-bcef6b411fbe" xlink:to="loc_dei_EntityDomain_168f4883-8215-44a7-88e7-3885a0d30b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_cb1d0925-d909-4b03-af35-0a38a0bed53e" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_168f4883-8215-44a7-88e7-3885a0d30b25" xlink:to="loc_vyne_FoamixMember_cb1d0925-d909-4b03-af35-0a38a0bed53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_719e3e9a-009b-48c5-9504-79f05282773a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_srt_ProductOrServiceAxis_719e3e9a-009b-48c5-9504-79f05282773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bd125217-db22-4270-8552-4718707871ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_719e3e9a-009b-48c5-9504-79f05282773a" xlink:to="loc_srt_ProductsAndServicesDomain_bd125217-db22-4270-8552-4718707871ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_debce777-ba16-4d29-ae79-8738336694fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bd125217-db22-4270-8552-4718707871ab" xlink:to="loc_us-gaap_RoyaltyMember_debce777-ba16-4d29-ae79-8738336694fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AllowanceForSalesReturns1Member_868d7da8-d7ee-4e01-8f6a-428f9275bbe9" xlink:href="vyne-20210630.xsd#vyne_AllowanceForSalesReturns1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bd125217-db22-4270-8552-4718707871ab" xlink:to="loc_vyne_AllowanceForSalesReturns1Member_868d7da8-d7ee-4e01-8f6a-428f9275bbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_37ab4410-95dd-4f54-b63f-5fef4563e7cd" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_625bbea3-d164-4d14-a292-36c209a8e49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_625bbea3-d164-4d14-a292-36c209a8e49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances_762ea092-120a-4294-80d1-af7aca866cf1" xlink:href="vyne-20210630.xsd#vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances_762ea092-120a-4294-80d1-af7aca866cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0644e819-8550-4680-91b9-8bbb245c0277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0644e819-8550-4680-91b9-8bbb245c0277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EstimateOfProductReturnRateMinimum_8d4de2f6-c71a-40eb-9558-c2cefbfa7af6" xlink:href="vyne-20210630.xsd#vyne_EstimateOfProductReturnRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_vyne_EstimateOfProductReturnRateMinimum_8d4de2f6-c71a-40eb-9558-c2cefbfa7af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EstimateOfProductReturnRateMaximum_a28416da-1053-4314-844d-b943aa80c894" xlink:href="vyne-20210630.xsd#vyne_EstimateOfProductReturnRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_vyne_EstimateOfProductReturnRateMaximum_a28416da-1053-4314-844d-b943aa80c894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_a5db294c-2164-43c2-841d-3f3063384acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_a5db294c-2164-43c2-841d-3f3063384acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_UpfrontRoyaltyReceipt_006c48fc-88c0-41ac-b775-c1644d27a6d2" xlink:href="vyne-20210630.xsd#vyne_UpfrontRoyaltyReceipt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_vyne_UpfrontRoyaltyReceipt_006c48fc-88c0-41ac-b775-c1644d27a6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_f0badb02-e446-4995-ba64-af97939eaa4c" xlink:href="vyne-20210630.xsd#vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_f0badb02-e446-4995-ba64-af97939eaa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec7d6884-21fc-4fe8-882e-3883ede5512b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b247e760-cc75-4e34-8ece-af215dd75213" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec7d6884-21fc-4fe8-882e-3883ede5512b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT" xlink:type="simple" xlink:href="vyne-20210630.xsd#FAIRVALUEMEASUREMENT"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bcd551d1-0b63-4f44-b9bc-0ad9adf015b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4fe8e191-a790-4a08-aaa6-e3b9af890fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bcd551d1-0b63-4f44-b9bc-0ad9adf015b4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4fe8e191-a790-4a08-aaa6-e3b9af890fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables" xlink:type="simple" xlink:href="vyne-20210630.xsd#FAIRVALUEMEASUREMENTTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9c236173-8d9c-4130-8231-a44aa243fe09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_24028807-2f3e-4a57-a795-620eb9ba03e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9c236173-8d9c-4130-8231-a44aa243fe09" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_24028807-2f3e-4a57-a795-620eb9ba03e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2014d74e-3bed-46f3-84cf-2ff1f94c0d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b712dab0-4971-463a-8cd9-5c2569c46542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2014d74e-3bed-46f3-84cf-2ff1f94c0d23" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b712dab0-4971-463a-8cd9-5c2569c46542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1b885a-bbbf-452f-81aa-d8eba40885db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b712dab0-4971-463a-8cd9-5c2569c46542" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1b885a-bbbf-452f-81aa-d8eba40885db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f9809a6-d0e1-48ce-b552-6321eb684601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1b885a-bbbf-452f-81aa-d8eba40885db" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f9809a6-d0e1-48ce-b552-6321eb684601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ae6865ed-771e-4ec1-8cfe-cdd13a1dfd19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f9809a6-d0e1-48ce-b552-6321eb684601" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ae6865ed-771e-4ec1-8cfe-cdd13a1dfd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_dd49dfd6-1e0e-434c-943f-d5be4c2d90ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f9809a6-d0e1-48ce-b552-6321eb684601" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_dd49dfd6-1e0e-434c-943f-d5be4c2d90ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_69edeb1d-88af-4163-bb3a-72a0ebb5118b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f9809a6-d0e1-48ce-b552-6321eb684601" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_69edeb1d-88af-4163-bb3a-72a0ebb5118b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55896c7f-5713-445d-aeed-5e59f64084f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b712dab0-4971-463a-8cd9-5c2569c46542" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55896c7f-5713-445d-aeed-5e59f64084f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_ceab75d8-db1b-4ff3-98f8-8f8e9f94ad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_55896c7f-5713-445d-aeed-5e59f64084f5" xlink:to="loc_us-gaap_MarketableSecurities_ceab75d8-db1b-4ff3-98f8-8f8e9f94ad6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIES" xlink:type="simple" xlink:href="vyne-20210630.xsd#MARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9733d374-82e5-4fc4-be19-cce61ac61968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_565eca76-17e2-41d2-b025-867df6568f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9733d374-82e5-4fc4-be19-cce61ac61968" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_565eca76-17e2-41d2-b025-867df6568f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables" xlink:type="simple" xlink:href="vyne-20210630.xsd#MARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9cbcaf0-1253-4581-a096-9916a618aba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_bee0f382-69ca-49c7-ac7b-b445efb8c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d9cbcaf0-1253-4581-a096-9916a618aba8" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_bee0f382-69ca-49c7-ac7b-b445efb8c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#MARKETABLESECURITIESMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9dd5806c-4f3f-458e-aae1-2ab065d3cc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_668b0b61-e169-484c-8530-f840da22f2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9dd5806c-4f3f-458e-aae1-2ab065d3cc9c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_668b0b61-e169-484c-8530-f840da22f2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e1c4e3a5-93ed-4af0-a1f8-9a8fb56c3aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_668b0b61-e169-484c-8530-f840da22f2f8" xlink:to="loc_us-gaap_InvestmentTypeAxis_e1c4e3a5-93ed-4af0-a1f8-9a8fb56c3aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7be3650f-3e77-4556-9170-a9b255b0e455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_e1c4e3a5-93ed-4af0-a1f8-9a8fb56c3aa9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7be3650f-3e77-4556-9170-a9b255b0e455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_IsraeliMutualFundsMember_80e154ab-f846-4784-9fb2-50d4c83b05cd" xlink:href="vyne-20210630.xsd#vyne_IsraeliMutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7be3650f-3e77-4556-9170-a9b255b0e455" xlink:to="loc_vyne_IsraeliMutualFundsMember_80e154ab-f846-4784-9fb2-50d4c83b05cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3630e222-f1ba-4484-a136-ac97c82017ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_668b0b61-e169-484c-8530-f840da22f2f8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3630e222-f1ba-4484-a136-ac97c82017ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c61ae58e-10a8-45c5-8e9a-6712c20e16a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3630e222-f1ba-4484-a136-ac97c82017ab" xlink:to="loc_us-gaap_ShortTermInvestments_c61ae58e-10a8-45c5-8e9a-6712c20e16a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#MARKETABLESECURITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a48456a9-9a85-45a6-a90c-97437b9aa231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96b2ae48-a8ec-4960-ae5d-30290f6c8ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a48456a9-9a85-45a6-a90c-97437b9aa231" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96b2ae48-a8ec-4960-ae5d-30290f6c8ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_3ff0bc3c-ee86-404b-ad8b-9646a5366b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a48456a9-9a85-45a6-a90c-97437b9aa231" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_3ff0bc3c-ee86-404b-ad8b-9646a5366b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_968e2589-0628-4cd1-b877-1862909900ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a48456a9-9a85-45a6-a90c-97437b9aa231" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_968e2589-0628-4cd1-b877-1862909900ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments_22baaa28-7b72-4872-8038-4413bf6d0c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a48456a9-9a85-45a6-a90c-97437b9aa231" xlink:to="loc_us-gaap_RestrictedInvestments_22baaa28-7b72-4872-8038-4413bf6d0c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORY" xlink:type="simple" xlink:href="vyne-20210630.xsd#INVENTORY"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_485f3b43-8110-4151-9f31-779ea7b9abf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_4d0ce978-acad-42c3-abf3-de1a697e8429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_485f3b43-8110-4151-9f31-779ea7b9abf1" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_4d0ce978-acad-42c3-abf3-de1a697e8429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORYTables" xlink:type="simple" xlink:href="vyne-20210630.xsd#INVENTORYTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d1b9254e-428b-4019-8911-a677464025bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_26ecfbe0-ab34-41d8-889e-18fb1410255c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d1b9254e-428b-4019-8911-a677464025bc" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_26ecfbe0-ab34-41d8-889e-18fb1410255c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORYNarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#INVENTORYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f80ac821-37c7-4ac6-bf07-2edf251536ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_4bc46e08-3ec4-4ce7-8d15-23298766c219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f80ac821-37c7-4ac6-bf07-2edf251536ed" xlink:to="loc_us-gaap_InventoryWriteDown_4bc46e08-3ec4-4ce7-8d15-23298766c219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#INVENTORYScheduleofInventoryComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_33e605e2-9119-4134-9cc6-5531b763fb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_8842ac1b-3e25-45f0-b551-431939ee9937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_33e605e2-9119-4134-9cc6-5531b763fb1e" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_8842ac1b-3e25-45f0-b551-431939ee9937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_cdfae18f-c975-43af-9487-ae13e2d6ae7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_33e605e2-9119-4134-9cc6-5531b763fb1e" xlink:to="loc_us-gaap_InventoryWorkInProcess_cdfae18f-c975-43af-9487-ae13e2d6ae7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_f632927f-f884-4095-b6e4-bd66dee6e594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_33e605e2-9119-4134-9cc6-5531b763fb1e" xlink:to="loc_us-gaap_InventoryFinishedGoods_f632927f-f884-4095-b6e4-bd66dee6e594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_88ee3931-a220-43b1-816c-9e4f0b8c825a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_33e605e2-9119-4134-9cc6-5531b763fb1e" xlink:to="loc_us-gaap_InventoryGross_88ee3931-a220-43b1-816c-9e4f0b8c825a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/DEBT" xlink:type="simple" xlink:href="vyne-20210630.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ca840289-a473-440d-ae85-fa5fbcfad394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_9b554a20-4cac-49ab-8b0e-a01ec4c7faca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ca840289-a473-440d-ae85-fa5fbcfad394" xlink:to="loc_us-gaap_LongTermDebtTextBlock_9b554a20-4cac-49ab-8b0e-a01ec4c7faca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_36045f44-3b3c-4636-898b-52706e388346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_36045f44-3b3c-4636-898b-52706e388346" xlink:to="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_85b3642d-c198-4e4b-b30a-2dfc89c2945d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_85b3642d-c198-4e4b-b30a-2dfc89c2945d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0b3d7511-72b1-488e-b737-2888cbb125a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_85b3642d-c198-4e4b-b30a-2dfc89c2945d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0b3d7511-72b1-488e-b737-2888cbb125a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RegisteredOfferingMember_598b2714-23d0-498c-84e7-701132c83e8b" xlink:href="vyne-20210630.xsd#vyne_RegisteredOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0b3d7511-72b1-488e-b737-2888cbb125a9" xlink:to="loc_vyne_RegisteredOfferingMember_598b2714-23d0-498c-84e7-701132c83e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_786b7f99-03e9-4877-be57-abc62e2d41d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_786b7f99-03e9-4877-be57-abc62e2d41d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bf920b3c-0a54-4bbb-9830-2aeebb1fcdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_786b7f99-03e9-4877-be57-abc62e2d41d7" xlink:to="loc_us-gaap_RelatedPartyDomain_bf920b3c-0a54-4bbb-9830-2aeebb1fcdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareholderLenderMember_469fc674-6aca-4e1b-8349-c4fcf849a58e" xlink:href="vyne-20210630.xsd#vyne_ShareholderLenderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_bf920b3c-0a54-4bbb-9830-2aeebb1fcdb0" xlink:to="loc_vyne_ShareholderLenderMember_469fc674-6aca-4e1b-8349-c4fcf849a58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f1f77a95-be04-490d-9036-a608f9a92fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_DebtInstrumentAxis_f1f77a95-be04-490d-9036-a608f9a92fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f8765fe5-387e-42dc-89e3-1d4116ed9b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f1f77a95-be04-490d-9036-a608f9a92fbe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f8765fe5-387e-42dc-89e3-1d4116ed9b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_dfef687e-d0dd-46d7-ac1f-a3808a11f0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f8765fe5-387e-42dc-89e3-1d4116ed9b04" xlink:to="loc_us-gaap_SecuredDebtMember_dfef687e-d0dd-46d7-ac1f-a3808a11f0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementMember_c4476d80-7b7b-4be3-b40f-309feec58d25" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f8765fe5-387e-42dc-89e3-1d4116ed9b04" xlink:to="loc_vyne_AmendedAndRestatedCreditAgreementMember_c4476d80-7b7b-4be3-b40f-309feec58d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember_108334c4-b598-4b80-ac70-0b7639d8d4b9" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vyne_AmendedAndRestatedCreditAgreementMember_c4476d80-7b7b-4be3-b40f-309feec58d25" xlink:to="loc_vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember_108334c4-b598-4b80-ac70-0b7639d8d4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember_d2d3b76e-f3d4-4d06-9612-57b33e5829ad" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vyne_AmendedAndRestatedCreditAgreementMember_c4476d80-7b7b-4be3-b40f-309feec58d25" xlink:to="loc_vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember_d2d3b76e-f3d4-4d06-9612-57b33e5829ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember_7de74fdb-6259-4727-bda1-20a82daeaf43" xlink:href="vyne-20210630.xsd#vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vyne_AmendedAndRestatedCreditAgreementMember_c4476d80-7b7b-4be3-b40f-309feec58d25" xlink:to="loc_vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember_7de74fdb-6259-4727-bda1-20a82daeaf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_31c1a11a-d487-4bab-ae5b-39074788b1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_VariableRateAxis_31c1a11a-d487-4bab-ae5b-39074788b1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d969b70a-b405-46cb-9ea9-e9075d9aed73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_31c1a11a-d487-4bab-ae5b-39074788b1ed" xlink:to="loc_us-gaap_VariableRateDomain_d969b70a-b405-46cb-9ea9-e9075d9aed73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_092bc9bf-2f83-4ec8-b44a-49670db14df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_d969b70a-b405-46cb-9ea9-e9075d9aed73" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_092bc9bf-2f83-4ec8-b44a-49670db14df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_110be6db-06a3-4ae3-878a-7c817d6cd812" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_srt_StatementScenarioAxis_110be6db-06a3-4ae3-878a-7c817d6cd812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_78506293-9be7-4d53-b3ba-d046956b9b28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_110be6db-06a3-4ae3-878a-7c817d6cd812" xlink:to="loc_srt_ScenarioUnspecifiedDomain_78506293-9be7-4d53-b3ba-d046956b9b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c139e64a-bf6c-4e38-b9de-e42b82142891" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_78506293-9be7-4d53-b3ba-d046956b9b28" xlink:to="loc_srt_ScenarioForecastMember_c139e64a-bf6c-4e38-b9de-e42b82142891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c0c41a5f-0ee7-4dec-b76b-866189e5597f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_dei_LegalEntityAxis_c0c41a5f-0ee7-4dec-b76b-866189e5597f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd2b10cd-7056-4da3-9bed-a9ffee04eaad" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c0c41a5f-0ee7-4dec-b76b-866189e5597f" xlink:to="loc_dei_EntityDomain_bd2b10cd-7056-4da3-9bed-a9ffee04eaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_c87f8770-9919-4546-b84e-6873d7d533dc" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bd2b10cd-7056-4da3-9bed-a9ffee04eaad" xlink:to="loc_vyne_FoamixMember_c87f8770-9919-4546-b84e-6873d7d533dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fde14b3e-967c-424d-9bc9-ec36a4c9a315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fde14b3e-967c-424d-9bc9-ec36a4c9a315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46340261-a482-460a-a336-5e36a78a7993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fde14b3e-967c-424d-9bc9-ec36a4c9a315" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46340261-a482-460a-a336-5e36a78a7993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6e4cce86-c6fd-4a24-a5c7-26daf69e8437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46340261-a482-460a-a336-5e36a78a7993" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6e4cce86-c6fd-4a24-a5c7-26daf69e8437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7767a3b1-f6fc-4aae-83a5-e35b2668ce38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_srt_RangeAxis_7767a3b1-f6fc-4aae-83a5-e35b2668ce38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_933422b7-2cfb-4694-b21e-499325fbecb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7767a3b1-f6fc-4aae-83a5-e35b2668ce38" xlink:to="loc_srt_RangeMember_933422b7-2cfb-4694-b21e-499325fbecb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1eb691bc-4e88-4feb-92ac-4a37d07c9dc5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_933422b7-2cfb-4694-b21e-499325fbecb3" xlink:to="loc_srt_MinimumMember_1eb691bc-4e88-4feb-92ac-4a37d07c9dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_688457c6-fbeb-4594-9c90-a0d06395f0fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_933422b7-2cfb-4694-b21e-499325fbecb3" xlink:to="loc_srt_MaximumMember_688457c6-fbeb-4594-9c90-a0d06395f0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_99067bbc-9504-427d-831c-812e3c563b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_99067bbc-9504-427d-831c-812e3c563b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ad15f0e0-cab5-48bb-b756-74607c84a165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_99067bbc-9504-427d-831c-812e3c563b30" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ad15f0e0-cab5-48bb-b756-74607c84a165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dd0edc2b-319d-470f-adac-00a5943fe300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ad15f0e0-cab5-48bb-b756-74607c84a165" xlink:to="loc_us-gaap_SubsequentEventMember_dd0edc2b-319d-470f-adac-00a5943fe300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9432a48a-7fcd-4796-bef3-45b8aa8e4488" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8d1bab1f-81eb-4c91-b2a9-7b765946ea47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8d1bab1f-81eb-4c91-b2a9-7b765946ea47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_NumberOfLenders_179a706e-1b63-47a8-ae70-1939c5d39c30" xlink:href="vyne-20210630.xsd#vyne_NumberOfLenders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_vyne_NumberOfLenders_179a706e-1b63-47a8-ae70-1939c5d39c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_GrossProceedsFromIssuanceOfCommonStock_b52a5c7a-1b0d-4d4e-8019-1a687d4010f3" xlink:href="vyne-20210630.xsd#vyne_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_vyne_GrossProceedsFromIssuanceOfCommonStock_b52a5c7a-1b0d-4d4e-8019-1a687d4010f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_41e7e456-aeff-490f-b7a3-c5a4a7a9ab0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_41e7e456-aeff-490f-b7a3-c5a4a7a9ab0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_edee9d16-31b4-482a-9bf4-bbf70ce02f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_edee9d16-31b4-482a-9bf4-bbf70ce02f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9f65e190-02a4-4beb-a250-af4ba85aeddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9f65e190-02a4-4beb-a250-af4ba85aeddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0554600a-61eb-4087-944a-201b4d3fe0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0554600a-61eb-4087-944a-201b4d3fe0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_374ec64b-e887-4a7d-8aac-632167dbea2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_374ec64b-e887-4a7d-8aac-632167dbea2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RepaymentOfDebtPrepaymentFeePercentage_7b052d52-8118-434c-b8ee-59d4f012dacf" xlink:href="vyne-20210630.xsd#vyne_RepaymentOfDebtPrepaymentFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_vyne_RepaymentOfDebtPrepaymentFeePercentage_7b052d52-8118-434c-b8ee-59d4f012dacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_6f760d4d-f342-4bce-9556-bbc13f57a9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_6f760d4d-f342-4bce-9556-bbc13f57a9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ClassOfWarrantAbstract_ca2a57ac-12a0-47df-99e3-32ae14f76801" xlink:href="vyne-20210630.xsd#vyne_ClassOfWarrantAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_vyne_ClassOfWarrantAbstract_ca2a57ac-12a0-47df-99e3-32ae14f76801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c276863d-926c-405e-be2b-97b66ee07b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vyne_ClassOfWarrantAbstract_ca2a57ac-12a0-47df-99e3-32ae14f76801" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c276863d-926c-405e-be2b-97b66ee07b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9af128cb-d5ae-49b6-a99c-b252fefb19f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vyne_ClassOfWarrantAbstract_ca2a57ac-12a0-47df-99e3-32ae14f76801" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9af128cb-d5ae-49b6-a99c-b252fefb19f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e0ca46a6-5b8d-4ad4-be20-a888d75d56c1" xlink:to="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_18bf03b1-547c-4faf-9860-589943c7d7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_18bf03b1-547c-4faf-9860-589943c7d7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_7682bc9e-8c69-48af-bfeb-d6916aba57aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:to="loc_us-gaap_DebtInstrumentFairValue_7682bc9e-8c69-48af-bfeb-d6916aba57aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f94c8295-21df-456e-b67a-eff0b520bf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:to="loc_us-gaap_InterestExpenseDebt_f94c8295-21df-456e-b67a-eff0b520bf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_b4a57a9f-595a-47f4-8d91-f28147d03dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_b96e9b64-8209-4565-9aaa-9987d141e8be" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_b4a57a9f-595a-47f4-8d91-f28147d03dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITAL" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITAL"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_2df3c38f-4ca6-478c-93bc-27d57b9cc13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4cc2113c-22d8-4284-b2fe-a9f062456083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_2df3c38f-4ca6-478c-93bc-27d57b9cc13a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4cc2113c-22d8-4284-b2fe-a9f062456083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALTables" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d28fe416-bb15-4445-b087-2fb32e5469fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock_34ba38f9-c528-4897-ae7e-c78a647e5f3c" xlink:href="vyne-20210630.xsd#vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d28fe416-bb15-4445-b087-2fb32e5469fc" xlink:to="loc_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock_34ba38f9-c528-4897-ae7e-c78a647e5f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c06bfd6f-995a-4475-90e9-dcc09598f8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d28fe416-bb15-4445-b087-2fb32e5469fc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c06bfd6f-995a-4475-90e9-dcc09598f8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e549eef5-319a-483a-9c74-6ae4c9b8eb91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d28fe416-bb15-4445-b087-2fb32e5469fc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e549eef5-319a-483a-9c74-6ae4c9b8eb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_35e77b89-1407-4663-a58f-d265a4e46c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_35e77b89-1407-4663-a58f-d265a4e46c01" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7bd02571-51f6-4733-9897-2237584b7402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7bd02571-51f6-4733-9897-2237584b7402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e6b1541f-1d22-42c8-9845-64bc41359f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7bd02571-51f6-4733-9897-2237584b7402" xlink:to="loc_us-gaap_EquityComponentDomain_e6b1541f-1d22-42c8-9845-64bc41359f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_33b1706c-36f3-44a3-b5f3-508014112cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e6b1541f-1d22-42c8-9845-64bc41359f17" xlink:to="loc_us-gaap_CommonStockMember_33b1706c-36f3-44a3-b5f3-508014112cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4f0f2455-2c1e-4be7-aa4d-4d74cfeb3b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e6b1541f-1d22-42c8-9845-64bc41359f17" xlink:to="loc_us-gaap_WarrantMember_4f0f2455-2c1e-4be7-aa4d-4d74cfeb3b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3e7b41b3-2841-41f0-a6c8-2dcb1e98ad6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3e7b41b3-2841-41f0-a6c8-2dcb1e98ad6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60777077-e76b-4341-bdcf-03addf916b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e7b41b3-2841-41f0-a6c8-2dcb1e98ad6e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60777077-e76b-4341-bdcf-03addf916b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CantorSalesAgreementMember_3dab1303-0e3b-47a6-9398-274f5501e3f8" xlink:href="vyne-20210630.xsd#vyne_CantorSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60777077-e76b-4341-bdcf-03addf916b25" xlink:to="loc_vyne_CantorSalesAgreementMember_3dab1303-0e3b-47a6-9398-274f5501e3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RegisteredDirectOfferingMember_f8ebd414-4ed1-458f-a354-9c35cb7a5d93" xlink:href="vyne-20210630.xsd#vyne_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60777077-e76b-4341-bdcf-03addf916b25" xlink:to="loc_vyne_RegisteredDirectOfferingMember_f8ebd414-4ed1-458f-a354-9c35cb7a5d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_PublicStockOfferingMember_a88d1ef7-feaa-43c1-8f31-337afdb35d79" xlink:href="vyne-20210630.xsd#vyne_PublicStockOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60777077-e76b-4341-bdcf-03addf916b25" xlink:to="loc_vyne_PublicStockOfferingMember_a88d1ef7-feaa-43c1-8f31-337afdb35d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_be8e9d29-28c2-4cec-9e48-62ba7a80392b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_dei_LegalEntityAxis_be8e9d29-28c2-4cec-9e48-62ba7a80392b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e7523e98-5723-4568-b06e-b5a22af69347" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_be8e9d29-28c2-4cec-9e48-62ba7a80392b" xlink:to="loc_dei_EntityDomain_e7523e98-5723-4568-b06e-b5a22af69347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_71c1b9da-d732-48fd-9c8e-da1e465a4b8e" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e7523e98-5723-4568-b06e-b5a22af69347" xlink:to="loc_vyne_FoamixMember_71c1b9da-d732-48fd-9c8e-da1e465a4b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b380a773-3fea-428e-8875-40b6c93a7ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b380a773-3fea-428e-8875-40b6c93a7ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3edd4518-8760-4d02-8331-e40b5609428e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b380a773-3fea-428e-8875-40b6c93a7ff2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3edd4518-8760-4d02-8331-e40b5609428e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_07ce94c6-2574-4c7e-b029-c10976e0bfab" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3edd4518-8760-4d02-8331-e40b5609428e" xlink:to="loc_vyne_FoamixMember_07ce94c6-2574-4c7e-b029-c10976e0bfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d04ccd74-3930-4552-aedb-ee30cfaaced6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_srt_RangeAxis_d04ccd74-3930-4552-aedb-ee30cfaaced6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90eab45e-c21a-46c5-b172-c026659e0bfc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d04ccd74-3930-4552-aedb-ee30cfaaced6" xlink:to="loc_srt_RangeMember_90eab45e-c21a-46c5-b172-c026659e0bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_409e7acd-8099-4653-b629-781509191923" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90eab45e-c21a-46c5-b172-c026659e0bfc" xlink:to="loc_srt_MaximumMember_409e7acd-8099-4653-b629-781509191923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7da42509-b935-43be-bc24-a1c5f0d1b0f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90eab45e-c21a-46c5-b172-c026659e0bfc" xlink:to="loc_srt_MinimumMember_7da42509-b935-43be-bc24-a1c5f0d1b0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a9fe681a-4642-4e97-b6e4-759612476bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a9fe681a-4642-4e97-b6e4-759612476bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e4523ba1-9088-4f9c-8379-107ef4eaf850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a9fe681a-4642-4e97-b6e4-759612476bf5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e4523ba1-9088-4f9c-8379-107ef4eaf850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1f40787d-a99a-4134-924d-216ebd8bbbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e4523ba1-9088-4f9c-8379-107ef4eaf850" xlink:to="loc_us-gaap_SubsequentEventMember_1f40787d-a99a-4134-924d-216ebd8bbbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06eb6df8-743f-488e-84eb-5655c5ab7d13" xlink:to="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_98926162-3300-47b5-a480-9fa81656a526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_98926162-3300-47b5-a480-9fa81656a526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_617dee6b-3922-496f-9b42-efebc7d118a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_617dee6b-3922-496f-9b42-efebc7d118a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6e3cf4ec-9504-462c-bd11-828c4be57dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6e3cf4ec-9504-462c-bd11-828c4be57dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_77016069-0de5-49b2-9824-f25b759fdae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_77016069-0de5-49b2-9824-f25b759fdae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_17cdb2b6-fe80-48f9-b7da-bbe22d3d376a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_17cdb2b6-fe80-48f9-b7da-bbe22d3d376a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_23e2f5cb-dc67-4a0e-8fc9-fe64ece88e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_23e2f5cb-dc67-4a0e-8fc9-fe64ece88e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d80c2171-d257-458f-aa7e-af170587c229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d80c2171-d257-458f-aa7e-af170587c229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CommonStockVotingRightsNumberPerShare_9146d37d-04e6-43e9-8740-ea1441c63a6c" xlink:href="vyne-20210630.xsd#vyne_CommonStockVotingRightsNumberPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_CommonStockVotingRightsNumberPerShare_9146d37d-04e6-43e9-8740-ea1441c63a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_7dda4384-d0d5-4dde-afdc-7d5dc4033506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_7dda4384-d0d5-4dde-afdc-7d5dc4033506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock_1becd4bc-940b-473b-ac84-7fbce3fe6883" xlink:href="vyne-20210630.xsd#vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock_1becd4bc-940b-473b-ac84-7fbce3fe6883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b8bad167-e23c-4096-8a91-36b629580a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b8bad167-e23c-4096-8a91-36b629580a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1ac591a2-1393-4014-9bc2-dc2bc2aca5db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1ac591a2-1393-4014-9bc2-dc2bc2aca5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ee0350d2-06a8-44d6-a989-8b77efcfff90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ee0350d2-06a8-44d6-a989-8b77efcfff90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0756137d-08c8-4f77-b2e1-d2e69caaa1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0756137d-08c8-4f77-b2e1-d2e69caaa1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_22a30ae7-0672-411e-8adc-1f8dc5fefe99" xlink:href="vyne-20210630.xsd#vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_22a30ae7-0672-411e-8adc-1f8dc5fefe99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c167e622-f91e-4f8a-8bae-251861c3ac34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c167e622-f91e-4f8a-8bae-251861c3ac34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_StockIssuedDuringPeriodSharesWarrantsExercised_806c175f-f1fc-4e34-8296-da20b78ca220" xlink:href="vyne-20210630.xsd#vyne_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_StockIssuedDuringPeriodSharesWarrantsExercised_806c175f-f1fc-4e34-8296-da20b78ca220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessAcquisitionContingentStockRightIssued_7870f4d0-d08c-453b-a21c-795c8287d6ce" xlink:href="vyne-20210630.xsd#vyne_BusinessAcquisitionContingentStockRightIssued"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_BusinessAcquisitionContingentStockRightIssued_7870f4d0-d08c-453b-a21c-795c8287d6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_8fd2a8c0-7809-4471-9761-d8a09195c910" xlink:href="vyne-20210630.xsd#vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97e030b1-4b5d-4ee9-877f-c5cabd946e17" xlink:to="loc_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification_8fd2a8c0-7809-4471-9761-d8a09195c910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALSharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dc2560d0-5d0f-4704-bd36-87c26946cb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dc2560d0-5d0f-4704-bd36-87c26946cb80" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a1e96588-ec1c-4488-9746-c424465d3e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_us-gaap_PlanNameAxis_a1e96588-ec1c-4488-9746-c424465d3e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6af32290-fd6c-45f2-80d9-cb83629c9395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a1e96588-ec1c-4488-9746-c424465d3e8d" xlink:to="loc_us-gaap_PlanNameDomain_6af32290-fd6c-45f2-80d9-cb83629c9395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_A2019PlanMember_d3b4629a-c81c-4758-a8c0-508bb8d39d94" xlink:href="vyne-20210630.xsd#vyne_A2019PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6af32290-fd6c-45f2-80d9-cb83629c9395" xlink:to="loc_vyne_A2019PlanMember_d3b4629a-c81c-4758-a8c0-508bb8d39d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_A2018PlanMember_75119764-7918-49ec-a983-8ae03cee4886" xlink:href="vyne-20210630.xsd#vyne_A2018PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6af32290-fd6c-45f2-80d9-cb83629c9395" xlink:to="loc_vyne_A2018PlanMember_75119764-7918-49ec-a983-8ae03cee4886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EmployeeStockPurchasePlanMember_f415d478-e8f0-4cb5-8006-61a294fa176f" xlink:href="vyne-20210630.xsd#vyne_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6af32290-fd6c-45f2-80d9-cb83629c9395" xlink:to="loc_vyne_EmployeeStockPurchasePlanMember_f415d478-e8f0-4cb5-8006-61a294fa176f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_864438f1-7306-402b-9c01-f516df0d3267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_864438f1-7306-402b-9c01-f516df0d3267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33801eca-61ed-461a-b5a2-056d976bbb93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_864438f1-7306-402b-9c01-f516df0d3267" xlink:to="loc_us-gaap_EquityComponentDomain_33801eca-61ed-461a-b5a2-056d976bbb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_aeff66d4-8741-4a44-824e-9c7054253496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33801eca-61ed-461a-b5a2-056d976bbb93" xlink:to="loc_us-gaap_CommonStockMember_aeff66d4-8741-4a44-824e-9c7054253496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7050bbb7-9f5d-45d9-b1a1-985f684d53c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_dei_LegalEntityAxis_7050bbb7-9f5d-45d9-b1a1-985f684d53c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fe78770e-7333-4005-9521-2399f08116f3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7050bbb7-9f5d-45d9-b1a1-985f684d53c6" xlink:to="loc_dei_EntityDomain_fe78770e-7333-4005-9521-2399f08116f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_37dc3ae9-fe6a-4679-8496-af0a3c80adbb" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_fe78770e-7333-4005-9521-2399f08116f3" xlink:to="loc_vyne_FoamixMember_37dc3ae9-fe6a-4679-8496-af0a3c80adbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_520d1d78-5082-4003-9741-6f638e6cd896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_520d1d78-5082-4003-9741-6f638e6cd896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e10db87-9316-4778-a8b4-e419f0beb17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_520d1d78-5082-4003-9741-6f638e6cd896" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e10db87-9316-4778-a8b4-e419f0beb17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_580e8a3c-583d-4a0f-b011-c5947feb7624" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2e10db87-9316-4778-a8b4-e419f0beb17e" xlink:to="loc_vyne_FoamixMember_580e8a3c-583d-4a0f-b011-c5947feb7624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_69289dc3-de9d-4c89-a150-67e69d1fe44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_us-gaap_GranteeStatusAxis_69289dc3-de9d-4c89-a150-67e69d1fe44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_e34fb97a-8c9a-45a4-9a6f-eee7fa14294b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_69289dc3-de9d-4c89-a150-67e69d1fe44d" xlink:to="loc_us-gaap_GranteeStatusDomain_e34fb97a-8c9a-45a4-9a6f-eee7fa14294b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_83493f76-03f0-4d1b-961a-95bcb4808a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_e34fb97a-8c9a-45a4-9a6f-eee7fa14294b" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_83493f76-03f0-4d1b-961a-95bcb4808a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_31df66d7-d49e-4667-ad15-8a9a300d0d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_e34fb97a-8c9a-45a4-9a6f-eee7fa14294b" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_31df66d7-d49e-4667-ad15-8a9a300d0d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_54bcd8c5-629f-4932-baeb-f45915914a83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_srt_CounterpartyNameAxis_54bcd8c5-629f-4932-baeb-f45915914a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5d6ef40-254c-467a-befb-0b09849cb5fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_54bcd8c5-629f-4932-baeb-f45915914a83" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5d6ef40-254c-467a-befb-0b09849cb5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FoamixMember_e234de89-44c7-434e-af80-03bd383ce7d5" xlink:href="vyne-20210630.xsd#vyne_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5d6ef40-254c-467a-befb-0b09849cb5fe" xlink:to="loc_vyne_FoamixMember_e234de89-44c7-434e-af80-03bd383ce7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9151be1b-cc8b-4ec0-8b2e-b9bd5dec458a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e30250d6-bd2d-486f-93e4-3ab520638c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e30250d6-bd2d-486f-93e4-3ab520638c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_a556cc21-dfa6-48b7-936d-1d7cbba8c56c" xlink:href="vyne-20210630.xsd#vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_a556cc21-dfa6-48b7-936d-1d7cbba8c56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_58dab4df-49a3-4073-88f0-a5d7876de132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_58dab4df-49a3-4073-88f0-a5d7876de132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7ea48fb8-70bf-485d-9d29-37627b3e7edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7ea48fb8-70bf-485d-9d29-37627b3e7edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4e964893-e9ed-4040-b729-af95ffd28a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4e964893-e9ed-4040-b729-af95ffd28a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_ef0f234a-09ed-47a3-b1c4-943663f3ef96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_ef0f234a-09ed-47a3-b1c4-943663f3ef96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BusinessAcquisitionContingentStockRightIssued_dfb71382-b127-4212-9cc9-29f2332e0bd7" xlink:href="vyne-20210630.xsd#vyne_BusinessAcquisitionContingentStockRightIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_BusinessAcquisitionContingentStockRightIssued_dfb71382-b127-4212-9cc9-29f2332e0bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_dc5b6025-8af3-4999-87ee-0bcf044f6dd9" xlink:href="vyne-20210630.xsd#vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_dc5b6025-8af3-4999-87ee-0bcf044f6dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ContingentStockRightSharesConversion_79e44955-8dcc-4453-86bd-43ddf87d45ae" xlink:href="vyne-20210630.xsd#vyne_ContingentStockRightSharesConversion"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_ContingentStockRightSharesConversion_79e44955-8dcc-4453-86bd-43ddf87d45ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_EffectiveExchangeRatio_fe68584e-9ca6-482a-8135-977c0350b27e" xlink:href="vyne-20210630.xsd#vyne_EffectiveExchangeRatio"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_EffectiveExchangeRatio_fe68584e-9ca6-482a-8135-977c0350b27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_eeee87bb-21b8-4abf-9ca7-6744e454c5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_eeee87bb-21b8-4abf-9ca7-6744e454c5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_3256cb78-fa4c-4294-9c9f-80afa736de64" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_3256cb78-fa4c-4294-9c9f-80afa736de64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_9a9abfb1-897f-4ce8-9def-ba0e0668a2bb" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_9a9abfb1-897f-4ce8-9def-ba0e0668a2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_f90d1255-7b28-4ac2-a1a7-aeead014a540" xlink:href="vyne-20210630.xsd#vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_f90d1255-7b28-4ac2-a1a7-aeead014a540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_719219b9-8772-44d8-9ad9-ff0ea8f841cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84cefd47-1929-4166-9e70-7c9bd6896fc7" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_719219b9-8772-44d8-9ad9-ff0ea8f841cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALOptionsandRSUGrantsDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_beb174d6-c8bc-4a55-be55-7896e844c790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206a078-5ebf-431b-a9cd-658a538cc48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_beb174d6-c8bc-4a55-be55-7896e844c790" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206a078-5ebf-431b-a9cd-658a538cc48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99005a19-fd31-47ed-b514-d731296397fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206a078-5ebf-431b-a9cd-658a538cc48f" xlink:to="loc_us-gaap_AwardTypeAxis_99005a19-fd31-47ed-b514-d731296397fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5496ed3-6905-45b4-b464-0cc158f92311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_99005a19-fd31-47ed-b514-d731296397fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5496ed3-6905-45b4-b464-0cc158f92311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_03c0d88b-a45f-4aca-b24a-1168ad72b5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5496ed3-6905-45b4-b464-0cc158f92311" xlink:to="loc_us-gaap_EmployeeStockOptionMember_03c0d88b-a45f-4aca-b24a-1168ad72b5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4007dd3e-0377-4a6c-b14e-cf8d731b823d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5496ed3-6905-45b4-b464-0cc158f92311" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4007dd3e-0377-4a6c-b14e-cf8d731b823d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_48bd5a08-0256-4a31-84cd-f78596a0ae2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206a078-5ebf-431b-a9cd-658a538cc48f" xlink:to="loc_srt_RangeAxis_48bd5a08-0256-4a31-84cd-f78596a0ae2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb2050d3-c6f1-4429-9c9f-821df5bb0b7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_48bd5a08-0256-4a31-84cd-f78596a0ae2a" xlink:to="loc_srt_RangeMember_cb2050d3-c6f1-4429-9c9f-821df5bb0b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca875fe3-d2d3-4203-b416-31065cadc251" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb2050d3-c6f1-4429-9c9f-821df5bb0b7f" xlink:to="loc_srt_MinimumMember_ca875fe3-d2d3-4203-b416-31065cadc251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6d234977-fe59-43fa-8179-94bae2fb1508" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb2050d3-c6f1-4429-9c9f-821df5bb0b7f" xlink:to="loc_srt_MaximumMember_6d234977-fe59-43fa-8179-94bae2fb1508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206a078-5ebf-431b-a9cd-658a538cc48f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0c8e719f-5dc6-4001-9661-7ea409662444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0c8e719f-5dc6-4001-9661-7ea409662444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba74842c-6f09-48b8-8722-31eaca69e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ba74842c-6f09-48b8-8722-31eaca69e4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_d670d0db-6a21-45ed-830f-df889e11b88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_d670d0db-6a21-45ed-830f-df889e11b88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_a3f61464-ac37-4a05-b0ca-ab4d45dbdea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_a3f61464-ac37-4a05-b0ca-ab4d45dbdea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74b6b26a-9289-48eb-b0b4-440cc0331f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74b6b26a-9289-48eb-b0b4-440cc0331f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3becf7ff-a0b3-4ec2-9688-c5d5bf2b52c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49685876-2e32-4fcb-9033-8fc4e4cf08d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3becf7ff-a0b3-4ec2-9688-c5d5bf2b52c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALFairvalueassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e32bd243-ba67-4dff-a35c-8ff6b38aac27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a7e29fa-8fa0-44b2-97e2-f383f9590e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e32bd243-ba67-4dff-a35c-8ff6b38aac27" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a7e29fa-8fa0-44b2-97e2-f383f9590e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dd733497-a8dc-4811-bf8a-417425c4b42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a7e29fa-8fa0-44b2-97e2-f383f9590e18" xlink:to="loc_us-gaap_AwardTypeAxis_dd733497-a8dc-4811-bf8a-417425c4b42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d96b9218-67c4-41ed-8c94-ba4b6f52fe59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dd733497-a8dc-4811-bf8a-417425c4b42d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d96b9218-67c4-41ed-8c94-ba4b6f52fe59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_55040afa-2434-44ac-ad3b-2ef2a7fc0677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d96b9218-67c4-41ed-8c94-ba4b6f52fe59" xlink:to="loc_us-gaap_EmployeeStockOptionMember_55040afa-2434-44ac-ad3b-2ef2a7fc0677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ebd8c108-7a47-4c16-93fa-43c061ebdd22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a7e29fa-8fa0-44b2-97e2-f383f9590e18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ebd8c108-7a47-4c16-93fa-43c061ebdd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ebd8c108-7a47-4c16-93fa-43c061ebdd22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_95ade927-78e3-4236-88eb-ee33d232a284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_95ade927-78e3-4236-88eb-ee33d232a284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_98d398df-9a73-406a-80f8-3d269d446a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_98d398df-9a73-406a-80f8-3d269d446a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ad970c72-a6cf-4d51-a01d-16e2882a84ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ad970c72-a6cf-4d51-a01d-16e2882a84ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_d4799da0-1bf2-4f7d-9694-3fefdf520ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_d4799da0-1bf2-4f7d-9694-3fefdf520ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_518a1b29-a714-4d6d-840b-bf0a78c365c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_518a1b29-a714-4d6d-840b-bf0a78c365c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_00296b2d-79b1-48bf-b3cd-50dabca718a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_d36257e8-88ca-495a-8bdd-a3456119332b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_00296b2d-79b1-48bf-b3cd-50dabca718a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#SHARECAPITALScheduleofSharebasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_bb2936b2-0f12-461c-8588-17a3c1c19771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_99a058d2-6ce7-4c6e-ba08-0d20142b04cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_bb2936b2-0f12-461c-8588-17a3c1c19771" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_99a058d2-6ce7-4c6e-ba08-0d20142b04cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6ed09453-236f-477d-bf7c-84b25d8ccb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_99a058d2-6ce7-4c6e-ba08-0d20142b04cc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6ed09453-236f-477d-bf7c-84b25d8ccb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3e4a1f10-6a8c-4790-b4b0-35fe3035c3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6ed09453-236f-477d-bf7c-84b25d8ccb08" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3e4a1f10-6a8c-4790-b4b0-35fe3035c3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba9224fc-3b13-4dac-836a-86df65e74166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3e4a1f10-6a8c-4790-b4b0-35fe3035c3a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba9224fc-3b13-4dac-836a-86df65e74166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_755817d2-6bf7-4dae-9a7d-3141cbffa571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3e4a1f10-6a8c-4790-b4b0-35fe3035c3a9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_755817d2-6bf7-4dae-9a7d-3141cbffa571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_432ce279-0158-41c6-9a73-e8d4966135b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_99a058d2-6ce7-4c6e-ba08-0d20142b04cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_432ce279-0158-41c6-9a73-e8d4966135b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0cf74076-2868-4b4f-acbe-0d1299bd2f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_432ce279-0158-41c6-9a73-e8d4966135b1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0cf74076-2868-4b4f-acbe-0d1299bd2f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASE" xlink:type="simple" xlink:href="vyne-20210630.xsd#OPERATINGLEASE"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_33cfcf27-6fd3-4604-890f-1c653848dfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d8246b05-09c9-4a04-b6c4-d5c50e2383a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33cfcf27-6fd3-4604-890f-1c653848dfc0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d8246b05-09c9-4a04-b6c4-d5c50e2383a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASETables" xlink:type="simple" xlink:href="vyne-20210630.xsd#OPERATINGLEASETables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ba19694b-cce7-41f9-9689-9158537d8efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a3a116fc-d41f-47f8-92e1-87fd1b530c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ba19694b-cce7-41f9-9689-9158537d8efe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a3a116fc-d41f-47f8-92e1-87fd1b530c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#OPERATINGLEASENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d5c13c14-d1aa-4b4e-8993-6c8f69b9278a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a25cfd4b-bd20-421e-94de-1fc74461d0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d5c13c14-d1aa-4b4e-8993-6c8f69b9278a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a25cfd4b-bd20-421e-94de-1fc74461d0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58e5e0fc-140e-4996-9f53-102e3104a102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a25cfd4b-bd20-421e-94de-1fc74461d0f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58e5e0fc-140e-4996-9f53-102e3104a102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96a1317d-7c8d-4dcd-968d-18b511c3963d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58e5e0fc-140e-4996-9f53-102e3104a102" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96a1317d-7c8d-4dcd-968d-18b511c3963d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_OriginalSpaceMember_e41a9091-a3ca-42c3-9056-16a0070982ba" xlink:href="vyne-20210630.xsd#vyne_OriginalSpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96a1317d-7c8d-4dcd-968d-18b511c3963d" xlink:to="loc_vyne_OriginalSpaceMember_e41a9091-a3ca-42c3-9056-16a0070982ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_AdditionalSpaceMember_3d104f88-f6b2-466e-bf6c-b1c66daaf093" xlink:href="vyne-20210630.xsd#vyne_AdditionalSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96a1317d-7c8d-4dcd-968d-18b511c3963d" xlink:to="loc_vyne_AdditionalSpaceMember_3d104f88-f6b2-466e-bf6c-b1c66daaf093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d38180e1-0f54-4bff-a067-4c50ff86fe19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a25cfd4b-bd20-421e-94de-1fc74461d0f6" xlink:to="loc_srt_StatementGeographicalAxis_d38180e1-0f54-4bff-a067-4c50ff86fe19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d76c19f2-6cbb-4bfa-a46f-6018a12ec0d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d38180e1-0f54-4bff-a067-4c50ff86fe19" xlink:to="loc_srt_SegmentGeographicalDomain_d76c19f2-6cbb-4bfa-a46f-6018a12ec0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_BridgewaterNewJerseyMember_2bf14343-c84c-4485-af9a-35691f4f8863" xlink:href="vyne-20210630.xsd#vyne_BridgewaterNewJerseyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d76c19f2-6cbb-4bfa-a46f-6018a12ec0d7" xlink:to="loc_vyne_BridgewaterNewJerseyMember_2bf14343-c84c-4485-af9a-35691f4f8863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IL_74354db2-4759-47be-8fa7-61691d62a442" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d76c19f2-6cbb-4bfa-a46f-6018a12ec0d7" xlink:to="loc_country_IL_74354db2-4759-47be-8fa7-61691d62a442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a25cfd4b-bd20-421e-94de-1fc74461d0f6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_FacilitySpaceUnderLease_e8330a62-3cee-4cff-b3b3-8ab2ea85b0df" xlink:href="vyne-20210630.xsd#vyne_FacilitySpaceUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:to="loc_vyne_FacilitySpaceUnderLease_e8330a62-3cee-4cff-b3b3-8ab2ea85b0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7246691d-44c0-417a-91ff-e07c9470590d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7246691d-44c0-417a-91ff-e07c9470590d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_bc24b642-7c1d-4bca-81d8-a841be5d5b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_bc24b642-7c1d-4bca-81d8-a841be5d5b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vyne_RestrictedInvestmentsToSecureLeaseAgreements_ba2bdeb8-a7b6-40c4-8a59-fa55c552ccfe" xlink:href="vyne-20210630.xsd#vyne_RestrictedInvestmentsToSecureLeaseAgreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_411e08fc-0f4f-442e-a9cc-50b17156811f" xlink:to="loc_vyne_RestrictedInvestmentsToSecureLeaseAgreements_ba2bdeb8-a7b6-40c4-8a59-fa55c552ccfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="vyne-20210630.xsd#OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a677addf-1aa5-44db-b58d-162ea5a7488b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4dbb37df-0027-4ff5-8667-9ca69f26f17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a677addf-1aa5-44db-b58d-162ea5a7488b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4dbb37df-0027-4ff5-8667-9ca69f26f17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_aa776f97-3b2e-43d5-9aba-a6b253d42337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a677addf-1aa5-44db-b58d-162ea5a7488b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_aa776f97-3b2e-43d5-9aba-a6b253d42337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_682ac436-94cc-4364-ad7e-714875a56de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a677addf-1aa5-44db-b58d-162ea5a7488b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_682ac436-94cc-4364-ad7e-714875a56de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e45cfef7-28ec-43a6-b55a-22fc9bb56430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a677addf-1aa5-44db-b58d-162ea5a7488b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e45cfef7-28ec-43a6-b55a-22fc9bb56430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cd81f44b-6315-4da2-9e05-6f2eac443451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a677addf-1aa5-44db-b58d-162ea5a7488b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cd81f44b-6315-4da2-9e05-6f2eac443451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_23e2b49a-4f90-4ed5-8654-e9343bef4ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a677addf-1aa5-44db-b58d-162ea5a7488b" xlink:to="loc_us-gaap_OperatingLeaseLiability_23e2b49a-4f90-4ed5-8654-e9343bef4ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="vyne-20210630.xsd#OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="vyne-20210630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a53274f-6efd-40af-a9ab-23fefbdd70b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cc29a933-ce00-4794-84bb-ce9ee5f15629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a53274f-6efd-40af-a9ab-23fefbdd70b0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cc29a933-ce00-4794-84bb-ce9ee5f15629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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MMO:CVG9L1Y:;;=B6"[3G YT%0%N1]DTW)QJK;],4M0)FPI'J&2")<K9GVX6
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ME'XI6I+[H3EUH*3M3QR EM1A:$P:* #6XAZ*1M=@U"?U%UH4.B&MN/J98X"
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MY+A["&J](W$\64W.M9W["M=%@&EV]0$YIMUIUP+E6XS]1+<L<1+L=%;F[!P
MF@[B2-J%QHI6EYKIP$<PX:)"M6<H\K(N 0Z^;8* V0+'G;6R<D,N;5UY/@E'
M0B"AL9BT9\H( 1*LFR_Q041)RBAP$F&N"R"7R4DJRGOT3(\[)'H9?S<'O:AY
M"!<6D(F9?:)<BHX).WG'E?XW7_92(J66OQG!0YM$J1;(N1>!G/M  *%8T['T
M7H17/H2.I?>(+TX@^RZ$EOX%#4]?BEKW*/45H!>C:Y HW^H3_X!6[R"4IXS
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M10]+[ <"*X&#9RHW:8Q&<&&8O0/S_ZJ!=J/M,;"P0!"WJJ%UC-7)YJ7WX]O
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M_D'&&H];)=3NED#3C)G#E2@14\CRNP:C.E$5F@1+B5_B'0]L7:UID+-J."1
M(G%3$\\2$5UBDIC8K=3W"1<D'(E?NNO$HL??%'*3AC$&1B?A2)H8&$IL<C1:
M&L47@@1!@VTO.A0!&:-/,==\A@<Y?HI>&N"(:<56F40$2AF@X2%;BZ6HL0F4
M7TDG9^8CR[]285EW-L&$&PZB9$4BFE9,%B A:(AB-?LN= JP/*1 0A Q!_4I
M;2_>*,0FFF@CTW$IM33]0AS.GB9KXXQI4-@(4:B^NNTX7O[1Z$&VU..E7:VB
M#YF[M0'S]K1@QIJCF/)9!1[]M!R/?7$4KB\.P&=F/.Y7K .& T\;@R?;4-)_
MMHWL%WNV8Y:K'M9LFI0?]*'UPPS9]H"$1D*D-2B!A!W+)46R^PQXC"/KU)9
M%*QJ!=J=_QD.<5N&A#YH31LI>A%1:(H)]&#9&B W[2H@]R.CK%.08+'DXY3/
M D$<D/ !^[MY04[VGOG9UE^(A+_QAGE>6'A))P!TU@.'-N!PQC6H3!XEAH4D
M2(:+($="[D-BL;KZBPEWBW<82CUC9$\6-.S38$5BFQ,C1A&/;7EX9IN*SL:N
MT*C]#XOTBY]?"202K2Q0I6(Y$R37P^TN"M;C4-95XG%-T&"_R?*V>[ 83'*)
MGZMRM=YSD#OK!J#@2P43WP$<S;Q20E^2,V X"<N-4?\@$=(HVD@8 ;].9B=6
MQ+2U%,?Y9VCTI$"BN@\+"*KC4'\B<AY</6*?L&\4,(8(N,2 )!:RD6E0'*(8
MIAR.+EL+!]E:<B+Y.'1Q8A5^R_=>SNQ [U&98;C94#W:OUJ,AN53T);SB(!&
M*/M.X4C:LQ]!6_8DN1?(_BN".1,06'ZW+!>'EDY XYSQ$@V=_B54]G"YD.[1
M^Q;>I1:3 -[9<@0O?%N!^=L;,?^'6KRRTX<7MOOP[(]U6+B[!7.V-6#ZVF(\
MN>:8@,CD3ROPQ.>%6'6@@:YHT@#6IDP'B1(S^] .I+CQ<\( Y+-Q!X' S-@2
M#.?H.AR>?:6L6EC/9H(AE^=DB=0]&,>R+L'Q]^<"G35J]&-"TI5_G(ECZ><;
M+F2HQ-]L=C-ZV!^$0ZMDU/,%]YJ]6*0FCB@F],=_]A!.Z21 0B,8HW\0(+7/
M.UR':DJ$&/B;#&8EC;"8X',K"$X8E-E]:/D@'06NL:CW#)< 0710JV=X/D;7
MHD\-([@G]1:GN&.SKT;[C@_-%I*Z;:7D1M%"G :Y;[*I@S2QC4BFOB%<K._!
M+;%\)_N<$I"H5[;Z4Y';8L3^2K2M?1YYGLM03SU0XEGJ7"@1XH9*%#>9%%*&
M2'#JXH43U&W?OQV%WHM%%)4!F6@Y [4IX5XR8B*?]ZZTP4D!,:Y.<BG_?@Y(
M:%W<,S8L 4)%%@WS2$-  DA,B:H@8\,J4N2T!^F5QG/L,X*0&!&F#M#PD*TE
MVM(LCW/$)N&3=<.IW!..1.9%D<\IYM"NMAFHVH&JUY/0N/SQ'J(-@80'@T23
M2Z&.A$K7]B7W()(S$:%%-XES4[W[' $2K@1499R+7<_=(2;7ATNKL/R[8KR\
MPX_Y.UKPXJY&S/^Q&L]OK\,+.QOQS#8?4C=5X='/BO#HYZ5X]/,*3/FD% D?
MYV(W:82U,U:J/3HJKGTLB,CO?-YI.'Z) Q%>TU G%!8%L-C2=!:C>/$C8N D
MLK'X$)F O-Z!8G;-X,D'YMX!M!P&N&=RN%W"]F_+NDY"&$I8!=J-,'X& R5Y
M5=''Y>6VC:^J)W&XP]EXFX/+%E$NI =9SI, B>FG6#WBZF>X-14VS'T"B2RY
M,P=:X-(;6_4:,G'X]^#@W!O$^I,BJ1"E>-4.E=F-1,E[7+&H7/*(,<@S91-;
M# *Q=<94PG3 1$0^ED8=+<7V1]J?[]A^D,KV_/<3(-$]>CC(=+5#![AR)"?L
MB,@\::;?<0REJY)EXRX:TW'E1CR5W8-%#R2A![B:ECI<.-#2UZ<#-6O$=H;6
MS 12SNS.RHJ+=B0&2.AK$VF*9_9BY7>(3LE.^_/O (FKM_$PUJ5U"7"4=H$H
M=AF1C0>WP>">.P5IEPLP4,2BOD;/EX!!K*@+L4N_^9F7(R]3WY7EWXZJGF6T
M=!17WM@#IWXERE8:,%FV5U"6+"(W'=K_"6I6)<"W]"%QX NM>$"<^*@GB61/
M0&@IN13:E-!8[7Z)8Q)>=A=:G_L3:A)'B6U)@Z<_CF:,QKY%]XF"\HL]A5AD
M;$,6;JW'PNT->'Y'O2A:%V[WP?-5%1[]N @/K3F.![X\CDE?5,BR[](M%6*H
M)B"ANT^;@?C32O_ZMM$!H0/,#+Q0$P+;WA9[ EHV<C,KB< N6RYH^ 1Z"G.=
M']\1%)HD1FADXXLXFG$)JKWG*%MI#-!HO\#E7RKJ<KDG2MLA@*M$9K\<!82?
MUD'OL'PG?%BY7ZC@W_DY#DAYR5 '50A_]YKL9D>9FH>(IDF#T2K!J_J)/H%V
M"3A TW *E_P8W5H\,,>72ZYC8-&S7']G)CP5( E6:7/8#'@FYT6=1^=1Y,V_
M V7I8V169WA+QLEE?]0D#A3/;HH#M-N@^SX^>U+"1E!G1 !A]'W:>/ @@+$/
M9=4F_RT-4'VRKI!Z:PO)I?S[*9!8BU;F(VTN<6H&0XSLUF>:O6<8I(C!BLI5
M].*^P5W<YYGG*CUX'7_P?L $-PKRNE(M864"L:3#\A#,%>2UM*?WOY=-C .4
MR0;D@AW1 K04P[=N$6I>3X0_9S(8FX2 T?;*'<"*>T!1IG/)/6I*OXQ^.!/1
MO>)^A%[],_P9-#D?)HYPQ5GC</RC+!E J[[)QXO;&O#R-A]>V=DH0+)@IP_S
M?JR%=U,YGEQ3AD?75.'^M36X][-R//Y9,9(^W(/]C:JD%:KA+'M&/@HD(0:(
M89(\@ET2IN\ N0O/:''MMD#2F$!+T,%B[%25.AR^G(<T]D97.6I>>P!<D6$P
M).I1-))<?_$@%G^=AX7/U0  ( !)1$%4M O1\#=&YRY7#Z,3%,5GI#JGF@@G
MC+ ?;3^L1J'W D>Y9X&$ TZ6>UW#U!:!<3C$N5 SBG<[.-6L?_'Y4P*2RI\
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M\<A')7CLBUH\\GD='ONB&D]^7HKDCW+%VI6^MC1>ZW26&JF I#U"B%%*S"K
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MT[?+YE"%F1?*%H\E<Z]"ON=B',B\"MNS;@$*UXF),TVS600IAG18C 47 A3
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M\_V$_N![3L%8RA/J97YG?CSD62.B.=_YC).,>9_@29/K+B[=T^VA#NBHUJ!
MK LW(.=LS4!7W+;!;I]!19EP$)KF_VGN.X"LNLXT6P*49CRS:>R:,1EK:W>\
M-5-3M>/RNFKL#;8U:RLA"8&$D94#0>34)"')TDB69&-YD"6"L 0=WNL$(G73
M=(2FZ::;T#G00 ---QWH'%[ZMK[_/_]]KY'&LS:X-*_JOOO>O>></YS__\Y_
MPCW7*]BMV2"KI.L!M1&FG*X,WN<B11'+R2:\,A?7:?"=M1R+X,&=Z.3@*FJ^
MWY;ON^6B,#=3Q_S>X4#, 8DKVA$R@"-G000X_L5??,Y*&.9K+=J OE9YK$&>
MPJ7\@19@Y(HNNN2X"MO<ZV15.DZOQ@N-D7KB9?X>ZG'Z9$3 <JG;J_J.HR#U
MSJ/5+>ITR]KY@"#3B1Y:]3D<7I/KU$^K*X?I7!Y&'++BO!48O*S/&9'>4)>G
MLYLY:QBG_5WG>2:\IWG/ZIQ)\)7>96@]OA!-25/0G?XGN.:/0Y?O%AE@C1S\
M%I#]?Q')>1 X?!_".?<B7/00.O*?PT#3'G82L6-_*<9-_1'NFO0(;O_ZHQ@[
M\3'<-ODQ 98_O_M1S'C^UP(FC#Q>F/<;S%_Z,=B5(8@\LV@K&(FPB\/U)XL6
M;L&\ES_ @J4?X*5%[R(SK\(S7-I$5%&N<EF;)J,YHIB1&5>TM93+])41-50:
MO)0G_3LMA]@C:YR<004"0M6S,/[CH>IT-(P5(1#% V''>),STUN$J(EC;ZN+
MTAG,@;1@7M&]4?76*!Z4$2%J/PEXWC,CQIO<9+BNY<ML*2T@%)$N),M4+V(&
M]QG-G <B+$'2,YFE<;KG7]Z/UE-L5X"R,TK4:7S#6<VJE2%CZ5Z9,7PPD0,L
MWO;J0-*:3E58+[O[(>\HXD;6='JV2K8<VQA@-E??5JY71JR,O"@D'#T1U#,&
MU:5HF'-Z ;ZG4'H! HP1?:Z=ED?=R.'B5?='38/W+(ZU=->=R;X\@.L>>*6_
M,\\HGIWJ;N2D[_Z-54!45BE7G8,_J8F+0' ?:E+_ 5=2_A.Z_''H38U#>](M
M&-CSGX&\'R"8_8\(Y=V/0,Z]&,E[  /9T]&1.Q]H.RJ#BWRVYLXI]^"V"0]@
M[(09&#/A4<2-?P1C)L_"[5,?PYT3'\:/Y_P"SW+V9@G'2;0K(]._"[?BF7D?
M8M["[5BX:#OFS?\-7IB_&<\M^#7F+_M0P&0PI)P.!J(AIBI(#2>J07-LAK5T
M)IXUCQD_E2T?6U D%S0$9^5Z]_D4QY#VQ_6:,V27P-+QS(,&:$;H\3,J+7DE
M%VI]O&7_E#?>IYE9%X8A*O_'K#AVK!LMCYY<5SF5I.83/L1R6:R6+2\ 8WHF
M=/Q9>;HRE]RXCZUZEC&#V/*=WD<7$_-LE^77,TLD=4%H.K0X<#2SL:)Z&'W=
M9+0T/#.=I141^$66Y(_6PV#0K?*1:T&$[ 7CK'=I*50&+BL@F.ID8!A\D;QU
M41UJZ,F4Q#.SRL=Q8H D<]$Z1L-A!.72)28?P@N[O1Q#T^T";,L D\?(\+^7
MQ5'C?]YW5!U,*3W9JU=L_B8.MCJZHQ1+!N0CPN@MV> (YX"S;Z$Q^:_1D7H7
M>@DD*7'H2OX*PMG?03CO/@$0!9'[,)CW, 8+YN#*X>5 \!RW..-C4WA^]8>X
M;>+]$HF,F?PXQGUC#N+&S\(M$Q_''5/G8,Q?/H0?SGH;SRS>@><Y/<Q9FP4<
M;-TNQ]R7MV'!HFUX42(6CI5\B&?G?8"7E_T&_CU'O?T^^ K)Z$>-(:IQ!R14
MJ!SJ1;$50#WHFA2V*D0H3<,R&:WRT*T:54=6<?)68SKV=0_EL6RK6(\S_G!_
MA)[\):^:DBV(E6MYM2]N_V+/.G#+*U*D?*EQ>F1&76/9VAI*!F84T@Z8(D%]
M'('EN?$CZ3J*4IF80.:("8 X8'/C($)*'(=IKP=0 S_ESW3 E)17Y+?GD3P:
M43TSC:1S]WCB?TMJ]_5LXU!2L)<H-BWITLTT,@C*6>M 9>*#H4P?W=F..;C*
M6W.J+F@GID-EB'GT'4PLG;$BNSI:)H&(%)GZ]ATJ   @ $E$050FFM$5(%UM
MWB/OS*O[[XS(COPJ#V4S?6D9,>6X"Y:&E%F*TB%]OEV0_#O].]7\H:?H]*]K
M84TM4J!CAB<=%#N+X=*7<35E&GI]=Z O*0Y]R7=A9,\W@-Q[$,AY$*&\A_2<
M,QV#N;/05? 2@G5;]7D;/N8 (._T97SE[AF(&_\XXB8]CKC)<Q W\0F,F_8,
MXL;/ENX.QTW^]@<K,7O!%LQ=^:F,D^A"M6UX<>Y'$I5P&3T!AH.N\Y=\@I=>
M_@WF+GH;77SBVE.<4XT($:LF5V$T=%?[EH1G-4#>X3^W&I*#EZZUBDXO:Z@H
M43 [;V)P;MQ!*HH2$[34RJU<^R]GYP"\1\-1+6DK9;RX[%XYE,3N69W96<L@
M33,8&@T=U\!34](X1Q#$$&N%A?&R$'+AN!BS7>--RF\LD#^")?.Z(P;TU'"C
M>=4AHGI5.E96M%Y&R2\ ;WPSC>E&>9$R>(D\"_.J,Z83,:18IM7'.C1-#$W:
M/)$A'-T54#?/TN4/6M=L:((:)KF'3BD;TS$JB])1</!X<BRR3@?ED1*"//^9
M3MQ/-S0C(@C?3J]25S%IQ4X)!;H[H"YR=*(;$U[]&B^NLEPQ%D5+5RD<5!F4
MC1O^_AR0$/&(Q_)1Z1P1(FD]!O)GHV/77V#(?Q?Z=HU#]ZZO MG?123[7H0.
M/XPPCYQ'9/U(?^Y3N)B_&A@IT<$ZRN>V#_C>C/48-]6!R-0G,6;JTP(L8Z<^
MB5LG_P1QXQ_%N,DS,>7;<_'X_*UX8=D. 9-Y"[>"@#)OR0X\MV"+1"L$E.?G
M;P7OS5_X'O8>*%8@D;#4L6_*=G]C3[S%>G?5++<LN=SCV_BD(@D:NDL;$W&3
M;%8LT]"X&&TQ6.2AGVB$H 9& ]<PU5(P+^G:04>R(WK-I8YABOR2)EV$]+CU
M L^\[CFC1$4$$1TDM>Q6+M,R/]?<"G^\81\F=I8G"[=<R\HD<LL Q,XQ#1'Y
M,CV87GF-A_UG&?SPS#))ROCB6=M@O29I^26 Y1PM%BPD :\;8$3I:!Z3,MKU
M,UY$=(Z!.IZE*(%(QP%W^V>7EVU#2&70&E<G%;9$$M+7]_>0FEU7741$QR)?
MU+<%E+DW%S?PBNI'(P\!3;JA*(=%&X@JR&D=QQ 2@BR<&HX!$N(PRZ!^^?NZ
M+%H+-_X=!1)'P .26(J\QZ8H7(M+ON^B-_'?83#I#O3M^G,$TOX[D'F?6S,R
M'3AX/Y S T/9LV1L)'!Q-Q"Y)$_ :G]3J[NPH@-W3;M7(Y(I3[FH9";8U8F;
M,%/ A O7N KVJW_['!YX]GT\M60;GEN\!<_,Y^"JZ^9P)H? LG [.,OSTOQ?
M8.GR=T3_(H(\#>RL7.J#B@YK7]?5$Z_$&I:!AK5LHF86YAR!:5DW\@DQ/-57
M97 O%1[<7X6.S?$@[K'"QQEUIS<U!G9-.$E @Z,!\RQ&%E&0&8[0\/0Z>1/2
MCCXC'][CYD^VIPOW>.%_TC'>]/D2&M:(M#RDP_0\R*.E-]HD0DPP75 V[D!'
MOE@FRR8=_A9\H2C"DTW;1HV4+L6T1L?H\BS:YTZ6!AP,]IRLO$^],6^7R\\]
M]RT?Y*7M&B&0;Z8UF;5D4N;0I5Z7^1CRR+$6-WYD?+%>^'L@I'5 ?9"FZ6\H
M3-"QAD/'7;44NBFE<)&2Z2$2E$%-ED&>>9B.R8?4KY-?=.SD9IEF*Y:>=26Z
MI<_9(0U9M!RY3]H>?35'R^K,)5HIO.!=C*:]6;_BE!/EB"@W"DB,2>&. T^5
MN)3\]QA(O!/]2;>C+_FKP('O SFS@$Q.]TYWJUEG8Z!@(;K+-P$1[O+-*B/"
M T-#SO'"P.)7M^+6B0]BS+0G(6M*[IZ-6R?-Q*U3"":S<<N4)[Q[8R=.Q_^>
M]2:>)'"L^ 3/+_X8S[^\31:J,1)Y_J7-,AV\>.F'6+CH'1POK1FM-T^1*JN%
MZ*Q@<Q[^]L)_-?FHGETE6%JO3MQ:C4,GJY%==P7[JZYB7U47LFJ[<;"F'9EU
M+<BITO>NLM(YID+CH48**BXBO_(B.EW(+  #H.[*5>16-(HAT@B5EH;K-+J\
MB@O(K+R" Y4M.%S3@L-5%Y!;U8R"RB8T7.Z2\IVI"_^D=[#B$O9R#YCJ5F16
MMV)O52MR&[MD^TL:+O5!0I:/0$2ZPV%URC-=(\BLN8#ZK@$!OQ$JR^$STUE$
MP?R7NP>16W,1!VI:L+_Z,@[67L&!ZJMHY),&3M_B6!**JS/7M/<CI_XR#IP^
MK[)5=2*KO@<'ZKMPX'23@*=P-S((3@#0Z0Y6GA?9#6AHOZ1_MJ,/F6=:4-WN
M!D:#:GL$GX;N >367T1650NR:SIPJ*H+F57MR*R^A.S*)ISO[!/]46>,U%A>
M>W\0^6=:4-4R+%&G7F6(PFA%]<"R^>JPS+-MV'*T K_:7X ]9\ZBK&U  -4
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M]M0E7XPJ;/"5:J0V*%M^PU6LVIF+5?X2O))6C/B$?,0G'\-K*<4XUCP@$8;
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M;/"585WR"? ]\>Q3,S]!);'T,M[P%\MFV-+/9PG!8:D! M!:_U$L3RU'%11
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M,J9RN+8-6=7-N!)4IY1&+J"62)#9D)2%#4G9WIL8.4A-GCD>M#+Y!)+J1AQ
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MZXEZJ&D;P+KD(_!5]XA\*K-&*P3)C_-.XXWTHQ+A];HH4"J=IL0RV+ Z/7&
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MYIW%FN1"B6@8BM->R#?;2AHN!R\7IU<BX0J0T0JDGX\@\V(011=Z)9PF.,M
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MHB4$"4"BHY@2C1<ZNPQ"ZE/!K!9+Y6T@Q>+I**[.I"[9&'#]AI?:ZLHU4G3
M<$1:;0%V*B**7U'=<1O+""=R0[)_"IV5=L-QEJ XH]%P40\5$R;XL4X8:SB]
MDKS#Y5A;$_W++2E91B($2%@'PJ-3C:K?^_: 5>J5L\OL?KCX+Z+Z9!USRE<(
M2U=(>1V1_6+UMQ/;TQ-52!'L.G_SD(_08CX%(;O\99Z_ $AH'HJ@*H16A!J"
M.I^ .RL[QFG_4"'4Z+5V:1B>YFA?O"QTM'3RXU6<QZ6V.F;DDE^*<Y54.M\
M  .'241!5-9(M/<<A%-ZO'D3/U;3PJ=8K[.XZ]Y2:+)0 %JR= W5-*AM*T;N
MT>DDC'6\TJA8+4SD/J(+S^Q<"RLM)^\H;4GC_(K9N%Y'."2O C9L=W7 4^N!
M='5V@_6MD1$7M5E[[7AW]L&RF-MC*WI;GTO@?T%KO2&.+\9C4D0C7N'5(B$W
MH69*T<V'5&U4@VA-(LJ -G+RN+\ZI W&,B^!2274;P%HTA!VG'UP0)/_G7H9
M8RBX,DK@?K&B,5W\PZZ&!!G"@9?']FM1=V!A 80#[#3I9 5E(P<2J7C ;*:N
M:Z^\Z)B@%^%+U51.4N)A->#I^CI@5@F^O.__+R"A0>FAK2L51H%$,7]$WDUI
M2FNT8JVR645B"9;(SJQ/^VUGLQBU),UWH_Q[9?^.@BR-G:^C;Y=YUH]8>I0_
M3]]1D9PWB)&I6=/(73_:QI><PYOS\<Q#Z+@T_&W&*BVPY(GQ+(]7YJ2SJL,:
M?4__QCH+9'86&E,,+ZN].-GT0HS#$$X)9*Y;P&16ELLB9;I\4K;]CM&/QR[I
MNU9=Y6<A5KX!^76TI(NEP&JZ$+%BZ A/_._DL6=8O'0D8[*;#(99[I9D=V4Z
M-J/J%/UR4'NT_KRZ8UDQ@_>.%67H2_S^/8!$=V<0$/$JCN)1XIO_<7KVZDT#
M3K87=KA6QC3^^0QJB-=?%U:MEFX&[U:6DC--&-FH &:\ED+/7CJ/+[OORF4"
MYU,T.L_P)&*A#AQ= 1$;D",MK1O>MWQVU@(MZM'\=B]:GBM8Z-/)[8C5.VD8
ML"B?PI"IY#H'(@W]D#]CW/ACN>3_.N>V=#%E:MZ8,AP=*=O2N=OF@+0;!3TG
MMP#IZ#)HRPH,Y,4*<BP;'W86]BT]TSIY+)N=K].!ESWF.J]%R>G82?3_%]</
MY:(^):]2_U*_OP!(G 8<AVI C$@<D#CF[?J- HDIUL[_LC:L9NRLCO+Y]';_
M"\Y_%*T;G:AOF"Q"3KYHL&; 48XMG5XQQXZ6)[J5+A"O1<O7/Z[/+Q;'FZH/
M&A=_"5E)&%L>+]A_=Y;R8PHWIN1,OM79^-? 1@V8^4G)@(3_/U^.\6-Y-1'3
M6=G&CXMV>)V7G "D8&&]TN4MC5[4Z<D7,S _9[9XIH-[L"'@H/?UWB@=F+Q"
M,UJNI;';=E80,RE4-\JKRJ%=10/=J,XH!WF*S6\\>M=%CA@@\<"&Y=F'=%@:
:S_]V/O\/<G-AD)77%D@     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>vyne-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vyne="http://www.menlotherapeutics.com/20210630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vyne-20210630.xsd" xlink:type="simple"/>
    <context id="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i87270e9b78864085be8909ec1039d600_I20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="i74a36af260014e1f802fe734fdffb5e9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i591be1e0085c41d689fc49b8c603ab69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84342aca68b243ada9b41fbbc8cf270b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9dea735dd11c45e69052123ac0c08ca2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3b27fc8830c2496393ef337b50de9d1d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if0fbd34450c84e6a85650df0d4e02142_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2debda6fea544c33bd0f7cd7fb0d1eda_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9554f0529f7f46d3b0d37c39bef0330b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9398115216164c628d93c5faa7c9acae_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i60c6c82cc7d9438c92ca5e369586fa89_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i100dc25a3ccc4b50b433b69ea956736e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idabf5cabf5d146209830192ebd3a2c01_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i53788555bd1f4b04be712a3744df4cc3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1dc49910e5a5430584764df10f7cf924_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i797c66ad7b9c49b5a2ddd97631ae27f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i08d3a379e953425a9974062231d7dcd0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i03d13b3790624d87bc0cad0e41052e6d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iedde2720a7af4dba914dd3438edc3894_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6a3d7596a5a540f69eee45235f538a4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a850254855c4cf1ba7c87d12f8bcf5d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7abf6f21fe40411c8914385be9741d3f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie7a23cc6461f4ef8bf1b007c53b237f9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3ff10b2c08844eabaa679bba7720742e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3d6791bfcf14401e94eb092718e67ad9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1ade32f44d84447498707d4ecef4407a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icd67e51186d44f0aa1480b690576bb0d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib4f9738453474c059f491621e59dc79b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1f2fa509856a406c9e42f24a5f55ac1e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie50700e6e0f1422a89d1383e91db69f6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0fe5419b81c14a06b772ea4bc01565d0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6f29689ea1944eedbbcf9400e04d7ef0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieee26fdc1fa14f05a6f311e845ab576b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4227e51ef1044e2b823e33b150d24f26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if02af391415841e4b82ed9d48c82edc3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2fbd72aac51444cc8e66833339c2e2f3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idda95e6e7c234d489db3397bca35bb75_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2b6eb2e10a04475ab11b11c04ece8082_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibb4b5e3e1eb74f53b54afa625f0fd048_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib8d5a2a3933f4cfbbb3fbb51c20df06d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i22fcfd7ed9a543ddb72129476634c780_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i78735453789f4a8abdc6053070d56b14_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i10e7f7d4ebf643ee959c05a474f9c948_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia694da22cf534b119d5bfa52040066d2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9b04039f72414cc68135a0028a7ebd45_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibc3c6f2f161a493b8e5395bce6f28971_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7c74f98bea814d89ae592c883580eba5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i44747ec4fa294f50a7469563ddcbafeb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iad82d516ac8944c3ab74858aecd5b316_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1755861e14c849d2a5109ccface73c4d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ide8e978d00c845e78cd00eaea3509c91_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9a34e2be4ddc40a287e56721af2404d1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id78a66c4d2a848feb68215cc74cf142d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0c0c1b558463459aaba416b532ab05b9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i41f66d5268c24630ad030416639966ce_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9ba6c46ad1554816bcc03cae4a40ea5e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib1751f8eb9f24fd8843cb5ad13f6a9e7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5741436efcf7422d8c1efec1a5674e74_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7ba9266a3f21470b9aea71eb689ca61e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i425a84c0240f40dfb5087d836e1a583b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icb79d419a25c4a54bd7d489adc952e95_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7dff1b7af5184588b64b59aa4e8c1aa3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib29bbbec2a784133904ebf772b749830_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ica61d474584c4143988ae02e9fa3856a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i25e633a691ef420b992fc44538fdc8a7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie36f0645785e4cabba23e0ebc501434b_D20210806-20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="i833be515ce11411f87485dfaea471f94_D20210806-20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vyne:TopicalBETiOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="i6fcd46d67d92482a938a2ff751b727d8_D20210806-20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vyne:OralBETiOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="i3a4133507eae4a3293528a38e4dc4312_I20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="i4a701835f72e475097f033580f5deea7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibace252288db423ca83fb8257a0d36f9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i20cbba757ccb4615a4d0cfe3c3f988dd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if12e854e598f4a50aee8bc4d0c1ba30d_I20210211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:MenloPremergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="i4ed43e98e5c24ad3a531ae837852997f_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i9efde75313c64f94acd2d57c0ac7ad36_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic25e62d0cd134ea88998d63b633a4770_D20210811-20210811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-11</startDate>
            <endDate>2021-08-11</endDate>
        </period>
    </context>
    <context id="i271ffaaf0e574d60ad9235c64c92906e_I20210811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="i2a0505b712e847e481143283b66db10b_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="ie37f3b5248df46e8a5d24d2bfdf923c7_D20200401-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb1d0e22f202476fa595bb840d395cd9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i68da95855f63445cb75b88e2107393a8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa2d29a04a9d429e8c602ba8cac18f30_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib7eaae92ef0840c2b50b035cf1e0a2e0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vyne:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibf646184c9df4d2991aed59bbf06b647_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vyne:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8a7f4503f7384e2faaa1111b3d6139c9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vyne:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iff048461f0274e04bac7ba4406b49f1c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vyne:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9596c2a29d47439a95abf5bafe122581_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib38e1be8e95d46dc90c6daa98174ed11_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ife9a680c8a894189a633707b6fc4831d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70a8f4a8fcca4b248c457bd74ec68078_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib008e08d218f4edca1a33f7677210b30_I20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2020-04-06</instant>
        </period>
    </context>
    <context id="i6382cc7a653d404095454dba66f62190_I20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="i6945c947006648c0ac8f5b0f8e054f7c_I20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2020-04-06</startDate>
            <endDate>2020-04-06</endDate>
        </period>
    </context>
    <context id="i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2020-04-07</startDate>
            <endDate>2020-04-07</endDate>
        </period>
    </context>
    <context id="i1a7cf85ce0eb405d8a9d3d0c8302a988_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1e7b882797fb4a558b75c52ad0d3f597_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="i32f810ffe926407c90d135528dbc7806_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="iccc41b531a42468fbf923e22fdb7eabb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6db72496b07944a0b0be6eb4aa4ba37a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icb5bafa21e104483ae7f0f9dc374ea00_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i16efb1e654494773b9d6ff2b23dc030b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4b69cba5a49141e6bb1ce4370c794990_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vyne:FourCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic43c6e8d9ce64e2d8a1368960b3a7873_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vyne:FourCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if85566c685134979a79b4ce6fd888d53_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vyne:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i76d0289842ec41d6a4fcf604ba120cc7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vyne:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i27b7eaef51134e98829287ba6d768e11_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vyne:AllowanceForSalesReturns1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i17d3ea68f84b490b9ee1aafc7167b26a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vyne:AllowanceForSalesReturns1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1c6d1a11d554c199e8d8a169359a9a4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibd77d34132ca467485ab82d588391ab6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i097981da69d34227853b3f274c4a9834_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b5f9de8edf74567a2af3deb4d32b9e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2d8c62eaafd4e3b828916f7e572cd7d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i659a1487487a4e54b0c16d985e15bce3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vyne:IsraeliMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic9adec3b7e764dbea542fb51debbc4a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vyne:IsraeliMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69de8b4ead5948b29019da8f6937bc7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4ace227df814c6da96b3d3c17e550ca_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vyne:ShareholderLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="i2384945abf164135b470fbd163ec1a30_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vyne:ShareholderLenderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="id528c304a55c4353ba23843e402628f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b6c184538354bce82077ac6310639ce_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementTrench1LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="i0a8f341036bc4b7ea7dc739c6499f873_I20191217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementTrench2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-17</instant>
        </period>
    </context>
    <context id="i9f230d62899b4d71845a983074150045_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementTrench3LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id65641d8ed054571b83e832dbc10772f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic3e2f164495a40aeb89e017df3b2607c_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vyne:ShareholderLenderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="i29a95d4d274e49d39b10611f8aa1e359_I20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vyne:ShareholderLenderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="i48f8896bfdb14e839b03b101221cb89b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vyne:ShareholderLenderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i08340dd9766c473889a05f2e9e452090_D20190729-20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2019-07-29</startDate>
            <endDate>2019-07-29</endDate>
        </period>
    </context>
    <context id="i615924500e1a48a1b14b32e08fe70444_D20190729-20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vyne:AmendedAndRestatedCreditAgreementTrench2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-29</startDate>
            <endDate>2019-07-29</endDate>
        </period>
    </context>
    <context id="i3ee35236062d43f9aceb739ebad9b33d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i742062b5041f42418de6c43a30fbe8a2_I20210719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-19</instant>
        </period>
    </context>
    <context id="i038228081e6f4f1790fdcab0a61c49d4_D20190201-20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="i3f7bc2d54cd0447d85aaad2c755a7b4d_D20190201-20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:CantorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="i9a2f164c78754c5d9affd590f3137bf8_D20210101-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:CantorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i49b0dcc45925492cb597c2d5ec8cb906_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:CantorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="i6a2f99820bb84452aea13ec915c8fa3b_D20210126-20210126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-26</startDate>
            <endDate>2021-01-26</endDate>
        </period>
    </context>
    <context id="i50b0c0ff85cd433787d5bfdd753d8bab_I20210126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-26</instant>
        </period>
    </context>
    <context id="iac7823d514fa4758beb050e55878ced3_D20200609-20200609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-09</startDate>
            <endDate>2020-06-09</endDate>
        </period>
    </context>
    <context id="i8689f9a9a2e144918aa468473d6f4f11_I20200609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vyne:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-09</instant>
        </period>
    </context>
    <context id="if21d5501c5f34c17ae7cdfe02a371143_D20200406-20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-06</startDate>
            <endDate>2020-04-06</endDate>
        </period>
    </context>
    <context id="ie871aeb88d164ac194fee5617757929b_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="i428a7beb16304a1c98e79a87b85028ab_D20190729-20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-29</startDate>
            <endDate>2019-07-29</endDate>
        </period>
    </context>
    <context id="i27760351ca2c4c7ba4e2acabf5d90f82_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="i5dae593c3d39464ba022d2c59437553f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iec332474ea174f79b645e790d02cd783_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:A2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i641098fa043e48aa8855d84732b16182_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i65cc49f7fccb4771b6f817252050651d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3b522232200e4ef29470815637a89d61_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i22a2ca05fede4ed3bb2d86f4e96744a8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i22b9c5bc79864c4ebd2e17fb68853be3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i376c62cb8cbc4fefa5c7f2ab24075e54_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4225a6209ef44ddaaa5e82e900a35d56_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="ib3dbfc262f3d4d6e9849df3ec34b7adf_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vyne:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vyne:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e1b4af058494e31a6baf54a62b10e9f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icaeba42a65bb4908a12b6c42bbe13190_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i524e30b547814ce3bcc5776c00614d79_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia05c23f9d5dd402b979cd7db4bad4117_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i35b1d069ce7e4403bcfb8dc34bb20fdd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8fb7478f500346ca86fa53d3e5c1bea3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2ef2613cb84a47d9b3d12f99f63f3c4b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibc383d8b15744bd285e423d24f50602f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibd075c5d380f49b1987fa8d6713944de_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id19d638103a64be2acf8ac79042f7740_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i753ec734b4784e41991f04acf5c5cc91_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8f58347fa5a54704957bea4315cd276b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8a28af5f07da4b9898e192b1f7e656df_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i650dc6e79b0646b69e2927249fe8ffd5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id374e55b59954cc8a6044053d732e5bb_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="i62ea0913d468447f90567f896b4278c8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i414facc7c16542e9bd4fb7ab3efbe2da_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2f1e26cb367a4d819caeb25260e38425_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if6624a5563c848348d3967b0dc37ffed_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vyne:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie4e62a8b45834716a1bfce75e6f69049_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic5dd41a666f44f10b6f7fcf9d08a4914_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0486d94e40b54296be6348fab054286d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i84198dfa6a324c93a59ee66d0eee6e13_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1691ef974cfc49b4b36a9537faf2c710_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3146e6cf023a4b3dbb9950d620581293_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i81a2e62b1f87439290f96db45c549d64_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icea6504990b84f5cbc69647e56ecc4a9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i722a736ad61a4de08b6ba7e77f1bc3bc_D20190313-20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vyne:BridgewaterNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vyne:OriginalSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="i381692c3937a48fc9cf55bbc32a4a79f_D20190313-20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vyne:BridgewaterNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vyne:AdditionalSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="i1d1e8908692340b4b78b852928f985fa_I20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vyne:BridgewaterNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vyne:OriginalSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-13</instant>
        </period>
    </context>
    <context id="i54987e1926fd4ff78e485bd30599b12a_I20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vyne:BridgewaterNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vyne:AdditionalSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-13</instant>
        </period>
    </context>
    <context id="i0c8acb1983b042eca15f9a025c2d4572_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>vyne:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="employee">
        <measure>vyne:employee</measure>
    </unit>
    <unit id="derivativeinstruments">
        <measure>vyne:derivativeInstruments</measure>
    </unit>
    <unit id="contingentstockright">
        <measure>vyne:contingentStockRight</measure>
    </unit>
    <unit id="lender">
        <measure>vyne:lender</measure>
    </unit>
    <unit id="vote">
        <measure>vyne:vote</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80L2ZyYWc6YmRmZDdhNzgwZjhjNDM0ZTk3M2EwYzNjMDgwNzNiNmYvdGFibGU6MWM1NzRmMDU2NmJmNDJjMmI3OGFlN2QwMDk4ZmUzZjMvdGFibGVyYW5nZToxYzU3NGYwNTY2YmY0MmMyYjc4YWU3ZDAwOThmZTNmM18yLTEtMS0xLTA_f0b44b40-41da-45fe-8a8d-cc43163bf952">0001566044</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80L2ZyYWc6YmRmZDdhNzgwZjhjNDM0ZTk3M2EwYzNjMDgwNzNiNmYvdGFibGU6MWM1NzRmMDU2NmJmNDJjMmI3OGFlN2QwMDk4ZmUzZjMvdGFibGVyYW5nZToxYzU3NGYwNTY2YmY0MmMyYjc4YWU3ZDAwOThmZTNmM18zLTEtMS0xLTA_8c6e9518-430c-4929-bd46-98915425c9cc">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80L2ZyYWc6YmRmZDdhNzgwZjhjNDM0ZTk3M2EwYzNjMDgwNzNiNmYvdGFibGU6MWM1NzRmMDU2NmJmNDJjMmI3OGFlN2QwMDk4ZmUzZjMvdGFibGVyYW5nZToxYzU3NGYwNTY2YmY0MmMyYjc4YWU3ZDAwOThmZTNmM180LTEtMS0xLTA_69962c1b-0ae7-462f-8e75-93e8dae484e7">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80L2ZyYWc6YmRmZDdhNzgwZjhjNDM0ZTk3M2EwYzNjMDgwNzNiNmYvdGFibGU6MWM1NzRmMDU2NmJmNDJjMmI3OGFlN2QwMDk4ZmUzZjMvdGFibGVyYW5nZToxYzU3NGYwNTY2YmY0MmMyYjc4YWU3ZDAwOThmZTNmM181LTEtMS0xLTA_8f10d7bd-823a-4e2c-990f-399f05594455">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80L2ZyYWc6YmRmZDdhNzgwZjhjNDM0ZTk3M2EwYzNjMDgwNzNiNmYvdGFibGU6MWM1NzRmMDU2NmJmNDJjMmI3OGFlN2QwMDk4ZmUzZjMvdGFibGVyYW5nZToxYzU3NGYwNTY2YmY0MmMyYjc4YWU3ZDAwOThmZTNmM182LTEtMS0xLTA_13a2a578-949a-464d-94e2-e0830c915334">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80MC9mcmFnOjg2YzU3MzIwOGQyODQzMjY5MzFiODJiNjA2N2MzYmM5L3RleHRyZWdpb246ODZjNTczMjA4ZDI4NDMyNjkzMWI4MmI2MDY3YzNiYzlfMzU_eda3327b-bfaf-4cc2-a2d6-a57f58ba29f8"
      unitRef="number">0.25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82Ny9mcmFnOmZiMjViZDYxZjA0NDQzMTg5OGNmYmY4MzVlNDY3YTYyL3RleHRyZWdpb246ZmIyNWJkNjFmMDQ0NDMxODk4Y2ZiZjgzNWU0NjdhNjJfMzU_eda3327b-bfaf-4cc2-a2d6-a57f58ba29f8"
      unitRef="number">0.25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjU1_33064f69-071f-4156-b480-26a8326fab8f">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjUx_ae95d00a-37ef-4fc9-8dbe-166feb8b9158">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMTE_81a4aec1-1928-48b3-b1ee-8626bb268a09">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQx_dc28c65b-30cf-43e2-a94a-ff59d05d1e0b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ2_d759e18b-efcc-444e-bc84-7d6f46bdad79">001-38356</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjU2_640378c1-2491-4492-b59d-f5cd5e9ff75c">VYNE THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6ODM0MDg5N2E0NGZjNDgyN2JlOWE3ZGYwYTZlYjAyM2QvdGFibGVyYW5nZTo4MzQwODk3YTQ0ZmM0ODI3YmU5YTdkZjBhNmViMDIzZF8wLTAtMS0xLTA_a21be062-3baa-4bbd-98d6-e86177ed824a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6ODM0MDg5N2E0NGZjNDgyN2JlOWE3ZGYwYTZlYjAyM2QvdGFibGVyYW5nZTo4MzQwODk3YTQ0ZmM0ODI3YmU5YTdkZjBhNmViMDIzZF8wLTItMS0xLTA_8f26a2e4-e83d-4d27-90bd-6bb23966b784">45-3757789</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjUy_b877a289-916a-4458-a347-da208ac76a3a">520 U.S. Highway 22, Suite 204</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ4_6669f126-8d8f-41e4-afc0-8b53a44f295b">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ5_2c32427c-439d-4e37-a8b9-1c836173dd1f">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ3_07387024-d4e8-42c9-9dc7-c43982880a16">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjUw_4bd615cc-bd4c-4023-84e2-03a12710bf6d">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQz_f9d43822-d5ca-4563-b211-cba3cb11f8d3">775-7936</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6ODQ3ZDY5OTE1NGExNGJiNDg5ZGIwNzQ1MjdhZGIwMWQvdGFibGVyYW5nZTo4NDdkNjk5MTU0YTE0YmI0ODlkYjA3NDUyN2FkYjAxZF8xLTAtMS0xLTA_897e52dc-ed26-4af1-b5aa-51daf4546c5e">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6ODQ3ZDY5OTE1NGExNGJiNDg5ZGIwNzQ1MjdhZGIwMWQvdGFibGVyYW5nZTo4NDdkNjk5MTU0YTE0YmI0ODlkYjA3NDUyN2FkYjAxZF8xLTItMS0xLTA_4d01365b-6a00-46e4-9f70-20b0e47c1714">VYNE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6ODQ3ZDY5OTE1NGExNGJiNDg5ZGIwNzQ1MjdhZGIwMWQvdGFibGVyYW5nZTo4NDdkNjk5MTU0YTE0YmI0ODlkYjA3NDUyN2FkYjAxZF8xLTQtMS0xLTA_25854f6c-ba77-4c3d-b808-9da6225af843">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ0_73893873-0492-4137-b2a0-17410379e47a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQ1_ffe2adc0-1e83-4e37-90c5-995893f58ccb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6MGI0ZjAwMWNlNTE5NDM0Nzg1ZDNhMjNhMDg4NjUyNjAvdGFibGVyYW5nZTowYjRmMDAxY2U1MTk0MzQ3ODVkM2EyM2EwODg2NTI2MF8xLTAtMS0xLTA_2740668e-b53a-49fb-9d45-0edcc056b244">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6MGI0ZjAwMWNlNTE5NDM0Nzg1ZDNhMjNhMDg4NjUyNjAvdGFibGVyYW5nZTowYjRmMDAxY2U1MTk0MzQ3ODVkM2EyM2EwODg2NTI2MF8xLTQtMS0xLTA_4cd2c804-198d-4b19-9a85-d7e7d2cb2908">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGFibGU6MGI0ZjAwMWNlNTE5NDM0Nzg1ZDNhMjNhMDg4NjUyNjAvdGFibGVyYW5nZTowYjRmMDAxY2U1MTk0MzQ3ODVkM2EyM2EwODg2NTI2MF8yLTQtMS0xLTA_da0c5c52-6339-40b9-9ae6-c0672d165f8a">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjU0_63480783-9f56-4930-8d85-a14fa1ec9277">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMjQy_a45dc573-9884-4d51-aa62-d511c24685d9">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i87270e9b78864085be8909ec1039d600_I20210806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xL2ZyYWc6ZjdkYTBmMzAwNjc1NDhjMDk1YzFkODhiMDRiNzBiNTYvdGV4dHJlZ2lvbjpmN2RhMGYzMDA2NzU0OGMwOTVjMWQ4OGIwNGI3MGI1Nl8yMTU0_d677401a-c828-4156-8f43-b734624a7e9a"
      unitRef="shares">51511845</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNC0xLTEtMS0w_19e9c7de-d1a9-4115-8a23-f5af6bf01bbf"
      unitRef="usd">103406000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNC0zLTEtMS0w_7d3fc502-056c-4f1f-8667-7631975ccbc4"
      unitRef="usd">57563000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNS0xLTEtMS0w_4ac4cd80-698b-4155-8b2e-d1d26d7a8679"
      unitRef="usd">605000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNS0zLTEtMS0w_b16c7644-402a-4b42-8ef4-c7206deb0ebb"
      unitRef="usd">855000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNy0xLTEtMS0w_7536fe34-c1bd-479b-bb62-173307243e2a"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNy0zLTEtMS0w_e8ad3f82-6af7-419b-b168-1cc3de202b44"
      unitRef="usd">1027000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfOS0xLTEtMS0w_4f837139-c326-4e64-a830-d895cfc2bd62"
      unitRef="usd">10868000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfOS0zLTEtMS0w_7b49feb6-5051-41b8-a0fd-3f825f507773"
      unitRef="usd">15819000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTEtMS0xLTEtMA_347d97d1-ed18-4ab5-b8a7-9c0aaf95331d"
      unitRef="usd">5268000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTEtMy0xLTEtMA_7f249bbb-709a-43b0-a1c5-1c4b4598adc9"
      unitRef="usd">4591000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTItMS0xLTEtMA_6fb0f9e0-aa42-410f-a232-ea77986d563a"
      unitRef="usd">8279000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTItMy0xLTEtMA_5868baa6-af8c-45cf-a6e0-b9e27d371cb2"
      unitRef="usd">7404000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTMtMS0xLTEtMA_9c2ae584-3d96-4813-9379-bb5462192699"
      unitRef="usd">128426000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTMtMy0xLTEtMA_f610d563-c779-4ef6-8f6f-bc6e34f2dcc8"
      unitRef="usd">87259000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTQtMS0xLTEtMA_86e5715f-06d3-475c-b1cc-665da7051821"
      unitRef="usd">501000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTQtMy0xLTEtMA_9f0bba90-a0e6-478d-b0db-69d09629db42"
      unitRef="usd">555000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTUtMS0xLTEtMA_06bccdf3-b2b4-4ca3-96af-e03ab6864c69"
      unitRef="usd">1225000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTUtMy0xLTEtMA_31b6ef4a-fa25-4897-af05-0677c5eb8138"
      unitRef="usd">1583000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTYtMS0xLTEtMA_7b627e97-c945-45c2-b531-6840b82841bf"
      unitRef="usd">3831000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTYtMy0xLTEtMA_2ec414d5-a133-4ea4-89d5-7b346a5d5e9d"
      unitRef="usd">4345000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTctMS0xLTEtMA_86a8289b-19c2-4167-9baa-9d456cc787c9"
      unitRef="usd">133983000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMTctMy0xLTEtMA_980aa88c-3308-4f1b-b74c-51b93d415713"
      unitRef="usd">93742000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjEtMS0xLTEtMA_66903bd0-c68b-47fe-9a70-739f8bbfdd3c"
      unitRef="usd">10080000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjEtMy0xLTEtMA_d4b2e240-6857-49c4-98d0-4340a940e868"
      unitRef="usd">4780000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjItMS0xLTEtMA_c31e0eb1-fb76-496d-ad8c-aaacb5e5a255"
      unitRef="usd">10146000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjItMy0xLTEtMA_6f61f2e2-b106-4699-a911-1cd406afc083"
      unitRef="usd">11452000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjMtMS0xLTEtMTY4Ng_602d2156-b5b1-4279-8b5b-d0755303da22"
      unitRef="usd">33375000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjMtMy0xLTEtMTY5MQ_56f73af4-355f-4c91-b0fa-4ba461a61e3f"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjMtMS0xLTEtMA_5a9bb3b9-9533-48b2-a6f2-abe2b3c76be4"
      unitRef="usd">3481000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjMtMy0xLTEtMA_970580d3-06f2-4cbd-9d76-adc17dcdd4cb"
      unitRef="usd">4360000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjQtMS0xLTEtMA_a042fe5b-6ef0-4dae-ad45-29e3c422e04e"
      unitRef="usd">434000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjQtMy0xLTEtMA_6bf94f3c-bcd7-4213-a226-2b1b3f0e71a5"
      unitRef="usd">757000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjUtMS0xLTEtMA_406653d1-af3b-4155-a5ac-c12c1fedec5e"
      unitRef="usd">104000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjUtMy0xLTEtMA_90ddbd45-179b-4971-9022-9d93127f1322"
      unitRef="usd">104000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjYtMS0xLTEtMA_103bc037-9c8e-4991-847e-b5ea84cf3117"
      unitRef="usd">57620000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjYtMy0xLTEtMA_e3f795ef-8cf9-448c-b736-9de8ccf16a44"
      unitRef="usd">21453000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjctMS0xLTEtMA_a3f1e373-b6fb-4cea-8750-e6dddb3a3796"
      unitRef="usd">206000</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjctMy0xLTEtMA_37e7df20-5768-44d4-8560-497e2917610d"
      unitRef="usd">312000</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjgtMS0xLTEtMA_3cde9068-e43f-464c-b30c-07f63ff922ab"
      unitRef="usd">812000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjgtMy0xLTEtMA_2f8ca954-c70a-4834-aeeb-11b59df3fdfe"
      unitRef="usd">853000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjktMS0xLTEtMA_5cc3f1b5-e0f2-4117-b279-a227d5bdcd5b"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMjktMy0xLTEtMA_b4388d30-b1e5-4db0-b9c2-425943ac628c"
      unitRef="usd">33174000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzAtMS0xLTEtMA_f29bfe81-8863-424f-9f3c-6af6c2e80a10"
      unitRef="usd">452000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzAtMy0xLTEtMA_cabaafe5-9359-4ba9-8ca7-e528f3a60fea"
      unitRef="usd">457000</us-gaap:OtherLiabilities>
    <us-gaap:Liabilities
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzEtMS0xLTEtMA_3a5eacc4-ade3-4a64-aea5-a74712a8503a"
      unitRef="usd">59090000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzEtMy0xLTEtMA_e0e3c06c-067a-453d-aa41-d40d0e0d6ff6"
      unitRef="usd">56249000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzItMS0xLTEtMA_557164a0-38e9-4069-8975-3665c0ff14e9"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzItMy0xLTEtMA_93a66ea0-e9ce-4404-99cb-83499109e967"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzIy_2b3cfcab-9cac-4f6e-8fdc-66e60d5288ff"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzIy_7d887bf1-afbc-4f9a-827e-d7c4658025cf"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzM2_b5c50f3a-b6c5-4216-8e8d-8392f4629677"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzM2_d7622f47-04f7-4ed4-b914-eb8a32b83a6d"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzg1_5df6a45c-d40a-4cda-9645-377bfb928e97"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzg1_6cca90ab-2baf-46f3-8d74-a26004e97526"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzg1_9cf05cbc-35f9-4f51-acb7-012c9d53fc80"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0MDI2MDJhOWM3NTQ4MGRiNDM3MDM3MmM0YTQzYTQzXzg1_fff4efc9-4b07-4fb6-bb43-dcf783ddf1b2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMS0xLTEtMA_c6ddc237-0e1e-4346-836e-b5312063ed7f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzQtMy0xLTEtMA_f9a21af7-f5ed-4d00-b18b-bc2a11baa7cf"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4XzE5_56e9b572-a891-4eac-8102-2a4448e4440c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4XzE5_9f494ed9-b898-4c86-b0de-8f7b28096340"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4XzMz_9090f16b-753e-4576-b3c7-dc73c3c7dc87"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4XzMz_e9a06499-a5ba-4fa1-b5d7-033854630f99"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4Xzgy_16d3b562-940c-451c-ad10-687f1ecc9f18"
      unitRef="shares">51511845</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4Xzgy_fde61675-e2f2-4055-9a30-678351188ac4"
      unitRef="shares">51511845</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4Xzg5_185b1923-81e8-470d-8efb-0f68952b1627"
      unitRef="shares">43205221</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjdlYjQ0YmU2Y2IyNjQwZDBiNTBmYWEwZGViZDkwZmI4Xzg5_d1b759f6-9d5c-43dc-9520-81f6c8578140"
      unitRef="shares">43205221</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMS0xLTEtMA_84d1d0b2-963b-4543-a7ad-45c5f9c701ec"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzUtMy0xLTEtMA_8f3b896a-a196-41d0-a5b1-43a98c29e902"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzYtMS0xLTEtMA_e1725ee6-39f1-4a68-bfa9-fa3067b226ee"
      unitRef="usd">681558000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzYtMy0xLTEtMA_4fa1ac1c-c878-4e7a-8054-28a737e03747"
      unitRef="usd">603685000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzctMS0xLTEtMA_0f0b1a5b-0f57-4962-bde7-23201cfbc360"
      unitRef="usd">-606670000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzctMy0xLTEtMA_78c6363f-c2d5-457b-b3f1-800a0932b748"
      unitRef="usd">-566196000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzktMS0xLTEtMA_b4034d40-27de-44e2-a9aa-78f7f934bfa2"
      unitRef="usd">74893000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfMzktMy0xLTEtMA_fdff644d-7aa5-4ea9-9544-1c2b164c461d"
      unitRef="usd">37493000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNDAtMS0xLTEtMA_c92cc7f4-2a49-44bd-a9eb-339d5a0b9f5f"
      unitRef="usd">133983000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xNi9mcmFnOjgxMWI1ZDY1ZTlkNjQzNzNhYzNlOTFmYzIxMzY0MjNkL3RhYmxlOmJmMDVkZmVjZGZlNDRiNWQ5ZDA0NzEyYWU4NzYyNDkyL3RhYmxlcmFuZ2U6YmYwNWRmZWNkZmU0NGI1ZDlkMDQ3MTJhZTg3NjI0OTJfNDAtMy0xLTEtMA_9b7a8e3c-f210-4f67-bb32-5b478308b1ca"
      unitRef="usd">93742000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84342aca68b243ada9b41fbbc8cf270b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMy0xLTEtMS0w_f4aaf638-bb30-4b21-a72c-2e52d1722702"
      unitRef="usd">3963000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9dea735dd11c45e69052123ac0c08ca2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMy0zLTEtMS0w_f0b2f0c3-4488-4ea7-8967-1397ee698059"
      unitRef="usd">1483000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b27fc8830c2496393ef337b50de9d1d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMy01LTEtMS0w_a14e8573-0e93-493f-a636-51fe4ecf309d"
      unitRef="usd">7852000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0fbd34450c84e6a85650df0d4e02142_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMy03LTEtMS0w_2234604f-58ff-4e7d-aa73-e750d7095598"
      unitRef="usd">3233000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2debda6fea544c33bd0f7cd7fb0d1eda_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNC0xLTEtMS0w_79c9f034-6789-4781-9c09-1e1e2da4ee8d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9554f0529f7f46d3b0d37c39bef0330b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNC0zLTEtMS0w_b9107611-df85-488e-8917-c231f39dc5e9"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9398115216164c628d93c5faa7c9acae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNC01LTEtMS0w_2d658133-1c0d-4fb3-a01d-b55ca50c4c62"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60c6c82cc7d9438c92ca5e369586fa89_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNC03LTEtMS0w_c35a6322-e90a-4c5c-9a61-b398c7c4973f"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i100dc25a3ccc4b50b433b69ea956736e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNS0xLTEtMS0w_d4d6b87e-1933-4fef-b9d2-6a4b2b5f7eb8"
      unitRef="usd">295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idabf5cabf5d146209830192ebd3a2c01_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNS0zLTEtMS0w_417eda27-7fd2-4b50-a390-cfc1ab1f4461"
      unitRef="usd">205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53788555bd1f4b04be712a3744df4cc3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNS01LTEtMS0w_11f6e887-2fcd-4a17-9819-9f41669d085e"
      unitRef="usd">525000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dc49910e5a5430584764df10f7cf924_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNS03LTEtMS0w_1175b79c-69ea-451c-b25f-f6fe7d0e93c6"
      unitRef="usd">205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNi0xLTEtMS0w_b95ba77e-8ba7-493f-98e3-9cac24654e74"
      unitRef="usd">4258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNi0zLTEtMS0w_1419d0eb-f07a-4b35-becc-04fe504c40ae"
      unitRef="usd">11688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNi01LTEtMS0w_8d357f03-9a39-4eb2-ac19-68cf963270d6"
      unitRef="usd">8377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfNi03LTEtMS0w_3a6b5bf3-3dbc-4933-947e-3cd4fb3af4cd"
      unitRef="usd">13438000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfOC0xLTEtMS0w_203a5290-df2f-43cc-82fb-edf2aeb3a0f6"
      unitRef="usd">795000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfOC0zLTEtMS0w_a5d17872-b8f5-4894-83ff-f843d7ed4890"
      unitRef="usd">216000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfOC01LTEtMS0w_21097004-b0ef-4106-aeb7-a1713d958a14"
      unitRef="usd">1396000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfOC03LTEtMS0w_fa5ebead-3a0a-4ec8-9225-4586d5017a1d"
      unitRef="usd">487000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTEtMS0xLTEtMA_b9bfbc6a-96e0-439e-9b91-ff438252f8a1"
      unitRef="usd">6409000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTEtMy0xLTEtMA_ace2451b-15fd-43d0-af2c-34934e096d38"
      unitRef="usd">13119000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTEtNS0xLTEtMA_e026f8c1-710f-446c-84c0-23a4845d059d"
      unitRef="usd">12742000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTEtNy0xLTEtMA_8effc660-2855-4c61-b6fb-1ae0705893e9"
      unitRef="usd">29072000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTItMS0xLTEtMA_644530f4-cef1-4d92-880e-62062a3916dd"
      unitRef="usd">15835000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTItMy0xLTEtMA_35a5d08a-975f-4f01-b1ca-352858d41076"
      unitRef="usd">26459000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTItNS0xLTEtMA_4ca5a4bf-bdd9-46d8-98f5-ac8dc7a105f5"
      unitRef="usd">32451000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTItNy0xLTEtMA_b08091c7-2fea-44ce-8722-e7c27c472125"
      unitRef="usd">51874000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTMtMS0xLTEtMA_780d9719-38f0-4b09-a49f-de95f8d1a73f"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTMtMy0xLTEtMA_b966b0b7-8fed-4dfa-bd90-cafdd8dbd903"
      unitRef="usd">54345000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTMtNS0xLTEtMA_4639bf90-808e-42ec-87d9-dd98e2770ae7"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTMtNy0xLTEtMA_52a4a1ec-49dd-429d-b3de-2bbf681e7d22"
      unitRef="usd">54345000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <vyne:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTQtMS0xLTEtMA_d78d469a-789c-4988-946b-b80e93290ea4"
      unitRef="usd">0</vyne:ContingentStockConsiderationRemeasurementGainLoss>
    <vyne:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTQtMy0xLTEtMA_21774dce-ef63-4c39-940d-171cf9400fdd"
      unitRef="usd">-84726000</vyne:ContingentStockConsiderationRemeasurementGainLoss>
    <vyne:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTQtNS0xLTEtMA_560a3ce8-923c-4d8b-b172-255c3dd243bf"
      unitRef="usd">0</vyne:ContingentStockConsiderationRemeasurementGainLoss>
    <vyne:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTQtNy0xLTEtMA_d50d0407-fbd1-40e0-a0f7-e3994e00d270"
      unitRef="usd">-84726000</vyne:ContingentStockConsiderationRemeasurementGainLoss>
    <us-gaap:CostsAndExpenses
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTUtMS0xLTEtMA_da3093bc-0d47-415e-882c-adbebca2833c"
      unitRef="usd">22244000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTUtMy0xLTEtMA_9ba6be25-4a56-4341-96e9-66291abf5a62"
      unitRef="usd">178649000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTUtNS0xLTEtMA_ee28bb64-aca5-49d9-a570-e80b42a6f56d"
      unitRef="usd">45193000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTUtNy0xLTEtMA_0e4f8f07-d75a-4747-837e-141d088c7ecd"
      unitRef="usd">220017000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTYtMS0xLTEtMA_c9b30233-7a2f-4ed9-93c6-caed568067fd"
      unitRef="usd">-18781000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTYtMy0xLTEtMA_5e8487f0-a849-42e9-9fcd-f859feacafec"
      unitRef="usd">-167177000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTYtNS0xLTEtMA_d0e109b5-58a2-4530-80a5-ded27c7a05b3"
      unitRef="usd">-38212000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTYtNy0xLTEtMA_bbc82b24-2a06-4dac-9af7-2fe1f90dc32b"
      unitRef="usd">-207066000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTctMS0xLTEtMA_ebea6ea3-4863-4e75-b418-bd1aec07c56f"
      unitRef="usd">1074000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTctMy0xLTEtMA_bffbabce-6bac-477e-b48f-b2caa516288c"
      unitRef="usd">1070000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTctNS0xLTEtMA_0dfa509a-44a0-48ec-80e1-f1c73839043f"
      unitRef="usd">2136000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTctNy0xLTEtMA_1af95414-df58-4a3e-976c-e661749eded3"
      unitRef="usd">2137000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTgtMS0xLTEtMA_abdb68b7-d0e9-4a19-9398-ce13aabc0f65"
      unitRef="usd">-69000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTgtMy0xLTEtMA_ed7c77e7-8eb2-4e18-bffc-14cbc745d179"
      unitRef="usd">548000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTgtNS0xLTEtMA_0fce063a-3ece-478b-8b44-3dcc037216b8"
      unitRef="usd">-126000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTgtNy0xLTEtMA_402de31a-2d69-4b37-a6ef-6cf28820562e"
      unitRef="usd">1271000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTktMS0xLTEtMA_6d02801f-1267-4316-9a7a-43b742de2caf"
      unitRef="usd">-19924000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTktMy0xLTEtMA_3e70ac33-c746-427b-9cd3-dbffaaf000ad"
      unitRef="usd">-167699000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTktNS0xLTEtMA_75ae4003-4465-4fb0-afe3-73a82fb8fe4c"
      unitRef="usd">-40474000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMTktNy0xLTEtMA_e7ce1836-911f-4122-9fb6-0ae04862331f"
      unitRef="usd">-207932000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjAtMS0xLTEtMA_de98432a-0919-4086-9312-c0cd71905851"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjAtMy0xLTEtMA_475b4cdf-9a1d-4810-9fe0-83d0cbffd2f8"
      unitRef="usd">-259000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjAtNS0xLTEtMA_3f51494d-facb-4f97-b0e0-4da967c8a544"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjAtNy0xLTEtMA_21f83f9e-b440-49c6-8d99-1a4acdd22a83"
      unitRef="usd">-259000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjEtMS0xLTEtMA_3f4a7d40-0349-4d9d-a2d5-b10325e90325"
      unitRef="usd">-19924000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjEtMy0xLTEtMA_8d1c82c6-93b0-48f3-8e6e-418180a0cf8b"
      unitRef="usd">-167440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjEtNS0xLTEtMA_252aaa66-7407-4685-9c24-7e482ee9e7ff"
      unitRef="usd">-40474000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjEtNy0xLTEtMA_05e52c25-5a24-4aa3-960d-7b84216b71a9"
      unitRef="usd">-207673000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtMS0xLTEtMA_b258f01f-e1e8-46ce-81a2-9fb70490f0d9"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtMS0xLTEtMA_c84a4c9f-a0ea-4889-9924-174a32091860"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtMy0xLTEtMA_183aa1ed-1044-4438-aaf1-0d79ca2b287b"
      unitRef="usdPerShare">-4.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtMy0xLTEtMA_5283bf85-bc7e-409c-a97f-935abc74a022"
      unitRef="usdPerShare">-4.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtNS0xLTEtMA_5ffe0b07-7ef6-46b8-9ac2-0be84057f98b"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtNS0xLTEtMA_a362689f-54ea-43ae-81e9-1a9c953ba849"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtNy0xLTEtMA_c4de9380-7a94-4d84-97b5-55ca28682df5"
      unitRef="usdPerShare">-9.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjMtNy0xLTEtMA_d3a49046-5d4a-4e2e-99af-cfa5cc4bc9ad"
      unitRef="usdPerShare">-9.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtMS0xLTEtMA_7742f984-459d-4a73-998e-5494ecf6968f"
      unitRef="shares">51411000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtMS0xLTEtMA_e02b26aa-9b12-4474-bc9f-2f0f145bfa9c"
      unitRef="shares">51411000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtMy0xLTEtMA_0de3337f-039c-4a1e-9dd3-4eb8d49c8c48"
      unitRef="shares">34663000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtMy0xLTEtMA_98ba314d-a68c-4f9c-8fc0-01be55e6623a"
      unitRef="shares">34663000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtNS0xLTEtMA_8233b164-c75b-48e2-8097-f2f55069b1e0"
      unitRef="shares">50162000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtNS0xLTEtMA_c499a0a5-febf-4bd7-8039-beaf817f702a"
      unitRef="shares">50162000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtNy0xLTEtMA_af0792ba-fe9a-4642-b00b-e45221e7aed0"
      unitRef="shares">22656000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xOS9mcmFnOmMxNTQ5OTc0MWVmMjQ5ODY4ZGM1ODhkZmZlZmQ2MTlhL3RhYmxlOjFjNzZiZmJmMWFiMTRhNjE5MzUwY2ZiZDNhODUwMWQyL3RhYmxlcmFuZ2U6MWM3NmJmYmYxYWIxNGE2MTkzNTBjZmJkM2E4NTAxZDJfMjUtNy0xLTEtMA_f3fbd780-ead4-4e94-adb5-4a90cc51121a"
      unitRef="shares">22656000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfMi0xLTEtMS0w_557f9e59-43fb-4af3-8bbd-75a23a3dc18c"
      unitRef="usd">-19924000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfMi0zLTEtMS0w_63e39a81-eb8c-4379-8ebd-0bb77c441e03"
      unitRef="usd">-167440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfMi01LTEtMS0w_25a4ae09-7d06-4b16-8e77-998362432da6"
      unitRef="usd">-40474000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfMi03LTEtMS0w_027cd975-2952-4fcf-88a2-a26d84c8366e"
      unitRef="usd">-207673000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNC0xLTEtMS0w_3ee0f274-1650-4c70-949a-a05bbc82fe03"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNC0zLTEtMS0w_548900dc-d82b-46fb-8981-37d465e4414d"
      unitRef="usd">43000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNC01LTEtMS0w_43e99696-5153-4618-947d-528a9ca50b88"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNC03LTEtMS0w_dce2d32e-2a71-42bb-96ce-4588992a2268"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNS0xLTEtMS0w_e1a48a9a-cc4c-4956-ae53-c9d802218b3c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNS0zLTEtMS0w_836d066b-95ed-427b-94c8-35817ffd6ef8"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNS01LTEtMS0w_9fe8d50e-51c0-46cc-a861-3b61a7db34c7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNS03LTEtMS0w_e9272768-a42f-40ef-81e6-399238b055ac"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNy0xLTEtMS0w_be0afd21-9dea-41f4-a7db-210ccf5451bf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNy0zLTEtMS0w_50935457-cebd-4943-aeec-9a872d5e0b4a"
      unitRef="usd">40000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNy01LTEtMS0w_c1fa8f5c-7689-4a2e-838b-73d57be700d4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfNy03LTEtMS0w_88b1adc5-d39c-4bd2-9401-fca1ef4370f7"
      unitRef="usd">-5000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfOC0xLTEtMS0w_2da00c7c-dd12-4665-b6c5-a0f1ea14d022"
      unitRef="usd">-19924000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfOC0zLTEtMS0w_72b9f7be-2b1e-4f0f-9bda-a2467dea497e"
      unitRef="usd">-167400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfOC01LTEtMS0w_9d6d7fca-1a80-4a33-a646-0a2bfe665b61"
      unitRef="usd">-40474000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yMi9mcmFnOmUyNWIzYmE4MzAwMjQzYmNhZTMwMGQ5NjMxZjFlMDdiL3RhYmxlOmMzNzVkZTk2NmMyZjRmYjA4M2NjYzZmNzhjZmIyYjBhL3RhYmxlcmFuZ2U6YzM3NWRlOTY2YzJmNGZiMDgzY2NjNmY3OGNmYjJiMGFfOC03LTEtMS0w_fa34df8a-da96-4a0c-b16e-278a73343431"
      unitRef="usd">-207678000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i797c66ad7b9c49b5a2ddd97631ae27f5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi0xLTEtMS0w_79f5070c-a060-4b74-b0f0-7e05db5e0147"
      unitRef="shares">9120078</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i797c66ad7b9c49b5a2ddd97631ae27f5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi0zLTEtMS0w_3336c8a2-dba1-463e-a26e-379e41e2616b"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08d3a379e953425a9974062231d7dcd0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi01LTEtMS0w_b06efdf0-de07-4b22-84a8-6a63526f60ce"
      unitRef="usd">328156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i03d13b3790624d87bc0cad0e41052e6d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi03LTEtMS0w_84ea1141-f746-4069-bc88-350007315e1b"
      unitRef="usd">-310587000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedde2720a7af4dba914dd3438edc3894_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi05LTEtMS0w_89d0567d-d24d-45cc-99e6-bed6f5b31c5d"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a3d7596a5a540f69eee45235f538a4b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMi0xMS0xLTEtMA_a1063d45-a2d4-4e2f-88aa-372282d6e2f9"
      unitRef="usd">17575000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3a850254855c4cf1ba7c87d12f8bcf5d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNC03LTEtMS0w_3f1e7457-00c5-431d-8a54-79d58aa83ee1"
      unitRef="usd">-207673000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7abf6f21fe40411c8914385be9741d3f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNC05LTEtMS0w_0288d5f7-f6ac-459c-a1c9-8565594b3a83"
      unitRef="usd">-5000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNC0xMS0xLTEtMA_9af7ebbb-b826-4931-b549-b4f382a27644"
      unitRef="usd">-207678000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie7a23cc6461f4ef8bf1b007c53b237f9_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNS0xLTEtMS0w_7a356048-c5d8-407b-b7b8-4be425151f55"
      unitRef="shares">258000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNS01LTEtMS0w_8c869c8a-885b-4842-aa75-c2a98a978bc4"
      unitRef="usd">260000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNS0xMS0xLTEtMA_ba87f639-467d-4711-bfe3-922d74c9c584"
      unitRef="usd">260000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNi01LTEtMS0w_dd401b6e-de73-4641-a7c0-0894c8a73834"
      unitRef="usd">12527000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNi0xMS0xLTEtMA_933e277c-fb39-4e6b-a3b8-8d58b621eca5"
      unitRef="usd">12527000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification
      contextRef="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNy01LTEtMS0w_b7b3ce8f-f7c5-406c-8249-b3c031e75f4b"
      unitRef="usd">-41000</vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification>
    <vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification
      contextRef="i3a850254855c4cf1ba7c87d12f8bcf5d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNy03LTEtMS0w_41c92940-4f07-4f05-9738-a28003ceb03e"
      unitRef="usd">41000</vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification>
    <vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfNy0xMS0xLTEtMA_c0260189-ad32-4c25-a978-daf389825c3e"
      unitRef="usd">0</vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification>
    <vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment
      contextRef="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOC01LTEtMS0w_3b7e8514-fba2-40a4-bff3-36473e5b2111"
      unitRef="usd">975000</vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment>
    <vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOC0xMS0xLTEtMA_588e816e-5adb-41ad-be39-00c4e914dfd7"
      unitRef="usd">975000</vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0wLTEtMS02My90ZXh0cmVnaW9uOjY2NjljYzY5MGExODQ4Njg5YzhiMjAwODIwOTRiMGRlXzEwOTk1MTE2Mjc4NjY_222dbbf0-71d4-4b26-b3cd-dcdc24f1a6c1"
      unitRef="usd">3903000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3ff10b2c08844eabaa679bba7720742e_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0xLTEtMS00NQ_28aa4988-d9b0-4b13-9cd3-ebbba0df2264"
      unitRef="shares">7776875</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie7a23cc6461f4ef8bf1b007c53b237f9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0zLTEtMS00OA_70bebc60-9006-40fd-8bf1-4243d9211820"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3d6791bfcf14401e94eb092718e67ad9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS01LTEtMS01MQ_cfbfeb2f-9784-4fd6-8699-bb48c0659c63"
      unitRef="usd">53648000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1ade32f44d84447498707d4ecef4407a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0xMS0xLTEtNjA_44666c9f-ce9a-4f64-ac77-b4c82c68d688"
      unitRef="usd">53649000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ie7a23cc6461f4ef8bf1b007c53b237f9_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0xLTEtMS0w_f668b0a7-2902-4d8b-9eeb-b106cffcba8b"
      unitRef="shares">24765999</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ie7a23cc6461f4ef8bf1b007c53b237f9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0zLTEtMS0w_21656225-d117-4735-8b66-c4f354af1939"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i615b4ce95ce24e4b912207bf71b33fa4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS01LTEtMS0w_86569afe-94dd-4db9-b1ce-a804553c5e85"
      unitRef="usd">196168000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfOS0xMS0xLTEtMA_9fb807bf-1709-47ee-b264-7dc813a358ab"
      unitRef="usd">196170000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icd67e51186d44f0aa1480b690576bb0d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtMS0xLTEtMA_a2c9563e-8c4a-49d9-abc0-efb51a3c03d5"
      unitRef="shares">41920952</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icd67e51186d44f0aa1480b690576bb0d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtMy0xLTEtMA_dcd9b355-0821-4c5d-80c5-c47278f5f1fc"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4f9738453474c059f491621e59dc79b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtNS0xLTEtMA_7ee7588e-bade-49b2-a84c-9eedd5b2e708"
      unitRef="usd">589825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f2fa509856a406c9e42f24a5f55ac1e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtNy0xLTEtMA_fe3371cb-8346-448d-aa04-97fcfaeb495f"
      unitRef="usd">-518301000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie50700e6e0f1422a89d1383e91db69f6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtOS0xLTEtMA_80fac675-45ce-4d38-97cf-a55018626d7f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTAtMTEtMS0xLTA_97b412ee-ac22-4b7c-85f9-582b8eb9f774"
      unitRef="usd">71528000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6f29689ea1944eedbbcf9400e04d7ef0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTItMS0xLTEtMA_fde6f359-be00-428d-a3a8-001d0f2e4b1b"
      unitRef="shares">43205221</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6f29689ea1944eedbbcf9400e04d7ef0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTItMy0xLTEtMA_6debd325-dbbb-4608-b396-d155af32bdbc"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieee26fdc1fa14f05a6f311e845ab576b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTItNS0xLTEtMA_ac29c3bb-5280-42b1-b27b-8d358841f957"
      unitRef="usd">603685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4227e51ef1044e2b823e33b150d24f26_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTItNy0xLTEtMA_2c3ce29f-9122-40e0-a193-5c927b7e5556"
      unitRef="usd">-566196000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTItMTEtMS0xLTA_550a4e28-45a8-495c-a762-efb4a7035e73"
      unitRef="usd">37493000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if02af391415841e4b82ed9d48c82edc3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTQtNy0xLTEtMA_97bdb0e8-a3a2-4982-9f0f-d0586950d0fc"
      unitRef="usd">-40474000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTQtMTEtMS0xLTA_3dd0b57d-efd9-4711-b758-813883afb8f7"
      unitRef="usd">-40474000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2fbd72aac51444cc8e66833339c2e2f3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTUtMS0xLTEtMA_f29f970f-4687-4d49-a069-cb3412a3a425"
      unitRef="shares">254351</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idda95e6e7c234d489db3397bca35bb75_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTUtNS0xLTEtMA_438cf187-d889-4e19-99b2-4b486d5daf8f"
      unitRef="usd">403000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTUtMTEtMS0xLTA_e801deba-312c-488e-a392-432e20ca7369"
      unitRef="usd">403000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="idda95e6e7c234d489db3397bca35bb75_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTYtNS0xLTEtMA_a976852a-64e3-4d50-adb7-517f68739f4e"
      unitRef="usd">4343000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTYtMTEtMS0xLTA_e63cff2d-e14e-4e79-b5cf-4fba2a5cf7d0"
      unitRef="usd">4343000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2b6eb2e10a04475ab11b11c04ece8082_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTctMC0xLTEtMC90ZXh0cmVnaW9uOjBlODJiNGI0M2RmYTQzZWY4MmMwMjlmZDIyODY5OWZmXzY2_9c77193c-2d51-4bcf-afe3-5ebac64ffe9f"
      unitRef="usd">814000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibb4b5e3e1eb74f53b54afa625f0fd048_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTctMS0xLTEtMA_5f4f0977-4855-4296-ac36-57a04eada0b8"
      unitRef="shares">2778012</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib8d5a2a3933f4cfbbb3fbb51c20df06d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTctNS0xLTEtMA_53f089c1-3435-4ab6-9aef-b7c02e840409"
      unitRef="usd">26304000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2b6eb2e10a04475ab11b11c04ece8082_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTctMTEtMS0xLTA_f0cfc22d-f6f1-43f7-b189-d8538077007f"
      unitRef="usd">26304000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i22fcfd7ed9a543ddb72129476634c780_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTgtMC0xLTEtMC90ZXh0cmVnaW9uOmEyY2E0MjlmYzI1OTQ0NTI4ODY4NDAwOWMwZjQ3NzkwXzc0_220daa08-569f-4e36-a975-e6c9256966b4"
      unitRef="usd">3177000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i78735453789f4a8abdc6053070d56b14_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTgtMS0xLTEtMA_8ba90271-bca7-4bb2-a013-efd350a3f357"
      unitRef="shares">5274261</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2fbd72aac51444cc8e66833339c2e2f3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTgtMy0xLTEtMA_83b01551-5597-4a16-9d38-9ad95b4b072b"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i10e7f7d4ebf643ee959c05a474f9c948_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTgtNS0xLTEtMA_8953d83b-83bf-4334-b337-914bacbf3807"
      unitRef="usd">46823000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i22fcfd7ed9a543ddb72129476634c780_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTgtMTEtMS0xLTA_a77b12f8-26e4-4a0b-ad08-c4d0914bd1d0"
      unitRef="usd">46824000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia694da22cf534b119d5bfa52040066d2_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTktMS0xLTEtMA_10455f01-872a-4d3c-b3d3-13667dec8c94"
      unitRef="shares">51511845</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia694da22cf534b119d5bfa52040066d2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTktMy0xLTEtMA_5f4841a4-fcbb-41dc-846b-ce8925c3df81"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b04039f72414cc68135a0028a7ebd45_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTktNS0xLTEtMA_fe4565f8-9d26-49fb-b9f6-e01b1a986dd0"
      unitRef="usd">681558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc3c6f2f161a493b8e5395bce6f28971_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTktNy0xLTEtMA_e405f15e-f86f-4691-bba0-1dd8044a19fc"
      unitRef="usd">-606670000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yNS9mcmFnOmIxYWUxN2MzM2NkMDQ5YzRhYTNlZjgxNzdlYjc4Njg3L3RhYmxlOmY5ODI4YjVkNTc2ZDQ2NTJiZmIzMzRjNjcwMTQzMTlhL3RhYmxlcmFuZ2U6Zjk4MjhiNWQ1NzZkNDY1MmJmYjMzNGM2NzAxNDMxOWFfMTktMTEtMS0xLTA_991d3664-ee61-41b1-9aba-9cb0db362400"
      unitRef="usd">74893000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7c74f98bea814d89ae592c883580eba5_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi0xLTEtMS0zMg_d96e89d8-2787-4a33-862e-baf04f04b7ff"
      unitRef="shares">15375282</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7c74f98bea814d89ae592c883580eba5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi0zLTEtMS0zMg_1f19ef07-7568-45d5-a7dc-480617ab269f"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i44747ec4fa294f50a7469563ddcbafeb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi01LTEtMS0zMg_ee77a6b3-7c70-46e8-adc4-640b9b417033"
      unitRef="usd">420434000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad82d516ac8944c3ab74858aecd5b316_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi03LTEtMS0zMg_223f5a8d-0f9f-4b36-9ae7-c7a6b9c16fce"
      unitRef="usd">-350861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1755861e14c849d2a5109ccface73c4d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi05LTEtMS0zMg_2723d211-8433-4a8a-b82c-1046facaf43e"
      unitRef="usd">-40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ide8e978d00c845e78cd00eaea3509c91_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMi0xMS0xLTEtMzI_0999333f-8710-4484-a3b6-056615496fbd"
      unitRef="usd">69535000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9a34e2be4ddc40a287e56721af2404d1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNC03LTEtMS0zMg_1ed3087e-f261-447f-bc2b-70c0becdcb93"
      unitRef="usd">-167440000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id78a66c4d2a848feb68215cc74cf142d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNC05LTEtMS0zMg_a1dad459-8ba8-4eb2-bf8d-a01571989d23"
      unitRef="usd">40000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNC0xMS0xLTEtMzI_daaa1b07-6d3a-4492-9778-829dc7213692"
      unitRef="usd">-167400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0c0c1b558463459aaba416b532ab05b9_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNS0xLTEtMS0zMg_6fb56afc-95e3-4691-a6b4-ee7451135710"
      unitRef="shares">132692</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i41f66d5268c24630ad030416639966ce_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNS01LTEtMS0zMg_510c0e86-8afd-4e15-9b05-12c631d16d75"
      unitRef="usd">-43000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNS0xMS0xLTEtMzI_6735b8ba-7e0a-4cbd-8441-8079d02af7e3"
      unitRef="usd">-43000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i41f66d5268c24630ad030416639966ce_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNi01LTEtMS0zMg_c42fa6cf-05aa-4d07-8a12-ce8bfc3fe3ad"
      unitRef="usd">10768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNi0xMS0xLTEtMzI_86b0e907-319d-47e2-806b-6dbfb8adea11"
      unitRef="usd">10768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment
      contextRef="i41f66d5268c24630ad030416639966ce_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNy01LTEtMS0zMg_610196c4-2f0d-4764-a958-09f211b50d35"
      unitRef="usd">-657000</vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment>
    <vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfNy0xMS0xLTEtMzI_ee43be82-4a47-43f4-adff-4e361b9acca1"
      unitRef="usd">-657000</vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOC0wLTEtMS0xMzgvdGV4dHJlZ2lvbjo1ZDcwZGI2YWM1ZjI0N2U3YjM0N2NjZjkyNGEzZDhkNl8xMDk5NTExNjI3ODY2_222dbbf0-71d4-4b26-b3cd-dcdc24f1a6c1"
      unitRef="usd">3903000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9ba6c46ad1554816bcc03cae4a40ea5e_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOC0xLTEtMS0zMg_b88023d1-d916-4e0d-97c2-3f8d5c2407ca"
      unitRef="shares">7776875</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0c0c1b558463459aaba416b532ab05b9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOC0zLTEtMS0zMg_885a3d8e-2b2a-4027-8980-93dbff46d5d6"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib1751f8eb9f24fd8843cb5ad13f6a9e7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOC01LTEtMS0zMg_5a327701-9be5-419b-a01e-022de9dd429c"
      unitRef="usd">53648000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5741436efcf7422d8c1efec1a5674e74_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOC0xMS0xLTEtMzI_a020899b-5e00-402b-8469-25cda9d60b84"
      unitRef="usd">53649000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i0c0c1b558463459aaba416b532ab05b9_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOS0xLTEtMS0zMg_f8454389-09fc-49d7-bbe9-25a2ea3a3bd4"
      unitRef="shares">18636103</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i0c0c1b558463459aaba416b532ab05b9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOS0zLTEtMS0zMg_bf4029e3-e825-4f4e-a59a-d3fb07600ad5"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i41f66d5268c24630ad030416639966ce_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOS01LTEtMS0zMg_3d4ffa73-ab7f-4f17-8d62-33e2e0e071ae"
      unitRef="usd">104361000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfOS0xMS0xLTEtMzI_41d8a218-8bca-460d-ba98-89a5c41076a3"
      unitRef="usd">104362000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icd67e51186d44f0aa1480b690576bb0d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtMS0xLTEtMzI_185c90b1-068a-4b39-be15-02fe7ddd899a"
      unitRef="shares">41920952</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icd67e51186d44f0aa1480b690576bb0d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtMy0xLTEtMzI_e324ef39-5db5-49f6-85ff-712726fa94ad"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4f9738453474c059f491621e59dc79b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtNS0xLTEtMzI_521f89f9-f56c-42b0-a169-c72d7e32bc47"
      unitRef="usd">589825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f2fa509856a406c9e42f24a5f55ac1e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtNy0xLTEtMzI_a1083b87-dee5-4e11-855c-118fae1b7646"
      unitRef="usd">-518301000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie50700e6e0f1422a89d1383e91db69f6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtOS0xLTEtMzI_49978a08-aec1-4601-a6dc-6b430f0b6e8c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTAtMTEtMS0xLTMy_71f3a45a-dc1b-4615-8e1b-af3eebbb83b2"
      unitRef="usd">71528000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7ba9266a3f21470b9aea71eb689ca61e_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTItMS0xLTEtMzI_21c94fae-ed90-4bd5-bdca-03635c72c252"
      unitRef="shares">51386596</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7ba9266a3f21470b9aea71eb689ca61e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTItMy0xLTEtMzI_e50c65d1-19e3-4838-9009-65c5b22fb347"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i425a84c0240f40dfb5087d836e1a583b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTItNS0xLTEtMzI_d9412b2e-3743-44a5-93ab-e0d93809ca30"
      unitRef="usd">679642000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb79d419a25c4a54bd7d489adc952e95_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTItNy0xLTEtMzI_2c88997f-9281-46f9-a943-57bbb733e999"
      unitRef="usd">-586746000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7dff1b7af5184588b64b59aa4e8c1aa3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTItMTEtMS0xLTMy_9fcf2550-b659-47dd-b633-9feebc088ec1"
      unitRef="usd">92901000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib29bbbec2a784133904ebf772b749830_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTQtNy0xLTEtMzI_2c6cc73b-365c-4e38-b549-bb7ae4a66962"
      unitRef="usd">-19924000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTQtMTEtMS0xLTMy_3086e1d3-ee0a-422f-8a6d-4365d474c6ab"
      unitRef="usd">-19924000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ica61d474584c4143988ae02e9fa3856a_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTUtMS0xLTEtMzI_01dcda0a-a3b5-4e92-8dca-e748e25c3c2f"
      unitRef="shares">125249</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i25e633a691ef420b992fc44538fdc8a7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTUtNS0xLTEtMzI_feb55282-d219-4cb3-8325-9810ca7a286c"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTUtMTEtMS0xLTMy_b8890b37-f4ec-4715-aa45-204b9d230690"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i25e633a691ef420b992fc44538fdc8a7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTYtNS0xLTEtMzI_323a97e7-80a9-4010-8979-4e7bf083bb84"
      unitRef="usd">1901000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTYtMTEtMS0xLTMy_1bc9b6ce-9910-41a7-9e07-7c0cb68efd6b"
      unitRef="usd">1901000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia694da22cf534b119d5bfa52040066d2_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTktMS0xLTEtMzI_9731c83a-2fda-47e7-b7dd-7616e5e2d685"
      unitRef="shares">51511845</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia694da22cf534b119d5bfa52040066d2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTktMy0xLTEtMzI_8d7cbbbb-56c7-4768-a9ab-bdb7dc8cb825"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9b04039f72414cc68135a0028a7ebd45_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTktNS0xLTEtMzI_08b9c4e4-0c50-4e54-b0fa-58efb206ce64"
      unitRef="usd">681558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc3c6f2f161a493b8e5395bce6f28971_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTktNy0xLTEtMzI_8e72b4c5-524d-4b2d-9e5a-21da912ad487"
      unitRef="usd">-606670000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8yOC9mcmFnOjFjODZlY2M4MTc0NzQzMjU4ODZjODhmZjMyOTViZGYzL3RhYmxlOmUwMmY1Njk4MjlmNDQxMjZiZmNlMjc1MDk0NTA1Nzc5L3RhYmxlcmFuZ2U6ZTAyZjU2OTgyOWY0NDEyNmJmY2UyNzUwOTQ1MDU3NzlfMTktMTEtMS0xLTMy_8f025613-a24d-426d-8b43-f9cbadcb7c2f"
      unitRef="usd">74893000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMy0xLTEtMS0w_4a866e72-7c7d-4adb-9040-5f15a5ec890a"
      unitRef="usd">-40474000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMy0zLTEtMS0w_5254cbe5-570d-4192-8f2b-25fb222dea2f"
      unitRef="usd">-207673000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNS0xLTEtMS0w_25893ac4-a115-4d8a-910f-1f9d1721c2a2"
      unitRef="usd">55000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNS0zLTEtMS0w_b851d970-a398-4e34-88aa-9a4dcc5eb401"
      unitRef="usd">187000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNi0xLTEtMS0w_d6867db1-d8e4-411e-b6a4-7cba76b6d0eb"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNi0zLTEtMS0w_e15e6152-7372-4a41-a8e8-2505138623db"
      unitRef="usd">54345000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <vyne:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNy0xLTEtMS0w_0798da1a-9c38-4b37-9cc1-8fade65daa04"
      unitRef="usd">0</vyne:ContingentStockConsiderationRemeasurementGainLoss>
    <vyne:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNy0zLTEtMS0w_1c8a876c-8b98-44ea-be71-89c9ee762219"
      unitRef="usd">-84726000</vyne:ContingentStockConsiderationRemeasurementGainLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfOS0xLTEtMS0w_90ec903a-69a2-4f57-b90d-0196a971b23d"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfOS0zLTEtMS0w_bd8ea882-bd1e-4d90-831c-d62a68b1493e"
      unitRef="usd">142000</us-gaap:UnrealizedGainLossOnInvestments>
    <vyne:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTAtMS0xLTEtMA_3446b69f-879d-4681-aa2f-782123270e2e"
      unitRef="usd">-108000</vyne:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits>
    <vyne:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTAtMy0xLTEtMA_1d056cfc-7279-4346-8381-25dc3215d05b"
      unitRef="usd">-21000</vyne:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits>
    <us-gaap:ShareBasedCompensation
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTEtMS0xLTEtMA_972c4d64-4374-4a21-b243-c8bd7729df47"
      unitRef="usd">4343000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTEtMy0xLTEtMA_22793730-0fee-4060-afc7-e9dceed22c63"
      unitRef="usd">12527000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTItMS0xLTEtMA_c45f9d81-2389-4fb0-9230-15f2d9fe6808"
      unitRef="usd">150000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTItMy0xLTEtMA_9d2c1d99-4fc6-4c8c-8d1e-f3f111c6e05f"
      unitRef="usd">833000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTQtMS0xLTEtMA_e51ed8c0-6225-4efa-ac74-87410ee2fbe9"
      unitRef="usd">-4266000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTQtMy0xLTEtMA_c27e1fe0-7980-4a19-887e-dce453a347b9"
      unitRef="usd">9807000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTUtMS0xLTEtMA_88575303-aa39-478d-a2d4-49c284e29eb4"
      unitRef="usd">-876000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTUtMy0xLTEtMA_4ba9ce6d-7810-40a5-b16e-f2f46496290b"
      unitRef="usd">6026000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTYtMS0xLTEtMA_d6ee2501-a065-42f1-8341-247cffa86afe"
      unitRef="usd">3259000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTYtMy0xLTEtMA_c416a56a-b50d-4a11-a2c7-af85bde13a7c"
      unitRef="usd">-10908000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTctMS0xLTEtMA_92d44cb1-9fdf-469e-9503-cb4483cd6478"
      unitRef="usd">875000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTctMy0xLTEtMA_bc82f7b1-98da-412b-820b-454df31d96d8"
      unitRef="usd">4445000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTgtMS0xLTEtMA_bc187eb9-0bb1-42ea-a924-1eed5609249d"
      unitRef="usd">-28808000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMTgtMy0xLTEtMA_592584d7-8331-43c9-80a2-032dcf3dbc2e"
      unitRef="usd">-88070000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjAtMS0xLTEtMA_537b2fbb-718d-4a55-a55b-e73e79ab4fce"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjAtMy0xLTEtMA_15336a83-9467-4c45-848e-704c56f600fa"
      unitRef="usd">113000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <vyne:ProceedsFromBusinessMerger
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjQtMS0xLTEtMA_5e3e6fbf-7a54-4c41-85ed-615e504df777"
      unitRef="usd">0</vyne:ProceedsFromBusinessMerger>
    <vyne:ProceedsFromBusinessMerger
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjQtMy0xLTEtMA_cc33bdc2-dcfd-418c-8fc2-2e738a36f055"
      unitRef="usd">38641000</vyne:ProceedsFromBusinessMerger>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjUtMS0xLTEtMA_bc25472d-f84f-4853-9fcc-ff9843ac217f"
      unitRef="usd">1027000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjUtMy0xLTEtMA_a957e76e-b996-4711-8cb5-a96d8b03b65e"
      unitRef="usd">48577000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjYtMS0xLTEtMA_2fac94d8-81e2-4703-9f05-3a27370cf93a"
      unitRef="usd">1027000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjYtMy0xLTEtMA_3f81f25e-3e91-424c-b1b1-3f468c5d8a84"
      unitRef="usd">87105000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjgtMS0xLTEtMA_e441dc7e-eefa-4a86-ac7e-6d6053d8e0b7"
      unitRef="usd">73127000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMjgtMy0xLTEtMA_fcb7925a-74a5-4e7d-be22-89dadffb11dc"
      unitRef="usd">53646000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzAtMS0xLTEtMA_42c660cc-e953-4f7f-80ea-80105d319bb9"
      unitRef="usd">247000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzAtMy0xLTEtMA_98097883-a4ec-4172-8b3d-49070d095b09"
      unitRef="usd">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzEtMS0xLTEtMA_36623c34-340a-4cb4-a729-bf2293d1fffa"
      unitRef="usd">73374000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzEtMy0xLTEtMA_ddbac837-e43c-4d20-b357-670a9670d67e"
      unitRef="usd">53746000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzItMS0xLTEtMA_3fba2631-1e9d-4ced-a2f4-c303d2269d83"
      unitRef="usd">45593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzItMy0xLTEtMA_b4eb0239-8b73-4513-8d4c-133eb206484a"
      unitRef="usd">52781000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzMtMS0xLTEtMA_268a4b87-9c75-486b-ad75-6825c3f213da"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzMtMy0xLTEtMA_8f648159-2320-4ab3-9db0-63cb64010721"
      unitRef="usd">1000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzQtMS0xLTEtMA_e57f73f7-fb1c-4339-ac39-9f6ab18ff83a"
      unitRef="usd">58418000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a3d7596a5a540f69eee45235f538a4b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzQtMy0xLTEtMA_b5c90992-5c72-4cce-b6db-bb12e1558306"
      unitRef="usd">44584000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzUtMS0xLTEtMA_cffda923-04e5-40b9-aaeb-dbf186a819d2"
      unitRef="usd">104011000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzUtMy0xLTEtMA_4b93c93f-175d-40c9-a8dd-8de1e375ef76"
      unitRef="usd">97366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzYtMS0xLTEtMA_e2e84b8e-9202-4998-aabe-2e8a2eba81ae"
      unitRef="usd">103406000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzYtMy0xLTEtMA_3767c3d7-8558-4d35-8558-46df2539b5fb"
      unitRef="usd">96511000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzctMS0xLTEtMA_3b3784e2-9536-452c-9d65-9bfcd8eed3a5"
      unitRef="usd">605000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzctMy0xLTEtMA_44ea6c5f-3aca-428e-8eaf-91bf996fd923"
      unitRef="usd">855000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzgtMS0xLTEtMA_b2508ba0-528e-4aaf-a424-422f87646a9d"
      unitRef="usd">104011000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfMzgtMy0xLTEtMA_8b484371-ad05-4f2d-9c14-42f77424f6a1"
      unitRef="usd">97366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDEtMS0xLTEtMA_931b533f-94ac-4eb7-afff-35c2ffa89d83"
      unitRef="usd">144000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDEtMy0xLTEtMA_18c98214-11df-4bec-9a44-88dbcf09fc1d"
      unitRef="usd">163000</us-gaap:StockIssued1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDItMS0xLTEtMA_c2a5769d-89c9-425d-bc02-a01467956eba"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDItMy0xLTEtMA_5be62ff7-a823-4c4e-8b41-e81bee392a18"
      unitRef="usd">1120000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDMtMS0xLTEtMA_aa2b167f-309b-4f57-8e4b-ff1a7265b4f2"
      unitRef="usd">0</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDMtMy0xLTEtMA_f1058bfb-90f5-46d5-84df-6c29d95132a7"
      unitRef="usd">1120000</us-gaap:CapitalLeaseObligationsIncurred>
    <vyne:InterestReceived
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDYtMS0xLTEtMA_1226896f-81ac-4289-b6cc-46f78163f802"
      unitRef="usd">11000</vyne:InterestReceived>
    <vyne:InterestReceived
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDYtMy0xLTEtMA_c1bbfff5-fd4d-46cb-8b5d-b40685a289e8"
      unitRef="usd">298000</vyne:InterestReceived>
    <us-gaap:InterestPaidNet
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDctMS0xLTEtMA_eb7bf17b-5520-4565-a258-b0a2f56a88a3"
      unitRef="usd">1936000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDctMy0xLTEtMA_1a721954-d7ec-41a3-9db5-28b3934f000c"
      unitRef="usd">1946000</us-gaap:InterestPaidNet>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDktMS0xLTEtMA_689f4df8-6d10-4d78-818c-aa7529e5244f"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNDktMy0xLTEtMA_98f427b8-bb05-426c-a8ad-b9ac80c75019"
      unitRef="usd">117270000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTAtMS0xLTEtMA_8e73422f-ed75-4bb4-9fc4-f07129c5fb5d"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTAtMy0xLTEtMA_537e7d01-f3f7-4514-8cda-1a303ef68cd8"
      unitRef="usd">5827000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTEtMS0xLTEtMA_9d09f0e5-2e27-4865-9284-a66dba8b27c4"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTEtMy0xLTEtMA_283d3225-883e-492e-8c9e-3465db301305"
      unitRef="usd">111443000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <vyne:NonCashAcquisitionOfBusinessCashAcquired
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTItMS0xLTEtMA_d4627c6e-e7f9-46cf-a976-c60f81bf1af8"
      unitRef="usd">0</vyne:NonCashAcquisitionOfBusinessCashAcquired>
    <vyne:NonCashAcquisitionOfBusinessCashAcquired
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTItMy0xLTEtMA_1eeb9a62-ec60-48ea-a52b-47334c2a7349"
      unitRef="usd">38641000</vyne:NonCashAcquisitionOfBusinessCashAcquired>
    <vyne:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTMtMS0xLTEtMA_cce8a857-2438-40ab-8d0d-a18bb355e1bb"
      unitRef="usd">0</vyne:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired>
    <vyne:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zMS9mcmFnOmUxZjU1YzlmZjYwNTRjYjM4NjZjNmZkZmFkZjA5M2Y3L3RhYmxlOjAzNDgxODhjYzA1ZTQ3MzRhZmRlZTIzMjM2OWUwYjVmL3RhYmxlcmFuZ2U6MDM0ODE4OGNjMDVlNDczNGFmZGVlMjMyMzY5ZTBiNWZfNTMtMy0xLTEtMA_a567790c-d2a1-43c8-9f9f-4621535db94d"
      unitRef="usd">72802000</vyne:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired>
    <us-gaap:NatureOfOperations
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMTA4ODU_1057b06b-5911-44e7-b4d6-56ec220ede03">NATURE OF OPERATIONS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VYNE Therapeutics Inc. ("VYNE" or the "Company") is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory diseases of high unmet medical need. The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as&#160;one&#160;business segment. The Company currently has two commercial products, AMZEEQ&#xae; (minocycline) topical foam, 4%, and ZILXI&#xae; (minocycline) topical foam, 1.5%. As discussed below, the Company has initiated a process to explore a possible sale or license of its topical minocycline franchise. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Strategic Business Review&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the second quarter of 2021, the Company conducted a review of its commercial and research and development portfolio to determine how to optimally deploy capital and drive shareholder value. During the course of this review, the Company carefully considered the revenues received from the commercialization of AMZEEQ and ZILXI and the associated costs to drive those revenues, the protracted negative impact of the COVID-19 pandemic over the past 18 months during the commercial launches of both AMZEEQ and ZILXI, the current payor landscape, as well as the costs to develop each of its pipeline products. During this process, the Company evaluated several strategic options including the acquisition of marketed assets, out-licensing its approved products outside of the United States, and possible partnering or co-development relationships with interested parties. Following its review, the Company has determined to initiate a process to explore a possible sale or license of its topical minocycline franchise, including AMZEEQ, ZILXI, FCD105 (the Company&#x2019;s Phase 3 proprietary novel topical combination foam formulation of minocycline and adapalene for the treatment of moderate-to-severe acne vulgaris) and the underlying Molecule Stabilizing Technology platform. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;By leveraging its drug development and clinical development capabilities and strong network of discovery and preclinical science partners, the Company will transition its strategic focus to develop therapies for the treatment of immuno-inflammatory diseases of high unmet medical need. The Company expects to continue to invest in FMX114 for the treatment of mild to moderate atopic dermatitis and anticipates the first patient in its Phase 2a proof-of-concept study will be enrolled in the third quarter of 2021. The Company expects results from this study by the end of 2021. In addition, on August 12, 2021, the Company announced a transaction with In4Derm Limited, a company incorporated and registered in Scotland (&#x201c;In4Derm&#x201d;). In4Derm is a spin-out of the University of Dundee&#x2019;s School of Life Sciences which has discovered and is developing proprietary Bromodomain and Extra-Terminal Domain Inhibitors (&#x201c;BETi&#x201d;) for the treatment of immunology and oncology conditions. On April 30, 2021, the parties entered into an Evaluation and Option Agreement (the &#x201c;Option Agreement&#x201d;) pursuant to which In4Derm granted the Company an exclusive option to obtain exclusive worldwide rights to research, develop and commercialize products containing In4Derm&#x2019;s BETi compounds, which are new chemical entities, in both topical (the &#x201c;Topical BETi Option&#x201d;) and oral (the &#x201c;Oral BETi Option&#x201d;) treatments in all fields for any disease, disorder or condition in humans. On August 6, 2021, the Company exercised the Topical BETi Option and the parties entered into a License Agreement granting the Company a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of In4Derm&#x2019;s BETi compounds identified to be suitable for topical administration in all fields. The Company paid a $1.0&#160;million cash payment to In4Derm upon the execution of the Option Agreement and $0.5 million in connection with the exercise of the Topical BETi Option. Pursuant to the License Agreement, the Company has agreed to make cash payments to In4Derm upon the achievement of specified clinical development and regulatory approval milestones with respect to each licensed topical product in the U.S. of up to $15.75&#160;million for all indications. In addition, the Company currently expects to exercise the Oral BETi Option following the selection of a lead candidate for the program. Upon exercise of the exclusive Oral BETi Option, the parties will sign a license agreement (the &#x201c;Oral License Agreement&#x201d;), and the Company will be required to pay In4Derm a $4.0&#160;million cash payment. The Oral License Agreement will include cash payments of up to $43.75 million payable to In4Derm upon the achievement of specified clinical development and regulatory approval milestones with respect to each licensed oral product in the U.S. for all indications. The license agreements also provide for tiered royalty payments of up to 10% of net annual sales across licensed BETi products by the Company. In4Derm is entitled to additional milestones upon the achievement of regulatory approvals in certain jurisdictions outside the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial BETi candidates that the Company plans to develop are VYN201 and VYN202. VYN201 is a pan-bromodomain or pan-BD BET inhibitor.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is a first-in-class &#x201c;soft&#x201d; pan-BD BET inhibitor that is designed to mitigate systemic drug exposure and will be developed for topical applications. The Company intends to progress VYN201 into rare, neutrophilic, dermatological &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;indications where there is significant unmet need due to a lack of indicated treatment options. The Company plans to enter this program into the clinic in 2022 after the prerequisite non-clinical safety assessments have been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The second candidate, VYN202, is an orally-delivered, first-in-class BET inhibitor that is highly selective for Bromodomain 2 ("BD2"). Recent research has suggested that the majority of pro-inflammatory signaling via BET protein action is via interactions with BD2. By selectively inhibiting BD2, the Company believes VYN202 could have a more targeted anti-inflammatory effect with an improved benefit/risk profile. The Company views VYN202 as having significant potential as a novel, oral treatment for major immuno-inflammatory indications. Following the exercise of the Oral BETi Option, the Company intends to commence a IND-enabling non-clinical safety program for VYN202 and enter the clinic in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company transitions from a commercial organization to one focused on research and development, the Company intends to streamline operations by eliminating the vast majority of planned expenditures supporting its commercial operations. Furthermore, the Company intends to reduce its workforce by terminating approximately 70 employees, which the Company expects to be completed by December 31, 2021. The Company expects to incur a one-time charge in the range of approximately $1.5 million to $2.0&#160;million, excluding non-cash charges, in connection with this restructuring plan, consisting primarily of employee termination costs, including severance and other benefits. This charge is expected to be incurred during the quarter ending September 30, 2021 with related cash payments expected to be substantially paid out by December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reverse Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 10, 2019, Menlo, Foamix Pharmaceuticals Ltd. (&#x201c;Foamix&#x201d;) and Giants Merger Subsidiary Ltd. (&#x201c;Merger Sub&#x201d;), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the &#x201c;Merger Agreement&#x201d;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the &#x201c;Merger&#x201d;) on March 9, 2020 (the &#x201c;Effective Date&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For accounting purposes, the Merger is treated as a &#x201c;reverse acquisition&#x201d; under generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#x2019;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See &#x201c;Note 3 &#x2013; Business Combination&#x201d; for more information on the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reverse stock split and recasting of per-share amounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2021, the Company's Board of Directors approved a one-for-four reverse stock split of its outstanding shares of common stock.  The reverse stock split was effected on February 12, 2021, at 5:00 p.m. Eastern time.  At the effective time, every four issued and outstanding shares of the Company's common stock were converted into one share of common stock.  No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each stockholder holding fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company's transfer agent in an amount equal to such stockholder's respective pro rata shares of the total net proceeds from the Company's transfer agent sale of all fractional shares at the then-prevailing prices on the open market.  In connection with the reverse stock split, the number of authorized shares of the Company's common stock was also reduced on a one-for-four basis, from 300 million shares to 75 million shares.  The par value of each share of common stock remained unchanged.  A proportionate adjustment was also made to the maximum number of shares issuable under the Company's 2019 Equity Incentive Plan, 2018 Omnibus Incentive Plan and 2019 Employee Share Purchase Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise noted, all common shares and per share amounts contained in the unaudited interim condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Topical Minocycline Franchise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the Company launched AMZEEQ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the U.S. Food and Drug Administration (the "FDA") approved ZILXI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of inflammatory lesions of rosacea in adults.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ZILXI became available in pharmacies nationwide in October 2020. AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA for any condition.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMZEEQ and ZILXI utilize the Company&#x2019;s proprietary Molecule Stabilizing Technology (MST)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; that is also being used in the development of the Company&#x2019;s product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, the Company announced positive results from a Phase II clinical trial evaluating &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held an end-of-Phase II meeting with the FDA in the fourth quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Serlopitant &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company was developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, or&#160;NK1-R, given as a once-daily, oral tablet, for the treatment of pruritus, or itch, associated with various conditions including prurigo nodularis, or PN. On April 6, 2020, the Company announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN, studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. The Company does not currently intend to further pursue the development of serlopitant. As a result, in the second quarter of 2020, the Company recorded a full impairment charge related to the IPR&amp;amp;D and Goodwill assets in its unaudited condensed consolidated statement of operations and comprehensive loss. See "Note 3 - Business Combination" for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company launched AMZEEQ in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company also launched ZILXI in the United States in October 2020 and commenced generating revenues in the fourth quarter of 2020. The Company&#x2019;s activities prior to the commercial launches of AMZEEQ and ZILXI had primarily consisted of raising capital, developing product candidates, and performing research and development activities. Since inception, the Company has incurred recurring losses and negative cash flows from operations. For the six months ended June&#160;30, 2021, the Company incurred a net loss of $40.5 million and used&#160;$28.8 million of cash in operations. As of June&#160;30, 2021, the Company had cash, cash equivalents, restricted cash and investments of $104.0 million and an accumulated deficit of $606.7 million.  The Company's outstanding debt under its Amended and Restated Credit Agreement at June 30, 2021 was $35.0&#160;million. On August 11, 2021, the Company prepaid the entirety of its outstanding indebtedness, including a prepayment premium and accrued but unpaid interest, for a total amount of approximately $36.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. In addition, the commercial launches of both AMZEEQ and ZILXI have been negatively impacted by unfavorable payor decisions in March 2021 on product pricing. These conditions have impaired the Company's ability to generate revenue consistent with internal forecasts, which has had a negative impact on its financial condition and liquidity. The Company and its lenders discussed revenue expected to be generated for the trailing twelve month period ended June 30, 2021, the revenue targets included in the Amended and Restated Credit Agreement and the Company&#x2019;s strategic transition discussed above. Following such discussions, the Company determined to prepay its outstanding indebtedness in addition to a 4% prepayment fee and accrued but unpaid interest in the total amount of approximately $36.5&#160;million on August&#160;11, 2021. Following the prepayment, the Amended and Restated Credit Agreement has been terminated and the security interests thereunder will be terminated. As a result of the above, the Company determined that its projected cash flows from operations, combined with its cash balance after the debt prepayment, would not provide sufficient resources to fund its existing operations, for at least the next twelve months from the issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed above, the Company completed a strategic review of its business and has determined to initiate a process to explore a sale or license of its minocycline franchise, including AMZEEQ, ZILXI, FCD105 and the underlying MST platform. The Company will refocus its resources on its immuno-inflammatory pipeline and intends to support the FMX114 and the BETi development programs. Research and development activities for these programs, including preclinical and clinical testing of the Company&#x2019;s drug candidates, will require significant additional financing. The future viability of the Company is dependent on its ability to successfully pivot to its research and development business strategy and develop commercially viable drug candidates and raise additional capital to finance its operations.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue as a going concern is contingent on its ability to sell or license its minocycline franchise, develop future commercially viable products and/or to raise sufficient working capital through either debt or equity financing.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There is no assurance the Company will be able to achieve these objectives under acceptable terms or at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-15, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that its unaudited condensed consolidated financial statements are issued. The accompanying condensed &lt;/span&gt;&lt;/div&gt;consolidated financial statements have been prepared assuming that the Company will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company&#x2019;s ability to continue as a going concern is expected to be impacted by the outcome of the plans outlined above, including the successful sale or license of its minocycline franchise, positive results from clinical trials for FMX114, and the successful development and positive results from clinical trials for the BETi programs. Based on current plans and assumptions, the Company believes that absent sufficient proceeds received from a sale or license of the minocycline franchise, business development transactions or financing transactions, which are all beyond its control, it will not have sufficient cash and cash equivalents to fund its operations beyond one year from the issuance of these financial statements. Accordingly, the Company will, over the course of the next twelve months, require significant additional financing to continue its operations. Each of these factors are subject to uncertainty, and therefore, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. Failure to successfully complete a sale or license of the minocycline franchise, develop the noted assets, and receive additional financing will require the Company to delay, scale back or otherwise modify its business and its research and development activities and other operations. The accompanying financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfReportableSegments
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfNDMy_a85b6248-8187-4be9-99a2-fdff608917f1"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <vyne:PaymentsForLicensingAgreements
      contextRef="ie36f0645785e4cabba23e0ebc501434b_D20210806-20210806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMTA5OTUxMTY3MTY1OA_2186a4be-8313-4c36-86e0-68ce3d72053b"
      unitRef="usd">1000000.0</vyne:PaymentsForLicensingAgreements>
    <vyne:PaymentsForLicensingAgreements
      contextRef="i833be515ce11411f87485dfaea471f94_D20210806-20210806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMTA5OTUxMTY3MTUzMA_6fec7139-df9d-422c-818e-020488b75fa0"
      unitRef="usd">500000</vyne:PaymentsForLicensingAgreements>
    <vyne:MilestonePaymentsUponAchievingCertainCriteriaMaximum
      contextRef="i833be515ce11411f87485dfaea471f94_D20210806-20210806"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTExOTYzMw_d773d401-709b-4475-9582-49185b725b22"
      unitRef="usd">15750000</vyne:MilestonePaymentsUponAchievingCertainCriteriaMaximum>
    <vyne:PaymentsForLicensingAgreements
      contextRef="i6fcd46d67d92482a938a2ff751b727d8_D20210806-20210806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMTA5OTUxMTY3MTU2OQ_c1ee09e4-4d9f-444f-92f7-6a06ce831bde"
      unitRef="usd">4000000.0</vyne:PaymentsForLicensingAgreements>
    <vyne:MilestonePaymentsUponAchievingCertainCriteriaMaximum
      contextRef="i6fcd46d67d92482a938a2ff751b727d8_D20210806-20210806"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTExOTY0OQ_afd0b587-e66f-4622-b54a-b1fbd96eb1cb"
      unitRef="usd">43750000</vyne:MilestonePaymentsUponAchievingCertainCriteriaMaximum>
    <vyne:RoyaltyPaymentPercentMaximum
      contextRef="i3a4133507eae4a3293528a38e4dc4312_I20210806"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMTA5OTUxMTY3MTYwMQ_f4e7d058-eb8e-42d1-9019-13f86997f196"
      unitRef="number">0.10</vyne:RoyaltyPaymentPercentMaximum>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="i4a701835f72e475097f033580f5deea7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTExODcyOQ_9d24e302-b2cc-4a5d-8462-1cdb444e4417"
      unitRef="employee">70</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ibace252288db423ca83fb8257a0d36f9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMzg0ODI5MDc0NTY2OQ_ce1447a2-9598-4ec6-b232-d2c6f1fdd513"
      unitRef="usd">1500000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i20cbba757ccb4615a4d0cfe3c3f988dd_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMzg0ODI5MDc0NTY3Ng_5582bfd0-d3bb-498e-b711-05d098e87bd2"
      unitRef="usd">2000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if12e854e598f4a50aee8bc4d0c1ba30d_I20210211"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjU0OQ_02bac963-578a-4583-8b77-13bb8e27f29f"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4ed43e98e5c24ad3a531ae837852997f_I20210212"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjU2Mg_0fd6f62b-db5d-4bbd-995e-b5a4aabdf691"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:NetIncomeLoss
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfNzAyNw_596f0e8f-a266-4cee-aed9-c9efd95fd851"
      unitRef="usd">-40500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfNzAzOQ_490c7af2-bd31-4345-82b2-6aea0106aa0d"
      unitRef="usd">-28800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfNzE1MA_e4cf6873-ae0d-42d2-ae44-96c509b6e588"
      unitRef="usd">104000000.0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfNzE4Mw_b025bd3d-dd06-4bd0-87a7-6a21fd74f28b"
      unitRef="usd">-606700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LongTermDebt
      contextRef="i9efde75313c64f94acd2d57c0ac7ad36_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTEyNTY4Nw_df2782d6-8fa0-4824-ad2f-990b6c1cfaf6"
      unitRef="usd">35000000.0</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic25e62d0cd134ea88998d63b633a4770_D20210811-20210811"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTEyNTcwMg_3b3ac47f-1b32-46e0-9cc9-dab4b3c2034c"
      unitRef="usd">36500000</us-gaap:RepaymentsOfLongTermDebt>
    <vyne:RepaymentOfDebtPrepaymentFeePercentage
      contextRef="i271ffaaf0e574d60ad9235c64c92906e_I20210811"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMzg0ODI5MDc1MjQ5MQ_246aa10b-9de0-4405-bb25-4d6d0852d60b"
      unitRef="number">0.04</vyne:RepaymentOfDebtPrepaymentFeePercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic25e62d0cd134ea88998d63b633a4770_D20210811-20210811"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8zNy9mcmFnOmNkYjFiMmZiNTEzODRkMThiYzY2NWI3ODU2OTVmMmZhL3RleHRyZWdpb246Y2RiMWIyZmI1MTM4NGQxOGJjNjY1Yjc4NTY5NWYyZmFfMjc0ODc3OTEyNTcxNw_4050a060-1488-41bd-839d-b2e994f75269"
      unitRef="usd">36500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTc_2c5e2690-906e-405a-bd97-14228cabead6">SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. In the opinion of management, the Company has made&#160;all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company&#x2019;s condensed consolidated financial position, results of operations, cash flow and statement of stockholders' equity for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.  Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC on March 4, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results expected for the year ending December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.94pt"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.07pt"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition and liquidity will depend on future developments that are highly uncertain, subject to change and will continue to evolve with geographical re-openings, surges in cases, the development of new strains and the vaccination effort. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of  June&#160;30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2020, the Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;d.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.94pt"&gt;Business Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited interim condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet.&#160;Transaction costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, the Company uses fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; The Company estimates fair value using an exit price approach, which requires, among other things, that Company determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following techniques:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Income approach, which is based on the present value of a future stream of net cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fair value methodologies depend on the following types of inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Asset Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews all of its long-lived assets for impairment indicators throughout the year. Impairment testing is performed for indefinite-lived intangible assets annually (or sooner if warranted) and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.07pt"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenue transactions under FASB ASC Topic 606,&#160;Revenue from Contracts with Customers. In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customers include a limited number of national and select regional wholesalers (the &#x201c;distributors&#x201d;) and certain independent and specialty pharmacies (together, the &#x201c;customers&#x201d;). These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when customers obtain control of the Company&#x2019;s products, which occurs at a point in time, typically upon delivery of product to the customers. The Company evaluates the creditworthiness of its customers to determine whether it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur. The Company does not assess whether a contract has a significant financing component if the expectation is such that the period between the transfer of the promised goods to the customer and the receipt of payment will be less than one year. Standard credit terms do not exceed 75 days. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that would have been recognized is one year or less or the amount is immaterial. Shipping and handling costs related to the Company&#x2019;s product sales are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product revenues through&#160;June&#160;30, 2021&#160;were primarily generated through sales of AMZEEQ, which was approved by the FDA in October 2019 and was commercially launched in the United States in January 2020, and ZILXI, which was approved by the FDA in May 2020 and was commercially launched in the United States in October 2020. Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, copay program coupons, chargebacks, estimated returns and other incentives. These reserves are classified as either reductions of accounts receivable or as current liabilities. The estimates of reserves established for variable consideration reflect current contractual and statutory requirements, known market events and trends, industry data and forecasted customer mix. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net product revenues only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from these estimates. If actual results vary, estimates may be adjusted in the period such change in estimate becomes known, which could have an impact on earnings in the period of adjustment. See &#x201c;Note 4 &#x2013; Revenue Recognition&#x201d; for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for our minocycline products and product candidate, if approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commercial use.  The Company received an upfront cash payment of $10.0 million in 2020 ($6.0 million received in the three months ended June 30, 2020 and $4.0 million received in the three months ended September 30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The Company will also receive royalties on net sales of any licensed products.  The license is determined to be a distinct performance obligation of the arrangement, therefore the Company recognized the revenues from the upfront license fee when the license was transferred to the licensee and the licensee was able to use and benefit from the license.  See "Note 4 - Revenue Recognition" for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;f.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.17pt"&gt;Allowance for credit losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be&#160;collected.&#160;Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were not material for the three and six months ended June&#160;30, 2021 and June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"&gt;Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes all derivative instruments as either assets or liabilities in the unaudited condensed consolidated balance sheet at their respective fair values. All gains and losses associated with derivatives are reported as other expense (income), net in the accompanying condensed consolidated statements of operations.  As of June&#160;30, 2021 and June&#160;30, 2020, the Company had no derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;h.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.94pt"&gt;Fair value measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1:&#160;&#160;&#160;&#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2:&#160;&#160;&#160;&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3:&#160;&#160;&#160;&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.73pt"&gt;Loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury share method when dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of the weighted-average number of common stock outstanding during the period in which the reverse merger occurs was based on:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The number of common stock outstanding from the beginning of that period to the merge date was computed on the basis of the weighted-average number of common stock of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt"&gt;The number of common outstanding common stock outstanding from the merge date to the end of that period was the actual number of common stock of the legal acquirer (the accounting acquiree) outstanding during that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following average stock options, restricted stock units (&#x201c;RSUs&#x201d;), warrants and incremental shares to be issued under the employee stock purchase plan (&#x201c;ESPP&#x201d;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-right:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock options, RSUs and shares under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,378,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,365,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,020,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the above, the CSR was excluded from the calculation of the 2020 diluted net loss per share because its effect would have been anti-dilutive for the periods presented. On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective exchange ratio (the "Exchange Ratio") in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020. See "Note 3 - Business Combination" for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;j.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.17pt"&gt;Newly issued and recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Guidance Issued:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes," which clarifies and simplifies certain aspects of the accounting for income taxes.  The standard is effective for years beginning after December 15, 2020, and interim periods &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;beginning after December 15, 2020.  This guidance became effective during the first quarter of 2021.  The adoption of the new standard did not have a material impact to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Accounting Standards Update No. 2020-4, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" (ASU 2020-4), which provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying generally accepted accounting principles to contracts, hedging relationships, and other transactions impacted by reference rate reform. The provisions of ASU 2020-4 apply only to those transactions that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-4 are optional and are effective from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-4 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued Accounting Standards Update No. 2016-13,&#160;&#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;&#160;(ASU 2016-13), which requires companies to measure credit losses of financial instruments, including customer accounts receivable, utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. As a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023 or at such time where it is no longer a smaller reporting company.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTg_4d23bd3f-7722-40cf-ad49-4f5f23de3268">Basis of Presentation&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. In the opinion of management, the Company has made&#160;all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company&#x2019;s condensed consolidated financial position, results of operations, cash flow and statement of stockholders' equity for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.  Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC on March 4, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results expected for the year ending December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTQ_881e1b82-675d-4d08-982d-18b944ecb822">Principles of ConsolidationThe consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTA_c1c85fb7-533a-41ec-9bdd-7929711cf7cd">Use of Estimates&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition and liquidity will depend on future developments that are highly uncertain, subject to change and will continue to evolve with geographical re-openings, surges in cases, the development of new strains and the vaccination effort. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of  June&#160;30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2020, the Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The &lt;/span&gt;&lt;/div&gt;Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAyMDA_876ea1fd-3410-45a5-93ba-4d4871f2dedb">Business Acquisition&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited interim condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet.&#160;Transaction costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, the Company uses fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; The Company estimates fair value using an exit price approach, which requires, among other things, that Company determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following techniques:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Income approach, which is based on the present value of a future stream of net cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fair value methodologies depend on the following types of inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Asset Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews all of its long-lived assets for impairment indicators throughout the year. Impairment testing is performed for indefinite-lived intangible assets annually (or sooner if warranted) and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTU_9217d043-e473-48db-918b-34142a2a53a9">Revenue RecognitionThe Company accounts for its revenue transactions under FASB ASC Topic 606,&#160;Revenue from Contracts with Customers. In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customers include a limited number of national and select regional wholesalers (the &#x201c;distributors&#x201d;) and certain independent and specialty pharmacies (together, the &#x201c;customers&#x201d;). These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when customers obtain control of the Company&#x2019;s products, which occurs at a point in time, typically upon delivery of product to the customers. The Company evaluates the creditworthiness of its customers to determine whether it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur. The Company does not assess whether a contract has a significant financing component if the expectation is such that the period between the transfer of the promised goods to the customer and the receipt of payment will be less than one year. Standard credit terms do not exceed 75 days. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that would have been recognized is one year or less or the amount is immaterial. Shipping and handling costs related to the Company&#x2019;s product sales are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product revenues through&#160;June&#160;30, 2021&#160;were primarily generated through sales of AMZEEQ, which was approved by the FDA in October 2019 and was commercially launched in the United States in January 2020, and ZILXI, which was approved by the FDA in May 2020 and was commercially launched in the United States in October 2020. Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, copay program coupons, chargebacks, estimated returns and other incentives. These reserves are classified as either reductions of accounts receivable or as current liabilities. The estimates of reserves established for variable consideration reflect current contractual and statutory requirements, known market events and trends, industry data and forecasted customer mix. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net product revenues only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from these estimates. If actual results vary, estimates may be adjusted in the period such change in estimate becomes known, which could have an impact on earnings in the period of adjustment. See &#x201c;Note 4 &#x2013; Revenue Recognition&#x201d; for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for our minocycline products and product candidate, if approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commercial use.  The Company received an upfront cash payment of $10.0 million in 2020 ($6.0 million received in the three months ended June 30, 2020 and $4.0 million received in the three months ended September 30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The Company will also receive royalties on net sales of any licensed products.  The license is determined to be a distinct performance obligation of the arrangement, therefore the Company recognized the revenues from the upfront license fee when the license was transferred to the licensee and the licensee was able to use and benefit from the license.  See "Note 4 - Revenue Recognition" for more information.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="ie37f3b5248df46e8a5d24d2bfdf923c7_D20200401-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTI0NDk_ed6b43d7-b62c-4ed8-a31b-294bf5c06e03"
      unitRef="usd">10000000.0</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="ieb1d0e22f202476fa595bb840d395cd9_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTI0NjE_ab6072c8-fcab-4de1-a126-e3336b216c3f"
      unitRef="usd">6000000.0</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="i68da95855f63445cb75b88e2107393a8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTI1MTc_b4de7d63-69ab-4653-99bf-d692b9527122"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromRoyaltiesReceived>
    <vyne:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents
      contextRef="iaa2d29a04a9d429e8c602ba8cac18f30_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTI2MjE_537a6bad-1917-40b4-b502-b64433dd11da"
      unitRef="usd">1000000.0</vyne:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxODc_c5f96ce6-8e49-49ae-95e2-89cad39c7396">Allowance for credit lossesAn allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be&#160;collected.&#160;Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were not material for the three and six months ended June&#160;30, 2021 and June&#160;30, 2020.</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTY_4baa9240-ae80-49ec-b2b2-f84a2a4f1b10">Derivative instrumentsThe Company recognizes all derivative instruments as either assets or liabilities in the unaudited condensed consolidated balance sheet at their respective fair values. All gains and losses associated with derivatives are reported as other expense (income), net in the accompanying condensed consolidated statements of operations.  As of June&#160;30, 2021 and June&#160;30, 2020, the Company had no derivative instruments.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTQwNjg_c30300ac-2df7-44ef-9d59-df9c30dbbcc3"
      unitRef="derivativeinstruments">0</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i0fe5419b81c14a06b772ea4bc01565d0_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTQwNjg_f26da241-f82d-432a-9001-0a1d8db1e301"
      unitRef="derivativeinstruments">0</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTE_b36db963-b3ac-4885-bbb9-cb9802f877bd">Fair value measurement&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1:&#160;&#160;&#160;&#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2:&#160;&#160;&#160;&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3:&#160;&#160;&#160;&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTI_57a23386-95f3-4b89-a151-3ac07f3dc71b">Loss per share&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury share method when dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of the weighted-average number of common stock outstanding during the period in which the reverse merger occurs was based on:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The number of common stock outstanding from the beginning of that period to the merge date was computed on the basis of the weighted-average number of common stock of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt"&gt;The number of common outstanding common stock outstanding from the merge date to the end of that period was the actual number of common stock of the legal acquirer (the accounting acquiree) outstanding during that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following average stock options, restricted stock units (&#x201c;RSUs&#x201d;), warrants and incremental shares to be issued under the employee stock purchase plan (&#x201c;ESPP&#x201d;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-right:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock options, RSUs and shares under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,378,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,365,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,020,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the above, the CSR was excluded from the calculation of the 2020 diluted net loss per share because its effect would have been anti-dilutive for the periods presented. On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective exchange ratio (the "Exchange Ratio") in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020. See "Note 3 - Business Combination" for more information.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxODg_09bd14a9-8feb-4d19-a10c-5bd0f61efed7">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following average stock options, restricted stock units (&#x201c;RSUs&#x201d;), warrants and incremental shares to be issued under the employee stock purchase plan (&#x201c;ESPP&#x201d;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-right:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock options, RSUs and shares under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,378,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,365,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,020,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib7eaae92ef0840c2b50b035cf1e0a2e0_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMi0xLTEtMS0w_a524eaa9-08a6-44a8-b27d-06a2b67e188b"
      unitRef="shares">5378428</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf646184c9df4d2991aed59bbf06b647_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMi0zLTEtMS0w_8e9bf37b-1216-491f-ad46-24974b645bf4"
      unitRef="shares">3743846</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8a7f4503f7384e2faaa1111b3d6139c9_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMi01LTEtMS0w_5a3904c4-65f4-4e45-bd5e-befab1201e5c"
      unitRef="shares">5365232</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff048461f0274e04bac7ba4406b49f1c_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMi03LTEtMS0w_4b241cd4-a0dd-4b8b-95e8-3c8f11d85d80"
      unitRef="shares">3020509</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9596c2a29d47439a95abf5bafe122581_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMy0xLTEtMS0w_7882a228-4e97-42fa-910b-802b6bbf48e1"
      unitRef="shares">495165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib38e1be8e95d46dc90c6daa98174ed11_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMy0zLTEtMS0w_c569fb0c-6ac8-4f23-bc41-534082b01a2a"
      unitRef="shares">473258</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ife9a680c8a894189a633707b6fc4831d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMy01LTEtMS0w_e98b6829-507d-4344-9411-d80c1ec4644c"
      unitRef="shares">495165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i70a8f4a8fcca4b248c457bd74ec68078_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RhYmxlOmYyZTZiMjc3MzA1OTQxODZhYzMyMTA1Y2M3M2ExZTdjL3RhYmxlcmFuZ2U6ZjJlNmIyNzczMDU5NDE4NmFjMzIxMDVjYzczYTFlN2NfMy03LTEtMS0w_09b549ed-881c-42a4-9395-c63e81a84183"
      unitRef="shares">318084</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <vyne:ContingentStockRightSharesConversion
      contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTczOTE_844db8f1-310c-4a5f-b0b5-9fa9d7327a56"
      unitRef="number">1.2082</vyne:ContingentStockRightSharesConversion>
    <vyne:BusinessCombinationEffectiveExchangeRatio
      contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMTc1MDU_d29ccb27-8ee7-41d2-a511-f75a24f5ed16"
      unitRef="number">1.8006</vyne:BusinessCombinationEffectiveExchangeRatio>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80My9mcmFnOjMyYTNlNTZiMGI1ZTRjNGVhN2NhZDJhMWRhNjJhODVkL3RleHRyZWdpb246MzJhM2U1NmIwYjVlNGM0ZWE3Y2FkMmExZGE2MmE4NWRfMjAxOTM_f77dd37b-468d-454e-b3c1-6d0fc380fb41">Newly issued and recently adopted accounting pronouncements&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Guidance Issued:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes," which clarifies and simplifies certain aspects of the accounting for income taxes.  The standard is effective for years beginning after December 15, 2020, and interim periods &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;beginning after December 15, 2020.  This guidance became effective during the first quarter of 2021.  The adoption of the new standard did not have a material impact to the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Accounting Standards Update No. 2020-4, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" (ASU 2020-4), which provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying generally accepted accounting principles to contracts, hedging relationships, and other transactions impacted by reference rate reform. The provisions of ASU 2020-4 apply only to those transactions that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-4 are optional and are effective from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-4 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued Accounting Standards Update No. 2016-13,&#160;&#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;&#160;(ASU 2016-13), which requires companies to measure credit losses of financial instruments, including customer accounts receivable, utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. As a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023 or at such time where it is no longer a smaller reporting company.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NjM_92861837-3a6c-4bb3-b77e-29af4d54c8aa">BUSINESS COMBINATION&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 10, 2019, Menlo entered into the Merger Agreement with Foamix, and Merger Sub, a direct and wholly-owned Israeli subsidiary of Menlo. On March 9, 2020, the Merger was completed and Foamix is now a wholly-owned subsidiary of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the Effective Date, each ordinary share of Foamix was exchanged for 0.5924 shares of common stock of Menlo. In addition, on the Effective Date, Foamix shareholders received one contingent stock right (a &#x201c;CSR&#x201d;) for each Foamix ordinary share held by them. The CSRs were issued pursuant to the Contingent Stock Rights Agreement (the &#x201c;CSR Agreement&#x201d;), dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp;amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#x2019;s phase III clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of prurigo nodularis (the &#x201c;Phase III PN Trials&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 additional shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of 74,544,413 additional shares of Menlo common stock underlying the CSRs, adjusted retrospectively to 18,636,103 shares of common stock upon the reverse stock split effective February&#160;12, 2021.  Following the conversion of the CSRs, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders owned approximately 82% and 18% of post-Merger Menlo, respectively, each calculated on a fully diluted basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For accounting purposes, the Merger is treated as a &#x201c;reverse acquisition&#x201d; under U.S. GAAP and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#x2019;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under reverse acquisition accounting, the U.S. dollar amount for common stock in the financial statements is based on the value and number of shares issued by Menlo (reflecting the legal structure of Menlo as the legal acquirer) on the Merger date plus subsequent shares issued by the Company. The amounts in additional paid-in capital represent that of Foamix and include the fair value of shares deemed for accounting purposes to have been issued by Foamix on the merger date and the fair value of the Menlo equity awards included in the purchase price calculation. The Foamix additional paid-in capital was also adjusted for the difference between the number of common stock and the historical number of shares of Foamix&#x2019;s ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2020, the Company incurred transaction costs of approximately $11.7 million, which are recorded in the condensed consolidated statements of operations and comprehensive income. This amount includes $8.1 million of severance benefits for employees terminated after the Effective Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Purchase Price&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deemed (for accounting purposes only) conversion of Menlo equity awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $19.6 million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders&#x2019; relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $111.4 million, as shown in the purchase price allocation table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on Foamix&#x2019;s closing share price of $2.99 as of March 9, 2020, the Merger Consideration under reverse acquisition accounting was approximately $131.1 million, consisting of $123.8 million for the deemed (for accounting purposes only) issuance of 41.4 million Foamix shares assuming that no upwards adjustment was made to the Exchange Ratio relating to the CSR, and $7.3 million for the fair value of Menlo equity awards deemed (for accounting purposes only) to be converted into Foamix equity awards. The converted stock options represent the fair value of such options attributable to service prior to the Merger date using the Foamix closing share price of $2.99 as of March 9, 2020 as an input to the Black Scholes valuation model to determine the fair value of the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Purchase Price Allocation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 9, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchase price*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#x2019;s outstanding shares being owned by Menlo stockholders following the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually. None of the Goodwill recognized is expected to be deductible for income tax purposes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 9, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: fair value of net assets acquired, including other identifiable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to further pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $4.5 million related to goodwill in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020.  There were no impairment charges in the three and six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In-Process Research and Development (&#x201c;IPR&amp;amp;D")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IPR&amp;amp;D recognized relates to Menlo&#x2019;s once&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired indefinite life intangible assets*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of identified intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Represents acquired IPR&amp;amp;D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of IPR&amp;amp;D has been estimated utilizing a multi-period excess earnings method under the income approach, which reflects the present value of the projected cash flows that are expected to be generated, less charges representing the contribution of other assets to those cash flows that use projected cash flows with and without the intangible asset in place.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to further pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $49.8 million related to the IPR&amp;amp;D asset in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020.  There were no impairment charges in the three and six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CSR&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CSR was issued pursuant to the CSR Agreement, dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp;amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#x2019;s Phase III PN Trials. The Company recognized a liability of $19.6 million in the unaudited condensed consolidated balance sheet as of March 9, 2020. The liability was measured at fair value and categorized as level 3 as of the acquisition date in accordance with ASC 805-31-25-5 and subsequently at each reporting date thereafter. The fair value of the CSR was estimated as the incremental value that Foamix would be able to achieve on a probability weighted basis assuming three different potential probabilities of the following scenarios: (a) serlopitant significance was achieved in both Phase III PN Trials (b) serlopitant significance was achieved in only one Phase III PN Trial and (c) serlopitant significance was not achieved or was not determined on or before May 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 additional shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of 74,544,413 additional shares of Menlo common stock underlying the CSRs, adjusted retrospectively to 18,636,103 shares of common stock upon the reverse stock split effective February&#160;12, 2021.  Following the conversion of the CSRs, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders own approximately 82% and 18% of post-Merger Menlo, respectively, each calculated on a fully diluted basis.  The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020 and increased the awards available for grant under the Company's equity plan.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration associated with the CSR was recognized and measured at fair value as of the acquisition date in accordance with ASC 805-30-25-5. An acquirer's obligation to pay contingent consideration should be classified as a liability or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equity in accordance with ASC 480, Distinguishing Liabilities from Equity, ASC 815 Derivatives and Hedging, and other applicable U.S. GAAP.&#160;The contingent consideration associated with the CSR was initially measured at fair value and will subsequently be measured at fair value at each reporting date. The CSR was classified as a liability, as it is settled by issuing a variable number of the Company's common stock.  On April 6, 2020, the Company recorded $84.7 million of expense in its unaudited condensed consolidated statements of operations and comprehensive loss to remeasure the CSR liability in its consolidated balance sheet to its fair value of $104.4 million (calculated based on 74,544,413 shares issued, adjusted retrospectively to 18,636,103 shares of common stock upon the reverse stock split effective February&#160;12, 2021, and a share price of $1.40 on April 6, 2020) and then settled in connection with the issuance of shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pro Forma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actual Menlo net loss included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive income for the three and six months ended June&#160;30, 2020 (for the period from the March 9, 2020, the Effective Date, through June&#160;30, 2020, which are not indicative of the results to be expected for a full year) and the supplemental unaudited pro forma revenue and net loss of the combined entity had the acquisition been completed on January 1, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss attributable to Menlo&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Unaudited)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acceleration of stock based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited pro forma condensed consolidated financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the first day of the earliest period presented, or of future results of the consolidated entities. The unaudited pro forma condensed consolidated financial information does not reflect any operating efficiencies and cost savings that may be realized from the integration of the Merger.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <vyne:ExchangeRatio
      contextRef="i6382cc7a653d404095454dba66f62190_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMzU1_55f37f45-6977-46f7-ad2e-697d12ad8afe"
      unitRef="number">0.5924</vyne:ExchangeRatio>
    <vyne:BusinessAcquisitionContingentStockRightIssued
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDU2_5414f45c-0c8e-4b06-b242-41386782e168"
      unitRef="contingentstockright">1</vyne:BusinessAcquisitionContingentStockRightIssued>
    <vyne:ContingentStockRightSharesConversion
      contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTQ2Mw_0e9530c3-1034-4224-a4dc-bdd36dabe19b"
      unitRef="number">1.2082</vyne:ContingentStockRightSharesConversion>
    <vyne:EffectiveExchangeRatio
      contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTU2NQ_50f5ba14-dcbd-49df-bad9-f707d8ac4582"
      unitRef="number">1.8006</vyne:EffectiveExchangeRatio>
    <vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement
      contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTY5MA_d307c451-ef4e-4735-ba5e-430c57f4866c"
      unitRef="shares">74544413</vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement>
    <vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement
      contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTc4Mg_3146b19f-bb79-4305-829f-26d3dc841acb"
      unitRef="shares">18636103</vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement>
    <vyne:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders
      contextRef="i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTk3NQ_971c7d64-4d36-472a-8424-e66ff8ee4480"
      unitRef="number">0.82</vyne:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders>
    <vyne:PostMergerParentOwnershipByPreMergerParentStockholders
      contextRef="i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTk4Mg_a8c2ad64-5666-42d5-9092-9551bb2e2392"
      unitRef="number">0.18</vyne:PostMergerParentOwnershipByPreMergerParentStockholders>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i1a7cf85ce0eb405d8a9d3d0c8302a988_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMzI3Nw_85881940-caf8-43af-ba79-d9af7f2fff03"
      unitRef="usd">11700000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i1e7b882797fb4a558b75c52ad0d3f597_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMzQwMg_96d7b0ac-6a17-4ea7-b565-5b2ea7164b88"
      unitRef="usd">8100000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <vyne:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NTQ_bc5aad09-9cf7-4b7e-af78-55070663c843">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deemed (for accounting purposes only) conversion of Menlo equity awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $19.6 million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders&#x2019; relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $111.4 million, as shown in the purchase price allocation table below.&lt;/span&gt;&lt;/div&gt;</vyne:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmE1MWNiZDk0MGJmYjRlMWQ4N2E5NGQwZTQ0NDZmNDViL3RhYmxlcmFuZ2U6YTUxY2JkOTQwYmZiNGUxZDg3YTk0ZDBlNDQ0NmY0NWJfMS0xLTEtMS0w_dd3d88f4-a8b8-4e66-ad1f-a69a7ef8107e"
      unitRef="usd">123757000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <vyne:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmE1MWNiZDk0MGJmYjRlMWQ4N2E5NGQwZTQ0NDZmNDViL3RhYmxlcmFuZ2U6YTUxY2JkOTQwYmZiNGUxZDg3YTk0ZDBlNDQ0NmY0NWJfMi0xLTEtMS0w_df450f9b-5466-45f8-b1b5-03c0dffc3e85"
      unitRef="usd">7322000</vyne:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards>
    <vyne:BusinessCombinationConsiderationTransferredGross
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmE1MWNiZDk0MGJmYjRlMWQ4N2E5NGQwZTQ0NDZmNDViL3RhYmxlcmFuZ2U6YTUxY2JkOTQwYmZiNGUxZDg3YTk0ZDBlNDQ0NmY0NWJfMy0xLTEtMS0w_51a41563-df01-4577-899b-0c31ae48a829"
      unitRef="usd">131079000</vyne:BusinessCombinationConsiderationTransferredGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMzcyNQ_de7c9e0c-a4b8-435a-9e8f-d9de348bc4fb"
      unitRef="usd">19600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDA4NQ_54f04f93-a261-4697-8018-bd4760d0fcf2"
      unitRef="usd">111400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:SharePrice
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDE4NQ_0636a692-765e-4e0c-9e4c-d9f43f1b6602"
      unitRef="usdPerShare">2.99</us-gaap:SharePrice>
    <vyne:BusinessCombinationConsiderationTransferredGross
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDI4OQ_b3a59b13-739c-42dc-9881-2ec043e11210"
      unitRef="usd">131100000</vyne:BusinessCombinationConsiderationTransferredGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDMwNw_420b2186-06e0-4d90-be74-ea9583ed594e"
      unitRef="usd">123800000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <vyne:BusinessCombinationSharesDeemedIssuedForAccountingPurposes
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDM2OA_6b0a75b6-39d5-4b6a-a198-bcd9ad6306b9"
      unitRef="shares">41400000</vyne:BusinessCombinationSharesDeemedIssuedForAccountingPurposes>
    <vyne:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDQ3Nw_4689fe05-488e-47a2-8aaf-ee96a0b23e92"
      unitRef="usd">7300000</vyne:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards>
    <us-gaap:SharePrice
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNDc2MQ_9b21def0-9476-45d1-abb0-1de555e815e0"
      unitRef="usdPerShare">2.99</us-gaap:SharePrice>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NjQ_5bd06b1a-6048-4239-8282-a6f3cc092a08">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 9, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchase price*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#x2019;s outstanding shares being owned by Menlo stockholders following the Merger.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfMS0xLTEtMS0w_53472506-9959-4c3a-88ec-fe81b9d932c8"
      unitRef="usd">38641000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfMi0xLTEtMS0w_d537e4f9-17a7-4a39-b2d0-848c77c3cc14"
      unitRef="usd">22703000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfMy0xLTEtMS0w_fc404cbd-3812-4ba1-8e39-7f2005e521bf"
      unitRef="usd">1581000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfNC0xLTEtMS0w_f494ef6d-47bd-43e3-ad23-5c15c359e3bf"
      unitRef="usd">49800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:Goodwill
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfNS0xLTEtMS0w_8c35bf47-cd51-41fb-9674-b4bc569d9877"
      unitRef="usd">4545000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfNi0xLTEtMS0w_de526a90-8dba-4ba7-9e29-328f7493b4b1"
      unitRef="usd">117270000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfNy0xLTEtMS0w_e4678338-5bfa-4147-bb90-fb8fd3f67891"
      unitRef="usd">5827000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfOC0xLTEtMS0w_d8538ffe-091c-46ac-a14d-8d8870bd289a"
      unitRef="usd">5827000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjVhNDIzNDIwNWFlZTQ2NTJiMjAwMzBlMDYwMTI2MmM3L3RhYmxlcmFuZ2U6NWE0MjM0MjA1YWVlNDY1MmIyMDAzMGUwNjAxMjYyYzdfOS0xLTEtMS0w_3020578d-7044-4c65-acbd-95e775045ea6"
      unitRef="usd">111443000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <vyne:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock
      contextRef="i32f810ffe926407c90d135528dbc7806_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNTIwMw_b4e54b56-6ae6-4277-b9ed-8716b72ab337"
      unitRef="usd">19600000</vyne:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNTc1Mg_35eaef23-d3ee-4bce-8815-3f9c0ba58dd2"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <vyne:ScheduleOfBusinessCombinationGoodwillTableTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NjA_eb388260-2c5d-492a-8e5f-315c60984147">The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 9, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: fair value of net assets acquired, including other identifiable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</vyne:ScheduleOfBusinessCombinationGoodwillTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjMzZTJlNzQ3NzgyMTQxNmM4ODFjYWM5MWM1YjU0OWQ3L3RhYmxlcmFuZ2U6MzNlMmU3NDc3ODIxNDE2Yzg4MWNhYzkxYzViNTQ5ZDdfMS0xLTEtMS0w_7fd4067e-55da-4f42-a97b-f99bbe3fe0dc"
      unitRef="usd">111443000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <vyne:BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjMzZTJlNzQ3NzgyMTQxNmM4ODFjYWM5MWM1YjU0OWQ3L3RhYmxlcmFuZ2U6MzNlMmU3NDc3ODIxNDE2Yzg4MWNhYzkxYzViNTQ5ZDdfMi0xLTEtMS0w_f9cdfaf2-a21f-44ef-b8cd-b6d22281c7ea"
      unitRef="usd">106898000</vyne:BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOjMzZTJlNzQ3NzgyMTQxNmM4ODFjYWM5MWM1YjU0OWQ3L3RhYmxlcmFuZ2U6MzNlMmU3NDc3ODIxNDE2Yzg4MWNhYzkxYzViNTQ5ZDdfMy0xLTEtMS0w_586581bb-1046-4ac5-a334-0159f867939c"
      unitRef="usd">4545000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjQ2OQ_a4ee1d62-f696-4611-9708-7409adafb778"
      unitRef="usd">4500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjQ2OQ_c84fb5ff-58cc-4a4f-99d9-fbf078888570"
      unitRef="usd">4500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjYzMA_0125203b-198a-42b4-ac8a-03c27cae28e6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="iccc41b531a42468fbf923e22fdb7eabb_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjYzMA_4d6af5fc-cff5-42ed-9271-bf90809619a8"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjYzMA_4e779641-125b-4324-bf39-a02281b11007"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i6db72496b07944a0b0be6eb4aa4ba37a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfNjYzMA_614f9c46-8700-41a6-900b-6911bdc5af23"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <vyne:ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NjE_5387762c-cab1-4dd2-998d-099c17022401">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IPR&amp;amp;D recognized relates to Menlo&#x2019;s once&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired indefinite life intangible assets*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of identified intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;* Represents acquired IPR&amp;amp;D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing.</vyne:ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwNmI1NDdhMGMxMDQwMDJiNjQ5MjZiZmE5NjAyMWI1L3RhYmxlcmFuZ2U6ZjA2YjU0N2EwYzEwNDAwMmI2NDkyNmJmYTk2MDIxYjVfMi0yLTEtMS0w_303f5bc3-5701-4e7b-942a-d3153748475b"
      unitRef="usd">49800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwNmI1NDdhMGMxMDQwMDJiNjQ5MjZiZmE5NjAyMWI1L3RhYmxlcmFuZ2U6ZjA2YjU0N2EwYzEwNDAwMmI2NDkyNmJmYTk2MDIxYjVfMy0yLTEtMS0w_bec77355-1c52-4505-8319-ffadc06be77f"
      unitRef="usd">49800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="icb5bafa21e104483ae7f0f9dc374ea00_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODE1MQ_5f64d3ce-cbfa-4bcf-96d8-73d62b496104"
      unitRef="usd">49800000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i16efb1e654494773b9d6ff2b23dc030b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODE1MQ_96da811a-84c3-48bb-b4bc-c015791967d4"
      unitRef="usd">49800000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODMxOQ_0125203b-198a-42b4-ac8a-03c27cae28e6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="iccc41b531a42468fbf923e22fdb7eabb_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODMxOQ_4d6af5fc-cff5-42ed-9271-bf90809619a8"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODMxOQ_4e779641-125b-4324-bf39-a02281b11007"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i6db72496b07944a0b0be6eb4aa4ba37a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODMxOQ_614f9c46-8700-41a6-900b-6911bdc5af23"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <vyne:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfODcwNg_92a113e7-6281-40be-bf40-d540c0e4c338"
      unitRef="usd">19600000</vyne:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock>
    <vyne:ContingentStockRightSharesConversion
      contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfOTg1OQ_0e9530c3-1034-4224-a4dc-bdd36dabe19b"
      unitRef="number">1.2082</vyne:ContingentStockRightSharesConversion>
    <vyne:EffectiveExchangeRatio
      contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfOTk2MQ_50f5ba14-dcbd-49df-bad9-f707d8ac4582"
      unitRef="number">1.8006</vyne:EffectiveExchangeRatio>
    <vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement
      contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTAwODY_d307c451-ef4e-4735-ba5e-430c57f4866c"
      unitRef="shares">74544413</vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement>
    <vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement
      contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTAxNzg_3146b19f-bb79-4305-829f-26d3dc841acb"
      unitRef="shares">18636103</vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement>
    <vyne:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders
      contextRef="i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTAzNjk_971c7d64-4d36-472a-8424-e66ff8ee4480"
      unitRef="number">0.82</vyne:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders>
    <vyne:PostMergerParentOwnershipByPreMergerParentStockholders
      contextRef="i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTAzNzY_a8c2ad64-5666-42d5-9092-9551bb2e2392"
      unitRef="number">0.18</vyne:PostMergerParentOwnershipByPreMergerParentStockholders>
    <vyne:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTEzOTU_fd879fc2-5b0d-4c19-8dbd-afbecc34b60d"
      unitRef="usd">-84700000</vyne:ContingentStockConsiderationRemeasurementGainLoss>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTE1ODM_32b77eb0-1801-4b61-b4c1-9b6f537ca591"
      unitRef="usd">104400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement
      contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTE2MDc_d307c451-ef4e-4735-ba5e-430c57f4866c"
      unitRef="shares">74544413</vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement>
    <vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement
      contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTE2NTM_3146b19f-bb79-4305-829f-26d3dc841acb"
      unitRef="shares">18636103</vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement>
    <us-gaap:SharePrice
      contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTE3NDM_fb61f625-8b20-4a79-a991-3d150d308be6"
      unitRef="usdPerShare">1.40</us-gaap:SharePrice>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RleHRyZWdpb246Njg5MWViZWVhZDk5NGFkMTk0NTEyMWU1MTEyYzBkNmJfMTI5NjI_0feb1dec-c3b7-4063-a002-d28f2dbfa21e">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss attributable to Menlo&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;br/&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended&lt;br/&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Unaudited)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acceleration of stock based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmNlM2U4YzcxODBhYjQyODA5NDZlMTM3OGMyZTQzOTYzL3RhYmxlcmFuZ2U6Y2UzZThjNzE4MGFiNDI4MDk0NmUxMzc4YzJlNDM5NjNfMi0xLTEtMS0w_27df456e-9a2f-482f-a090-5abdd919de1e"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmNlM2U4YzcxODBhYjQyODA5NDZlMTM3OGMyZTQzOTYzL3RhYmxlcmFuZ2U6Y2UzZThjNzE4MGFiNDI4MDk0NmUxMzc4YzJlNDM5NjNfMi0zLTEtMS0w_4c4f12f8-7e74-451f-ae52-a16e630e89ef"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmNlM2U4YzcxODBhYjQyODA5NDZlMTM3OGMyZTQzOTYzL3RhYmxlcmFuZ2U6Y2UzZThjNzE4MGFiNDI4MDk0NmUxMzc4YzJlNDM5NjNfMy0xLTEtMS0w_732dc8ea-16c9-4b5b-b302-1393c4f0bed5"
      unitRef="usd">-7594000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmNlM2U4YzcxODBhYjQyODA5NDZlMTM3OGMyZTQzOTYzL3RhYmxlcmFuZ2U6Y2UzZThjNzE4MGFiNDI4MDk0NmUxMzc4YzJlNDM5NjNfMy0zLTEtMS0w_7af11836-8a87-42e9-98d4-5246cb335e28"
      unitRef="usd">-19637000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNC0xLTEtMS0w_f0936ece-7300-4984-9ad6-290fab38a9d6"
      unitRef="usd">11688000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNC03LTEtMS0w_2e580624-41cb-4e0b-9ef9-334fca468074"
      unitRef="usd">13438000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNS0xLTEtMS0w_00ca3e65-ed50-4a87-b058-e8c9414b4fd1"
      unitRef="usd">-167441000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNS03LTEtMS0w_b12a1cb1-005e-4b83-b493-92f1afcfdd5f"
      unitRef="usd">-205082000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNi0xLTEtMS0w_fd13f99a-ae04-4bfc-955e-bb3eb96cffd3"
      unitRef="usdPerShare">-1.21</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNi0xLTEtMS0w_ffccaf32-2d0f-4271-b5b3-4e330bda91f8"
      unitRef="usdPerShare">-1.21</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNi03LTEtMS0w_3356e9ad-b4c2-4664-9a7c-befb831e9a16"
      unitRef="usdPerShare">-1.23</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfNi03LTEtMS0w_423dbe1d-888c-4f74-acd7-1a1e6f91245b"
      unitRef="usdPerShare">-1.23</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <vyne:AdjustmentsToSupplementalProformaTransactionCosts
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfOS0xLTEtMS0w_cfdb391c-36f2-49df-a63d-879e2ed0435d"
      unitRef="usd">0</vyne:AdjustmentsToSupplementalProformaTransactionCosts>
    <vyne:AdjustmentsToSupplementalProformaTransactionCosts
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfOS03LTEtMS0w_fc7f5b66-a386-4354-9e7d-54f2c846d585"
      unitRef="usd">14931000</vyne:AdjustmentsToSupplementalProformaTransactionCosts>
    <vyne:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfMTAtMS0xLTEtMA_3116f6a6-ce2e-483a-a258-6013a48df50a"
      unitRef="usd">0</vyne:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation>
    <vyne:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfMTAtNy0xLTEtMA_3e688c95-7463-4d0f-9d0a-8d95a287bc82"
      unitRef="usd">7199000</vyne:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation>
    <vyne:AdjustmentsToSupplementalProformaCombinedResultsOfOperations
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfMTEtMS0xLTEtMA_a3dfe3aa-d3b3-4a5a-a61c-0984c3eaf920"
      unitRef="usd">0</vyne:AdjustmentsToSupplementalProformaCombinedResultsOfOperations>
    <vyne:AdjustmentsToSupplementalProformaCombinedResultsOfOperations
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80Ni9mcmFnOjY4OTFlYmVlYWQ5OTRhZDE5NDUxMjFlNTExMmMwZDZiL3RhYmxlOmYwZGRhMDUwYTdmMzRkM2RiNjMxZmQzZWI5MjM1NmNiL3RhYmxlcmFuZ2U6ZjBkZGEwNTBhN2YzNGQzZGI2MzFmZDNlYjkyMzU2Y2JfMTEtNy0xLTEtMA_93f64d17-759b-4f67-b2fd-48e85708abef"
      unitRef="usd">22130000</vyne:AdjustmentsToSupplementalProformaCombinedResultsOfOperations>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfODU2NQ_52c782c6-e561-428a-9ad0-a9700b3865d3">REVENUE RECOGNITION&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues for the three and six months ended&#160;June&#160;30, 2021&#160;were primarily generated from sales of AMZEEQ&#160;which was commercially launched in the United States in January 2020 and ZILXI which became available in pharmacies nationwide on October 1, 2020.  The Company&#x2019;s customers include a limited number of national and select regional distributors and certain independent and specialty pharmacies, together (the "customers").  The distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when customers obtain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;control of the Company&#x2019;s products, which occurs at a point in time, typically upon delivery of product to the customers. For the three months ended June&#160;30, 2021, there were three major customers that each accounted for more than 10% of total product revenues and, as a group, represented 56% of total product revenues.  For the six months ended June&#160;30, 2021, there were four major customers that each accounted for more than 10% of total product revenues and, as a group, represented 70% of total product revenues.  For the three months ended June&#160;30, 2020, there were three major customers that each accounted for more than 10% of total product revenues and as a group, represented 100% of total product revenues.  For the six months ended June&#160;30, 2020, there were three major customers that each accounted for more than 10% of total product revenues and as a group, represented 99% of total product revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, chargebacks, estimated returns and other incentives, described below. &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company calculates its net product revenue based on the wholesale acquisition cost that the Company charges its customers less provisions for (i) trade discounts and allowances, such as distributor fees and discounts for prompt payment, (ii) estimated rebates to third-party payers, patient co-pay assistance programs, chargebacks and other discount programs and (iii) reserves for expected product returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for distribution fees, trade discounts and chargebacks are reflected as a reduction to trade receivables, net on the condensed consolidated balance sheet. All other provisions, including rebates, other discounts and return provisions are reflected as a liability within accrued expenses on the condensed consolidated balance sheet. Provisions for revenue reserves described below reduced product revenues by&#160;$16.2 million and $5.9 million for the three months ended June&#160;30, 2021 and June&#160;30, 2020, respectively.  Provisions for revenue reserves described below reduced product revenues by&#160;$31.8 million and $14.1 million for the six months ended June&#160;30, 2021 and June&#160;30, 2020, respectively. The revenue reserve accrual at June&#160;30, 2021 and December&#160;31, 2020 was $7.6 million and $5.8 million, respectively, reflected in accrued expense in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Distribution Fees and Trade Discounts and Allowances&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company pays fees for distribution services and for certain data that distributors provide to the Company and generally provides discounts on sales to its distributors for prompt payment. These fees and discounts are contractual in nature and the Company expects its distributors to earn these fees and discounts, and accordingly deducts the full amount of these fees and discounts from its gross product revenues at the time such revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Rebates, Chargebacks and Other Discounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales made under managed-care and governmental pricing programs in the U.S. are subject to rebates.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share. Chargebacks relate to contractual agreements to sell products to government agencies and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these government agencies or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers. The Company estimates the rebates and chargebacks it expects to be obligated to provide and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates the rebates and chargebacks that it expects to be obligated to provide based upon (i) the Company's current contracts and negotiations, (ii) estimates regarding the payer mix&#160;based on third-party data and utilization, (iii) inventory held by distributors and (iv) estimates of inventory held at the retail channel. Other discounts include the Company&#x2019;s co-pay assistance coupon programs for commercially-insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to pay associated with product that has been recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, customers are generally allowed to return products within a specified period of time before and after its expiration date.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company estimates the amount of product&#160;that will be returned and deducts these estimated amounts from its gross revenue at the time the revenue is recognized. T&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he information utilized to estimate the returns provision includes: (i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; historical industry information regarding rates for comparable pharmaceutical products and product portfolios&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;demand&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for products and (iv) remaining shelf lives of products at the date of sale. The Company estimates that approximately 2% to 3% of product will be returned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commercial use.  Outside of the license transferred, the Company does not have any additional performance obligations under the arrangement.  In exchange for the license, the Company received an upfront cash payment of $10.0 million in 2020 ($6.0 million received in the three months ended June 30, 2020 and $4.0 million received in the three months ended September 30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The license is considered functional IP as the licensee is able to use and benefit from the license without the continued involvement of the Company.  There was no license revenue in the three months ended June&#160;30, 2021.  The Company recorded $10.0 million of license revenue in the three and six months ended June&#160;30, 2020.  The Company will also receive royalties on net sales of any licensed products, such royalties will be recognized in the period the sales or usage occurs under the royalties sales-and usage based exception.  The Company has not recorded revenue related to the $1.0 million payment due upon receipt of marketing approval for the licensed product as such amount is constrained under the variable consideration guidance under ASC 606, Revenue from Contracts with Customers.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets and Contract Liabilities&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any contract assets (unbilled receivables) related to product sales as of&#160;June&#160;30, 2021 and December&#160;31, 2020, as customer invoicing generally occurs before or at the time of revenue recognition.  The Company did not have any contract assets (unbilled receivables) related to its license revenues as of June&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any contract liabilities as of&#160;June&#160;30, 2021 and December&#160;31, 2020, as the Company did not receive payments in advance of fulfilling its performance obligations to its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales Commissions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financing Component&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.&#160;Standard credit terms do not exceed 75 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Revenues&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is entitled to royalty payments with respect to sales of a product developed by a customer in collaboration with the Company. Revenues in the amount of $0.3 million and $0.5 million were recorded during the three and six months ended June&#160;30, 2021, respectively.  Revenues in the amount of $0.2 million were recorded during the three and six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4b69cba5a49141e6bb1ce4370c794990_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzA0NQ_3ac04f0b-fa72-4574-9754-61b1c2566019"
      unitRef="number">0.56</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic43c6e8d9ce64e2d8a1368960b3a7873_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfOTg4_c400edbc-1fc5-4882-a46b-ead6c6aa1b9f"
      unitRef="number">0.70</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if85566c685134979a79b4ce6fd888d53_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzA1OA_fb94e564-50d1-4025-947e-77388af33afd"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i76d0289842ec41d6a4fcf604ba120cc7_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTE2OQ_f0c7ddc2-cd0e-46c0-8151-5877cf9a44f8"
      unitRef="number">0.99</us-gaap:ConcentrationRiskPercentage1>
    <vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzQzNw_8749ac8b-b59a-4ce5-acd7-f3ae34865de7"
      unitRef="usd">16200000</vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances>
    <vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzUwMw_134bac2b-19c3-4a50-b911-4dad2fd59ab8"
      unitRef="usd">5900000</vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances>
    <vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMjIxOQ_21d452b5-843b-4152-ac1c-d225c82e6755"
      unitRef="usd">31800000</vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances>
    <vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMjIyNg_4a728821-178a-458b-8cd1-ec12c846ff4e"
      unitRef="usd">14100000</vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i27b7eaef51134e98829287ba6d768e11_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMjMyMw_f14634be-9e10-4950-a402-b5e290c378fa"
      unitRef="usd">7600000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i17d3ea68f84b490b9ee1aafc7167b26a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMjMzMA_49467d9f-bb10-496d-aeef-66efb590e173"
      unitRef="usd">5800000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <vyne:EstimateOfProductReturnRateMinimum
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNTQ1MQ_445ad0da-3925-47fc-ba78-29b9b476ed67"
      unitRef="number">0.02</vyne:EstimateOfProductReturnRateMinimum>
    <vyne:EstimateOfProductReturnRateMaximum
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNTQ1Nw_bedbce1a-1d02-4701-b4da-aa792f3404d5"
      unitRef="number">0.03</vyne:EstimateOfProductReturnRateMaximum>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="ie37f3b5248df46e8a5d24d2bfdf923c7_D20200401-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjI1NA_ed6b43d7-b62c-4ed8-a31b-294bf5c06e03"
      unitRef="usd">10000000.0</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="ieb1d0e22f202476fa595bb840d395cd9_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjI2Ng_ab6072c8-fcab-4de1-a126-e3336b216c3f"
      unitRef="usd">6000000.0</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="i68da95855f63445cb75b88e2107393a8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjMyMg_b4de7d63-69ab-4653-99bf-d692b9527122"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromRoyaltiesReceived>
    <vyne:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents
      contextRef="iaa2d29a04a9d429e8c602ba8cac18f30_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjQyNg_537a6bad-1917-40b4-b502-b64433dd11da"
      unitRef="usd">1000000.0</vyne:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents>
    <vyne:UpfrontRoyaltyReceipt
      contextRef="ib1c6d1a11d554c199e8d8a169359a9a4_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjY3OA_74380de3-fdf1-4d10-8d8a-7653441fef7a"
      unitRef="usd">0</vyne:UpfrontRoyaltyReceipt>
    <vyne:UpfrontRoyaltyReceipt
      contextRef="ibd77d34132ca467485ab82d588391ab6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzY0Ng_ee7e8804-2033-4333-b1db-572281cc7f3a"
      unitRef="usd">10000000.0</vyne:UpfrontRoyaltyReceipt>
    <vyne:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents
      contextRef="iaa2d29a04a9d429e8c602ba8cac18f30_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfNjk5NA_537a6bad-1917-40b4-b502-b64433dd11da"
      unitRef="usd">1000000.0</vyne:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i100dc25a3ccc4b50b433b69ea956736e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzODAwMw_bfa6f8ba-4e97-4745-b027-29fccac19412"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53788555bd1f4b04be712a3744df4cc3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfODQ1OQ_53703e1c-7e02-47c2-a99a-d12aad788017"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dc49910e5a5430584764df10f7cf924_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzgwMA_5e948d55-f8ca-4448-a7b8-d733493d03f6"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idabf5cabf5d146209830192ebd3a2c01_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl80OS9mcmFnOmM1ZjYyOTQzMGVmNzQ2MWJiYTY0YjdmNDdjYWUyOTI1L3RleHRyZWdpb246YzVmNjI5NDMwZWY3NDYxYmJhNjRiN2Y0N2NhZTI5MjVfMTA5OTUxMTYzNzgwMA_8391b13c-4a9a-48e2-a1c4-27da59e7a021"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RleHRyZWdpb246OTliYzRjM2NmNmNhNDEyYjg4YTM4Yjk5Nzc2ZGY4YWRfOTk2_2f1398b3-b9d7-4ec4-bbbf-7629ff709b8b">FAIR VALUE MEASUREMENT&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s assets and liabilities that are measured at fair value as of December&#160;31, 2020, are classified in the table below in one of the three categories described in "Note 2 - Fair value measurement" above:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sold its marketable securities during the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RleHRyZWdpb246OTliYzRjM2NmNmNhNDEyYjg4YTM4Yjk5Nzc2ZGY4YWRfOTk3_8299311e-c438-4358-96aa-f0e15caef3be">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s assets and liabilities that are measured at fair value as of December&#160;31, 2020, are classified in the table below in one of the three categories described in "Note 2 - Fair value measurement" above:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:MarketableSecurities
      contextRef="i097981da69d34227853b3f274c4a9834_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RhYmxlOmU2OTk0NGU0MjQxYzRjYTZiYWQwZTI1MWUyOWU5YTdmL3RhYmxlcmFuZ2U6ZTY5OTQ0ZTQyNDFjNGNhNmJhZDBlMjUxZTI5ZTlhN2ZfMi0xLTEtMS0w_13e6039d-da08-4ff2-bea0-fbff14d87275"
      unitRef="usd">1027000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i9b5f9de8edf74567a2af3deb4d32b9e7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RhYmxlOmU2OTk0NGU0MjQxYzRjYTZiYWQwZTI1MWUyOWU5YTdmL3RhYmxlcmFuZ2U6ZTY5OTQ0ZTQyNDFjNGNhNmJhZDBlMjUxZTI5ZTlhN2ZfMi0zLTEtMS0w_ec8d64ae-3365-4580-8fca-a655471524bc"
      unitRef="usd">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="ie2d8c62eaafd4e3b828916f7e572cd7d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RhYmxlOmU2OTk0NGU0MjQxYzRjYTZiYWQwZTI1MWUyOWU5YTdmL3RhYmxlcmFuZ2U6ZTY5OTQ0ZTQyNDFjNGNhNmJhZDBlMjUxZTI5ZTlhN2ZfMi01LTEtMS0w_3756b7f6-ff25-4f34-9d6e-e5843e770d1f"
      unitRef="usd">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81Mi9mcmFnOjk5YmM0YzNjZjZjYTQxMmI4OGEzOGI5OTc3NmRmOGFkL3RhYmxlOmU2OTk0NGU0MjQxYzRjYTZiYWQwZTI1MWUyOWU5YTdmL3RhYmxlcmFuZ2U6ZTY5OTQ0ZTQyNDFjNGNhNmJhZDBlMjUxZTI5ZTlhN2ZfMi03LTEtMS0w_deb9e20d-a54b-4dfa-8b3f-7eac612bdec5"
      unitRef="usd">1027000</us-gaap:MarketableSecurities>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTM5NA_3b0f1502-3891-485e-8172-099fa2e60f19">MARKETABLE SECURITIESMarketable securities as of December&#160;31, 2020 consist mainly of mutual funds securities. The debt securities are classified as available-for-sale and are recorded at fair value. Changes in fair value, net of taxes (if applicable), are reflected in other comprehensive loss. Realized gains and losses on sales of the securities, as well as premium or discount amortization, are included in the condensed consolidated statement of operations as other expense (income), net.&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities with readily determinable fair value are measured at fair value. The changes in the fair value of equity investments are recognized through other expense (income), net in the condensed consolidated statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company&#x2019;s marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Israeli mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021 and December&#160;31, 2020 there were no available-for-sale debt securities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has considered factors regarding other than temporary impaired securities and determined that there are no securities with impairment that is other than temporary as of June&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2021 and June&#160;30, 2020 the Company received aggregate proceeds of $1.0 million and $36.4 million, respectively, upon sale and maturity of marketable securities.&lt;/span&gt;&lt;/div&gt;As of June&#160;30, 2021 and December&#160;31, 2020, there were no restricted marketable securities.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTM5MA_920befd6-0b44-4a61-a0ce-7b52209ef56f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company&#x2019;s marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Israeli mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="i659a1487487a4e54b0c16d985e15bce3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RhYmxlOjY2OWI4MzA3MzAzNTQxNzc5MDg3MmMyYzQyNWY4MGRlL3RhYmxlcmFuZ2U6NjY5YjgzMDczMDM1NDE3NzkwODcyYzJjNDI1ZjgwZGVfMi0xLTEtMS0w_b60e5b7c-f1c4-48c9-8f2d-7dc81a262693"
      unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ic9adec3b7e764dbea542fb51debbc4a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RhYmxlOjY2OWI4MzA3MzAzNTQxNzc5MDg3MmMyYzQyNWY4MGRlL3RhYmxlcmFuZ2U6NjY5YjgzMDczMDM1NDE3NzkwODcyYzJjNDI1ZjgwZGVfMi0zLTEtMS0w_42cda056-03ef-4a53-b462-e2882ba53dc4"
      unitRef="usd">1027000</us-gaap:ShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfODQz_8c80ef53-eda5-4605-8a9d-04cd2ac1a5c2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfODQz_b034a3b5-c6a9-4e77-8e20-75c0dc7fc968"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTAwMQ_dcd5e102-0a4f-4e12-824b-c23f977fe1fa"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i69de8b4ead5948b29019da8f6937bc7a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTAwMQ_f20e00f6-0f19-488e-b9cc-ab1c45cfc874"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTA5OTUxMTYyOTQzMA_4666e816-a472-4f98-acc2-ae7ab08a8291"
      unitRef="usd">1000000.0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTI3Mg_6bb817d9-566a-4e4c-aeb2-d400a627b05f"
      unitRef="usd">36400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:RestrictedInvestments
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTM1Mw_88bb51e8-8364-464f-90a4-c6eae6d15776"
      unitRef="usd">0</us-gaap:RestrictedInvestments>
    <us-gaap:RestrictedInvestments
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81NS9mcmFnOmMyNzVmNWI1ODFkNzRkNmJhODQ3ZjgxOTBhMGQxNDE1L3RleHRyZWdpb246YzI3NWY1YjU4MWQ3NGQ2YmE4NDdmODE5MGEwZDE0MTVfMTM1Mw_fb284c48-b8af-400a-8a67-bdcd9cf85dfa"
      unitRef="usd">0</us-gaap:RestrictedInvestments>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfOTM3_b0ae47da-c89f-4ef8-882c-6836f02bf40f">INVENTORY&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. The Company commenced capitalizing inventory for AMZEEQ and ZILXI upon FDA approval in October 2019 and May 2020, respectively. The Company periodically reviews its inventory levels and, if necessary, writes down inventory that is expected to expire prior to being sold, inventory in excess of expected sales requirements and inventory that fails to meet commercial sale specifications, with a corresponding charge to cost of goods sold. There were no inventory write-downs during the three and six months ended June&#160;30, 2021 and June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company&#x2019;s inventory:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfODE0_691e56db-5f72-4072-9373-ea8355759ad3"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfODE0_9290801d-4457-4cca-a85f-66d703ed335e"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfODE0_adc69feb-1e32-40dc-a5b7-da134f86e9f9"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfODE0_c9fba298-a68a-428a-899d-6ede014c7d71"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RleHRyZWdpb246ZDRmZDJiZDNiMDRjNDI1MGI3NzM2YmYwOTg3ZTQ2MzlfOTM0_7e4377bb-f936-4132-87e9-fd0494a3e77f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company&#x2019;s inventory:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfMi0xLTEtMS0w_6109a239-535a-4b88-8770-7491ab2860e3"
      unitRef="usd">3466000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfMi0zLTEtMS0w_2057c16d-21f0-427e-ba38-9d35095a96d7"
      unitRef="usd">4042000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryWorkInProcess
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfMy0xLTEtMS0w_a466555f-0e3e-43ce-abb9-4f3acacc486f"
      unitRef="usd">680000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfMy0zLTEtMS0w_04c146c2-c7bf-4c35-87c5-1a89cd2a76ba"
      unitRef="usd">662000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfNC0xLTEtMS0w_0a33b663-f865-489a-bc56-2ce4b45fa6d6"
      unitRef="usd">4133000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfNC0zLTEtMS0w_33dc553d-c8c4-45d6-88cc-515141d3b0ab"
      unitRef="usd">2700000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfNS0xLTEtMS0w_7c63b58b-8504-45f0-9174-295a9043d0b0"
      unitRef="usd">8279000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl81OC9mcmFnOmQ0ZmQyYmQzYjA0YzQyNTBiNzczNmJmMDk4N2U0NjM5L3RhYmxlOjUwYmVlNjU3MDMyZTQ1NzhiM2NjNDQyMzNiZTEwNTIwL3RhYmxlcmFuZ2U6NTBiZWU2NTcwMzJlNDU3OGIzY2M0NDIzM2JlMTA1MjBfNS0zLTEtMS0w_d6a7e714-9cbd-453a-b7ba-2c62564d1a34"
      unitRef="usd">7404000</us-gaap:InventoryGross>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI4Mw_f2e2ca2f-298d-4cbb-851e-cd3405148168">DEBT&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 29, 2019, Foamix entered into a Credit Agreement (the "Credit Agreement") to secure up to $50&#160;million from two lenders, one of which is a significant stockholder of the Company and is considered a related party, and a Securities Purchase Agreement with one of the lenders for gross proceeds of approximately&#160;$14 million, before deducting offering expenses (see &#x201c;Note 9- Share Capital&#x201d; for more information). On March 9, 2020, the Company entered into an Amended and Restated Credit Agreement and Guaranty (as further amended on August 5, 2020, the &#x201c;Amended and Restated Credit Agreement&#x201d;), whereby the Company has guaranteed the indebtedness obligations of the borrower and granted a first priority security interest in substantially all of our assets for the benefit of the lenders. As of June&#160;30, 2021 and December&#160;31, 2020, $35.0&#160;million was drawn under the Amended and Restated Credit Agreement.  The Company did not incur the remaining $15.0&#160;million under the Amended and Restated Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The term loans available under the Amended and Restated Credit Agreement were comprised as follows: (a) $15 million that was funded on July 29, 2019 (the &#x201c;Tranche 1 Loan&#x201d;), (b) $20 million that was funded on December 17, 2019 (the &#x201c;Tranche 2 Loan&#x201d;) and (c) up to $15 million that was available prior to September 30, 2020 (the &#x201c;Tranche 3 Loan&#x201d;). The Tranche 2 Loan was borrowed following the FDA&#x2019;s approval of the NDA for AMZEEQ and listing of AMZEEQ in the FDA&#x2019;s &#x201c;Orange Book,&#x201d; in addition to maintaining arrangements with a third party for the commercial supply and manufacture of AMZEEQ. The Company did not incur the Tranche 3 Loan. Interest on the loans was equal to the sum of (A) 8.25% (subject to increase in accordance with the terms of the Amended and Restated Credit Agreement) plus (B) the greater of (x) the one-month LIBOR as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the second business day immediately preceding the first day of the calendar month or the date of borrowing (if such loan is not outstanding as of the first day of the calendar month), as applicable, and (y) 2.75%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loans were scheduled to mature on July&#160;29, 2024. However, the Company and its lenders discussed the revenue expected to be generated for the trailing twelve month period ended June&#160;30, 2021, the revenue targets included in the Amended and Restated Credit Agreement and the Company&#x2019;s strategic transition discussed above. Following such discussions, the Company determined to prepay its outstanding indebtedness in addition to a 4% prepayment fee and accrued but unpaid interest in the total amount of approximately $36.5&#160;million on August&#160;11, 2021. Following the prepayment, the Amended and Restated Credit Agreement has been terminated and the security interests thereunder will be terminated. The Company reclassified the outstanding indebtedness as a current liability based on the conditions existing as of June&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, on July 29, 2019, the lenders under the Credit Agreement were issued warrants to purchase up to an aggregate of 1,100,000 of Foamix ordinary shares, at an exercise price of $2.09 per share (the &#x201c;Warrants&#x201d;), which represented the five-day volume weighted average price of the Foamix ordinary shares as of the trading day immediately prior to the issuance of the Warrants. In connection with the completion of the Merger, the exchange ratio was applied to the Warrants such that they became exercisable for 651,640 shares of the Company&#x2019;s common stock, and the exercise price was adjusted to $3.53. Following the Phase 3 PN Trial results, the Warrants were further adjusted for the CSR and reverse stock split and they are currently exercisable for 495,165 shares of our common stock with an exercise price of $4.64 per share. Payment of the exercise price will be made, at the option of the holder, either in cash or as a reduction of common stock issuable upon exercise of the Warrant, with an aggregate fair value equal to the aggregate exercise price ("cashless exercise"), or any combination of the foregoing.&#160;The Warrants are exercisable pursuant to the terms, and subject to the conditions, thereof and expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants' expiration date, if in the money. The Warrants issued were classified as equity in accordance with ASC 815-40. Proceeds received under the Tranche 1 Loan were allocated to the Warrants and the Tranche 1 Loan on a relative fair value basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred offering expenses of $1.1 million in connection with transactions contemplated by the Credit Agreement and the Securities Purchase Agreement, which were allocated to the Warrants, shares and debt consistently with the allocation of proceeds. The Company incurred additional expenses in the amount of $0.3 million from the borrowing of Tranche 2 Loan, allocated only to the debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts allocated to the debt, net of issuance cost, are subsequently recognized at amortized cost using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the debt as of June&#160;30, 2021 was $36.9 million and is categorized as Level 3. The valuation was performed by applying the income approach, under which the contractual present value method was used. The estimation of risk adjusted discount curve was based on public information reported in the financial statements of publicly traded venture lending companies.&lt;/span&gt;&lt;/div&gt;During the three months ended June&#160;30, 2021 and June&#160;30, 2020, the Company recorded interest expense of $1.0 million and discount cost of $0.1 million. During the six months ended June&#160;30, 2021 and June&#160;30, 2020, the Company recorded interest expense of $1.9 million and discount cost of $0.2 million.</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if4ace227df814c6da96b3d3c17e550ca_I20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTI3_82e48305-bd50-450a-bd89-b13fe6ccfb62"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <vyne:NumberOfLenders
      contextRef="i2384945abf164135b470fbd163ec1a30_I20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMjgx_57e35412-f6b6-4687-8787-deb4ee438e34"
      unitRef="lender">1</vyne:NumberOfLenders>
    <vyne:GrossProceedsFromIssuanceOfCommonStock
      contextRef="i2384945abf164135b470fbd163ec1a30_I20190729"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMzM1_07fbcc0d-626c-4c9a-8db8-cd857bd0b450"
      unitRef="usd">14000000</vyne:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id528c304a55c4353ba23843e402628f1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzgx_2cdecd04-0d2b-44fe-bd60-05340fae1a1d"
      unitRef="usd">35000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9efde75313c64f94acd2d57c0ac7ad36_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzgx_b45110fe-1932-4a76-a8e9-ef51dd3bc6a0"
      unitRef="usd">35000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="id528c304a55c4353ba23843e402628f1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfODg0_22d2d38c-ac81-46cf-9aad-ab8db271c92e"
      unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i9efde75313c64f94acd2d57c0ac7ad36_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfODg0_88068a6a-0c81-4553-b99f-d9254b47101d"
      unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0b6c184538354bce82077ac6310639ce_I20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTAzOQ_7240e90c-d1f8-4466-99f4-152e3d9d32d1"
      unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0a8f341036bc4b7ea7dc739c6499f873_I20191217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTEwMw_66fb7196-e5b7-41af-9f23-161fb805f071"
      unitRef="usd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9f230d62899b4d71845a983074150045_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTE4MA_fcddd69d-9a78-49a1-b290-6f35065923e4"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9efde75313c64f94acd2d57c0ac7ad36_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTY1MjAzMg_8e26d10c-ae02-4009-a7b6-4c5c97e894ed"
      unitRef="number">0.0825</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id65641d8ed054571b83e832dbc10772f_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTY1MjAzNg_3863203d-735f-4e3a-9f55-3439d4d0b94b"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <vyne:RepaymentOfDebtPrepaymentFeePercentage
      contextRef="i271ffaaf0e574d60ad9235c64c92906e_I20210811"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMzg0ODI5MDcyMTE2Mg_246aa10b-9de0-4405-bb25-4d6d0852d60b"
      unitRef="number">0.04</vyne:RepaymentOfDebtPrepaymentFeePercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic25e62d0cd134ea88998d63b633a4770_D20210811-20210811"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMjc0ODc3OTA5NDAzOA_cb9a855d-9401-44a2-a1df-3c0e6e72e6eb"
      unitRef="usd">36500000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic3e2f164495a40aeb89e017df3b2607c_I20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNDc4NQ_8fe490ac-f34e-42e8-894b-e7f75ed9dd49"
      unitRef="shares">1100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic3e2f164495a40aeb89e017df3b2607c_I20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNDgzOQ_6b88ebb8-b6a4-4fc7-b36f-cffd05ef5bda"
      unitRef="usdPerShare">2.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i29a95d4d274e49d39b10611f8aa1e359_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNTE2OA_f65141e5-42cb-4a0e-bff4-0e775268a058"
      unitRef="shares">651640</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i29a95d4d274e49d39b10611f8aa1e359_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNTI0OA_1c3f2842-61e8-44ec-8dd7-3e0a999c0d30"
      unitRef="usdPerShare">3.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i48f8896bfdb14e839b03b101221cb89b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI4MA_b01fa099-515b-4b3d-84a4-bf6a1611b2ac"
      unitRef="shares">495165</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i48f8896bfdb14e839b03b101221cb89b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI4MQ_319aaed4-aa8a-4464-b4b7-b98df1cd0212"
      unitRef="usdPerShare">4.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="i08340dd9766c473889a05f2e9e452090_D20190729-20190729"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNjI0NA_bd96596a-d0de-4d53-b4b9-f5ad174c889b"
      unitRef="usd">1100000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="i615924500e1a48a1b14b32e08fe70444_D20190729-20190729"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNjUxMw_c26eb408-5f6e-458d-a158-9436a389cbcd"
      unitRef="usd">300000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i3ee35236062d43f9aceb739ebad9b33d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNjg1Ng_a0f6b11e-5ca6-44fa-a908-2b07d6c9aa53"
      unitRef="usd">36900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InterestExpenseDebt
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTYzNjY3Mw_16fd3a4e-f051-4d38-a5b6-398713b5ce09"
      unitRef="usd">1000000.0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTYzNjY3Mw_e67507b9-c66a-4472-ae1b-244c76e45576"
      unitRef="usd">1000000.0</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTYzNjY3Nw_16533189-4fd1-44eb-bda3-d2e4d069b0dc"
      unitRef="usd">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfMTA5OTUxMTYzNjY3Nw_66042f9a-222b-42e8-bc25-3afa306e03fc"
      unitRef="usd">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI1MQ_2e5891e6-4ec5-41fd-b536-678f0bd516f2"
      unitRef="usd">1900000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI1MQ_c4ef6a1d-4759-4663-b0b4-0d16687d7eb8"
      unitRef="usd">1900000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI3NQ_5b118f55-0b44-4c13-bbd5-ce2676807c17"
      unitRef="usd">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82MS9mcmFnOjRjNGQ1ODI4NGU1OTQzZGE5YWFmMmJmMDBlNTc3MDVkL3RleHRyZWdpb246NGM0ZDU4Mjg0ZTU5NDNkYTlhYWYyYmYwMGU1NzcwNWRfNzI3NQ_dc04c59c-3acc-4d0c-806e-3e37bea9417f"
      unitRef="usd">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTEwMTQ_b0402e86-0e24-4b4d-a34a-79202fe383cc">SHARE CAPITAL&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company's Certificate of Incorporation, as amended, authorizes the Company to issue 20,000,000 shares of preferred stock, par value $0.0001 per share.  There were no shares of preferred stock issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of preferred stock may be issued from time to time in one or more series.  The voting powers (if any), preferences and relative, participating, optional or other special rights, and the qualifications, limitations and restrictions of any series of preferred stock will be set forth in a Certificate of Designation filed pursuant to the Delaware General Corporation Law, as determined by the Company's Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares of common stock authorized under the Company's Amended and Restated Certificate of Incorporation was proportionately reduced in connection with the Company's one-for-four reverse stock split in February 2021. On July 19, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021, the Company held its annual meeting of stockholders (the "Annual Meeting"). Following the approval by the holders of a majority of the outstanding shares of common stock at the Annual Meeting, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 75,000,000 to 150,000,000 shares, effective as of July 19, 2021. Accordingly, the Company is authorized to issue 150,000,000 shares of common stock, par value $0.0001 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of preferred stock outstanding. The Company has never declared any dividends on common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuance of stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2019, the Company entered into a Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp;amp; Co., or Cantor Fitzgerald, to sell shares of the Company's common stock, from time to time, with aggregate gross sales proceeds of up to $50.0 million through an at-the-market equity offering program under which Cantor Fitzgerald will act as our sales agent.  The issuance and sale of shares of common stock by us pursuant to the Sales Agreement are deemed an "at-the-market" offering under the Securities Act.  Cantor Fitzgerald is entitled to compensation for its services equal to up to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement.  From January 1, 2021 through January 25, 2021, the Company issued and sold 2,778,012 shares of common stock at a weighted average price per share of $9.76 pursuant to the Sales Agreement for $26.3 million in net proceeds. Effective as of January 25, 2021, the Company terminated the Sales Agreement and will not make any additional sales thereunder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 26, 2021, the Company entered into a Securities Purchase Agreement with certain institutional and accredited investors for the sale of an aggregate of 5,274,261 shares of common stock of the Company, at a purchase price of $9.48 per share in a registered direct offering. The offering was completed on January 28, 2021 and the Company received approximately $46.8 million in net proceeds, after deducting placement agent fees and other offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 9, 2020, the Company completed an underwritten public offering of 7,776,875 shares of common stock at a price to the public of $7.40 per share.  The net proceeds of the offering were approximately $53.6&#160;million, after deducting underwriting discounts and commissions and other offering expenses.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the completion of the merger, on March 9, 2020, the Company issued 36,550,335 shares to Foamix shareholders.  On April 6, 2020, pursuant to the terms of the CSR Agreement, the Company issued 74,544,413 shares to Foamix shareholders, adjusted retrospectively to 18,636,103 shares of common stock upon the reverse stock split effective February 12, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with entering into the Credit Agreement on July 29, 2019, Foamix issued to the lenders Warrants to purchase up to an aggregate of 1,100,000 of its ordinary shares, later exchanged to Warrants to purchase up to 1,980,660 shares of Menlo&#x2019;s common stock, adjusted retrospectively to 495,165 shares of common stock upon the reverse stock split effective February 12, 2021. Upon the closing of the Merger, each Warrant received one CSR as described in Note 3- Business Combinations.  The Warrants were exercisable immediately following the closing of the Credit Agreement, subject to the terms of the warrant, and are due to expire on July 29, 2026.  Any Warrants left outstanding will be cashless exercised on the Warrants&#x2019; expiration date, if in the money. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exchange of Warrants from Foamix warrants to Menlo warrants and the additional CSR was accounted for as a modification, by analogy, from the modification&#x2019;s guidance under ASC 260-10-S99-2. The Company assessed the significance of the modification of the Warrants by comparing the fair value of the Warrants immediately before and after the amendments. In its assessment, it also considered additional qualitative factors. The Company concluded that the change of terms was not significant. Therefore, the incremental fair value, in the amount of $41,000, of the modified Warrants over the original ones (as of modification date) was recognized in retained earnings as a deemed dividend to the Warrants holders in the six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Equity incentive plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon closing of the Merger, the Company adopted Foamix&#x2019;s 2019 Equity incentive plan (the &#x201c;2019 Plan&#x201d;). As of June&#160;30, 2021, 1,240,195 shares remain issuable under the 2019 Plan.  In addition, the Company adopted the 2018 Omnibus Incentive Plan (the "2018 Plan") in January 2018.  In January 2020, the number of shares reserved under the 2018 Plan automatically &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;increased by 750,000 shares of common stock pursuant to the terms thereof.  As of June&#160;30, 2021, 519,928 shares remain issuable under the 2018 Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Employee Share Purchase Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon closing of the Merger, the Company adopted Foamix&#x2019;s Employee Share Purchase Plan ("ESPP") pursuant to which qualified employees (as defined in the ESPP) may elect to purchase designated shares of the Company&#x2019;s common stock at a price equal to&#160;85%&#160;of the lesser of the fair market value of the common stock at the beginning or end of each semi-annual share purchase period (&#x201c;Purchase Period&#x201d;). Employees are permitted to purchase the number of shares purchasable with up to 15% of the earnings paid (as such term is defined in the ESPP) to each of the participating employees during the Purchase Period, subject to certain limitations under Section 423 of the U.S. Internal Revenue&#160;Code.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, 2,261,108 shares remain available for grant under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2021, 42,989 shares were issued to employees pursuant to the ESPP. During the six months ended June&#160;30, 2020, 61,031 Foamix ordinary shares were purchased by Foamix employees pursuant to the ESPP prior to the Merger. Such shares were later exchanged for 36,155 shares of the Company's common stock and one CSR in the Merger, adjusted retrospectively to 9,038 shares of common stock and one CSR upon the reverse stock split effective February 12, 2021.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Options and RSUs granted to employees and directors:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the six months ended June&#160;30, 2021 and 2020, the Company granted options and RSU as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award&lt;br/&gt;amount*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise price&lt;br/&gt;range*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vesting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees and Directors:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.02-$11.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award&lt;br/&gt;amount*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise price&lt;br/&gt;range*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vesting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees and Directors:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.80-$12.52&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* All amounts and exercise prices for pre-Merger grants are presented following the exchange to Menlo options and RSUs at the Exchange Ratio described in Note 3-Business Combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options and RSUs granted to employees and directors during the six months ended June&#160;30, 2021 and the six months ended June&#160;30, 2020 was $7.5 million and $11.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs granted is based on the share price on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.38%-69.12%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.44%-69.83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5%-1.07%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.44%-1.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Merger, all outstanding options and RSUs granted by Foamix were exchanged for stock options and RSUs of Menlo&#x2019;s common stock according to the Exchange Ratio. In addition, for each option and RSU the holder received a CSR as &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;described in Note 3- Business Combination. This transaction was considered by the company to be a modification under ASC 718, Compensation - Stock Compensation. The modification did not affect the remaining requisite service period. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded immaterial incremental compensation expense for the three months ended March 31, 2020.  As described in Note 3 - Business Combination, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The conversion was considered by the company to be a modification under ASC 718. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded incremental compensation of $0.5 million and $1.4 million for the three and six months ended June&#160;30, 2021, respectively and $9.3 million for the three and six months ended June&#160;30, 2020.  As of June&#160;30, 2021 there is $1.9 million of unrecognized incremental compensation expense related to the modification which will primarily be amortized using a graded vesting method over the next 2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards granted to holders who are no longer employed or providing services to the Company are accounted for in accordance with ASC 815-40, Derivatives and Hedging. Under this guidance, the awards are classified as a derivative liability because the award no longer exchanges a fixed amount of cash for a fixed number of shares. Accordingly, as of March 9, 2020 the Company reclassified $1.6 million from additional paid-in capital to derivative liability on the unaudited condensed consolidated balance sheet. Prior to the reclassification of these awards as a liability instrument, the Company recorded an incremental compensation expense of $0.6 million due to the above mentioned modification in accordance with ASC 718. Subsequent to the reclassification of these awards as a liability instrument, the Company recorded incremental compensation expense of $0.5 million and $1.0 million million for the three and six months ended June 30, 2020.  There was no incremental compensation expense for the three and six months ended June&#160;30, 2021.  As described in Note 3 - Business Combination, on April 6, 2020, the Company announced that study MTI-105 and study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis.  Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  On April 6, 2020, the awards are exchangeable for a fixed amount of cash for a fixed number of shares and were remeasured to fair value and reclassified from derivative liability to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Merger, Menlo recognized all expenses relating to awards outstanding as of the Effective Date. These awards were subject to acceleration upon the change of control per the previous Menlo stock option plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the effect of share-based compensation on the statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTQy_772d950c-1e2a-4d17-b225-c22e70bac62b"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTgy_f799d240-bcc6-449c-ab17-68fe8fcad25e"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjA4_7beda4fe-72ba-490b-aeca-b7109ede6385"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i591be1e0085c41d689fc49b8c603ab69_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjA4_83b6b3a8-faed-405b-9d1f-94040d09874b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjA4_98ae118d-7121-4069-b343-f96efcaf8a9c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjA4_bdad4b32-27e6-4d84-917c-3564623fab88"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTY0MTMzMw_26b052fe-fe3a-4784-9aa2-1b5b0ac990ef"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i742062b5041f42418de6c43a30fbe8a2_I20210719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTY0MTM0Nw_ec424366-276f-49d9-a234-e53827f0b0a5"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i742062b5041f42418de6c43a30fbe8a2_I20210719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTY0MTM2MQ_ec424366-276f-49d9-a234-e53827f0b0a5"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i742062b5041f42418de6c43a30fbe8a2_I20210719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTAxNA_2f7112a7-5774-406a-aaf5-b3dd79beb248"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTAxNA_4fb880d9-d9ef-45e5-aecf-65bb38ded0e0"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <vyne:CommonStockVotingRightsNumberPerShare
      contextRef="ia694da22cf534b119d5bfa52040066d2_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA3MQ_b0bf8797-68bd-4593-980a-f09970bd535a"
      unitRef="vote">1</vyne:CommonStockVotingRightsNumberPerShare>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="i038228081e6f4f1790fdcab0a61c49d4_D20190201-20190201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTY1Mg_23f55e19-e9b2-44bf-9128-ef2d8d3ba133"
      unitRef="usd">50000000.0</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <vyne:CommissionFromGrossProceedsFromIssuanceOfCommonStock
      contextRef="i3f7bc2d54cd0447d85aaad2c755a7b4d_D20190201-20190201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTk5NA_9ea3b184-7643-4c2b-8bc1-aeff39d8014f"
      unitRef="number">30.0</vyne:CommissionFromGrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9a2f164c78754c5d9affd590f3137bf8_D20210101-20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjE1Nw_c695fbd8-deec-4a78-a58e-9c77a6a6a8a6"
      unitRef="shares">2778012</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i49b0dcc45925492cb597c2d5ec8cb906_I20210125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjIyNA_6b63ad23-bb2e-41fa-9e68-7c0b64fba252"
      unitRef="usdPerShare">9.76</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i9a2f164c78754c5d9affd590f3137bf8_D20210101-20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjI2Mw_39c54c60-41bc-4f94-9ab9-65418a5e4bf6"
      unitRef="usd">26300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6a2f99820bb84452aea13ec915c8fa3b_D20210126-20210126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjU3Mw_aeafbd11-c45b-4603-8eea-d0f4c318005b"
      unitRef="shares">5274261</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i50b0c0ff85cd433787d5bfdd753d8bab_I20210126"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjYzOA_2e9b3d94-bae5-41ce-8621-b1a99cc5d9eb"
      unitRef="usdPerShare">9.48</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6a2f99820bb84452aea13ec915c8fa3b_D20210126-20210126"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjc3MA_4a505e08-b659-4273-8175-4d3c73e1fbdb"
      unitRef="usd">46800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iac7823d514fa4758beb050e55878ced3_D20200609-20200609"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjkzMQ_41b11520-0fe3-4b19-8c14-df8a144da566"
      unitRef="shares">7776875</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i8689f9a9a2e144918aa468473d6f4f11_I20200609"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMjk4NQ_dc5d2002-af39-429f-a0e2-91cabe6513ec"
      unitRef="usdPerShare">7.40</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iac7823d514fa4758beb050e55878ced3_D20200609-20200609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzA1Mg_f26b4563-6dd0-45d0-8013-31dd290bb894"
      unitRef="usd">53600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzIyMQ_b330c401-9cd9-4578-bdc2-109847db3426"
      unitRef="shares">36550335</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="if21d5501c5f34c17ae7cdfe02a371143_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzMzNw_4f7701be-1e0e-49c5-b798-a76a47ed431c"
      unitRef="shares">74544413</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement
      contextRef="i2a0505b712e847e481143283b66db10b_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzM5OQ_a1932318-2e26-439a-93c9-e0ad11dcd2f7"
      unitRef="shares">18636103</vyne:SharesIssuedUponConversionOfCommonStockRightsPerAgreement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie871aeb88d164ac194fee5617757929b_I20190729"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzYzNg_cecc631e-a168-4cb4-8a22-fb2fef428239"
      unitRef="shares">1100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <vyne:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i428a7beb16304a1c98e79a87b85028ab_D20190729-20190729"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzcwOQ_e8f6a41c-b6a8-4f11-a303-373705759e3c"
      unitRef="shares">1980660</vyne:StockIssuedDuringPeriodSharesWarrantsExercised>
    <vyne:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i27760351ca2c4c7ba4e2acabf5d90f82_D20210212-20210212"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzc3Mg_3f26064a-5367-43c1-b9b5-51dde2db83c0"
      unitRef="shares">495165</vyne:StockIssuedDuringPeriodSharesWarrantsExercised>
    <vyne:BusinessAcquisitionContingentStockRightIssued
      contextRef="i6945c947006648c0ac8f5b0f8e054f7c_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMzkxMA_5273aa91-f8c3-4f4f-90f3-012e1625aa45"
      unitRef="contingentstockright">1</vyne:BusinessAcquisitionContingentStockRightIssued>
    <vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification
      contextRef="i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNDc5MQ_fc72b054-3fcd-4532-92d6-91fca36dd8f8"
      unitRef="usd">41000</vyne:DeemedDividendToWarrantsHoldersDueToWarrantModification>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i5dae593c3d39464ba022d2c59437553f_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNTEzOQ_fd79e7e6-6c76-4b77-af44-006232244cbd"
      unitRef="shares">1240195</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <vyne:CommonStockIncreaseInCapitalSharesReservedForFutureIssuance
      contextRef="iec332474ea174f79b645e790d02cd783_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNTM4Mg_8e6e0601-4d3d-4814-a5ad-5763fc337888"
      unitRef="shares">750000</vyne:CommonStockIncreaseInCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iec332474ea174f79b645e790d02cd783_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNTQ1MA_77f4fbb2-6385-4a38-ada7-bd3751b28736"
      unitRef="shares">519928</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i641098fa043e48aa8855d84732b16182_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNTc3Nw_8567405b-97f8-43b2-bcd0-a3f941cc1d37"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i65cc49f7fccb4771b6f817252050651d_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjAwNg_edf43709-0082-457b-8e09-4fe6ffb0b2d9"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i65cc49f7fccb4771b6f817252050651d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjIyOQ_ab5e8883-f951-40e2-b7c8-f5a69799e336"
      unitRef="shares">2261108</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i3b522232200e4ef29470815637a89d61_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTYzOTUxNQ_fb22cd75-aab4-4460-aef1-5da86d5258ac"
      unitRef="shares">42989</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i22a2ca05fede4ed3bb2d86f4e96744a8_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjQyOQ_4aaca6eb-fad0-4386-9272-7376c5b593d5"
      unitRef="shares">61031</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="i22b9c5bc79864c4ebd2e17fb68853be3_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjU2OQ_21de6847-af23-454d-b54a-95a47d256fcf"
      unitRef="shares">36155</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <vyne:BusinessAcquisitionContingentStockRightIssued
      contextRef="i376c62cb8cbc4fefa5c7f2ab24075e54_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjYxMw_55d627a2-a4f0-4199-bbed-b151c0bd4103"
      unitRef="contingentstockright">1</vyne:BusinessAcquisitionContingentStockRightIssued>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="i4225a6209ef44ddaaa5e82e900a35d56_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjY2Mw_65b98b2a-41f5-4516-ad42-7f3504017a49"
      unitRef="shares">9038</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <vyne:BusinessAcquisitionContingentStockRightIssued
      contextRef="ib3dbfc262f3d4d6e9849df3ec34b7adf_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNjY5Mw_bd049163-57c0-4999-b218-9c692e51248e"
      unitRef="contingentstockright">1</vyne:BusinessAcquisitionContingentStockRightIssued>
    <vyne:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTEwMTU_24a01f00-df08-4cf4-82d3-e1821d08972c">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the six months ended June&#160;30, 2021 and 2020, the Company granted options and RSU as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award&lt;br/&gt;amount*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise price&lt;br/&gt;range*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vesting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees and Directors:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.02-$11.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award&lt;br/&gt;amount*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise price&lt;br/&gt;range*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vesting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees and Directors:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.80-$12.52&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* All amounts and exercise prices for pre-Merger grants are presented following the exchange to Menlo options and RSUs at the Exchange Ratio described in Note 3-Business Combination.&lt;/span&gt;&lt;/div&gt;</vyne:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy0xLTEtMS0w_2d344645-4d2a-49d3-a9ab-330b25b15b72"
      unitRef="shares">957682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy0zLTEtMS0wL3RleHRyZWdpb246ODFmNWYzZDM5ZjhiNDFmODlhYWIxZjNlNTI4OWU0Y2ZfNA_12b2dc41-a6be-42df-a713-ab2899d3fcc1"
      unitRef="usdPerShare">5.02</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy0zLTEtMS0wL3RleHRyZWdpb246ODFmNWYzZDM5ZjhiNDFmODlhYWIxZjNlNTI4OWU0Y2ZfNw_b0dd06c8-ea2e-4084-856b-f0f8a5c2ae15"
      unitRef="usdPerShare">11.08</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7e1b4af058494e31a6baf54a62b10e9f_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy01LTEtMS0wL3RleHRyZWdpb246NDQwODhkNTZiYWRkNDE0NTg1YzI3ZTk1ZDRmNzU4ZjNfNA_651b44ab-2b73-4e88-8588-767608443f27">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icaeba42a65bb4908a12b6c42bbe13190_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy01LTEtMS0wL3RleHRyZWdpb246NDQwODhkNTZiYWRkNDE0NTg1YzI3ZTk1ZDRmNzU4ZjNfOA_2e3149ab-07e1-495f-9ae9-c2de436cf413">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfMy03LTEtMS0w_a0801322-2822-427b-9d5c-21a2d23d20b0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i524e30b547814ce3bcc5776c00614d79_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfNC0xLTEtMS0w_f51d0454-acb9-43dd-a9da-e6775e166706"
      unitRef="shares">366678</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia05c23f9d5dd402b979cd7db4bad4117_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfNC01LTEtMS0wL3RleHRyZWdpb246MjJlMmM0YWQ2ZDBhNDFiYjgwMjM4Yjc1OWE4MGE1NzNfNA_feb0c6bb-7eef-4d6d-9cbb-c5fe3a4e57b6">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i35b1d069ce7e4403bcfb8dc34bb20fdd_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmU4ZWY0YWEwN2I5ZTQ1ZGRiM2Y2ZDBlODZlZWFhN2RmL3RhYmxlcmFuZ2U6ZThlZjRhYTA3YjllNDVkZGIzZjZkMGU4NmVlYWE3ZGZfNC01LTEtMS0wL3RleHRyZWdpb246MjJlMmM0YWQ2ZDBhNDFiYjgwMjM4Yjc1OWE4MGE1NzNfOA_ab71173d-9e2a-404c-bb14-b06ff43cc83c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy0xLTEtMS0w_7e762fc7-b3c6-4de7-b93d-1b7552238560"
      unitRef="shares">1195611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy0zLTEtMS0wL3RleHRyZWdpb246MDI5ZTk0NzYyOTAzNDRjNGI1YWY3Mjc4MDNkYzcwMzRfNA_8d1e1823-9813-4712-ad54-ca46fe2c957a"
      unitRef="usdPerShare">7.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy0zLTEtMS0wL3RleHRyZWdpb246MDI5ZTk0NzYyOTAzNDRjNGI1YWY3Mjc4MDNkYzcwMzRfNw_17d32f85-f4dc-4527-acef-6815d99312ed"
      unitRef="usdPerShare">12.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8fb7478f500346ca86fa53d3e5c1bea3_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy01LTEtMS0wL3RleHRyZWdpb246ODVkNTBjOGI4OWVkNGUyNDg4YjMxMjMyZDVhNjUyNThfNA_9a5cdef6-b91a-416a-9214-64a0acdaa4d3">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2ef2613cb84a47d9b3d12f99f63f3c4b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy01LTEtMS0wL3RleHRyZWdpb246ODVkNTBjOGI4OWVkNGUyNDg4YjMxMjMyZDVhNjUyNThfOA_d074ca12-3536-4be3-8e77-87214ab9bb3b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfMy03LTEtMS0w_2f595636-dd24-49ba-8ed5-757067235618">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibc383d8b15744bd285e423d24f50602f_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfNC0xLTEtMS0w_6c25aab6-b459-4edb-b914-534e2afc3b11"
      unitRef="shares">647427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibd075c5d380f49b1987fa8d6713944de_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfNC01LTEtMS0wL3RleHRyZWdpb246ZWRhZjk1ZmE1NmM5NGRlNGJmMzMwZTQ1Nzk0Mjk5ODlfNA_62597a65-2b4b-4386-9b7f-e9390fb390cb">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id19d638103a64be2acf8ac79042f7740_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjc1ZWRhMWZiNGI2YTQ3MjFhNTkyNWViMzNiMjdlMGY3L3RhYmxlcmFuZ2U6NzVlZGExZmI0YjZhNDcyMWE1OTI1ZWIzM2IyN2UwZjdfNC01LTEtMS0wL3RleHRyZWdpb246ZWRhZjk1ZmE1NmM5NGRlNGJmMzMwZTQ1Nzk0Mjk5ODlfOA_287676df-3b59-457c-91f2-bb75f8d9300e">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <vyne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNzIxNg_7df0035f-beff-448f-a11a-55ed98c86f7d"
      unitRef="usd">7500000</vyne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue>
    <vyne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfNzIyMw_887c8535-a700-47b5-80a3-5ec23ce04d06"
      unitRef="usd">11400000</vyne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTEwMTY_230c0939-99d7-49e9-8955-0e5fc6a6dc9d">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.38%-69.12%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.44%-69.83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5%-1.07%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.44%-1.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMi0xLTEtMS0w_37a51ab2-58cd-43e8-b9bf-58f9a887cfcf"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMi0zLTEtMS0w_de753d46-494e-4134-8045-2b0585bc3c4d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMy0xLTEtMS0wL3RleHRyZWdpb246Njk1ZTNmYzQxZmFiNDUyMjhmNzQwNmY2NDhmODRhOGRfNA_cb6c5dc1-57dc-4c4c-973c-c97b1db5447d"
      unitRef="number">0.6838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMy0xLTEtMS0wL3RleHRyZWdpb246Njk1ZTNmYzQxZmFiNDUyMjhmNzQwNmY2NDhmODRhOGRfNw_5dc2f41b-65ac-4c28-9fca-63eec6701a6a"
      unitRef="number">0.6912</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMy0zLTEtMS0wL3RleHRyZWdpb246ZTcyZDcwMjc3ZmVhNDVhMzkyNGUxYWVmYTMzM2ZjNTVfNA_975ebdb1-418d-449f-9044-d7aa4144db4a"
      unitRef="number">0.6044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfMy0zLTEtMS0wL3RleHRyZWdpb246ZTcyZDcwMjc3ZmVhNDVhMzkyNGUxYWVmYTMzM2ZjNTVfNw_a16c5cb6-ad26-42ab-aed4-aeccde38b4d6"
      unitRef="number">0.6983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNC0xLTEtMS0wL3RleHRyZWdpb246YmQxMmEyNjc4NDFkNGY0MzgxYTA2MTg3ZmM3NzQyZWVfNA_6407e72e-7816-49e0-af98-c19dfe3e35f8"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNC0xLTEtMS0wL3RleHRyZWdpb246YmQxMmEyNjc4NDFkNGY0MzgxYTA2MTg3ZmM3NzQyZWVfNw_1c43c316-a7f3-43c3-b115-fd7ab96d17df"
      unitRef="number">0.0107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNC0zLTEtMS0wL3RleHRyZWdpb246OWZiOWIwYWI0Y2UxNGM1ODkzZWI1YjYyYTFjZmJhMDJfNA_ede475b0-408b-4653-b06d-9ce1d45b64ae"
      unitRef="number">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNC0zLTEtMS0wL3RleHRyZWdpb246OWZiOWIwYWI0Y2UxNGM1ODkzZWI1YjYyYTFjZmJhMDJfNw_45b3dfce-537e-43c2-8b30-32442e41a934"
      unitRef="number">0.0126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNS0xLTEtMS0w_124ab78a-0cf3-4e42-9721-ea640b600176">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iac977fdf280d490ab653d0bf7c14e1cc_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOjU5YWRiODg0ZDFmNDRiMTQ5NzQ1YThhMmYyZDc4N2MyL3RhYmxlcmFuZ2U6NTlhZGI4ODRkMWY0NGIxNDk3NDVhOGEyZjJkNzg3YzJfNS0zLTEtMS0w_5fa1b5d5-7689-40f4-8070-f0959a8969c1">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <vyne:ContingentStockRightSharesConversion
      contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfODMwMQ_b81553da-afc3-4bc0-b78a-184707d40834"
      unitRef="number">1.2082</vyne:ContingentStockRightSharesConversion>
    <vyne:EffectiveExchangeRatio
      contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfODM5Mg_c7be5fdc-d8a4-45ff-a8ff-9d55c04c95e0"
      unitRef="number">1.8006</vyne:EffectiveExchangeRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i753ec734b4784e41991f04acf5c5cc91_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTYzOTE0Mg_a7e5ccdf-924a-40fc-8b02-66ef7f027f9e"
      unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i8f58347fa5a54704957bea4315cd276b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfODY5OA_ffe3fdbb-398c-4789-8fc6-f616e4639897"
      unitRef="usd">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i8a28af5f07da4b9898e192b1f7e656df_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTYzOTExNw_5a0d212f-0331-4b56-9806-f240b3da7e1a"
      unitRef="usd">9300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i650dc6e79b0646b69e2927249fe8ffd5_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTYzOTExNw_de81dff0-3ae6-49bc-8bd0-3dffb63f54ce"
      unitRef="usd">9300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vyne:ShareBasedPaymentArrangementPlanModificationUnrecognizedCost
      contextRef="i8f58347fa5a54704957bea4315cd276b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfODc0OA_3227d95c-80a1-4538-91c8-58a8066fa38c"
      unitRef="usd">1900000</vyne:ShareBasedPaymentArrangementPlanModificationUnrecognizedCost>
    <vyne:ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod
      contextRef="i8f58347fa5a54704957bea4315cd276b_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfODkwNg_c93d10af-c577-40ec-bd95-1d069a491b54">P2Y</vyne:ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod>
    <vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment
      contextRef="id374e55b59954cc8a6044053d732e5bb_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfOTI5Ng_cc69a039-010f-450d-a114-bce04d5960e4"
      unitRef="usd">1600000</vyne:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost
      contextRef="id374e55b59954cc8a6044053d732e5bb_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfOTU0Mw_26792529-7c91-4952-ada2-7922c67e6518"
      unitRef="usd">600000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i62ea0913d468447f90567f896b4278c8_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfOTc0OQ_6a2ca766-4286-46c3-8b60-01ba9cef1f88"
      unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i414facc7c16542e9bd4fb7ab3efbe2da_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA5OTUxMTYzOTIyMw_7420b9dc-0b8d-4ede-b5e0-0595381b8556"
      unitRef="usd">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i2f1e26cb367a4d819caeb25260e38425_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfOTgwNg_6495eed3-5d52-4161-9f8c-702d9bc0ce93"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="if6624a5563c848348d3967b0dc37ffed_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfOTgwNg_f1dbe07e-7ee4-4135-b255-55e97b36acde"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <vyne:ContingentStockRightSharesConversion
      contextRef="ib008e08d218f4edca1a33f7677210b30_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTAzMjQ_b81553da-afc3-4bc0-b78a-184707d40834"
      unitRef="number">1.2082</vyne:ContingentStockRightSharesConversion>
    <vyne:EffectiveExchangeRatio
      contextRef="i4af3f431e20a41e3ba361b2d595ab3c1_D20200406-20200406"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTA0MTU_3468e6b0-8dda-41a4-b94a-67a6bc7d129b"
      unitRef="number">1.8006</vyne:EffectiveExchangeRatio>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RleHRyZWdpb246MTljOTIyZmFiN2Q5NGFiMWFhNWEwZjdkYTM2ZWY0YmNfMTEwMTc_792ebd01-6180-44cf-a4a1-22c6b1a2e94d">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the effect of share-based compensation on the statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six months ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie4e62a8b45834716a1bfce75e6f69049_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMi0xLTEtMS0w_fb80f893-fb64-44c4-a752-6420d9d9116c"
      unitRef="usd">442000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic5dd41a666f44f10b6f7fcf9d08a4914_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMi0zLTEtMS0w_acbe5c01-ef36-45f1-b346-62d4ac57f8dc"
      unitRef="usd">3050000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0486d94e40b54296be6348fab054286d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMi01LTEtMS0w_757b2602-19e2-4372-8259-69c3503541b2"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84198dfa6a324c93a59ee66d0eee6e13_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMi03LTEtMS0w_6da52471-abc1-4b37-94c1-a5eb10699206"
      unitRef="usd">3566000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1691ef974cfc49b4b36a9537faf2c710_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMy0xLTEtMS0w_6cd6737a-f57d-4a5d-be8b-0495591a3720"
      unitRef="usd">1459000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3146e6cf023a4b3dbb9950d620581293_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMy0zLTEtMS0w_626672df-84fa-4ef0-a697-fe44d3c05f0b"
      unitRef="usd">7718000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81a2e62b1f87439290f96db45c549d64_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMy01LTEtMS0w_c8312677-9f32-4c8f-a4cc-3433bdffb2eb"
      unitRef="usd">3443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icea6504990b84f5cbc69647e56ecc4a9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfMy03LTEtMS0w_7743382b-90d7-4003-a32e-1434b5eb4994"
      unitRef="usd">8961000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfNC0xLTEtMS0w_9bc6971d-5135-4589-b4b9-1a4c29d12544"
      unitRef="usd">1901000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfNC0zLTEtMS0w_ef817be6-d81c-4309-a55c-f1784f5254bf"
      unitRef="usd">10768000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfNC01LTEtMS0w_89aee8bd-9e04-49ad-a127-8f4a10f365c9"
      unitRef="usd">4343000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ica1584044dca44e28740fa114ae23f1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl82NC9mcmFnOjE5YzkyMmZhYjdkOTRhYjFhYTVhMGY3ZGEzNmVmNGJjL3RhYmxlOmZmMWZmZWFhYTI4MjQzZDQ5YmRmZjhhMWIwYTZiZjE0L3RhYmxlcmFuZ2U6ZmYxZmZlYWFhMjgyNDNkNDliZGZmOGExYjBhNmJmMTRfNC03LTEtMS0w_cdaab3f1-c22a-4861-991a-ab514fe866a6"
      unitRef="usd">12527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMTcxMQ_ae762630-4be1-4935-8c6d-185819d97609">OPERATING LEASE&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating lease agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for corporate offices and vehicles. The properties primarily relate to the Company&#x2019;s principal executive office in Bridgewater, New Jersey and office space in Israel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 13, 2019, the Company signed an amendment to the original lease agreement for its principal executive office in Bridgewater, New Jersey (the &#x201c;Lease Amendment&#x201d;). The Lease Amendment includes an extension of the lease period of the 10,000 square feet previously leased under the original agreement (the &#x201c;Original Space&#x201d;) and an addition of 4,639 square feet (the &#x201c;Additional Space&#x201d;). The Company entered the Additional Space following a period of preparation by the lessor completed during September 2019 (the &#x201c;Commencement Date&#x201d;). The Lease Amendment is due to expire on August 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Lease Amendment, the Company recognized an additional right of use asset and liability in the amount of $0.7 million. The Additional Space was considered a new lease agreement and was recognized as a right of use asset and liability, in the amount of $0.3 million, on the Commencement Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease agreement for the office space in Israel is a one year lease that expires in December 2021.  Given the short-term nature of the lease term, the Company did not recognize a right-of-use asset and liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company entered into operating lease agreements in connection with the leasing of vehicles. The lease periods are generally for three years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company had a lien in the amount of $0.6 million on the Company&#x2019;s cash in respect of bank guarantees granted in order to secure the lease agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <vyne:FacilitySpaceUnderLease
      contextRef="i722a736ad61a4de08b6ba7e77f1bc3bc_D20190313-20190313"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfNDk3_38ebd0f3-9740-4319-b272-bc9666d8828d"
      unitRef="sqft">10000</vyne:FacilitySpaceUnderLease>
    <vyne:FacilitySpaceUnderLease
      contextRef="i381692c3937a48fc9cf55bbc32a4a79f_D20190313-20190313"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfNjAx_8b50bef1-6cf8-449a-bd10-ea9bc9ad21de"
      unitRef="sqft">4639</vyne:FacilitySpaceUnderLease>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1d1e8908692340b4b78b852928f985fa_I20190313"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfOTY3_c15953ec-420a-4fad-adda-b478505747e1"
      unitRef="usd">700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i54987e1926fd4ff78e485bd30599b12a_I20190313"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMTEwNA_f3a17e95-76ed-4f34-961e-7b7261fad4be"
      unitRef="usd">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i0c8acb1983b042eca15f9a025c2d4572_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMjc0ODc3OTA3MTE2Mg_92f07aba-0996-4a3c-9b6d-0d146f2f4377">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMTcxMg_73235b14-943d-4991-92bf-b6a3e1a4833f">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMTcxMw_4be0ec94-f1b8-47f4-a0d9-e4f18ffb93eb">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfMS0xLTEtMS0w_ab83f527-14ef-4913-9331-87a7d0fd9be6"
      unitRef="usd">458000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfMi0xLTEtMS0w_f58dceb0-bd1d-47d9-8df3-a64c5336466a"
      unitRef="usd">761000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfMy0xLTEtMS0w_40ebdcca-8349-41c8-96b7-ed5c30960aeb"
      unitRef="usd">151000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfNS0xLTEtMS0w_866635a8-e119-490c-8384-1524efd5a015"
      unitRef="usd">1370000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfNi0xLTEtMS0w_274ee47c-3544-4a19-92ba-8e17efebf2d4"
      unitRef="usd">124000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RhYmxlOjE5ZTFkNjUyNTA5YzRhZjNhMjUxYmM4NTg2YzViZjBkL3RhYmxlcmFuZ2U6MTllMWQ2NTI1MDljNGFmM2EyNTFiYzg1ODZjNWJmMGRfNy0xLTEtMS0w_e31a0fce-d66a-4835-a591-e0d3e3a03e16"
      unitRef="usd">1246000</us-gaap:OperatingLeaseLiability>
    <vyne:RestrictedInvestmentsToSecureLeaseAgreements
      contextRef="i74a36af260014e1f802fe734fdffb5e9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83MC9mcmFnOmE0NDQ4NDQ2YWMwMzQxNjg4MTQxYWM3NWEzMGRiZjRhL3RleHRyZWdpb246YTQ0NDg0NDZhYzAzNDE2ODgxNDFhYzc1YTMwZGJmNGFfMTYwOQ_a635e8ea-2d4e-4206-b771-c98ca6dc473a"
      unitRef="usd">600000</vyne:RestrictedInvestmentsToSecureLeaseAgreements>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83My9mcmFnOmVhMjhjZGRlYjMyYzRmYjE4M2M3OGQwY2RlZDNlNWEzL3RleHRyZWdpb246ZWEyOGNkZGViMzJjNGZiMTgzYzc4ZDBjZGVkM2U1YTNfMzIx_71b42217-8842-4e11-8772-c462f18b11ed">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may periodically become subject to legal proceedings and claims arising in connection with its business. As of June&#160;30, 2021, no claims or actions are pending against the Company that, in the opinion of management, are likely to have a material adverse effect on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, on June 30, 2021, the Company received a paragraph IV certification notice (the &#x201c;Notice&#x201d;) from Padagis Israel Pharmaceuticals Ltd. (f/k/a Perrigo Israel Pharmaceuticals Ltd. (&#x201c;Padagis&#x201d;)) advising that Padagis has submitted to the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) seeking approval to manufacture and sell a generic version of the Company&#x2019;s product AMZEEQ&#xae; (minocycline) topical foam, 4% in the United States prior to the expiration of the Company&#x2019;s U.S. patents Nos. 8,865,139, 8,945,516, 8,992,896, 9,675,700, 10,086,080, 10,137,200, 10,213,512, 10,265,404, 10,398,641, 10,517,882, 10,821,187, and 10,849,847 (the &#x201c;Listed Patents&#x201d;), which are listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the &#x201c;Orange Book.&#x201d; The Notice alleges that the Listed Patents are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Padagis&#x2019;s ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 9, 2021, the Company initiated a patent infringement suit against Padagis in the United States District Court for the District of Delaware arising from Padagis&#x2019;s ANDA filing with the FDA. The patent infringement suit asserts each of the Listed Patents. As a result, under applicable law, the FDA cannot grant final approval to Padagis&#x2019;s ANDA before December 30, 2023, or a court decision in Padagis&#x2019;s favor. VYNE is seeking, among other relief, an order that the effective date of any FDA approval of Padagis&#x2019;s ANDA be no earlier than the expiration of the Listed Patents, the latest of which expires on September 8, 2037, and such further and other relief as the court may deem appropriate.&lt;/span&gt;&lt;/div&gt;The Company intends to vigorously defend its intellectual property rights, including the Listed Patents.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ibace252288db423ca83fb8257a0d36f9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83OS9mcmFnOjIwNWE2MThjMzE5NzQyOTFhZjNmY2NhZjViOGQ0OTRlL3RleHRyZWdpb246MjA1YTYxOGMzMTk3NDI5MWFmM2ZjY2FmNWI4ZDQ5NGVfMzg0ODI5MDcwOTc3Ng_ce1447a2-9598-4ec6-b232-d2c6f1fdd513"
      unitRef="usd">1500000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i20cbba757ccb4615a4d0cfe3c3f988dd_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl83OS9mcmFnOjIwNWE2MThjMzE5NzQyOTFhZjNmY2NhZjViOGQ0OTRlL3RleHRyZWdpb246MjA1YTYxOGMzMTk3NDI5MWFmM2ZjY2FmNWI4ZDQ5NGVfMzg0ODI5MDcwOTc4Mw_5582bfd0-d3bb-498e-b711-05d098e87bd2"
      unitRef="usd">2000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="i4a701835f72e475097f033580f5deea7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xMzYvZnJhZzo3MTg3NjRkNDdmODA0YjkyOTY3MDcyODRiMTZkZjNlOS90ZXh0cmVnaW9uOjcxODc2NGQ0N2Y4MDRiOTI5NjcwNzI4NGIxNmRmM2U5XzM4NDgyOTA3MDg1MDA_9d24e302-b2cc-4a5d-8462-1cdb444e4417"
      unitRef="employee">70</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ibace252288db423ca83fb8257a0d36f9_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xMzYvZnJhZzo3MTg3NjRkNDdmODA0YjkyOTY3MDcyODRiMTZkZjNlOS90ZXh0cmVnaW9uOjcxODc2NGQ0N2Y4MDRiOTI5NjcwNzI4NGIxNmRmM2U5XzM4NDgyOTA3MDg2NTY_ce1447a2-9598-4ec6-b232-d2c6f1fdd513"
      unitRef="usd">1500000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i20cbba757ccb4615a4d0cfe3c3f988dd_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1YjAwYzdlNTI5NzQ1OWJhZmRiMjI4MmFhNDZmZWMyL3NlYzoyNWIwMGM3ZTUyOTc0NTliYWZkYjIyODJhYTQ2ZmVjMl8xMzYvZnJhZzo3MTg3NjRkNDdmODA0YjkyOTY3MDcyODRiMTZkZjNlOS90ZXh0cmVnaW9uOjcxODc2NGQ0N2Y4MDRiOTI5NjcwNzI4NGIxNmRmM2U5XzM4NDgyOTA3MDg2NjM_5582bfd0-d3bb-498e-b711-05d098e87bd2"
      unitRef="usd">2000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674072105544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VYNE THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3757789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">520 U.S. Highway 22, Suite 204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">775-7936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VYNE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001566044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,511,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674072148440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 103,406<span></span>
</td>
<td class="nump">$ 57,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities (Note 6)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net of allowances</a></td>
<td class="nump">10,868<span></span>
</td>
<td class="nump">15,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other assets</a></td>
<td class="nump">5,268<span></span>
</td>
<td class="nump">4,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory (Note 7)</a></td>
<td class="nump">8,279<span></span>
</td>
<td class="nump">7,404<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">128,426<span></span>
</td>
<td class="nump">87,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets (Note 10)</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid and other assets</a></td>
<td class="nump">3,831<span></span>
</td>
<td class="nump">4,345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">133,983<span></span>
</td>
<td class="nump">93,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">10,080<span></span>
</td>
<td class="nump">4,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (Note 4)</a></td>
<td class="nump">10,146<span></span>
</td>
<td class="nump">11,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Debt (Note 8)</a></td>
<td class="nump">33,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related obligations</a></td>
<td class="nump">3,481<span></span>
</td>
<td class="nump">4,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities (Note 10)</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">57,620<span></span>
</td>
<td class="nump">21,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits', window );">Liability for employee severance benefits</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities (Note 10)</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">59,090<span></span>
</td>
<td class="nump">56,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.0001 par value; 20,000,000 shares authorized at June&#160;30, 2021 and December&#160;31, 2020, respectively; no shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.0001 par value; 75,000,000 shares authorized at June&#160;30, 2021 and December&#160;31, 2020, respectively; 51,511,845 and 43,205,221 shares issued and outstanding at June&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">681,558<span></span>
</td>
<td class="nump">603,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(606,670)<span></span>
</td>
<td class="num">(566,196)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity</a></td>
<td class="nump">74,893<span></span>
</td>
<td class="nump">37,493<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders&#8217; Equity</a></td>
<td class="nump">$ 133,983<span></span>
</td>
<td class="nump">$ 93,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674163869528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD/share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (USD/share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="nump">51,511,845<span></span>
</td>
<td class="nump">43,205,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in shares)</a></td>
<td class="nump">51,511,845<span></span>
</td>
<td class="nump">43,205,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674072268376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 4,258<span></span>
</td>
<td class="nump">$ 11,688<span></span>
</td>
<td class="nump">$ 8,377<span></span>
</td>
<td class="nump">$ 13,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">795<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,409<span></span>
</td>
<td class="nump">13,119<span></span>
</td>
<td class="nump">12,742<span></span>
</td>
<td class="nump">29,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">15,835<span></span>
</td>
<td class="nump">26,459<span></span>
</td>
<td class="nump">32,451<span></span>
</td>
<td class="nump">51,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and in-process research &amp; development impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,345<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ContingentStockConsiderationRemeasurementGainLoss', window );">Contingent Stock Right Remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,726<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,726<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">22,244<span></span>
</td>
<td class="nump">178,649<span></span>
</td>
<td class="nump">45,193<span></span>
</td>
<td class="nump">220,017<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="nump">18,781<span></span>
</td>
<td class="nump">167,177<span></span>
</td>
<td class="nump">38,212<span></span>
</td>
<td class="nump">207,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">1,074<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">2,136<span></span>
</td>
<td class="nump">2,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">69<span></span>
</td>
<td class="num">(548)<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="num">(1,271)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss Before Income Tax</a></td>
<td class="nump">19,924<span></span>
</td>
<td class="nump">167,699<span></span>
</td>
<td class="nump">40,474<span></span>
</td>
<td class="nump">207,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="nump">$ 19,924<span></span>
</td>
<td class="nump">$ 167,440<span></span>
</td>
<td class="nump">$ 40,474<span></span>
</td>
<td class="nump">$ 207,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share basic (in dollars per share)</a></td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 9.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share diluted (in dollars per share)</a></td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 9.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">51,411<span></span>
</td>
<td class="nump">34,663<span></span>
</td>
<td class="nump">50,162<span></span>
</td>
<td class="nump">22,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">51,411<span></span>
</td>
<td class="nump">34,663<span></span>
</td>
<td class="nump">50,162<span></span>
</td>
<td class="nump">22,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 3,963<span></span>
</td>
<td class="nump">$ 1,483<span></span>
</td>
<td class="nump">$ 7,852<span></span>
</td>
<td class="nump">$ 3,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ContingentStockConsiderationRemeasurementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Stock Consideration, Remeasurement Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ContingentStockConsiderationRemeasurementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674075077320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 19,924<span></span>
</td>
<td class="nump">$ 167,440<span></span>
</td>
<td class="nump">$ 40,474<span></span>
</td>
<td class="nump">$ 207,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (gains) losses from marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Losses on marketable securities reclassified into net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total Other Comprehensive Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total Comprehensive Loss</a></td>
<td class="nump">$ 19,924<span></span>
</td>
<td class="nump">$ 167,400<span></span>
</td>
<td class="nump">$ 40,474<span></span>
</td>
<td class="nump">$ 207,678<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674075762952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-the-market Offering</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th">
<div>Common stock </div>
<div>At-the-market Offering</div>
</th>
<th class="th">
<div>Common stock </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>At-the-market Offering</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 17,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (310,587)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,120,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE PERIOD:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">(207,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(207,673)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</a></td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">12,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification', window );">Deemed dividend to warrants holders due to warrant modifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment', window );">Classification of stock awards to derivative liability</a></td>
<td class="num">(975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,649<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,776,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of stock related to merger</a></td>
<td class="nump">196,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of stock related to merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,765,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">71,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(518,301)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,920,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">69,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350,861)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,375,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE PERIOD:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">(167,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167,440)<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">10,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment', window );">Classification of stock awards to derivative liability</a></td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,649<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,776,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of stock related to merger</a></td>
<td class="nump">104,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of stock related to merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,636,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">71,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(518,301)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,920,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 37,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(566,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Dec. 31, 2020</a></td>
<td class="nump">43,205,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,205,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE PERIOD:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (40,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</a></td>
<td class="nump">403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">4,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,304<span></span>
</td>
<td class="nump">$ 46,824<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,304<span></span>
</td>
<td class="nump">$ 46,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778,012<span></span>
</td>
<td class="nump">5,274,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 74,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(606,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Jun. 30, 2021</a></td>
<td class="nump">51,511,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,511,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 92,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">679,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(586,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,386,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE PERIOD:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">(19,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">1,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 74,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 681,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (606,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Jun. 30, 2021</a></td>
<td class="nump">51,511,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,511,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from modification of warrants that is deemed dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the fair value of the modified award over the fair value of the award immediately before the modification pertaining grantees not employed or providing services after the modification and reclassified from additional paid-in capital to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674067816328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 3,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_AtTheMarketOfferingMember', window );">At-the-market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vyne_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vyne_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674074995720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="nump">$ 40,474<span></span>
</td>
<td class="nump">$ 207,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and in-process research &amp; development impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ContingentStockConsiderationRemeasurementGainLoss', window );">Contingent Stock Right Remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Changes in marketable securities and bank deposits, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits', window );">Changes in accrued liability for employee severance benefits, net of retirement fund profit</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,343<span></span>
</td>
<td class="nump">12,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash finance income, net</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of businesses acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in trade receivables, prepaid and other assets</a></td>
<td class="nump">4,266<span></span>
</td>
<td class="num">(9,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Decrease (increase) in other non-current assets</a></td>
<td class="nump">876<span></span>
</td>
<td class="num">(6,026)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="nump">3,259<span></span>
</td>
<td class="num">(10,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(875)<span></span>
</td>
<td class="num">(4,445)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(28,808)<span></span>
</td>
<td class="num">(88,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ProceedsFromBusinessMerger', window );">Cash acquired through merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale and maturity of marketable securities</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">48,577<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">87,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds related to issuance of common shares through offerings, net of issuance costs</a></td>
<td class="nump">73,127<span></span>
</td>
<td class="nump">53,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds related to issuance of stock for stock-based compensation arrangements, net</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">73,374<span></span>
</td>
<td class="nump">53,746<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">45,593<span></span>
</td>
<td class="nump">52,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of the period</a></td>
<td class="nump">58,418<span></span>
</td>
<td class="nump">44,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the period</a></td>
<td class="nump">104,011<span></span>
</td>
<td class="nump">97,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">103,406<span></span>
</td>
<td class="nump">96,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in statement of cash flows</a></td>
<td class="nump">104,011<span></span>
</td>
<td class="nump">97,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplementary information on investing and financing activities not involving cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of shares under employee stock purchase plan</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Additions to operating lease right of use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Additions to operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_InterestReceived', window );">Interest received</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,936<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">117,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Less liabilities assumed</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net acquired (See &#8220;Note 3- Business combination&#8221;)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">111,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_NonCashAcquisitionOfBusinessCashAcquired', window );">Less cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired', window );">Merger net of cash acquired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 72,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ContingentStockConsiderationRemeasurementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Stock Consideration, Remeasurement Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ContingentStockConsiderationRemeasurementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash increase (decrease) in employee severance benefit liability net of profit from retirement fund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_InterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_InterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_NonCashAcquisitionOfBusinessCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as part of a non-cash business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_NonCashAcquisitionOfBusinessCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net assets acquired in non-cash acquisition, net of cash acquired included in the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ProceedsFromBusinessMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from business merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ProceedsFromBusinessMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674069653720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text">NATURE OF OPERATIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VYNE Therapeutics Inc. ("VYNE" or the "Company") is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory diseases of high unmet medical need. The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as&#160;one&#160;business segment. The Company currently has two commercial products, AMZEEQ&#174; (minocycline) topical foam, 4%, and ZILXI&#174; (minocycline) topical foam, 1.5%. As discussed below, the Company has initiated a process to explore a possible sale or license of its topical minocycline franchise. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Business Review</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2021, the Company conducted a review of its commercial and research and development portfolio to determine how to optimally deploy capital and drive shareholder value. During the course of this review, the Company carefully considered the revenues received from the commercialization of AMZEEQ and ZILXI and the associated costs to drive those revenues, the protracted negative impact of the COVID-19 pandemic over the past 18 months during the commercial launches of both AMZEEQ and ZILXI, the current payor landscape, as well as the costs to develop each of its pipeline products. During this process, the Company evaluated several strategic options including the acquisition of marketed assets, out-licensing its approved products outside of the United States, and possible partnering or co-development relationships with interested parties. Following its review, the Company has determined to initiate a process to explore a possible sale or license of its topical minocycline franchise, including AMZEEQ, ZILXI, FCD105 (the Company&#8217;s Phase 3 proprietary novel topical combination foam formulation of minocycline and adapalene for the treatment of moderate-to-severe acne vulgaris) and the underlying Molecule Stabilizing Technology platform. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By leveraging its drug development and clinical development capabilities and strong network of discovery and preclinical science partners, the Company will transition its strategic focus to develop therapies for the treatment of immuno-inflammatory diseases of high unmet medical need. The Company expects to continue to invest in FMX114 for the treatment of mild to moderate atopic dermatitis and anticipates the first patient in its Phase 2a proof-of-concept study will be enrolled in the third quarter of 2021. The Company expects results from this study by the end of 2021. In addition, on August 12, 2021, the Company announced a transaction with In4Derm Limited, a company incorporated and registered in Scotland (&#8220;In4Derm&#8221;). In4Derm is a spin-out of the University of Dundee&#8217;s School of Life Sciences which has discovered and is developing proprietary Bromodomain and Extra-Terminal Domain Inhibitors (&#8220;BETi&#8221;) for the treatment of immunology and oncology conditions. On April 30, 2021, the parties entered into an Evaluation and Option Agreement (the &#8220;Option Agreement&#8221;) pursuant to which In4Derm granted the Company an exclusive option to obtain exclusive worldwide rights to research, develop and commercialize products containing In4Derm&#8217;s BETi compounds, which are new chemical entities, in both topical (the &#8220;Topical BETi Option&#8221;) and oral (the &#8220;Oral BETi Option&#8221;) treatments in all fields for any disease, disorder or condition in humans. On August 6, 2021, the Company exercised the Topical BETi Option and the parties entered into a License Agreement granting the Company a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of In4Derm&#8217;s BETi compounds identified to be suitable for topical administration in all fields. The Company paid a $1.0&#160;million cash payment to In4Derm upon the execution of the Option Agreement and $0.5 million in connection with the exercise of the Topical BETi Option. Pursuant to the License Agreement, the Company has agreed to make cash payments to In4Derm upon the achievement of specified clinical development and regulatory approval milestones with respect to each licensed topical product in the U.S. of up to $15.75&#160;million for all indications. In addition, the Company currently expects to exercise the Oral BETi Option following the selection of a lead candidate for the program. Upon exercise of the exclusive Oral BETi Option, the parties will sign a license agreement (the &#8220;Oral License Agreement&#8221;), and the Company will be required to pay In4Derm a $4.0&#160;million cash payment. The Oral License Agreement will include cash payments of up to $43.75 million payable to In4Derm upon the achievement of specified clinical development and regulatory approval milestones with respect to each licensed oral product in the U.S. for all indications. The license agreements also provide for tiered royalty payments of up to 10% of net annual sales across licensed BETi products by the Company. In4Derm is entitled to additional milestones upon the achievement of regulatory approvals in certain jurisdictions outside the U.S. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial BETi candidates that the Company plans to develop are VYN201 and VYN202. VYN201 is a pan-bromodomain or pan-BD BET inhibitor.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is a first-in-class &#8220;soft&#8221; pan-BD BET inhibitor that is designed to mitigate systemic drug exposure and will be developed for topical applications. The Company intends to progress VYN201 into rare, neutrophilic, dermatological </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indications where there is significant unmet need due to a lack of indicated treatment options. The Company plans to enter this program into the clinic in 2022 after the prerequisite non-clinical safety assessments have been completed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second candidate, VYN202, is an orally-delivered, first-in-class BET inhibitor that is highly selective for Bromodomain 2 ("BD2"). Recent research has suggested that the majority of pro-inflammatory signaling via BET protein action is via interactions with BD2. By selectively inhibiting BD2, the Company believes VYN202 could have a more targeted anti-inflammatory effect with an improved benefit/risk profile. The Company views VYN202 as having significant potential as a novel, oral treatment for major immuno-inflammatory indications. Following the exercise of the Oral BETi Option, the Company intends to commence a IND-enabling non-clinical safety program for VYN202 and enter the clinic in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company transitions from a commercial organization to one focused on research and development, the Company intends to streamline operations by eliminating the vast majority of planned expenditures supporting its commercial operations. Furthermore, the Company intends to reduce its workforce by terminating approximately 70 employees, which the Company expects to be completed by December 31, 2021. The Company expects to incur a one-time charge in the range of approximately $1.5 million to $2.0&#160;million, excluding non-cash charges, in connection with this restructuring plan, consisting primarily of employee termination costs, including severance and other benefits. This charge is expected to be incurred during the quarter ending September 30, 2021 with related cash payments expected to be substantially paid out by December 31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Merger</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2019, Menlo, Foamix Pharmaceuticals Ltd. (&#8220;Foamix&#8221;) and Giants Merger Subsidiary Ltd. (&#8220;Merger Sub&#8221;), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the &#8220;Merger Agreement&#8221;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the &#8220;Merger&#8221;) on March 9, 2020 (the &#8220;Effective Date&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#8217;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See &#8220;Note 3 &#8211; Business Combination&#8221; for more information on the Merger.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse stock split and recasting of per-share amounts</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2021, the Company's Board of Directors approved a one-for-four reverse stock split of its outstanding shares of common stock.  The reverse stock split was effected on February 12, 2021, at 5:00 p.m. Eastern time.  At the effective time, every four issued and outstanding shares of the Company's common stock were converted into one share of common stock.  No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each stockholder holding fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company's transfer agent in an amount equal to such stockholder's respective pro rata shares of the total net proceeds from the Company's transfer agent sale of all fractional shares at the then-prevailing prices on the open market.  In connection with the reverse stock split, the number of authorized shares of the Company's common stock was also reduced on a one-for-four basis, from 300 million shares to 75 million shares.  The par value of each share of common stock remained unchanged.  A proportionate adjustment was also made to the maximum number of shares issuable under the Company's 2019 Equity Incentive Plan, 2018 Omnibus Incentive Plan and 2019 Employee Share Purchase Plan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise noted, all common shares and per share amounts contained in the unaudited interim condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Topical Minocycline Franchise</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company launched AMZEEQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the U.S. Food and Drug Administration (the "FDA") approved ZILXI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of inflammatory lesions of rosacea in adults.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZILXI became available in pharmacies nationwide in October 2020. AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA for any condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMZEEQ and ZILXI utilize the Company&#8217;s proprietary Molecule Stabilizing Technology (MST)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that is also being used in the development of the Company&#8217;s product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, the Company announced positive results from a Phase II clinical trial evaluating </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held an end-of-Phase II meeting with the FDA in the fourth quarter of 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Serlopitant </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company was developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, or&#160;NK1-R, given as a once-daily, oral tablet, for the treatment of pruritus, or itch, associated with various conditions including prurigo nodularis, or PN. On April 6, 2020, the Company announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN, studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. The Company does not currently intend to further pursue the development of serlopitant. As a result, in the second quarter of 2020, the Company recorded a full impairment charge related to the IPR&amp;D and Goodwill assets in its unaudited condensed consolidated statement of operations and comprehensive loss. See "Note 3 - Business Combination" for more information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched AMZEEQ in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company also launched ZILXI in the United States in October 2020 and commenced generating revenues in the fourth quarter of 2020. The Company&#8217;s activities prior to the commercial launches of AMZEEQ and ZILXI had primarily consisted of raising capital, developing product candidates, and performing research and development activities. Since inception, the Company has incurred recurring losses and negative cash flows from operations. For the six months ended June&#160;30, 2021, the Company incurred a net loss of $40.5 million and used&#160;$28.8 million of cash in operations. As of June&#160;30, 2021, the Company had cash, cash equivalents, restricted cash and investments of $104.0 million and an accumulated deficit of $606.7 million.  The Company's outstanding debt under its Amended and Restated Credit Agreement at June 30, 2021 was $35.0&#160;million. On August 11, 2021, the Company prepaid the entirety of its outstanding indebtedness, including a prepayment premium and accrued but unpaid interest, for a total amount of approximately $36.5&#160;million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. In addition, the commercial launches of both AMZEEQ and ZILXI have been negatively impacted by unfavorable payor decisions in March 2021 on product pricing. These conditions have impaired the Company's ability to generate revenue consistent with internal forecasts, which has had a negative impact on its financial condition and liquidity. The Company and its lenders discussed revenue expected to be generated for the trailing twelve month period ended June 30, 2021, the revenue targets included in the Amended and Restated Credit Agreement and the Company&#8217;s strategic transition discussed above. Following such discussions, the Company determined to prepay its outstanding indebtedness in addition to a 4% prepayment fee and accrued but unpaid interest in the total amount of approximately $36.5&#160;million on August&#160;11, 2021. Following the prepayment, the Amended and Restated Credit Agreement has been terminated and the security interests thereunder will be terminated. As a result of the above, the Company determined that its projected cash flows from operations, combined with its cash balance after the debt prepayment, would not provide sufficient resources to fund its existing operations, for at least the next twelve months from the issuance of these financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the Company completed a strategic review of its business and has determined to initiate a process to explore a sale or license of its minocycline franchise, including AMZEEQ, ZILXI, FCD105 and the underlying MST platform. The Company will refocus its resources on its immuno-inflammatory pipeline and intends to support the FMX114 and the BETi development programs. Research and development activities for these programs, including preclinical and clinical testing of the Company&#8217;s drug candidates, will require significant additional financing. The future viability of the Company is dependent on its ability to successfully pivot to its research and development business strategy and develop commercially viable drug candidates and raise additional capital to finance its operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is contingent on its ability to sell or license its minocycline franchise, develop future commercially viable products and/or to raise sufficient working capital through either debt or equity financing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance the Company will be able to achieve these objectives under acceptable terms or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-15, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that its unaudited condensed consolidated financial statements are issued. The accompanying condensed </span></div>consolidated financial statements have been prepared assuming that the Company will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company&#8217;s ability to continue as a going concern is expected to be impacted by the outcome of the plans outlined above, including the successful sale or license of its minocycline franchise, positive results from clinical trials for FMX114, and the successful development and positive results from clinical trials for the BETi programs. Based on current plans and assumptions, the Company believes that absent sufficient proceeds received from a sale or license of the minocycline franchise, business development transactions or financing transactions, which are all beyond its control, it will not have sufficient cash and cash equivalents to fund its operations beyond one year from the issuance of these financial statements. Accordingly, the Company will, over the course of the next twelve months, require significant additional financing to continue its operations. Each of these factors are subject to uncertainty, and therefore, raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Failure to successfully complete a sale or license of the minocycline franchise, develop the noted assets, and receive additional financing will require the Company to delay, scale back or otherwise modify its business and its research and development activities and other operations. The accompanying financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071172264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. In the opinion of management, the Company has made&#160;all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company&#8217;s condensed consolidated financial position, results of operations, cash flow and statement of stockholders' equity for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.  Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC on March 4, 2021.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results expected for the year ending December&#160;31, 2021.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.94pt">Principles of Consolidation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.07pt">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition and liquidity will depend on future developments that are highly uncertain, subject to change and will continue to evolve with geographical re-openings, surges in cases, the development of new strains and the vaccination effort. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of  June&#160;30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2020, the Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.94pt">Business Acquisition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited interim condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet.&#160;Transaction costs are expensed as incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, the Company uses fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; The Company estimates fair value using an exit price approach, which requires, among other things, that Company determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following techniques:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach, which is based on the present value of a future stream of net cash flows.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Asset Impairment</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews all of its long-lived assets for impairment indicators throughout the year. Impairment testing is performed for indefinite-lived intangible assets annually (or sooner if warranted) and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.07pt">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenue transactions under FASB ASC Topic 606,&#160;Revenue from Contracts with Customers. In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers include a limited number of national and select regional wholesalers (the &#8220;distributors&#8221;) and certain independent and specialty pharmacies (together, the &#8220;customers&#8221;). These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when customers obtain control of the Company&#8217;s products, which occurs at a point in time, typically upon delivery of product to the customers. The Company evaluates the creditworthiness of its customers to determine whether it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur. The Company does not assess whether a contract has a significant financing component if the expectation is such that the period between the transfer of the promised goods to the customer and the receipt of payment will be less than one year. Standard credit terms do not exceed 75 days. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that would have been recognized is one year or less or the amount is immaterial. Shipping and handling costs related to the Company&#8217;s product sales are included in selling, general and administrative expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues through&#160;June&#160;30, 2021&#160;were primarily generated through sales of AMZEEQ, which was approved by the FDA in October 2019 and was commercially launched in the United States in January 2020, and ZILXI, which was approved by the FDA in May 2020 and was commercially launched in the United States in October 2020. Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, copay program coupons, chargebacks, estimated returns and other incentives. These reserves are classified as either reductions of accounts receivable or as current liabilities. The estimates of reserves established for variable consideration reflect current contractual and statutory requirements, known market events and trends, industry data and forecasted customer mix. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net product revenues only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from these estimates. If actual results vary, estimates may be adjusted in the period such change in estimate becomes known, which could have an impact on earnings in the period of adjustment. See &#8220;Note 4 &#8211; Revenue Recognition&#8221; for more information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for our minocycline products and product candidate, if approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commercial use.  The Company received an upfront cash payment of $10.0 million in 2020 ($6.0 million received in the three months ended June 30, 2020 and $4.0 million received in the three months ended September 30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The Company will also receive royalties on net sales of any licensed products.  The license is determined to be a distinct performance obligation of the arrangement, therefore the Company recognized the revenues from the upfront license fee when the license was transferred to the licensee and the licensee was able to use and benefit from the license.  See "Note 4 - Revenue Recognition" for more information.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.17pt">Allowance for credit losses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be&#160;collected.&#160;Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were not material for the three and six months ended June&#160;30, 2021 and June&#160;30, 2020.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Derivative instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all derivative instruments as either assets or liabilities in the unaudited condensed consolidated balance sheet at their respective fair values. All gains and losses associated with derivatives are reported as other expense (income), net in the accompanying condensed consolidated statements of operations.  As of June&#160;30, 2021 and June&#160;30, 2020, the Company had no derivative instruments.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">h.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.94pt">Fair value measurement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:&#160;&#160;&#160;&#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:&#160;&#160;&#160;&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.73pt">Loss per share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury share method when dilutive.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of the weighted-average number of common stock outstanding during the period in which the reverse merger occurs was based on:</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The number of common stock outstanding from the beginning of that period to the merge date was computed on the basis of the weighted-average number of common stock of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt">The number of common outstanding common stock outstanding from the merge date to the end of that period was the actual number of common stock of the legal acquirer (the accounting acquiree) outstanding during that period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following average stock options, restricted stock units (&#8220;RSUs&#8221;), warrants and incremental shares to be issued under the employee stock purchase plan (&#8220;ESPP&#8221;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):</span></div><div style="margin-top:5pt;padding-right:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended June 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options, RSUs and shares under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,378,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,365,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,020,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, the CSR was excluded from the calculation of the 2020 diluted net loss per share because its effect would have been anti-dilutive for the periods presented. On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective exchange ratio (the "Exchange Ratio") in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020. See "Note 3 - Business Combination" for more information.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">j.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.17pt">Newly issued and recently adopted accounting pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Guidance Issued:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes," which clarifies and simplifies certain aspects of the accounting for income taxes.  The standard is effective for years beginning after December 15, 2020, and interim periods </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beginning after December 15, 2020.  This guidance became effective during the first quarter of 2021.  The adoption of the new standard did not have a material impact to the Company's consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update No. 2020-4, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" (ASU 2020-4), which provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying generally accepted accounting principles to contracts, hedging relationships, and other transactions impacted by reference rate reform. The provisions of ASU 2020-4 apply only to those transactions that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-4 are optional and are effective from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-4 on its consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update No. 2016-13,&#160;&#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;&#160;(ASU 2016-13), which requires companies to measure credit losses of financial instruments, including customer accounts receivable, utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. As a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023 or at such time where it is no longer a smaller reporting company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674069638200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATION</a></td>
<td class="text">BUSINESS COMBINATION<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2019, Menlo entered into the Merger Agreement with Foamix, and Merger Sub, a direct and wholly-owned Israeli subsidiary of Menlo. On March 9, 2020, the Merger was completed and Foamix is now a wholly-owned subsidiary of the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Effective Date, each ordinary share of Foamix was exchanged for 0.5924 shares of common stock of Menlo. In addition, on the Effective Date, Foamix shareholders received one contingent stock right (a &#8220;CSR&#8221;) for each Foamix ordinary share held by them. The CSRs were issued pursuant to the Contingent Stock Rights Agreement (the &#8220;CSR Agreement&#8221;), dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#8217;s phase III clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of prurigo nodularis (the &#8220;Phase III PN Trials&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 additional shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of 74,544,413 additional shares of Menlo common stock underlying the CSRs, adjusted retrospectively to 18,636,103 shares of common stock upon the reverse stock split effective February&#160;12, 2021.  Following the conversion of the CSRs, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders owned approximately 82% and 18% of post-Merger Menlo, respectively, each calculated on a fully diluted basis. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under U.S. GAAP and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#8217;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under reverse acquisition accounting, the U.S. dollar amount for common stock in the financial statements is based on the value and number of shares issued by Menlo (reflecting the legal structure of Menlo as the legal acquirer) on the Merger date plus subsequent shares issued by the Company. The amounts in additional paid-in capital represent that of Foamix and include the fair value of shares deemed for accounting purposes to have been issued by Foamix on the merger date and the fair value of the Menlo equity awards included in the purchase price calculation. The Foamix additional paid-in capital was also adjusted for the difference between the number of common stock and the historical number of shares of Foamix&#8217;s ordinary shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2020, the Company incurred transaction costs of approximately $11.7 million, which are recorded in the condensed consolidated statements of operations and comprehensive income. This amount includes $8.1 million of severance benefits for employees terminated after the Effective Date. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deemed (for accounting purposes only) conversion of Menlo equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration*</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $19.6 million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders&#8217; relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $111.4 million, as shown in the purchase price allocation table below.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Foamix&#8217;s closing share price of $2.99 as of March 9, 2020, the Merger Consideration under reverse acquisition accounting was approximately $131.1 million, consisting of $123.8 million for the deemed (for accounting purposes only) issuance of 41.4 million Foamix shares assuming that no upwards adjustment was made to the Exchange Ratio relating to the CSR, and $7.3 million for the fair value of Menlo equity awards deemed (for accounting purposes only) to be converted into Foamix equity awards. The converted stock options represent the fair value of such options attributable to service prior to the Merger date using the Foamix closing share price of $2.99 as of March 9, 2020 as an input to the Black Scholes valuation model to determine the fair value of the options.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 9, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,827)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,827)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price*</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#8217;s outstanding shares being owned by Menlo stockholders following the Merger.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually. None of the Goodwill recognized is expected to be deductible for income tax purposes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 9, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: fair value of net assets acquired, including other identifiable intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to further pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $4.5 million related to goodwill in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020.  There were no impairment charges in the three and six months ended June&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Process Research and Development (&#8220;IPR&amp;D")</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D recognized relates to Menlo&#8217;s once</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:84.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired indefinite life intangible assets*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of identified intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Represents acquired IPR&amp;D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D has been estimated utilizing a multi-period excess earnings method under the income approach, which reflects the present value of the projected cash flows that are expected to be generated, less charges representing the contribution of other assets to those cash flows that use projected cash flows with and without the intangible asset in place.&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to further pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $49.8 million related to the IPR&amp;D asset in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020.  There were no impairment charges in the three and six months ended June&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CSR</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CSR was issued pursuant to the CSR Agreement, dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#8217;s Phase III PN Trials. The Company recognized a liability of $19.6 million in the unaudited condensed consolidated balance sheet as of March 9, 2020. The liability was measured at fair value and categorized as level 3 as of the acquisition date in accordance with ASC 805-31-25-5 and subsequently at each reporting date thereafter. The fair value of the CSR was estimated as the incremental value that Foamix would be able to achieve on a probability weighted basis assuming three different potential probabilities of the following scenarios: (a) serlopitant significance was achieved in both Phase III PN Trials (b) serlopitant significance was achieved in only one Phase III PN Trial and (c) serlopitant significance was not achieved or was not determined on or before May 31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 additional shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of 74,544,413 additional shares of Menlo common stock underlying the CSRs, adjusted retrospectively to 18,636,103 shares of common stock upon the reverse stock split effective February&#160;12, 2021.  Following the conversion of the CSRs, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders own approximately 82% and 18% of post-Merger Menlo, respectively, each calculated on a fully diluted basis.  The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020 and increased the awards available for grant under the Company's equity plan.    </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration associated with the CSR was recognized and measured at fair value as of the acquisition date in accordance with ASC 805-30-25-5. An acquirer's obligation to pay contingent consideration should be classified as a liability or </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity in accordance with ASC 480, Distinguishing Liabilities from Equity, ASC 815 Derivatives and Hedging, and other applicable U.S. GAAP.&#160;The contingent consideration associated with the CSR was initially measured at fair value and will subsequently be measured at fair value at each reporting date. The CSR was classified as a liability, as it is settled by issuing a variable number of the Company's common stock.  On April 6, 2020, the Company recorded $84.7 million of expense in its unaudited condensed consolidated statements of operations and comprehensive loss to remeasure the CSR liability in its consolidated balance sheet to its fair value of $104.4 million (calculated based on 74,544,413 shares issued, adjusted retrospectively to 18,636,103 shares of common stock upon the reverse stock split effective February&#160;12, 2021, and a share price of $1.40 on April 6, 2020) and then settled in connection with the issuance of shares. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual Menlo net loss included in the Company&#8217;s condensed consolidated statements of operations and comprehensive income for the three and six months ended June&#160;30, 2020 (for the period from the March 9, 2020, the Effective Date, through June&#160;30, 2020, which are not indicative of the results to be expected for a full year) and the supplemental unaudited pro forma revenue and net loss of the combined entity had the acquisition been completed on January 1, 2019 are as follows:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June&#160;30, 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:59.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss attributable to Menlo</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended<br/>June 30, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share - basic and diluted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of stock based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Adjustments</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,130)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited pro forma condensed consolidated financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the first day of the earliest period presented, or of future results of the consolidated entities. The unaudited pro forma condensed consolidated financial information does not reflect any operating efficiencies and cost savings that may be realized from the integration of the Merger.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071200312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues for the three and six months ended&#160;June&#160;30, 2021&#160;were primarily generated from sales of AMZEEQ&#160;which was commercially launched in the United States in January 2020 and ZILXI which became available in pharmacies nationwide on October 1, 2020.  The Company&#8217;s customers include a limited number of national and select regional distributors and certain independent and specialty pharmacies, together (the "customers").  The distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when customers obtain </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">control of the Company&#8217;s products, which occurs at a point in time, typically upon delivery of product to the customers. For the three months ended June&#160;30, 2021, there were three major customers that each accounted for more than 10% of total product revenues and, as a group, represented 56% of total product revenues.  For the six months ended June&#160;30, 2021, there were four major customers that each accounted for more than 10% of total product revenues and, as a group, represented 70% of total product revenues.  For the three months ended June&#160;30, 2020, there were three major customers that each accounted for more than 10% of total product revenues and as a group, represented 100% of total product revenues.  For the six months ended June&#160;30, 2020, there were three major customers that each accounted for more than 10% of total product revenues and as a group, represented 99% of total product revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales Provisions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, chargebacks, estimated returns and other incentives, described below. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company calculates its net product revenue based on the wholesale acquisition cost that the Company charges its customers less provisions for (i) trade discounts and allowances, such as distributor fees and discounts for prompt payment, (ii) estimated rebates to third-party payers, patient co-pay assistance programs, chargebacks and other discount programs and (iii) reserves for expected product returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for distribution fees, trade discounts and chargebacks are reflected as a reduction to trade receivables, net on the condensed consolidated balance sheet. All other provisions, including rebates, other discounts and return provisions are reflected as a liability within accrued expenses on the condensed consolidated balance sheet. Provisions for revenue reserves described below reduced product revenues by&#160;$16.2 million and $5.9 million for the three months ended June&#160;30, 2021 and June&#160;30, 2020, respectively.  Provisions for revenue reserves described below reduced product revenues by&#160;$31.8 million and $14.1 million for the six months ended June&#160;30, 2021 and June&#160;30, 2020, respectively. The revenue reserve accrual at June&#160;30, 2021 and December&#160;31, 2020 was $7.6 million and $5.8 million, respectively, reflected in accrued expense in the consolidated balance sheet.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Distribution Fees and Trade Discounts and Allowances</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company pays fees for distribution services and for certain data that distributors provide to the Company and generally provides discounts on sales to its distributors for prompt payment. These fees and discounts are contractual in nature and the Company expects its distributors to earn these fees and discounts, and accordingly deducts the full amount of these fees and discounts from its gross product revenues at the time such revenues are recognized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Rebates, Chargebacks and Other Discounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under managed-care and governmental pricing programs in the U.S. are subject to rebates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share. Chargebacks relate to contractual agreements to sell products to government agencies and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these government agencies or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers. The Company estimates the rebates and chargebacks it expects to be obligated to provide and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates the rebates and chargebacks that it expects to be obligated to provide based upon (i) the Company's current contracts and negotiations, (ii) estimates regarding the payer mix&#160;based on third-party data and utilization, (iii) inventory held by distributors and (iv) estimates of inventory held at the retail channel. Other discounts include the Company&#8217;s co-pay assistance coupon programs for commercially-insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to pay associated with product that has been recognized as revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return products within a specified period of time before and after its expiration date.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company estimates the amount of product&#160;that will be returned and deducts these estimated amounts from its gross revenue at the time the revenue is recognized. T</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he information utilized to estimate the returns provision includes: (i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> historical industry information regarding rates for comparable pharmaceutical products and product portfolios</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demand</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for products and (iv) remaining shelf lives of products at the date of sale. The Company estimates that approximately 2% to 3% of product will be returned.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commercial use.  Outside of the license transferred, the Company does not have any additional performance obligations under the arrangement.  In exchange for the license, the Company received an upfront cash payment of $10.0 million in 2020 ($6.0 million received in the three months ended June 30, 2020 and $4.0 million received in the three months ended September 30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The license is considered functional IP as the licensee is able to use and benefit from the license without the continued involvement of the Company.  There was no license revenue in the three months ended June&#160;30, 2021.  The Company recorded $10.0 million of license revenue in the three and six months ended June&#160;30, 2020.  The Company will also receive royalties on net sales of any licensed products, such royalties will be recognized in the period the sales or usage occurs under the royalties sales-and usage based exception.  The Company has not recorded revenue related to the $1.0 million payment due upon receipt of marketing approval for the licensed product as such amount is constrained under the variable consideration guidance under ASC 606, Revenue from Contracts with Customers.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets and Contract Liabilities&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets (unbilled receivables) related to product sales as of&#160;June&#160;30, 2021 and December&#160;31, 2020, as customer invoicing generally occurs before or at the time of revenue recognition.  The Company did not have any contract assets (unbilled receivables) related to its license revenues as of June&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract liabilities as of&#160;June&#160;30, 2021 and December&#160;31, 2020, as the Company did not receive payments in advance of fulfilling its performance obligations to its customers.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Commissions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Component</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.&#160;Standard credit terms do not exceed 75 days.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to royalty payments with respect to sales of a product developed by a customer in collaboration with the Company. Revenues in the amount of $0.3 million and $0.5 million were recorded during the three and six months ended June&#160;30, 2021, respectively.  Revenues in the amount of $0.2 million were recorded during the three and six months ended June&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674069714584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text">FAIR VALUE MEASUREMENT<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s assets and liabilities that are measured at fair value as of December&#160;31, 2020, are classified in the table below in one of the three categories described in "Note 2 - Fair value measurement" above:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sold its marketable securities during the six months ended June 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071012520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text">MARKETABLE SECURITIESMarketable securities as of December&#160;31, 2020 consist mainly of mutual funds securities. The debt securities are classified as available-for-sale and are recorded at fair value. Changes in fair value, net of taxes (if applicable), are reflected in other comprehensive loss. Realized gains and losses on sales of the securities, as well as premium or discount amortization, are included in the condensed consolidated statement of operations as other expense (income), net.<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair value are measured at fair value. The changes in the fair value of equity investments are recognized through other expense (income), net in the condensed consolidated statements of operations.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s marketable securities:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israeli mutual funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020 there were no available-for-sale debt securities.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered factors regarding other than temporary impaired securities and determined that there are no securities with impairment that is other than temporary as of June&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021 and June&#160;30, 2020 the Company received aggregate proceeds of $1.0 million and $36.4 million, respectively, upon sale and maturity of marketable securities.</span></div>As of June&#160;30, 2021 and December&#160;31, 2020, there were no restricted marketable securities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071155912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. The Company commenced capitalizing inventory for AMZEEQ and ZILXI upon FDA approval in October 2019 and May 2020, respectively. The Company periodically reviews its inventory levels and, if necessary, writes down inventory that is expected to expire prior to being sold, inventory in excess of expected sales requirements and inventory that fails to meet commercial sale specifications, with a corresponding charge to cost of goods sold. There were no inventory write-downs during the three and six months ended June&#160;30, 2021 and June&#160;30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s inventory:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,279&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,404&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071249896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2019, Foamix entered into a Credit Agreement (the "Credit Agreement") to secure up to $50&#160;million from two lenders, one of which is a significant stockholder of the Company and is considered a related party, and a Securities Purchase Agreement with one of the lenders for gross proceeds of approximately&#160;$14 million, before deducting offering expenses (see &#8220;Note 9- Share Capital&#8221; for more information). On March 9, 2020, the Company entered into an Amended and Restated Credit Agreement and Guaranty (as further amended on August 5, 2020, the &#8220;Amended and Restated Credit Agreement&#8221;), whereby the Company has guaranteed the indebtedness obligations of the borrower and granted a first priority security interest in substantially all of our assets for the benefit of the lenders. As of June&#160;30, 2021 and December&#160;31, 2020, $35.0&#160;million was drawn under the Amended and Restated Credit Agreement.  The Company did not incur the remaining $15.0&#160;million under the Amended and Restated Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term loans available under the Amended and Restated Credit Agreement were comprised as follows: (a) $15 million that was funded on July 29, 2019 (the &#8220;Tranche 1 Loan&#8221;), (b) $20 million that was funded on December 17, 2019 (the &#8220;Tranche 2 Loan&#8221;) and (c) up to $15 million that was available prior to September 30, 2020 (the &#8220;Tranche 3 Loan&#8221;). The Tranche 2 Loan was borrowed following the FDA&#8217;s approval of the NDA for AMZEEQ and listing of AMZEEQ in the FDA&#8217;s &#8220;Orange Book,&#8221; in addition to maintaining arrangements with a third party for the commercial supply and manufacture of AMZEEQ. The Company did not incur the Tranche 3 Loan. Interest on the loans was equal to the sum of (A) 8.25% (subject to increase in accordance with the terms of the Amended and Restated Credit Agreement) plus (B) the greater of (x) the one-month LIBOR as </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the second business day immediately preceding the first day of the calendar month or the date of borrowing (if such loan is not outstanding as of the first day of the calendar month), as applicable, and (y) 2.75%. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loans were scheduled to mature on July&#160;29, 2024. However, the Company and its lenders discussed the revenue expected to be generated for the trailing twelve month period ended June&#160;30, 2021, the revenue targets included in the Amended and Restated Credit Agreement and the Company&#8217;s strategic transition discussed above. Following such discussions, the Company determined to prepay its outstanding indebtedness in addition to a 4% prepayment fee and accrued but unpaid interest in the total amount of approximately $36.5&#160;million on August&#160;11, 2021. Following the prepayment, the Amended and Restated Credit Agreement has been terminated and the security interests thereunder will be terminated. The Company reclassified the outstanding indebtedness as a current liability based on the conditions existing as of June&#160;30, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on July 29, 2019, the lenders under the Credit Agreement were issued warrants to purchase up to an aggregate of 1,100,000 of Foamix ordinary shares, at an exercise price of $2.09 per share (the &#8220;Warrants&#8221;), which represented the five-day volume weighted average price of the Foamix ordinary shares as of the trading day immediately prior to the issuance of the Warrants. In connection with the completion of the Merger, the exchange ratio was applied to the Warrants such that they became exercisable for 651,640 shares of the Company&#8217;s common stock, and the exercise price was adjusted to $3.53. Following the Phase 3 PN Trial results, the Warrants were further adjusted for the CSR and reverse stock split and they are currently exercisable for 495,165 shares of our common stock with an exercise price of $4.64 per share. Payment of the exercise price will be made, at the option of the holder, either in cash or as a reduction of common stock issuable upon exercise of the Warrant, with an aggregate fair value equal to the aggregate exercise price ("cashless exercise"), or any combination of the foregoing.&#160;The Warrants are exercisable pursuant to the terms, and subject to the conditions, thereof and expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants' expiration date, if in the money. The Warrants issued were classified as equity in accordance with ASC 815-40. Proceeds received under the Tranche 1 Loan were allocated to the Warrants and the Tranche 1 Loan on a relative fair value basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred offering expenses of $1.1 million in connection with transactions contemplated by the Credit Agreement and the Securities Purchase Agreement, which were allocated to the Warrants, shares and debt consistently with the allocation of proceeds. The Company incurred additional expenses in the amount of $0.3 million from the borrowing of Tranche 2 Loan, allocated only to the debt.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liabilities. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts allocated to the debt, net of issuance cost, are subsequently recognized at amortized cost using the effective interest method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt as of June&#160;30, 2021 was $36.9 million and is categorized as Level 3. The valuation was performed by applying the income approach, under which the contractual present value method was used. The estimation of risk adjusted discount curve was based on public information reported in the financial statements of publicly traded venture lending companies.</span></div>During the three months ended June&#160;30, 2021 and June&#160;30, 2020, the Company recorded interest expense of $1.0 million and discount cost of $0.1 million. During the six months ended June&#160;30, 2021 and June&#160;30, 2020, the Company recorded interest expense of $1.9 million and discount cost of $0.2 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071039896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
<td class="text">SHARE CAPITAL<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company's Certificate of Incorporation, as amended, authorizes the Company to issue 20,000,000 shares of preferred stock, par value $0.0001 per share.  There were no shares of preferred stock issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of preferred stock may be issued from time to time in one or more series.  The voting powers (if any), preferences and relative, participating, optional or other special rights, and the qualifications, limitations and restrictions of any series of preferred stock will be set forth in a Certificate of Designation filed pursuant to the Delaware General Corporation Law, as determined by the Company's Board of Directors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock authorized under the Company's Amended and Restated Certificate of Incorporation was proportionately reduced in connection with the Company's one-for-four reverse stock split in February 2021. On July 19, </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, the Company held its annual meeting of stockholders (the "Annual Meeting"). Following the approval by the holders of a majority of the outstanding shares of common stock at the Annual Meeting, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 75,000,000 to 150,000,000 shares, effective as of July 19, 2021. Accordingly, the Company is authorized to issue 150,000,000 shares of common stock, par value $0.0001 per share. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of preferred stock outstanding. The Company has never declared any dividends on common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuance of stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2019, the Company entered into a Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp; Co., or Cantor Fitzgerald, to sell shares of the Company's common stock, from time to time, with aggregate gross sales proceeds of up to $50.0 million through an at-the-market equity offering program under which Cantor Fitzgerald will act as our sales agent.  The issuance and sale of shares of common stock by us pursuant to the Sales Agreement are deemed an "at-the-market" offering under the Securities Act.  Cantor Fitzgerald is entitled to compensation for its services equal to up to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement.  From January 1, 2021 through January 25, 2021, the Company issued and sold 2,778,012 shares of common stock at a weighted average price per share of $9.76 pursuant to the Sales Agreement for $26.3 million in net proceeds. Effective as of January 25, 2021, the Company terminated the Sales Agreement and will not make any additional sales thereunder.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 26, 2021, the Company entered into a Securities Purchase Agreement with certain institutional and accredited investors for the sale of an aggregate of 5,274,261 shares of common stock of the Company, at a purchase price of $9.48 per share in a registered direct offering. The offering was completed on January 28, 2021 and the Company received approximately $46.8 million in net proceeds, after deducting placement agent fees and other offering expenses. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, the Company completed an underwritten public offering of 7,776,875 shares of common stock at a price to the public of $7.40 per share.  The net proceeds of the offering were approximately $53.6&#160;million, after deducting underwriting discounts and commissions and other offering expenses.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the completion of the merger, on March 9, 2020, the Company issued 36,550,335 shares to Foamix shareholders.  On April 6, 2020, pursuant to the terms of the CSR Agreement, the Company issued 74,544,413 shares to Foamix shareholders, adjusted retrospectively to 18,636,103 shares of common stock upon the reverse stock split effective February 12, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entering into the Credit Agreement on July 29, 2019, Foamix issued to the lenders Warrants to purchase up to an aggregate of 1,100,000 of its ordinary shares, later exchanged to Warrants to purchase up to 1,980,660 shares of Menlo&#8217;s common stock, adjusted retrospectively to 495,165 shares of common stock upon the reverse stock split effective February 12, 2021. Upon the closing of the Merger, each Warrant received one CSR as described in Note 3- Business Combinations.  The Warrants were exercisable immediately following the closing of the Credit Agreement, subject to the terms of the warrant, and are due to expire on July 29, 2026.  Any Warrants left outstanding will be cashless exercised on the Warrants&#8217; expiration date, if in the money. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange of Warrants from Foamix warrants to Menlo warrants and the additional CSR was accounted for as a modification, by analogy, from the modification&#8217;s guidance under ASC 260-10-S99-2. The Company assessed the significance of the modification of the Warrants by comparing the fair value of the Warrants immediately before and after the amendments. In its assessment, it also considered additional qualitative factors. The Company concluded that the change of terms was not significant. Therefore, the incremental fair value, in the amount of $41,000, of the modified Warrants over the original ones (as of modification date) was recognized in retained earnings as a deemed dividend to the Warrants holders in the six months ended June&#160;30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-based compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity incentive plans:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the Merger, the Company adopted Foamix&#8217;s 2019 Equity incentive plan (the &#8220;2019 Plan&#8221;). As of June&#160;30, 2021, 1,240,195 shares remain issuable under the 2019 Plan.  In addition, the Company adopted the 2018 Omnibus Incentive Plan (the "2018 Plan") in January 2018.  In January 2020, the number of shares reserved under the 2018 Plan automatically </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased by 750,000 shares of common stock pursuant to the terms thereof.  As of June&#160;30, 2021, 519,928 shares remain issuable under the 2018 Plan.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Share Purchase Plan:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the Merger, the Company adopted Foamix&#8217;s Employee Share Purchase Plan ("ESPP") pursuant to which qualified employees (as defined in the ESPP) may elect to purchase designated shares of the Company&#8217;s common stock at a price equal to&#160;85%&#160;of the lesser of the fair market value of the common stock at the beginning or end of each semi-annual share purchase period (&#8220;Purchase Period&#8221;). Employees are permitted to purchase the number of shares purchasable with up to 15% of the earnings paid (as such term is defined in the ESPP) to each of the participating employees during the Purchase Period, subject to certain limitations under Section 423 of the U.S. Internal Revenue&#160;Code.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, 2,261,108 shares remain available for grant under the ESPP.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, 42,989 shares were issued to employees pursuant to the ESPP. During the six months ended June&#160;30, 2020, 61,031 Foamix ordinary shares were purchased by Foamix employees pursuant to the ESPP prior to the Merger. Such shares were later exchanged for 36,155 shares of the Company's common stock and one CSR in the Merger, adjusted retrospectively to 9,038 shares of common stock and one CSR upon the reverse stock split effective February 12, 2021.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options and RSUs granted to employees and directors:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended June&#160;30, 2021 and 2020, the Company granted options and RSU as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award<br/>amount*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price<br/>range*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.02-$11.08</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year -4 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year -4 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award<br/>amount*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price<br/>range*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.80-$12.52</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year -4 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year -4 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* All amounts and exercise prices for pre-Merger grants are presented following the exchange to Menlo options and RSUs at the Exchange Ratio described in Note 3-Business Combination.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options and RSUs granted to employees and directors during the six months ended June&#160;30, 2021 and the six months ended June&#160;30, 2020 was $7.5 million and $11.4 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs granted is based on the share price on the grant date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.38%-69.12%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.44%-69.83%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5%-1.07%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.44%-1.26%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 years</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger, all outstanding options and RSUs granted by Foamix were exchanged for stock options and RSUs of Menlo&#8217;s common stock according to the Exchange Ratio. In addition, for each option and RSU the holder received a CSR as </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">described in Note 3- Business Combination. This transaction was considered by the company to be a modification under ASC 718, Compensation - Stock Compensation. The modification did not affect the remaining requisite service period. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded immaterial incremental compensation expense for the three months ended March 31, 2020.  As described in Note 3 - Business Combination, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The conversion was considered by the company to be a modification under ASC 718. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded incremental compensation of $0.5 million and $1.4 million for the three and six months ended June&#160;30, 2021, respectively and $9.3 million for the three and six months ended June&#160;30, 2020.  As of June&#160;30, 2021 there is $1.9 million of unrecognized incremental compensation expense related to the modification which will primarily be amortized using a graded vesting method over the next 2 years.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards granted to holders who are no longer employed or providing services to the Company are accounted for in accordance with ASC 815-40, Derivatives and Hedging. Under this guidance, the awards are classified as a derivative liability because the award no longer exchanges a fixed amount of cash for a fixed number of shares. Accordingly, as of March 9, 2020 the Company reclassified $1.6 million from additional paid-in capital to derivative liability on the unaudited condensed consolidated balance sheet. Prior to the reclassification of these awards as a liability instrument, the Company recorded an incremental compensation expense of $0.6 million due to the above mentioned modification in accordance with ASC 718. Subsequent to the reclassification of these awards as a liability instrument, the Company recorded incremental compensation expense of $0.5 million and $1.0 million million for the three and six months ended June 30, 2020.  There was no incremental compensation expense for the three and six months ended June&#160;30, 2021.  As described in Note 3 - Business Combination, on April 6, 2020, the Company announced that study MTI-105 and study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis.  Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  On April 6, 2020, the awards are exchangeable for a fixed amount of cash for a fixed number of shares and were remeasured to fair value and reclassified from derivative liability to additional paid-in capital.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, Menlo recognized all expenses relating to awards outstanding as of the Effective Date. These awards were subject to acceleration upon the change of control per the previous Menlo stock option plan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the effect of share-based compensation on the statements of operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071189144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASE</a></td>
<td class="text">OPERATING LEASE<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating lease agreements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for corporate offices and vehicles. The properties primarily relate to the Company&#8217;s principal executive office in Bridgewater, New Jersey and office space in Israel.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2019, the Company signed an amendment to the original lease agreement for its principal executive office in Bridgewater, New Jersey (the &#8220;Lease Amendment&#8221;). The Lease Amendment includes an extension of the lease period of the 10,000 square feet previously leased under the original agreement (the &#8220;Original Space&#8221;) and an addition of 4,639 square feet (the &#8220;Additional Space&#8221;). The Company entered the Additional Space following a period of preparation by the lessor completed during September 2019 (the &#8220;Commencement Date&#8221;). The Lease Amendment is due to expire on August 31, 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Lease Amendment, the Company recognized an additional right of use asset and liability in the amount of $0.7 million. The Additional Space was considered a new lease agreement and was recognized as a right of use asset and liability, in the amount of $0.3 million, on the Commencement Date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease agreement for the office space in Israel is a one year lease that expires in December 2021.  Given the short-term nature of the lease term, the Company did not recognize a right-of-use asset and liability.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company entered into operating lease agreements in connection with the leasing of vehicles. The lease periods are generally for three years. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company had a lien in the amount of $0.6 million on the Company&#8217;s cash in respect of bank guarantees granted in order to secure the lease agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071176728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may periodically become subject to legal proceedings and claims arising in connection with its business. As of June&#160;30, 2021, no claims or actions are pending against the Company that, in the opinion of management, are likely to have a material adverse effect on the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on June 30, 2021, the Company received a paragraph IV certification notice (the &#8220;Notice&#8221;) from Padagis Israel Pharmaceuticals Ltd. (f/k/a Perrigo Israel Pharmaceuticals Ltd. (&#8220;Padagis&#8221;)) advising that Padagis has submitted to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) an Abbreviated New Drug Application (&#8220;ANDA&#8221;) seeking approval to manufacture and sell a generic version of the Company&#8217;s product AMZEEQ&#174; (minocycline) topical foam, 4% in the United States prior to the expiration of the Company&#8217;s U.S. patents Nos. 8,865,139, 8,945,516, 8,992,896, 9,675,700, 10,086,080, 10,137,200, 10,213,512, 10,265,404, 10,398,641, 10,517,882, 10,821,187, and 10,849,847 (the &#8220;Listed Patents&#8221;), which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as the &#8220;Orange Book.&#8221; The Notice alleges that the Listed Patents are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Padagis&#8217;s ANDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2021, the Company initiated a patent infringement suit against Padagis in the United States District Court for the District of Delaware arising from Padagis&#8217;s ANDA filing with the FDA. The patent infringement suit asserts each of the Listed Patents. As a result, under applicable law, the FDA cannot grant final approval to Padagis&#8217;s ANDA before December 30, 2023, or a court decision in Padagis&#8217;s favor. VYNE is seeking, among other relief, an order that the effective date of any FDA approval of Padagis&#8217;s ANDA be no earlier than the expiration of the Listed Patents, the latest of which expires on September 8, 2037, and such further and other relief as the court may deem appropriate.</span></div>The Company intends to vigorously defend its intellectual property rights, including the Listed Patents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674075336440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. In the opinion of management, the Company has made&#160;all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company&#8217;s condensed consolidated financial position, results of operations, cash flow and statement of stockholders' equity for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.  Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC on March 4, 2021.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results expected for the year ending December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of Estimates<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition and liquidity will depend on future developments that are highly uncertain, subject to change and will continue to evolve with geographical re-openings, surges in cases, the development of new strains and the vaccination effort. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of  June&#160;30, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2020, the Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The </span></div>Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Acquisition</a></td>
<td class="text">Business Acquisition<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited interim condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet.&#160;Transaction costs are expensed as incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, the Company uses fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; The Company estimates fair value using an exit price approach, which requires, among other things, that Company determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following techniques:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach, which is based on the present value of a future stream of net cash flows.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Asset Impairment</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews all of its long-lived assets for impairment indicators throughout the year. Impairment testing is performed for indefinite-lived intangible assets annually (or sooner if warranted) and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue RecognitionThe Company accounts for its revenue transactions under FASB ASC Topic 606,&#160;Revenue from Contracts with Customers. In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customers include a limited number of national and select regional wholesalers (the &#8220;distributors&#8221;) and certain independent and specialty pharmacies (together, the &#8220;customers&#8221;). These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when customers obtain control of the Company&#8217;s products, which occurs at a point in time, typically upon delivery of product to the customers. The Company evaluates the creditworthiness of its customers to determine whether it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur. The Company does not assess whether a contract has a significant financing component if the expectation is such that the period between the transfer of the promised goods to the customer and the receipt of payment will be less than one year. Standard credit terms do not exceed 75 days. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that would have been recognized is one year or less or the amount is immaterial. Shipping and handling costs related to the Company&#8217;s product sales are included in selling, general and administrative expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues through&#160;June&#160;30, 2021&#160;were primarily generated through sales of AMZEEQ, which was approved by the FDA in October 2019 and was commercially launched in the United States in January 2020, and ZILXI, which was approved by the FDA in May 2020 and was commercially launched in the United States in October 2020. Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, copay program coupons, chargebacks, estimated returns and other incentives. These reserves are classified as either reductions of accounts receivable or as current liabilities. The estimates of reserves established for variable consideration reflect current contractual and statutory requirements, known market events and trends, industry data and forecasted customer mix. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net product revenues only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from these estimates. If actual results vary, estimates may be adjusted in the period such change in estimate becomes known, which could have an impact on earnings in the period of adjustment. See &#8220;Note 4 &#8211; Revenue Recognition&#8221; for more information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for our minocycline products and product candidate, if approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commercial use.  The Company received an upfront cash payment of $10.0 million in 2020 ($6.0 million received in the three months ended June 30, 2020 and $4.0 million received in the three months ended September 30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The Company will also receive royalties on net sales of any licensed products.  The license is determined to be a distinct performance obligation of the arrangement, therefore the Company recognized the revenues from the upfront license fee when the license was transferred to the licensee and the licensee was able to use and benefit from the license.  See "Note 4 - Revenue Recognition" for more information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Allowance for credit losses</a></td>
<td class="text">Allowance for credit lossesAn allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be&#160;collected.&#160;Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were not material for the three and six months ended June&#160;30, 2021 and June&#160;30, 2020.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative instruments</a></td>
<td class="text">Derivative instrumentsThe Company recognizes all derivative instruments as either assets or liabilities in the unaudited condensed consolidated balance sheet at their respective fair values. All gains and losses associated with derivatives are reported as other expense (income), net in the accompanying condensed consolidated statements of operations.  As of June&#160;30, 2021 and June&#160;30, 2020, the Company had no derivative instruments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value measurement</a></td>
<td class="text">Fair value measurement<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:&#160;&#160;&#160;&#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:&#160;&#160;&#160;&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text">Loss per share<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury share method when dilutive.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of the weighted-average number of common stock outstanding during the period in which the reverse merger occurs was based on:</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The number of common stock outstanding from the beginning of that period to the merge date was computed on the basis of the weighted-average number of common stock of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt">The number of common outstanding common stock outstanding from the merge date to the end of that period was the actual number of common stock of the legal acquirer (the accounting acquiree) outstanding during that period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following average stock options, restricted stock units (&#8220;RSUs&#8221;), warrants and incremental shares to be issued under the employee stock purchase plan (&#8220;ESPP&#8221;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):</span></div><div style="margin-top:5pt;padding-right:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended June 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options, RSUs and shares under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,378,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,365,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,020,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, the CSR was excluded from the calculation of the 2020 diluted net loss per share because its effect would have been anti-dilutive for the periods presented. On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective exchange ratio (the "Exchange Ratio") in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020. See "Note 3 - Business Combination" for more information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly issued and recently adopted accounting pronouncements</a></td>
<td class="text">Newly issued and recently adopted accounting pronouncements<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Guidance Issued:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes," which clarifies and simplifies certain aspects of the accounting for income taxes.  The standard is effective for years beginning after December 15, 2020, and interim periods </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beginning after December 15, 2020.  This guidance became effective during the first quarter of 2021.  The adoption of the new standard did not have a material impact to the Company's consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update No. 2020-4, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" (ASU 2020-4), which provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying generally accepted accounting principles to contracts, hedging relationships, and other transactions impacted by reference rate reform. The provisions of ASU 2020-4 apply only to those transactions that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-4 are optional and are effective from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-4 on its consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update No. 2016-13,&#160;&#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;&#160;(ASU 2016-13), which requires companies to measure credit losses of financial instruments, including customer accounts receivable, utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. As a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023 or at such time where it is no longer a smaller reporting company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120269220-210453<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267969-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 35<br> -Paragraph 13A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515542&amp;loc=SL120267917-210453<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 35<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124266218&amp;loc=SL120267834-210445<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120269210-210444<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919260-210447<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL120267845-210446<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 30<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=124256539&amp;loc=SL120254536-210444<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3C<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267966-210447<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 30<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=124268681&amp;loc=SL120267897-210452<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267862-210455<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.Q4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122651532&amp;loc=SL122037091-237805<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267859-210455<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071137208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following average stock options, restricted stock units (&#8220;RSUs&#8221;), warrants and incremental shares to be issued under the employee stock purchase plan (&#8220;ESPP&#8221;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):</span></div><div style="margin-top:5pt;padding-right:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended June 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options, RSUs and shares under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,378,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,365,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,020,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674067901864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock', window );">Schedule of Merger Consideration to be Transferred</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deemed (for accounting purposes only) conversion of Menlo equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration*</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $19.6 million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders&#8217; relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $111.4 million, as shown in the purchase price allocation table below.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of the Purchase Price to the Fair Values of Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 9, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,641&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,827)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,827)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase price*</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#8217;s outstanding shares being owned by Menlo stockholders following the Merger.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock', window );">Schedule of the Calculation for Goodwill of Merger</a></td>
<td class="text">The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 9, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: fair value of net assets acquired, including other identifiable intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock', window );">Schedule of In Process Research and Development Assets Acquired Through Business Combination</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D recognized relates to Menlo&#8217;s once</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:84.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible asset</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired indefinite life intangible assets*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of identified intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>* Represents acquired IPR&amp;D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Information</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June&#160;30, 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:59.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss attributable to Menlo</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended<br/>June 30, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share - basic and diluted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acceleration of stock based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Adjustments</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,130)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of consideration to be transferred to effect the Merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the calculation of goodwill from the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of in-process research and development indefinite lived intangible assets acquired in the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071715240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s assets and liabilities that are measured at fair value as of December&#160;31, 2020, are classified in the table below in one of the three categories described in "Note 2 - Fair value measurement" above:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674069639912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s marketable securities:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israeli mutual funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674069668840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company&#8217;s inventory:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,279&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,404&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674165573816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock', window );">Schedule of Share Based Compensation by Share Based Payment Award Grants in Period</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended June&#160;30, 2021 and 2020, the Company granted options and RSU as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award<br/>amount*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price<br/>range*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.02-$11.08</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year -4 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year -4 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award<br/>amount*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price<br/>range*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.80-$12.52</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year -4 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year -4 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* All amounts and exercise prices for pre-Merger grants are presented following the exchange to Menlo options and RSUs at the Exchange Ratio described in Note 3-Business Combination.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.38%-69.12%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.44%-69.83%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5%-1.07%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.44%-1.26%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the effect of share-based compensation on the statements of operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the share-based compensation awards granted during the period, exercise price range, vesting period and expiration of awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071197816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674065847976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 11, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 06, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>employee</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 19, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio (share/share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,924<span></span>
</td>
<td class="nump">$ 167,440<span></span>
</td>
<td class="nump">$ 40,474<span></span>
</td>
<td class="nump">$ 207,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,808)<span></span>
</td>
<td class="num">(88,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(606,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(606,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (566,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Pro forma cash, cash equivalents, restricted cash and restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,011<span></span>
</td>
<td class="nump">$ 97,366<span></span>
</td>
<td class="nump">104,011<span></span>
</td>
<td class="nump">$ 97,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,418<span></span>
</td>
<td class="nump">$ 44,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementMember', window );">Amended And Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Number of employees expected to be terminated | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance | Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Employee termination costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Employee termination costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments on outstanding debt</a></td>
<td class="nump">$ 36,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_RepaymentOfDebtPrepaymentFeePercentage', window );">Prepayment fee, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_PaymentsForLicensingAgreements', window );">Payments for licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_RoyaltyPaymentPercentMaximum', window );">Royalty percent, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vyne_TopicalBETiOptionAgreementMember', window );">Topical BETi Option Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_PaymentsForLicensingAgreements', window );">Payments for licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum', window );">Milestone payments upon achieving certain criteria, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vyne_OralBETiOptionAgreementMember', window );">Oral BETi Option Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_PaymentsForLicensingAgreements', window );">Payments for licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum', window );">Milestone payments upon achieving certain criteria, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=vyne_MenloPremergerMember', window );">Menlo - Premerger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Upon Achieving Certain Criteria, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_PaymentsForLicensingAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Licensing Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_PaymentsForLicensingAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_RepaymentOfDebtPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of Debt, Prepayment Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_RepaymentOfDebtPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_RoyaltyPaymentPercentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment, Percent, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_RoyaltyPaymentPercentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vyne_TopicalBETiOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vyne_TopicalBETiOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vyne_OralBETiOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vyne_OralBETiOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vyne_MenloPremergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vyne_MenloPremergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674161746440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>derivativeInstruments</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>derivativeInstruments</div>
</th>
<th class="th"><div>Apr. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of derivative instruments held | derivativeInstruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ContingentStockRightSharesConversion', window );">Number of common stock shares issued per CSR (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationEffectiveExchangeRatio', window );">Effective exchange ratio of Foamix ordinary shares into Menlo common stock (share/share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=vyne_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from royalties</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents', window );">Additional royalty upon receipt of marketing approval in China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional royalty receipt upon occurrence of certain event related to licensed products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessCombinationEffectiveExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective exchange ratio of ordinary shares for shares of common stock from the merger as adjusted for the conversion of contingent stock rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessCombinationEffectiveExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ContingentStockRightSharesConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued per each contingent stock right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ContingentStockRightSharesConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674069481864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Schedule of AntiDilutive Equity Awards Not Included in the Calculation of EPS (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember', window );">Outstanding stock options, RSUs and shares under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">5,378,428<span></span>
</td>
<td class="nump">3,743,846<span></span>
</td>
<td class="nump">5,365,232<span></span>
</td>
<td class="nump">3,020,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">495,165<span></span>
</td>
<td class="nump">473,258<span></span>
</td>
<td class="nump">495,165<span></span>
</td>
<td class="nump">318,084<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674163527000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 07, 2020</div></th>
<th class="th">
<div>Apr. 06, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($) </div>
<div>contingentStockRight </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ContingentStockRightSharesConversion', window );">Number of common stock shares issued per CSR (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_EffectiveExchangeRatio', window );">Effective exchange ratio (CSR per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement', window );">Share issued and delivered upon CSR conversion (in shares) | shares</a></td>
<td class="nump">18,636,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,544,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders', window );">Ownership percentage of parent by subsidiary stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_PostMergerParentOwnershipByPreMergerParentStockholders', window );">Ownership percentage of parent by parent stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing share price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock', window );">Value of CSR converted into additional shares of the combined company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ContingentStockConsiderationRemeasurementGainLoss', window );">Contingent Stock Right Remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,726,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,726,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, fair value of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">In process research and development impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 49,800,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">49,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessAcquisitionContingentStockRightIssued', window );">Number of contingent stock rights issued (in CSR) | contingentStockRight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing share price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationConsiderationTransferredGross', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,079,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,757,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes', window );">Number of shares deemed (for accounting purposes only) issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards', window );">Deemed (for accounting purposes only) conversion of Menlo equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,322,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock', window );">Value of CSR converted into additional shares of the combined company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, fair value of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember', window );">Foamix | Employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember', window );">Foamix | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ExchangeRatio', window );">Exchange ratio per ordinary share for common stock (share per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessAcquisitionContingentStockRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of contingent stock right issued in connection with the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessAcquisitionContingentStockRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquiree Common Stock Rights Converted to Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred consisting of the conversion of equity awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessCombinationConsiderationTransferredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer prior to the reduction in respect of the contingent stock rights issued to acquired shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessCombinationConsiderationTransferredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares deemed, for accounting purposes only, to be issued in the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ContingentStockConsiderationRemeasurementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Stock Consideration, Remeasurement Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ContingentStockConsiderationRemeasurementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ContingentStockRightSharesConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued per each contingent stock right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ContingentStockRightSharesConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_EffectiveExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_EffectiveExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the exchange of ordinary shares of acquiree for common stock of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_PostMergerParentOwnershipByPreMergerParentStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of post-merger Menlo ownership held by pre-merger Menlo stockholders, as a percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_PostMergerParentOwnershipByPreMergerParentStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of post-merger Menlo ownership held by pre-merger Foamix shareholders, as a percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number shares issued upon conversion of common stock rights arising form the certain events as provided for in the commons stock rights agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674163758616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Consideration Transferred in Merger (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 09, 2020</div></th>
<th class="th"><div>Apr. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, fair value of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</a></td>
<td class="nump">$ 123,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards', window );">Deemed (for accounting purposes only) conversion of Menlo equity awards</a></td>
<td class="nump">7,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationConsiderationTransferredGross', window );">Total consideration</a></td>
<td class="nump">131,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, fair value of liability</a></td>
<td class="nump">19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration net of the effect of CSRs</a></td>
<td class="nump">$ 111,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred consisting of the conversion of equity awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessCombinationConsiderationTransferredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer prior to the reduction in respect of the contingent stock rights issued to acquired shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessCombinationConsiderationTransferredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674163622856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Purchase Price Allocation (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Allocations of purchase price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock', window );">Value of CSR converted into additional shares of the combined company</a></td>
<td class="nump">$ 19,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Allocations of purchase price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">38,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="nump">22,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">In-process research and development</a></td>
<td class="nump">49,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,545<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="nump">117,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(5,827)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities</a></td>
<td class="num">(5,827)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Purchase price</a></td>
<td class="nump">111,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock', window );">Value of CSR converted into additional shares of the combined company</a></td>
<td class="nump">$ 19,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquiree Common Stock Rights Converted to Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674069425352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Goodwill (Details) - Foamix<br></strong></div></th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationGoodwillAbstract', window );"><strong>Business Combination, Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for income tax purposes</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Purchase price</a></td>
<td class="nump">111,443,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets', window );">Less: fair value of net assets acquired, including other identifiable intangibles</a></td>
<td class="num">(106,898,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 4,545,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of net assets acquired including other identifiable intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674069736936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS COMBINATION - IPRD and CSR (Details) - Foamix<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>In-Process Research and Development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired indefinite life intangible assets</a></td>
<td class="nump">$ 49,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Fair value of identified intangible assets</a></td>
<td class="nump">$ 49,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674176774328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Pro Forma (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Loss attributable to Menlo</a></td>
<td class="num">(7,594)<span></span>
</td>
<td class="num">(19,637)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenues</a></td>
<td class="nump">11,688<span></span>
</td>
<td class="nump">13,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 167,441<span></span>
</td>
<td class="nump">$ 205,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Loss per share - basic (in USD per share)</a></td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Loss per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalIncomeStatementElementsAbstract', window );"><strong>Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_AdjustmentsToSupplementalProformaTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (14,931)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation', window );">Acceleration of stock based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,199)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations', window );">Total Adjustments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (22,130)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalIncomeStatementElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalIncomeStatementElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of acceleration of stock based compensation as adjustment to pro-forma results of the combined operation after business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustments to supplemental proforma combined results of operations of the combined operation after business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_AdjustmentsToSupplementalProformaTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount pertaining to transaction costs as adjustment to pro-forma results of the combined operation after business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_AdjustmentsToSupplementalProformaTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674164151064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances', window );">Product sales provisions</a></td>
<td class="nump">$ 16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 31,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_EstimateOfProductReturnRateMinimum', window );">Minimum estimate product return (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_EstimateOfProductReturnRateMaximum', window );">Maximum estimate product return (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 4,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,688<span></span>
</td>
<td class="nump">$ 8,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vyne_AllowanceForSalesReturns1Member', window );">Allowance For Sales Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Revenue reserve accrual</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=vyne_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_UpfrontRoyaltyReceipt', window );">Upfront royalty receipt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents', window );">Additional royalty upon receipt of marketing approval in China</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customers | Revenue from Contract with Customer, Product and Service Benchmark | Four Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customers | Revenue from Contract with Customer, Product and Service Benchmark | Three Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional royalty receipt upon occurrence of certain event related to licensed products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_EstimateOfProductReturnRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum estimate of product sales return rate at reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_EstimateOfProductReturnRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_EstimateOfProductReturnRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum estimate of product sales return rate at reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_EstimateOfProductReturnRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate of fee the entity pays for distribution services and certain date that distributors provide to the entity and sales discounts given by the entity, including, but not limited to, early payments of accounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_UpfrontRoyaltyReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront royalty receipt upon delivery of licensed products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_UpfrontRoyaltyReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vyne_AllowanceForSalesReturns1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vyne_AllowanceForSalesReturns1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vyne_FourCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vyne_FourCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vyne_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vyne_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674075243112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 1,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">1,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674071243496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES - Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=vyne_IsraeliMutualFundsMember', window );">Israeli mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=vyne_IsraeliMutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=vyne_IsraeliMutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674067814872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Permanent impairment loss, debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturity of marketable securities</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">$ 36,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Restricted Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674164943192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674069709528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY - Schedule of Inventory Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials</a></td>
<td class="nump">$ 3,466<span></span>
</td>
<td class="nump">$ 4,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">4,133<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 8,279<span></span>
</td>
<td class="nump">$ 7,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674067966632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 11, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 29, 2019 </div>
<div>USD ($) </div>
<div>lender </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 17, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt offering expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Incurred expenses related to Credit Agreement and Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_RepaymentOfDebtPrepaymentFeePercentage', window );">Prepayment fee, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments on outstanding debt</a></td>
<td class="nump">$ 36,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember', window );">Credit Agreement | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt offering expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instrument, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementMember', window );">Amended And Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Base interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementMember', window );">Amended And Restated Credit Agreement | One-month LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember', window );">Amended and Restated Credit Agreement, Trench 1 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember', window );">Amended and Restated Credit Agreement, Trench 2 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt offering expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Incurred expenses related to Credit Agreement and Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember', window );">Amended and Restated Credit Agreement, Trench 3 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vyne_ShareholderLenderMember', window );">Shareholder Lender | Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ClassOfWarrantAbstract', window );"><strong>Warrants issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of ordinary shares that may be purchased by exercise of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vyne_ShareholderLenderMember', window );">Shareholder Lender | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_RegisteredOfferingMember', window );">Registered offering per securities purchase agreement | Shareholder Lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_NumberOfLenders', window );">Number of lenders involved | lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ClassOfWarrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ClassOfWarrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from issuance of common stock before deducting offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_NumberOfLenders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of lenders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_NumberOfLenders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_RepaymentOfDebtPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of Debt, Prepayment Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_RepaymentOfDebtPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vyne_ShareholderLenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vyne_ShareholderLenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_RegisteredOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vyne_RegisteredOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674065040600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Common Stock, Preferred Stock, and Warrants Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 26, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 06, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($) </div>
<div>contingentStockRight </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 29, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 19, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD/share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio (share/share)</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (USD/share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payments of financing and stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement', window );">Share issued and delivered upon CSR conversion (in shares)</a></td>
<td class="nump">18,636,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,544,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification', window );">Deemed dividend to warrants holders due to warrant modifications | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (USD/share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued pursuant to the merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,544,413<span></span>
</td>
<td class="nump">36,550,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessAcquisitionContingentStockRightIssued', window );">Number of contingent stock rights issued (in CSR) | contingentStockRight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification', window );">Deemed dividend to warrants holders due to warrant modifications | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_CantorSalesAgreementMember', window );">Cantor Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock', window );">Commission from gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (USD/share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received in a transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,274,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (USD/share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received in a transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_PublicStockOfferingMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,776,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (USD/share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received in a transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_CommonStockVotingRightsNumberPerShare', window );">Number of votes entitled to each ordinary share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Foamix | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of ordinary shares that may be purchased by exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Number of shares issued for warrants exercised</a></td>
<td class="nump">495,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,980,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessAcquisitionContingentStockRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of contingent stock right issued in connection with the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessAcquisitionContingentStockRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission from Gross Proceeds From Issuance Of Common Stock, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_CommonStockVotingRightsNumberPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes entitled to each ordinary share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_CommonStockVotingRightsNumberPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from modification of warrants that is deemed dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number shares issued upon conversion of common stock rights arising form the certain events as provided for in the commons stock rights agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_CantorSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vyne_CantorSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vyne_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vyne_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vyne_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674160470552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Share-based Compensation Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>contingentStockRight </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 06, 2020</div></th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($) </div>
<div>contingentStockRight</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>contingentStockRight</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>contingentStockRight </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue', window );">Fair value of options and RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ContingentStockRightSharesConversion', window );">Number of common stock shares issued per CSR (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_EffectiveExchangeRatio', window );">Effective exchange ratio (CSR per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment', window );">Additional paid in capital reclassified to derivate liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (657,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessAcquisitionContingentStockRightIssued', window );">Number of contingent stock rights issued (in CSR) | contingentStockRight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember', window );">Foamix | Employees and consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost', window );">Incremental compensation costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod', window );">Incremental compensation costs, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember', window );">Foamix | No longer employed or providing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment', window );">Additional paid in capital reclassified to derivate liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost', window );">Incremental compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued during the period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,989<span></span>
</td>
<td class="nump">61,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vyne_A2019PlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vyne_A2018PlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance', window );">Increase in shares reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vyne_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,261,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,261,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Percentage of fair market value used as purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percent of annual earnings that may be used to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vyne_EmployeeStockPurchasePlanMember', window );">ESPP | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Stock issued during period, conversion of units (in shares) | shares</a></td>
<td class="nump">9,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vyne_EmployeeStockPurchasePlanMember', window );">ESPP | Common stock | Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_BusinessAcquisitionContingentStockRightIssued', window );">Number of contingent stock rights issued (in CSR) | contingentStockRight</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_BusinessAcquisitionContingentStockRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of contingent stock right issued in connection with the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_BusinessAcquisitionContingentStockRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Increase in Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ContingentStockRightSharesConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued per each contingent stock right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ContingentStockRightSharesConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_EffectiveExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_EffectiveExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of options and equity instruments other than options granted during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Plan Modification, Unrecognized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Plan Modification, Unrecognized Costs, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the fair value of the modified award over the fair value of the award immediately before the modification pertaining grantees not employed or providing services after the modification and reclassified from additional paid-in capital to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vyne_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vyne_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vyne_A2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vyne_A2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vyne_A2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vyne_A2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vyne_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vyne_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674075504456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Options and RSU Grants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option, award amount (in shares)</a></td>
<td class="nump">957,682<span></span>
</td>
<td class="nump">1,195,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, minimum (in usd per share)</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, maximum (in usd per share)</a></td>
<td class="nump">$ 11.08<span></span>
</td>
<td class="nump">$ 12.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU, award amount (in shares)</a></td>
<td class="nump">366,678<span></span>
</td>
<td class="nump">647,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674069548712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Fair value assumptions (Details) - Options<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based payment assumptions for computing fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">68.38%<span></span>
</td>
<td class="nump">60.44%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">69.12%<span></span>
</td>
<td class="nump">69.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.44%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.07%<span></span>
</td>
<td class="nump">1.26%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674164112216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Schedule of Share-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 1,901<span></span>
</td>
<td class="nump">$ 10,768<span></span>
</td>
<td class="nump">$ 4,343<span></span>
</td>
<td class="nump">$ 12,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">3,050<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">3,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 1,459<span></span>
</td>
<td class="nump">$ 7,718<span></span>
</td>
<td class="nump">$ 3,443<span></span>
</td>
<td class="nump">$ 8,961<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674074959880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASE - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 13, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225<span></span>
</td>
<td class="nump">$ 1,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_RestrictedInvestmentsToSecureLeaseAgreements', window );">Lien on marketable securities to secure lease agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vyne_OriginalSpaceMember', window );">Original Space | Bridgewater, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_FacilitySpaceUnderLease', window );">Facility space leased | ft&#178;</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vyne_AdditionalSpaceMember', window );">Additional Space | Bridgewater, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vyne_FacilitySpaceUnderLease', window );">Facility space leased | ft&#178;</a></td>
<td class="nump">4,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_FacilitySpaceUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Size of the facility under lease, in square feet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_FacilitySpaceUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vyne_RestrictedInvestmentsToSecureLeaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lien on marketable securities in respect of bank guarantees granted in order to secure lease agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vyne_RestrictedInvestmentsToSecureLeaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vyne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vyne_OriginalSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vyne_OriginalSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vyne_BridgewaterNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vyne_BridgewaterNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vyne_AdditionalSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vyne_AdditionalSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139674067927784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASE - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 1,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:W-H965T<R]S:&5E=#(N>&ULO5EK4^,V%/TKFNS.MCL3B"7Y%5XS;)+.LJ5
M"=M./RJ.0CS85E:28>FOK^28V+%DP?3U 6([YUX?75W=HZN</#'^(-:42O ]
MSPIQ.EA+N3D:C42RICD1AVQ#"_7-BO&<2'7+[T=BPRE95D9Y-D*>%XYRDA:#
MLY/JV0T_.V&ES-*"WG @RCPG_/D3S=C3Z0 .7A[<IO=KJ1^,SDXVY)[.J?RZ
MN>'J;K3SLDQS6HB4%8#3U>G@'!Y-L*\-*L1O*7T2K6N@A[)@[$'?7"Q/!YYF
M1#.:2.V"J(]'.J%9ICTI'M]JIX/=.[5A^_K%^T_5X-5@%D30"<M^3Y=R?3J(
M!V!)5Z3,Y"U[^DSK 07:7\(R4?T'3S76&X"D%)+EM;%BD*?%]I-\KP/1,H!^
MCP&J#=!;#7!M@*N!;IE5PYH22<Y..'L"7*.5-WU1Q::R5J-)"SV-<\G5MZFR
MDV>3ZZOI[&H^FP)U-;^^O)B>WZF;3^>7YU>3&9A_GLWNYN  ?)U/P8_O/X+W
M("W W9J5@A1+<3*2BH/V-$KJ]WW:O@_UO.]+61P"[ T!\A"TF$_<YE.:*'-8
MF7O[YB,U\MWPT6[XJ/*'^X9?<DX+"<Z%H%(<.3SBG4=<>?3[/!*Q!BHV(-$7
M]%N9/I),O<(:JZVKL'*E%]SC&?2P[X4GH\=V3$Q8$ 4AWJ'VB/H[HKZ3Z"T5
MDJ>)I%NJ-GI;!T'KO:$7=+B9F#@([,R"';/ R>RB>%3<<CTO*ME4=7F@DBPR
M"@1-2I[*E KPXQ63%(0?;;0#@Y+7(6TBH(<B.^MPQSITLK[C9$E594NHFG'%
M5@Q!H<HP6P&2J6))BH1:<R"T<(G#N,/8@@IB.+93CG:4(R?E&TXW)%U6Z<KD
MFG) JG5@HQD9! )DL#1!?C"&=I+QCF3\:C84DO'G>LXCZYS'9AJB:-RA9X(B
MW_/M],8[>F/WM#-),K!?1VP$Q^8$HMA'W:5NPN((!3WS#+VFRGNOS+02?BZ?
MJZG616FCEU>5H=8:[IFS[<$.51NH;^G#EAY!)]-KQ9/(M+@'&57R#+C6X0.V
M.BC5S38]ZT2 GC43:O_[D4;=LF5#!7%/286-G$#TKZVHVE6; HZQ$643Y6._
M+\R-2D&W3&W3MC]=:_.]^& \;D6HIF?BQCCR40^_1IR@_R9AODS)(LVJFN]2
M9]AH"W2+R[9,;\AS5:.M0[>I@Q=W-<0"\Z,6:I]?HR+0+2/G2<)+I<GTN]JI
MBYW2^?9<MXD']+M%Q0:#?M W28U\0+=^3.E"UOQB.S]3$##&D;$835A?'!O5
M@&[9F.6;C#U3K<@9T9L<MLC2>Z)[!_NLF^* _=A8C2;*QV$?V49#H%M$ND4O
M:[+^E6)GZH6J#EW2)B@*>G8[J)$4Y):4:UW>;)R0J0O0ZW)Z!;3/J1$/Y!:/
M?3%NU0XK3U,"@BA$W75N@2&U>'JD K4Z#[=4O+![!JH9!_0E705]5+F@-HM@
M00NZ2NWE&9FJ@(RVP0+"L&?1HT8YD%LY_G:N(E,JXA:=FK,%U!OK1DV0N]>Y
M9,7]@:0\5QW^*R4+F0V-D1$F!&,8]65O(TW(+4W5BFK'T\K/(CN!$44;J&_%
M-]*$7NEPJM7UVJHRM288>V,CAA98B/R>C2YJ) FY)6G"\CRM>D=1;<(FK-"Y
M2HNDE9_0/O,N%:I9OUFH4"-4*';N=.9WUY.?/U]?3F>W\Q_ [->O%W=_N+8Z
MJ%$5Y%85M1E=454*ET!(ECP<@??>H>=Y4.U^.'@D64F/ ?*&ZI'^ V)-N(H1
M*>6:\?1/948D^%(6],,[&'K'+X<V55BGJLW-%Y377]4',D,EMF)#JY.Y[/D8
M%.S%:2J$WM14V^)2"JDN= 7Y9R^P3J*I=<8DNB#[9SZ-&&*W&.JT8X4CSE'P
M'\8Y@,, PF'L!Y61CX?("X9(^?B_PX\M/6'W,,N$]%1.W.@^=NO^^7*9ZIV=
M*D^Z_3I("Y"03:K*E96DJ>AA#(.@>YIAPWDXC'N:+]Q(/W9+O]KCEWFYW98N
ME<8GJ;4+QZ9^'X1>&$;=C+8!@S"$X["':>LP\RUMXEQGT9IE2\J%*E'?2K5K
ML1(VQ3ORXW&W9[3 5,LX[E%YW*@\=JN\H4]5*K?)?W@7(Q@=NX;@FT>RMK[7
M@K/UO:/6R;S^6>07PN_30JBMTTK9>8>1"@+?_M*PO9%L4QW6+YB4+*\NUU1U
MK%P#U/<KIA2LOM'G_[O?>\[^ E!+ P04    " #C10Q3J',U$>@"  "O"0
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M,_B5$*$38#_E7.T#?4#S<PK^ E!+ P04    " #C10Q3E*47SY\(  #!(@
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M)=D T2*ZW%C--%$9S5CI/1%$\/P-5V)T,#QV8R""D_Y$:K6+YZ'E\/4P]"W
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M!05F1,;TAYFA'A,GGMSAQ-7EA.>%R"N^>7]Q2#I/F\KG9T#/QG+-2(:*J+6
M7VTSA(U4E=J1ZFV=E7U+@U N;I]T@V;H/5=AJMV@,MQ$3,L>.A*;QZ"8>#.Y
M^7DEZ0NMS0IQ8.&4V!@#MM-#(294LL, I-\Z!CT:"KWS^T94.@H.KLVZR%*[
MI#V64MZ4,1DSYD(SZKC^JX,"3!X<7-Y3(]@"C810HD>SOSQ@:QL9XI-"7:RM
M!9QW<?7N:[W9_G N-2R$7VY2R8!I'$3K8=(]\"B!(E:SOF8<!G/@,=<THTI#
M'\Z'O/H@9-2'H[GTP6@6/56_6J#+T@;M?AG&IM\9#V]$Z/_] _AHM$YBAPBK
MGR5B8Y0:3"BX2#A+X]/1#[+CON,&<T(XAB9J)&K?1TR.)^XGY@X1]SCC]R-Q
MF7&JS')*N2-VY,8GJ>_@C;4NLUIR*# ;KC@T6L)X&&>?[,W'#>% G#XV#<E7
M3G7/-'U/,G3'4CW:\B#DG?Z,O&L0"L\P!GR@A4GK0E:09L\Y95Y6[C9XV$$S
M(GA#;S_%D7.IIC*\.!DKO/3;:LYV:4MBR:/3?**'*& 8]>CX^?1YNDP9')%#
M/>N,C#->X8$]UUJ*Y!-YG-JF-X0LJ#C&W0!;I#JZ%!]HAC45Q1[-9_D<APRF
M4@FPXSEFJMT;N%HI"CUZ!H_^;;QYH%K?#,M%I5FT(3TD[W$6*M&T/ RUY85?
M@E-8-ZM!M\.#,D)X=/*TIR^?9YO/Q]@!/\-] "X?(=UIC+2E]NM9MB8235GS
MB'X?O+6L(%44?-Q89,#,E:)HJ-BSZ.A@O$>LK0B.T*'.$4HF=YL])\]Z+0B\
MN_.V ^VTHOG2F@G8&.VY@=;JCX9#G$0@GY+T]"1GHJ0,^NZ[%?5>CCY0L"(.
MVZ^-KMHUO3,2IU,:S];$^6T5!W7[6=BX#T4YWHG"@ RF#*>)L*4,C^_",%71
MM6:_$QA&OG=W1G#VO<_(\-8?>0,DR]G'#H#,JZN7^@;P2-Z'V''EK+ ^P+S0
M(F %[3$XEYZ@0"Q8;W)DR/M)%#8/L"6X]O3.3'*K=9N]:E%SQB0E8I\+XU[1
M$YO[VD4_)$H,J6(HW0M6Y"?P6$56V^3O=D7:]AIQD?8R Y&A)-?>F@KTL L-
M5?7['6E<7N8,(JCN4\XO]"-#[4M1KW^I('O;H#^;7L#P\MD +G:&[TF20T\S
M?']%O,:#;D:J#('[/%9S^E7N;9;&?,[3I/'^+_<T^9A^ZH4.YQ]Z&B9_@,O)
M,\3V<7@BX-2.!P(BX5Z*W1(1X@Q4_^  [<8,C^5Q/\^Y.,&O6KK?31_C1L/Y
M)*3-,0U@UT-W+W0EO>TT>\21*^?(+4_!$*B/,WN^HXS*AH0@H$X&^,%NS*?0
M;\\IX!C1TCRH;T,&^ZD=F$=6%N<2*Q$FO/!FM/RX]^+E",/Z<0:=J?_P?<;T
M@BE)[X^_F77/"UG_XHM88R\X7;_/7F+*_10K4F/D%2%YURR*(SB^L4F@]-Y>
M:"NGF1<94I$BA[S?$ZGA8:#!NYTRS>.IB_=9P!J=HD]COP/(D;\I-7C_"O@X
MM@''W!D/%^90.K"#6[:#)#D;\0QJ% (55)8&=&A^+ 2BX5XRX4B#/)S8"4^S
MF 4/20HA[YAN[8WC@!TD,<Z6_G7F&.^S.[) 7NV8*NC6WCFE1ZJI-)Z=*[X]
M2V;(1Q1\D2.=T42H/TMZT8M+1BO'20S52YHZ-,E)&/?P@=X9S6S@ 0.()PV<
M'SMP7PZNRR-)SN2\F>.AX:<LS5+Q78E0;6$OAD>--&*&4I>9S]I1BM_);$^[
M;U4+\K\R=!TF@(,&N\7O4K;Q =_+9(+<+-,=[.=P( %J/#C F[#K/>NG"ZXI
M2NH&UO=AR\7A.+!P=OTAC2H<S^:GA_.G$W4./U?)("V4]$,=)H[EA<0%]3KI
M/29JC?;B/>M%]'(@WC^S>%\&\3Z^[A;RCM[Q[.GAZ>S)W8RR?W'W=FV8Q1S0
ME/P%@(3UN-YV(]E7-E81PK9>(7JN>!25PU>4:IIB4J4#)>$X8S;_A?I*G*9$
M$JI'#9@\O!&?4^S\;%5GM.FE4^M;C(I$S&0&$L)"8W_.XBC[FR(\X4-_.86,
M"RHA?UXD74U_G.5,_B9)?[O\91? \)6M":0N\>AL^NW3 WE#+/X"B?)?*$$6
MT+H-?T2* X'0#4^INN3:^ MMD/YDS<__#5!+ P04    " #C10Q3;&SND<P;
M  ":4P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6S-7%ESV\:6_BM=
MFM1<J8JBM5EV["15LFQG="=>KF3?3-VI>6@"3;)C$,V@ <G,KY^S]0(0E.1D
M'N;%%DF@^_19OK,"/]RYYHM?&M.JKZNJ]C_N+=MV_>+)$U\LS4K[J5N;&GZ9
MNV:E6_C8+)[X=6-T23>MJB<G1T?G3U;:UGL__4#??6Q^^L%U;65K\[%1OENM
M=+-Y92IW]^/>\5[XXMHNEBU^\>2G']9Z86Y,^WG]L8%/3^(JI5V9VEM7J\;,
M?]R[.'[QZ@ROIPO^:<V=S_Y6>)*9<U_PPU7YX]X1$F0J4[2X@H;_;LVEJ2I<
M",CX7=;<BUOBC?G?8?6W='8XRTQ[<^FJ7VW9+G_<>[ZG2C/77=5>N[O_,'*>
MI[A>X2I/_ZH[OO;T9$\5G6_=2FX&"E:VYO_U5^%#=L/SHQTWG,@-)T0W;T14
MOM:M_NF'QMVI!J^&U? /.BK=#<39&H5RTS;PJX7[VI]NKGY^?_7VZO+B_2=U
M<7GYX?/[3U?O?U8?/_QR=7GUYN:')RUL@I<^*63!5[S@R8X%S]4[5[=+K][4
MI2G[]S\!XB*%)X'"5R?W+OCWKIZJTZ.).CDZ.;YGO=-XXE-:[W3'>A=%X;JZ
MM?5"?725+:SQZK\O9KYM0$/^YYX-SN(&9[3!V?\=2__2@DI/U2OMK5=NKCXV
MQINZU:3RGY9&=;7N2MN:4MFZ-8U=J<*!9&H/W\!?'EA0:OQY;FM=%U97RL/M
M!@ROI15;6.32K=:ZWJBEOC5J9DRM  '6NJ%5P;(*UY1PLP'E;9?T63B\;BRL
MN:Z QPM3FT97U09_-VNFB%;_7!-]-[@M;7FQ D(+K?;W/D]OINKGBXN/>P<*
M$"B>88S8J;KB]=S:UGA\6&FE:X 6_'DR.(B'WTJC@"!5F\)X#Y"D=/D;F!RM
M-E%W2ULL8<>BZN#"&C&@ APJNJ;!HV779BL@D5K-M6T290,N_ON_/3\Y?O;2
M/RR(M?,6!3F!;3W ##$'\+@A\0*)A?9+-0=@5;HN^QL"<A1?EJXJ3>/_ILSO
MG6V9.J0DL!&6LJ[T*$W4&E-.U:5I6L!RN(01GZ 3%B^M+RKG.[A2> &2%.9$
M2>JZ[H#NA_7J/O6),L_4+;$*3N!6MNW1"EH&7_-AE%ZA\OGL9I!9I;VW<POW
MMPX7P[/1GR!,9-C&Z"9P@<X\1>/Q?]5\_-)U50E4*'28>%BXY[>N9H]$I\T4
MXV]>A<T>7AJNP+,GWJ=%+E@*UV;M&M"%6J'_4L='A_\9%8#.:Q"AU6O0W=7,
M-.KTF# 6D!:,8VXK^"U2>//F$A=ZIQLPB3/&8F)1U,RP<KMLC&%UM%_5BGT!
M[P1(;B*2*Q _*%(;;<>2/I5@]^BG@\V$Y<W7-?AQ9,;@!&B*PR, :;,I0&'$
M'ECL,G(T(./#/ ZV3ZK-H+8%B7A2BZ+N9MZ6%LYA"(E 60JY9*8KU&Y/UX*;
MJ;TF!<AUU%06O#N1TJU=G1%'REA,U6=/3'GC6[LBH,0SL!WQF>#'I*W?HJ6L
MEF@2B!$#&VP0.M#H$Y2BX:ST%Z-,I 5/!B;6K=9\L':I6Z7G<Y"9B!%UT23K
M!&+A>M/RK975,UL!ULE2"6SP0E1U$#/NO.L>W@7/&.3S+0S Y<8H!/F[%2LS
MZA^LYE79$?JG0Y&;8QR=JAN[J %G"@VT@AQ6I!>_$1<<_ G&LYMG0=LR]XG*
M/NL\F+E'BU_-4$48^BWHEFVBEUXX5]Y9<&:DCP -]<+.*I,SK#&WINZ0[,(!
ME:Q8%T7;D5MC,RL(KTH+DFO4O'&K4<<5S\ 0</GAGU>O#X^_5W!1:5:VH.T6
M[M8T->G+RFAV'"UH#;H6W ^T'#0:V(([Q#O)(I: E1J 8<%0@$<M",CZ.)<\
M(9X#40276QI=M<L"X67=N%N+#I#\/=D9FAE(.7AW_#[L@_A#.X$2>%T%>^WC
M,ZG<!O<Q7R$4 'VSQ+85A"RB5D"368@=X3E%^A?O_O7FS3]HS7]=_?)?5\R[
MRM0+N Z5UD95:\7(F,9VE,4D[!(LLVB!< J-XB=A6)_TH$<[@@G:.ED'FH^-
MSK^R  (EHP-N:\ 82A3(O&O12$M0K<JM61O9]N';)61$0 VX._;3D]P8BB6H
M*!^8UF0C[T@CS*VK;B4:6!BW:/0:.$%J>HCI*)B&Q\6:A6'T@K3,<X"748+G
MJR$M1(G8.DGS%@Q,[$B9.9A82Y&C+DL)MG)XGW<-?&S(CCRAB<0<F96"*;2H
M9'3P%.8*<A+^H!9&E(8M#9#<AZ,\WF) ;D$1D@?.?X=@PKM:SS"6OM6VTFCI
M8DFY7VHI_O]2N[LH*58-]HA!IS1]''AGNKUQW6(Y@%;(,QCX6(%'^!!Y%<+#
M"2@?',6(QQ<;!(HGH_ "W'-W% \B_I6NF[7SKDH>&&DK('BTL)3S)'I; [:U
MKMD(TE4$]AC/-;=F&RTK5R\.*[#Y\D& !,W@H"AG+E[14-Q[#PH7,9(N#<@9
MCBQ;;L'S2[5T=[!Y0[L *A*KNCJ<0T0;<# 3W?X-!%M[[QT(YU0=JE?!5UPF
M7[%'7%RYIJ=#!P+= ]:+EK $\]QEI9$CY)[0/W=)FP,M%#;>&3P\\(*,9@[D
MN@;S%'(KC#NHW>@\&M)Z4<>^\N89TL.QB]"\Y8T59 B1(1<%&"-G4Z,'_VMQ
M?AXH9I"*00XB!>% F3RYGL,6$J6L($ -K.0X,Q+:$U%2?THQAVL"$.)?B^$:
MX'O;)61%2$JTU.#]0FPWP: '[F6I@8D3OA*<K9Q/45?8="O\PBC&2)Y#MO,'
M7D4>"!+A$"Z4G!??ZJJCFT:.S#C#X"-!7;H'K[^J#S\VCGS]-5@*Y2-X^>L,
M]_'SS\$2A2:R5HD@)!Y75#4#)J>('.3A\:"@3A+P(4"@>#%/!'VZD. P 0!!
M=6VRC"Z(7$X$L6#0? JHM C]JP)PLIR<_-:5"PE%9PZ@4E0:\4BP*3K1&"/S
MNN "(."YQ>0)W=FNX+*O2@3A(DN,Y3D\2ZYM9Y"=9#%1QI*V4+:"Z&:Y.A*0
M$T,2U%3,BV ODDMR%?!#M-<IYJ? ;XU<Z>-LAWJ=*8"DNJ/;H;/?5E4\SF@(
MS9''TM1R?*0JH;DXEC[;$G<SDMCJ0!;F*_BC=6-!L?0:(D]=++_!SL(>I0%H
M@$R0L827HPON4B6A,.1&,*,@N!6)(5.!?G87J-,8P^LHP@WQ N4"L0BHRTHW
M7XPX\;!K!/7^>:R/00P:<4@+ .@HNI5TG1<$$D"JD'=K*J*%^P(T84QH/-OH
M#/_H.*VM77V8H#5IX(24*%/#":LUKR<0T5C_)2P"1)&3XW(2 P!>X_4*4VV,
MO=@X(@8'7DW5KZ@.(F5*OS)UYYB7=)>5$)C5R5IBT,CC &E!()'[?<5>Z0V?
M' 2-< YTRIUSA]$/'<\4RQH";^-?*/13)^<O ?XX(QTH& @(6Q,1X:22E6!3
M!TB!8-CH5;"66#\$30];O&,QWK=%D#0J!^,$:W0>HY*6R(6]F@>$:A#=D[F!
M?VTIK@<64+&DT5G.VI=[(O"27-(#'$ @1T,0(. =:CA]!Q'4UEX3R,/0+]>#
MV',NI3I-$=T3A"E8Q6'^Y680$QA?&+AVJCYT30X*['1=Y18(G"E=&@AXLS92
M9UAW;2;E?W0.O:7PE^K>D56CS.$R*ADBL]RK_5_0(ZIC6?Q@>L_J'@+R2C>/
M77N"5_Q^#XV/63+0&;-%S QXGPFGLTAVA$H037_'>-^.'!CD [$_RCA?+MT%
MD'3+JV&1D!(V5-D):TK3N)EK*&:9@>FFQ8)*0YP"?F5#EV*4+AZ/R06/4D<)
MG&Q+X'.=+9A3UI@YMBOO*1+)HJ=IT0N%'JA*U3A*,9,N_C^)/RX($:^2A_W4
MRZ=NL=T:<!!+*MLI&NE8NE]JQ8X2;TI4D?)0&I[F6[5(%P*.5^(>I)#\<&HF
M+0TXWCYJM0/ AMOFZDXW &J@'P=<. D@3O+?IAT##4SP=AR BU6$V>*%8D=I
M+/'T6#VAXD>?)SMRVU RY\HF:FTJ+.7!E6<4)&,C#(4S;I!OT8UP=LK+3A7@
MWK6DS-=9)+8S:;$4./,-/9?0@1@:]?;BYI6ZN+E4G]P: /;\Z'P2UR?-O70U
M-6D]Q]F7U!V'&(3+-X,NTF"A(1,I1XGDL("XE!=6!:.G:!@K,8V+>@ENIT0?
M0A*O T]SZ_6A_IQ5?2"4X@X&I;H2PO&I^IM:#+RD-L9RTVW8$V(UEP6((^4*
MNJ6(;,K03FZBX'!&@;0O(%.E;NMN3HFU^('CFB/QOC5K\%G[]D"0?[X)!Z?M
M]_V!Y$/Q>"_AZN'E>;SF9I5=Z! F]%:C6^'>?GR<:1'[!;SL]H"\>(%0.'I1
M+#H_=FNT\'U8-BI.Y#VI#2*#AM/FG/.PEI];X^_9J9]=N!K+>>MU%6Y"+A\B
MER$)+P'SN7,9+(#UE2 -?!57 $,\'):4PFI5A3;,EE):[,VUMJU8,[:USU!-
MBQPX>BQRO;:-,7.LW 010RA4%Z;'/]QD2P%1,X3/CU%$*2GZ'10!"U;62\,2
M#P&18=J?*E:! %S">9-L8Y<6B ?C;8'=A.RT<-P-"<GHH(-:=#5%VY=MN^0V
M=( =G0%A F;) $;T%6FU/JIUK A*>P'-<?P8K"?4>-IQ 2P;=+4<KPGFX"0=
MJEC"K3OJNV(ZH5.@K'CJ"LA;\'=W2XR5=86+["/A% D=O41N-7;6H1.DKXY?
M'FS53C%X#F4=/"XDB)!HK<$#KC1-[^RW;D'B89V1M2/98>'0TL\WS<H35+&G
MA)HS*(+<"4I@Q<UI FZ@JLKW)M' BE0LRN_$R]? $YY,>6\BBD?) ^<A \"
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M]2P;3"*#4(LX,BK*"Q0X<!=M>"HBD<RZE.;'0]-2,D"USV/D!RST4,PHY.D
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ME<\G+]2'Q++A=$#45^$EXIT,$KCMN08<4QXT_WL-?YJ\S&Z1;^=QW.'A48U
M]NF+T3$ I)GD39X';FDYYZ]=;TML!H3)[T?Q$Z0^SL[3R,ZK.@92P^&G'$@@
MGJY(<[D*C(:8)I68\2O]%?CQ!\=1,N U<E10=]QK>.68"?03Z[4+NE>7L01
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MN-V43OO327NCB&BZ<[M_62G$.;N37Z.-UK;<LD\DR"# ]XLV+ID,)\$I_4&
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MH&4#^EX8XW<O[&#X-[+\!U!+ P04    " #C10Q3#K(.+R,*  #Q&0  &0
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M2MQJ1DC?=@0Q5,!](,PBN:621;W,$'_7E;G7&"%00$36C\8/I^S#'[SNUT&
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MF^6X&?_2E BOAZYV>GOW.33,!]&"^ W4V ]T>.*&B:QM6B:E5NO";)1?>]V
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M,CH^ ZVX57,(77#CM_BW6T6?:7+J<7EV">KQ1F98/FAYS=<D'CK=?@KX":3
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MP\M$5^);',1X=+% UTCW:W?DY'3D!#PP\O+ V/Y\9K&"7PO [*@^.'U-&5(
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M1>T#W'FAW)6U"R_0M?#Q7U!+ P04    " #C10Q3FCO')'@"   9!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q]5&UOVC 0_BNG;)HZJ6I"H"^B
M@ 24:6RK5 '=/DS[X"0'L9K8J7TI[;_?V8&,284OL>_M>>XN=QYLM7FR.2+!
M:UDH.PQRHJH?AC;-L13V0E>HV++6IA3$HMF$MC(H,A]4%F$<15=A*:0*1@.O
M>S"C@:ZID H?#-BZ+(5YFV"AM\.@$^P5"[G)R2G"T: 2&UPB/58/AJ6P1<ED
MB<I*K<#@>AB,._U)S_E[AY\2M_;@#JZ21.LG)\RS81"YA+# E!R"X.,%IU@4
M#HC3>-YA!BVE"SR\[]&_^-JYED18G.KBE\PH'P8W 62X%G5!"[W]BKMZ+AU>
MJ@OKO[!M?"^9,:TMZ7(7S'(I57.*UUT?#@)NHB,!\2X@]GDW1#[+.T%B-#!Z
M"\9Y,YJ[^%)]-"<GE?LI2S)LE1Q'H_OQXOML-9[\F,%R-GU<S%?SV1+.5B(I
MT'X>A,0<SC-,=WB3!B\^@G<%]UI1;F&F,LS^CP\YMS;!>)_@)#X)^*U6%]"-
MSB&.XLX)O&Y;<-?C=8_@S=4+6N*Q(GL.=Y@0")7![+F6] 9+3&LC2:*%W^/$
MDN&A^7."M->2]CQI[UB7A7E"<CT]H'BON2=AW(+V;252' :\@1;-"P:C58ZP
MU@5OEU0;:$@LDF6EH1R(S5-=5D*]??IP$W>N;RW/3YN.;=/I [<:N=7<E13+
M! UT.W F%4/HVG*7[&?_$]PG@KDU @L)94VU*&!=LQT^@N>(;_G6.8_B:WBO
M>>'!N)9H-GXI+:2Z5M1,;JMM]W[<C/L_]^;1X,9NI+)0X)I#HXOKRP!,LXB-
M0+KRPY]HXE7RUYS?+C3.@>UKK6DO.(+V-1S]!5!+ P04    " #C10Q3MV)Q
MII0"   P!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q]5&UOVC 0
M_BNG;)I:B38A28$Q0"I]T3JI7459JVG:!Y,<Q*IC9[93VG^_LP,9DPI?8M_+
M\]Q+[CQ:*_UL"D0+KZ609AP4UE;#,#19@24SIZI"29:ETB6S).I5:"J-+/>@
M4H1Q%/7"DG$93$9>=Z\G(U5;P27>:S!U63+]-D6AUN.@&VP5,[XJK%.$DU'%
M5OB ]D=UKTD*6Y:<ER@-5Q(T+L?!>7<X39V_=WCDN#8[=W"5+)1Z=L)-/@XB
MEQ *S*QC8'2\X 4*X8@HC3\;SJ -Z8"[]RW[M:^=:EDP@Q=*//'<%N-@$$".
M2U8+.U/KK[BIY\SQ94H8_X5UXYO$ 62UL:K<@"F#DLOF9*^;/NP !M$>0+P!
MQ#[O)I#/\I)9-AEIM0;MO(G-77RI'DW)<>E^RH/59.6$LY.;N\>KN_GWV4\X
MFK.%0',\"BWQ.FN8;3BF#4>\AZ,'MTK:PL"5S#'_'Q]2/FU2\3:I:7R0\%LM
M3R&).A!'<?< 7](6F7B^9%^1\@6E5?H-+KG)A#*U1OAUOC!6TU3\/A A;2.D
M/D*Z)\(#+4M>"P2UA&TTCN:]7AXD<CLX-!7+<!S0DAG4+QA,Y@7"4@E:("Y7
M8-U_ H/6D%+; BR9+U19,?GVZ<,@[O:_&.#;DH= W43J)EQBAN4"-21=..*2
M8*HV3.;FV/?9?2*8L36-ET7-F3#P$9).VNO1F7:B-(8GVK 3+D\JK3(T!GJ#
M"'J]&*ZYY#2#.:R4R@TY=Y,$XDX_BF"N+!-$,.C$_<]T]CMIE,)[+0]WIKA$
MO?*[:B!3M;3-0+?:]CDX;[;@GWOSEMPRO>+2@, E0:/3_ED NMG/1K"J\CNQ
M4)8VS%\+>M)0.P>R+Y6R6\$%:!_)R5]02P,$%     @ XT4,4W'M^%;A!
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MER5/([76QX++;ZG4$Q>/_>=OHQOP= N>AC>C_O/]T^,8'%T3@6D0?P0? (W
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M5%KD-1@5Y(Q7__2Y3L0!(/!/ ((:$+P#](,3@%X-Z)T;H5\#^N=&&-2 P3N
MWS\!"&M :'-?)<MF>D8UG8RDV!-I=B.;>;"ORZ(QP8R;REIKB:L,<7JR7GQ=
M+N:+:+K\2:91].-A^7.Q_$I6/[XOHL7MFES,0%.6J<_D$V&<W+$LPX)0(U=C
M<$/AQG6@FRI0<")0C]P)KE-%;GD"20M^UHT/._ NFFZ<!Z_.;X).PC44EZ3G
M_44"+_ >UC-R\>ESBZRHF^5;R3^P)"#9CIHO9L&5EB5^B+HM8[,_(O#V?('^
M;PJ<=U-/"WE)O+ 2V/%&>DTM]BQ?[P3?=Z$4*0#/O91*Z"#L-X1]2]@_0;@L
M\T>D$QORYABKN+%,4L@2\A\Y-Q]1%6Y@PYDS>S=!W[O#E]&UX\C#H/$P.--#
M+/(<SV(\$N*G*D6*,*5*2&S2HO4]N<!/M%IIJY1Y%0FO@3=U_F7@#8-VB6$C
M,>R4>+O9@+T@"#S'*>5;(!*S*8SHN: Y>R9")HSCS=7HYEJ0.^"9.+9U8===
M^]MJ(6RS,,1KM-W"56/AJM-");.CY(8-T?#/U/"7AO!+I[*5%#% HLA&BIQ(
M\4(SS:#U *Z(PH/4](^K,_JX(SS>,?NXPS]1P+[W=L5XG1:F2<),&T&S6O\+
M*0O;F,3 "FW*!+N:)]",;PDM"BEVN!5+.4JQ:-J.O#K@D<QW*MV#.S$'N;7=
MB\)J*[FN+HEFMNF0IK8O>#=_XU]'59_S1E.U77=4;O$T(1ELD-*[O,+O2U:=
M3#70HK W[Z/0>(_;QQ2[/Y!F ZYOA-"O Q.@Z2<G_P-02P,$%     @ XT4,
M4_%(EM<2 P  _ @  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULM5;;
M<MHP$/V5'3^U,VUL? $G \P0X[1T$L*$IGU6;($UD24BR2'Y^TJR<0EQF$PO
M+UB7/6=WSRY>#[=<W,L"8P5/)65RY!1*;<Y<5V8%+I$\X1O,],V*BQ(IO15K
M5VX$1KD%E=3U/:_OEH@P9SRT9PLQ'O)*4<+P0H"LRA*)YW-,^7;D])S=P0U9
M%\H<N./A!JWQ$JO;S4+HG=NRY*3$3!+.0.#5R)GTSM+8V%N#'P1OY=X:3"9W
MG-^;S2P?.9X)"%.<*<. ].,1)YA20Z3#>&@XG=:E >ZO=^P7-G>=RQV2..'T
M)\E5,7)B!W*\0A55-WS[%3?Y1(8OXU3:7]@VMIX#6245+QNPCJ DK'ZBIT:'
M/8#FZ0;X#< _!(1O ((&$+S70]@ PO=ZB!J 3=VM<[?"39%"XZ'@6Q#&6K.9
MA57?HK5>A)D^62JA;XG&J?%R]F4^NY@ED_EWF"3)]>W\^VS^!1;7E[-DEB[A
M,RQU:^85Q<!7,&&*3 FM3'$A?:B(>H;)%HE<PIPKF+&,5CG.@3!0!88$T:RB
MR':$1J>+)7R88H4(E1\ULRR0P'+H*IV'B<;-FIC/ZYC]-V(.X(HS54A(F7;6
M@9\>Q_>/X%VM7RNBOQ/QW#]*^*UB)Q!XG\#W_%Y'/,G[X5Y7.G_G/?UC[R_$
M"-J."BQ?^ ;?=:6D0BPG; VZ?;-[X!O3 ?(3W"QO)>BKIO)0:?V%[91TN5@<
M\1VVOD/K.WC#]R67$C::TSHX0ABUA-'19$S#Y[N&ESBK!%%$1_Y!=WB=Q,>N
M_JU)(TMJWM2/XR@8Q*$?#]W'_;YX;1<,PB .^R_MIEU\_<@/_)=V:0>?+FKD
MG;9V+U3HMRKTCZKP$PF!F))'!!VT5(-_4Z&X)8S_1X7B5TJ%IU&O'QT4J,-L
M$/C101VG[V-+7YL%O=B+PX/JN'NO\Q*+M9VC$C)>,57_#]O3=E1/[(0Z.#_O
MG26]CO.I'NWU)/Y-7W\77"&Q)DP"Q2OMRCL9Z&!%/6OKC>(;.TSNN-*CR2X+
M_7F"A3'0]RO.U6YC'+0?/.-?4$L#!!0    ( .-%#%/JUI8I3 8  $P:   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;+59;6_;-A#^*X31 2G0V2(E
M6W*1!&ABI_6PI$&\=A^&?: E.B8JB2I)Q0G0'S^24B0YIF@/;?JAT0OO[KD7
MWG.B3[>,?Q,;0B1XS-)<G TV4A;O1R,1;TB&Q9 5)%=OUHQG6*I;?C\2!2<X
M,4)9.D*>-QEEF.:#\U/S[):?G[)2IC0GMQR(,LLP?[H@*=N>#>#@^<$=O=](
M_6!T?EK@>[(D\DMQR]7=J-&2T(SD@K(<<+(^&WR [Q=^H 7,BJ^4;$7G&FA7
M5HQ]TS>+Y&S@:40D);'4*K#Z\T N29IJ30K']UKIH+&I!;O7S]JOC//*F146
MY)*E?]-$;LX&T0 D9(W+5-ZQ[2=2.S36^F*6"O,_V-9KO0&(2R%95@LK!!G-
MJ[_XL0Y$1P#U":!: +T0@$&/@%\+^"\$_+!'(*@%@A<"XSZ!<2TP?ND#[!&8
MU *38P7"6B \5B"J!:)C!::UP-240Y4_D_P9EOC\E+,MX'JUTJ8O3 49:95S
MFNMB7TJNWE(E)\\OOBP7-_/E$EQ^OKY8W'SX:_'Y!OP.;C#G6)<A.)D1B6DJ
MWIZ.I+*GI49QK?NBTHUZ=%^1U1! ] X@#T&QP9P(BY)+MY(/!1\"+S1*/(OX
M[!CQ227^93D#)V_>O@$C4,'I!35W:[W&6NMT1VO,<DGS>Y++I63Q-],VCK!T
MY;;T1YD/@>]5,:PM6;1\/%Z+UZ_ETR_!LOA9+"-5PTTAHZ:0D5'K]Q5R*=03
M(<"'^'M)!36M])\_U3.PD"03_SIL^(T-W]@(>FS<E-F*<,#6(&99IO0+G>DZ
MPX *49($%&K%Y?(.G-"\?F,+TJRR!#UC2E/2PSD<(B]"IZ,'"\2@@1@X(<[7
M:V+X Y#'>(-5/0*]D1DXT9@T-H/)"BFP08H4:]HAC1M(8R>DI3;X'!V<)XJ+
M4@60J[NR4$'4P-3F44\,@W;B!GZ WGUS41D==\%&$W\"/;^!6[FUOS ,QD$0
M0-_NUZ3Q:^+TZ_,V5Y WM-!AC=6^5\.!KHU"(<XE6#VI"6(E:$+5$%%5RH:E
MB1*Q-4&WJ0@-/>\W1P6'#>;P)S'75X?PNLW Z #>J,$;.15=IDQMZ_NJ#$#!
M:4Q,@90BZ12SJI.VT]HJNS(2[11V8,_^M$$V=2+[R%BRI6D*:%9@RC,=- 76
MVN(K39..>6^W1C_NKPC&GOZWN^[304V+PYIVW(5>.RAX3H>_XK0TM=+N5ZFV
M,,TE SA)3,/%Z7,S5.ODAN@^N5)Z$GU1X/S)2K7>'F0XG;@P=X8;Z"Z?AI.!
M(65@6!G<D8Q@47*BLV:=*> >I"@(+0FYJE>.';FU+%'*T&0_NX>5+8Y1MANL
MED A.C98*KVJ<1'#'/D[L%8%#AZ>\Y]2O*(IE;9DSFH;.\GT@L"5S99]H9M^
M%SFXY2S6)']'!,$\WA@^F9$']=%6["=SUTY+H3!XM5$"MJP(W;2HO"EJ;WC7
MFZ3UIM-;K)/C^&!?L2P)II&MLQQ6MH#[3+JG;#<8+95"-\%=,9S11U=<6X:#
MX>MEK^4EZ":F[BC8;)MJ'.2ZQS3CH&8KU3$U1]F^$*P-,=H?;7H"W+(5=-/5
MKR'2>6VERZ1H.)W:T:&66Y";6RZ[_09(CG.Q)EQ-B#8,R,(7/O3":6\=HI8P
MD)LP9D1Q@DK:FG& XYB5)F.@*'G!A*:U/'UZ:U*+\]ATPZIRGVE/<>$UR5-V
M:'Z:HWV&@<@/QV&_$YTO(7<C;VNS1I4<[55=L$?,W_,:Q$XW@*Y&C]I&C]R-
M_K@L=+X9E*M5V(G:\O()X"WFB1VUOQ?WT$>H'W3+&LC]Y?5J\U%M=WST?(1:
M#D)N#OH5E#]'^\QQ %]+"^@86E!E.,^*E#T1 E8D)VLJA>O$H*4*]'I4@5JJ
M0&ZJZ"KG),72I%N\]*'B6+3?^R/HBF7+ ,C- $TLER15[^[? 95WE>_43!TX
MR6A.A:Q._5QG)6U3][W7.Y%I.[;O[MC_*[J^I>O"T!%>OVVZ_J'IN7,B] ,<
M'&C\SJ&3_WIQ;-N7?^#@:/>X2,\$C"<T-X<79FC0W7CGW.ND'B9<ATISWW*J
MY W'4_3R^WO4.<36O[-<8WY/<P%2LE:"WC!4>X)7/UU4-Y(5YEQ[Q:1DF;G<
M$*Q:F%Z@WJ\9D\\W^JB\^0'I_#]02P,$%     @ XT4,4[$>(ZT! P  4 @
M !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULM5;);MLP$/V5@=!# K31
MXBTN; .QTZ(&F@5QTAZ*'AAY9!&A2)6D[.3O.Z0<U85EMX?V8G%[\]X\+N/1
M1NDGDR-:>"Z$-.,@M[9\'X8FS;%@YDR5*&DF4[I@EKIZ%9I2(UMZ4"'")(KZ
M8<&X#"8C/W:K)R-56<$EWFHP55$P_3)%H3;C( Y>!^[X*K=N()R,2K;"!=J'
M\E93+VRB+'F!TG E06,V#B[B][,X<@"_X@O'C=EI@TOE4:DGUYDOQT'D%*'
MU+H0C#YKG*$0+A+I^+$-&C2<#KC;?HW^T2=/R3PR@S,EOO*ES<?!>0!+S%@E
M[)W:?,)M0CT7+U7"^%_8;-=& :25L:K8@DE!P67]9<];(W8 <?< (-D"DK\%
M=+: CD^T5N;3NF26349:;4"[U13--;PW'DW9<.FV<6$US7+"V<GT83&__K!8
MP.SF:CJ_OKB?WUS#.Y@IVJ@E:N:]OM=,F@RUQB5P"5>H5ZCAY!(MX\*<TOJ'
MQ26<O#F%-V[^/E>587)I1J$EB8XH3+=RIK6<Y("<*Z;/(!J^A21*HA;X[#C\
MHG3P?AL\)&,:=Y+&G<3'ZQQRIS(T8@Q<I#\J;KAWX]MG&H.YQ<)\/\+1:3@Z
MGJ-[@(.LMERN4%I(=UU_"QGC&M9,5 @J \'9(Q?<OK394E/T/86[N>M)''6[
M$7FP;I'6;:1UCTK[J%C!GX_DV&L"]?Z;C_V&HW]4["5B0>?SA)XV>AQ257E;
MH:QTJ0P:4%*\G (WIF(R]8[6Z8')F:9YJ^A@2Z& [ESZE"M!&]%Z@OO[7B>=
M06_0[O6@D3_X!_+IA*Q)EK./$JCU(EEJ7X!MF&Z_<C5Q;T?PH),D[7+/&[GG
M1^7>*\O$[P>VC?I\CSKNQ-%@V$X^;,B'__W*3(?[TH;]0S<FCGZ]I]&?M.V\
MG)(*,0FQ.0)F&94NUYLM[MJ?QFC_9,7Q_BT.=YY[5VOIT5QQ:4!@1L#H;$!)
MZ;I\U1VK2E\!'I6E>N*;.95\U&X!S6=*V=>.*RK-GXC)3U!+ P04    " #C
M10Q3*2R/L4<#   $"@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6S%
M5LMNVS 0_!5"Z*$%FNAAR8_"-A [??B0U(B3]DQ+ZX@():HD93M_WR6ER"XB
M*>BAZ,4F)>[,['(YXO0@Y)-* 30Y9CQ7,R?5NOCDNBI.(:/J4A20XYN=D!G5
M.)6/KBHDT,0&9=P-/&_H9I3ESGQJGZWE?"I*S5D.:TE4F654/B^ B\/,\9V7
M!W?L,=7F@3N?%O01-J ?BK7$F=N@)"R#7#&1$PF[F7/E?UKXD0FP*WXP.*BS
M,3&I;(5X,I-5,G,\HP@XQ-I 4/S;PQ(X-TBHXU<-ZC2<)O!\_(+^Q2:/R6RI
M@J7@/UFBTYDS=D@".UIR?2<.WZ!.R J,!5?VEQRJM:/0(7&IM,CJ8%20L;SZ
MI\>Z$&<!@=\1$-0!@=5=$5F5UU33^52* Y%F-:*9@4W51J,XEIM=V6B);QG&
MZ?GB8;.Z_;S9D.7WF\7J]NI^]?V67)!U*>,4DR5KR6(@5YR+F-HROK\&31E7
M'\@[PG)RGXI2T3Q14U>C' /JQC7UHJ(..JAOJ+PDWN0C";S >]A<D_?O/OR)
MXF(R349!DU%@80<=L">MBH@=*5XR*4PF/?B#!G]@\<,._!^4EV"0EYL[$HM\
M#U)#@K70@M D88:9<J)2*L$JT"G@NFR+.(D9%#1_;JM613NTM.8P[>?^9.AY
M4W??HC9LU(:]:K\(FK%C3]I1 Q3]D[(.&_QAK] E52G!1B*Q&<"ODNTIAURW
M-E8%%9V5:C >AGY[J4:-@E&O@A5NI=+H.-HT-GK4$W;ZE@-1$)<2]Q5:M8Q>
M:0F"D3=HUS)NM(Q[M:PE%)0E!(YHOPK[R%1&8"=)- 4IC4:J%+179_Q*D1^-
M.XHS:01-WBC.12%%#$JA%RN@N/M64P)[=/;"5*U-RN25E' R[NIIWSN9EM>K
MYJL0R8%QWFHZWFO.*(PZ*,]\TN^EO!<:3W5WT>OP/ZKNC[ 3.HA/=N8'_0>C
MWF_.Z);QSC:L4<[Y+Z)Q,.J@/[F=WV]W5=YOD0_^BOQD7GZ_>ZU[7*9F#EO*
M[H=AQ_GS3W;G1__'YFO>MWS>/?NFF_L1?BT?&7HOAQW&>9<CA)'5E:.::%'8
MS_Q6:+PTV&&*US209@&^WPFA7R;FYM!<_.:_ 5!+ P04    " #C10Q3C"6O
M=X "  "?!0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R-5-U/VS 0
M_U>L: \@ ?EHFD&51J)E;)4&5'1L#],>W.326#AVL)VF^^]W3D+6B1;M);'/
M_GW<V>>XD>I9%P"&[$HN]-0IC*DFKJO3 DJJ+V0% E=RJ4IJ<*HVKJX4T*P%
ME=P-/"]R2\J$D\1M;*F26-:&,P%+171=EE3]G@&7S=3QG=? (]L4Q@;<)*[H
M!E9@GJJEPID[L&2L!*&9%$1!/G6N_<DLLOO;#=\9-'IO3&PF:RF?[62131W/
M&@(.J;$,%'];F /GE@AMO/2<SB!I@?OC5_;;-G?,94TUS"7_P3)33)U+AV20
MTYJ;1]E\@3Z?L>5+)=?MES3]7L\A::V-+'LP.BB9Z/YTU]=A#Q#X1P!!#PA:
MWYU0Z_*&&IK$2C9$V=W(9@=MJBT:S3%A#V5E%*XRQ)ED]K1:W']:K<C\X6ZV
MN+_^MGBX)^?DLY19PS@G)S=@*./Z%(.WDI9L%[L&=2W:37N-6:<1'-&XH^J"
M>%=G)/ "[VEU0TX^G/[+XJ+KP7HP6 ]:VM$QZ[7&B-9D+LLU$]2>\ME?YS^O
MU]HH//5?[VB-!JU1JQ4>T1I8,\AJO$AK#@0[@C"1RA*(H3M2U:J2&O2A^G3D
M44MNVV2;>+&[/> G'/R$[_I9UBHM\#*22K$4#DEV^/&>I._[83CRO"/2XT%Z
M_*[T5RSYA.24*;*EO 8B<R+P]:!:@]'89B\U4Y"=V=KP.F-B0Z0I &N5@3 L
M9]06CPE#Q<;6\6#!QF_<G_M>='EU>=1^--B/_NLD#ZE&;XXI'(?CMY+N7K_9
MIPLO^(8)33CDB/0N/J)QU3T'W<3(JFW!M338T.VPP!<4E-V Z[F4YG5BNWIX
MDY,_4$L#!!0    ( .-%#%.-2[\%,P(  )4$   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;(U42T_C,!#^*Z.( T@+":$\E4;J8]'V %0-W3V[R:2Q
M<.Q@.VWWW^_8*5%7HHA+XK%GOH<]=K)5^LU4B!9VM9!F&%36-@]A:/(*:V8N
M5(.25DJE:V8IU.O0-!I9X8MJ$<91=!/6C,L@3?S<7*>):JW@$N<:3%O73/\=
MHU#;87 9?$PL^+JR;B),DX:M,4.[;.::HK!'*7B-TG E06,Y#$:7#^.!R_<)
MOSENS<$8G).54F\NF!7#('*"4&!N'0*CWP8G*(0#(AGO>\R@IW2%A^,/]$?O
MG;RLF,&)$G]X8:MA<!= @25KA5VH[2_<^[EV>+D2QG]AV^7>1@'DK;&JWA>3
M@IK+[L]V^WTX*(@OCQ3$^X+8Z^Z(O,HILRQ-M-J"=MF$Y@;>JJ\F<5RZ0\FL
MIE5.=38=+[/9\\\L@\G+TWCV/'J=O3S#.<SFBRDP6< D6\#I%"WCPIS1PJ-B
M-=_!"7 )KY5J#269)+0DQ0&&^9YVW-'&1VB?F+Z Z/X'Q%$<+;,IG)Z<_8\2
MDI'>3=R[B3WLU1'8F3R?:Y6C,;! @TSGE7<QQ0VU7T/-9+]@N>I9KCS+X C+
M*']ON<:"]H#.GTMN$00OD6++Y)JO! (S!NVG&]-AWWAL=V4VZ>#^+HJ2</.)
MI$$O:?"EI$?&-6R8:!%4";P@H[SD7N(W) V^)2D\Z#)W8>D,UUP:$%A2771Q
M>QV [BY!%UC5^,9;*4MM[(<5O1NH70*METK9C\#U<O\2I?\ 4$L#!!0    (
M .-%#%._K:]XX0,  +L+   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM
M;)U66X_J-A#^*U9T'G:E97/CN@(D8%EUJ^4B NU#U0>3&)*N$Z>V Z?_OF,G
M&S@00GM>P)>Y?#,3SWS](^.?(B1$HN\Q3<3 "*5,7TQ3^"&)L7AF*4G@9L=X
MC"5L^=X4*2<XT$HQ-1W+:ILQCA)CV-=G2S[LLTS2*"%+CD06QYC_,R:4'0>&
M;7P=K*)]*-6!.>RG>$\\(C?IDL/.+*T$44P2$;$$<;(;&"/[96(WE8*6^"TB
M1W&V1BJ4+6.?:O,># Q+(2*4^%*9P/!W(!-"J;($./XNC!JE3Z5XOOZR_J:#
MAV"V6) )H[]'@0P'1M=  =GAC,H5._Y"BH!:RI[/J-"_Z%C(6@;R,R%97"@#
M@CA*\G_\O4C$F0+8J59P"@7GORJXA8*K \V1Z;!>L<3#/F='Q)4T6%,+G1NM
M#=%$B2JC)SG<1J GA^.-]SZ?>AZ:+&;C]_EH_;Z8HP9:<H9TFM##*Y$XHN(1
M3C?>*WKX]HB^(1.)$',B4)2@31))\02'L%Z'+!,X"43?E(!.^3#] LDX1^+<
M0.*B&4MD*- T"4A0H3^IUV_7Z)N0E3(USE=JQDZMP5^SY!FYUA-R+,>JPO/3
MZC_ <<M*N=J>>ZM2F8 3(="$Q=LHP>H5"/3':"LDA\?P9XV+9NFBJ5TT;[A8
MD0-),E)9O%RSK355;S@,(:C#>3KJ)'Z TRKAM&KA?#"(%DO)HVTF\982)!F:
MD82R*H"YK=:9^T:GU6M>@*R0LGMMMU.-M%TB;=?6QMLLEQ_3V72^'GV@Y6J!
MWA:KV:AX4]-7M)IZFX^UAQ9O:+&<KO0K\UYJ*M8I'7=^NF*=JU!MN]WM7B2D
M0LIMNMWJ?'1+6-U:6'.8/Q2J5P6K>_69V.U.LVE?X+H6<ZR6U76J@?5*8+W[
MGU1*>-Z^H*7!"(A\]*#:&#2W\N:Q"GENNGN._-FYQ%TIY%:CMJU3E[;^'^X@
MHIDD@48>,$HQ%W?0%Q[NP*^6NH7_;,K8M0]D%/P%LPS&OQ3J$<N0 '%(4TK4
M$:8HA7FC.0GR=7>#R&"ZP"@6B.T0D!:>][LG&#(^S:#!JVFCS. M.Y GI+*"
M!=B@0$Q$W=.RG1-HIS;I:XX3@7.ZX3,AJX>:<[<Q5H@T[&;/M6]D]301;+<6
MX,CW@0_EJ5%Y K;@?VI6$Z@\ M43^JX2MWOU\*]P7XLT.G:O=P/V:<K8]6-F
MS53)SSZ)2GSW!TZ%2,-Q;/=R[)AG]"@F?*]9HX ,98G,F5)Y6C+3D>9CYDD\
MI[4SS/<1C%U*=J!J/7<@.3QGBOE&LE23K2V30-WT,@1V3;@2@/L=8_)KHQR4
M?'WX+U!+ P04    " #C10Q3N^P*VKP$  #N$P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6R]6&MOJS@0_2M6=%=JI6X!$PBITDAMDCY6:F^5M'<_
MN^ $JV"SMDE:Z?[X-89 0@A)M]5^2<#,.9[C&8\?@Q7C;R+$6(+W.*+BLA-*
MF5P8AO!#'"-QSA),U9<YXS&2ZI4O#)%PC (-BB,#FJ9KQ(C0SG"@VY[X<,!2
M&1&*GS@0:1PC_G&-([:Z[%B==<.4+$*9-1C#08(6>(;E2_+$U9M1L@0DQE00
M1@''\\O.E75Q![L90%O\(G@E-IY!)N65L;?LY3ZX[)B91SC"OLPHD/I;XA&.
MHHQ)^?%/0=HI^\R F\]K]ALM7HEY10*/6/0W"61XV?$Z(,!SE$9RRE9WN!#D
M9'P^BX3^!:O"UNP /Q62Q058>1 3FO^C]V(@-@"*IQD "P"L [I[ '8!L(\%
M= M ]UB7G +@'-N#6P#<8P&] M [%N 5 $]'-P^'CN48230<<+8"/+-6;-F#
M3@B-5B$D-,O=F>3J*U$X.9Q.?DT>7R9@.AG]O'V\?[[_^0A.QE@B$HE3\"=X
MF8W!R8]3\ ,0"IY#E@I$ S$PI.H[8S#\HI_KO!^XIQ\;/# J0P$F-,!! W[2
MCG=;\(;27 J':^'7L)7PKY2> ]L\ ]"$5H,_HW;X#"<EW&R CX_OO0D^^9KS
M-U]S_O9KSM^UP\?85W"K";X52;M,85OSV7OXGC@+4E^"&8JP:.'KEGQ=S=<]
MP"<R/I!PMB19I6Y,^IS)U4S9,K$<6JY:-@;&<C,7=JV<?MUHLFMD6U[=ZK:A
MPZZU8;6EV"D5.ZV*'P@E<1H#+"11RP'.1.LAX%BFG((3)  "">8^IO*T:1S:
M^>&Y:?[1E.6?AFW)<TMY;KL\]/Y%>>W\]CYYGX9MR>N5\GJM/%.\Q#2MIW[N
M>&\G7;K0\6KIF1LYFSEEN5[-:K)+Y=F]7BT]&ZCLKNTUIZ=7"O3:!;(/%,D/
M%:XFH5N4_9*R_RTUPS*K==3\SU$HH)O# OM.+0I-1F;-:-)@Y,":T>T!IFV!
M&QL%JU7@5:3VN8CZ&*A-8SYP8*HG4.L PHH??D](JG7!LH\)B<H;@?D2JWVR
MSU,4-4;(WAFRGKM3HH^RNBNLMLJ]MZ]$6]6J9+4O2S<,Q>2];6"J<F\YWS/4
M586UVFN98O0Q#@28<Q8#KB<L:9P,HX)IJR:9.TMF@Y6[8W738*46P[UC7554
MJ[VDOB1*!Y6%D*SR^)@DLC%S=DM>?<VV=DMGFY=56;3:Z^)5$)#L (BBTM$T
MT4=*[2U@<W52X&]8$KH *,EV,LI4[>-'(:&H48S7Z&E]&ARPVI93E62KWRIG
MI$\[F OP&ZRGKDZGD0H%5X=<=322(5B;G8%U&JL3"9BI&4Y4;;K&U \SU8KD
MAJ6\-&_+<UA5>6A^R\R!55F%[655B<NV'1SIHSPGXNULO15!"]P4I .$CKMO
M.W( V#,/;$A@5<LA_']#^1QRC(^+9;4\P.\Y-\"J1,/V$OWI6(X/$*IIM2>8
MMP>0_?Z^8!H;EP5J+!?ZXD@ GZ54YH>NLK6\G+K25S*U]FOK8FPUM$^LB]O\
MZJFBSV_"'A!?$"I A.>J*_.\IZHFSR^7\A?)$GU5\<JD"K1^##$*,,\,U/<Y
M8W+]DG507O$-_P502P,$%     @ XT4,4^P2H8"' @  <P@  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&ULS59-;^(P%/PK3U$/K=1M/BC05B$2%*JM
M!%4%I7M8[<$D#V+5B5G;@?;?K^VD+JLM; \]]$)LQS-O9D+\$F^Y>)(YHH+G
M@I6RY^5*K:]\7Z8Y%D2>\366^LZ2BX(H/14K7ZX%DLR""N9'0=#Q"T)++XGM
MVKU(8EXI1DN\%R"KHB#B98",;WM>Z+TN3.DJ5V;!3^(U6>$,U7Q]+_3,=RP9
M+;"4E)<@<-GS^N'5((P,P.YXI+B5.V,P5A:</YG);=;S J,(&:;*4!!]V> U
M,F:8M([?#:GG:AK@[OB5_<::UV861.(U9S]HIO*>=^%!ADM2,37EV^_8&&H;
MOI0S:7]AV^P-/$@KJ7C1@+6"@I;UE3PW0>P HG /(&H -@B_+F15#HDB22SX
M%H39K=G,P%JU:"V.EN:IS)30=ZG&J>2F?SN%Q_YX/H+)J#^;3T>3T=T#?(.^
ME*@DD#*#,24+RJBB*&&"1%8",R *;@@5\$A8A7 \1$4HDR=P!+2$AYQ74D-E
M["LMTI3RTT;0H!84[1$TQ/0,6N$I1$$4S&=#.#XZ^9O%UQ:=S\CYC"QM:Y]/
MI_7TO];TGV6*:24$+5=VUQTOA5L8$$DE_!SK G"KL)"_#LAK.7DM*^]\C[P)
M$4\ZP05#D*:25?1>>#5-Q]*8-VZ3A$'4C?W-.\7/7?'S@\7'N$$&X0$;;<?4
M_HHI=YR\SN>D7-.T/Y1RUQ7O?B#EZ("-"\=T\153OG3R+C\GY<M_4@[>CS@,
MWDZSX ,AMPZX"'=.QO KQAR^'6EA]#E!-SR= TG[.RW$M&/-O:*E!(9+C0G.
MNOHQB;K#U1/%U[:K++C2/<H.<_U5@,)LT/>7G*O7B6E4[CLC^0-02P,$%
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MGKD-2TIR8))PA@2LA\ZHVY^&)M\F/!(HY<$8&2<KSI_,Y"X=.I[9$%!(E&'
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M\CH?]"4758NK)HIO[1U><:4[@AUF^J\ PB3H]37G:C\Q LU_)GH%4$L#!!0
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M7C\5FAO4BA5L5M\!PUP</##=DWU=:)-!?[#3[ :S+G;< [L(4HD'L8L'<?
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M+VUADBW1YUM0F%#Y14_Y7MD&@=+^#4NPV/N:5+ZB,[X2],29RB2Z8RFDI_A
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MS 0]ON1<'3K&0?UV&OT%4$L#!!0    ( .-%#%.,ZCJ9!P,  -P)   9
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M>'Z5R">2;<U9^<RD.GG-,%;7+^ :H+ZO&9.'B3907NB&_P!02P,$%     @
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M(D#?48?3> 8KHH1=H#OUE;D%+F!MV0I[V\KHG<A.O%-ML36 :Q+1A,HU$B8
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M2-.928?99&!9)S,_^1YF_F@:DC0,E@F$[G+$81896-9(%$.O9O/D3Q,(,\;
MLC+&X>BBYS Q#"R;(?WF0SH+_$64^5,3"A/!P+()?J56R%Y3&.NAB86E_H'E
MW \9:Q9E]7.7$C\^:JJ&#./K_(I98-"F!BXF30ZF <>R!G!,<]KD8$9P+!NA
MR5;D ZS2"J9^,R'1!4<K;FC$Q"3AM"&)1DK,%LY[V:*1#-.&8UD;%ZFZD0X3
MB6-9)%<YNY$/<XICV2E-$W?R8<PTY<4E):88Q[)B\+1H+M0<3#).JY(QEVHN
M)AFWA;4&Z9*82@F5#R8F)AFW#<ET20#5>'ZQ]^9BFG$M:^8&YF(OUUNJF(F)
M[FQ9ULP-S$<A\A=>%"8FYAG7LF=N8$:+9$QHE9N8F'1<R]*YU>E2D FT9V)B
M]G$MVZ=AY=Z8W%U,0:YE!=V8IW6)KQ33RL3$'.1:=E#S/*U+9E0^0T1-3,Q!
MKF4'W<+\E=W-+6S,09YE![W.)U_%PQK'IH<YR+/L(!,SA?;R?<&(V)"H.L 7
MA8F).<BS[*!ZZ^2_ XGIQ[.LG\M9>FWQLA052;58/_].%B8F^FK%LGZN,=,M
ME:R[ H_G-;*)B>G'>]<U3Y?,=\<JM2%)DBY-3$P_WGONH@'FA'))#K38,T*5
MVIN8F( \RP)ZT^G&@PX#P,3$!.19%M#U4O+J>3<Q,0%YE@7T%G-&]5YRS9F"
MB)JO)S$!W1T%U#N_R,_9AE<LC^$G%)2O:;%>2%(?3N\@O+MZ>W&S+XH RN;5
M5-#\_+^ \W\:OOX+4$L#!!0    ( .-%#%,X@V\FQ $   T>   :    >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V3MNPD 4A>&M("\@PWV8A BHTM!&
MV8!%AH=BL.69*+#[(%*0@U*D07,J:VSY^J\^6^/9:VR;O.L.:;OKT^BX;P]I
M7FUS[I]#2*MMW#?IH>OCX7QEW0W[)I^7PR;TS>JCV<2@X_$D#+]G5(O9[YFC
MMU,?_S.Q6Z]WJ_C2K3[W\9#_&!R^NN$C;6/,U>BM&38QSZMP;*^G4[@<Y.$\
MN1HMW^?5L'R7*I0.4@C2\D$&058^R"'(RP?5$%27#YI T*1\T",$/98/>H*@
MI_)!4PB:E@^2,<HX)DBZP9I :T&NA<!K0;"%0&Q!LH7 ;$&TA4!M0;:%P&U!
MN(5 ;D&ZA<!N0;R%0&]%O95 ;T6]E4!OO?G8)M!;46\ET%M1;R706U%O)=!;
M46\ET%M1;R706U%O)=!;46\ET-M0;R/0VU!O(]#;4&\CT-MN-DL(]#;4VPCT
M-M3;"/0VU-L(]#;4VPCT-M3;"/0VU-L(]';4VPGT=M3;"?1VU-L)]';4VPGT
M]IO-;@*]'?5V KT=]78"O1WU=@*]'?5V KT=]78"O6O4N[ZGWBF?VIBN/3]K
M?/X]J<[G>^/U\9?ESTE\7]07G /\_5U\ U!+ P04    " #C10Q3@(3XG< !
M    '@  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4!=!?0=E6Q'B
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M2P$"% ,4    " #C10Q3%9^@,>\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #C10Q3F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( .-%#%.@Q%V%3@4  /D5   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #C10Q3@_-4[X(&  #[&0
M&               @(&2#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ XT4,4ZAS-1'H @  KPD  !@              ("!2A0  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( .-%#%-+H5C7%P8
M #T:   8              " @6@7  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " #C10Q3FPP]IUD#  #S"@  &               @(&U
M'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ XT4,4Z<S
M<;I["   >"X  !@              ("!1"$  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( .-%#%/PL\Q0C@(  *@&   8
M  " @?4I  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #C
M10Q3E*47SY\(  #!(@  &               @(&Y+   >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ XT4,4Z0N<$45&0  OD8  !@
M         ("!CC4  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( .-%#%-L;.Z1S!L  )I3   9              " @=E.  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ XT4,4X!"/+9<$@  _3X
M !D              ("!W&H  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " #C10Q3PD(MUM4-  "G*0  &0              @(%O?0
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( .-%#%/;D;6*
MN0(  /\%   9              " @7N+  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ XT4,4P]H)D1 !   U0D  !D
M ("!:XX  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #C
M10Q3$L3VI2,$  "9"   &0              @('BD@  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .-%#%,.L@XO(PH  /$9   9
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M970R,"YX;6Q02P$"% ,4    " #C10Q3+4E<_6<#  #9!@  &0
M    @(%2VP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M .-%#%,RE_GSZ <  #84   9              " @?#>  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ XT4,4R==%OO! @  S@4  !D
M             ("!#^<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " #C10Q3FCO')'@"   9!0  &0              @($'Z@  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( .-%#%.W8G&FE (
M # %   9              " @;;L  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ XT4,4W'M^%;A!   ?@L  !D              ("!
M@>\  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #C10Q3
MQ@&YFW("   :!0  &0              @(&9]   >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( .-%#%/Y17<#LP8  #4A   9
M      " @4+W  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ XT4,4^M?UL5O P  6PH  !D              ("!+/X  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #C10Q3\4B6UQ(#  #\"
M&0              @('2 0$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( .-%#%/JUI8I3 8  $P:   9              " @1L% 0!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ XT4,4[$>(ZT!
M P  4 @  !D              ("!G@L! 'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " #C10Q3*2R/L4<#   $"@  &0
M@('6#@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( .-%
M#%.,):]W@ (  )\%   9              " @502 0!X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ XT4,4XU+OP4S @  E00  !D
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M=#,Y+GAM;%!+ 0(4 Q0    ( .-%#%,A.%AWY@(   0(   9
M  " @:TE 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
MXT4,4T.259-4 @  <P8  !D              ("!RB@! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " #C10Q3.LP$LWT"   _!@  &0
M            @(%5*P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( .-%#%._P0J\:@8  #<>   9              " @0DN 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ XT4,4S],*;DK!P
M/R$  !D              ("!JC0! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " #C10Q3:=A2,4$&  !Z'@  &0              @($,
M/ $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( .-%#%,U
MC1,OM@,  !H0   9              " @81" 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ XT4,4P7_<-#1 @  1PD  !D
M     ("!<48! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M   6$@  #0              @ &W4@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( .-%#%.7BKL<P    !,"   +              "  0!6 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( .-%#%.D C2^3@0  %<A   /              "
M >E6 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #C10Q3.(-O)L0!   -
M'@  &@              @ %D6P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #C10Q3@(3XG< !    '@  $P              @ %@
L70$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .@ Z ,T/  !17P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>192</ContextCount>
  <ElementCount>357</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - BUSINESS COMBINATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION</Role>
      <ShortName>BUSINESS COMBINATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/MARKETABLESECURITIES</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/INVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITAL</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - OPERATING LEASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/OPERATINGLEASE</Role>
      <ShortName>OPERATING LEASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - BUSINESS COMBINATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables</Role>
      <ShortName>BUSINESS COMBINATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables</Role>
      <ShortName>MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/MARKETABLESECURITIES</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/INVENTORYTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/INVENTORY</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SHARECAPITAL</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2339307 - Disclosure - OPERATING LEASE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/OPERATINGLEASETables</Role>
      <ShortName>OPERATING LEASE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/OPERATINGLEASE</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - NATURE OF OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails</Role>
      <ShortName>NATURE OF OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of AntiDilutive Equity Awards Not Included in the Calculation of EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Schedule of AntiDilutive Equity Awards Not Included in the Calculation of EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - BUSINESS COMBINATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails</Role>
      <ShortName>BUSINESS COMBINATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - BUSINESS COMBINATION - Consideration Transferred in Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails</Role>
      <ShortName>BUSINESS COMBINATION - Consideration Transferred in Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - BUSINESS COMBINATION - Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails</Role>
      <ShortName>BUSINESS COMBINATION - Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - BUSINESS COMBINATION - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails</Role>
      <ShortName>BUSINESS COMBINATION - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - BUSINESS COMBINATION - IPRD and CSR (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails</Role>
      <ShortName>BUSINESS COMBINATION - IPRD and CSR (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - BUSINESS COMBINATION - Pro Forma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails</Role>
      <ShortName>BUSINESS COMBINATION - Pro Forma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - REVENUE RECOGNITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails</Role>
      <ShortName>REVENUE RECOGNITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/REVENUERECOGNITION</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - MARKETABLE SECURITIES - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES - Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - MARKETABLE SECURITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails</Role>
      <ShortName>MARKETABLE SECURITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - INVENTORY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/INVENTORYNarrativeDetails</Role>
      <ShortName>INVENTORY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - INVENTORY - Schedule of Inventory Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails</Role>
      <ShortName>INVENTORY - Schedule of Inventory Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - SHARE CAPITAL - Common Stock, Preferred Stock, and Warrants Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails</Role>
      <ShortName>SHARE CAPITAL - Common Stock, Preferred Stock, and Warrants Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - SHARE CAPITAL - Share-based Compensation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails</Role>
      <ShortName>SHARE CAPITAL - Share-based Compensation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - SHARE CAPITAL - Options and RSU Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails</Role>
      <ShortName>SHARE CAPITAL - Options and RSU Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - SHARE CAPITAL - Fair value assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails</Role>
      <ShortName>SHARE CAPITAL - Fair value assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - SHARE CAPITAL - Schedule of Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails</Role>
      <ShortName>SHARE CAPITAL - Schedule of Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - OPERATING LEASE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails</Role>
      <ShortName>OPERATING LEASE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vyne-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - OPERATING LEASE - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>OPERATING LEASE - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="vyne-20210630.htm">vyne-20210630.htm</File>
    <File>ex101zeronda-executiveempl.htm</File>
    <File>vyne-20210630.xsd</File>
    <File>vyne-20210630_cal.xml</File>
    <File>vyne-20210630_def.xml</File>
    <File>vyne-20210630_lab.xml</File>
    <File>vyne-20210630_pre.xml</File>
    <File>vyne-20210630xexx311.htm</File>
    <File>vyne-20210630xexx312.htm</File>
    <File>vyne-20210630xexx321.htm</File>
    <File>vyne-20210630xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vyne-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "contextCount": 192,
   "dts": {
    "calculationLink": {
     "local": [
      "vyne-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vyne-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vyne-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vyne-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vyne-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "vyne-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 465,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 7
   },
   "keyCustom": 48,
   "keyStandard": 309,
   "memberCustom": 26,
   "memberStandard": 29,
   "nsprefix": "vyne",
   "nsuri": "http://www.menlotherapeutics.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.menlotherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - BUSINESS COMBINATION",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION",
     "shortName": "BUSINESS COMBINATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - REVENUE RECOGNITION",
     "role": "http://www.menlotherapeutics.com/role/REVENUERECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - MARKETABLE SECURITIES",
     "role": "http://www.menlotherapeutics.com/role/MARKETABLESECURITIES",
     "shortName": "MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - INVENTORY",
     "role": "http://www.menlotherapeutics.com/role/INVENTORY",
     "shortName": "INVENTORY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - DEBT",
     "role": "http://www.menlotherapeutics.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - SHARE CAPITAL",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITAL",
     "shortName": "SHARE CAPITAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - OPERATING LEASE",
     "role": "http://www.menlotherapeutics.com/role/OPERATINGLEASE",
     "shortName": "OPERATING LEASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i591be1e0085c41d689fc49b8c603ab69_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vyne:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - BUSINESS COMBINATION (Tables)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables",
     "shortName": "BUSINESS COMBINATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vyne:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - MARKETABLE SECURITIES (Tables)",
     "role": "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables",
     "shortName": "MARKETABLE SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - INVENTORY (Tables)",
     "role": "http://www.menlotherapeutics.com/role/INVENTORYTables",
     "shortName": "INVENTORY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vyne:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - SHARE CAPITAL (Tables)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALTables",
     "shortName": "SHARE CAPITAL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vyne:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339307 - Disclosure - OPERATING LEASE (Tables)",
     "role": "http://www.menlotherapeutics.com/role/OPERATINGLEASETables",
     "shortName": "OPERATING LEASE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - NATURE OF OPERATIONS (Details)",
     "role": "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
     "shortName": "NATURE OF OPERATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DerivativeNumberOfInstrumentsHeld",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i0fe5419b81c14a06b772ea4bc01565d0_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "derivativeinstruments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DerivativeNumberOfInstrumentsHeld",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i0fe5419b81c14a06b772ea4bc01565d0_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "derivativeinstruments",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ib7eaae92ef0840c2b50b035cf1e0a2e0_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of AntiDilutive Equity Awards Not Included in the Calculation of EPS (Details)",
     "role": "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of AntiDilutive Equity Awards Not Included in the Calculation of EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ib7eaae92ef0840c2b50b035cf1e0a2e0_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ib008e08d218f4edca1a33f7677210b30_I20200406",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vyne:ContingentStockRightSharesConversion",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - BUSINESS COMBINATION - Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
     "shortName": "BUSINESS COMBINATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i7ea94aab319947a592c24b80e4a7b492_D20200407-20200407",
      "decimals": "2",
      "lang": "en-US",
      "name": "vyne:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ib008e08d218f4edca1a33f7677210b30_I20200406",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - BUSINESS COMBINATION - Consideration Transferred in Merger (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
     "shortName": "BUSINESS COMBINATION - Consideration Transferred in Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "vyne:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i33adde55bdbc4eebaed01d1de7051d4d_D20200309-20200309",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i32f810ffe926407c90d135528dbc7806_D20200309-20200309",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vyne:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - BUSINESS COMBINATION - Purchase Price Allocation (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails",
     "shortName": "BUSINESS COMBINATION - Purchase Price Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i6945c947006648c0ac8f5b0f8e054f7c_I20200309",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i6945c947006648c0ac8f5b0f8e054f7c_I20200309",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - BUSINESS COMBINATION - Goodwill (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
     "shortName": "BUSINESS COMBINATION - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i6945c947006648c0ac8f5b0f8e054f7c_I20200309",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vyne:ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i6945c947006648c0ac8f5b0f8e054f7c_I20200309",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - BUSINESS COMBINATION - IPRD and CSR (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
     "shortName": "BUSINESS COMBINATION - IPRD and CSR (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vyne:ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i6945c947006648c0ac8f5b0f8e054f7c_I20200309",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - BUSINESS COMBINATION - Pro Forma (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails",
     "shortName": "BUSINESS COMBINATION - Pro Forma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - REVENUE RECOGNITION (Details)",
     "role": "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
     "shortName": "REVENUE RECOGNITION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vyne:RevenueRecognitionDistributionTradeDiscountsAndAllowances",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i591be1e0085c41d689fc49b8c603ab69_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i591be1e0085c41d689fc49b8c603ab69_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i659a1487487a4e54b0c16d985e15bce3_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - MARKETABLE SECURITIES - Marketable Securities (Details)",
     "role": "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails",
     "shortName": "MARKETABLE SECURITIES - Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i659a1487487a4e54b0c16d985e15bce3_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - MARKETABLE SECURITIES - Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails",
     "shortName": "MARKETABLE SECURITIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - INVENTORY - Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/INVENTORYNarrativeDetails",
     "shortName": "INVENTORY - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - INVENTORY - Schedule of Inventory Components (Details)",
     "role": "http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails",
     "shortName": "INVENTORY - Schedule of Inventory Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i08340dd9766c473889a05f2e9e452090_D20190729-20190729",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentOfFinancingAndStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - DEBT - Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
     "shortName": "DEBT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - SHARE CAPITAL - Common Stock, Preferred Stock, and Warrants Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
     "shortName": "SHARE CAPITAL - Common Stock, Preferred Stock, and Warrants Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i742062b5041f42418de6c43a30fbe8a2_I20210719",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vyne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - SHARE CAPITAL - Share-based Compensation Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails",
     "shortName": "SHARE CAPITAL - Share-based Compensation Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vyne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vyne:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - SHARE CAPITAL - Options and RSU Grants (Details)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails",
     "shortName": "SHARE CAPITAL - Options and RSU Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vyne:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - SHARE CAPITAL - Fair value assumptions (Details)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
     "shortName": "SHARE CAPITAL - Fair value assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ied3542c13ea84d0b9055a47046ff6feb_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - SHARE CAPITAL - Schedule of Share-based Compensation (Details)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails",
     "shortName": "SHARE CAPITAL - Schedule of Share-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - OPERATING LEASE - Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails",
     "shortName": "OPERATING LEASE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "ia9528b37507c4aee95ce81ba5586896d_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - OPERATING LEASE - Maturities of Lease Liabilities (Details)",
     "role": "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "OPERATING LEASE - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i74a36af260014e1f802fe734fdffb5e9_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i6a3d7596a5a540f69eee45235f538a4b_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i6a3d7596a5a540f69eee45235f538a4b_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i951bd7b3459a46ec95ac1e0619458018_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF OPERATIONS",
     "role": "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vyne-20210630.htm",
      "contextRef": "i8c7634a7f5af4b1e80dbbde7c8d59c52_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 57,
   "tag": {
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL",
        "terseLabel": "ISRAEL"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r53",
      "r55",
      "r109",
      "r110",
      "r258",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r177",
      "r328",
      "r333",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r257",
      "r285",
      "r348",
      "r351",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r534",
      "r538",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r257",
      "r285",
      "r348",
      "r351",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r534",
      "r538",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r177",
      "r328",
      "r333",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r174",
      "r328",
      "r331",
      "r477",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r174",
      "r328",
      "r331",
      "r477",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r257",
      "r285",
      "r337",
      "r348",
      "r351",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r534",
      "r538",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r257",
      "r285",
      "r337",
      "r348",
      "r351",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r534",
      "r538",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r54",
      "r55",
      "r109",
      "r110",
      "r258",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r122",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r122",
      "r127",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r328",
      "r332",
      "r536",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r328",
      "r332",
      "r536",
      "r561",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r122",
      "r127",
      "r241",
      "r349",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r10",
      "r35"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r178",
      "r179"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade receivables, net of allowances"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses (Note 4)"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r59",
      "r68",
      "r69",
      "r70",
      "r114",
      "r115",
      "r116",
      "r410",
      "r539",
      "r540",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r375",
      "r463"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r372",
      "r373",
      "r374",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Recognition and Exercise",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r355",
      "r368",
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r79",
      "r93",
      "r270",
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Discount cost"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r107",
      "r163",
      "r166",
      "r172",
      "r193",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r406",
      "r411",
      "r435",
      "r461",
      "r463",
      "r497",
      "r521"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r52",
      "r107",
      "r193",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r406",
      "r411",
      "r435",
      "r461",
      "r463"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r181",
      "r184",
      "r209",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r357",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r347",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r347",
      "r350",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of shares issued pursuant to the merger (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "negatedLabel": "Loss per share - basic (in USD per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "negatedTerseLabel": "Loss per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill deductible for income tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "negatedLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r395",
      "r396",
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration net of the effect of CSRs"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails": {
       "order": 2.0,
       "parentTag": "vyne_BusinessCombinationConsiderationTransferredGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r394",
      "r397",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, fair value of liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "BUSINESS COMBINATION"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Goodwill [Abstract]",
        "terseLabel": "Business Combination, Goodwill [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Loss attributable to Menlo"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Investment in marketable securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedLabel": "Current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Acquired indefinite life intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "totalLabel": "Fair value of identified intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTotalLabel": "Total liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Allocations of purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Lease Obligation Incurred",
        "terseLabel": "Additions to operating lease liabilities"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r33",
      "r95"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash and investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r88",
      "r95",
      "r100"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period",
        "terseLabel": "Pro forma cash, cash equivalents, restricted cash and restricted cash equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r88",
      "r436"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of ordinary shares that may be purchased by exercise of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r240",
      "r505",
      "r527"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r242",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (USD/share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (shares)",
        "periodStartLabel": "Balance (shares)",
        "terseLabel": "Common stock shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r463"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock: $0.0001 par value; 75,000,000 shares authorized at June\u00a030, 2021 and December\u00a031, 2020, respectively; 51,511,845 and 43,205,221 shares issued and outstanding at June\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r74",
      "r509",
      "r529"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "negatedTotalLabel": "Total Comprehensive Loss",
        "terseLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r177",
      "r432",
      "r433",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r177",
      "r432",
      "r433",
      "r544",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r177",
      "r432",
      "r433",
      "r544",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Product Sales"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r150",
      "r151",
      "r177",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r147",
      "r150",
      "r151",
      "r152",
      "r432",
      "r434",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r177",
      "r432",
      "r433",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r309",
      "r310",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Revenue reserve accrual"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r77",
      "r477"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total Operating Expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r148",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customers"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r106",
      "r112",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r275",
      "r276",
      "r277",
      "r278",
      "r448",
      "r498",
      "r499",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r19",
      "r272",
      "r499",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r254",
      "r275",
      "r276",
      "r446",
      "r448",
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r263",
      "r275",
      "r276",
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt instrument, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Base interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt instrument information"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r106",
      "r112",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r275",
      "r276",
      "r277",
      "r278",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r106",
      "r112",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r275",
      "r276",
      "r277",
      "r278",
      "r300",
      "r303",
      "r304",
      "r305",
      "r445",
      "r446",
      "r448",
      "r449",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net [Abstract]",
        "terseLabel": "Debt offering expenses"
       }
      }
     },
     "localname": "DeferredFinanceCostsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r93",
      "r161"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of derivative instruments held"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r413",
      "r415",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r75",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r128",
      "r130",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r421",
      "r422",
      "r510",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "negatedTerseLabel": "Loss per share basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r75",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r130",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r421",
      "r422",
      "r510",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "negatedTerseLabel": "Loss per share diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee benefits",
        "verboseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r68",
      "r69",
      "r70",
      "r114",
      "r115",
      "r116",
      "r118",
      "r124",
      "r126",
      "r139",
      "r194",
      "r299",
      "r306",
      "r372",
      "r373",
      "r374",
      "r380",
      "r381",
      "r420",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r539",
      "r540",
      "r541",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r263",
      "r275",
      "r276",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r424",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r263",
      "r338",
      "r339",
      "r344",
      "r346",
      "r424",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r263",
      "r275",
      "r276",
      "r338",
      "r339",
      "r344",
      "r346",
      "r424",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r263",
      "r275",
      "r276",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r424",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r263",
      "r275",
      "r276",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r221",
      "r222",
      "r224",
      "r225",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r221",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r216",
      "r218",
      "r463",
      "r495"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill and in-process research &amp; development impairments"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r93",
      "r217",
      "r219",
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r93",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "In process research and development impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r72",
      "r163",
      "r165",
      "r168",
      "r171",
      "r173",
      "r492",
      "r507",
      "r512",
      "r531"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedTotalLabel": "Loss Before Income Tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r229",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r125",
      "r126",
      "r162",
      "r379",
      "r382",
      "r383",
      "r532"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Increase (decrease) in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of effects of businesses acquired:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Decrease (increase) in other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease (increase) in trade receivables, prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "CHANGES DURING THE PERIOD:"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r71",
      "r160",
      "r444",
      "r447",
      "r511"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r79",
      "r268",
      "r274",
      "r277",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r87",
      "r90",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r51",
      "r463"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory (Note 7)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Inventory, Raw Materials and Supplies, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYScheduleofInventoryComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r493",
      "r515",
      "r560",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Operating Lease"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "OPERATING LEASE"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r107",
      "r167",
      "r193",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r407",
      "r411",
      "r412",
      "r435",
      "r461",
      "r462"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r107",
      "r193",
      "r435",
      "r463",
      "r500",
      "r525"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r107",
      "r193",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r407",
      "r411",
      "r412",
      "r435",
      "r461",
      "r462",
      "r463"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "One-month LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r262",
      "r273",
      "r275",
      "r276",
      "r499",
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Outstanding debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Debt (Note 8)"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt (Note 8)"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r506"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r39"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "verboseLabel": "Investment in marketable securities (Note 6)"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r142",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r88",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "verboseLabel": "Cash used in operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r62",
      "r65",
      "r70",
      "r73",
      "r94",
      "r107",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r125",
      "r126",
      "r131",
      "r163",
      "r165",
      "r168",
      "r171",
      "r173",
      "r193",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r422",
      "r435",
      "r508",
      "r528"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "negatedTerseLabel": "Net Loss",
        "negatedTotalLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Newly issued and recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplementary information on investing and financing activities not involving cash flows:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net acquired (See \u201cNote 3- Business combination\u201d)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "terseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "terseLabel": "Less liabilities assumed"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r163",
      "r165",
      "r168",
      "r171",
      "r173"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "Operating Loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities (Note 10)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities (Note 10)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets (Note 10)",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r63",
      "r66",
      "r404",
      "r405",
      "r409"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "negatedTotalLabel": "Total Other Comprehensive Loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other Comprehensive Loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r191"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Losses on marketable securities reclassified into net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r56",
      "r58"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "negatedLabel": "Net unrealized (gains) losses from marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r40",
      "r463"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Non-cash finance income, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other expense (income), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Permanent impairment loss, debt securities, available for sale"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "terseLabel": "Payments of financing and stock issuance costs",
        "verboseLabel": "Incurred expenses related to Credit Agreement and Securities Purchase Agreement"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r357",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (USD/share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r463"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock: $0.0001 par value; 20,000,000 shares authorized at June\u00a030, 2021 and December\u00a031, 2020, respectively; no shares issued and outstanding at June\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r15",
      "r496",
      "r520"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "terseLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds related to issuance of common shares through offerings, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for royalties during the current period.",
        "label": "Proceeds from Royalties Received",
        "terseLabel": "Proceeds from royalties"
       }
      }
     },
     "localname": "ProceedsFromRoyaltiesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r81",
      "r82",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale and maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale and maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r84",
      "r371"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds related to issuance of stock for stock-based compensation arrangements, net"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r228",
      "r463",
      "r516",
      "r526"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r345",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r345",
      "r458",
      "r460",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Repayments on outstanding debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r378",
      "r476",
      "r577"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r12",
      "r95",
      "r100",
      "r494",
      "r523"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r12",
      "r95",
      "r100"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestments": {
     "auth_ref": [
      "r562",
      "r563"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Investments",
        "terseLabel": "Restricted Investments"
       }
      }
     },
     "localname": "RestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r230",
      "r233",
      "r234",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Employee termination costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "terseLabel": "Number of employees expected to be terminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r306",
      "r375",
      "r463",
      "r524",
      "r542",
      "r543"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r114",
      "r115",
      "r116",
      "r118",
      "r124",
      "r126",
      "r194",
      "r372",
      "r373",
      "r374",
      "r380",
      "r381",
      "r420",
      "r539",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r158",
      "r159",
      "r164",
      "r169",
      "r170",
      "r174",
      "r175",
      "r177",
      "r327",
      "r328",
      "r477"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total Revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r330",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r454",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Additions to operating lease right of use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenues"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received in a transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock (USD/share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable": {
     "auth_ref": [
      "r335",
      "r336",
      "r357",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting equity-based arrangements (such as stock or unit options and stock or unit awards) with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]",
        "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r355",
      "r367",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r355",
      "r367",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Allocation of the Purchase Price to the Fair Values of Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r357",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r45",
      "r104",
      "r140",
      "r141",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r292",
      "r297",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Percentage of fair market value used as purchase price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSU, award amount (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Share-based payment assumptions for computing fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percent of annual earnings that may be used to purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Option, award amount (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Incremental compensation costs incurred"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r354",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Exercise price range, minimum (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "verboseLabel": "Exercise price range, maximum (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost",
        "terseLabel": "Incremental compensation cost"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r353",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees and consultants"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r352",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "No longer employed or providing services"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Closing share price (in usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r364",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r17",
      "r501",
      "r502",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r101",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r47",
      "r68",
      "r69",
      "r70",
      "r114",
      "r115",
      "r116",
      "r118",
      "r124",
      "r126",
      "r139",
      "r194",
      "r299",
      "r306",
      "r372",
      "r373",
      "r374",
      "r380",
      "r381",
      "r420",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r539",
      "r540",
      "r541",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r139",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of shares under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r20",
      "r21",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of stock related to merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r20",
      "r21",
      "r299",
      "r300",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Stock issued during period, conversion of units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r20",
      "r21",
      "r299",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued during the period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r299",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r299",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r47",
      "r299",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of stock related to merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r299",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r306",
      "r356",
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r107",
      "r180",
      "r193",
      "r435",
      "r463"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r306",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHARE CAPITAL"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITAL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio (share/share)"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r443",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r443",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r443",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalIncomeStatementElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Income Statement Elements [Abstract]",
        "terseLabel": "Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:"
       }
      }
     },
     "localname": "SupplementalIncomeStatementElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.",
        "label": "Supplemental Unemployment Benefits, Severance Benefits",
        "terseLabel": "Liability for employee severance benefits"
       }
      }
     },
     "localname": "SupplementalUnemploymentBenefitsSeveranceBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r230",
      "r231",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Changes in marketable securities and bank deposits, net"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r153",
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r129",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r128",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "vyne_A2018PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Plan",
        "label": "2018 Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "A2018PlanMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_A2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Plan",
        "label": "2019 Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "A2019PlanMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional royalty receipt upon occurrence of certain event related to licensed products",
        "label": "Additional Royalty Receipt Upon Occurrence Of Certain Events",
        "terseLabel": "Additional royalty upon receipt of marketing approval in China"
       }
      }
     },
     "localname": "AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_AdditionalSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the additional leased facility space.",
        "label": "Additional Space [Member]",
        "terseLabel": "Additional Space"
       }
      }
     },
     "localname": "AdditionalSpaceMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails": {
       "order": 1.0,
       "parentTag": "vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of acceleration of stock based compensation as adjustment to pro-forma results of the combined operation after business acquisition.",
        "label": "Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation",
        "negatedLabel": "Acceleration of stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of adjustments to supplemental proforma combined results of operations of the combined operation after business acquisition.",
        "label": "Adjustments to Supplemental Proforma Combined Results of Operations",
        "negatedTotalLabel": "Total Adjustments"
       }
      }
     },
     "localname": "AdjustmentsToSupplementalProformaCombinedResultsOfOperations",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_AdjustmentsToSupplementalProformaTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails": {
       "order": 2.0,
       "parentTag": "vyne_AdjustmentsToSupplementalProformaCombinedResultsOfOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount pertaining to transaction costs as adjustment to pro-forma results of the combined operation after business acquisition.",
        "label": "Adjustments To Supplemental Proforma Transaction Costs",
        "negatedLabel": "Transaction costs"
       }
      }
     },
     "localname": "AdjustmentsToSupplementalProformaTransactionCosts",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_AllowanceForSalesReturns1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Sales Returns1",
        "label": "Allowance For Sales Returns1 [Member]",
        "terseLabel": "Allowance For Sales Returns"
       }
      }
     },
     "localname": "AllowanceForSalesReturns1Member",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_AmendedAndRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Amended and Restated Credit Agreement entered into on March 9, 2020.",
        "label": "Amended And Restated Credit Agreement [Member]",
        "terseLabel": "Amended And Restated Credit Agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedCreditAgreementMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_AmendedAndRestatedCreditAgreementTrench1LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents trench 1 loan of the Amended and Restated Credit Agreement.",
        "label": "Amended And Restated Credit Agreement Trench1 Loan [Member]",
        "terseLabel": "Amended and Restated Credit Agreement, Trench 1 Loan"
       }
      }
     },
     "localname": "AmendedAndRestatedCreditAgreementTrench1LoanMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_AmendedAndRestatedCreditAgreementTrench2LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents trench 2 loan of the Amended and Restated Credit Agreement.",
        "label": "Amended And Restated Credit Agreement Trench2 Loan [Member]",
        "terseLabel": "Amended and Restated Credit Agreement, Trench 2 Loan"
       }
      }
     },
     "localname": "AmendedAndRestatedCreditAgreementTrench2LoanMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_AmendedAndRestatedCreditAgreementTrench3LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents trench 3 loan of the Amended and Restated Credit Agreement.",
        "label": "Amended And Restated Credit Agreement Trench3 Loan [Member]",
        "terseLabel": "Amended and Restated Credit Agreement, Trench 3 Loan"
       }
      }
     },
     "localname": "AmendedAndRestatedCreditAgreementTrench3LoanMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market Offering",
        "label": "At-the-market Offering [Member]",
        "terseLabel": "At-the-market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_BridgewaterNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the location in Bridgewater, New Jersey.",
        "label": "Bridgewater New Jersey [Member]",
        "terseLabel": "Bridgewater, New Jersey"
       }
      }
     },
     "localname": "BridgewaterNewJerseyMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_BusinessAcquisitionContingentStockRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of contingent stock right issued in connection with the business acquisition.",
        "label": "Business Acquisition, Contingent Stock Right Issued",
        "terseLabel": "Number of contingent stock rights issued (in CSR)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentStockRightIssued",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vyne_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Acquiree Common Stock Rights Converted to Common Stock",
        "label": "Business Combination, Acquiree Common Stock Rights Converted to Common Stock",
        "terseLabel": "Value of CSR converted into additional shares of the combined company"
       }
      }
     },
     "localname": "BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of net assets acquired including other identifiable intangible assets.",
        "label": "Business Combination Assets Acquired Including Other Identifiable Intangible Assets",
        "negatedLabel": "Less: fair value of net assets acquired, including other identifiable intangibles"
       }
      }
     },
     "localname": "BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails": {
       "order": 1.0,
       "parentTag": "vyne_BusinessCombinationConsiderationTransferredGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred consisting of the conversion of equity awards.",
        "label": "Business Combination Consideration Transferred Conversion Of Acquirer Equity Awards",
        "terseLabel": "Deemed (for accounting purposes only) conversion of Menlo equity awards"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_BusinessCombinationConsiderationTransferredGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer prior to the reduction in respect of the contingent stock rights issued to acquired shareholders.",
        "label": "Business Combination Consideration Transferred Gross",
        "terseLabel": "Consideration transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredGross",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_BusinessCombinationEffectiveExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective exchange ratio of ordinary shares for shares of common stock from the merger as adjusted for the conversion of contingent stock rights.",
        "label": "Business Combination, Effective Exchange Ratio",
        "terseLabel": "Effective exchange ratio of Foamix ordinary shares into Menlo common stock (share/share)"
       }
      }
     },
     "localname": "BusinessCombinationEffectiveExchangeRatio",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "vyne_BusinessCombinationSharesDeemedIssuedForAccountingPurposes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares deemed, for accounting purposes only, to be issued in the merger.",
        "label": "Business Combination Shares Deemed Issued For Accounting Purposes",
        "terseLabel": "Number of shares deemed (for accounting purposes only) issued (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationSharesDeemedIssuedForAccountingPurposes",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vyne_CantorSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cantor Sales Agreement",
        "label": "Cantor Sales Agreement [Member]",
        "terseLabel": "Cantor Sales Agreement"
       }
      }
     },
     "localname": "CantorSalesAgreementMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_ClassOfWarrantAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Class Of Warrant [Abstract]",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantAbstract",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vyne_CommissionFromGrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission from Gross Proceeds From Issuance Of Common Stock, Percent",
        "label": "Commission from Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Commission from gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "CommissionFromGrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vyne_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Increase in Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Increase in Capital Shares Reserved for Future Issuance",
        "terseLabel": "Increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockIncreaseInCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vyne_CommonStockVotingRightsNumberPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes entitled to each ordinary share.",
        "label": "Common Stock Voting Rights Number Per Share",
        "terseLabel": "Number of votes entitled to each ordinary share"
       }
      }
     },
     "localname": "CommonStockVotingRightsNumberPerShare",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vyne_ContingentStockConsiderationRemeasurementGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Stock Consideration, Remeasurement Gain (Loss)",
        "label": "Contingent Stock Consideration, Remeasurement Gain (Loss)",
        "negatedTerseLabel": "Contingent Stock Right Remeasurement"
       }
      }
     },
     "localname": "ContingentStockConsiderationRemeasurementGainLoss",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_ContingentStockRightSharesConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued per each contingent stock right.",
        "label": "Contingent Stock Right Shares Conversion",
        "terseLabel": "Number of common stock shares issued per CSR (in shares)"
       }
      }
     },
     "localname": "ContingentStockRightSharesConversion",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "vyne_DeemedDividendToWarrantsHoldersDueToWarrantModification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from modification of warrants that is deemed dividend",
        "label": "Deemed Dividend To Warrants Holders Due To Warrant Modification",
        "negatedTerseLabel": "Deemed dividend to warrants holders due to warrant modifications",
        "terseLabel": "Deemed dividend to warrants holders due to warrant modifications"
       }
      }
     },
     "localname": "DeemedDividendToWarrantsHoldersDueToWarrantModification",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_EffectiveExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Exchange Ratio",
        "label": "Effective Exchange Ratio",
        "terseLabel": "Effective exchange ratio (CSR per share)"
       }
      }
     },
     "localname": "EffectiveExchangeRatio",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "vyne_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_EstimateOfProductReturnRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum estimate of product sales return rate at reporting date.",
        "label": "Estimate of Product Return Rate, Maximum",
        "terseLabel": "Maximum estimate product return (as a percent)"
       }
      }
     },
     "localname": "EstimateOfProductReturnRateMaximum",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vyne_EstimateOfProductReturnRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum estimate of product sales return rate at reporting date.",
        "label": "Estimate of Product Return Rate, Minimum",
        "terseLabel": "Minimum estimate product return (as a percent)"
       }
      }
     },
     "localname": "EstimateOfProductReturnRateMinimum",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vyne_ExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the exchange of ordinary shares of acquiree for common stock of the entity.",
        "label": "Exchange Ratio",
        "terseLabel": "Exchange ratio per ordinary share for common stock (share per share)"
       }
      }
     },
     "localname": "ExchangeRatio",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "vyne_FacilitySpaceUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Size of the facility under lease, in square feet.",
        "label": "Facility Space Under Lease",
        "terseLabel": "Facility space leased"
       }
      }
     },
     "localname": "FacilitySpaceUnderLease",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "vyne_FoamixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the merger of Foamix.",
        "label": "Foamix [Member]",
        "terseLabel": "Foamix"
       }
      }
     },
     "localname": "FoamixMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails",
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_FourCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Customers",
        "label": "Four Customers [Member]",
        "terseLabel": "Four Customers"
       }
      }
     },
     "localname": "FourCustomersMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross proceeds from issuance of common stock before deducting offering expenses.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash increase (decrease) in employee severance benefit liability net of profit from retirement fund.",
        "label": "Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits",
        "terseLabel": "Changes in accrued liability for employee severance benefits, net of retirement fund profit"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_InterestReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received.",
        "label": "Interest received",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceived",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_IsraeliMutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Israeli Mutual Funds",
        "label": "Israeli Mutual Funds [Member]",
        "terseLabel": "Israeli mutual funds"
       }
      }
     },
     "localname": "IsraeliMutualFundsMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_MenloPremergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Menlo - Premerger",
        "label": "Menlo - Premerger [Member]",
        "terseLabel": "Menlo - Premerger"
       }
      }
     },
     "localname": "MenloPremergerMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_MilestonePaymentsUponAchievingCertainCriteriaMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Upon Achieving Certain Criteria, Maximum",
        "label": "Milestone Payments Upon Achieving Certain Criteria, Maximum",
        "terseLabel": "Milestone payments upon achieving certain criteria, maximum"
       }
      }
     },
     "localname": "MilestonePaymentsUponAchievingCertainCriteriaMaximum",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_NonCashAcquisitionOfBusinessCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as part of a non-cash business acquisition.",
        "label": "Non Cash Acquisition Of Business, Cash Acquired",
        "terseLabel": "Less cash acquired"
       }
      }
     },
     "localname": "NonCashAcquisitionOfBusinessCashAcquired",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net assets acquired in non-cash acquisition, net of cash acquired included in the acquisition.",
        "label": "Non Cash Acquisition Of Business, Net Assets After Cash Acquired",
        "terseLabel": "Merger net of cash acquired"
       }
      }
     },
     "localname": "NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_NumberOfLenders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of lenders.",
        "label": "Number Of Lenders",
        "terseLabel": "Number of lenders involved"
       }
      }
     },
     "localname": "NumberOfLenders",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vyne_OralBETiOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral BETi Option Agreement",
        "label": "Oral BETi Option Agreement [Member]",
        "terseLabel": "Oral BETi Option Agreement"
       }
      }
     },
     "localname": "OralBETiOptionAgreementMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_OriginalSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the original leased facility space.",
        "label": "Original Space [Member]",
        "terseLabel": "Original Space"
       }
      }
     },
     "localname": "OriginalSpaceMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_PaymentsForLicensingAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Licensing Agreements",
        "label": "Payments for Licensing Agreements",
        "terseLabel": "Payments for licensing agreements"
       }
      }
     },
     "localname": "PaymentsForLicensingAgreements",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_PostMergerParentOwnershipByPreMergerParentStockholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of post-merger Menlo ownership held by pre-merger Menlo stockholders, as a percent.",
        "label": "Post Merger Parent Ownership By Pre Merger Parent Stockholders",
        "terseLabel": "Ownership percentage of parent by parent stockholders"
       }
      }
     },
     "localname": "PostMergerParentOwnershipByPreMergerParentStockholders",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vyne_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of post-merger Menlo ownership held by pre-merger Foamix shareholders, as a percent.",
        "label": "Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders",
        "terseLabel": "Ownership percentage of parent by subsidiary stockholders"
       }
      }
     },
     "localname": "PostMergerParentOwnershipByPreMergerSubsidiaryShareholders",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vyne_ProceedsFromBusinessMerger": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow from business merger.",
        "label": "Proceeds From Business Merger",
        "terseLabel": "Cash acquired through merger"
       }
      }
     },
     "localname": "ProceedsFromBusinessMerger",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered Direct Offering",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_RegisteredOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of entity stock pursuant to a Securities Purchase Agreement.",
        "label": "Registered Offering [Member]",
        "terseLabel": "Registered offering per securities purchase agreement"
       }
      }
     },
     "localname": "RegisteredOfferingMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_RepaymentOfDebtPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of Debt, Prepayment Fee, Percentage",
        "label": "Repayment of Debt, Prepayment Fee, Percentage",
        "terseLabel": "Prepayment fee, percentage"
       }
      }
     },
     "localname": "RepaymentOfDebtPrepaymentFeePercentage",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vyne_RestrictedInvestmentsToSecureLeaseAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lien on marketable securities in respect of bank guarantees granted in order to secure lease agreements.",
        "label": "Restricted Investments To Secure Lease Agreements",
        "terseLabel": "Lien on marketable securities to secure lease agreements"
       }
      }
     },
     "localname": "RestrictedInvestmentsToSecureLeaseAgreements",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_RevenueRecognitionDistributionTradeDiscountsAndAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate of fee the entity pays for distribution services and certain date that distributors provide to the entity and sales discounts given by the entity, including, but not limited to, early payments of accounts",
        "label": "Revenue Recognition, Distribution, Trade Discounts and Allowances",
        "terseLabel": "Product sales provisions"
       }
      }
     },
     "localname": "RevenueRecognitionDistributionTradeDiscountsAndAllowances",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_RoyaltyPaymentPercentMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payment, Percent, Maximum",
        "label": "Royalty Payment, Percent, Maximum",
        "terseLabel": "Royalty percent, maximum"
       }
      }
     },
     "localname": "RoyaltyPaymentPercentMaximum",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vyne_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of consideration to be transferred to effect the Merger.",
        "label": "Schedule of Business Acquisition Consideration [Table Text Block]",
        "terseLabel": "Schedule of Merger Consideration to be Transferred"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionConsiderationTableTextBlock",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vyne_ScheduleOfBusinessCombinationGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the calculation of goodwill from the business combination.",
        "label": "Schedule Of Business Combination Goodwill [Table Text Block]",
        "terseLabel": "Schedule of the Calculation for Goodwill of Merger"
       }
      }
     },
     "localname": "ScheduleOfBusinessCombinationGoodwillTableTextBlock",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vyne_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of in-process research and development indefinite lived intangible assets acquired in the merger.",
        "label": "Schedule Of In Process Research And Development Assets Acquired Through Business Combination [Table Text Block]",
        "terseLabel": "Schedule of In Process Research and Development Assets Acquired Through Business Combination"
       }
      }
     },
     "localname": "ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vyne_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the share-based compensation awards granted during the period, exercise price range, vesting period and expiration of awards.",
        "label": "Schedule Of Share Based Compensation By Share Based Payment Award Grants In Period [Table Text Block]",
        "terseLabel": "Schedule of Share Based Compensation by Share Based Payment Award Grants in Period"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vyne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total fair value of options and equity instruments other than options granted during the reporting period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options And Equity Instruments Other Than Options Grants in Period Total Grant Date Fair Value",
        "terseLabel": "Fair value of options and RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Plan Modification, Unrecognized Cost",
        "label": "Share-based Payment Arrangement, Plan Modification, Unrecognized Cost",
        "terseLabel": "Incremental compensation costs incurred"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPlanModificationUnrecognizedCost",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Plan Modification, Unrecognized Costs, Recognition Period",
        "label": "Share-based Payment Arrangement, Plan Modification, Unrecognized Costs, Recognition Period",
        "terseLabel": "Incremental compensation costs, recognition period"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vyne_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The excess of the fair value of the modified award over the fair value of the award immediately before the modification pertaining grantees not employed or providing services after the modification and reclassified from additional paid-in capital to derivative liabilities.",
        "label": "Share-based Payment, Modification of Terms, Incremental Compensation, Modification of Terms, Incremental Compensation Cost, Reclassified Adjustment",
        "negatedLabel": "Classification of stock awards to derivative liability",
        "terseLabel": "Additional paid in capital reclassified to derivate liabilities"
       }
      }
     },
     "localname": "ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALSharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vyne_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share options RSUs and Shares Under ESPP [Member]",
        "label": "Share Options Restricted Stock Units R S U And Shares Under Espp [Member]",
        "terseLabel": "Outstanding stock options, RSUs and shares under the ESPP"
       }
      }
     },
     "localname": "ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESScheduleofAntiDilutiveEquityAwardsNotIncludedintheCalculationofEPSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_ShareholderLenderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to shareholders that are also lenders of debt.",
        "label": "Shareholder Lender [Member]",
        "terseLabel": "Shareholder Lender"
       }
      }
     },
     "localname": "ShareholderLenderMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_SharesIssuedUponConversionOfCommonStockRightsPerAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number shares issued upon conversion of common stock rights arising form the certain events as provided for in the commons stock rights agreement.",
        "label": "Shares Issued Upon Conversion of Common Stock Rights, Per Agreement",
        "terseLabel": "Share issued and delivered upon CSR conversion (in shares)"
       }
      }
     },
     "localname": "SharesIssuedUponConversionOfCommonStockRightsPerAgreement",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vyne_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for warrants exercised during the current period.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Number of shares issued for warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALCommonStockPreferredStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vyne_ThreeCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Customers",
        "label": "Three Customers [Member]",
        "terseLabel": "Three Customers"
       }
      }
     },
     "localname": "ThreeCustomersMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_TopicalBETiOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Topical BETi Option Agreement",
        "label": "Topical BETi Option Agreement [Member]",
        "terseLabel": "Topical BETi Option Agreement"
       }
      }
     },
     "localname": "TopicalBETiOptionAgreementMember",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vyne_UpfrontRoyaltyReceipt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront royalty receipt upon delivery of licensed products",
        "label": "Upfront Royalty Receipt",
        "terseLabel": "Upfront royalty receipt"
       }
      }
     },
     "localname": "UpfrontRoyaltyReceipt",
     "nsuri": "http://www.menlotherapeutics.com/20210630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124256539&loc=SL120269210-210444"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124256539&loc=SL120254536-210444"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124266218&loc=SL120267834-210445"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL120267845-210446"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919260-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267966-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 6.M.Q4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122651532&loc=SL122037091-237805"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124268681&loc=SL120267897-210452"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=125515542&loc=SL120267917-210453"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=125515542&loc=SL120269220-210453"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267859-210455"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267862-210455"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20517-108367"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4),(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r578": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r579": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r580": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r581": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r582": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r583": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r584": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r585": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001566044-21-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001566044-21-000034-xbrl.zip
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MRN8,Z!A8I#<LM14[#0&/7R._3) ) R>Z@LU.1H#0(#XOZR_([P92(T!%I$@
M_TCX\YO!.BCPRP1TKF+.PP19JFTWD:B?!EF$:!?I#$1Y"J+6U9\,JJS"AGZ)
M6_LV&YAGCAJ%4R=3E1-P\-A)K4$=YZ,:I3%BUKRC4T2<+"P'ENO8P^@#]N0Y
M"$2#<XBHYB3Y7N%F*'G#8*(+N#T+--TP8#':PB]<B)X^R5)@!.Z3\:L^.GA0
M25/7$_0.Y(2P]7T0=9B-U#;.4HD4P!BX36)OD9?2H4%5)#? OX.G*%GCH(^T
MA&KFS2)_/?G//-I$$(W3'/:C$M1;E67(F1'8P!/PL-(I*KG*0(PIK@7E"MM@
M@9AAYJ.&/ '6!IHC'A;<?7+I#<HDM)H[4G5O+@.!E33Z]F _*'4"YU"+45JB
M8X^9I$?*Y%P^8I&'-#I4^L*1SQP*<"-'Q3I'W0K?BEF+P[ Z6+$CY9B9 NII
M,B(M*[V9JR'.B>0WL*45\5D.;-7RD$VS(3SH/WP)O@(@>LGZ,UP)''^L%$N/
M04E:&HC5*'=/E<FV8^_W"OV#"?"8(&1I2P=&R%6=2YK01U<*+\X]L'NB? =@
M4P-I$]P(9*$55)IRE*QP0O#K1Q2UP-5(V_)9T =>/XCQ>!'@9$@B%18J'*%@
M!')*X:. +:$F"H)V%,=P)&W=@E2+,4"<D1O>"-0$1]ZFH&=5?(TL4" (I'1X
MM8$N$'-Y>PF\:0$J')A8JLR0XE0RU; <Z1/%*""U,9HE<&HA+0-\HXQ!0TC!
M4H =10M0QGA_GQ.R&"IXP>@]57/=Y()CN]4M03]/8Y!5<V^9!!&2]0ZYU5_L
M[#_O/:OCI_5AWVQE--;:>]Q[LK]9;+/8[1=;@@T>(M'-8WZ[2ZFB?\Z C[6\
MD\N^PPVD\J5?H9M_/][?]=[U+GK>[_#A%8C:_7W?NR@U:*?[NP>^]S+3T5!=
M =\&SH8RXQ_(@&?>[K-GNT_K;^K^/<JJEQZJG3X8RA]WR.7Y(HCA,7F=B7Q2
M(&\3'$/@7$Q4J,'"K]1*\0,9?[(KO:S7%KX;@XJ"3D O&&:@IG2[4H_!FB8U
MON;DJP0Y71B$K)I9+5#,UYI9X5C+?L.D!H4U,M;+."#'KN\JOD5PS0)0YQ_A
M@@1.E(0D*L^HW_ID6^A03P+6L)(N^Q5U,W@"+#T$D9O!?IVEX,I*]94]V/7I
MX59') N_[,<$\GBN\;)^P2W19N:ZEGR.Y+3Q*"/MQ?53617Z-__LQQ\>/?OY
MD"PZ1_$&U0NU[KH>#4>9!9$2A1BNUGTV90F-V)DV<^P74MD[73@A.;FJ(TN-
MDPL-"CDO.,.$K-/*("<?&VP(_68U?T?; IB+O6AP!P8XU<&OR)E\6Z9 ^KG0
ML<]  MZI _(:>^T#G ^&BOJ(CLA@E2/<(2@"3['47-FX:P@O%L&1"L47\0(V
MHC*\ZL&OG>?[K8YQ*=II<BO?D@T>28UR:BC_$:1X-Y&0,PNCC-?R+7#)))Q9
MPL?O(J"Z= C<P)+DNPN''L4B*F9M;>CVVMZ3WOYJ3-YNK0]M=K!2"56^S!O<
M"6!THZCUT_0Q*JXCLKMS4!' ^ 9>'F"0'/Y+2O)0%F2-_]]'N[L^; OE]HR,
M8W2QA$!^$1GLE:.^BC02RL+E68H^H12D+\73*:P< )6  H(+12HJ'>'AQ,E!
MB4!V[1V5&<;N,?C9]8A,#4O8.3[*(Y]!A&9X7^^, 10C("1R@^\]_BILX2D9
M!#>RJ[8]C]'0G0/"C(;VBH?!G*P8K9*5T7$\VMV [99@ W)1Z$DC]-M>X/+Y
M@@QG+9D+',=0BR,-5'I%&2>@B^4C4/:3DIS=Y02_??3XOVU:DLN+^A0=1FT3
MM<>I5?QAXZC[)1(C*< @5)BXH J,Q"P36_6V0.W<]CW2&]C_FP5C1:JKN'L=
M'L7;107+9CB9F U@IIIBP'"F@FRY)(A'O0/R\=6._W'O^9>2-X^;3HK5^YN!
M-X]-^M4P"_@4R2JPV "J[< +KL (5)%?F;UCU* 24&/0GX%.UL3[(\B O#8,
M_5,X$\,\5DD$$A-1%A YCM,K$[RBCX BKT9:@@$@4@'7QR3FV4B HZ+P$^!]
M7 8F0D+$ZUYL/!++TZZA*7<5W) OYF&GQ@'_)SLAJPC63U 1+.@/'YP  *L7
MZ#N9U3//.#PE]PFV8GX9 F,.+[,W+.L_O($P[S"-.QDNPN=9?U3_+L&B8+(F
M4SX(X9-,D;4!, =$"#_BR1)/E2C0A),5,XJ<9R'&M2<9ND ,?J03UA=A=0Q[
M<EQR$.@,N$7V$1 )$9/T5HQ:\5*&;]<>+*?.'"FBQ$?D5O7-T[?L4\% >UAP
MPE)?[E.$F<R3;, 271-D0?/KH$Z*_BHD$43HO$%U<9#C\V<M"H47S J.Y584
MR=N]0H<@F9=F-<XC\_91F"82+LUR9+J)1F->$G3Q"]R?EC 8)@Q6Z(ZO *I(
MM8:[-])K,#T00,-^E?H^T7?4_PM A  BAF!<4%%WNC'&TA-E$CYKB8?%*,-P
M=E,4FYWS:7EGE$$& H)R,\!VP3BVO4A 'Z6P'ESB!>.TY+Q;$",D^L&(Q@L%
M+$X>*FT/@YNT;7*Q#B0]=0C03&1MR1>IHXH57@XTVHD@@IA$&^S1;0#GIA1?
MO.AO.2>Z'O,&3A)TL2,!G@'O\\V+\%7/O--QHOO X.9<#5A&)PQ"6?GD<.94
M5\J>144LLS]*=).S@P=9.O8*X"?THO#OTDKO_>6(1^C#RPM[HHC?Q@A&T"+L
M^K'.1UWPJQFZM<1#8BF4CX0.#5B*O>64?\P./$-Y?Z5]5Y#Z2UOLSB81(2@Q
M_%9'_(6.\^DZ'6?-KDFH,(Y 32Q]ZV#;NU+J(U$EN52F04B*$;,'8%#F ^2D
M.9Y#!@(J"PI*':=3;6MF2&-(@<BY^OAEEF'J#YPHL0PZ$J.OT;]IQD]/RP+=
M.(9WZ,0J:143]@&%0C4I\)@C2F'N4T0)Y BNHT6A(PH'&7"%S"!AA0A34$%%
M@J<X23^PP4UNPV:QS6*;W(9-;L,ZY#;<";'JBM(J(\!FBS9UDY$"P(Y"+AT)
MJ H--'&KI:"^ZQO)U[Q7Q9S-6=>M4+ZR"L6U)RE6YX68Q$_E *!N3W6$QB Y
M_S@/&PT&5/BG**T+5LK@6"OK+U-ZW"\!,2NS@9*XU5B78^-=R,7W2 9+XT'B
M8(''H0T[,+?TO,.XRG5 <4Y>"0P4SQQ/9DNC@Q5S*Z4CQ3H!)?C&&&@45PCK
M%[!P]9:RM[S,N)"E$O=N:D'#/;+$.1[L[FU]W#;^F2^C$=YAY?*R4]D'I$R'
M"2SCA6BG BA'H)JC_M@3I3+BDCQQIW Z*UK::,.10MAP<AF%DJL6Q;M.F&;3
M!2C]^<OK]FL3";ZLZ\/'5A^^!V\\UW)IUWJ[6 ':? !K$-X)@O0KPX%=I4I3
MI0RRLS2KXU1!/A&V6FGME,NOT0C!Y))T(8G?=>B>,(-34_%N!S6+"UG_45 "
MJ6Z1F34@M@M?K*X::U'FS.%D N:GOO8.5QFFV&ZP+;^C70%Z0# D,!ZK" N3
M)5T&<0ZL9>U$'US>=U-Q,ZT["J84<!J4&>$\?"<2MDC9C8U4(,;S@$SNF8EM
M;.UM$S4 [\6#[L-VRH1,<B>JZ7M;^WR93BAN82ZT:D.CM(O\/+C5K4=\'[L/
MS&TEWE#W+Y G5%WKO'!*_"/)Y2!HSO4+5+Y*\EV)T4],P/H"YM3.K[+$\%!
M\E(E0&5%O@[5AO--K_O&]0BE(A4P]^_P.S4IF(J+N#JFNE_GAM*86UH]M:'&
M8%5NFD88\2E&VQV^TD4DO(!Z<9TF'M7"$#4*JKTN!UHD2M)X&Q!_]U@ HD7
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MHP#1"R.QI8*LT0\$B<+TT)#>"@Y/:31&R!O(3$;=LD:K3ZEOA@VE96'>"#M
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MK!HV]'UP*<QINJ#'TF2Q$;RZPV\ZO^;+<6&THG9@<WRR#V.[WK6?7)1Q.9Z
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MU]^MYYT,K( @2RN.^<HXN")^:'2?VB/7TM ".*S2IOH\7=BO]8O(R_XD54E
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M!&H\C(RT,,-@/BXM?JX)$'L^,F4&Z)O2P RXYI*L,8RHT(\8@_#=OJ/U-VU
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M6D?$N6:,\Z75S^0%H5T#7'V);=,<5G#^#$YR'4Y,#3%<JDPS#7 *YN%7(%E
M"@0SR&)*V=)J-,UNN ?1]X5QR6ZM]=OY$,]VOV5#L7038V(01]Q*3()B$H0
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M]4?/IF2&"A,)3!QF 4>%2 R2LNACM#SHT6S.!C'?G,WK]/FXV;PQ UQC&W!
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MIB YDW*<ME)X% ]7LR<V9L>%^MZAQP^-@%^_]"GI#8EC-":BP"7S AFO">7
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M-$[09(1J%V:?CW\=HMTBY1_PQXYISPE#I07)E&%$!5BF*>8OO9, DV!:QU3
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M*EVM-,E86B.MJV7TET1T7FCH/C1TI9468)Y$(BR2(6+$/83$0%P@:@)SG-*
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M%DE;K*T+T\1F457@M<F?7&!\X1EC?;GYDP7KLV)]*G$2!^:P='E$.2 NF$<
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MB)AD=? 8(K+&4R2!6VI%5,'JM75JRC2>)PQA#S8F^S)]\81+BHUFF!@:K&=
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M7UOG3;JP*7NUZ>99VKTO)LN 6*\LX\( E\$9 8X$+(GA0F.B2Y;!2C'#)*I
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M?ZF:Y.$'ICXY GCZ'+" @$7A@,?@@*G@A<>!8&,%$AHHRCV7D,8@D ^>*J<
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M8P2(:<^"'Q4X2//@'1D*G:PBG3Q*C4.AD_K0R51810D(:4,QQ+D4B$>+$<3
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M/ +J!;($,RJ"R5^?:09)X;K"=77(EBE<-Q?73>Q,[8G3U.4HK,UE^9$A'61
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M($\;MXM,BBI0K254)U$%S:3'4B;S0@2?# V57G&G$1.Y;4_T,L1D:,QXU%9
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MB.M.^B5J'L4(NL]AQ)VA^LC'CP]+.34BY4J6_W@P,<X@OCHQ[0TFXKUH]I:
MY[B+XG:R]H;GQ=";E4#/OQ&H=]Y8)@3"R2-#W F/=!YS[KBB2D<1272)0 MO
M%MXLO/DHO&EYS,W N&!<<8>%B=R0W.E7&.^4L;?SYFP>=:'4>2BU-;%)D[.L
M<N$BLN!#LDDM1:"YRT>^W@M+@\(Y0T6;IJ;7:RD*L19B+<1Z[^>>I<R<1!I!
M8*.%A-PWU01.(^4@HJBJ26]GUF^-;PO%+I%B)U9K#(PIXBS2C$O$N?8( '-D
M5'01@N5&Q$2Q1#<97D#7S$)QA>+J\]RS9!L)G*X19,"1<$I!&T^89L$0GSSO
M*.]F.W[?J[)PVL(X;6]B-FH<P4DE$!<NF8V>Z41G+B(0 A,MJ?0JWMZ)LIB-
MA5,+IRZ#4W$,@A-C-7&$ Y96*1J 6X>)D,+CXH_7@5AW1]E>B5PW/AAE.:$A
M('"4(FZ50UI$@X2F5@=KHE*YO0%I"GH]WZL0ZRUG[)<W\NUPNJ+-12?6E&N4
M:SSE:SRSA)6-UKN-MX<-4J6LD*<ZYVP162DR4B.U"4 ,YR%X:UTT24\$S+T*
M<6QF$,I(R4JI@<6Q,YV5$GV0D0F#;, 8<9K#4PPTPIAX'&G@EN213*Q)L6A2
M>CU"M7)&QPHY;$_?)WN2;M?]^+"DCSP$TTT"\=('ZUFNC;/6(BZQ1I89B3P1
M B*CUMNGD3Y2"*X0W /'ZD.@,GI'(I \ @Z2"4%(T%R S2ERMQ-<B2LMC_NF
M\CS 4>-8HCU!=;;R+$&6*HNT9T)K3J(1:FU=8M:4^@GD>10&+ SXP D9G-*<
M(APBP;F(S&K* F.6".PICU3>3H$E(>,QN'!B!U+'7* FHEP:CWBRRE$RU!D2
MSB1*3$(50JZM"RF;Q,@G-<:T<-'J<-&WP_.B>LMV?_K;?0;-*PRQ@02,M7"<
M>*E-=-Q8[9+Y"E::XGS40>%.'VH+@2$7VJ/D'Z8O1C@$2M)<^<A!82:"8FOK
M3#6YN3[PXEDRX():,,XRG>=1SMLV_]AHO=K>;VR]>[O3>M4X^&.[\7K[[<[>
MULN?##99];/4<HURC5NN,34IZWO2&.OF]?^Q_7^MWX"09S[4:T0IO9/3?C@*
MW4$U8+LW>)8SDDIG\"*E(J4BI><CI5F"MQ%3B,P0GCN!D<"MIL$;S[7++QRK
M6H"1RQ9@9#%E=5<4TT[7]4Y"*PSWX@%\+=[E3-[EF^EPKE'66QQT3ENBR;G4
M%)F((_)8:&D$]KCJ"H&;7%T_VU_E:.[3AG,AW560TBRDJYV2C(.* B*W)&CL
MK?5!.>V%<8(6TJTYZ4Z'])CWV KE48@^-UTD!%DE--*$:<T@6AU5O5AWD5--
MB+QYK$GU?;OK0W?X$IG3ND"U\HNWOX:^:P^J.2>]TZKK:+/Q.0R&Z>'RS_KI
M9;_M\N"3T1B4#.5! [KI^RKANIH\G-Y-2Q3ZC7!RVNF=AS#^\.E9WQU!NOII
M![IE7LKMN?(T6J\H@!.$<^Z<#E)JEOYG' TT_LST7."\E.KK;TEF/I-D8DC(
MMU]RZ6=BQ7=7<NFIB48EVY-+K1#WW"# TB!G&2<TV:><BK5U*GB3B;FGG)8.
MTZM@D!8IU82,K]NCWH,1028#E+*$56V\32RLK ,F;#)F[F"/WKW9]T_(MIB@
M=R/;J916SK2+)/&LUSI9H($89'+_,FZYEEYXB#IF"_3ZB7*!<*TA7(BV2*E(
M:>GJ< 'AF:(.E^U[3$5DDL"(#Q80(]0AGIMZ C-)'[+D5V('BDE3-WU8\A76
MUBN8()NQD-9@ H:2M5""_D5*14JKX0G?.22YX8_/!L.3T!T.#GH;:5'SS4'G
M-;3]3G<33MM#Z%36@?W>.MCH^LL8]EZL6'/OM S/FMUL.+Q2&&J4U(("DCPP
MQ+W "+Q52! 5I5;,1!Z2U=!D?&Z[H1! H>DBI2*E5932<OWHHDQ72)E>\<$E
M<S%2CP+A ?&@#++"1<2C!0KIE?*X?MKT$8J-;O3"B9C*JIC*HG@<OSQ'KJ#K
MJGP)5S6?^Y87D?,?8(B&1P&=0/]3&*;/Q)!#7,U&M_JN\8\9&(-:&2P-! /F
M7 FPA*1_'.;!)?;0LT?>7L-YQ0EC9%\^R69O,"SXG@W?;KB[.3:6-PU^_Y\C
M[$[^ZL+?YFSO^+=.>J9VZ]4.WJ5O3]*S7;S_^S"MR^Z7W>/.R?NM_,SI/O]^
M?_*?BT/ZP3BEB&$.42\(XC;W2X_)Z!:)G9WD:0>9N+:NR?5\J2KSIMJ++HMP
MCLC0TPMDWYAD8RVW(K! @E4\"F8%APB2BHBCQUPO+\DF/7WUUJ#DU<R*NXF3
M*B*/V"B%N!8"<6HD L<D$BHQ9@ /V.JU==I42C<QN3XXM1Q2U1K;Y2AQ%:0T
MRQC Y.HD>Y<9QB)WT5K+TA=!',4^8ND7Z0+]Z)3Q.OD6H^=NY#L5(10L8FT<
M0<EI2>0+5B(#(2*K'*9!<\RQ2>0KFPQ?MUP*IFN-Z<*\14I%2DO7CPMP^(M^
M?%SG9"KH%[&+CE*/HHS)KV=1(4NT05X+IK%2&.=A:+53D'7)O5F1J-_P*"W&
MQZ,&-/KA8WLP#/W@&[[=#V[>Z!^-+GH5O '!F?=6);(W7$G)N%,:+Y(,2F!P
M81SP\?; X,GV^2'=QCD(>'BQ0_8.WJ3GW>%[6X>\M;7Q9>_OW2_OC]^PUL6G
M+_^Y</@#36X1 -9(2!,1#TPB,$J@()VAZ6=26KZVSII$J0<,#3Z]L[D;0X-*
M*R:X8$J;R$&#]4YBP;#"7DA+> D-K@#RIB:16C"8*H*L X6XS0/L,6&Y+)D)
M#"RRW-A<-*GB32KG+KHKY^XUP?8->G2^PMK9\M>+Y7QO[$XZMVAF,1&"("%,
MPBX0B4PU2AB\$99;K*A=6R^8?;J8)3BHJ#P/-DK.0C#"."R *QZ-,S\]IRN.
M\*/#>2I0K(U@/F$:I7^3&<L81Y8QA0SA:7?;F)WAM74NFYK6*?NE8+ID*18I
M%2G543\N,S94]..#F+M3@6)0RA(:-:(R\&3O8HO 8XT<]S@K24^J[-"L(.<.
M%*]P>NB#0O+G8Y_?M;8;#,\Q]'G\^./9]J/'>LG2XOO>F>V$;_/MQQ\8]DY?
M9M$,>IVV__9FG6EM$2.C01KN@5(7!>.6$..%C2 H3IPII:?5$(\YHV]E9/3"
MB.S3=,R-8"Y$3#I'*PJ(>^:2H>\9(DQ*E62AD^NVMBY(4Q#2U'R5YPDN',N/
M? 3_R*15(]Z?<:#2XM=G-<G\NHUZ/R8OPZX?@J//IU.F-2? 471YV#7Q#FDN
M+7)!&RH<\U&3Q-&%F@LU%VI^JM1L;")A9J*BG'#GI"9, ,94@PK6<W$[-9=)
M><MC[:D0>@Q<2!$U,IY*Q$VTR)HH4<#$$C!:^APA2')L"J$+=Q?N+MR]4MP]
MR[@$ZYB3D48BDQEGF-5!,".L"^F'VBAR.WF7 >./P>(3VSMP+"(1 44M<R]P
M0Y"U@!'Q7F/.@9@\D49BV90*SS$<H;!H8='GR*(K-QJ] +4 ]3D"=09K1W%@
M$B*5&!,>2-28QJ 8CSY&*X(IKFH=C)SITVQCB&=2<A2")(@G!Q49L(",L]A;
M)FFBSK5UQ9MZI8>ZUX:[JV/X?PTA_='+^HZIDJH3Z']L=ZL_GXNIKE18F:D?
M5'^H^LG47W<A(;%_I0*+Z,578!%\I\/X@Z/0 )=;(4/W/ ^GZO:&Z>K03S_N
M-MKI5C_VH=,XA7Y5:S4\"H.0J 7.?'M8]5#.3S#JIMRMQ #YQ['=A:YKIU\<
M#-,/JC*H%U?+9:HOHQ]<GZ^=U[KB""HLQDX%08WBPEB(WE*J*0"7,3CZ@>JU
M&P1T;;G7?ORWQK\V7AE.1T5RI[U!U>/M93]T8-C^''[]TO;#HTN^G?K%\4[%
MDU\!FU;C;'C[K]QVBP^W 6ZNP=/?53%-?3WJ3VH(/P9D^P$^(8CI7E]"YPN<
M#];^=146"1/?+>'W3W_K,\;X8,\X@EK24[U^U8WO9=53+'\JW1/4YEX:1_VL
MG/_KYWM>)=AF9AJ53::]T\VU:+!^DR0?=<?=3#E_';:V&P=_;+_=>+W][F!G
M<[^QT]J\S@YU \KF7FMKN[6_O=5(K_;W_MS9VCA(W^P?I/_L;K<.]AM[OS<V
M_]AHO=K.3Y3>V-O\WS_V_MS:?KO_WXWM-^]V#@YO?<@IC5+=3ET>^I=W+_9?
M).W;Z4!_D-1!4@"]LW1!/V@VPE<7LO+-V3Z-Q/OPS]K+\)=WEYKK]GN]1;F/
M=/E84U>&P83\*V/$Y44Z'827ER]^]>W!:0?.7[:[U9U4O_3K^/)CC2&NCZVL
MUFKT]I@^C7G!B<@,.DX,'/_A,;F^J,CU.]MJ]![#+Y+1>.O;^ 6Y];T?7=:\
MD$S<ZZH_?D_<\ZKE7LN]_NA>"7Z!E5R1FS4O&+_;57^2*_S3A']S[:-SM)EX
M<(J_6W+QYE0;B9_4Y\^P4M<_NOHK->E@G;R[MD^^Z..I[[O=L1OUV+ZS6*^&
M$6X/%-Q!['>]U!/8%LZ=G9QU*C?>A]AV[6%9\"4M>-T!V!L>A7[=;S+'LOKA
M*'0'[<^A[C>[TTVW&QJ_='J#P3\+SAYRJ0]Z-^N.>:VH:VMYIZCT"B]DZ^S$
MAGX./HT*?6;=MC]>G[+.WQ3#2>^L^],N4S/L5$K*$MX1]4^LSG+C]=N=/QND
MJK/$"ZBS?)YEE,KE5BG:!M"$>VT@"$.=UDQH'"R,,KPQ9HP\\3+*O<WQ"?KQ
M[\=[6^\[AW27[^;?N7ASL7O\CJ>?I9\?G;P_WDW7^JO]_M7AQ>0$_=V7W9-#
MTJI.PSLGK:TW7W>/W[??G[0ZN\>.[&Y]2G][@[0NG+AV@GZP<?[^^!W=._AX
MOO?W(6YM;9^W\@DZ?7?>NGCW9>_@3?K]=ZQUT8F[[7&*X#Z^V/WXP1L9M/$:
M4:5S^R/&D)8T( L1\_2/53&NK1/19$HTJ;X^UF!5#]&?2G[3,T]?>D[92?>B
MV96J<5P1 KV8(E 2B0D1*Z2$U(@++Q HGV>?8TD46"KS0*7"FX4W"V\^#F]R
MKK@*CD>@AD>!07%IA&3>NV3E!'L[;SZ%K,X5H50R1:DA* 72,I0T'D8\&:@(
MO.-(<FR-Y40E6:VM<XJ;G%WO452(=4YBO5<XJK#N<V#=64H'P>L\8U*"TX9S
MQ\ JKH6&X+RPC,C;:?=)E0ZN"/^R*?ZEE$4!VB,<\R@ RZIA6PJYS,K&$1E=
M6%MG C?U#<W,[ULZ6/BO\-]3XC^BA$CX"(0[S8VG( @VSD5P03''_1WXKY#<
M8DE.3).<HLQ30I#FC*$\A -931TBF,LD(XB<)9+CBRN-+OQ6^*WN_#8#O?F@
M@U':8YSH302E77H9($"R"XPSI'C5-2"\K]\:9E[L?,#&&,981%J1Y%9SS1$P
M*Q$64A+!C8S6KZU+TQ3LZ;1D>^!2R.6.KGN<S.%QZ<[6N[<[K5>Y0*GQ>OOM
MSM[6R[LGN-R[]WJY1KE&7:^QH%29BGS4U/C)QS:);BGSFTX?'2=F-MI5FN8\
MB3-USHTI@Y"+E(J4BI2>NY1FB7H98#Q0&[CWCF.@6@4A%240*<?<DVI8#,9\
M-"P&+Z9SX!7=-"H=:(7A7CR K\5CG,%C;&U>.0<@P3.<!(@BS<UUN(K(.FJ1
MP@[;X+RSAJVM$ZF:?!%QLH+G)>%YEBB/TB"EXYZ"YCH&*Q-A"^<4=Y%PZN\
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M75T&IU.#FAT8/8=@(G\ "\(T/WT.-5VW%W=&9E]<DO5-%GF7'373S0TU=Z@
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M5E@%9=/,;9?XJL Q-)< ^ T.3FBZ0&)5%'"WR?FB&VSW&U4U0P^MG="7^\Z
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MK&,(^GY7\+_4)E52'F92A(0C\C,!R"\892 (:)&E"4M$KN\LZ/O(:C\'(!R
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M"X >D^T=T'R7NO<_+<]]IYY-1?DU/;L'9]73<%;=Y]3?EC9? 6F>F&%^YG9
MO-1"Q\A4%E$J"><X,HHGG C*,R)#00N>B"P3F"L]RN-OT(9V\,CO$*\/(+=;
M'OD!Y+X2Y'JYU"*E4<X9T:D!<S82=BX>)S23<1ZS LA+69!CCP?D!@_\H_+
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MA>3ZKLOX=BB2/O#XSNHE Z/? :/WBM/BU*0:CJ_ 0?2,1XQD2@L2B3B,39'
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M/P+D\VIA4%1JC@ )VZC-!S.NIJ@I3NMJ6I<V\6H$FN*D^F"U-3N36I=%86I
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MS2=8Q'[P2V^IXZOV>?!R\/&RWTW"3H"H]<*28M[>6#O"$<$E9C?-1'WN<KJ
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MR8@/@)6/'L.@N]Z9.!P;]/;GXV[9O]X#T@P:2L,C^[W2SUB P92^Q>LZ2#5
M_^D/1L.-QJ;![#(@E.YELV''@Q*JZ-H[SV 3^M:GJ TKX!F?FH)^2^UJD#(>
MQ0F>TH.'#G^'7X<CI^R".S5.4)\X,_(9>?X-'5,/32$L#3QE8SZ)N;&2@:=;
M_>S3E7D3HD('L$;((%=Y-\9 !)TKW!C5.$4(*Q)6J 2A*%>X<>I&Q_"Q3ZL-
MH!,!3D6=G0WZ"O,* ZT.2E XCP,7*'P:K0*N/PDP+;[->(YNYN"@1N*=P7 Y
M<CW,+L)BPBZ.IPPC#LK34](4[MN@H\<EF%(H."P(P2,9]8=N[HWCX37C\8YS
M)$_\H3\>%5.>UCA]0BBF>&[,,.$G0RWKU-UUZFZ5:*5CK7+%J*.1$!E7+LVC
M7%H#)K)34?20>9[+)FN\M,3/W:UMVOIT&.>)L-PX8GR/ &UR(A.;D93;A&DA
M$]BII6P.FKA<4Y?$0H#ED7(M;9+G3#,.BB:/]$.F9Z_W^$Y[#!NJ,DH5R83A
M1&1:^QY?Q$0T3B6526H%*O\;\X6_=\KN'4T%WBNY]9B)OE/9/>MLWZ=)O*V+
MW4_K;-\7L<OK;-]GN*?K;-\7L,OK;-]'RO9]M_=Y):=QJ^\(!MXX1[?A$$Q3
M&TQ4M(T+31*_WCP:.*\5-ANVA!-%MT =\;")F.6XX25*=< OQT\VO7<79N>A
M[1O[!1)UPVNH\"LL06GD-AM__?6NZ>^J'#XN@*0"Y9$2Q-HG'GH'$)#B6'4;
MWOV,0P8CV:%V.L%X-QY5/P"I5\X,X$-G+J"O%[T' J#[\$[NCFE[O^Z>K7"R
M+Y=N3L"5M2Z.M=5&.*>5LQ&U%+3;**96V'5S@E7@L>:\?70HF:*4NY0D(#B)
M +$'DE1$Q,8B,I$#JXYGMS0G*/GDK0:95EV%V._#8^?QUN;.7:#%"=GA43YU
M:C@>+ P7&'CJ47\0J'78Z*(7JL&+!R\$EL?^!MZM[\?A76B;>^\:6103#I(]
M)H6[;ZR'[C]C.*_=RT;I.X0SC.Y[.&7^4;YY@H>]"*.>!S8NF='$7UW X'=Z
M9N!9$!SV<(?W4!8]&L[[XZ[UX0)D#-CMP1QW8&H-[\0[&_1UM3R>_?F%'78*
M*/O@44:!58+MCQIG?02#@,->N[LS:1HQZ<0P-*ZG!IW^\+?&:_5FRKLX<5+B
MPJEA.2J,931T'Q.U%[E2]1)/Z?<P:;SG%CS)[\IK<\O#/&Q_^4 PYLO/K(-=
M.O6M*T)H2#M@+PYH[[+!:4%Z3T_@K=W?/\7]/17WZ\^M\:Q.@:0UK!_YFH+A
M%[UD Z:4/R'Z=ZTX!6FGW6!&HNHHRER464:S7#AK%%6<YVF2IF",:!X5Z18B
M2N;,DIJX?.?#@T<PMHE<W//*11".0QC(RS4Z]H\H.H7 GN>1X4#J7!#!P+14
MPAJBK>6)5=I1J4$@;K H8_,B<6%GGJ"EU76WYDS/G1Z&G8OSLWT!]@=L4N,S
MZC.SS:7R)0E'J)SG@E/'(B6HXV#-)E0S&\M8:6YHY3-/R%TH:+L<9CE*/\@7
M3#/?&$8ZHCS6B@IBL=^;D#8G6B'$11JE-E-&Q!E#FLFB:($:=1.A>*>T9R.%
M=N!9$[)7?U?P/GL68ZH37-!6$*I>WQ@BQS*NR%A W\+@\D92"D/Z":1T-[4^
M\*0=;\1] 08]X4Z[^9Q>_]$-*I;[8@FQM;]YOKMU<&@Y.B5C2AR("2)2'@,E
MQO 3L+0XS466).;5VQ0Q_D13T'E@ZKMRL)!+T;TL,QA":SME427RZ36C0;]4
M"4#(WR3P%A(;4U$<Q3JES&4B=2*C5'"6<9TD5M.H=*4SRDCYPYK8?AVQ7;2O
MC@XY%8FF$IB=3B626$PR!K^RQ')K,D&505&9-1.>-$&<WL3ZIFGKK')DX%:X
MXN/A&1@N-4GYWNG!&'AA\,!15GC@&L KZ[WE:IQQHJ8!L9X-'"G$ZH+V>)Y9
MUBY9T,*N?]X+&407WKX#,E].-J=.2:& =U(I1:IBR0P3.@.K6Z5:2%8QU+1D
MJ&F=QMD4&7_L#T=AJ!\56GV[YST8XW'G[(_+CP,7OMD#N[9C.[!D>[695G1,
MV,LCY*OVR;=#F5*3V@34/=#Q@&MB%R4!BI]+DCS/G!,BBUZ]7:#O_<M3R8KO
M>OAFKT:Y+WS'KPX.56:8PAV/DP1[<MJ8R$@R(N.8:LT<XQ(UMOFLA7_YFG58
M]2F^T*P9P&@V>HVMUK+*&Z"8Z'0)QC,BP!8^FT)_6\BA&K#=_8;RW*YP&\^8
M!E5*XBP?<_\9^T+X<S6P@9'!3P/E,R%JO3H7>.!"[T;T3WG3V3O1BJ=\5YVN
M*MO1'>'3:OF4A=?AOX?EN\$$[\'L&D\T"=54EO),Z\E9>(*ZHZ_N/(=EO,YS
M>3_W9.3=DQN-S5Z9<3V U>YK6+"B*6:_<:8NKQ_Y\+AT+$ZG6$_Y^0<S^[5&
M1IY%1J9K9.35&,LO1$:^-]+Q:C&V@C5?PV5 QVDVMCJ^F@#8TC%*B%HA52,?
M]$\;V_X1S<"6:-S8@I%\]X<]R)G_ZRS,_2A$/8LL]C-0VXU?_R\;>QN-#YN;
M'XN4\WMSVDD]R0WA(5] ,17* =YWW?4+@SP;E7?%.W"O8YM-7ZGBFP0/W6C4
M#3VOT>L22A.^JT'1W=+K@Y6,KV1FW?@!H7FS8[]*G5XF(ON#OANLVT,_/?QT
M5[-ZQM?\KKZWGUVQ#6A&?U"=WHO&R86?KW;WOQSF-DME;A@!?F:),%22S&H+
M$D0[8[C0263!"A$;Z?6A6" MK$'I#=U/2Y/UB0G%_E6'<J)"%*^](? +#\ K
MI@.FRQ#S_8(A2Z5_+T@LF!#T%"V7+/+R)=,OW=UJ'7*FT]3IB- ,@0IT0HD&
M*B92)WG,4P.F+L4^4&)#7$_ KVM64PC?P8=K/_4SHA76VC(/X*<N7(<ATVOM
M>7XYY-/>;ZVHYSEHO2H\>](I_4;1!MOJR>"AX_VE(/,/_XA#><E$P]L@GW*0
M2'G"@%0TBX@ HXXH*2GAEL81,*1,8[D'W1#S, 5S>2!ORG[WO4KE!\4'MK#G
MPAY7)DL5?,7"2$]T&ZOI$ULR1_CCH-]XCVQN)2=SJX.OR+4-41UL_^IUV]#R
M=1(Y+VRN*E_JQU7HHO#\7K5FC=?E;469NS?)?7;(=/:R]Q57S&H+!H>?>:CC
M!8]MUH :0JFO!7O=WUI8JF4^<:AJKXK<<31%_>ZE4X/J3(#1#39_F>$X,4#.
M@&2\9/3<M5>8Z=7B%R\S7N6&RS%G$0R*8V7GO*4>!Z" >P@JXI^JAPRYX=/Y
MJ/23N18(]N< 4<_:#IN3 <-A\6=EIQ<T P28?M'8TCN'4>XT!=%%#-<I 4'&
MB8HB1BS+$'[$EW(_2:SHS3IGJ67BU]C"+)NYC:U,W7X_WK&Z4,CI1DS%?:"0
M8[D!)_WA08NSC5C\#(1E+G_28-D:8?G>",L+IAOB2X\$S#8'Z!L%C06/^O4]
MI^XPX6G,K&E4K&NA ^_[G*>QJGLW]O&:6M,['IYKUT_.KM\\--G*+MXU)^Y+
MJ=>]N<]*/1D$S\]!5;T&GW/!K)XV".;S1*O\T<:>,["55V[0MVIX?(>HP0+-
MOZ"HW;PL5=P#?=#5K 4TV((6^4Q0*=O=%OLB#J[,Q>[6'\<')Y_@^9MPS]=N
M:[_%=S^T+K_N?[K:W3^XFD6E/&!?KK[N'Y^TK[9%Z\/[3GL+YK(%EL4IO._*
MP#/_[+:W6F!1M!$U>=+KG*4V%W'BB%0L)R*#OU0D(Q(K;:VDTCHP+]YZPY[]
MOAPLY4/@1RXG1M9<YDEPF1_M-;OF,D^#RUQ57$88D5.69R1UJ2 BIL!E7,R(
MHHF#W769=/DC<IG[-OA8,5OP1OT,4T<::A3@,\N2:>]\61;U_OFPU[M-\=GP
MW0?0[NZ>W+0<%]XN$&AW!TBG:V;\T,SXLJ;RI9Q9DSE%:&(D$3K61/.($<HE
M!SX=:6?C5V_39BSG\T_NUR?CYVF"#]Y :,W<5FENOU:I7#.WI\K<)IIFJG)*
M,YZ03&4IHAA*(C,K2,Q$8C3G,5 &XO0T$SZ?'OIXW&U!GX2;0D]A@'KP[[=S
MX:I?'9>"@[H1A<.Z=& JWN#\;D&991[+,(1TW^#3C8&I3/R<P=ZMH^B/^M:?
M3U#'4_ZR@9UGNSZSX9E;5N<6,BKY O!%=_,J_:HK7TY MND;<ISY%BE%=J15
M(W67..W/ZC6Z:G6%B\)I#]C<]K[+^'P"CP_N['JT9LA[7SY^_&N[M=W>W_RK
M\?'S;N/][N?69N/=;NN/G?;V5N/S]MZ7O_;W&KOO&[L?MS]O[N_LMO=^NS-5
M+6UZKL0S'J&CY,PQ)'C];Y1NL(DNNY+!ZCNMQ7/S$2R:XK/Q$3QP>/M.KH&:
M?3\L?0,%^3T3*__@_.N'S\>MK2_G!_OVM'7U^5N+?>ZT3UH77T\_77W]9R=N
MG;1H^[3=F>^E^,>WKQ^VS]O[?QRWV<%5^P-<_V&'M:[>GW[=@GF<?+ML77UA
M!^S/O/VNYL+,(\EA_QQ).2*>RTP0J6Q"F(QRI7FFI,42!=I,LGEHDOOU4OR5
M/LP?;%2[YD^K-+?'"XRO^=.OY4]\DE7C0)XD3!!!C2;"19I(ETO"N<AA:Y,L
M2@7P)]X4?)7XTR.8!BNH'+:+0ILEE<-U .EI,]]'C8XOXL) ASN^"FX*]6/-
MB^_ B_=JNF(4&<5=$A-G8RQGS5*BHS@C+C-24*%%;A%N(4F;0M 5"@FM ]YK
M?K6R >\UOWI@?C71'35E"K1&2J((@3YTQHD6DA/)<JIRDUL;YZ_>LBAN+D+6
M?^00]HOW+/HTRTGXAGC\4A,0Y0.BZ=KG^+QM^FN02GY0O60U;GWG,OHR\:@<
MTE:@P*>.</)K>7.]6@9419Y+J8AR$1CW.C>(A.R(UMQIF9@\M_S)4L<?R*G6
MM'%OVLB-43EGA-DH)\*WSHTU)\)Q'FFK),TSWQ!GWLA8(1?0VD6]%F=W85@_
M:'VLQ=GCL:R)J<%YG#BI+.)/,B*2!,-HJ2':Y6!V4/B*WM+8?86I8RW.?H@V
M!.-6.VI)EF6&B#P51!F;$JJH2W))F8A#?[=YT, 5$F>%45J^J^1Z(@#XK$A.
MSJH\XQ$L^,?)#-OT(*@!B*YH3SD%Q38!8*M UA8"5#7G$*J4[G]WS9M1U1Y2
MSUJ)9ZS#ACY-'?N4%R+2](>C=?SP9?GC?S)VBD="KC&N_?Y>C66!$N1OKA'A
M.Z3!M1M^"?UGMQXV-+G57%)#>)*ST*M4)1S4H50ZYFPD>&SO"5FP#ANNV=0#
MY_JO6)+9FEG]"F8U,=9RD^:Q3A*B>)808$U@R+O4DECDS&0BL7$6@[$FFI+/
M>Q_GRHO6T<)?I3-NPHIV2[Q:!#[W*/JAGP?"-CLX'_C=+08$6V[=%O+KU6-J
M3TWWJF_F;NY;4OR!._FNMI%K%K<$BVOM;R)["SK9YB&G-,D3E1 #"A@1&5=$
ML3@C242Y$IG-XT@]F$:V>B&59W[:GZ8*LS[S/^',MR\G9]XE60;LG*0BX41@
M9%7:2)', HN'?=<F8XA51*7\ ;UFG4+_P [6_3ZZ46NGYWZ^L#M78S]3"_3N
M\U]MWO[4-+EWA=?_<W#Z[^:[E<M_S<R78N;;=05.<9L[KA2Q'/-B5 P*7$(-
MB60F#'<JERQZ:)?:,H .J^QO6[/"Y\$*GZ::NV:(#\<0:]JMY'DB+$U)&DM-
M1)ZD1+/<@FWKLCB-,J41%IFQ)N7SO?:6=MO]=%:X ,3NWU,MQ&X M0NOZF!_
MI]%O/+D-Y6X!+-&C]\H;NH4]W*YI6I5W>JIG.J FEZD%Q^J["QW;S@;N3 V*
MSG&=;A=F-@B-YL[&@[/^$!MR]KJ7H:J@[YO1^2\&HZ+UW/6MZ:8;;(V.U:AH
M\0>/.^^/NS8,(USN[,*N<GUCQH-!Z">'W^6=P7#4L.JR?)E3@V['#4=E_SV8
MSQ !DFRST?=MW?/Q"+MBUP95M/>:K(_O:M?!+I#8AO!>"]N90'#",L&BX4(-
M7-YU!F;=NRQ7HG>$+4L[IN/@/E=V(X3A#]5WS"@+RW0*\],X9B"W*U=K*MB!
MF1U-?+B^SZ ;'+G!QHS5 V<!^7NG-U8A3PH)V?-,%NLH,JF+F4Q!\]4JMYJQ
MC"G0@7-GV*&0KV[&A40R?21CK[V[O]T0#:^WT=\;/[EK8(%-\!Y6'SN-(S?\
MIS,Z?@=GI ]O7)5V@;M[A30Z;=&O)P=P_:>KUH>_3^$]K/7/GYV#_8/HX,2>
MMK?LR<$_^+P=.MLN\. *KC^!L6V!M/KG@+>W#BX.3O\\;I^ 9&('49NUC[_N
MHV3Z.]_=^L+:GPYC9M*,F82X.*%$L$PA,$I$E(2]TSQ+8LN#E@%4Z.PFJ@;P
M8:YT0A4%/5R81%.59KDU"8NYB:-XMKO@Y^V_M]M?MAN?M]_M?FCO(&S6')^?
M;2-9I_NP,;>_=7J4FN=P89R8/$M$9KFBSH).A"[A*!;Q"G4]O#L"8-D@UHZ!
M(>V!%C6\5M"M;!O'<OA%J]+A'=HN!DMNKO<B#;^=N] 4&F8,HVT<N1XRZ9+A
M#G&5D,UNMKYN;W\J;O%]6<_5T#>I=@/D_G!K5XU[YGB2G/>EYR7('K:+Q.:2
M53-4WS061_IUYZ__;Z=H\ZJ= <;34-]5I^L1=>&&LV,% L4+B8#V?-ZQ#L7@
MKAGUM1N$MJHLVFAXJ377%K=@4E5GRX9J=#NG?E2@G>,#8&;AR2"__-HY+ZT&
M[BA\9CO#T,*A/R@$%6AD"H:&JM.9\_I3N/',X3*,+FN#;H)Z<.1@*0:-U[@@
MKZH!O7I3#'GJ^<.Q'KK_C.&1L)HHP[O=T%8W['FSMDTC[.$) ^G6U\C+383T
M1#%=OQ,O/X-IHL6QT4# C;-I,FITX.[+,U0U_:M-_ZCGI>XYMI*>K&-?^\G?
M1=!.IP +MI&BV@G:E%=J?ANXKE>8)K#&_YIF*04H<C2Y16G0.L:CZV]9%=!,
MQF86J/;W\6#B/SYR1(-^\XVH' ;[F^J>J\OAJW]/,R+@0C-K.#O]:R>9YS]M
MDH$A@G';#YK8;V#_N %>!6-2*S.6!C!%4(3^U^T:7PHVA6<[P!&\#N6]Z.KM
MHIU<*&!O%9@S I8I;HU3CL6)%LRE.G+4R2Q66L@\SO/5$; WTCI.:M#OEIKX
M+ LN^,RP;.;M;1ELC .L^*P/JKP7%C"@9HW_C,_0@G!=8 \#;^34V)@W7$I^
MM(&MWFO2[^9FP]1W( =IYT5><8<Z@2=,&)QGH4YAVW%CP*@O^XF?]OTML+XT
M^I>?;+_(7)^6QB *FIB*KAKH$SAKPC>5-=:XUA<5A-&,.TKH1!JM8B4D%=0E
M6E/C!$^!C*60,BJ4=S&EO$\5]4QK\J"^(U<,9^1S9_CM(TAN=#L=.5IYE0A[
M88I\:W\SWMW_<M':/[AJ7VU&H-1S92+LRP(')F5$Q*D@,HT%22CL !S7)*)@
M'L;)G(OH!L( <5^2ZNU=L:<)->^/!ZM,IT9PD[C,2N,28'@V4Y0GF4S _@$3
M(^4+C<PUG2YK<.X?B4,#/-A9;0C-34Q$EC$"\DL3IVQB$J6HEB WTGGGY=TH
M\RY,-/HU3/2!:#//8CBO)LEBRH5,I4JE%D"GN<VRS,;\]CK_-6TNS4/I[N9A
MKJ5P<2)('%E*1,1B(D7J2)KR+%,YYZ" O7H+.NQ/8Z)/BU#3Q$8L P62.2.H
M393(#2B.0BM0LXQ);Z_@71/J70AUF^U^.LQ!A;+6,&)LY(A(3$0R&E,29VEJ
M<JF$0.B(!2E.-]'F2KJ2?L0WUH#?OG>&&+A8R;DMXR9#_P9Z-0;(*GINA/M8
MN5[P=.;.NVL&RGJ?C&<&\('"@E(%1VF(AUNC(ZO9,,<P:X=Q/^P@ K,\]?ZR
M@1N-![W %/K>Z=/Q9Q"L&+C.NJ&!M\%UVL$S-RH?RH+5892!G?H35V<ZM^,Q
M]J?NKVL -S+C;O 2CH9^?V;]4R%'OPB G1_W@3Z!1J?"9#Z$Y#GZJ/YLOUGA
MP1/&#[=[V[2@;\_T7W?>S!) 8/ U&AB.458,ZVX[3SH%X%AY&SX.GGZ*K674
M)<;VF_!X>'Z=6CPU!9.V,[#D3 W0>:@N87S-TEL'DX(O+N&50W@C#@*?>S10
MI]-T6".Z<A35A?X[>#N\'H73X'OA-'879\X4(;YBK3T!KR8GN^VTUW?R]I,=
M7+GU]?/A41^J=(5,'SA<%7P$[I&_'UB(ZWQ'-Q$\TK.17AE)710:U:KKMVQX
M[-QHH['9[19[-*&\LJ0=@Z(5@YG>R##8L#EUFETPY&Y'Z4ZW W1TW@&JZJ%:
M,QAC=/?"^X2'RPUX9EG+LUA1T0Q/"RLV15"%GJ0O \?YKR6R<92,6:9Y&D>I
M$<HY&1N74:WB.$/KTM[B_B#Q7;-QB@CGY^#T]HTA:_2SCQN_56[%9L]N5NR@
MTJ.2%Z=&U?7]3U?M\\,L%5*93!,=2T7 Q(H#?$G.E>,"XZ N1=3?C7D(S08P
MA"X2 Y+Y,A3RH[FK:PKY113RY;QU?@@&.+!:I@F5QF>C1D1+"K:A59;E%O90
M@](=;\QKW16!Y,LX>STY+;(*@7VAX .UK'L)%N6C,KE[)6BL2?B7D/#)S@78
MBHQ:$3,=DTQP302-&3 V:HAE+#89<TD:QZ_><KHQWUCBWHSM1Q-1UU3Q,ZGB
MLGUT"$>691FCA*89B+L8!%]F+"7.4%\ GN?"80'XQGSY]QPWNT,\X(Z\;-\G
M'D[QKZ !8G+#Z+KG;H%2BQZIXJLBI<*G=RQ#M"S5J5,NCREP>B=A=206C*G$
MIDGF*#W<N3<'JSFUYA+0-H=#-VJ[T3M,D>R-7C!AMBY!RN94@$#1CDA'L5,7
M2%DE(@9JF6,R,CS-<O7J;;HQ'[RZ-[>BJ>5.)5F>"2UDI*5S5*G<I#1)-4N4
MW_B(,D[7&_]S-OZJM7DHI$A2*W.BM=_XQ!(PFG*2)"X'G3QR-.6H7ETOIJ:Y
M2;-F6\X;DF6*UPW6XTIZ$9;RA]Z4XU*7DXWWI0?(2\S&UI3A/A&:C^EO^VW*
MX7:F+H?!;S7G+D&IT3'%?/#;,N$-.R-7&6:3G#7OD(!)%ZD9Y1OP[I!*B D=
MQ47#FD\#7^6]S' C^N:F'CKO/_/"#>AN@;,-_2"F8!!CGX:.*7V8[X[7U0<5
M/%[#^??!&)P:>))>^(YF< 0:="!W>D<P(^N=0\.0CS_N@GP]]4ZWD :S>* ^
MH1+??33H#X<+HDG!<XG9,,'1./G&NWK*I+QG?K0^EVZP=S/^S5WO%JM.U^,>
MI\=TWY?!C7" 3I'G^/6#'WOJR%EB5$']1_WO;M"K8#8[!OV,E6.XS-/=V-OP
M)#8<ZQ,7TJP*7^3&H\8(6F$ZC7>!_H/#W">.>GY3/_3J:.!<A3#J,V?+U#/\
MH%B8AE^8_N!(P4$J:G)PF8H<6BPXZ;F\,RJN#XEJ]=>$06"=31%,]8OH+LRQ
MZATYS[>^][OC4[_Z_\9(LAI\<Z.@6OL6)1M39'VOR4PV%:ZLU="402?;&> N
M3J(=,Y- .BBSA7$]0#ZY00AW(SET.UA)5%XS'TFIHB^8?_</Y@<'CK=H6%A^
M=-VHSL8#>.30U>9V/.B/CX[K;RB8XM#5_"X='XJ9"@0-JM'51UQ:6+:3YPZ4
M1(/U7J-S%X9<FR-*Q(Z=$V"UBV 8(8'17PTZ3_GM9%M";=+L-#>F!&\9_QD6
M16*!I&>#$4" I:@*]65]#3S<ZUB8R%U(7"]<)F((EF@270K2Z#:1,R5Q1C7C
ML8B6%N+F'C/PM'6W:83(GD_Y]!&XR;O^&R-V7KFOR#>\J>>.^J-.B0D\%5C#
M@1\I+Z7#!F$\#33<BW $:V'$2<S-:S;X7-" N@5?:!81LTX/5@1TA,O&L8,]
MUY?S%0&O.]_K[P<-8.:F8I6+?'UD%3W7W2C$V40]*&L4%J71SH<!X29<LHJ7
M>U6M5HU!.KWA&(L&R[S_QBEHY;@LI4+G8#,Z1;AHX/XS!L(]#04"N-]E3+96
M95>Z$L*K9@<$-%.M+G"2<D%\/G57=8HX9# :0JEB^'P^9%LCFN(=?9@3D@U&
MM2;)P'@?,)!0PUFK65##DI"?N:94Z@&?0^#VY2I$[X 1 !TBI_ D FP8:WC1
M\$ CU[AF71J"R)N8)CZZ'SC2),0:F&H90PVU/7D'#U,HL,4#@3Q3N[Q?:%J^
MA,.S6B#?3E&>BG;QXZI0U[/NB<%23#AP2'^JSCN@<OCB6UP1/%++RYIE9<QC
MTH^7W)/BY2 ' E%4?*Q@X3[%IXK"ETQ[^!L*KT?=Z6,X /T!5E!,R+\^J8E<
M''@:* 0&B$!?]E*HP&[L\08FA\"KQP6?P8KWO-_M]&]B-3]]LTJ)?P$'SI?H
MH?CVQ[[P7WF70B6"NT!OW<K6F:0.37D]"J%<2OV;GXTYGF;0.?-W/N:>6P>/
ML(^Y%Z6G9D(K7AL"30(T#*2U(6A >0,K>88U5E/Y.FRA(>".7*]GHIUR!K=>
M^$^ :2^96RL43U3.DBBBPM$\BUCN4BYRF^<Z=G)Q9()-1<JVB^'LYH70#3+W
M,WS4@IF>CD]?;E9M>_\3;7TZ%")6-K**<,EB(M+<$*W2C#"II19IXFR2OGH[
MG__Q+SQ3J[6CZF*]H^WS0XVU)HXJ0FW$8$<C2K2 #58JE2SG(A(68]^+TZ1+
MH3&K2SP#G?S5V[] I\0P2!% ?X()TKN]QN;9 .Q1QFOE$C7W1P^T.O2W5*8\
M%E3[8! <5TPU#"M0^:J"F'P'\E1YJ1   ] 8.T<'%H(%%(;G=*DH6/G!101K
MY%6/TTZO;RX-#KDB(@.BQ4>9,#L2K4TO#[Y[A)M@;EZ 'C9$ !YL .S%_8>!
M4ZB3OP,E7FTT&E^\BW1=NGYSZ3I?EZZOQEA^8>GZ,RE%]V:F&YQ6 %<5;VH6
M?,G+(@^X-<4R2EX&C*T N !C"9U?:#\$3J-\A7M JBJ=;#"T@LLU"R037U7;
MR2ON5(^P-!OOWVW1*"X_FV)/..Y!!]\W#6421NR;I5T6V%^]SA Q5HHQVRD7
M](3[(OOTW'1ZR(WQ$/3LQNYX-/1(*GGA\2_FCPU"<H=88]/2H$+S*M8.5L7:
M3@&;<N8&WLI$MEQX>'U@)82D_#X,!A@>"7'<QLY,P*0V@NFWAFQ[[WUHC,_R
M01\=P6IX7,:$<?C+)*HXGN9<QPRQZT7B,A5;)BS3H#5*QJL:NRI?6/Y JA+H
ME,8Y.T3<K,_]2]5%;+7/Q81>;*X*7$?;FX=@"6C!;4ITP@P1SF9$<:K!4A Z
MCTV4N(AC<>C&?'5HE:4$I\BGJ;U>B@(T:+*.L1QN!8LD5[&,M<Y$9+F,C94/
MD3&^IH!;*("UCPZ53J*4F8SD1FDBK*-$4980QSE/-*.)X2!UDIL(H.(.!3^]
M)BF\429++IW7EF16R3B+XSSA8-L:G<8ZRQS8E2F77)7E!>F:7?P\8FE=MHX.
MP>9TJ4TX22022Q)S(J7.B4TDTS)F*67LU5OQ@\2RY\Y&/@^VHI@WGF1*^S6$
MR[HN1 K\XU PU03A4M5-BEDF5224M())EYDD8EIE1AF:Y3SZ@6S9 F*X'%8@
MITM/3&>C+V?]WF[ $P5YO9N_"S;9-GI+7VY6=_OD$V9UQSQ5B5:64$E3(B(M
MB(XQ>381@G-K*;4*>S#?0&BE:N*#LR%DX-<==960"X)>T4JG!'(,^E^AB05H
MUUG=KM )2S6M,_1YEZ# ><Q:,-,+ MSYB&9V39_RUZJ":,?#$*DJ<UPJ0-7R
MN6C ]\>C,K$S8%6A)[W?_>Y*A:NFH(5A(<("O'4)VM?4))8J6,TX%H9*H'X$
MC4DDCZ622BQ7V0?6@L&#<-X?V*'K39V"+T%KG#X"+YC*#_CNYF$J>!99QPGH
MO5A^12."ZT]28*Q"T-SE*5!YKS]/Y"6A5"&\&R7O=*G!C%U3%>,OPS2U35/+
M!>7,@.V;"K10,V;C+..2@DKQ8'4Q:[JYOI@/OCLZ="YU618)6&?."3!'3D"U
MUB1.&<NH,6!HJ=LT^'Y^,T$M@C)=4 2SR&"&[9X(Z4&I3Z&K$(NV*TQ3O'[.
MCBZ*_"=W31S8589),<XB&\ 7\81G#H#+*K!K"YB[B0D\>9R_DOAT(W]I2)H!
MB]CY@.+,=#"_)<!H%^=E4M_3+3.I\/EKW>.IGJ[VR;<8;.('U#TLD(?7/V[6
M/69\+Y,POQH6.!<A0Z10-T8#A2TI:C3]70TZ7KDHM9'@4CP:=ZQW!H4K-_?>
M-9(H:9:QDJ!WE!4]PS)L4*5+-E8REK)D?*B<7L-7*87(>/797P5* W"#F28[
MJS3CV]HO3)R#'3OM&RR3-3%S#R?_>MR#^78]\ZKP,][4.=C95$*[0N9\'6CU
M#26+'M"PS//R>FO(=Y\D>Q5LN4C; OJO)R?!*9DPUZH@=H8?/\!D,45J1O 5
M<UZN0G,U ZD/0#;=R?GX,5H8+7A=J144S-)'"I7]'KS7V"FCFR,[!;+!?;K.
MMUULXR3+>R7W8DFF%5"_8,%..\,G"OL5IF F4YC-]AR%G*^"[7C]#:3=<7\P
M*DL@^CW7N'1J4*8K#XH<3_A3%#\6J.B=7FC+LM%8_-8B-=!KBUC# 335+(<2
M4D;M*49SREXS)4;/LZ"E]Z$K#!PC/("PIKW12D[KSNP*%7%7U,,B'\$D"-_&
M:T;[*;4JE^<^B1W-##!C0)KD':- G<JKE3'ER@1ZJED4]2J5,B@7GH15D1TD
MP:,^YB$/RGK-66CLX+HL'UM]&@H__1!!],T^H[1TJB, WR%2VD;@K7LC>*@:
MV(8!JN^,BEAKT1 )#1@85AIC8Z+G0<.%]5(E^3P'9:TS#)V>ND7*>S'%2AK.
MYKI.;.5*2;.84-L_<[X:1M45+NS,V%6ZR&4(SYKR%Y8K61K0DQSTI0 'HL@:
M%BMNC!%@)&DPD'0BG9)QDO+$/00RV!W;'VU?%.!MJ.?#?W9?7;Q82[;N)]K=
MVD30)YVK),^T(L))L&I3$1,=L90PF1MT-TA!V:NWT<9\#N&]X2C D,ZR.(ZU
MI;G0D= NI4SQ5 B;"V-N@R-?4\=/ZY@%X_^$?HZ(.VI(ZGQ.J6%$2:F(A4U2
M%K8NHBE21'P]17A Y\HA9L>#LMAO&;\AG0,">R#F9(V0DD8N5K'@49R)- '*
MHU&.T,),/(2/>DU^/^K$/CIO;1[&3HK,QC'),P,<2HB,J%1GQ*:<"\EMQ/-D
MJ6;:5F'Z"OYEJ4A8)#,>4<F<MEPQ$]&'3"]9[_T/[3U&C#3EA@B%>)69 S9$
MC2 LM2J6+E7 (9 -S9<K_&2^-.O6^9$NEC%;\2Z6<8/\[/Z5[U5G\+?JCCV0
M7;>/-='#%6E:25M5"^5O\<%I*P+J//D*_\(U%ZW3';'[8?MJ]\,.T*[A[=//
MI[L?WG^;/0>[^/RKSR<MUCZ%?V$\VY<')T?B8+\E#C"T<&78UP\'XN"?S_GN
M_C=VR'+*9:8YT=*"2N: Z+76.4D34,KR-)(ZT[.]JE2FXI2*6*0J$3R3RD0Y
MBV*JG%,F3Y+9EI7O-W<^-_[>_.O+=J.UO;GWY?-V:[N]?X^NE;>^^.VO(I_@
MR-_LV9KWON64K['?[7UVZ M"=MNS[7YO4/[Z!Q8C^.3L%TQS_#!C4G)*'3&P
MB43P.",R48KDD:,@,%W.M9NEH:=F6E=8#6H2\JE[LBNXE=.":C#XD -Y-;XC
M?141@&N]V0ARU46X!5^'7@;*??@MX-)V@NNR2-$)(L>HD3OJ#SI3,+9PX:MV
M?^0:#+CO^\D BG&=>C ]L.*_N]^6ZP,>1E/5P/CNY]XC<#9TOY4__([]*;OJ
M\K=.SR^GO^GW8H.+PAFL%)GI?.Y?&+XNBDBDW$BC%.M(L WZI!][46*RX4M,
M9GJUA^\$W)G*:[^.-NBUW]WT6!IM  .YUV-O_B[F?#W8IS58=J?'_MM3;J!>
M.!]XUO[/*_YJ4F5E48/_+6I0KZ:5SZLN973N6G9V@5?_/E=/-GN@PEGZ]<J?
M+_TJN5RC9' 5HWF(99E<6C A+S?.1@T/5=DHIW?#DG5=/L>!J@5[U*J]Q<KT
M7^B2;= 9R^$'UV6]OC/K.]O5=[V^#[N^LZ6GZ_5]J/7=QY9E"U;W%DZ+6&[8
MV:YG23%28YS+\WLOS6.HZ"V?^1944S3+O#8^)6\F(OK:"=^94*+&BJ^)E[__
M]?/F7Y_W %^Y4A-?PID;R51FU*I$6BX82[.8:YZS5!BA9,;%-;#F? D?[H0T
M]RK*K)RT_&DZ"HX/3B^ZNZ=?&!C^4?O#EZAU\ND"G04'^U_A79_.O^[OT!8Z
M=?_Y$A_LV]/R'GC7^"O[DGS=/X!G?HJ^[G^Z;&^]/VE_:!^W3V%>6W]T6R=?
M+M"I^W6_>]QF7_-6)[KX:W][U-J+L,&,2R(N+;$JRHC(<T:T4Q')=9Y38;.4
MI?&KM[09L73.ASL3VG_H4X'?+GDZ;I):M['E6<FWYFYK[C;;.TO'N;0N<S9/
M19RDBJF<6Z>%Y4Q+E]Z-NUVY0=^JX?&:L3T\8[NJ&)LSF4V$<H3S),9F,Q')
M<J.(2N)8I#1F0AOLZ9DQRGY?L[8U:WO9K,TQFYF$.:5R*QS7&<LD3?+4Q2DS
M-K5KUO;8K(U6K(VG<:+3/"&@K0%KR[D@TB:.N#@3W*5I9&F^9FUKUK9F;2&W
M45+MJ(NB+#:"VB23N1%28P$G5SJ1:YMT)?@;K_@;:-32L<@2%0O$N<D5R33/
M2>J422C3L E/S2;U/L-_>PJIYRC5\SIN"Q2'&>G!O]\N%V!^[.1YW_8#Z[Y.
M%_D4ZQE?"_.\&A46PA(@E+74A_BFS(?KUO..F6+QBF>*)3\_4VRG]]T-1[X,
M8J>WY?1HLV<GW'#[/^/.Z'+"$^'+HGX=F[X5B9:CX23+;%42?MJ39,O+-B9-
M_K-#=[?>?VM???Z&/&QWZQ/_>G)TL;O_QW'KPZ>+]M;V@F3+'=[^YP#&^46T
M_OG$VQ\^L8/3;='>LJ>[6]MQZ\/V^=>M[:BUC\F6+:QGYSK**1:P<]"^B<AB
M1S*:,A))F2OF$OA6SJ:917E.P;)-@3"Y2&@DK>9*9L!$F5!6T-D4H=;FY_^W
MO;_YQU_;C;WM=U\^[^SO;._=G&7V%)**%J?"W;XXTXO)0'66(':L,)%($Y-I
M8U6<9RY5)LH<NR8R<F,>4JAU&V)_K$X/ZZGSQNG8]Y3*01(-:X\)8.XPN-'4
MLZ>SF.!5ZKOJ='$(!#04XH'Y?6ED/9-V*D_*]\_J%8VW)A\W/;(')C^I"_CN
M=0#A[((4@V>_:18/K#6T#)C#6((W<,>N%W! ^\,A%BFIT/WA""99Y''U,8MZ
MTK.P2+*:S*Q9QSF&)YYVQJ>-_J2[#Q83@$PM>PO-EH<6B$LV5)=.-=4<CN!_
M)?A2_ZPH,PS;Y*=0=N1\#0_LG^)<>[[[YIQ0N>X<O$B88[&&.5Z-L?Q*F./;
M..(,!Z4ZMM+DB5&9%";!_L8R=HDP<22=$/*)Y*@&S:7.AHLB3U!;?"=3K./M
M]/S2UO-1KTU5+1J$3=BP1ZZ;W G[X\([.Q.5:J:':=7K[P8F=E?..)QFC7,0
M,C]7;5QD,+]DW:^U>2A9I%UN$Q)I(8A0"24J,HZD.F8,SDX>)_F33??.^]@Q
MS!MZA>HT\B7UT[7.53;X0E/Q^L3JNYA[3R7/.HTV@'$^?((MVXAY\E2R@7&P
MZ2_)!IZ_]&DD Q>ND5E'UTM:@EH^]'TRH5?$O7]W> T_Z==>O/?'\%0[?'.'
M[;]OMN8*;C@J$P]+\,]K<98J"'CJ::I^TCO#@7+=SI0_99VENHX(WM:D():*
MBBR%_Y3X_]E[TZ:VDF5=^*\H..^^I_L&Q:YYZ+[7$;2Q?>AHB;:-VQ>^$#6"
ML)#8DC"&7_]FU5H:$8,PML%H[S -TAIJK<IZ<JC,)Z/@#GLB@]$B$N%\9-=P
MN=XQV>%])D;;!?=P*C;^:#8#[^G<5)N!QWMTYR.,X7*3P;_+UBY\?^E%<^N0
M->%Z>Y=O82Q[O/GF76=^,[!UO"?VC@\OFUL>_C4)7)>U+C^=[VQY.._/X];6
M-H'[GN^_^6<V0=5)'(53'J7,-,"U-T@G&I *7A-+)96&K9(=5M"V@K8";=Y8
M0"SF5,P,.BY:P6ER@H3HG.>6/$"RPPK?OA[?)GFJG/I@L9 (LY@0MX(AQR5%
MD6I-'?P9/'^*R0[76YZC& L\2;P9$+_7D:L!KP:\&O"/&/"=4Z)N#?%6'[7S
MIL?P-R;'B3=/)65J<WDN\XIHN6+06L)$N%\?\+LU$!K9")NC#(77O7XF>I[L
M\N0<H05)DOAIV@WWWO2!ZUT>:*]Q3*#Q8[ "<8D%TM8$A+D/U'IBA:??(]5U
M-;4//K4.,UAF3B OK4$\*H5TI!@IX7'P*GDC]<)^45>9\A9D^\RE"-W4_^.G
MRB7-?.+37=S@%?7Z@]QXV/:SV3IJBIXIZ8?QY+37M_V+1AM.;N?CIY.J %5'
MF_BC?NT5G-KET/1>F^&3M;?=>KW,XMO)8]R%Q]L=/=UV>;CLA/W5&\PMP?FE
M^M2]M*_88M\\;[X]"#Z(2#!%V'+PM2*A2%/ND*<L&:42*$.[7" Q5X,Z'BW,
M-=>.&DQ,L#I)PY3SRL[QULX#[VKRO^/D)XI!,29PM!,!1-8Z(F>\1]81SX5/
M7BM^1T2>SPIJCZ>A I+V8#$0/8]^-5NW9/0O>/:KA*[7]#0_/,Q8/XR95[_T
M_EV6:?HKX?K>_8GS"BRI\<,L.1<[Z7HSZK$P#O^(A3IB'*[8C3</N)0R:B*1
MY8HBGHQ&UF?V\ZBLP]IJ:L@M#=Z6I<+WE@C-,>?!6\XC!5C R1+";00U0=Q#
M<I&O)&19"=EFS<,#Z9PF*A@DI,Q=$CB@>'04!0 D*ZER6*2U%TQN\&O%8I;(
M?KUJ_3?.I#^I)V'2!' N%^V>Q4B/"Z@7)_S>GL![CU#%^CUC%?=S:)>TJ][%
MP;#?SC4./]&.QM>DHY+F^8'6S@G0CT@SR1&78# ;,)O!GXTVRD"$4LOQ_-\O
M[+2:RJ^?RN2HYIYKY+0%MP<P$FDK%7+@#\%*UR*DQ;VKKZ)G?_Q^K\7%>2A<
M%)NX8WVE?N3UE:I1\@[([]^CRK([[/4O'E^EY,[+D4R_Q?LG;R_V3MY>POUP
MV2S=_:/=NO27(-LGS:U/O$4_X-9Q4\S+]/[6NY/]K3_;^UNM=G/K7=DL;;X!
M.;]L@FSOG>_L'L)8WM+F92?M[#;9@<,V<A4L\J 0P !( %.:>B0!K!*F+H')
M-E^8XGD %] ';Z3EH%*<5I1)%^!8$X2^0J6^W?KG56MWY]W>/1CX;[W7TS 0
M1F(WJD(LQ2-AU/^UTSNO&NSYWF!8='\N/^F70L ""U5A2_&0RR%3\;9LES=2
MNS_(6S;K]6^]LV%N[ W>L[L8-4[;F&DD"_-3,F4O2PE-O2;*Q0N#?,^WRP#+
M+4>MR:=J#\!W/.O8<LZXH7-I]Y?.P-Z+I1EE[,-%.G71X:B-<QUOA%-<>;*Z
MR^7HO C']$Y@W;O8C:E= @"Y.,?7+3-+'_2J/G+N>?(-NSX7Z8R>K#11'3]:
M[CJXV=Q_]>IMN>?^]E__;[NR55]O;4X>HMUM[/AA+R=#@S5DRK%->U&;7K,M
MFZ;O7W5.S!OYG>QE?V['\T&IU9^,H)-99DN\=+W13C#%/@X&M@\F\SE ?B[@
M[YUWIXX?!4"FGQ]^;_>SS][.313S^\A/F8D!UJ?.A(?(_1 'Q;H<GU[5CO9S
M;52_+ES*3S=WPP2N4FDP>Q+C<&H>*Y,^/W[I)%E*G=8K^;!P6#^_FEZWA([]
M$2S#TA*R""N,(7=Z')1AEK=V#_/5&D&U8TI@Y<%_C$9X\&:=%4*#*2O#+4WW
MEC1^QEKB8YZ9+9B71V/Y?'<M 1;0@30D"AD<$BD'#S#\,$PQ%*UF0BAA;&#+
M\?\)XH)R#*P5L%&B-\)Z0'=)3.:7(_J65E6KZ?RJZ3348'C+ 7$N%.(^D_EI
MD9"4(7?'"XR)N%RNW-=%>E;3^573:8.7)D6'2&1Y=0:/K' *!4O *=0RFF26
MFL[ONQ.WFL[9Z?0F.4MS?%9JBSB%']J8@&0,$1Q^KX(B=W,R[^"&3K1_,4)0
MMD$&]VYJ><T6Q,;W+(A^[X]B..O$G306K)>Y47IW^*@:8?T ;P\?J,B94LZA
M9)A$G !<:!4-2@%SPVVF/'PVE=%CR;]K-?2J]'E5^OQSU?VN2I]7I<^KTN=5
MZ?/S+GU^9\_S-C6<#-[+@Y4 />NJP)^T)/">^?[+E 2.?1:0RN9(*#>[X?U9
MIA-\1%S(]_1?ZO+ #^=[)_]T6L<?6'.K>0$^"FE='K6;M 4^S-N+YF6KO;_[
MZAS&?7ZE/!"NO?_Q VWM^O/FY9^=UM8'MO-F^W*/-C'X/^#Y_-EI[FZ2YO$?
ML^7/F;/24F:08 +<:J<U^#X*(\4-L8YJB2-;>\'6N93?NCQP5?G\$V#<SPMS
MWX'F?05S#PMSDRIHBH7*'!R(DH01IRHB9YE&)C"!C;!&!K7V@J]C3G^2*NBG
M9&M^[/4_H787E:3KP15K<_QT=.'3+838)PTU][>HKMM#@!>\W?V[>KTK%%D&
M12ZFC"4+5I 0(B$PBB+BS$=DG3.Y18[UUGNN95I[(?75;/$;,>3;V3VW-RM_
M)BOJ_LI[M:(>?D5-]#+FGG#I*?+*)<0]$^!^>(&(U2;7*"OI+*PHN:16_@[Z
M]:<(\KQN=]N#H\RJGU.1[J!W[_34/Q]\?,\0QVA.WN0I62'+$LC2>CFEJ[%E
MS$G)4-*Y/Z<V%CDO)*(^<L=%LC+(;/$3QA[(XG]$X8O5ROT17OMJY7[%RIW8
M!(P%+P0#.=69D5$$B;3V'@DB"$PA<]BZM1=T7>$E[>QONG)_(G=\MS>TG>O>
M8176J!,V&+RLT#O+Z1^C83V7R.C#O8>?!FN_IY7TIM];^5W+8>S[*>M(><F<
MT YI@3/&)HP,41S1' O%G 7L\-H+O4Z561)C'VQ=?)](R K65K#VB$S(%:S=
M ]8FIF.05D5%.#+>!8 U!DZ?<A:</DF%Y(%8QM=>J'6.KS(W/')8NP.=Y6*6
MB+O50DORR&NA];?O-?M7KWN8>:<SS]4C28BGS5%)__&[X]8;N/;6-F^]^4 R
M?\W^FU=B[^/KDV99@G_ _3TLM7\^S2?$M]XT\?[6!]X\/L1P3]'::GW:V^T<
M[7W<N\@)\4VX'BSE\];'=ZEU"6,^/T@T4F]I H- PT+R+EL*)"(?&,?@AFDB
M]7P!M"-:X\P++D/@3F$C?.)",4*$C@"?\RGT6Z_^V+U'[?/MMYD=%F-9V)6U
MF&$0#&V$2!YC)XB7P7OR1'+Y=[J-/\\Z%PUJUDL-[GKC=0_N\Z51\B5+Q])A
MKV$;+^'W]K"Q>=B/58?27W*:_]K\QVN_YDK40JP0&V>G^8]E2(P2MSY2JD+2
MA,-[M$8Z%I@G #$">YMU(C%847-3"=3-2O$O> <[J1KX:^O;G?;PHFF_M$_.
M3O[H]?NEJ.&E/85OAA>/A;'HNZ_7S%ATH&GDFF&!7! 8U!X&M1>T08ZP%*7W
MR4FZ]D)<%RX9,5FE?N^D,3SO-3JYDJD_6&_TNJ5QY/E1VQ_EHFO;&,!***7.
M(%F#(>#C4:\3JC+]:4:U4D(]4]MN&Z5U;:YRM_WAQ7K54;@Q(9UJ_'W6]T=V
M$*=DMQ127RN6U3#G)),RS0T7UB4B.6'"<863"T2RZ$']X[M)YC7%>9\ONO$W
MP"H7^SOIK^HM/18>VN\O>L>'7PZ$BDQP0E&23B(NM4):P8\0'8^1,QVSQ05R
M=+7(KA:96M@*%<%A-G]GN/<*!0&L>9"<SD4EKLO@U/VD <D[P%21A6*O3[.L
M;0\&9[;K,W#U3DYZW??#8D,\5W2Z;)(#K)+S'@<DJ?1@2QB+=' :; DME O8
M 6"MO2 W<:FY"-.1:8DSXT;AX4TIEF+,ND?MH/'+(,9"ET/Q[ZW>,#8,:KP_
MRJPB+ROJB_(=^;W(V4FO]/JNYACN\.M& _1KTP( -<P4H]@8SV:5;+>Q>5(5
M>V80RYQ0!=BNJ-[\[9LSVP>PO&C\8D'&S_J%M]/6IX/P;IX=@EW1$--WK1_C
M3C>I'^O7]<PTTH_N8F;<F=#XL!I!C!6G2*:P=W"E;F'"<&#:U,W+Z_7HBF[-
M@X3;'I8SPXA,I:+8F&I<G%DU\IL9E+[ @S,'HP3CJ_!]P(_2 _BLG[E3ZK+#
MZA8UC<DL FPT[D7\M@P<!$&U!S/0"G#EF6#.9H!@D6,JJ4[7=:]9AG(Q.P_;
MW0&8N'EV7MI^_P+D=/,D-YQ_MCC0N@1503V\LH YPH$ZQ'F*8*5(C+!@F1<A
M$DO"<G09,8&#)QAA7O)DP"0-- CEL?7*!B;OU&A@-9OWFTU ;4(PS"$QF5[!
M*HFLC@;%)$@(S'EI =696$"=>HL9>@Z8%?KV/,]]B!5BW D*-QHSY$.A'1K=
M7@8F@*IRE7X\L>UN5AN/##06N3KO1H-=.3LCP=O9.L0'E,(J9]HCZS4!B],G
M9*P-R#JP*J@BWM#E:%J^ XRLYO?N\ZLUEMI*BW"97Y$;EAF34#!4<+#?"<YJ
M@MP#6):%DZ='C9[A+W/@-3H]N,JDL\>RCUX1D7D TGY[D \>L=P-?@,[]M>E
MX!,[Z8GF@FEP%)V/FF*EK)<L+RGCXT.$BF;5-*RP^,Q5='-W\W+G[8&B'$>#
M/0HD:3"YI$2PE#@B@D863& T9'IS<3V[>6&_.R^NR\ACF0E#5N'%VF'9!6_!
MPY^D\1?(W\0S^<4M*3)6)\8)9M)Y[E2T*G@%LB(YC%XK5HD,H42M1.8!1>;5
M>?/\0,KD%#$2Y:ZXB!,+ZC51AH@DR6DL$LX\2_0&0OP%(C/FDR#J!K&A,V)3
M$.H7_^L]HM-YP#B <6:,XT%E]+%&,ZPX$1AS<8U&OTO49Q6<7DZD>'/S(/D0
M@C0![#0%*&0L0;F5#9*)"2R%H6!+WQ&%)AIM3/;Y/IX.:[*246^/1<+%9H2K
MHBF=%;QR@SKZ$:9YD^"(UUN;8XJD,2MJ';YH;6W.\ZAVVH,Z3#7ZM'"+S%ZG
M'N .#.(P-O[H]3ZMCV)4<'3>,BYRGDE'P5 <UIX+N*#Y^(JIM"8:'1ZU^W5<
M?1QCF>8HS>6C%W7C@>Y9[FJ5=WW&@]NXQ6V:?84;C>U1R*?7K8EZL[&1WU[\
MSQG<#T9<FK.<G>1[_++YZ_4A_&Z)I3^(0<YO1OC1H-^!P?.^6#U_P^N!+^SA
MI'41HL]NA8Y;HI#F\>9E\_! 1RH#P;GE!<Z\B=@@JW)LWPMO5-2&1["_]0:]
MNE[_U?AE<.:.HQ]F&0 !ZL>\GY.EV?M>/^3 >"6SP]I0'4<=[V26_MHX[9P-
M&K_\\6LY!S[.1=)%R+Y4'_7 (BYL?(V_MO_8>9<-UR4Z:=2V-*<;*E.1G?8&
M90G^5G:NVI]CS4!69Q!-G5CGA>#)*=8->IVSX?6G7*&\^4$N0Y[&F1<T]?.H
M/TF?.XS(P?O^A&R"P?YF.^?V8K#V[UF_")RBN7<X__C7/F1*W^PA*_\,D*+7
M+W/^6_&&\E$P)OMHQM(XZF?X^Z_;DW44>'I%"19R=! >T 7_Y]_VQ:*97)A#
M<6M.Q%P.A>$D1JHE$YYS&KSQUAO+N8I>@._&GD@.18TU@\RG'AKN;- NFR#!
MYAZ.)X U99<13 LP5\-(]5<;'_F8^O2L*KK!]BO:ST:M;T/N&@9'N)'UU_BE
MG4 '^J.B'_-N>-:JO;-AWB(I5[=C]+OE'N!"V6)W=-H^SWNU>?[+Q;**-4@A
M.0DZ!BRX4,1I%C7X@,X3\,EINH7!]A8-^T>FUG\/+\^&G>X_MM_.0\WJEJST
MZTB_M@X/&"PCBEE BHG<6X)9<+"$0(PS$WC SO!<W@+P>56_;ES?A_71+KK=
MB868@TJ#FH@V5(9M98E6084J6E=%%BC?:/P/&.*?8W]V)[9DEH#I.TH;".V!
M/QL,ZLW-/IP J#7?'>$P=F._F!0C\WC8!T>B+/'SV/D<Z[5<]2NXELAW?>8>
MP\SG7WH9^,Y9*)O#2T381BT>Y@E8837!"8=MGX?8K:R)J8>TKO<Y;C1>C[V3
M@C#U]U7W@>FW-=V"MI>![31C'0QZ&H=F=H3G7 ^[),1015*R-N$H% \2VP#N
MG0 [WF=Z=1EKVUV3F<T2.I-4\2Z/,K^DG901YN_^Z._7,:Z,]IQ5<8CA'J*Y
MY2_ Q:9@M,,5K"78(1,B1ISG7#!'!8(I"%@+"C,!H'(UQ>)?M4P4D4PUI348
MZWW0_* @AS#;I[8=9G;YR_+))6(-6R)F5])TEFN'2$64-& ?"./1:FV,#I(Y
M"38*5PK7.@D$!BV2G*6V8<:"-=A)T\F^SS= <^Q!DCS; 375VMJ\W-D\\,Y8
M+41 )K>9X-Q29$E(B'D<9504?KC2^_"J>IK=;1GGME0?DRIA@TQC5Y:DB?RM
M+X&>.:_%Q=AM5/!6M0VJ$?5*:LJ@:@Y8[8&<P_"R2IB<.!O^ -NO8P%*4[M6
M*=<B93;)&KXB46]TP-HI0<#<8:@*>E91F&Z%I;EA31T4NJY+[U-4[ML3;;%^
M96]@?2:_;[(%M7BWJ3T89- Y+P&N86FV<SK*"*U"P/!XDP:]\ JO19E!SOL:
MS ,-BS1G 7(C+,<V.FTB)BHDYJC$RC_$/M3++#H[Z6/U##O]=_E5C?)%)ZFN
M+VT'#* _+NKC!O6!SS>5M+7E>>OM@4Z1&VP]2J *$*>Y.R18PRBJI$0,)H3<
M'I2L$XS7\8+J[RP4=59\KP\+-O?$KF1A/3<5L[D!5(Z)#DKXV,=;FSN#M5%R
M"!].E.X@+Z_J,?Z=ASC^<BPDY!E+R6'>U)1.Z^B<1DY:CGCR"CDF$_(I@5\;
MDW#!9@<*7RU=S09^)1$S>P2C5SR=2YDSWD$U@>S$D@%9N>F?(\I>^N=>!US>
M1@6-6?6 FP(FZ42J2JQ_H21.>?U@X!>M<C7^4&]ME'3-.J%X=-)HK#D,GZ6R
M&RNQ'8=5\ZY])Y;/ZE.:$1R5VHV*7P!1\WY#"3]5>RJ%7#*,;CBZ0>59E)T7
M^!CT6O0@NZ,55,)/V9E:#H2IL4: ETL5AZ4>F'$$2T*2!NLU,E'74F*&5R#\
M_9<7N!)@ ":9:38B^ [4.\0MCLBEQ!&.2@DJM<6Y;RH<M"[Y @BNI7RV'F3L
MW?J2%%]5CJR/+;8Y5"Y"&;)A4TGE?2#Z*P1M!=%?(T/;&&2(>):HYA3)W.&9
M\^B1#D$A%K$UQG@<6$X.W1!7N9?F_8._BP'(&G^W&KN9#S=WFSSK#.LXQQBL
MB@DY3J\?"<\HVO/R_;LB;#ETTQ_$2OX: \"]<2#FHG0@K<UY .&OPSFN$WBR
MTJ7@"(\:Q \SD$ "ZL6#M>#NUHQZA7/?K,1U\\!ADBPV)O,* <XY%I#F8%"X
M)"T!J'#4^K478.*M$[D@-6&"<[G 81K7ZEWYAS(VOT*45DCVE5+R]H 18VT,
M'%F;V\YQ"0+"'5B<1H=$?(!73T%*-N2"\J6QL;G1^+L.L=5J<5[AU3&)$QOB
M^JC]<>]TVH:KRBS7&[%=$*X-MI\=E,VG$H;H5Y51U?$SPECLQY("FKOZCF\\
M:TVNCV5VXF GV^[7+99GTCHF1\P]Q2]K>4B='!H9?;,&IG0>8M6*V.5XR]0S
MY9JNPQX _485"-F=!O2,QM,8?'K6SX;P<#2,DCU0F1!3.0>S,9?U*O"3XY-P
M6-TE>#9*0>5&8Q.&-[YOIFJ9B?F,)N?*PXV#/*-S_[NZ1?6,>3^P=#2N(Z8P
M(['NCCR^URCD49)M)U&G*I&FBF!=R9S8?/^RH0E89QBD:E0HF3<LP3<)4T&6
MV5S,ZAZ@"7K>#A?8^B-+;.ZLTD9[E/TP+1&EC?8339 >1?I*@E,NZKM:3'@;
M5,_GJVK&<0A&2>FY8@#78"0G&DWD@F)38MA5/  M+#==)H;]]VAKY#6LIJ[/
MU4C=4*I,1Z6G+W.[\F<;TFX=;^,6:/=@I##2HH!#1#SD*@+N#$K"!J*XASER
M:R_(!KD^Z;"]P+_.6W+5<8-*!,#7+@MJ5'=YW3;?C77NHWC#S8MT?1Q!@&OF
M.'157C\85@;K. !07Z &VE$Q]6R4>RS[H^@MX/M8^FO$FNSN++,6)!&&<H%Q
M))9K2\!H<8Q&K%-4F'.^6@O?<RU\^-(\/_!41L>Q1B))6 M"!Y0[4R/#F;1,
M&^]\6'N!-ZXZ8XU9:HAQ=7"=VSJ;/[L^);J]+DAD+;]95)^@JL@;@Y/HF\^"
M5(R2?L[="C-;/(7MJ8(!VRF'#XYB'"XPS4;;1( #3W&[IRJ1&%S%J#S'ZXUN
M+' Q\]+6RTO+E>%@TU1(E=_@81=N&TI4_J37'Y8_\N&-G)15>?X1U+(OAL=X
M]_DD#H]ZX0D*4^G$.S&?:@.X@/AUVX$E#+8,\K(8F:!,8DD#9\E8'YUB)CH;
MC&,L/'@Y]&MXH'_R\SQC@#TDK<,#BY-TA$0DO)6YLMTB:P!OJ<,J2 \>I&!E
MSWS!CL0(84>,.3GYI]>O%L>@\5?\'#L-5BGO+#N57L^B =YEGK?*]L@Q_(O1
MP@'EWCN)54Z&]4?KM5=0V1@U9 WS +)75^]PU()9+;!R_;/!:&L<5E[[9&Q0
M]-N#3Y,(6\X\*F8"V!.?J]#M> /\],QUVGZ:9R/OJ,!JG^1*I4IQYR*%O--?
M535DJZ6<FG5(WV:LS?2(.5,L;R;GQ_3%CLDHND1Z]Z-%A\5)NK<GW6[--Z2_
M7R/ZV92QL7X;HVYM&"YK"5HCJ'9,":P\MS$:X:,FS@JAI38RU)D]_)ILTZ6
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MR\P=L^)MO9FW5:YX6Q_'6+XC;^NM4=_YEKS42BUTTEQY<$"2(<R#Y1.HI=&
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M^B*N<!=A_7?+(NOGH%T^MFQ=#N))&]4LYU4-XZ1<M>Q3-WZI0Q^3Q54^GP1
M7HV74#D]E[$/AU7.Q_A:"WW,^MN"W"6UZ3[$0%)XSTU2R7O'E2).)DT4%10+
M+ 4)B[7[U:*9^\I_TWYIGYR=C%["^S.7=_M*DY=WSUOVX5E:AP<Q),X4-@AC
M37/.MD,ZPI\\19F2PXZ&G&*T0/9'\CR.59_:=B@P/3@#R<WF8B:@6HC9>?,R
MBW=]B9D>/%.8'\[&>U%SXCVS83HB$9CNP%.9&N_KS#Q.V>A>'S;>YQTI&%X.
MT;^+GR-X>=4Z?MD+\7%&QN_9<G9).H1[+=65(?ZMUB>,X>V!=2*"^Y8[SHG<
M@"Z";E)>HR2L-,J8R%BA3*(RIP'>:HI/&$CSSO1A28N96.5Y<3[!!; U@8G;
M][Z67A;,"4IS-!GCR&.B.?='$R&9LMH$2>YBS-V]X.^F;+2Q$BNUHS4@9EOZ
M&2?*3FCK+_-_6V\/DJ,Y<""0M8XCSB7.%'@$B6"U#((*;?W:"T[7C3;7+I>2
MVC-)QYZHI/FH2%DRC:4D$"\K@91:ZBT6*0:0P,# +P]:)AX-V*W<ZCJCH)9
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M.'(87$[.O->Y]\W#>_\KK?Y#M7IQ)/]=4O47U :LB@%^AI3UU6!7Q0"/KQ@
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M+C;5$7Z]TVIZ]<X8W;D(4S[J] ?=9K??Z0L76S<M^QM4CQT^3TMG6W8R2,.
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M7%%>+@352FF#F4NI0D.XRT"/#' IVI+YI3E<-H;5P D1@I8U-<5V>+E0MPO
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M!SK*L420'RM=CN4B"W,W#Z=:4TX$O-1*?,$2-"KHLQ)D%+X#]=]!+52]TDZ
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M9HSS9B5 R$1A@F4QR!PU)_'8\++16.%]F+*#7Z\$>S7OEKVZN/RFJF$7\;:
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MM(9.]>*S([H,!%J!S&ETO24L3FI+/].I(FCH^\)3'3&H+Z@"??7F>OV5E\C
M"%*6LLV^&'/-N\:L)(X#H0698'R/$0M#4HU?BUA&+9V]YV?.TR>O#T^?/)-=
M@RHM0DX:5%7?M$! "W30%!G$B>IP7< %Q4-3GK]$&V1J3:FFQ42W3!]5J0;+
MY<&D%1BGG4\%/P28P8SPBZ#M,]H$9C3#T:F3512B)CSR,M4!A((4;XX<LN)@
M^2@()A>8YL_8Y#Q)>)NID<Q371J))CJL4(KXS6$ZE0649@1JP+1[JAW5O.BI
M(..JBN7H75B#X^$V:*;/JQQ*Z]\"<UY]&G_*_)KV+K]F,\;RF&T 'UU7PY!Z
M%;NTS&#R64QD4R(M.$SE<0W163Y);T<)8)DPETU6A?8NJ%8:P$N-,B2%%_*>
M?\576"Q1XX(6&+%ZF.Z/1)G[V"VE) &MOD\: -I)41_,9\(JXRX(218D7&%N
M/#=*HA0@.4M+$ G9,0Z&.J92W=F,%$!*D<'RAQ7+:M@DJ5'H-)5J7***6!!Q
MR!+]HY(BE$IL'".'5TTNI+6[IC$5O":%SA 5<+8;3\%[>D%178JUW&Q;"D*I
M18,5O;4 W!$:(<]"SS93K)9;5H,%0Z]5$;P*ASW+RI@0I63B*PVUT.B#ZG5@
MB'SQ[UC0 &_8GX((QV"$JHGAWH3J8)E&!CQVTL(5<$!%=PG=1:0*+Y[,AW*S
MD((/%7]G,E?YNWP(>,P,!2&]K/8/A<GP5QEFKN'KC:TDU1:.N$2LSN@XI$WQ
M9IN*CDNCT^2I4!$)5DD01F$!QXSZ+UFE;"H$\HO;-+#__!5C9C:=I[_TK(X
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M1;-K#]JJ7&YI%?;C@)RS0*L]>J!LME'HPTO3YU(D;E6&3X/=\;(L"4>Y1J&
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M0ER"ER$E@G/D[OB<9FFJE8 G-OH(W6.Z+:\!BT/I+H@7QVX#%4&^H9^%AO6
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M4R)-D8=W$JW*&'![RYQMJP(2.4?!R*6 V>ZSF0+ADO']0H$\5SC*1NRJ&C+
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M1U!Z:T&_05R& /33U)3GEC$2\76Z@&]Y2#LR>V@RB_+YB"N+39EJ!*_4V"A
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MT>S1SC>3K$=XA!*N Z:JTQPEQ2H_D-$4"!C?%-I_]=7$DS%+059TLH-T"]G
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MT1TQ(XG)21U?4%23?$%,7BIHAE2*0II;XTAW>T4_-.IU: 2Y4=4U@!13_0W
M47?=COL&;ME#U7_51K6V$JZEW: 5>"_DOA+(MVD8H.K24\8WCWUVG'$ R$B
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M>14];H2=Z6Z() -LW#$RCXZBS@&\KP$L(5/1>5CO1;@@QT2U)X,S02@J?8V
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MLSS^';:BOB1]2;[2@3B:.VB0 *-C_MN745;Z1=7O7:__<0]0.YD'J!7- ^B
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MTZ\_\)#6[OPQ,E;JBG0+C_8A3CZ-2^GB;L)X<)B'_KS4XJ)GR*5JC)OM0SY
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M[IAO/HLDR/YZ,.T0\?W/[A3OZ-+WNQ3PO8_N &WS0>02+@.,NX1ZYW-OX5R
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MGKW_L:N .SP"%I#P;((Q3&XL7L^EU!'M7(B%@E$(XATHHA!)CLDFF>J8!DM
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M<2@^;"+RNFE+\RQD9RR>H5H397,F4J'7@S82_@<@6 $.C]$ZI;OWH.S?<>A
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M'\!D.AK" N,?5RB=^*D/GQ'D2QB7#*R7X_X4#W/_N__2O[R^[($!&7*FQ#,
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MD!9^0@M0G1M2:^'LWZSJ0%6C6G+N>K-8"RY(:I67EF@!N8R#2B2(9 C7V0H
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M.YN(5$FBBZR0D-:J;)6A4;;J_;'Q2_H0JIW.LKNI,]D(FE4(A G -\1G13R
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M4.[YN-0.N.4!6LV_VI@#]Z#LW^+M0$6C+N5;H8ILQ8G8,!N"8=RH1!1S$8]
M:XCW/)"4(Y<^4D]9G;ZA:P!]%[9#%\KH,#7\(5CS@-'\E6@#L*H%\2C$PU@3
MG2BT!4EVUT:%L^1QH")Y\#EQW.PROBO2..(X+1LKH@=J$FZTQT271VR-P[!E
M$R54;2PI#4#)P2"02@,A/&9)$!EMJ^A4F15)36Y7>7"8QI*5)+ZVX^0FXJI@
M.)P-X^@2;LSC-^4?+ B;K=(VBTQX%.5Z@&5B:=0DN0C2<P$YULF@>@#4=V%
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M*-%'T&4H,16.)(@Q*ZLDV"=U3CRVH!\OPU-C38>CK+N:S09)V5SZMCE0BDB
M4%)3*5$9%P&Y]#C9NBSEV4S,>TI\/81BNQQ>O77>*A/,,1V!:%F2DJ*C)+#$
MB/9!""^D4ZY.?L*SS"O?)<V@JFJ>>EYYBI'9I ,Q2B4B9=3$6VN(XE)G:;21
M<G]=Y)]37OE&)&B95[Z),@Z2(-P&X(^\\BT5NG&F\#;:. AMG!/*)69(<)'B
MX5NJNPP+1..N'+W*-N?]S<-YNGGE==FRB1*JYI6SF(T3*>+A' .1"?"L-CZ3
MK#.51D47:#L;^ZGGE6\D\;5YY9N(Z_!YY0MGH-M$\N5/K9PY_N BEE+%O:<
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M>YY^].KTQ8>W?EPRV#_ODM.U\G.Z],(?![KD:D-T3&:+DM="@A?!YB2!26F
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MK_O3KV]'981OP7HUZ$]?CH:?\5<H](LR<(#UF(DI\*!)!CS\I,T.W8WD20C
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MT=PF;MY#U%CW$>WWBN-E?BJW!/]:S''?6WTKM1TKC-D*=-?-NHSX>ZV1LJ"
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M9XNB^0E4/Y$&8&W(_-FT[Y]WOIZ+O-$3Y_3$X-5/_$PS:;&]+N#&."H+]RQ
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MIH==N4W0U-LHGH]1S\S;"+A.AM]'+;MC(%@N7[>WJX$KUAU3=[=(W=&GNS&
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M,;DU9Y3 &",N0N$AS@+C@.>M3L8VG=?QORM!ZR"C#I'0VX >G]NV8.IY?G=
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MX!C*''^-L[M^,!WJ#G ENPH5:$L/&O%!&_'+WA$W.!;L%?F!#@T?GSG 5=2
MI)H%3N=JV5ID8+']G0,L_[?26#WRFF>P&J(J?J!HTN?3,C&X7".SAKX %M)^
M J3)"(_766__8NFDLO-H'#W'-&]UN%/.SAIOG(%V;\7<F?:K_+Q>EB_U"7S
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MJX<:R)U@L[MW-I)@V+US%W!V]LZ=&NF8U8#27%)E<Q29\M4FCKHTD=MB!*E
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M4LDA39.41A%CN8AG:_<B;3MM>\V_$:JRU95(=P3T6X]W47-;?GMB,?!L= '
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M/11?Y7*Q JO-0-W+A4VV]%C*]I%/*_HP_UUO6AKUK@"M &WG6ZCX^,OA[EZ
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MD[BZ<4((M(:^ FR=W>KZ<U;,+4$$C(4Y T78Z)=3G8T;[W)&Y8,(EW//]RY
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M>H($#*(*A>)Y__.>[8_L?GX9"H?>YQ>VU\^:;:SCMFIG5' NDP12PA.(2%1
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M3, X93CC'&/J5X+Z>#=3(X2MCZOQ!P9_?%NM)<">=W<G$'6CA,MQ&I@0]MV
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ML=:#/==;]\J7_5?ZKW)I^S1Y6NL@,I:I/)<X@S1&VKQ(402QB N] \H%HJE
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M_X03F"DL]$CF::J\;O0"C-8HEWM-41UMZ:@&N1V3R@EP7H.OBFJ$&0HW+1^
MX,"JOSF/V>9?K:FM4IPUL*OZ!\.M"9Y$#;I0N/8]ZNKA2<C^DN+[]5'#@$Q
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MU*;C%B<H:Z"F_DXK2<BVN"_MX<)WDNWNB3P8AX%G=8N^!F,?1[V3+/G4WQF
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M/H?%?:L/BAD?T?7U)A,)#,V4' 5Q.7'J$D^4F4X6_MVWKH>!AJ\D=Q9E$^[
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MIU]@-%I1;YV54@M'@K*(;FX%VLS!$R>%D%P@ 6*W[/#'[UP/#0W?.>XHQB9
M\ XE-?6CHW&";_\#K@?(<')*1^(<LXABRHF-#HB*+BC'\,P+N]T_/?G:]:#0
M\!WD[L+L._2PM'H_#&?1C_XW^.DJ<3Q9;B,%1B"6+&&T?8D5N*UEJSQS#E@T
MNX4MGWOS>IAH^&*R$Y$VDGC]G8D/^)/9 $ D6T*LT2/AT@A&O!>*,"5UTM($
M*W>S(IYY\7J@:/C2L@N!-H6)99G)D@EI@_>: P%>3C_*T 22:"QSH3QEZ#-'
MM]M>\>RKU\-%PQ>9W0BU9V0<( =IP<7(GP]*RJ>R6A'-%252N%)?@J)@7&CI
M@DG2[&92WGO=>@AH^+YR>^$U84@>?OM>2K*$[R PT-$)2U@LQ00R>Q*RU,1Z
MI[E5,HG0A4_Q^,WK8:'YB\D=1=H$+- QNBAIXI/XC],O*+W9\=6\U(N7R-U
M9.&=Y KW,FI*K9$@I>J,9-!21ATBC;L%/%^G8;WBON:O+#L3<V>@^=>?'TGT
M(_Y@][K]XT_O#S^='K['+TZ//QZ]/S@[?/_+P<>#3^\.3_]V>'AV>I^5-8OZ
M7W]JQQ7_&[*Q8SN JQDY]_YRL,B<+(?,<?XP'/MQ'**Q,5EN,;=0#"F X$&0
MF+@CLD3(T"CEA$:-S@K/SKJ7,MNSGX4%.&Y>NER;,)K/5C]9R)Y0=M/,X;]M
M0MVV6]+J'0>S&<QGM[P*YR0$7'8)+2DB$P@2F*1(H3+49VW!OE3FL3VO]^GH
MI_% -52L-J@.A-[C*7:?^AMW_I:))#F7I392RU+I9 3'4QA]-V&84Q*,XNRE
M=-U=D?. G'X!M(M^GX3*+L)N #'O_.S+P3B5OP[_XVKXU8^0F=G!_)V?3J_Q
M2/YW/[J" >@$6D5&F"XI2Y(A4T))HF2T>#3EQ'B=O6<M\EI U$XPF-3620-
M.P&4S##.(:W'GD&1N:0YB4H!D5FAZ\ 3)T):FKA24H0ZD-N0T'Z:L-0#7TT]
M-0##W_ST'S#W800W"7E#6(EO (P+&Z(GD$Q"[\-HXC6>"#E;J;P-%MFI KD7
MB.JGI4L]>'4E_ZVAA)YLF'1E;L58"LIG)Q !UP<R]0GF*VZLU(;RJ(G*)78B
MA"0AR404"!$]Y0#ZI726':RN%ZCJIQE,/3AUIH$&MJ;/4[CTPW3X[1+&,\"=
M][@XY/=D-J .5P370$QT&5V;A+NMLA(%EKPT+'FHM$6M05P_+6;J8:MK?30
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M,[;A>Y=_&H0K8V8)=Z5A"T6C($ 9VX#&@#+9)._K^%K/4=1(<E%W -I9[ W
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M@:5UTDGVRV>_CEPU.[=AL#2PE)94'^>[G!R/=Y+9@,>,C&:*.BI!QS*(U7%
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M"A8W)+1?HZ<#:$SVIZ<&8/AQ&'$-EU34\RDLN;QA1.L<(?%$ "0OYP%'EEC
MD]];(4+0QM7I%/,L2?U"JRH0)C6TTK<I=3:Y'$8_^N7P;+AL)W;+S8J9&!08
MY@CS@N$AX".QFG$2G0X,.$0 OY99]=J;^D5.1]J<U!)MWS@YGK[$2=:26HE^
MA]=E'D?I#A^24\0;YS.+*GO&U@+)BZ_IU[BJ@)#NA-K *75Z%6;P'U=(_V&9
M*51.^<7!;ETL';(305\4#W:(&04#0 07N.DJ-")#G=X?SQ#4<T)D.R9Z%PIK
M$W<WWK+"A<ET+EE#!DJX2Z%_6QKMJ." XL%O91WKZ%F2^BXDZ$#AKX-H"^FW
M!Z.;/=A+(Z1S!GV1$N*D%+=V;@1!]R3*G!4UO%*9\%/D- >?;53],H"VD'L#
MX%DT:+B*96C$^/S=9#9?-FV Z=?E"@-@ HT]2C*UGDC<G/$4]X%05]HS4N&E
MJ+,3O4)8SYG6[9R%72JP 3PNKUCN,76S5+T,*09<3LXNHI09?8Z0-8G9NT3!
MZ>SK5 ,\2U*_FUJGBG_R#G17+30 I\.+R]'D&N 4OL*T-,&_V:53\,S2",10
M]&*E]T"<9)1 H/B?9%;[.JD<SQ#4PKWFSNI^V#FU ]EO#2%\99CL"*+9=#XX
M*3OY8CTER#FD3(G!'9G@$6])\(X3JHUV.>GDUQLPA$^] Q?\[B%4[KVVYX*+
M_L^Y[970X_9S2_3J0H1%$;S@A-O2ZEKX3*RVJ'3K1+#4RFS6JOY9'SM];BL[
MJ.RATK>07\]J_VTX'EY<7=P0+G1,E$(D*I8$!RX1[!)/8CR":=)2&T;7:GZ\
MEN+OO;IGU6^CN$D74NQ;_?[;7<(=#<&C'VB"27C414.L"HRP9%F*SC,%:S4L
M7$_]=U_=SXUS9^K?6HH]J_\VN_(TPMA/AY/%%N@CDD\U(UR6[DLAE[!=HH1I
MX16C0D)8R]I<"P9/DM!S 5T;9L3NRND;73=T_SZ>74(<YB&D&SL]E%Q=+RW1
M G(I,TTDB&0(U]D* !FY72M_8SV$/4=&?V=.!ZJ=="WG1L#R83*%Z&>K^TD5
M+4=Q*.+Q"$69,$$\^$0\-9H%M-&47:MUVD9(N4]#CS#I1K%/0&4'*3=P3?(>
MPOQH7-S_VZPF!V7M&$FD$8+(TLLMQ.R(3]JAVR^X-W4RPA[3TG--;O^'5T=J
M:@YHG_S%*A!C8THF MKTH$L2G;?$.FE(1I'0S+V@MDXR[',4]7LCMZNF7P3.
MEF+O.Y'GX&)1"GC35=R7GN)(P7#^,/M$)I4A*'0ZI$2>.,O$E3%C";SW63GE
MPGHI/6N^L"6D;*O:264Y-['U[+1[?QR.8=%$=1 ]:!$I)27O%TV%1=%*H$0'
ME3)USME8ZV3LAH.>)[*T=)[V (D&EL*GJ[* 2\3G<C*=%S&>POF"I8'",\8F
MDTC.K&0$H@GK8I*XQJ&,X04?1!UP/T]3W_MK'QAYV,*@&X7U?8*OA(+.TA,Y
MJ0/IK,O6>2("NDK2<?271&G$:3@/03F/SMA:!_?+[^DW&;=7/'6MA;X!]=MP
MA";*9 PKGGZ_1&FB!N!K28J :6F1_VXZQ-<-_<VE\@ ,R)#+]$T&I1<^Y^B;
MHQQI,C*"E#Y:O1;,MGE[OSF\_8.ONL;ZAN3)Y-J/YM<W['V&:2P6\PTC+J+1
M#"X2MAAZY(0F0;M,M+1!Z 19<K$6]%YZ2[^I<?U#K#,--&"IW<O)67ADHX5#
M-IG-#[]=0AFLM;(-/D^6#=UFAZ/AQ7!</C:0++'LE20V.D5DZ1AG1<IE>+W$
MG5V!92^U%>@H>W-CNOM->FG"XMNCXM\&S,O7;. 8*QVN@0A7"I:XR,1SQHA)
M3E/'HU1^#^G(+U#8;Z#UK4!W<V4V -+%/+ ODQ&J<%8F&<ZO/TWFL/CIZ>5H
M.'\W&7_%7Z'(3XK@V4#G8)3/F3!?>EXPBD(T+!+OK4W,A1QXG7&5FU+:;X"E
M"=!656X#X$7A7DS&2WZ*"&<'5_,OD^GP/_&P<#E0;X0ER91N*CIYXE10)$/0
MG@KI1:HSL?(%HOJ]HVP"DEVIK 'T?8+YT3A.+N#C9#8;9&LB<\KCTC%HG"3!
MB).E=T&6,8<L@.8ZR??WR.AW8G03"-M>+9MCRBTQ-8;S8@QTA:K2I?KS=()B
M@O3+]>^S,@[Q=@;B09RC $L[_H&!TC]6)J+*598T*"7'T.C@N4R?H '=OFJ0
M6Y/&GL=$MP+(&AKMM8KD=CM_/"X;C>-3W-'G9S"]6$YM7%[!BJ2$2C:B31Q1
MA!S0>Y,QD61!1"UYDK[.!-;U:>QYAG03:*VDT0;.ZQ-8SI8]]-,Q+KO908Q7
M%U<+-PXE/XS#^8"#9S1:181VR)90AEB!<HR:Q1BE96B*5/+$7Z.MYU&836"S
M8PTV@,DG5MOBIF&XN% HTRJ6"2O??W#GDP.TE@W+"*@@2V=C$QT:S,D1)I(P
M.3IG?"4?9Q>RUT/RCQDNVK_>&P#YQ\GXO)P=):MK()B2-CA%+-HS1%H'R$6(
M1/EH(D^4N5SG_N@N%>M!\,<,)^VLE080=0*7-[(XSO?XB-EF+JDF-GKDP]N
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MLX>+QV<>J*02S5 EB,P4?6$K0AGSD8RE,D98J]_=QCA[A;!^T\\K(:Q+932
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MXY!(=EP2R63II60Y$513(ZV@J=(,P@T)[7<CK :8]8&YL_8: .<KB9>K?A<
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MKNG=$8*#X%001C-THV@@,BV^,IRX+*ERE@>AUFLNVB%1ZV'SC<41^E): Y;
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MNQXX?XA81J=Z>XN=8)]SLX;C99BQVP:QZ[ZM>M_8K=C>RV@7B(Z+,HLWE])
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M4+!FI&P3E32*K/NW_<X)Y1)#@\1%-!N@&!"F+%-G:/0JVYSW-P+M#43*-@+
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M%"0ON!0A5;K#WIO$-G;LD7%XN-*:*$Q]1HHW/LD'6'SZBBIYZ9?3./%.1&U
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MQ%515P.;Z&4Q$I^_^MEG^/9]OO"+GV^_???311'HN_ERB[MM*4Q$SC1$$0F
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MEVR2P0T#HT?O'L?TU%/^7N@Z3A-G C1^C[W$DT!.@&21T!%(5!.G&2?*!"%
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M::O/THYDV_VGCJ?<PY4R'T)"#42LMR.J7_Z\_?@?4U@@45]_OH,?<+4^UD_
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M9UP62XPH4$&;9::I,0;_(U#FGDB!;(44,Z'"IY0=TV%[$OU0F/HE;>.WE!L
M!-O0&E8CH]]X0BL[7Q2FEMNSBD7R@0DJ" 412M<A39QP*"4CLU*4@<A;;=)W
MW7K:^8Z1 3*P*N?#RW5L>'R$+]-EJ9!+KZ<+B*MN8N=T]F7#2K80DF222$BX
MD$I&PPM5^@$+%8/Q*FV/!=EY"_>Y]XR\256$R8#R'1LJ'Z[#U32N3Z<><N&M
M30RR(1F\1^E$1FP6N)\(XW,*0B7C>J%DYRM&/@FI")!AI-K8M,( %ESB#O??
MB)%!A$@<2$LT#]YX2X5[ME=$G6F%]> QL)-[K$1;FEH(1G&!'A=1AI>VK-J2
M4!H=!N4Y+Q-DQ+,-1\]U:N%>ZMHUM7 ?V8V].3R8R6=89,$E3Y(1R+W-"3<T
M1'[R#&0Y#PGVE^>0K4XMW$LI.Z<6[B.A!J+4E]?+Z0R6RQ?QOZ^GRVDG] [F
MPE)OC" "]ZA24XK6S1I%) TZ.N%-KG3E;@=!X]XVJ)7L&$+ZC8*H?,3@:;.V
M!*0D%;/$&DV)3)03*]#C >1(:>H*BR>#TP/2QHUC!P% #U =KHVFMA]J(C@9
M->'*8&05#5IGBGMQ9-09#31D'\YD^ZFDK9W[TCZB:V'>6[<,$I4Q)J17.(&L
M*\6)AQ0(@* Q>Q\AZ3YFH\*XOVIM6H?>:PZ7: LPN!E_1<$'J8!$SM >ZJA(
M8(:32+G6RA7X#C?^J[&Q?WNI;-?8OSWDU]3<-TD=&!\3L=0Y)%P)$C2:+6.9
MHH[A__AP\Q[WG_M6?^S?/HK;.?=M'RF.K?X'\PI-\I(CB20X@=Z/"+AKQ3*I
MED65:6*!YEX%F)6F/M8?^W>H^@^68@/AQ*YY9-YET+:30VE'",X@BD$2HYQF
M7!H=\LGFMO7V$ZHUW:YY '^L]-L$T4V>1RHN@F?$T6X&JHOH3QM'&#60)?AL
MU<FF1[80@PZB\-[C__:1?GLPNAFCFR4UUJ32N0WEPX0DCLM$.,.%EVP((?WO
M^+_]5-UK_-\^<F\ /)L&@9U]?G?; ,X9H((&1F10"=<5.(SL329111]2&0-6
MJ;CY27+&[>A?:Q,[7O(-P.?A5:CN MWRQ?7JZWQ1+LE-G'5<,\V)$+2TK@R*
M>&DI<=E;II7VBO=*CNR-H^?I&M<:#:#X[19XPVFA.4Q]\(O+Q7K.1==\[0,L
M.@8GFID$H ,1KA0 NW().: 7@/\X1%QXS/I*'1=[T3=N55%MC VBE>:PMEXY
MI6TDKAH-(J(+<#-:6O-( M)/++=1!E F17LRV[6F:=Q*D]/8K0.DWRB.+J]7
MRY6?I>GLR\08RC35CM $JG14YL19+DGF*F"PDI,'>3(PW2-LW#/KTR#J4#TT
M *NGNR"L>?M^-5V]FL]^X(]071^+TMB$F9@"#YIDP U>EC8TZ(1Z$@)PGD02
M1I^R&]QN2L<]P!H>>%4UU0 2[]VK>^1?<@$\J](N/NHR (IB%)2C0\XT6G#
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M8EQ&1IXKU=3J:1A"3041O\WGJ61W[MU&^02+'],(RWMSYO:3T<2@^I@+W0@
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M0[A.7$B'VUL&Y=#@Y5+]95 &,B#L<V"*]JITZJ?^^Z\>9\L83/T'2[$!SW6
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MHO;J[S6;'Y0_2F_7__?_^;]02P,$%     @ XT4,4[JP)IWY!P  ="4  !@
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M'K,<IFP#<Q&3Y'DSQ[08.<MX6#+F_#,K#]&WF]*%$]03\835+CFN_;2T@K)
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MLL0&*>1#D1]\MJJNY4<T_3EO\"]02P,$%     @ XT4,4X,5MR5L!0  (!0
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MI+HU'SJ([)JQF:_UK$V%:@*[C5BV)[]8>?U9J6)<%)"K?XT[ATC>&9(S6KV
M5";5\'U XO?D[?Q PE8R_(UY\_G\*/_H0Q,N9TA"5[($\WC#'GQZNCL99EZ[
M=R8DQ.-1J(<F7_E:5?V7W\[,5[S!OU!+ 0(4 Q0    ( .-%#%- 'GTV.$(
M *[, 0 >              "  0    !E>#$P,7IE<F]N9&$M97AE8W5T:79E
M96UP;"YH=&U02P$"% ,4    " #C10Q3*,29RNT* @!+)Q, $0
M    @ %T0@  =GEN92TR,#(Q,#8S,"YH=&U02P$"% ,4    " #C10Q37?UE
MRAL1   ,K0  $0              @ &030( =GEN92TR,#(Q,#8S,"YX<V10
M2P$"% ,4    " #C10Q38X-'@6H;  #W!P$ %0              @ ':7@(
M=GEN92TR,#(Q,#8S,%]C86PN>&UL4$L! A0#%     @ XT4,4\90%P4O80
M<BD$ !4              ( !=WH" '9Y;F4M,C R,3 V,S!?9&5F+GAM;%!+
M 0(4 Q0    ( .-%#%.5.Q@>Z.$  &@-"0 5              "  =G; @!V
M>6YE+3(P,C$P-C,P7VQA8BYX;6Q02P$"% ,4    " #C10Q3@$!Y35^,  !
M-@8 %0              @ 'TO0, =GEN92TR,#(Q,#8S,%]P<F4N>&UL4$L!
M A0#%     @ XT4,4[JP)IWY!P  ="4  !@              ( !ADH$ '9Y
M;F4M,C R,3 V,S!X97AX,S$Q+FAT;5!+ 0(4 Q0    ( .-%#%/S:C)H\ <
M &XE   8              "  ;52! !V>6YE+3(P,C$P-C,P>&5X>#,Q,BYH
M=&U02P$"% ,4    " #C10Q39.M&3W$%   I%   &               @ ';
M6@0 =GEN92TR,#(Q,#8S,'AE>'@S,C$N:'1M4$L! A0#%     @ XT4,4X,5
MMR5L!0  (!0  !@              ( !@F $ '9Y;F4M,C R,3 V,S!X97AX
=,S(R+FAT;5!+!08     "P + .X"   D9@0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
